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NATIONAL INSTITUTE FOR HEALTH AND CARE 
EXCELLENCE 
Premeeting briefing 
Cabazitaxel for hormone-relapsed metastatic 
prostate cancer previously treated with a 
docetaxel-containing regimen (Review of 
TA255) 
This premeeting briefing presents: 
 the key evidence and views submitted by the company, the consultees and their 
nominated clinical experts and patient experts and 
 the Evidence Review Group (ERG) report.  
It highlights key issues for discussion at the first Appraisal Committee meeting and 
should be read with the full supporting documents for this appraisal.  
Key issues for consideration 
Decision problem 
 What are the relevant comparators: A) for people who had abiraterone or 
enzalutamide and then docetaxel; B) for people who did not have abiraterone or 
enzalutamide before docetaxel?  
 Is radium-223 dichloride a relevant comparator?  
Clinical effectiveness 
 The patients in the TROPIC trial did not have abiraterone or enzalutamide before 
docetaxel. Are the results of TROPIC generalisable to the population of NHS 
patients who have had this treatment sequence? 
 The company’s preferred analyses come from the subgroup in TROPIC with 
ECOG performance status of 0 or 1 who previously had at least 225 mg/m2 
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docetaxel. Is this subgroup representative of the patients who would be treated 
with cabazitaxel in the NHS?  
 Is a fixed effects indirect treatment comparison appropriate considering the 
heterogeneity between the trial outcomes? 
 Is it appropriate to use hazard ratios to inform the indirect treatment comparison 
when the proportional hazards assumption does not hold for 1 trial?  
Cost effectiveness  
 The company stated that ‘compounded IV bags of cabazitaxel can be supplied 
direct to NHS hospitals’. Is it appropriate to assume no wastage of cabazitaxel in 
the model? Is this assumption appropriate? 
 Both the company and the ERG consider the indirect treatment comparison to be 
uncertain. Is the ERG’s fully incremental cost-effectiveness analysis, which is 
informed by the indirect treatment comparison, suitable for decision-making? 
 Does cabazitaxel meet the end-of-life criteria: A) for people who had abiraterone 
or enzalutamide and then docetaxel; B) for people who did not have abiraterone 
or enzalutamide before docetaxel? 
1 Remit and decision problems 
 The remit from the Department of Health for this appraisal was to appraise 
the clinical and cost effectiveness of cabazitaxel within its marketing 
authorisation for treating hormone-relapsed metastatic prostate cancer 
previously treated with a docetaxel-containing regimen.  
 Cabazitaxel was previously appraised in NICE technology appraisal 255 
(Cabazitaxel for hormone-refractory metastatic prostate cancer previously 
treated with a docetaxel-containing regimen), for which the final appraisal 
determination was issued in January 2012. This determination did not 
recommend cabazitaxel (in combination with prednisone or prednisolone) 
for the treatment of hormone-refractory metastatic prostate cancer 
previously treated with a docetaxel-containing regimen.  Following a 
review it was agreed to reappraise cabazitaxel because more mature data 
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from the trial had been published and a patient access scheme was 
proposed by the company.  
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Table 1 Decision problem  
 Final scope issued by NICE Decision problem addressed by 
company in the submission 
Comments from the company Comments from the ERG 
Population People with hormone-relapsed 
metastatic prostate cancer 
previously treated with a 
docetaxel-containing regimen. 
People with hormone 
refractory/relapsed metastatic 
prostate cancer previously 
treated with a docetaxel-
containing regimen with or 
without prior treatment with 
abiraterone or enzalutamide. 
The additional wording was 
included to accommodate 
treatment with abiraterone or 
enzalutamide pre- or post-
docetaxel. 
The ERG noted that this is an 
appropriate population. 
Intervention Cabazitaxel in combination with 
prednisone or prednisolone 
Cabazitaxel in combination with 
prednisolone (or prednisone) 10 
mg per day up to a maximum of 
10 cycles (each cycle is 3 
weeks). 
None. None. 
Comparison Abiraterone in combination with 
prednisone or prednisolone 
Enzalutamide 
Mitoxantrone in combination with 
prednisolone (not licensed in the 
UK for this indication) 
Best supportive care (this may 
include radiotherapy, 
radiopharmaceuticals [apart from 
radium-223 dichloride], analgesics, 
bisphosphonates, and 
corticosteroids) 
For people with bone metastasis 
only (no visceral metastasis): 
radium-223 dichloride (NICE 
guidance is in development, 
funded by the CDF in the interim) 
Comparator in base case: best 
supportive care represented by 
mitoxantrone.  
Comparators in scenario 
analyses: abiraterone and 
enzalutamide. 
A comparison with radium-223 
was not presented. 
 
The company considers 
mitoxantrone to be equivalent to 
best supportive care.  
The company considered that it 
is established NHS practice to 
have abiraterone or 
enzalutamide and then 
docetaxel. Thus, the company 
considered the main comparator 
to be best supportive care (see 
section 2.2). 
 
Radium-223 is not considered to 
be a comparator due to 
differences in trial patient 
populations and resulting 
marketing authorisations (nor is 
The ERG’s clinical advisors 
acknowledged that best 
supportive care can be 
represented by mitoxantrone.  
 
 
 
 
 
 
 
 
 
The ERG noted that the 
company could have performed 
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 cabazitaxel considered to be a 
comparator in the ongoing NICE 
appraisal for Radium-223 
dichloride). Further the company 
note that its use is currently not 
established in the UK.  
a separate comparison between 
cabazitaxel and radium-223 
dichloride, using data from the 
relevant sub-group of the 
TROPIC trial. 
 
 
Outcomes The outcome measures to be 
considered include: 
overall survival 
progression-free survival (PFS) 
response rate 
adverse effects of treatment 
health-related quality of life. 
Primary outcome:  
overall survival 
Secondary outcomes:  
Progression-free survival (PFS) 
Adverse effects of treatment 
Health-related quality of life. 
 
No comments. No comments. 
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2 The technology and the treatment pathway 
 Cabazitaxel (Jevtana, Sanofi) is an anticancer drug known as a taxane. It 
disrupts the microtubular network and inhibits cell division and cell death. 
It is administered by intravenous infusion.   
 NICE clinical guideline 175 recommends that people are offered the 
following treatments for metastatic prostate cancer: orchidectomy 
(surgical removal of the testes, also known as surgical castration) or 
luteinising hormone-releasing agonists (known as medical castration). If 
the cancer becomes refractory to treatment NICE technology appraisal 
guidance 101 recommends docetaxel as a treatment option for those with 
metastatic hormone-refractory disease who have a Karnofsky 
performance-status score of 60% or more (a higher percentage reflects 
better function). NICE technology appraisal guidance 259 and 316 
recommend abiraterone or enzalutamide, as options for treating 
metastatic hormone-relapsed prostate cancer that has progressed during 
or after docetaxel-containing chemotherapy. Abiraterone and 
enzalutamide also have marketing authorisations for use before docetaxel 
and are available to people through the Cancer Drugs Fund. NICE 
technology appraisal guidance for abiraterone and enzalutamide in the 
pre-chemotherapy setting is under development. A NICE final appraisal 
determination recommends enzalutamide as an option for treating 
metastatic hormone-relapsed prostate cancer in people who have no or 
mild symptoms after androgen deprivation therapy has failed, and before 
chemotherapy is indicated, only when the company provides it with the 
discount agreed in the patient access scheme. A NICE final appraisal 
determination recommends radium-223 dichloride as an option for treating 
adults with hormone-relapsed prostate cancer with symptomatic bone 
metastases and no known visceral metastases, only if they have had 
treatment with docetaxel, and the company provides radium-223 
dichloride with the discount agreed in the patient access scheme.  
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Figure 1 Clinical pathway for cabazitaxel (figure 1, page 22 of ERG report) 
 
Key: LHRA/ADH; luteinizing hormone-releasing hormone agonists/androgen deprivation 
therapy  
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Table 2 Technology  
 Intervention Comparators 
 Cabazitaxel Mitoxantrone Abiraterone Enzalutamide Radium-223 
dichloride 
Marketing 
authorisation 
Cabazitaxel in 
combination with 
prednisone or 
prednisolone is 
indicated for the 
treatment of patients 
with hormone 
refractory metastatic 
prostate cancer 
previously treated 
with a docetaxel-
containing regimen 
Mitoxantrone is 
indicated for the 
treatment of 
metastatic breast 
cancer, non-
Hodgkin's lymphoma 
and adult acute non-
lymphocytic 
leukaemia. 
Abiraterone is 
indicated with 
prednisone or 
prednisolone for: 
 the treatment of 
metastatic 
castration 
resistant prostate 
cancer in adult 
men whose 
disease has 
progressed on or 
after a docetaxel-
based 
chemotherapy 
regimen 
 the treatment of 
metastatic 
castration 
resistant prostate 
cancer in adult 
men who are 
asymptomatic or 
mildly 
symptomatic after 
failure of 
androgen 
Enzalutamide is 
indicated for: 
 the treatment of 
adult men with 
metastatic 
castration-
resistant prostate 
cancer who are 
asymptomatic or 
mildly 
symptomatic after 
failure of 
androgen 
deprivation 
therapy in whom 
chemotherapy is 
not yet clinically 
indicated 
 the treatment of 
adult men with 
metastatic 
castration-
resistant prostate 
cancer whose 
disease has 
progressed on or 
after docetaxel 
Radium-223 is 
indicated for the 
treatment of adults 
with castration-
resistant prostate 
cancer, symptomatic 
bone metastases and 
no known visceral 
metastases. 
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deprivation 
therapy in whom 
chemotherapy is 
not yet clinically 
indicated. 
therapy. 
Administration 
method 
25 mg/m2 
administered as a 1 
hour intravenous 
infusion every 3 
weeks in combination 
with oral 
prednisolone 10 mg 
administered daily. 
14 mg/m2 
administered as a 
single intravenous 
dose which may be 
repeated at 21-day 
intervals. 
1,000 mg (4 x 250 
mg tablets) as a 
single daily dose. 
160 mg (4 x 40 mg 
capsules) as a single 
oral daily dose. 
The dose regimen of 
radium-223 is an 
activity of 50 kBq 
(kilobecquerel) per kg 
body weight, given at 
4 week intervals for 6 
injections. 
Cost  List price £3696 per 
vial, equivalent to 
£61.60 per mg [BNF 
2015]. 
 
A patient access 
scheme discount of 
xxxxx has been 
approved. 
This reduces the 
price of cabazitaxel 
to xxxxx per vial, or 
xxxx per mg. 
 
 
£30.36 per 
20mg/10ml solution 
for infusion (Drugs 
and pharmaceutical 
electronic market 
information [eMit]). 
List price £2930.00 
per 120-tab pack 
(250 mg). 
 
A confidential patient 
access scheme 
discount has been 
approved (see 
confidential appendix 
for details).  
 
 
 
List price £2734.67 
per 112-cap pack (40 
mg). 
 
A confidential patient 
access scheme 
discount has been 
approved (see 
confidential appendix 
for details). 
 
Radium 223 is 
available at a 
radioactivity of 6 MBq 
in a 6 ml vial at a net 
price of £4040 
(excluding VAT). 
 
A confidential patient 
access scheme 
discount has been 
approved (see 
confidential appendix 
for details). 
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3 Comments from consultees  
 A professional group commented on the treatment options available for 
people with hormone-relapsed metastatic prostate cancer. It was advised 
that in England, people are offered treatment with either abiraterone or 
enzalutamide. If the disease does not respond to these treatments, people 
may be offered docetaxel (if not previously taken), radium-223 dichloride 
(if they have symptomatic disease with metastasis in bone only) or 
cabazitaxel (if they previously had docetaxel). The professional group 
advised that mitoxantrone does not have a UK marketing authorisation for 
treating prostate cancer; it is used only rarely, as part of best supportive 
care, for people with symptomatic disease who have no other treatment 
options. 
 A patient group advised that the symptoms experienced by people with 
advanced prostate cancer include significant pain and fatigue which leave 
people unable to perform day-to-day activities. Other signs and symptoms 
associated with advanced disease include hypercalcaemia, urinary 
problems, swollen lymph nodes and occasionally, and spinal cord 
compression. In addition to physical symptoms people with advanced 
prostate cancer can experience anxiety and depression.  
 A patient group commented that radium-223 dichloride is contraindicated 
in people with liver metastases. The group noted that cabazitaxel is 
possibly the only treatment option available for people whose prostate 
cancer has metastasised to the liver following treatment with docetaxel or 
enzalutamide/abiraterone. 
4 Clinical-effectiveness evidence 
Overview of the clinical trials 
 The company identified 1 phase III randomised open label multi-centre 
trial (TROPIC) which compared cabazitaxel with mitoxantrone in men with 
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metastatic castration-resistant prostate cancer previously treated with a 
docetaxel-containing regimen.  Patients aged 18 years or older were 
randomised 1:1 to have either: 
  25 mg/m2 of cabazitaxel intravenously every 3 weeks in combination 
with 10 mg prednisone (or prednisolone) for a maximum of 10 cycles or  
 12 mg/m2 of mitoxantrone every 3 weeks with 10 mg prednisone (or 
prednisolone) for a maximum of 10 cycles  
(The investigators capped the treatment at a maximum of ten cycles to 
minimise the risk of mitoxantrone induced cardiac toxicity). 
 The trial included patients whose disease had progressed 6 months or 
less following treatment with a docetaxel containing regimen and who had 
an orchidectomy or treatment with a luteinising hormone-releasing 
hormone (LHRH) agonist. The trial excluded people previously treated 
with mitoxantrone. For a full list of trial inclusion and exclusion criteria, 
please see page 64-66 of the company submission.     
ERG comments 
 The ERG noted that the company’s systematic review process, including 
the inclusion and exclusion criteria, was appropriate and reflected the 
decision problem. The submission included all relevant studies of 
cabazitaxel in combination with prednisone or prednisolone (including 
data from ongoing or planned studies) but excluded studies of radium-223 
dichloride. 
Design of the clinical trial 
Outcomes 
 The primary outcome measure in TROPIC was overall survival, defined as 
the time from the date of randomisation to death from any cause. In the 
absence of confirmation of death, the survival time was censored at the 
last date the patient was known to be alive or at the data cut-off date. 
Secondary outcomes included progression free survival defined as the 
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time from randomisation to tumour progression, prostate specific antigen 
progression, pain progression (pain progression supported by clinical 
evidence and or radiological evidence of disease progression), or death 
due to any cause. For further details of secondary outcomes see page 69 
of the company submission.  
Statistical analysis 
 The company noted that in the original TROPIC study, final analyses had 
been planned after 511 deaths had occurred using the intention to treat 
principle.  The results for the whole trial population were first published 
after a median follow-up of 12.8 months (study cut-off date: 25 September 
2009), at which point 513 deaths had occurred.  The updated analysis 
was published after a median follow-up of 20.5 months (study cut-off date: 
10 March 2010), at which point 585 deaths (77.5%) had occurred.  All 
efficacy analyses used the intention to treat and estimates of the hazard 
ratio and corresponding 95% confidence intervals were provided using a 
Cox proportional hazard model stratified by factors specified at 
randomisation. 
 The trial included 2 analyses: intention to treat and per protocol. The 
intention to treat analysis included all randomised patients (n=755) and 
the per protocol analysis included only those patients who had received at 
least 1 dose of the study treatment (n=742).   
 A post-hoc subgroup analysis was conducted for patients in TROPIC with 
an ECOG performance status of 0-1 who had received at least 225 mg/m2 
docetaxel. See section 4.11. 
Baseline characteristics  
 In the intention-to-treat analysis, 378 patients were randomised to receive 
cabazitaxel and 377 patients were randomised to receive mitoxantrone. 
The median age of patients in the cabazitaxel group was 68 years and in 
the mitoxantrone group, 67 years. In the cabazitaxel group 92.6% of 
patients had an ECOG performance status of 0 or 1; this was 91.2% in the 
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mitoxantrone group. In the cabazitaxel group 71% of patients were 
previously treated with chemotherapy; this was 69% in the mitoxantrone 
group. No patients were previously treated with enzalutamide or 
abiraterone. For further details on patient characteristics see table 19 on 
page 73 of the company submission.   
ERG comments 
 The ERG noted that a lack of blinding of patients, care providers, and 
outcome assessors in the TROPIC study could bias the results.  The ERG 
noted that for objective outcomes, such as overall survival un-blinded 
assessment is unlikely to bias the trial results.  However, estimates of 
treatment effect for subjective outcomes such as pain and symptom 
deterioration (both of which were included in the definition of progression 
free survival) may be biased by unblinding.  
Results of TROPIC 
 In the intention-to-treat analysis, median survival was 15.1 months in the 
cabazitaxel group and 12.8 months in the mitoxantrone group. The 
difference was statistically significant (p = 0.0002). The hazard ratio (HR) 
was 0.72 (95% confidence interval [CI]: 0.61 to 0.84).   
 
Table 3 TROPIC overall survival results (table 22, page 78 of company submission)  
Outcome TROPIC 
Cabazitaxel + prednisone 
(n=378) 
Mitoxantrone + 
prednisone (n=377) 
Median survival in months 
(95% CI) 15.08 (13.96-16.49) 12.78 (11.53-13.73) 
Hazard ratio 0.72 (0.61 - 0.84) 
p value <0.001 
 
Subgroup analysis  
 The company presented a post hoc sub group analysis for patients in 
TROPIC with an ECOG performance status of 0-1 (a lower ECOG score 
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reflects better function) who had received at least 225 mg/m2 docetaxel1. 
The company highlighted that in NICE technology appraisal guidance 255  
the Committee had considered that this subgroup was representative of 
clinical practice in England because people who had an ECOG 
performance score of 2 or more were not suitable for treatment with 
chemotherapy and therefore unlikely to be treated with cabazitaxel.  
 The subgroup analysis was conducted on the updated TROPIC dataset 
(see section 4.5) and represented 632 (83.7%) patients out of the 
intention to treat population of 755.  
Baseline characteristics in the subgroup 
 The median age of patients in the cabazitaxel group was 68 years and in 
the mitoxantrone group 66 years. For further details of baseline 
characteristics see table 25, page 82 of the company submission. 
Results of the subgroup 
 The company included 632 patients in the subgroup analysis; 319 in the 
cabazitaxel group and 313 in the mitoxantrone group. Median overall 
survival was 15.6 (95% CI 13.96 - 17.28) months in the cabazitaxel group 
and 13.4 (95% CI 11.99 - 14.52) months in the mitoxantrone group. The 
difference was statistically significant (p <0.001). The hazard ratio was 
0.69 (0.57 - 0.82). 
Table 4 Overall survival in the subgroup of patients with ECOG performance score of 
0 -1 who have received at least 225 mg/m2 docetaxel (table 26, page 83 of company 
submission) 
 Cabazitaxel + 
prednisone (n=319) 
Mitoxantrone + 
prednisone (n=313) 
Median overall survival in months (95% CI) 15.61 (13.96-17.28) 13.37 (11.99-14.52) 
Hazard ratio (95% CI) 0.69 (0.57-0.82) 
P value <0.001 
Key: CI = confidence interval 
 
                                                 
1 The company noted that patients would need to receive at least 225 mg/m2 of docetaxel to gain the 
full benefit of first-line treatment before going on to second-line treatment with cabazitaxel (see page 
54 of the ERG report). 
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 Median progression free survival in the subgroup was 2.76 (95% CI 2.43-
3.12) months in the cabazitaxel group and 1.41 (95% CI 1.35-1.84) 
months in the mitoxantrone group. The difference was statistically 
significant (p = 0.001). The hazard ratio was 0.76 (95% CI 0.65-0.89).  
 
Table 5 Progression free survival in the subgroup of patients with ECOG performance 
score of 0 -1 who have received at least 225 mg/m2 docetaxel (table 27, page 84 of 
company submission) 
 Cabazitaxel + prednisone (n=319) 
Mitoxantrone + 
prednisone (n=313) 
Number of patients with PFS events (%) 305 (95.61) 304 (97.12) 
Median PFS in months (95%CI) 2.76 (2.43-3.12) 1.41 (1.35-1.84) 
Hazard ratio (95% CI) 0.76 (0.65-0.89) 
p value 0.001 
Key: CI = confidence interval; PFS = progression-free survival 
PFS was defined as a composite endpoint evaluated from the date of randomisation to the date of 
tumour progression, PSA progression, pain progression, or death due to any cause, whichever 
occurred first Source 
 
Indirect treatment comparison  
Overview  
 The company performed an indirect treatment comparison comparing 
cabazitaxel with abiraterone and enzalutamide. It identified the COU-AA-
301 (abiraterone) trial and the AFFIRM (enzalutamide) trial from its 
systematic literature review. The AFFIRM study compared enzalutamide 
with placebo. The COU-AA-301 study compared abiraterone plus 
prednisone with prednisone plus placebo (see section 4.1 page 52 of 
company submission for further details) (Figure 2). 
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Network diagram 
Figure 2 Company’s network diagrams for the included trials (figure 11, page 86 of 
company submission) 
 
 
* The NICE technical team suggests that there is a typographical error for the intervention group of 
the AFFIRM trial, which should read ‘Enzalutamide + prednisone and not placebo. 
 
  
 
Outcomes 
 The company noted that the definition of progression in TROPIC is 
different to the definition in COU-AA-301 and AFFIRM because it used a 
multiple-component endpoint. Therefore, to compare the trials, the 
company chose radiographic progression free survival to inform its 
indirect treatment comparison  which it defined as the time from 
randomisation to the first occurrence of tumour progression (based on the 
response evaluation criteria in solid tumours [RECIST] criteria) or death 
due to any cause. 
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 The company estimated the median radiographic progression free survival 
for the intention to treat population in TROPIC. This was 8.8 months (95% 
CI 7.6 - 9.7) in the cabazitaxel group and 5.9 months (95% CI 5.1 - 7.0) in 
the mitoxantrone group (p = 0.003 [HR 0.75; 95% CI, 0.65–0.88]). For 
further details of the methods informing this analysis see pages 11-13 of 
appendix B in the company submission. 
Table 6 Overview of the clinical trials included in the indirect treatment comparison in 
the intention to treat populations (adapted from table 8, page 14 of appendix b in the 
company submission) 
 TROPIC  
(cabazitaxel) 
COU-AA-301 
(abiraterone) 
AFFIRM  
(enzalutamide) 
Intervention Cabazitaxel + 
prednisone/prednisolone 
(n=371) 
Abiraterone Acetate + 
prednisone/prednisolone 
(n=797) 
Enzalutamide  
(n=800) 
Comparator Mitoxantrone + 
prednisone/prednisolone 
(n=377) 
Placebo + 
prednisone/prednisolone 
(n=398) 
Placebo  
(n=399) 
rPFS 
HR 
(95%CI) 
0.75 (0.65-0.88) 0.78 (0.65-0.88) 0.4 (0.35-0.45) 
Key: ITC, indirect treatment comparison; rPFS, radiographic progression free survival HR:  hazard ratio
 
Results  
 The results of the fixed effects indirect treatment comparison showed a 
nonsignificant decrease in overall survival between cabazitaxel and 
abiraterone and a nonsignificant increase in overall survival for 
enzalutamide (see Table 7). For radiographic progression free survival 
there was a nonsignificant decrease in risk of progression between 
cabazitaxel and abiraterone and a statistically significant difference 
between cabazitaxel and enzalutamide (in favour of enzalutamide) HR 
1.88 (credibility interval 1.54, 2.29). See Table 7 for details.  
 The company’s indirect treatment comparison assumed that the control 
treatments in all 3 trials had similar efficacy and a similar safety profile, 
but the company stated that these assumptions may not hold true. 
Specifically, radiographic progression free survival was longer in the 
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control group of TROPIC (median 5.9 months) than in the control groups 
of AFFIRM and COU-AA-301 (median 2.9 and 3.6 months respectively). 
Accordingly, the company advised that the results from the indirect 
treatment comparison should be treated with caution. See page 86-87 of 
the company submission for further details.  
Table 7 Results from the mixed treatment comparisons (table 28, page 87 of company 
submission) 
 
  
Overall survival Radiographic progression free survival 
HR Credible intervals HR 
Credible 
intervals 
Cabazitaxel compared with 
BSCa  0.72 0.61 0.85 0.75 0.65 0.88
Cabazitaxel compared with 
abiraterone 0.97 0.78 1.21 0.97 0.76 1.22
Cabazitaxel compared with 
enzalutamide 1.14 0.90 1.45 1.88 1.54 2.29
a mitoxantrone assumed equivalent to BSC. 
Key: HR: Hazard Ratio; BSC: Best Supportive Care. 
 
ERG comments 
 The ERG acknowledged the company’s concerns about the validity of its 
indirect comparisons (see section 4.20).  It noted that the validity of the 
analysis for both overall survival and radiographic progression free 
survival are dependent on the assumption that the control treatments of 
the 3 included trials can be considered exchangeable. If this is not the 
case (the control treatments are not exchangeable) then there will be 
considerable heterogeneity. In the presence of between-study 
heterogeneity a fixed effects model is not appropriate, so the ERG 
advised that a random effects model should have been used. 
 The ERG also noted that the company’s use of hazard ratios for the 
analysis may not have been appropriate because this analysis assumes 
that the difference in the risk of death between treatment groups within a 
trial is constant over time (the proportional hazards assumption). In the 
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COU-AA-301 study for abiraterone compared with placebo, the placebo 
overall survival curve crosses the abiraterone curve at 24 months, which 
means that the proportional hazards assumption may not hold. 
Accordingly, the ERG advised that the results of the indirect treatment 
comparison should be treated with caution. 
ERG exploratory analyses 
 To assess the impact of differences between-trials, the ERG conducted 
additional analyses using a random effects model. In the absence of 
information on which to base the choice of a prior probability, the ERG 
used a weakly informative half-normal prior with variance 0.322 (see Table 
8). The results showed no significant difference in overall survival or 
radiographic progression free survival between the 3 interventions.  
Table 8 Results of NMA using random effects model, half-normal prior with variance 
0.322 
  
Overall survival Radiographic progression free survival 
HR 
(mean) 
Credible 
intervals HR 
Credible 
intervals 
Cabazitaxel compared with 
BSCa  0.77 0.35 1.47 0.80 0.36 1.53
Cabazitaxel compared with 
abiraterone 1.10 0.35 2.74 1.09 0.34 2.74
Cabazitaxel compared with 
enzalutamide 1.29 0.41 3.19 2.12 0.66 5.22
a mitoxantrone assumed equivalent to BSC. 
Key: HR: Hazard Ratio; BSC: Best Supportive Care. 
A hazard ratio (HR) less than 1 indicates a lower risk of death or disease progression with 
cabazitaxel. 
 
Adverse effects of treatment  
 In the intention-to-treat population of TROPIC, adverse events associated 
with treatment of grade ≥3 occurred in 57.4% of patients in the cabazitaxel 
group and 39.4% of patients in the mitoxantrone group. The proportion of 
patients withdrawing from study treatment because of a ‘treatment 
emergent’ adverse event (including disease progression) was 18.3% in 
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the cabazitaxel group compared with 8.4% in the mitoxantrone group. The 
incidence of treatment emergent adverse events (not coded as disease 
progression) leading to death was 4.9% in the cabazitaxel group and 
1.9% in the mitoxantrone group. 
Table 9. 5 most common adverse events grade 3 and above reported in patients in 
TROPIC (adapted from table 42, page 113 of company submission). 
  
Proportion of patients – Subgroup 
(ECOG-PS 0-1 with 225mg/m2 prior 
docetaxel) 
Proportion of Patients - ITT 
Adverse Event Cabazitaxel Mitoxantrone Cabazitaxel Mitoxantrone 
Neutropenia 0.201 0.081 0.210 0.073 
Febrile neutropenia 0.080 0.019 0.073 0.016 
Diarrhoea 0.064 0.003 0.062 0.003 
Fatigue 0.051 0.023 0.049 0.030 
Asthenia 0.042 0.019 0.046 0.024 
Key: ITT, intention to treat 
 
5 Cost-effectiveness evidence 
Overview  
 The company produced a Markov model to assess the cost effectiveness 
of cabazitaxel compared with mitoxantrone. This was an updated version 
of the model presented for NICE technology appraisal guidance 255. In 
the base case the modelled population was the subgroup of patients in 
TROPIC (see section 4.12) who had: 
 An ECOG performance status of 0-1; and 
 Previously had at least 225 mg/m2 of docetaxel. 
 The company considered it standard NHS practice to treat metastatic 
castrate resistant prostate cancer with either abiraterone or enzalutamide 
in the pre-chemotherapy setting, that is, before docetaxel. Thus, in its 
main analyses, the company compared cabazitaxel with best supportive 
care (represented by mitoxantrone). However, for the alternative pathway 
(using abiraterone or enzalutamide after docetaxel) the company 
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compared cabazitaxel with abiraterone and cabazitaxel with enzalutamide 
(see 5.17).  
Model structure 
 The company developed a transition Markov model with 3 states to 
represent disease progression from stable disease through to progressive 
disease and death (see Figure 3). The model included a 10-year time 
horizon, 3-week cycle lengths and discounting of costs and health benefits 
at 3.5%. The company included the costs incurred by the NHS and 
personal and social services (see table 52, page 142 of company 
submission for further details).  
 
Figure 3 Company’s model structure (Figure 15, page 142 of company submission) 
 
 
 
Model details  
 The base-case model compared 2 treatments: 
 Mitoxantrone, 12 mg/m2 every 3 weeks in combination with 10 mg/day 
of prednisolone 
 Cabazitaxel, 25 mg/m2 every 3 weeks in combination with 10 mg/day of 
prednisolone. 
Stable disease
Dead
Progressive disease
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 In the base case, the company assumed that only patients in the stable 
disease health state received treatment with cabazitaxel or mitoxantrone. 
Patients in the model continued treatment from the start of the model until 
1 of the following events occurred: disease progression, death or 
treatment up to a maximum of 10 cycles of chemotherapy.  
 In TROPIC, 23% of patients in the cabazitaxel group and 16% in the 
mitoxantrone group stopped treatment for reasons other than progression. 
To reflect this, the company included a rate of discontinuation in the 
model. Based on the proportion of patients who discontinue treatment, the 
company derived a discontinuation rate over 10 cycles and applied it to 
patients on treatment: 2.6% over 10 cycles in the cabazitaxel arm and 
1.7% over 10 cycles in the mitoxantrone arm. In a sensitivity analysis, the 
company excluded these rates. 
Clinical parameters  
 To model time to progression and survival times, the company applied 
several parametric distributions to the subgroup data from TROPIC (that 
is, patients with an ECOG performance status of 0-1 and previously 
treated with at least 225 mg/m2 of docetaxel). It chose the distribution that 
had the best fit to the trial data, based on Akaike’s information criterion 
and the Bayesian information criterion. The company chose to use the 
same parametric distribution for both the cabazitaxel and mitoxantrone 
arms of the model. In its base case, the company used a Weibull curve to 
model survival times and a log-normal curve to model time to disease 
progression (see tables 53 and 54, page 146–148 of company submission 
for further details). 
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Figure 4 Weibull model for overall survival (figure 17, page 146 of company 
submission) 
 
 
 
Figure 5 Log-normal model for progression-free survival (figure 19, page 148 of 
company submission).  
 
Key; SG, subgroup; OS, overall survival. PFS, progression-free survival.  
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Health-related quality of life  
 The company did not collect data on health-related quality of life in 
TROPIC, so it took utility values from the UK Early Access Programme 
(EAP) for cabazitaxel. The programme measured the health-related 
quality of life (using the EQ-5D) of men who had been treated with 
cabazitaxel after docetaxel (see Table 10).  
 
Table 10 utility values used in company model (table 61, page 161 of company 
submission) 
State Utility value Reference in 
submission 
Justification 
Stable 
disease  
Drug Cycle Stable Disease 
1 0.704 
2 0.728 
3 0.728 
4 0.750 
5 0.753 
6 0.752 
7 0.778 
8 0.789 
9 0.803 
10 and 
thereafter 0.819 
UK EAP  
 
The company used the 
same utility values for 
patients having cabazitaxel 
and for patients having 
mitoxantrone, because it 
did not expect health-
related quality of life to 
differ between treatment 
groups. 
Progressive 
disease 
0.6266
until last 3 months of life which 
are set to 0 
UK EAP  
 
This utility value was 
measured 30 days after 
the last cycle of treatment 
with cabazitaxel for people 
with disease progression. 
This was the last measure 
of health-related quality of 
life in the trial. 
 
 Disutility values for adverse events were not collected in either the UK 
EAP or in TROPIC. The company derived disutility values associated with 
experiencing each adverse event from a literature review that was 
conducted for NICE technology appraisal guidance 255. These studies 
were of breast and lung cancer, not prostate cancer. See section 4.4.6 
pages 156-157 of the company submission for further details.  
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Treatment related adverse events 
 The company modelled 15 adverse events using the rates of adverse 
events in TROPIC and included all grade ≥3 which occurred in 2% or 
more of patients in any treatment group of TROPIC. In addition, the 
company included deep vein thrombosis and neuropathy, as they were 
classified as important based on clinical expert opinion (see section  
4.24). 
Resource use 
 The company estimated resource use based on data from TROPIC, a UK 
clinical audit and expert opinion. It estimated costs using the British 
national formulary (BNF), NHS reference costs and data from the 
Personal Social Services Research Unit. 
 In the stable disease state, the company included drug acquisition costs 
(for active treatment, pre-medications and concomitant medications), 
costs of chemotherapy administration, costs of disease management 
including hospitalisations and testing, and adverse event costs. Costs for 
active treatment, pre-medications and chemotherapy administration were 
applied for up to 10 cycles for cabazitaxel and mitoxantrone (the 
maximum number allowed in TROPIC). Cabazitaxel and mitoxantrone are 
both provided in vials with the required dosage dependent on body 
surface area. The company assumed that the mean body surface area 
was 1.9 m2 (based on clinical opinion; the mean body surface area 
observed in TROPIC was 2.01 m2) with vial sharing for cabazitaxel and 
mitoxantrone. After clarification, the company explained that it believes 
there will be no wastage of cabazitaxel because ‘patient specific doses in 
the form of compounded IV bags of cabazitaxel can be supplied direct to 
NHS hospitals’.  
 In the progressed disease state, the company included acquisition costs 
for post-progression chemotherapy and best supportive care, costs of 
chemotherapy administration, and cost of disease management including 
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hospitalisations and testing. For further details on costs see section 5.5 
(from page 162 onwards) of company submission. 
Table 11 Unit costs used in company model (table 62, page 164 of company submission) 
Item Cabazitaxel  Mitoxantrone Abiraterone Enzalutamide 
Drug cost  xxxxx per vial 
according to 
PAS discount
£100 per vial £2930.00 per 
120 tablet 
pack (list 
price) 
£2734.67 per 
112 capsule 
pack (list 
price) 
Administration cost 
per cycle 
xxxxx xxxxx n.a. n.a. 
Pre- & Concomitant 
medication per cycle 
xxxxx xxxxx xxxxx xxxxx 
Adverse event 
management costs  
£105.18 £53.78 £5.15 £5.05 
Progressive disease: 
active treatment  per 
cycle 
xxxxx xxxxx xxxxx xxxxx  
Progressive disease: 
best supportive care 
treatment cost  per 
cycle 
xxxxx xxxxx n.a. n.a. 
End of life cost – one 
off cost applied when 
patients transition to 
the dead state 
£1952.15 £1952.15 £1952.15 £1952.15 
 
Company's base-case results and sensitivity analyses 
 The company’s base case analysis (Table 12) showed that cabazitaxel 
(with PAS discount) compared with mitoxantrone resulted in a 
deterministic incremental cost-effectiveness ratio (ICER) of £49,327 per 
quality adjusted life year (QALY) gained (incremental costs £11,450, 
incremental QALYs 0.232). The probabilistic ICER was £50,682 per QALY 
gained (incremental costs £11,829; incremental QALYs 0.233). 
Table 12 Deterministic base-case results: cabazitaxel (with PAS) compared with 
mitoxantrone 
Treatment Total cost Total 
QALY 
Inc. cost Inc. QALY ICER 
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Mitoxantrone xxxxx xxxxx  
Cabazitaxel xxxxx xxxxx £11,450 0.232 £49,327
Abbreviations: Inc., incremental; QALY, Quality adjusted life year; ICER, incremental cost 
effectiveness ratio 
 
 Following the factual accuracy check, the company noted that its original 
base case assumed no drug wastage of mitoxantrone. This was an error, 
so the company submitted a new scenario assuming mitoxantrone 
wastage. The deterministic ICER reduced from £49,327 to £48,256 per 
QALY gained.   
 The company’s deterministic sensitivity analyses varied the utility values, 
time horizon, discount rates, method for extrapolating overall survival 
data, and the percentage of patients having best supportive care after 
disease progression. The company stated that the model was most 
sensitive to variations in the utility value for the progressive disease health 
state (see table 79, page 186 of company submission for further details).   
Company’s scenario analyses 
 The company’s scenario analyses compared cabazitaxel (including PAS 
discount) with enzalutamide (at list price) and, separately, abiraterone (at 
list price). These analyses used the intention-to-treat population of 
TROPIC (see page 188, section 5.8.4 of the company submission for 
further details). The company assumed that enzalutamide and abiraterone 
were taken until disease progression or death, whereas cabazitaxel was 
taken for up to 10 cycles.  
 Hazard ratios for abiraterone and enzalutamide were taken from the 
company’s indirect treatment comparison and applied to the parametric 
distributions modelling overall survival and progression-free survival with 
cabazitaxel. The company used a Weibull curve to model progression-free 
survival because the log-normal distribution (used in the base case) is not 
a proportional hazards model.  
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 Both enzalutamide and abiraterone have confidential PASs. Accordingly, 
the ERG re-calculated the company’s scenario analyses using the PAS 
discounts for enzalutamide and abiraterone (table 19 of the confidential 
appendix). The company did not report a fully incremental analysis.  
ERG comments and exploratory analysis  
Clinical parameters  
 Regarding the extrapolation of overall survival data, the ERG queried why 
the company had not used piecewise curves. Piecewise methods use the 
Kaplan-Meier curve from the trial to calculate transition probabilities for a 
period of time at the start of the model, then after a cut-off point use a 
parametric distribution. The ERG noted that, in NICE technology appraisal 
guidance 255, the Committee preferred the piecewise approach over the 
other methods presented by the company for that appraisal. This was 
because there were some early deaths due to neutropenia in the 
cabazitaxel group, which may have affected the predicted survival times 
from a single extrapolation curve. During clarification, the company 
presented results using a piecewise curve for the cabazitaxel arm 
(specifically, using the Kaplan-Meier curve for the first 2.1 months and a 
Weibull curve thereafter). The company did not alter the base-case 
methods for modelling the mitoxantrone arm. This scenario reduced the 
company’s base-case ICER by 1.6% to £48,543 per QALY gained 
(question B1, page 24 of clarification responses). The ERG advised that 
the piecewise curve for overall survival with cabazitaxel is likely to be 
more appropriate than the single Weibull curve the company used in its 
base case. However, a piecewise curve was not used in the ERG’s base 
case because the company had not provided full details of this analysis. 
Following the factual accuracy check, the company updated the ERG’s 
base case exploratory analysis (see section 5.27) using the piecewise 
curves it submitted during clarification. The results reduced the ERG’s 
ICER (assuming no vial wastage) from £51,308 to £50,195 per QALY 
gained. The ERG has not had an opportunity to critique this analysis.   
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 The ERG identified issues in the company’s methods for modelling 
stopping treatment. The company’s model assumed that patients who 
stopped treatment did not incur drug costs during the cycle when they 
stopped. The ERG stated that this would underestimate drug costs, as 
patients would stop only after receiving the drug. The company also 
assumed that patients who stop treatment would have increased utility 
related to additional treatment cycles. The ERG stated that this would 
overestimate utilities. Finally, the ERG noted that for any cycle, patients 
who had stopped treatment during a previous cycle and remained with 
stable disease would incorrectly incur drug costs. The ERG noted that this 
would overestimate drug costs. Correcting these issues by removing 
treatment discontinuation for any reason other than disease progression 
increased the ICER by 2.1% to £50,370 per QALY gained. 
Health-related quality of life 
 The ERG noted that the data on utility from the UK EAP are more mature 
than those in the company’s submission for NICE technology appraisal 
guidance 255. The ERG further noted that the model results are sensitive 
to the utility value for progressive disease, which is uncertain because it is 
based on data for 25 people. The ERG explored this uncertainty in 
sensitivity analyses (see Table 13).  
 The company included a disutility in the QALY calculations to account for 
the assumed reduced quality of life experienced by people with 
progressive disease in their last 3 months of life. The ERG noted that this 
disutility was calculated based on all deaths observed, not deaths 
amongst people with progressive disease. Removing this disutility 
increased the ICER by 0.74% to £49,691 per QALY gained. 
Resource use  
 The ERG advised that for generic drugs it is more appropriate to use 
prices from the electronic market information tool (eMIT) than the British 
National Formulary (BNF) because eMIT is based on the price paid by 
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English hospitals. Using eMIT prices increased the ICER comparing 
cabazitaxel with mitoxantrone by 4.8% to £51,675 per QALY gained. 
 The ERG highlighted that 3 different estimates were available for the 
costs of treatment in the progressed disease health state. The most 
expensive estimate (£1767.02) was for the mitoxantrone group in the 
TROPIC trial. The least expensive estimate (£1192.81) was for the 
cabazitaxel group in the TROPIC trial. The third estimate was from a UK 
clinical audit (£1364.07). The company’s model used the estimate from 
the cabazitaxel group in TROPIC for the costs of treatment after 
cabazitaxel, and the estimate from the mitoxantrone group in TROPIC for 
the costs of treatment after mitoxantrone, abiraterone or enzalutamide. 
The ERG noted that differences in post-progression treatment were 
unlikely to have contributed to differences in overall survival for the 
TROPIC trial. Therefore, in the ERG’s opinion the company should have 
used the same post-progression treatment costs for cabazitaxel and each 
of the comparators. The ERG performed an analysis which used the UK 
clinical audit to estimate the post-progression treatment costs for 
cabazitaxel and all of the comparators. This reduced the ICER comparing 
cabazitaxel with mitoxantrone to £48,908 per QALY gained. 
 The ERG noted that the company assumed no wastage of cabazitaxel. 
During NICE technology appraisal guidance 255, clinical experts advised 
that there is likely to be some wastage of cabazitaxel in NHS clinical 
practice, but there was uncertainty about how much wastage would occur. 
The ERG performed an analysis which assumed that a cycle of treatment 
with cabazitaxel would require the cost of a vial of cabazitaxel. This 
increased the ICER by XXXX to XXX per QALY gained. 
ERG exploratory analyses 
Cabazitaxel compared with mitoxantrone 
 The ERG’s exploratory base case included the following assumptions: 
 Use eMIT prices for generic drugs 
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 Do not model stopping treatment for reasons other than disease 
progression 
 Use UK clinical audit data to model costs of post-progression treatment 
resource use and the proportion of patients having best supportive care  
 Do not model a reduced utility value for the last 3 months of 
progressive disease. 
 The ERG presented 2 exploratory base cases (Table 13). When vial 
wastage was assumed (the ERG’s preferred assumption), the 
deterministic ICER for cabazitaxel compared with mitoxantrone was 
XXXXX per QALY gained. When there was no vial wastage, the 
deterministic ICER reduced to £51,308 per QALY gained. Under both 
assumptions, the probabilistic ICER was slightly higher than the 
deterministic ICER.  Of all the changes to the model made by the ERG, 
assuming drug wastage had the biggest impact on the ICER.  
 In addition, the ERG performed deterministic sensitivity analyses (ERG 
analysis numbers A7 to A10) which showed that the ERG’s ICER was 
sensitive to the method for extrapolating clinical effectiveness data and 
the utility value used for progressive disease. 
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Table 13 ERG exploratory analyses for cabazitaxel (with PAS) compared to mitoxantrone in the TROPIC subgroup of patients with 
ECOG performance score of 0 -1 who have received at least 225 mg/m2 docetaxel (table 36, page 123 of the ERG report erratum)  
Scenario Incremental  cost (£) 
Incremental 
QALY ICER (£) 
Company’s base case 11,450 0.232 49,327 
Company probabilistic base-case 11,829 0.233 50,682 
A1) Use eMIT prices 11,994 0.232 51,667 
A2) Discontinuation for reasons other than disease progression not modelled 11,693 0.232 50,370 
A3) Reduced disutility in the last 3 months of progressive disease not modelled 11,450 0.230 49,691 
A4) Post-progression treatment resource and proportion receiving BSC both from UK audit for 
all treatments. 11,353 0.232 48,908 
A5) Indirect treatment comparison results using a weakly informative prior (does not affect the 
comparison with mitoxantrone). 11,450 0.232 49,327 
A6) Cost of cabazitaxel and mitoxantrone based on vial cost (assuming wastage). XXX 0.232 XXX 
ERG Deterministic base-case 1 (changes A1 to A6) XXX 0.230 XXX 
ERG Probabilistic base-case 1 (changes A1 to A6) XXX 0.231 XXX 
ERG Deterministic base-case 2 (changes A1 to A5) 11,823 0.230 51,308 
ERG Probabilistic base-case 2 (changes A1 to A5) 12,133 0.234 51,849 
ERG sensitivity analyses    
A7) Use of log-logistic curves for both overall and progression-free survival. 12,627 0.309 40,887 
A8) Parametric curves for OS and PFS based on lowest AIC value (no requirement for same 
parametric form for both arms)* 9,347 0.137 68,168 
A9) Use of the 95% low confidence interval value for progressive disease utility (0.510). 11,450 0.207 55,248 
A10) Use of the 95% high confidence interval value for progressive disease utility (0.743). 11,450 0.257 44,560 
BSC, best supportive care, ICER: Incremental cost-effectiveness ratio. NR: Not reported. OS: Overall survival. PFS: Progression-free survival. QALYS: Quality-adjusted life-
years. 
* For cabazitaxel the Weibull curve is used for OS and the log-logistic curve for PFS. For mitoxantrone the curves are the log-logistic and the log-normal, respectively. 
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Cabazitaxel compared with enzalutamide, abiraterone and best supportive care 
 The ERG presented a fully incremental analysis comparing cabazitaxel 
with enzalutamide, abiraterone and best supportive care. The ERG used 
the assumptions in section 5.27 and it also used a weakly informative 
prior for the indirect treatment comparison. The ERG used the PAS price 
discounts for each drug so the results are presented in a confidential 
appendix.  The ERG also conducted a one-way sensitivity analyses using 
estimates from the limits (low and high) of the confidence interval for utility 
of progressed disease and using the median hazard ratios from the 
company’s indirect treatment comparison. 
 The ICERs for cabazitaxel compared with best supportive care were 
substantially higher in the ERG’s fully incremental analysis than in the 
ERG’s base-case pairwise comparison with mitoxantrone (see confidential 
appendix to the PMB). The incremental analysis used the indirect 
treatment comparison results to estimate the effectiveness of each 
treatment, whereas the pairwise comparison used data from the TROPIC 
trial. The ERG advised that the indirect treatment comparison assumes 
proportional hazards, but the data may not meet this assumption. Both the 
ERG and the company stated that the results of the indirect treatment 
comparison should be treated with caution (see section 4.22). 
 The ERG noted 2 further areas of uncertainty in the company’s model. 
The first was that the model restricted cabazitaxel use to a maximum of 
10 cycles (to reflect the TROPIC trial) but the marketing authorisation for 
cabazitaxel does not restrict treatment duration. The ERG advised that 
using cabazitaxel for more than 10 cycles would increase the lifetime 
costs associated with cabazitaxel but it could also increase overall 
survival and quality of life. Therefore, the ERG stated that the impact of 
longer treatment on the ICER is unknown.   
 The second area of uncertainty relates to the results of the indirect 
treatment comparison. Both the ERG and the company advised that the 
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results should be treated with caution (see 5.31). In addition, the ERG 
noted the uncertainty in using radiographic progression free survival. The 
company noted that because radiographic progression free survival was 
lower in the enzalutamide and abiraterone trials compared to TROPIC it 
could bias against cabazitaxel in the indirect treatment comparison (see 
4.18). Within the company’s economic model however, lower estimates of 
radiographic progression free survival are associated with improved cost-
effectiveness because less drug costs are incurred. The ERG notes that 
this may produce a favourable ICER for cabazitaxel. 
 The ERG noted that the company did not compare cabazitaxel with 
radium 223-dichloride. Following clarification (question A1, page 2 of the 
clarification responses), the company provided results from the 
ALSMYPCA trial which compared radium-223 dichloride with placebo. In 
ALSYMPCA, the subgroup of patients treated with radium-223 and who 
had previously had docetaxel had a median overall survival of 14.4 
months (95% CI 12.5 to 15.5 months). For comparison, patients in the 
cabazitaxel group of TROPIC (intention-to-population) had median overall 
survival of 15.1 months (95% CI 14.0 to 16.5 months). The ERG noted 
that both overall survival and progression-free survival with radium-223 
dichloride appeared to be similar to that with cabazitaxel and that if the 
cost effectiveness of these 2 drugs was compared, drug costs would likely 
be a key driver. As the company’s model did not compare the cost-
effectiveness of cabazitaxel and radium-223, the ERG presented a cost-
minimisation comparison of the price of these 2 drugs. This informal 
comparison is included in a confidential appendix to the PMB.   
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6 End-of-life considerations  
Table 14 End-of-life considerations (see page 20 of company submission for further 
details).  
Criterion Data available  
The treatment is indicated for 
patients with a short life expectancy, 
normally less than 24 months  
The company presented a literature review of life 
expectancy in castrate-resistant prostate cancer. In 
the 11 treatment groups identified that were treated 
with first-line docetaxel, median overall survival was 
19 months. Survival was shorter in the post-
docetaxel setting (see page 20 of company 
submission).  
 
NICE guidance recommends abiraterone or 
enzalutamide after docetaxel. The ERG noted that, in 
the trials of abiraterone and enzalutamide after 
docetaxel, patients in the intervention group lived for 
a median of 15.8 and 18.4 months respectively. 
There is sufficient evidence to 
indicate that the treatment offers an 
extension to life, normally of at least 
an additional 3 months, compared 
with current NHS treatment  
In the intention-to-treat population of TROPIC, 
cabazitaxel increased median overall survival by 2.3 
months compared with mitoxantrone.  
 
The company’s base-case model showed that 
cabazitaxel increased survival by a mean of 4.02 
months (95% CI 2.17, 5.91; derived from the 
probabilistic sensitivity analysis) compared with 
mitoxantrone.  
 
The ERG noted that the company did not assess the 
extension of life with cabazitaxel compared with 
abiraterone, enzalutamide or radium-223. The ERG 
observed that the indirect treatment comparison 
found no statistically significant difference in overall 
survival between cabazitaxel, abiraterone and 
enzalutamide. The ERG also noted that survival 
times appear to be similar with cabazitaxel and 
radium-223 (see section 7, page 128 of ERG report). 
The treatment is licensed or 
otherwise indicated for small patient 
populations  
According to the company, data from the CDF for the 
year 2013/14 showed that approximately 600 
patients were receiving cabazitaxel. 
The company estimated that the total eligible 
population is 1690 people in England. The ERG 
advised that this estimate was appropriate. 
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7 Equality issues 
 No equality issues were identified during scoping or in the patient expert 
submissions. During the development of NICE technology appraisal 
guidance 255, the Committee understood that people who have proposed, 
started or completed male to female gender reassignment can develop 
prostate cancer. The Committee therefore concluded that this appraisal 
should refer to people rather than to men. 
8 Authors 
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Appendix A: Clinical efficacy section of the draft European 
public assessment report  
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NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE 
Proposed Health Technology Appraisal 
Cabazitaxel for hormone-relapsed metastatic prostate cancer previously 
treated with a docetaxel-containing regimen (review of TA255) 
Final scope  
Remit/appraisal objective  
To appraise the clinical and cost effectiveness of cabazitaxel within its 
marketing authorisation for treating hormone-relapsed metastatic prostate 
cancer previously treated with a docetaxel-containing regimen.1 
Background   
Prostate cancer is a condition in which tumours develop in the prostate, a 
gland in the male reproductive system. Its cause is thought to be 
multifactorial, involving both environmental and genetic factors. The incidence 
of prostate cancer increases with age and is higher in people of black African 
or black Caribbean family origin. In England, approximately 35,600 people 
were diagnosed with prostate cancer in 2011, and over 9000 people died from 
prostate cancer in 2012 (Cancer Research UK, 2014).  
Around 55–65% of people with prostate cancer develop metastatic disease (in 
which cancer spreads to other parts of the body). Over 90% of people with 
metastatic prostate cancer initially respond to hormonal therapy but eventually 
become resistant to it. This clinical condition is known as hormone-relapsed 
prostate cancer (but the terms ‘castration-resistant prostate cancer’, 
‘androgen-independent prostate cancer’ and’ hormone-refractory prostate 
cancer’ are also used).  
 
For metastatic hormone-relapsed prostate cancer, NICE clinical guideline 175 
‘Prostate cancer: Diagnosis and treatment’ and NICE technology appraisal 
guidance 101 recommend docetaxel as a treatment option for men with 
metastatic hormone-refractory disease who have a Karnofsky performance-
status score of 60% or more. NICE technology appraisals 259 and 316 
recommend abiraterone and enzalutamide , respectively, as options for 
treating metastatic hormone-relapsed prostate cancer that has progressed 
during or after docetaxel-containing chemotherapy. Abiraterone and 
enzalutamide also have marketing authorisations to be used before 
chemotherapy, and are available through the Cancer Drugs Fund. NICE 
guidance for abiraterone and enzalutamide in the pre-chemotherapy setting 
                                            
1 The remit for this appraisal was formally referred to NICE in 2010 and described the 
condition as hormone refractory, metastatic prostate cancer. In January 2013, NICE and the 
Department of Health agreed that, following feedback received from stakeholders during 
scoping and appraisal consultations, the condition should be referred to as ‘hormone-relapsed 
prostate cancer’ (HRPC). The remit has therefore been reworded with the consent of the 
Department of Health. 
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are under development. Radium-223 dichloride has a marketing authorisation 
for the treatment of adults with hormone-relapsed prostate cancer, 
symptomatic bone metastases and no known visceral metastases, and is 
funded by the Cancer Drug Fund whilst NICE guidance is in development .  
NICE technology appraisal 255 did not recommend cabazitaxel for hormone-
relapsed metastatic prostate cancer previously treated with a docetaxel-
containing regimen.  NICE recommendations for abiraterone and 
enzalutamide have since resulted in a change in clinical practice. In addition, 
more evidence on the effect of cabazitaxel on survival, progression free 
survival and health-related quality of life is now available which may address 
some of the key uncertainties identified during NICE technology appraisal 
255. Therefore, the clinical and cost effectiveness of cabazitaxel will be 
reviewed and compared with the relevant technologies. 
The technology  
Cabazitaxel (Jevtana, Sanofi) belongs to a class of anticancer drugs known 
as taxanes. It works by disrupting the microtubular network and causes 
inhibition of cell division and cell death. It is administered by intravenous 
infusion.   
Cabazitaxel has a UK marketing authorisation 'in combination with prednisone 
or prednisolone for the treatment of patients with hormone refractory 
metastatic prostate cancer previously treated with a docetaxel-containing 
regimen'.  
Intervention(s) Cabazitaxel in combination with prednisone or 
prednisolone 
Population(s) People with hormone-relapsed metastatic prostate 
cancer previously treated with a docetaxel-containing 
regimen 
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Comparators  Abiraterone in combination with prednisone or 
prednisolone 
 Enzalutamide 
 Mitoxantrone in combination with prednisolone 
(not licensed in the UK for this indication) 
 Best supportive care (this may include 
radiotherapy, radiopharmaceuticals [apart from 
radium-223 dichloride], analgesics, 
bisphosphonates, and corticosteroids) 
For people with bone metastasis only (no visceral 
metastasis)  
 Radium-223 dichloride (NICE guidance is in 
development, funded by the CDF in the interim) 
Outcomes The outcome measures to be considered include: 
 overall survival 
 progression-free survival 
 response rate 
 adverse effects of treatment 
 health-related quality of life. 
Economic 
analysis 
The reference case stipulates that the cost effectiveness 
of treatments should be expressed in terms of 
incremental cost per quality-adjusted life year. 
The reference case stipulates that the time horizon for 
estimating clinical and cost effectiveness should be 
sufficiently long to reflect any differences in costs or 
outcomes between the technologies being compared. 
Costs will be considered from an NHS and Personal 
Social Services perspective. 
The availability of any patient access schemes for the 
intervention or comparator technologies should be taken 
into account. 
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Other 
considerations  
If the evidence allows the following subgroups will be 
considered.   
 People who have received abiraterone or 
enzalutamide 
 People with bone metastasis only (no visceral 
metastasis) 
Guidance will only be issued in accordance with the 
marketing authorisation. Where the wording of the 
therapeutic indication does not include specific 
treatment combinations, guidance will be issued only in 
the context of the evidence that has underpinned the 
marketing authorisation granted by the regulator.   
Related NICE 
recommendations 
and NICE 
Pathways 
Related Technology Appraisals:  
‘Enzalutamide for metastatic hormone-relapsed prostate 
cancer previously treated with a docetaxel-containing 
regimen’ (July 2014) NICE Technology Appraisal 316 
Review date TBC 
‘Abiraterone for castration-resistant metastatic prostate 
cancer previously treated with a docetaxel-containing 
regimen’ (June 2012) NICE Technology Appraisal 259 
Review date TBC 
‘Cabazitaxel for hormone-refractory metastatic prostate 
cancer previously treated with a docetaxel-containing 
regimen’ (May 2012) NICE Technology Appraisal 255  
 
Docetaxel for the treatment of hormone-refractory 
metastatic prostate cancer’ (June 2006) NICE 
Technology Appraisal 101 Guidance on static list. 
Appraisals in development  
‘Radium-223 dichloride for treating metastatic hormone-
relapsed prostate cancer with bone metastases’ NICE 
technology appraisals guidance [ID576] Publication 
expected January 2016 
‘Abiraterone for treating metastatic hormone-relapsed 
prostate cancer not previously treated with 
chemotherapy’ NICE technology appraisals guidance 
[ID503] Publication expected TBC 
‘Enzalutamide for metastatic hormone-relapsed prostate 
cancer when chemotherapy is not yet clinically indicated’ 
NICE technology appraisals guidance [ID683] 
Publication expected TBC 
Related Guidelines:  
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‘Prostate cancer: diagnosis and treatment’ (January 
2014) NICE guideline 175 Review date March 2016 
Related Quality Standards: 
 ‘Prostate cancer’ (June 2015) NICE Quality standard 
91]  
Related NICE Pathways: 
 ‘Prostate Cancer’ (2015) NICE pathway 
http://pathways.nice.org.uk/pathways/prostate-cancer  
Related National 
Policy  
NHS England, January 2014, ‘Manual for prescribed 
specialised services 2013/14’, Chapter 105: Specialist 
cancer services (adults). 
National Service Frameworks, Cancer 
Department of Health, 2013, ‘NHS Outcomes 
Framework 2014-2015’. 
Department of Health, 2011, ‘Improving outcomes: a 
strategy for cancer’. 
Department of Health, 2009, ‘Cancer commissioning 
guidance’. 
Department of Health, 2007, ‘Cancer reform strategy’. 
Department of Health, 2011, The national cancer 
strategy: stakeholder engagement report – Annex H: 
Prostate Cancer. 
Department of Health, NHS Outcomes Framework 
2014-2015, Nov 2013. Domains 1 and 2. 
https://www.gov.uk/government/uploads/system/uploads
/attachment_data/file/256456/NHS_outcomes.pdf 
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Final matrix of consultees and commentators 
 
Consultees  Commentators (no right to submit or 
appeal) 
Company 
 Sanofi (cabazitaxel) 
 
Patient/carer groups 
 Black Health Agency 
 Bob Champion Cancer Trust 
 Cancer Black Care 
 Cancer Equality 
 Equalities National Council 
 Everyman 
 HAWC 
 Helen Rollason Cancer Charity 
 Independent Cancer Patient’s Voice 
 Macmillan Cancer Support 
 Maggie’s Centres 
 Marie Curie Cancer Care 
 Muslim Council of Britain 
 Orchid  
 Prostate Cancer UK 
 Prostate Help Association 
 South Asian Health Foundation 
 Specialised Healthcare Alliance 
 Tackle Prostate Cancer 
 Tenovus 
 
Professional groups 
 Association of Cancer Physicians 
 British Association of Urological 
Nurses 
 British Association of Urological 
Surgeons 
 British Geriatrics Society 
 British Institute of Radiology 
 British Prostate Group 
 British Psychosocial Oncology Society 
 British Society of Urogenital Radiology
 British Uro-Oncology Group 
General 
 Allied Health Professionals Federation 
 Board of Community Health Councils in 
Wales 
 British National Formulary 
 Care Quality Commission 
 Department of Health, Social Services 
and Public Safety for Northern Ireland 
 Healthcare Improvement Scotland 
 Medicines and Healthcare products 
Regulatory Agency 
 National Association of Primary Care 
 National Pharmacy Association 
 NHS Alliance 
 NHS Commercial Medicines Unit 
 NHS Confederation 
 Scottish Medicines Consortium 
 
Possible comparator companies 
 Accord (mitoxantrone)  
 Astellas Pharma (enzalutamide) 
 Bayer (radium-223 dichloride) 
 Baxter (mitoxantrone) 
 Hospira (mitoxantrone)  
 Janssen (abiraterone) 
 
Relevant research groups 
 Cochrane Prostate Diseases and 
Urologic Cancers Group 
 Institute of Cancer Research 
 MRC Clinical Trials Unit 
 National Cancer Research Institute 
 National Cancer Research Network 
 National Institute for Health Research 
 Ovarian and Prostate Cancer Research 
Trust 
 Pro Cancer Research Fund 
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Consultees  Commentators (no right to submit or 
appeal) 
 Cancer Research UK 
 Pelican Cancer Foundation 
 Prostate Cancer Advisory Group 
 Royal College of General Practitioners
 Royal College of Nursing 
 Royal College of Pathologists 
 Royal College of Physicians 
 Royal College of Radiologists 
 Royal College of Surgeons 
 Royal Pharmaceutical Society 
 Royal Society of Medicine 
 Society and College of Radiographers 
 UK Clinical Pharmacy Association  
 UK Health Forum 
 UK Oncology Nursing Society 
 Urology Foundation 
 
Others 
 Department of Health 
 NHS England 
 NHS North East Essex CCG 
 NHS Wigan Borough CCG 
 Welsh Government 
 Prostate Cancer Research Centre 
 
Evidence Review Group 
 School of Health and Related Research 
(ScHARR) 
 National Institute for Health Research 
Health Technology Assessment 
Programme  
 
Associated Guideline groups 
 National Collaborating Centre for 
Cancer 
 
Associated Public Health groups 
 Public Health England 
 Public Health Wales  
 
 
NICE is committed to promoting equality, eliminating unlawful discrimination and 
fostering good relations between people who share a protected characteristic and 
those who do not. Please let us know if we have missed any important organisations 
from the lists in the matrix, and which organisations we should include that have a 
particular focus on relevant equality issues. 
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Definitions: 
 
Consultees 
 
Organisations that accept an invitation to participate in the appraisal; the company that 
markets the technology; national professional organisations; national patient 
organisations; the Department of Health and the Welsh Government and relevant NHS 
organisations in England. 
 
The company that markets the technology is invited to make an evidence submission, 
respond to consultations, nominate clinical specialists and has the right to appeal against 
the Final Appraisal Determination (FAD). 
 
All non-company consultees are invited to submit a statement1, respond to consultations, 
nominate clinical specialists or patient experts and have the right to appeal against the 
Final Appraisal Determination (FAD). 
 
Commentators 
 
Organisations that engage in the appraisal process but that are not asked to prepare an 
evidence submission or statement, are able to respond to consultations and they receive 
the FAD for information only, without right of appeal. These organisations are: companies 
that market comparator technologies;  
Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group 
commissioned by the Institute to develop clinical guidelines); other related research 
groups where appropriate (for example, the Medical Research Council [MRC], National 
Cancer Research Institute); other groups (for example, the NHS Confederation, NHS 
Alliance and NHS Commercial Medicines Unit, and the British National Formulary. 
 
All non-company commentators are invited to nominate clinical specialists or patient 
experts. 
 
Evidence Review Group (ERG) 
 
An independent academic group commissioned by the National Institute for Health 
Research (NIHR) Health Technology Assessment Programme (HTA Programme) to 
assist the Appraisal Committee in reviewing the company evidence submission to the 
Institute. 
 
 
                                                 
1Non-company consultees are invited to submit statements relevant to the group they are 
representing. 
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1. Executive summary 
 Prostate cancer is the most common cancer amongst men in England and 
currently affects ~40,000 people, around 6,000 of whom suffer from 
metastatic disease. 
 Docetaxel was the first agent to show survival benefit in metastatic Hormone 
Resistant Prostate Cancer (mHRPC) and has for many years been the 
mainstay of treatment.  
 Patients with metastatic disease post-docetaxel typically have a poor 
prognosis with a life expectancy of less than 24 months.  
 Cabazitaxel was developed and licensed to address docetaxel resistance. 
Prior to this, no active licensed option was available so mitoxantrone 
chemotherapy was used off-label.  
 Cabazitaxel has become well established in NHS clinical practice as second-
line chemotherapy after early progression on docetaxel. Use has largely 
displaced mitoxantrone which offers palliative benefits but no proven survival 
advantage over best supportive care (BSC). 
 Cabazitaxel has been approved for use through the CDF on the basis of its 
clinical effectiveness, and is now used to treat ~600 patients per year. 
 More recently, pathways have evolved which include the newer advanced 
hormonal agents (abiraterone and enzalutamide); although approved by NICE 
in the post-docetaxel setting, these agents are predominantly used by the 
NHS ahead of docetaxel, and funded by the Cancer Drug Fund (CDF). 
 Clinical guidelines state the use of one of the advanced hormonal therapies 
precludes the subsequent use of the other due to cross resistance. 
 The Phase III TROPIC study demonstrated that cabazitaxel has a significant 
mean overall survival benefit (4 months vs. mitoxantrone) even in those 
patients with aggressive disease who have progressed during or rapidly after 
docetaxel treatment and therefore may not be appropriate for advanced 
hormone therapy. 
 Disease heterogeneity and the emergence of hormone refractory tumours 
over time mean that patients need tailored treatment options to extend overall 
survival. 
 A simple Patient Access Scheme has been offered to enable NICE to 
reconsider the cost-effectiveness of cabazitaxel, a treatment with 
demonstrated survival benefit, in a small population of patients with particular 
treatment needs.  
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Background 
Prostate cancer is the most common cancer amongst men in the England and 
currently affects ~40,000 people around 6,000 of whom suffer from metastatic 
disease. Overall patients with metastatic disease have a life expectancy of less than 
24 months and a poor prognosis.  
Docetaxel was the first agent to show survival benefit in metastatic Hormone 
Refractory Prostate Cancer (mHRPC) and since approval by NICE in 2006 (TA101) 
has for many years been the mainstay of treatment. 
Cabazitaxel was developed specifically because of its activity in docetaxel resistant 
cell lines.1 The clinical benefit of cabazitaxel has been clearly demonstrated in the 
pivotal TROPIC study which was the first to show a survival advantage for a 
treatment in the post-docetaxel setting. Prior to cabazitaxel authorisation, no active 
licensed option was available so mitoxantrone chemotherapy was used off-label for 
palliation. Mitoxantrone has not demonstrated any significant overall survival benefit 
over BSC.2 
The manufacturer’s submission to support the review of TA255 presented here is 
based on: 
 The use of the updated Phase III pivotal trial data throughout. 
 The inclusion of a simple Patient Access Scheme (PAS). 
 Updated Health Related Quality of Life (HRQL) evidence. 
 Improved understanding of prostate cancer and the importance of non-
hormonal systemic therapies in improving outcomes  
 Consideration of the changes to the treatment pathway on the availability of 
new life-extending hormonal agents in the metastatic Castrate Resistant 
Prostate Cancer (mCRPC) setting. 
 
Sanofi reached agreement with NHS England to allow continued access for patients 
to cabazitaxel following delisting from the CDF, as an interim measure pending NICE 
re-review. 
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Description of the cabazitaxel marketing authorisation. 
Table 1. Technology being appraised 
UK approved name 
and brand name 
 Approved name: cabazitaxel 
 Brand name: Jevtana®  
Marketing 
authorisation/CE 
mark status 
Marketing authorisation for cabazitaxel was granted by the 
European Commission on 17th March 2011.3 
Indications and any 
restriction(s) as 
described in the 
summary of product 
characteristics 
Indication: 
 Cabazitaxel in combination with prednisone or 
prednisolone is indicated for the treatment of patients 
with Metastatic Castrate Resistant Prostate Cancer 
(mCRPC) previously treated with a docetaxel-
containing regimen.  
 Patients with mild hepatic impairment (total bilirubin > 1 
to ≤1.5 x Upper Limit of Normal (ULN) or AST >1.5 x 
ULN) should have their dose reduced to 20 mg/m2 and 
should be closely monitored during treatment. 
 For patients with moderate hepatic impairment (total 
bilirubin >1.5 to ≤ 3.0 x ULN) dose should not exceed 
15 mg/m2. 
 
Contraindications 
 Hypersensitivity to cabazitaxel, to other taxanes, or to 
any excipients of the formulation including polysorbate 
80.  
 Neutrophil counts less than 1,500/mm3. 
 Concomitant vaccination with yellow fever vaccine.  
 Severe hepatic impairment (total bilirubin >3 x ULN) 
Method of 
administration and 
dosage 
 The recommended dose of cabazitaxel is 25 mg/m2 
administered as a 1 hour intravenous infusion every 3 
weeks in combination with oral prednisone or 
prednisolone 10 mg administered daily throughout 
treatment. (Note: prednisone and prednisolone are 
considered to be equivalent; only prednisolone is 
available in the UK). 
 Dose modifications by down titration to 20 mg/m2 should 
be made if patients experience the adverse reactions 
tabulated in section 2.3.1: Table 8 or if they are 
experiencing hepatic impairment. 
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Cabazitaxel was appraised by NICE in 2010 (TA255).4 In this review the clinical 
benefit of cabazitaxel was acknowledged and the Committee agreed that it qualified 
for consideration under the End of Life (EoL) criteria. Nonetheless, negative 
guidance was received on the basis that the technology was considered not cost- 
effective at the submitted price (TA255).4 Cabazitaxel was subsequently made 
available via the CDF because of its clinical effectiveness and has become standard 
of care post-docetaxel in patients appropriate for cytotoxic therapy, displacing 
mitoxantrone use in the NHS.  
Changes in the patient pathway since TA2554 
The availability of advanced hormonal agents abiraterone and enzalutamide in the 
pre- and post-docetaxel setting have increased the options for patients, resulting in 
tailoring of the treatment pathway. NHS England does not fund sequential use of the 
advanced hormonal agents because there is significant observational and pre-
clinical evidence of cross resistance between abiraterone and enzalutamide. As a 
result two pathways tend to be followed with the advanced hormone therapies used 
either pre- (NHS standard practice) or post- (alternative practice) docetaxel.   
The use of the advanced hormone agents in the pre-docetaxel setting is the typical 
treatment pathway in England today with over two-thirds of patients following this 
treatment paradigm.5  Patients following this pathway initially tend to have less 
aggressive, asymptomatic or mildly symptomatic disease (unlikely to be resistant to 
further hormone therapy). These patients only become eligible for cabazitaxel 
following docetaxel. No alternative active treatment to cabazitaxel is available in this 
position in the pathway (left hand side). 
Younger, fitter patients with aggressive, symptomatic disease tend to follow 
alternative practice (right hand side) and depending upon the response to docetaxel, 
the next step in the pathway would be determined by disease assessment and 
patient choice. 
. 
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* Radium-223 is licenced for patients with two or more bone metastases but no visceral metastases 
The marketing authorisations for the advanced hormonal agents6, 7 are in metastatic 
Castrate Resistant Prostate Cancer (mCRPC) whilst the cabazitaxel authorisation is 
for metastatic Hormone Refractory Prostate Cancer (mHRPC). Whilst often used 
interchangeably, mHRPC and mCRPC have an important distinction in definition. 
Abiraterone and enzalutamide interrupt the production of testosterone (by the 
tumour) which means they work only on tumours with some sensitivity to hormones. 
Cabazitaxel has a different mechanism of action. It blocks tumour cell division and 
thus disrupts many pathways, related or not to androgen receptors. This means it not 
only works on tumour sensitive cell lines, but it also works on the aggressive clones 
which do not respond to advanced hormonal agents.  
Therefore, the disease characteristics of patients appropriate for chemotherapy will 
not be the same as those appropriate for hormone therapy at this stage in the 
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treatment pathway. This is reflected by the patient’s response to docetaxel within 
Phase III clinical trials.  
Understanding of disease heterogeneity and resistance 
Prostate cancer used to be perceived as a homogeneous disease resulting from 
malignant androgen dependent clonal tissue. It has become evident that prostate 
cancer tumours are in fact heterogeneous as they contain cells with a variety of 
malignant genetic changes. 
The majority of late-stage prostate cancers harbour mutations in the androgen 
receptor that convey resistance to currently available medicines targeting androgen 
signalling (i.e. the advanced hormonal agents). In addition, evidence suggests that 
sequential treatment with advanced hormonal agents is not beneficial due to 
acquired resistance. As a result, CDF guidance explicitly excludes sequential 
treatment with advanced hormonal therapy. 
It is therefore important that an effective second-line cytotoxic agent is available for 
treating prostate cancer, as a significant proportion of post-docetaxel patients with 
aggressive disease, who have progressed during or rapidly after docetaxel treatment 
may not be suitable for the advanced hormonal agents abiraterone or enzalutamide. 
Summary of the base-case analysis 
Base-case analysis – standard NHS practice 
The pivotal Phase III trial compares cabazitaxel to mitoxantrone as this was the 
comparator required by the regulator at the time. Mitoxantrone is unlicensed in this 
indication and is now rarely used in the UK since the introduction of cabazitaxel. 
Mitoxantrone, despite having palliative benefit, has not demonstrated any survival 
advantage over best supportive care2 so in the context of this decision problem is 
considered as at least equivalent to BSC.  
Scenario analysis – alternative practice 
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In line with the scope, analysis is also provided for patients who have not followed 
current standard practice and therefore could still receive abiraterone and 
enzalutamide in the post-docetaxel setting. However, based on the increased 
characterisation of the mechanisms of resistance to hormone therapy, it is not often 
considered as an alternative for patients eligible to receive cabazitaxel. Therefore we 
consider this analysis is of limited relevance to the decision problem. 
Clinical effectiveness 
The pivotal registration clinical trial (see Section 4.7) was the TROPIC study 
(EFC6193, NCT00417079).8 This was a large randomised, open-label, international, 
multi-centre, Phase III study in which 755 patients were randomised to receive either 
cabazitaxel 25 mg/m2 intravenously every 3 weeks for a maximum of 10 cycles with 
prednisone or prednisolone 10 mg orally daily (n=378), or to receive mitoxantrone 12 
mg/m2 intravenously every 3 weeks for a maximum of 10 cycles with prednisone or 
prednisolone 10 mg orally daily (n=377).8, 9  
The median study follow-up was 20.5 months. A 28% reduction in the risk of death 
was observed for cabazitaxel compared to mitoxantrone (p=0.0002  HR=0.72 
(95%CI, 0.61-0.85)).9 Overall survival (OS) in the ITT population is presented in 
Table 2. Median OS was significantly longer with cabazitaxel compared to 
mitoxantrone (15.1 versus 12.7 months respectively). The base-case estimate of the 
mean OS extrapolated using the Weibull distribution was (18.55 versus 14.53 
months; difference of 4.02 months). (See Section 5.6). 
Progression-free survival (PFS) defined as the earliest progression in tumour growth, 
PSA increase, pain or death was also statistically significantly longer in the 
cabazitaxel group compared to the mitoxantrone group (p<0.0001, HR = 0.74 
(95%CI, 0.64 - 0.86)). Median progression-free survival was 2.8 months versus 1.4 
months. Median Radiologic PFS (rPFS) was estimated using time to progression 
(TTP) plus mortality as it was not reported in the trial as a pre-specified end point 
although is common in other trials in mCRPC. Median rPFS was 8.8 months versus 
5.9 months, (p=0.0003, HR = 0.75 (95% CI: 0.65 - 0.88). The key results are 
presented in Table 2. 
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Table 2. OS and PFS – ITT population 
 
Mitoxantrone 
+ prednisone 
(n=377) 
Cabazitaxel + 
prednisone 
(n=378) 
Difference 
(months) 
Median Overall Survival8 
OS, months (95%CI) 12.8 (11.5 – 13.7) 
15.1 
(14.0 – 16.5) 2.3 
Hazard ratio (95% CI)* 0.72 (0.61 - 0.85) 
P value† 0.0002 
Estimated mean Overall Survival (extrapolated) 
OS, months (95%CI) 14.53 18.55 4.02 
Median Progression-free survival (PFS)8 
PFS, months (95%CI) 1.4 (1.4 – 1.8) 2.8 (2.4 – 3.1) 1.4 
Hazard ratio (95% CI) 0.76 (0.65 - 0.89) 
p value 0.0002 
Median progression free survival (r(PFS)) (analysed for the purposes of ITC) 
Number of patients with rPFS, n (%) 337 (89.4) 318 (84.1) - 
rPFS, months (95%CI) 5.9 (5.1 - 7.0) 8.8 (7.6 - 9.7) 2.2 
Hazard ratio (95% CI) 0.75 (0.65 – 0.88) 
p value 0.0003 
Key: CI = confidence interval. * P value from stratified log rank test, stratifying for ECOG performance 
status and measurable disease at baseline. † Hazard ratio is estimated using a Cox proportional 
hazards regression model, HR <1 indicates a lower risk with cabazitaxel plus prednisone with respect 
to mitoxantrone plus prednisone.  
Safety and tolerability 
In TROPIC the most common haematological adverse reactions were neutropenia 
and febrile neutropenia. However these can be managed effectively in clinical 
practice with primary G-CSF prophylaxis according to EORTC guidelines or careful 
monitoring and typically rates of neutropenia are lower in the real-world than 
observed in the trial. Patients currently treated by the NHS receive six cycles on 
average, consistent with TROPIC and this demonstrates tolerability in the real-world 
setting. 
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Table 3. Key adverse events (≥ grade 3) observed in the TROPIC study. 
Adverse event* Mitoxantrone (n=371) Cabazitaxel (n=371) 
Neutropenia 27 (7.3%) 78 (21%) 
Febrile neutropenia 6 (1.6%) 27 (7.3%) 
Leukopenia 5 (1.6%) 14 (3.7%) 
Anaemia 5 (1.6%) 13 (3.5%) 
Thrombocytopenia 1 (0.3%) 9 (2.4%) 
Diarrhoea 1 (0.3%) 23 (6.2%) 
Fatigue 11 (3.0%) 18 (4.9%) 
*Rates for AEs requiring clinical intervention. 
In response to the scope, and only relevant to an examination of the alternative 
treatment practice (right-hand-side in Figure 1), Indirect Treatment Comparisons 
(ITC) were carried out to evaluate the relative effectiveness of cabazitaxel in 
comparison with abiraterone and enzalutamide. The ITCs were based on the 
outcomes reported in the TROPIC,9 AFFIRM10 and COU-AA-30111 trials. 
The evidence from the ITC indicates that cabazitaxel and the advanced hormonal 
therapies offer broadly similar treatment effects for OS. The ITC is subject to 
uncertainty due to differences in patient populations and reported end points in the 
pivotal Phase III trials. 
Health Related Quality of Life 
Health Related Quality of Life (HRQL) data was not collected in TROPIC. However, 
EQ-5D data was collected in the UK arm of the international Early Access 
Programme (EAP) for cabazitaxel (NCT01254279).12 This study evaluated a similar 
population to TROPIC and provides the baseline utility values for the economic 
evaluation outlined in Section 5. A summary of the results for treatment cycles 1 to 
10 is provided in Figure 1 below and indicates that patients progressing on earlier 
lines of therapy (baseline) experience increases to their initial HRQL and maintain 
this over time whilst on cabazitaxel treatment in the stable disease. 
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Figure 1. Summary of utility results from the UK EAP.12 
 
End of Life criteria  
We consider that the End of Life (EoL) criteria continue to apply to cabazitaxel as 
was the case in the original NICE technology appraisal (TA255).4  
Despite newer agents becoming available, the life expectancy of patients with 
prostate cancer remains limited. A recent literature review examined, life expectancy 
with castrate resistant prostate cancer (CRPC)13 In the 11 treatment groups 
identified that were treated with first-line docetaxel, median OS was 19 months (IQR: 
17–20). In the post-docetaxel setting survival was shorter. For example in the four 
main RCTs with results in the post-docetaxel setting the observed median OS results 
for patients in the control arms were: TROPIC, 12.7 months, COU-AA-301 
(abiraterone): 11.2 months, AFFIRM (enzalutamide): 13.6 months and ALSYMPCA  
(Radium-223): 11.3 months.  These results suggest that typical life expectancy of 
patients suitable for cabazitaxel is considerably less than 24 months regardless of 
previous therapeutic interventions. 
Data from the CDF for the year 2013/14 showed that around 600 patients were 
receiving cabazitaxel.14 This number is below the ceiling of 7,000 patients required to 
meet End of Life (EoL) criteria. The total eligible population is estimated to be 1690 
patients in England. 
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Incremental mean OS (assessed by the best fit (Weibull) parameterisation of the 
TROPIC data: 4.02 months) is likely to be greater than 3 months (Table 2) with 
cabazitaxel versus mitoxantrone. Incremental OS using other parameterisations 
ranges between 3.6 and 8.1 months. This is consistent with the ERG estimates in 
the original NICE technology appraisal. 
For patients previously treated with the advanced hormonal agents, or for those no-
longer suitable for them, cabazitaxel represents an life-extending EoL therapy. 
Summary of the cost-effectiveness analysis  
A simple Patient Access Scheme (PAS) has been offered to enable NICE to 
reconsider the cost-effectiveness of cabazitaxel.  
A Markov model was used to represent the progressive nature of the disease for the 
economic evaluation. Patients start in the stable disease state at the first cycle of 
treatment. Once patients progress, they move to the ‘progressive disease’ state. 
Patients can die from all causes, and at any time. The cycle length in the model was 
three weeks, reflecting the timing of treatment cycles in both TROPIC and usual 
clinical practice. The time horizon was limited to ten years and discounting was 
applied at the usual rate of 3.5%. 
Given that current established use of cabazitaxel is almost entirely in patients who 
have already received either abiraterone or enzalutamide, we believe the most 
appropriate comparison for cabazitaxel remains mitoxantrone, as pivotal trial 
comparator and as a proxy for BSC and this is presented as the base-case analysis.  
The cost-effectiveness analysis presented here which incorporates the PAS has 
shown that cabazitaxel is associated with a base case ICER of £49,327/QALY. This 
arises from an average incremental increase in life years of 0.338 and an 
incremental QALY gain of 0.232, set against an increased lifetime cost of £11,450 of 
which a sizable cost (~18%) is incurred through additional survival gained in the 
high-cost progressive disease state. These results have been tested in one-way 
sensitivity analysis and were found not to vary greatly.  
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Table 4 Base-case incremental cost-effectiveness results 
 Cabazitaxel Mitoxantrone/BSC 
Total costs 
Commercial in confidence information 
removed. Total life years Total QALYs 
Incremental costs: cabazitaxel vs. mitoxantrone £11,450 - 
Incremental life years: cabazitaxel vs. mitoxantrone 0.338 - 
Incremental QALYs: cabazitaxel vs. mitoxantrone 0.232 - 
ICER £49,327 - 
Key: ICER = incremental cost-effectiveness ratio; LYG = life-years gained; QALY = quality-adjusted 
life-year. *Includes administration, premedication and concomitant medication. 
 
Supplementary analysis for alternative practice 
We have carried out a scenario analysis of cost-effectiveness analysis for 
cabazitaxel versus abiraterone or enzalutamide. As requested by NICE, this analysis 
is not based upon the net prices available through the patient access schemes for 
abiraterone and enzalutamide as they are confidential. Results from this analysis can 
be found in appendices B. 
Conclusions 
Disease heterogeneity and the emergence of hormone refractory tumours over time 
mean that patients need tailored treatment options to extend overall survival in 
mCRPC. Cabazitaxel is an established life-extending chemotherapy for a group of 
patients with poor prognosis and few remaining treatment options. As such it has a 
critical role in the armamentarium to tackle prostate cancer.  
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Statement of the decision problem 
Table 5. The decision problem 
 Final scope issued by NICE Decision problem addressed in 
the company submission 
Rationale if different from the final NICE 
scope 
Population People with hormone-relapsed 
metastatic prostate cancer previously 
treated with a docetaxel-containing 
regimen. 
People with hormone refractory relapsed 
metastatic prostate cancer previously 
treated with a docetaxel-containing 
regimen with or without prior treatment 
with abiraterone or enzalutamide. 
The addition of wording to accommodate 
treatment with advanced hormonal agents pre- 
or post-docetaxel reflects the influence of these 
agents in driving the two alternative pathways 
for metastatic Castrate-Resistant Prostate 
Cancer (mCRPC) patients discussed below. 
Intervention Cabazitaxel in combination with 
prednisone or prednisolone 
Cabazitaxel in combination with 
prednisolone (or prednisone) 10 mg/day 
up to a maximum of ten cycles 
N/A 
Comparator (s)  Abiraterone in combination with 
prednisone or prednisolone 
 Enzalutamide 
 Mitoxantrone in combination with 
prednisolone (not licensed in the 
UK for this indication) 
 Best supportive care (this may 
include radiotherapy, 
radiopharmaceuticals [apart from 
radium-223 dichloride], analgesics, 
bisphosphonates, and 
corticosteroids) 
Best supportive care represented by 
mitoxantrone and relevant to standard 
NHS practice and alternative practice.  
Abiraterone and enzalutamide in the 
context of alternative practice. 
 
In line with the scope, mitoxantrone is 
considered to be a valid comparator and can be 
considered to be equivalent to best supportive 
care for OS. This is the base-case analysis. 
A scenario analysis is provided comparing 
cabazitaxel to abiraterone or enzalutamide. 
However, it is not considered that patients 
eligible for chemotherapy in this setting would 
also be appropriate for hormone therapy due to 
disease heterogeneity and treatment resistance 
(see Section 4) 
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For people with bone metastasis only 
(no visceral metastasis) 
 Radium-223 dichloride (NICE 
guidance is in development, funded 
by the CDF in the interim) 
 
Radium-223 is not considered to be a 
comparator (nor is cabazitaxel considered to be 
a comparator in the ongoing NICE appraisal or 
EPAR for Radium-223) due to differences in trial 
patient populations and resulting marketing 
authorisations. Use is currently not established 
in the UK.  
Outcomes The outcome measures to be 
considered include: 
 overall survival 
 progression-free survival (PFS) 
 response rate 
 adverse effects of treatment 
 health-related quality of life. 
 Primary outcome: OS 
 Secondary outcomes:  
o Radiographic PFS (rPFS) 
o Adverse effects of treatment 
o Health-related quality of life. 
 
 
 
Economic 
analysis 
The reference case stipulates that the 
cost effectiveness of treatments should 
be expressed in terms of incremental 
cost per quality-adjusted life year. 
The reference case stipulates that the 
time horizon for estimating clinical and 
cost effectiveness should be sufficiently 
long to reflect any differences in costs or 
outcomes between the technologies 
being compared. 
Costs will be considered from an NHS 
and Personal Social Services 
perspective. 
The availability of any patient access 
The cost-effectiveness of cabazitaxel is 
expressed as an incremental cost per 
QALY. 
The time horizon in the base-case is the 
patient’s lifetime and constrained to a 
maximum of 10 years 
Costs are considered from an NHS and 
PSS perspective 
The availability of a Patient Access 
Scheme (PAS) for cabazitaxel is 
included in the analysis. 
The scenario analysis including 
abiraterone and enzalutamide are based 
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schemes for the intervention or 
comparator technologies should be 
taken into account. 
on NHS list prices, as requested by 
NICE, as the PAS arrangements are 
confidential. 
Subgroups to 
be considered 
If evidence allows the subgroups 
indicated in the ‘comparators’ section 
will be considered. People for whom 
abiraterone or enzalutamide are not 
suitable include people in whom 
 abiraterone or enzalutamide are 
not expected to be effective 
 the disease has progressed 
after abiraterone or 
enzalutamide 
Guidance will only be issued in 
accordance with the marketing 
authorisation. Where the wording of the 
therapeutic indication does not include 
specific treatment combinations, 
guidance will be issued only in the 
context of the evidence that has 
underpinned the marketing authorisation 
granted by the regulator. 
The base-case will be the population in 
TROPIC with Eastern Cooperative 
Oncology Group performance status 
(ECOG PS) 0 -1 and who have 
previously received ≥ 225 mg/m2 of 
docetaxel  
 
Sensitivity analysis will be conducted 
using the ITT population from the 
TROPIC study. 
 
In line with previous NICE opinion and the use of 
cabazitaxel in clinical practice, patients with 
lower performance score (ECOG PS ≥ 2) and 
limited exposure to docetaxel are excluded from 
the base-case population, as they are typically 
less likely to be fit enough to receive further lines 
of chemotherapy.  This base-case population 
makes up the large majority of patients in the 
TROPIC study (84%) and is the patient 
population that is expected to receive 
cabazitaxel in clinical practice..  
The licence for cabazitaxel is in the post 
docetaxel indication.  
No other subgroups are examined. 
 
 
Special 
considerations 
including 
issues related 
to equity or 
equality 
Guidance will only be issued in 
accordance with the marketing 
authorisation. Where the wording of the 
therapeutic indication does not include 
specific treatment combinations, 
guidance will be issued only in the 
context of the evidence that has 
No additional issues relating to equity or 
equality were identified by Sanofi or the 
commentators to the draft scope. 
It is expected that EoL considerations 
will apply to the population identified in 
standard NHS practice and alternative 
As agreed at the decision-problem meeting, 
NICE will look at the application of EoL criteria 
on a case-by-case basis and that it is 
appropriate to recognise where this applies 
given the new treatment pathway 
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underpinned the marketing authorisation 
granted by the regulator. 
practice pathways. 
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2. The technology 
2.1 Description of the technology 
2.1.1. Brand name, UK approved name, the therapeutic class and a brief 
overview of the mechanism of action. 
 Brand name: Jevtana®  
 Approved name: cabazitaxel 
 Therapeutic class: taxane 
 
Cabazitaxel (XRP6258) (Figure 2) is a semi-synthetic taxane derived from 10-
deacetylbaccatin III, the natural taxane extracted from European Yew tree needles. It has 
been developed for the treatment of prostate cancer because it has shown anti-tumour 
activity in docetaxel-resistant and docetaxel-sensitive cell lines and tumour models in 
preclinical studies.1, 15 
Figure 2. Cabazitaxel: molecular structure 
 
Microtubules play a critical role in cell division, intracellular transport and the development 
and maintenance of cell shape. Cabazitaxel inhibits microtubule disassembly.16 inhibiting 
mitotic and interphase cellular functions, leading to tumour cell cytotoxicity. 
Taxanes represent a well-established class of chemotherapy agents; however, efficacy is 
limited by intrinsic or acquired resistance. Cabazitaxel was selected from over 450 
candidates based on characteristics critical to overcoming taxane resistance.  
In vitro, cabazitaxel stabilized microtubules as effectively as docetaxel but was 10-fold more 
potent than docetaxel in cell lines resistant to taxanes or other chemotherapeutic agents 
such as doxorubicin, vincristine, or vinblastine1 The greater potency of cabazitaxel in 
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docetaxel-resistant tumours is attributed to a stronger suppression of microtubule dynamics, 
faster drug uptake, and better intracellular retention compared to docetaxel.17 
In vivo, cabazitaxel demonstrated excellent antitumor activity in a broad spectrum of 
docetaxel-sensitive tumour xenografts, including a castration-resistant prostate tumor 
xenograft, HID28, where cabazitaxel exhibited greater efficacy than docetaxel. Importantly, 
cabazitaxel was also active against tumours with innate or acquired resistance to docetaxel, 
suggesting therapeutic potential for patients progressing following taxane treatment and 
those with docetaxel-refractory tumours.  
2.2 Marketing authorization /CE marking and Health 
Technology Assessment 
2.2.1. UK marketing authorisation status. 
Marketing authorisation was granted by the European Medicines Agency (EMA) on 17th 
March 2011.3 
2.2.2. Indication 
Cabazitaxel in combination with prednisone or prednisolone is indicated for the treatment of 
patients with metastatic hormone-refractory prostate cancer previously treated with a 
docetaxel-containing regimen.15 
2.2.3. Summary of restrictions or contraindications in the summary of product 
characteristics (SmPC). 
 Hypersensitivity to cabazitaxel, to other taxanes, or to any excipients of the formulation 
including polysorbate 80.  
 Neutrophil counts less than 1,500/mm3. 
 Hepatic impairment (bilirubin ≥1 x ULN, or AST and/or ALT≥1.5 × ULN). 
 Concomitant vaccination with yellow fever vaccine. 
2.2.4. Summary of Product characteristics 
The summary of product characteristics (SmPC) is provided in Appendix 1. 
2.2.5 European Public Assessment Report3 
The European Assessment Report (EPAR) is provided in a separate annex. 
2.2.6. Summary of the main issues discussed by the regulatory authorities. 
Cabazitaxel has a full marketing authorisation, but should be confined to units specialised in 
the administration of cytotoxics and it should only be administered under the supervision of a 
physician experienced in the use of anticancer chemotherapy. Facilities and equipment for 
Company evidence submission template for Cabazitaxel for hormone-relapsed 
metastatic prostate cancer previously treated with a docetaxel-containing regimen 
 Page 29 of 211 
 
the treatment of serious hypersensitivity reactions like hypotension and bronchospasm must 
be available. 
The EMA considered that the principal adverse effects of cabazitaxel observed in the non-
clinical safety studies were consistent with the pharmacological (anti-mitotic) activity of a 
taxoid–type antineoplastic compound and resemble those reported for other taxoid 
anticancer drugs. In view of its therapeutic indication of the treatment of patients with 
mCRPC previously treated with a docetaxel containing regimen there were no major 
objections or other concerns raised about the results from these studies.  
The regulator recognised that the efficacy of cabazitaxel in combination with prednisone or 
prednisolone for the treatment of patients with mCRPC previously treated with a docetaxel 
containing regimen was established in the TROPIC study.  
However uncertainty in the efficacy for patients that had received less than <225 mg/m2 
cumulative dose of docetaxel was highlighted. A sub-group of 59 patients received prior 
cumulative dose of docetaxel <225 mg/m² (29 patients in cabazitaxel arm, 30 patients in 
mitoxantrone arm) and there was no significant difference in overall survival in this group of 
patients (HR (95%CI) 0.96 (0.49-1.86)). This observation may be due to a lower efficacy in 
this subgroup due to different patient or disease characteristics, however the low number of 
patients in this subgroup may also explain the lack of a clear effect. Thus, although there is 
insufficient evidence to conclude that the benefits are lacking in this subgroup, this 
information has been included in the SmPC to help make an informed treatment choice. 
The side effect profile for the < 25mg/m² dose was generally more favourable when 
compared to the ≥25mg/m² dose in the Phase II study submitted as part of the evidence 
package, in patients with taxane and/or anthracycline-resistant metastatic breast cancer 
(ARD6191). The EPAR states that it is unclear whether the <25mg/m² dose would have 
similar activity to the ≥25mg/m² dose but with a more acceptable safety profile. The 
PROSELICA study comparing cabazitaxel at 20 mg/m² and at 25 mg/m² in second line 
mCRPC patients will address this issue and is discussed in Section 4.14. 
The European regulatory submission, as described in the European Public Assessment 
Report (EPAR), concluded that cabazitaxel had a positive risk-benefit profile, with clinically 
meaningful benefits, and no requirement for a special risk-minimisation plan.3 
2.2.7. Date of availability in the UK. 
Cabazitaxel was made commercially available in the UK from 20th May 2011. 
2.2.8. State whether the technology has regulatory approval outside the UK. If 
so, please provide details. 
In June 2010, the US FDA approved cabazitaxel (Jevtana®) for use in combination with 
prednisone or prednisolone for the treatment of patients with mCRPC previously treated with 
a docetaxel-containing regimen. 
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The European Commission granted marketing authorization in all 27 countries of the 
European Union (EU) 17 March 2011. 
Cabazitaxel is approved in more than 85 countries worldwide. 
2.2.9 State whether the technology is subject to any other Health Technology 
Assessment in the UK. If so, give the timescale for completion. 
Summaries of previous UK Health Technology Assessments of cabazitaxel are presented in 
Table 6. 
Table 6. Previous UK Health Technology Assessments of cabazitaxel 
Agency Ref. Indication Status and date 
NICE TA255 
Cabazitaxel for hormone-refractory metastatic prostate 
cancer (mCRPC) previously treated with a docetaxel-
containing regimen 
Not recommended 
May 2012 
SMC Drug ID: 735/11 
Cabazitaxel for the treatment of patients with metastatic 
hormone refractory prostate cancer (mCRPC) previously 
treated with a docetaxel-containing regimen 
Not Recommended 
07/11/2011. 
Resubmission 
planned for Q4 
2015 with PAS. 
AWMSG Ref. No. 775 
Cabazitaxel in combination with prednisone or 
prednisolone for the treatment of patients with hormone 
refractory metastatic prostate cancer  (mCRPC) 
previously treated with a docetaxel-containing regimen 
Excluded due to 
NICE appraisal 
13/10/2011 
NICE: National Institute for Health and Care Excellence; SMC: Scottish Medicines Consortium; AWMSG: 
All Wales Medicines Strategy Group; mCRPC: metastatic hormone refractory prostate cancer 
 
2.3 Administration and costs of the technology 
2.3.1. Costs of the technology being appraised 
Relevant costs are presented in Table 7 overleaf 
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Table 7. Costs of the technology being appraised 
 Cost  Source 
Pharmaceutical 
formulation  
Cabazitaxel 60 mg/1.5 ml concentrate and 
solvent for infusion is supplied as a kit 
consisting of the following:  
 One single vial of cabazitaxel 
concentrate 60 mg/1.5 ml (contains 
60 mg cabazitaxel in 1.5 ml 
polysorbate 80)  
 One single vial of diluent for 
cabazitaxel injection 60 mg/1.5 ml 
(contains approximately 5.7 ml of 
13% (w/w) ethanol in water for 
injection). 
Both items are in a blister pack in one 
carton. 
 
Acquisition cost 
(excluding VAT) * 
£3696 per vial, £61.60 per mg 
The PAS adjusted cost will be Commercial 
in confidence information removed per vial, 
Commercial in confidence information 
removed per mg 
Cabazitaxel is given in combination with 
daily oral prednisolone 10 mg for the 
duration of treatment = £0.01 / mg (Non-
proprietary: 5 mg, 28-tab pack = £1.29) 
Intravenous premedication :  
 Antihistamine (dexchlorpheniramine 5 
mg or diphenhydramine 25 mg or 
equivalent) = £0.45 / mg. (Based on cost 
for chlorphenamine maleate, 10 mg/mL, 
1-mL ampule = £4.47) 
 Corticosteroid (dexamethasone 8 mg or 
equivalent), £0.52 / mg. (Based on cost 
for dexamethasone, 1-mL vial containing 
3.8 mg/mL = £1.99). 
 H2 antagonist (ranitidine or equivalent) = 
£0.01 /mg. (Based on cost for ranitidine, 
25 mg/mL, 2-mL ampule = 54p) 
List prices: 
BNF Sept. 
201518 
Method of administration Intravenous infusion over 60 minutes SmPC15 
Doses  
The recommended dose in the SmPC is 25 
mg/m2 with the option to down-titrate to 20 
mg/m2 if adverse events are experienced.† 
For patients with mild and moderate hepatic 
impairment 20 mg/m2 and 15 mg/m2 doses 
SmPC15 
Company evidence submission template for Cabazitaxel for hormone-relapsed 
metastatic prostate cancer previously treated with a docetaxel-containing regimen 
 Page 32 of 211 
 
 Cost  Source 
are recommended. 
Dosing frequency 
Intravenous infusion every three weeks, and 
prednisolone 10 mg orally given daily (Note: 
prednisone and prednisolone are 
considered to be equivalent; only 
prednisolone is available in the UK). 
SmPC15 
Average length of a 
course of treatment 
In TROPIC (see Section 4.7), the median 
number of cycles received was six. (The 
maximum number of permitted cycles is 
ten).  
In the UK Early Access Programme (EAP) 
(See SECTION 5.4.2), patients also 
received a median of six cycles of 
cabazitaxel. 
De Bono, 
20118 
 
Bahl, 
201512 
Average cost of a course 
of treatment 
Commercial in confidence information 
removed including administration, pre and 
concomitant medications. Based on a 
patient of 1.9m2 surface area). 
Estimated 
from the 
economic 
model  
Anticipated average 
interval between courses 
of treatments 
Only one course of cabazitaxel 
recommended according to the SmPC SmPC15 
Anticipated number of 
repeat courses of 
treatments 
No repeat courses will be given.  
Dose adjustments† See Table 8† SmPC15 
Anticipated care setting Secondary care setting in units specialising in the administration of cytotoxics. SmPC15 
* Indicate whether this acquisition cost is list price or includes an approved Patient Access 
Scheme. When the marketing authorisation or anticipated marketing authorisation recommends 
the intervention in combination with other treatments, the acquisition cost of each intervention 
should be presented. 
†Dose modifications should be made if patients experience the following adverse reactions 
(Grades refer to Common Terminology Criteria for Adverse Events (CTCAE 4.0)): 
Table 8 Dose adjustments* 
Adverse reactions 
 
Dose modification  
Prolonged grade ≥3 neutropenia 
(longer than 1 week) despite 
appropriate treatment including 
G-CSF  
Delay treatment until neutrophil count is >1,500 
cells/mm3, then reduce cabazitaxel dose from 25 
mg/m2 to 20 mg/m2.  
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Adverse reactions 
 
Dose modification  
Febrile neutropenia or 
neutropenic infection  
Delay treatment until improvement or resolution, and 
until neutrophil count is >1,500 cells/mm3, then 
reduce cabazitaxel dose from 25 mg/m2 to 20 mg/m2. 
Grade ≥3 diarrhoea or persisting 
diarrhoea despite appropriate 
treatment, including fluid and 
electrolytes replacement  
Delay treatment until improvement or resolution, 
then reduce cabazitaxel dose from 25 mg/m2 to 20 
mg/m2.  
Grade >2 peripheral neuropathy  Delay treatment until improvement, then reduce cabazitaxel dose from 25 mg/m2 to 20 mg/m2.  
* The treatment should be discontinued if a patient continues to experience any of these reactions at 
20 mg/m2. Taken from the SmPC.15 
2.3.2. Patient Access Scheme  
A simple, confidential discount Patient Access Scheme (PAS) was submitted to the 
Department of Health on 10th of April.  
The list price and details of the proposed scheme are provided in Table 9 below. 
Table 9. Current list price and PAS discount. 
 List price and discount  
Current UK list price(s) for all 
relevant brand names and 
preparations of the product 
Cabazitaxel 60 mg / 1.5 ml concentrate and solvent for 
infusion: £3696 per vial, £61.60 per mg.18 
Proposed discount (if 
appropriate, specify by brand 
name and preparation) 
The Patient Access Scheme will be a simple 
confidential reduction off the list price at the point of 
invoice. 
The PAS adjusted cost will be Commercial in 
confidence information removed per vial, Commercial in 
confidence information removed per mg. 
As this is a simple scheme, Sanofi will not collect any clinical or outcomes data. 
2.3.3. For devices, provide the list price and average selling price. 
No device is associated with cabazitaxel. 
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2.4 Changes in service provision and management 
2.4.1. Additional tests, investigations or particular administration requirements 
for the technology.  
There are no additional tests or investigations needed for selection of patients for treatment. 
However prognostic factors which may prompt clinicians to consider cabazitaxel include: 
suspected hormonal independence, (especially in those patients with a more aggressive 
potential; Gleason ≥ 8), rapid progression to mCRPC with primary ADT and patients who are 
clearly refractory to docetaxel (particularly if progression has occurred during treatment with 
this drug). Prior treatment with ketoconazole and baseline serum levels of adrenal 
androgens may also be taken into account.19 
Cabazitaxel is an intravenously administered chemotherapy drug. As such, cabazitaxel 
requires specialist administration by a qualified physician experienced in the use of anti-
neoplastic medicinal products similar to other intravenous (IV) chemotherapies. Facilities 
and equipment for the treatment of serious hypersensitivity reactions like hypotension and 
bronchospasm must be available. 
2.4.2. Estimated NHS resource use 
Similar costs of administration are incurred by other IV chemotherapies used in the first- and 
second-line treatment of mCRPC. Cabazitaxel, as established standard of care post-
docetaxel, has been used in chemotherapy units to treat mCRPC patients for the last 4 
years and its continued use is not anticipated to add a major resource burden. There are no 
implications for primary care resources. 
Cabazitaxel should be administered under the supervision of a qualified physician 
experienced in the use of anti-neoplastic medicinal products, in a unit with facilities suitable 
for administering IV chemotherapy. The infusion time is 60 minutes and, provided there are 
no AEs, patients can usually be discharged immediately after their infusion. The cost 
estimated for administration of chemotherapy in a day-case setting is estimated as £320 per 
administration according to NHS reference costs.20 
2.4.3. Additional infrastructure requirements for the NHS. 
No additional NHS infrastructure is required beyond that found in existing units specialising 
in the administration of cytotoxics.  
2.4.4. Effect on patient monitoring compared with established clinical practice. 
Cabazitaxel is an established therapy with over 36,500 patients worldwide having received it 
to date [Periodic safety review] and the safety and adverse event profile are well understood. 
The response to the scope provided by Tackle Prostate cancer stated that ‘…After talking 
with patients who have received this treatment, it has been shown to be well tolerated with 
fewer side effects that expected.’ Today clinicians are experienced in monitoring patients 
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requiring interventions during cytotoxic treatment and there are several guidelines which 
have contributed to established clinical practice (Table 13). 
For cabazitaxel, monitoring is required for infusion-related hypersensitivity reactions 
(common with all infusion-administered drugs) and neutropenic complications, which are 
common to the taxanes as a class. There are no other reasons for special monitoring of 
cabazitaxel patients.  
Infusion reactions can lead to temporary interruption or withdrawal of treatment. To mitigate 
the risk and severity of hypersensitivity, a premedication regimen consisting of an 
antihistamine, an H2 antagonist and a corticosteroid is recommended for all patients prior to 
the initiation of the infusion of cabazitaxel.15 Patients should be observed closely for 
hypersensitivity reactions, especially during the first and second infusions.  
Established clinical practice according to EORTC guidelines21 during the administration of 
cytotoxic drugs to minimise the risk of neutropenia and its complications requires monitoring 
of complete blood counts on a weekly basis during cycle 1 and before each treatment cycle 
thereafter. If necessary the dose can be adjusted or secondary prophylaxis with granulocyte-
colony stimulating factors (G-CSF) administered to reduce the risks of neutropenic 
complications. Primary G-CSF prophylaxis is used to reduce the haematological side effects 
in high risk patients (whilst this is variable, around 20 – 25% of patients are managed in this 
way in clinical practice). Lower risk patients are monitored and neutropenia is managed 
quickly and effectively with G-CSF as the need arises. 
2.4.5. Concomitant therapies administered with the technology. 
 Cabazitaxel is given in combination with OD 10 mg of oral prednisolone for the 
duration of treatment. 
 Premedication  is recommended at least 30 minutes prior to each administration of 
cabazitaxel to mitigate the risk and severity of hypersensitivity:  
o antihistamine (dexchlorpheniramine 5 mg or diphenhydramine 25 mg or 
equivalent) 
o corticosteroid (dexamethasone 8 mg or equivalent) 
o H2 antagonist (ranitidine or equivalent) 
 Antiemetic prophylaxis is recommended and can be given orally or intravenously as 
needed. Throughout the treatment, adequate hydration of the patient needs to be 
ensured, in order to prevent complications like renal failure. 
 G-CSF may be given at clinical discretion as primary prophylaxis to patients 
considered being at increased risk of neutropenia, and as secondary prophylaxis to 
prevent recurrent neutropenic complications. 
 It is expected that luteinising hormone-releasing hormone (LHRH) agonists would be 
given in parallel as part of standard care to patients who are not surgically castrated. 
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2.5 Innovation 
Taxanes have formed the bedrock of management of mHRPC, since the pivotal TAX327 trial 
of docetaxel,22 which was the first study to demonstrate a survival benefit in patients 
progressing on androgen-based therapies. The full benefit of docetaxel is still being 
explored, with results from the recent CHAARTED trial demonstrating a 13.6 month OS 
benefit when docetaxel was used earlier, in metastatic, hormone-sensitive disease. This 
reflects the nature of oncology drug development whereby drugs are initially investigated in 
later-stage oncology (for ethical reasons), but frequently show much greater benefits when 
they are used earlier in the treatment pathway.   
One of the key limitations of docetaxel is the development of resistance. Cabazitaxel was 
specifically designed to overcome this resistance and was the first agent to demonstrate a 
significant survival benefit in patients with mCRPC that has progressed on or after a 
docetaxel-containing regimen.   
Late-stage prostate cancer treatment has improved significantly over the last two to three 
years with the introduction of new agents including cabazitaxel and the advanced hormone 
therapies abiraterone and enzalutamide.  
There is clear evidence for cross-resistance between the hormonal agents, and reflecting 
this, the NHS does not allow sequential use of abiraterone and enzalutamide. Emerging 
evidence suggests that some patients, particularly those with aggressive disease and those 
who responded poorly to initial ADT, do not respond well to further hormonal therapy with 
abiraterone and enzalutamide.  
In patients with innate and acquired resistance to hormonal agents, there are few or no 
alternatives and in these patients cabazitaxel is an important innovation to extend survival 
and progression-free survival at the end of life.  
Late-stage prostate cancer is an area of active research and it is likely that our 
understanding of the disease and optimal sequencing of available agents will continue to 
evolve. It is important that UK clinicians and patients have access to all of the best available 
treatments at the right time in order to provide the greatest benefit for UK patients.   
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3. Health condition and position of the technology in the 
treatment pathway 
 
3.1.   Brief overview of metastatic Castration Resistant Prostate 
Cancer mCRPC. 
Prostate cancer can develop when cells in the prostate start to grow in an uncontrolled way. 
Prostate cancer is the most common form of cancer among men in the UK and in England 
there are around 40,000 patients with prostate cancer.23 It is estimated that one patient dies 
every hour from the disease in England.24The main risk factors for prostate cancer are age, 
ethnicity, family history, diet and hormone metabolism.  Prostate cancer mainly affects men 
over 50 years and risk increases with age. The average age for men to be diagnosed with 
prostate cancer is between 70 and 74 years.24Today the prognosis for early stage prostate 
cancer is good but, left untreated, it becomes significantly worse as the disease progresses 
and 5 year survival in patients with metastatic disease is less than 30%.19 
There is considerable variation in prostate cancer behaviour between patients but also 
significant variability in how the disease metastasises as it spreads through an individual 
patient.  During disease progression multiple chromosomal changes occur which explains 
why the response to Prostate Cancer specific drugs is heterogeneous and changes over 
time indicating that a single treatment plan would not be suitable for all patients with Prostate 
Cancer. Disease progression is also quite heterogeneous clinically; including patients who 
 Prostate cancer is a complex and heterogeneous disease 
 Heterogeneity is seen in the variation the cancer’s behaviour between 
patients and also in how the disease metastasises as it spreads through an 
individual patient. 
 Use of the newer hormonal therapies at different stages in disease 
progression has led to the evolution of pathways, characterised by use of 
these agents either pre- or post-docetaxel. 
 The eventual development of the tumour’s resistance to various different 
types of hormonal therapy is now becoming better understood. 
 Second-line chemotherapy is the only active option for many patients in 
those with acquired or innate resistance to hormonal therapies or for some 
patients with more aggressive disease.  
 Multiple treatment options are sought at each stage of the disease to 
address tumour variability, prognosis, and opportunities for sequencing of 
therapies is important. 
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are asymptomatic or mildly symptomatic, to patients with multiple bone and visceral 
metastases, pain and poor functional status.  
mCRPC develops when advanced prostate cancers treated with any form of androgen 
deprivation therapy begin to progress and tumours spread outside of the prostate. The 
mechanisms of progression to castration resistance have been extensively studied and may 
be classified in two main categories: (1) mechanisms allowing AR-positive tumour cells to 
adapt to a low testosterone environment and (2) clonal proliferation of AR-negative and/or 
independent tumour cells, which may be triggered by ADT.25  
The eventual development of resistance of Prostate Cancers to various different types of 
hormonal therapy is now better understood. A key discovery was that ARv7+ve tumours 
typically show limited response to advanced hormonal therapies and therefore exhibit 
resistance. This can be identified as primary or adaptive.  Primary resistant tumours already 
exhibit resistance at the time when they present but in secondary resistance 
unresponsiveness to androgens develop over time as the ARv7+ve tumour cells become 
more dominant when the clones of ARv7-ve tumour cells are eliminated by hormone therapy 
to which they are sensitive. 
These features make prostate cancer a very complex, heterogeneous disease to manage. 
Survival data from clinical trials in mCRPC suggest that many patients now die of treatment 
resistant prostate cancer.  As a result there is a growing awareness of the need for new 
treatments and better use of existing treatments either in terms of timing, sequencing or 
combination therapy or in terms of new mechanisms of action to overcome treatment 
resistance to existing medicines.  
3.2. Effect of mCRPC on patients, carers and society. 
Prostate cancer is usually a slowly progressing disease, which is asymptomatic in the early 
stages. In more advanced disease, a variety of symptoms occur, including frequent and 
difficult urination and in some cases haematuria, pain when ejaculating, testicle pain and 
erectile dysfunction. Metastatic disease is associated with a more extensive and severe 
pattern of symptoms. These are dependent on the location of metastases, and can include 
bone pain, lymphoedema, pain in the lower back, pelvis or upper thighs, and weight loss.26 
Bone metastasis is a common form of metastatic disease in prostate cancer, with studies 
reporting percentages as high as 80%.27-29 Bone metastases often lead to skeletal-related 
events (SREs), including pathological fractures, spinal cord compression, hypercalcaemia 
and severe pain requiring bone surgery, radiation therapy or opioid analgesics. Bone 
metastases and the pain associated with these, contribute substantially to the disease 
burden of patients with metastatic prostate cancer,27 although emerging treatments can help 
to alleviate or delay symptoms. 
In addition to the physical symptoms associated with prostate cancer there is an emotional 
impact of living with prostate cancer on patients, family members and carers. Prostate 
cancer is known to have an impact on quality of life (HRQL) for patients which deteriorates 
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with progression to metastatic disease.30 Depression, anxiety, stress and psychosocial 
factors all affect the patient with prostate cancer.31, 32 A higher rate of depression and anxiety 
in patients with a prostate cancer diagnosis has been described33 and the prevalence of 
psychological distress among cancer patients is higher and associated with advances in 
disease progress and poor prognosis.34, 35 
3.3. Clinical pathway of care contextualising the established use of 
cabazitaxel.  
Treatment for prostate cancer is guided by cancer stage and grade (along with patient 
performance status and suitability for treatment). Once the disease has become refractory 
and there is biochemical evidence of hormone-relapsed disease, treatment options should 
be discussed by the urological cancer MultiDisciplinary Team (MDT) with a view to seeking 
an oncologist and/or specialist palliative care opinion, as appropriate.  
Currently NICE36 recommends first line chemotherapy with docetaxel as a treatment option 
for patients with hormone-refractory metastatic prostate cancer only if their Karnofsky 
performance-status score is 60% or more. Repeat cycles of treatment with docetaxel are not 
recommended if the disease recurs after completion of the planned course of chemotherapy. 
As shown in Figure 3 there are two treatment pathways relevant to NHS practice (described 
below) which are defined by the use of abiraterone or enzalutamide in either the pre- or post-
docetaxel setting where both are licensed. The position of cabazitaxel in the context of 
current treatment pathways is also shown in Figure 3. 
NHS standard practice  
In standard NHS practice, comprising more than two thirds of patients in England (68%)5 
abiraterone and enzalutamide are currently established care and are funded by the CDF in 
the pre-docetaxel setting. Abiraterone and enzalutamide in the pre-chemotherapy setting are 
both currently under NICE review in this setting.The sequential use of these agents is 
outside NICE guidance6, 7 and is explicitly excluded from Cancer Drugs Fund (CDF) funding 
arrangements. Those patients who subsequently progress following docetaxel are therefore 
not eligible for further treatment with abiraterone or enzalutamide. In this case cabazitaxel or 
best supportive care are currently the only options.  
Alternative practice 
In the alternative practice pathway, in which abiraterone or enzalutamide have not been 
used before docetaxel, patients have more options from which a suitable agent might be 
selected to meet their individual characteristics and requirements. For those patients whose 
disease has progressed following docetaxel-containing chemotherapy, either the androgen 
receptor signalling inhibitor, enzalutamide or the androgen biosynthesis inhibitor abiraterone 
in combination with prednisone or prednisolone (TA316 and TA259 respectively)6, 7 are 
recommended by NICE within their marketing authorisations as options for treating mCRPC 
in adults. However, given the greater understanding of the mechanisms of resistance to 
hormonal therapy there are patients for whom cabazitaxel may be the most appropriate 
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treatment option, particulary those who progress during or rapidly (less than 3 months) after 
docetaxel exposure.  
 
Figure 3. mCRPC: current disease management and existing place in therapy for cabazitaxel. 
 
* Radium-223 is licenced for patients with two or more bone metastases but no visceral metastases 
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3.4. Life expectancy of people with mCRPC in England including 
the number of people with mCRPC for which cabazitaxel is being 
appraised.  
Life expectancy 
Despite newer agents becoming available, the life expectancy of patients with prostate 
cancer remains limited with 5 year survival rates of 30% in mCRPC19  A recent literature 
review examined, life expectancy with castrate resistant prostate cancer (CRPC)13. In the 11 
treatment groups identified that were treated with first-line docetaxel, median OS was 19 
months (IQR: 17–20). In the post docetaxel setting survival is shorter. For example in the 
four main RCTs with results in the post-docetaxel setting the observed median OS for 
patients in the control arms were: TROPIC, 12.7 months, COU-AA-301 (abiraterone): 11.2 
months, AFFIRM (enzalutamide): 13.6 months and ALSYMPCA (Radium-223): 11.3 months.  
These results suggest that typical life expectancy of patients suitable for cabazitaxel is 
considerably less than 24 months regardless of previous therapeutic interventions. 
Eligible patient population 
Table 10 provides overall estimates for the number of patients eligible to receive second-line 
chemotherapy. 
Table 10. Calculation of second line chemotherapy eligible patients in England 
Patients eligible for second line chemotherapy % N 
Patients diagnosed with prostate cancer - England 2015 
(inflated from 2011 assuming 0.75% per year)  40,980 
Of these, castration-resistant metastatic prostate cancer 
patients 15% 6,147 
Of these, patients receiving  first-line treatment with 
docetaxel 50%* 3,073 
Of these, patients eligible to receive second-line 
chemotherapy 55%* 1,690 
*sanofi-aventis. Data on file: Market research: Usual 2nd line chemo options after docetaxel 
are Mitoxantrone, Stilbestrol or BSC – with minor variations from wave 1, 2011 
There were 40,372 diagnosed cases of prostate cancer in England in 2013 according to the 
latest figures available from the Office for National statistic, this accounted for 26.9% of total 
male cancer registrations.23 
Figures from Cancer Research UK suggest that prostate cancer incidence rates have 
remained relatively static over the period 2003 to 201124 and so applying a conservative 
assumption that the rate rises by the observed annual rate of increase of 0.75% which is the 
average annual population increase over the last decade the number of patients diagnosed 
with Prostate cancer in England for 2015 is estimated to be 40,980. 
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There are very few estimates for the prevalence of mCRPC in patients with prostate cancer. 
The costing template for TA259: abiraterone estimates 19.5%. However in the systematic 
literature review by Kirby five studies were identified which examined the prevalence of 
mCRPC in patients with prostate cancer.37 Together, the data indicate that 10–20% of 
prostate cancer patients develop mCRPC within approximately 5 years of follow-up. Taking 
the mid-point of this range as 15% the number of mCRPC patients may be estimated as 
6,147. 
In support of this, data from the ONS states that there were 10,153 prostate cancer deaths in 
England and Wales in 2014.23 Given that the majority but not all deaths from prostate cancer 
are likely to occur in the mCRPC setting, the figure of 6,147 mCRPC appears valid. 
Market research shows that 50% of patients treated by oncologists are eligible to receive 
docetaxel first line.38 Of these patients, 55% are fit (PS 01) to receive further chemotherapy 
following docetaxel.38 Thus, there are estimated to be around 1,690 mCRPC patients eligible 
for second-line chemotherapy in England.  
With reference to the pathways discussed in Section 3.3 above 68%5 of patients receive 
abiraterone or enzalutamide prior to docetaxel in the UK and are therefore not eligible for 
treatment with further advanced hormonal therapies. Cabazitaxel is the only active 
alternative for these patients. This corresponds to 1150 patients in standard NHS practice. 
Of course, in discussion with their clinicians a proportion of patients may elect not to receive 
further treatment.14 
3.5 Details of NICE guidance, pathways and commissioning guides 
related to mCRPC for which cabazitaxel is being used.  
There are several published NICE guidance documents relating to the treatment of 
hormone-refractory prostate cancer (HRPC) and mCRPC. Recommendations from these 
appraisals are provided overleaf. (Table 11). 
The 2014 NICE Guideline CG175 entitled ‘Prostate cancer diagnosis and treatment’ updates 
the 2008 guideline CG58.36 The recommendations for the treatment of hormone-relapsed 
metastatic prostate cancer are contained in section 1.5.10 to 1.5.16 of CG175 and are taken 
entirely from the 2008 guideline. In addition bone targeted therapies such as spinal MRI, 
bisphosphonates and strontium-89 for pain relief may be considered. 
The advanced hormone agents received positive advice (TA259 and TA316) in the post-
docetaxel setting after the publication of the guidelines. Marketing authorisations in the pre-
docetaxel setting have also been granted since publication and technology appraisals are 
ongoing for this indication. 
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Table 11. Related NICE Health Technology Assessments 
Ref. Indication Recommendation Subgroups addressed 
ID683 
Enzalutamide for metastatic hormone-
relapsed prostate cancer when 
chemotherapy is not yet clinically 
indicated 
Advice in development (as of submission date for this appraisal). 
Advice expected: TBC. ACD published June 2015: not 
recommended). 
Draft: Enzalutamide is not recommended for treating metastatic 
hormone-relapsed prostate cancer in people who have no or mild 
symptoms after androgen deprivation therapy has failed, and 
when chemotherapy is not yet clinically indicated. The Committee 
concluded that with its preferred assumptions the resulting 
incremental cost-effectiveness ratio (ICER) for enzalutamide 
compared with best supportive care was above £40,000 per 
quality-adjusted life years (QALY) gained. 
No subgroups were considered 
relevant 
ID576  
Radium-223 dichloride for treating 
metastatic hormone relapsed prostate 
cancer with bone metastases 
Advice in development (as of submission date for this appraisal. 
Advice expected: TBC. ACD published May 2015: recommended). 
Draft: Radium-223 dichloride is recommended as an option for 
treating adults with hormone-relapsed prostate cancer, 
symptomatic bone metastases and no known visceral metastases, 
only if they have had treatment with docetaxel and the company 
provides radium-223 dichloride with the discount agreed in the 
Patient Access Scheme. 
No subgroups were considered 
relevant 
ID503 
Abiraterone for treating metastatic 
hormone-relapsed prostate cancer not 
previously treated with chemotherapy 
Advice in development (as of submission date for this appraisal. 
Advice expected: TBC. FAD published August 2014: Not 
recommended. 
The Committee concluded that current mean life expectancy in 
the population considered is unlikely to be less than 24 months, 
Predefined subgroups based on 
baseline ECOG (0 or 1), BPI (0–
1 or 2–3), bone metastasis only 
at study entry, age and baseline 
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Ref. Indication Recommendation Subgroups addressed 
and abiraterone at this stage in the treatment pathway did not 
meet the end-of-life criterion for short life expectancy. Therefore 
the ICER was not in the range normally considered to be cost-
effective. 
prostate-specific antigen. 
TA332 
Sipuleucel-T for treating asymptomatic 
or minimally symptomatic metastatic 
hormone relapsed prostate cancer 
Not recommended, February 2015: 
This appraisal has been withdrawn. This is because the marketing 
authorisation for sipuleucel-T was withdrawn on 19 May 2015 
 
TA3167 
Enzalutamide for metastatic hormone-
relapsed prostate cancer previously 
treated with a docetaxel-containing 
regimen’ 
Recommended July 2012: 
Enzalutamide is recommended within its marketing authorisation 
as an option for treating hormone-relapsed metastatic prostate 
cancer in adults whose disease has progressed during or after 
docetaxel-containing chemotherapy, only if the manufacturer 
provides enzalutamide with the discount agreed in the Patient 
Access Scheme. 
Patients who had received 1 
course of cytotoxic 
chemotherapy and in a separate 
analysis, patients who had 
received 2 or more courses of 
cytotoxic chemotherapy 
TA2596 
Abiraterone for castration-resistant 
metastatic prostate cancer previously 
treated with a docetaxel-containing 
regimen’ 
Recommended June 2012: 
Abiraterone in combination with prednisone or prednisolone is 
recommended as an option for the treatment of castration-
resistant metastatic prostate cancer in adults, only if: 
 their disease has progressed on or after one docetaxel-
containing chemotherapy regimen, and 
 the manufacturer provides abiraterone with the discount 
agreed in the Patient Access Scheme. 
A subgroup of the COU-AA-301 
trial who had received one prior 
chemotherapy 
TA2554 
Cabazitaxel for hormone-refractory 
metastatic prostate cancer previously 
treated with a docetaxel-containing 
regimen  
 
Not recommended 2012. The Committee agreed that cabazitaxel 
was an effective, life-extending treatment but the Committee 
concluded that the additional weight that would need to be 
assigned to the QALY benefits would be too great to justify it as 
an appropriate use of limited NHS resources 
Patients in TROPIC who 
received at least 225 mg/m2 of 
docetaxel and had an ECOG 
performance score of 0 or 1. 
TA101 Docetaxel for the treatment of hormone-refractory metastatic prostate cancer’ 
Recommended with the agreed confidential discount, June 2006 
 Docetaxel is recommended, within its licensed indications, as 
a treatment option for men with hormone-refractory metastatic 
None 
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Ref. Indication Recommendation Subgroups addressed 
prostate cancer only if their Karnofsky performance-status 
score is 60% or more.  
 It is recommended that treatment with docetaxel should be 
stopped:  
- at the completion of planned treatment of up to 10 cycles, 
or  
- if severe adverse events occur, or  
- in the presence of progression of disease as evidenced 
by clinical or l laboratory criteria, or by imaging studies. 
 Repeat cycles of treatment with docetaxel are not 
recommended if the disease recurs after completion of the 
planned course of chemotherapy. 
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3.6 Other clinical guidelines and national policies. 
In the absence of current NICE guidance in the pre-docetaxel setting, hormonal therapies 
are funded through the CDF. However, there is recognition that cross-resistance between 
the advanced hormone therapies is likely and funding should be limited to a single course of 
which ever agent is deemed appropriate for the patient. Cabazitaxel is positioned for use 
according to its licence in the post-docetaxel setting. Table 12.  
Table 12.  National CDF listing 
Ref. Product Indication CDF criteria for NHS use 
CABA1
_V3.0 
Cabazitaxel Castrate-
resistant 
Metastatic 
Prostate 
Cancer 
 
1. Application made by and first cycle of systemic anti-
cancer therapy to be prescribed by a consultant specialist 
specifically trained and accredited in the use of systemic 
anti-cancer therapy 
2. Castrate-resistant Metastatic Prostate Cancer 
3. Previous treatment with docetaxel based regimens 
ENZ_V
1.1 
Enzalutamide Chemother
apy naïve 
castrate-
resistant 
Metastatic 
Prostate 
Cancer 
1. Application made by and first cycle of systemic anti-
cancer therapy to be prescribed by a consultant specialist 
specifically trained and accredited in the use of systemic 
anti-cancer therapy 
2. 
a. Histologically/ cytologically confirmed adenocarcimoma 
of the prostate 
OR 
b. Clinical suspicion of prostate cancer is high due to high 
PSA value (>100ng/ml) and evidence of bone metastases 
(identified by a positive isotope bone scan or sclerotic 
metastases on plain radiographs) 
3. Documented metastatic disease 
4. Progressive disease despite the continued use of LHRH 
analogues or a previous bilateral orchidectomy 
5. No previous chemotherapy for metastatic disease 
6. Performance status 0 or 1 
7. Asymptomatic (0 or 1) or mildly symptomatic (2-3) as 
scored on the Brief Pain Inventory Short Form question 3 
8. No previous treatment with abiraterone unless 
abiraterone has had to be stopped within 3 months of its 
start solely as a consequence of dose-limiting toxicity and 
in the clear absence of disease progression 
ABI1_V
2.1 
Abiraterone Metastatic 
castration 
resistant 
prostate 
cancer 
1. Application made by and first cycle of systemic anti-
cancer therapy to be prescribed by a consultant specialist 
specifically trained and accredited in the use of systemic 
anti-cancer therapy 
2. 
a. Histologically/ cytologically confirmed adenocarcimoma 
of the prostate 
OR 
b. Clinical suspicion of prostate cancer is high due to high 
PSA value (>100ng/ml) and evidence of bone metastases 
(identified by a positive isotope bone scan or sclerotic 
metastases on plain radiographs) 
3. Documented metastatic disease 
4. Either PSA progression according to Prostate Cancer 
Clinical Trials Working Party Group 2 criteria or 
radiographic progression 
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Ref. Product Indication CDF criteria for NHS use 
5. Continuing androgen deprivation 
6. Performance status 0 or 1 
7. Asymptomatic (0 or 1) or mildly symptomatic (2-3) as 
scored on the Brief Pain Inventory Short Form question 3 
8. No visceral disease 
9. No previous chemotherapy 
10. No previous treatment with enzalutamide unless 
enzalutamide has had to be stopped within 3 months of its 
start solely as a consequence of dose-limiting toxicity and 
in the clear absence of disease progression 
NHS commissioning documents, SSC1438 and SSC1439 for abiraterone and enzalutamide 
respectively, recognise that abiraterone post enzalutamide (or vice versa) is not to be funded 
in England unless the alternative was stopped solely because of dose-limiting toxicities 
within 3 months and there is clear absence of disease progression. In line with this the 
Cancer Drugs Fund has stated that the sequential use of these agents will not be funded in 
the pre-chemotherapy setting with the same caveat as above. 
Despite the relatively recent granting of the marketing authorisations for the advanced 
hormonal agents before docetaxel there is a body of growing evidence for effectiveness in 
this indication beyond the pivotal clinical trials (COU-AA-30239 and PREVAIL40). This is 
reflected in the guidelines under development including NICE appraisals. This is the 
predominant positioning for these agents in UK clinical practice with 68% of patients5 
receiving these agents through the CDF ahead of docetaxel. 
 
Key European guidelines are summarised in Table 13 overleaf. 
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Table 13. Key European guidelines for the treatment of mCRPC 
Date Title Recommendation 
American Society of Clinical Oncology41 
2014 Systemic Therapy in 
Men with Metastatic 
Castration-Resistant 
Prostate Cancer 
(CRPC): American 
Society of Clinical 
Oncology and 
Cancer Care Ontario 
Clinical Practice 
Guideline  
 Continue androgen deprivation (pharmaceutical or 
surgical) indefinitely. Abiraterone acetate/prednisone, 
enzalutamide, or radium-223 should be offered; 
docetaxel/prednisone should also be offered 
accompanied by discussion of toxicity risk. Sipuleucel-
T may be offered to asymptomatic/minimally 
symptomatic men.  
 For men who have progressed on docetaxel, 
cabazitaxel may be offered, accompanied by 
discussion of toxicity risk. Mitoxantrone may be 
offered, accompanied by discussion of limited clinical 
benefit and toxicity risk 
There is insufficient evidence evaluating optimal 
sequences or combinations of therapies.  Palliative care 
should be offered to all patients 
European Society of Medical Oncology42 
2015 Prostate cancer: 
ESMO clinical 
recommendations for 
diagnosis, treatment 
and follow-up 
Recommendations (Level of evidence, grade of 
recommendation) 
 
Chemotherapy naive 
 Abiraterone or enzalutamide are recommended for 
asymptomatic/mildly symptomatic men with 
chemotherapy-naïvemetastatic CRPC [I, A]. 
 Radium-223 is recommended for men with bone-
predominant, symptomatic metastatic CRPC without 
visceral metastases [I, A]. 
 Docetaxel is recommended for men with metastatic 
CRPC [I, A]. 
 Sipuleucel-T is an option in asymptomatic/mildly 
symptomatic patients with chemotherapy-naïve 
metastatic CRPC [II, B]. 
 
The optimal sequence or combination of these agents 
(abiraterone,enzalutamide, radium-223, docetaxel and 
Sipuleucel-T) is unknown. In practice, sequencing 
decisions will be made in the light of the distribution, 
extent and pace of disease, co-morbidities, patient 
preferences and drug availability. 
 
Post docetaxel 
 In patients with metastatic CRPC in the post-docetaxel 
setting, abiraterone, enzalutamide, cabazitaxel and 
radium-223 (in those without visceral disease) are 
recommended options (1, A). 
National Comprehensive Cancer Network  
2015 NCCN clinical 
practice guidelines in 
oncology on prostate 
Docetaxel in combination with prednisone is 
recommended as first-line chemotherapy for patients with 
mCRPC 
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cancer, v 1.2015 No consensus exists for the best additional therapy for 
mCRPC patients after docetaxel failure. Options include 
abiraterone, enzalutamide, radium-223 for bone-
predominant disease without visceral metastases, 
cabazitaxel with prednisolone, spiuleucel-T if 
asymptomatic or minimally symptomatic and without 
visceral or liver metastases, clinical trial, docetaxel 
challenge, alternative chemotherapy (mitoxantrone) and 
secondary ADT. All patients should receive best 
supportive care. 
European Association of Urology21  
2015 EAU guidelines on 
prostate cancer 
Recommendations (Level of evidence, grade of 
recommendation) 
 Patients with mCRPC should be counselled, managed 
and treated by a multidisciplinary team. (3, A) 
 In non-metastatic CRPC, cytotoxic therapy should only 
be used in a clinical trial setting. (3, B) 
 Prior to treatment, the potential benefits of second-line 
therapy and expected side effects should be 
discussed with the patient. (N/A, C) 
 In patients with metastatic CRPC who are candidates 
for salvage cytotoxic therapy, docetaxel at 75 mg/m2 
every 3 weeks has shown a significant survival benefit. 
(1a, A) 
 Docetaxel chemotherapy improves HRQL and 
provides pain relief for men with symptomatic bone 
metastases due to mCRPC. (1a, A) 
 In patients with relapse following salvage docetaxel  
chemotherapy, cabazitaxel, abiraterone and 
enzalutamide are regarded as first-choice options for 
second-line treatment in mCRPC. (1a, A) 
 In men with mCRPC with symptomatic bone 
metastases, who are ineligible for or progressing after 
docetaxel, treatment with Ra 223 (alpharadin) has 
shown a survival benefit. (1b, A) 
Scottish Intercollegiate Guidelines Network (SIGN) 
None identified 
 
The guidelines and associated literature consistently state that patients require options after 
progression on docetaxel and that there can be no single approach to treatment.  
The primary literature is beginning to address the question of patient sub-groups who may 
benefit the most from the different available therapeutic options and biomarkers to predict 
response, but this information remains dispersed and yet to be synthesised into guidelines. 
For example a recent review by Fernandez19 on identifying potential cabazitaxel patients 
addresses patient factors and Crawford reviews on predictors of response / relevant 
biomarkers.43 These may include ECOG-PS, extent of metastases, duration of previous 
hormonal therapy, pain, rising PSA levels and time since last docetaxel dose. The 
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sequencing of advanced hormonal agents has been summarised in Section 3.3 and is 
discussed in more detail in Section 4.11.11. 
3.7 Describe any issues relating to current clinical practice, 
including any variations or uncertainty about established practice. 
There are a number of issues relating to current clinical practice and the availability of new 
medicines which, taken together with new discoveries about the cellular mechanisms and 
natural history of prostate cancer which signals change in thinking about the management of 
prostate cancer in general and metastatic castrate resistant prostate cancer (mCRCP) in 
particular.   
Epidemiology and change in life expectancy.   
Historically prostate cancer has been thought of as a hormone sensitive disease which 
patients die with rather than die of.  However, when this concept was first suggested in 
199744 life expectancy of men in the UK was 74 years whereas the average age at death for 
patients with prostate cancer was 77 years. Now according to the UK’s OPCS the average 
age at death for men in the UK is 85 years. But the age at diagnosis of prostate cancer has 
probably not changed since the last century or has got earlier due to the success of 
screening and disease awareness programmes.  Survival data from clinical trials in mCRCP 
suggest that many men now die of treatment resistant prostate cancer.  As a result there is a 
growing awareness of the need for new treatments and better use of existing treatments 
either in terms of timing, sequencing or combination therapy or in terms of new mechanisms 
of action to overcome treatment resistance to existing medicines.  
Drug, tumour and patient specific issues.   
Prostate cancer is a heterogeneous disease. Some patients have more indolent disease and 
some have highly aggressive disease, the latter group being overrepresented in the mortality 
data. These patients also show variation in sensitivity to hormone therapy and also the 
speed at which hormone resistant disease becomes the predominant phenotype within the 
cancer. Hence as the disease progresses in a given patient the pattern of drug sensitivity 
and drug resistance changes 45  Such variations require different treatments and clinical 
approaches. 
To demonstrate this oncologists in the UK are prescribing 13 drugs for prostate cancer but 
while they have 11 options which manipulate the androgen environment of prostate cancers 
they have only 2 licensed therapies which have cytotoxic modes of action (docetaxel and 
cabazitaxel) of which only one of (docetaxel) is currently approved by NICE and available for 
use in NHS England. Mitoxantrone has been used off-label in this setting but has been 
largely replaced. 
3.8 Equity and equality 
The risk for certain groups of people in the UK is higher than others. Prostate cancer is most 
prevalent in black men. A recent study estimating the lifetime risk over the period 2008  - 
2010 for a man being diagnosed with prostate cancer in the UK by major ethnic group 
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suggests that approximately 1 in 4 (29.3%; 23.5–37.2%) black men will get prostate cancer 
at some point in their lives compared with approximately1 in 8 white men (13.3 %; 13.2–
15.0%) 46, 47 The lifetime risk for Asian men was lower at approximately 1 in 13 (7.9%; 6.3 – 
10.5%). Lifetime risk of dying from prostate cancer was estimated at 1 in 12; (8.7%; 7.6 - 
10.6%) for black men, 1 in 24 (4.2%; 4.2 - 4.7%) for white men and 1 in 44 (2.3%; 1.9 - 
3.0%,) for Asian men. This suggests that once diagnosed the risk of dying is about one third 
for all ethnicities but that proportionally more black men will die of the disease. 
In the last few years attempts have been made by several charities and patient interest 
groups to raise the awareness of prostate cancer in the general and ethnic minority 
populations. The aim of these disease awareness programmes is to encourage men to 
present for screening tests so that early diagnosis can occur with the hope of improving 
treatment outcomes. 
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4.  Clinical effectiveness 
 The clinical effectiveness of cabazitaxel was established in the pivotal 
TROPIC study  
o Mean OS: 18.6 months (95%CIXXXX) for cabazitaxel and 14.5 months 
(95% Ci XXXX) for mitoxantrone. 
 Incremental OS is consistently greater than 3.5 months irrespective of the 
parameterisation used for curve fitting (3.6 to 8.1 months). 
 The Early Access Programme in the UK demonstrated that Health Related 
Quality of Life was maintained and even slightly improved whilst taking 
cabazitaxel. 
 The safety profile of cabazitaxel has been shown to be more favourable in 
clinical practice than in the trial setting and this may be due to improvements 
in the early identification and management of adverse events.  
 Network meta-analysis to compare outcomes for cabazitaxel with abiraterone 
and enzalutamide is challenging due to differences in patient characteristics, 
the PFS endpoint in the studies and consequent stopping rules along with the 
necessary assumption of equivalent efficacy for the control arms. 
 Despite these issues overall survival is shown to be similar for cabazitaxel, 
abiraterone and enzalutamide 
 Data from the use of cabazitaxel in the real world shows that efficacy is 
maintained in whatever sequence with the advanced hormonal agents. 
 
4.1 Identification and selection of relevant studies 
The following section describes the searches carried out for the original submission 
TA255. This is followed by a description of the updated search in Section 4.1.1 – 5. 
Three searches were developed for the submission which informed TA255 for cabazitaxel in 
2011.4  
 The objective of the first search was to identify all studies of cabazitaxel versus any 
comparator, to identify the complete evidence base for cabazitaxel.  
 The objective of the second search was to identify all randomised controlled trials 
(RCTs) in second-line metastatic hormone-resistant prostate cancer (mCRPC) 
(patients progressed after first-line docetaxel). This was done to identify any 
additional RCT evidence for comparators within the NICE scope that were not picked 
up by the first search (which would only pick up head-to-head evidence versus 
cabazitaxel).  
 The clinical effectiveness of cabazitaxel was established in the pivotal TROPIC 
study  
 Mean OS: 18.6 months for cabazitaxel and 14.5 months for mitoxantrone. 
 Estimated mean incremental OS is consistently greater than 3.5 months 
irrespective of the parameterisation used for extrapolation (3.6 to 8.1 months). 
 The Early Access Programme in the UK demonstrated that Health Related 
Quality of Life was maintained and even slightly improved whilst taking 
cabazitaxel. 
 The safety profile of cabazitaxel has been shown to be more favourable in 
clinical practice than in the trial setting and this may be due to improvements in 
the early identification and management of adverse events.  
 Network meta-analysis to compare outcomes for cabazitaxel with abiraterone 
and enzalutamide is challenging due to differences in patient characteristics, 
the PFS endpoint in the studies and consequent stopping rules along with the 
necessary assumption of equivalent efficacy for the control arms. 
 Despite these issues overall survival is shown to be similar for cabazitaxel, 
abiraterone and enzalutamide 
 Data from the real world shows that efficacy is maintained in whatever 
sequence cabazitaxel in used with the advanced hormonal agents. 
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 The objective of the third search was to identify all non-randomised studies in 
second-line mCRPC (post-docetaxel). This was done to identify any non-randomised 
evidence for cabazitaxel or comparators within the NICE scope that could potentially 
be relevant to the decision problem. 
These searches were carried out in MEDLINE, MEDLINE In-Process, EMBASE and the 
Cochrane Library for the period January 1st 2000 to December 31st 2010. A full description of 
the strategy and results are provided in Appendix 3 (searches 1 and 2) and Appendix 4 
(Search 3). 
In summary the three literature reviews identified the following number of studies: 
 The systematic review of studies of cabazitaxel identified one RCT sponsored by 
Sanofi-Aventis which met the criteria for inclusion. This was the TROPIC trial 
described in four publications.48-51  
 The broader systematic review of all RCTs in second-line mCRPC identified seven 
trials published in 18 publications and as expected one of which was the TROPIC 
study. These studies are summarised in Table 14 overleaf. 
 The review of non-randomised studies identified 40 studies published in 61 
publications. These studies are described in Appendix 4. 
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Table 14. RCTs identified in the original literature review carried out for TA255 in second-line mCRPC (post-docetaxel). 
Trial no. 
(acronym) 
Intervention Comparator Population Primary study ref Study conclusion 
EFC6193 
(TROPIC) 
(NCT0041
7079) 
Cabazitaxel plus 
prednisone or 
prednisolone 
Mitoxantrone 
plus prednisone 
or prednisolone 
Patients with mCRPC and 
disease progression during or 
after treatment with a regimen 
containing docetaxel 
de Bono 20108 Cabazitaxel provided significantly improved 
overall survival versus mitoxantrone (median 
improvement15.1 vs. 12.7 (HR 0.72: 95% CI 
0.61 - 0.84) 
COU-AA-
301 
Abiraterone 
acetate plus 
prednisone 
Prednisone Patients with mCRPC 
progressed after docetaxel 
de Bono 201152 Abiraterone produced a significant 
improvement in OS and PFS in comparison 
with prednisone alone 
The 
SPARC 
trial 
Satraplatin + 
prednisone 
Prednisone Patients with mCRPC 
progressed after docetaxel 
Sternberg 200953, 
Witjes 2009,54 
Sartor 2008,55  
Satraplatin did not improve OS, but did 
improve PFS, in comparison with prednisone  
Saad 2009 Docetaxel + 
prednisone + 
custirsen 
Mitoxantrone + 
prednisone + 
custirsen 
Patients with mCRPC 
progressed after docetaxel 
Saad 2008,56 Saad 
201157 
No statistical comparisons were reported; the 
authors reported both regimens were well 
tolerated and associated with better-than-
expected survival 
De Bono 
2010 
CNTO 328 + 
mitoxantrone 
Mitoxantrone Patients with mCRPC 
progressed after docetaxel 
De Bono 201058 CNTO 328 plus mitoxantrone did not improve 
OS, and enrolment was terminated after an 
interim analysis 
Fleming 
2010 
Cetuximab + 
mitoxantrone + 
prednisone 
Mitoxantrone + 
prednisone 
Patients with mCRPC 
progressed after docetaxel 
Fleming 201059 Cetuximab plus mitoxantrone did not improve 
survival compared with mitoxantone alone and 
is not recommended for further study 
Rosenberg 
2007 
Ixabepilone Mitoxantrone + 
prednisone 
Patients with mCRPC 
progressed after docetaxel 
Rosenberg 200760 Ixabepilone and mitoxantrone plus prednisone 
showed similar modest activity in docetaxel-
refractory mCRPC 
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TROPIC8 and COU-AA-30111 are pertinent to the decision problem and as outlined below 
these studies were also identified in the updated literature search. Mitoxantrone was 
identified in the last four entries in Table 14, but as direct head-to-head evidence exists from 
TROPIC it is not necessary to include these small studies in a network for comparative 
purposes. The other chemotherapies for which RCT data were available in 2010 include 
satraplatin, which failed to demonstrate an OS benefit, docetaxel in combination with 
curtirsen and ixabepilone. Hence the final five studies presented in Table 14 are not 
discussed further because they do not provide data relevant to the decision problem. 
A new search was carried out to identify efficacy and safety data from relevant randomized, 
controlled clinical trials of cabazitaxel and its comparators in patients with metastatic 
hormone-refractory prostate cancer (mCRPC) or metastatic castration-resistant prostate 
cancer (mCRPC) previously treated with docetaxel. In particular, this aimed to identify any 
evidence that may exist for comparators that have not been directly compared with 
cabazitaxel. This search is described in the following sections (4.1.2 to 4.2.2). 
The update to the search to identify non-randomised evidence is presented in Section 4.11. 
Sanofi internal projects were also examined for relevant information.  
4.1.1. Search strategy developed to identify relevant studies for cabazitaxel.  
The following sections describe the search carried out to update the original systematic 
literature review described above. 
In order to identify additional studies beyond those presented in Table 14 reporting data on 
the clinical effectiveness and safety of current interventions for patients with mCRPC or 
mCRPC previously treated with docetaxel, a systematic literature review covering the period 
from January 2010 to February 2015 was performed. The review was an adapted update of 
the systematic review conducted in 2010 and used similar search terms and sources. A full 
list of the search terms is provided in Appendix 4. 
4.1.2 Description of the search strategies used to retrieve relevant clinical 
data.  
A range of databases indexing published research were searched for studies about the 
clinical effectiveness and safety of cabazitaxel for people with mCRPC (defined as this or as 
metastatic castration-resistant prostate cancer [mCRPC]) who have progressed following 
treatment with docetaxel. The databases searched were Embase, MEDLINE (including 
MEDLINE In-Process) and the Cochrane Library in line with NICE methodological 
guidelines. Although the electronic databases contain information from a number of relevant 
conferences, these searches were supplemented by an electronic review of abstracts from 
several congresses, including: 
 American Society of Clinical Oncology (ASCO) 
 ASCO-Genitourinary (ASCO-GU) 
 European Society for Medical Oncology (ESMO) 
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 American Urological Association (AUA) 
 American Association for Cancer Research (AACR) 
 European Association of Urology (EAU) 
 Société Internationale d'Urologie (SIU) 
 
English and non-English language studies were included and full details of the search 
strategies, databases and resources searched are provided in Appendix 4. 
In order to be included in the systematic review, studies had to meet the inclusion criteria 
detailed in Section 4.1.3; Table 15. Similarly the exclusion criteria checklist is provided in  
Table 16. This process was fully compliant with the 2009 Preferred Reporting Items for 
Systematic reviews and Meta-Analyses (PRISMA) guidelines for the reporting of systematic 
reviews and meta-analyses.61 
4.1.3 Inclusion and exclusion selection criteria, language restrictions and the 
study selection process.  
The inclusion and exclusion criteria along with justifications are presented in Table 15 and 
Table 16 respectively. 
Table 15. Inclusion criteria (PICOS framework) used in search strategies 
PICOS Description  Rationale 
Population  mCRPC/mCRPC patients 
 Age: Adults (≥18 years) 
 Race: Any 
 Line of therapy: Second-line or later 
 Prior therapy: Previously treated 
with docetaxel-based regimen 
 The patient population has been 
restricted to match the stated 
decision problem for the treatment 
of mCRPC/mCRPC in patients who 
have been treated with docetaxel in 
any previous regimen 
 Because prostate cancer is a 
disease affecting older adult men, 
studies including children or 
adolescents were excluded 
Interventions The following treatments for 
mCRPC/mCRPC used in the second 
line or later: 
 Jevtana (cabazitaxel) 
 Zytiga (abiraterone) 
 Xtandi (enzalutamide) 
 Novantrone (mitoxantrone) 
 Yervoy (ipilimumab) 
 Xofigo (radium-223) 
 Provenge (sipuleucel-T) 
 Emcyt (estramustine) 
 Investigational agents used for the 
treatment of mCRPC/mCRPC 
following a previous docetaxel 
regimen are of interest for the 
review 
 The list was limited to interventions 
that have been approved in the 
European Union, are currently 
seeking approval, or are otherwise 
known to be used in the European 
Union in clinical practice within this 
patient population 
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PICOS Description  Rationale 
Comparator  No limitation on comparator  Any agent used for the treatment of 
mCRPC/mCRPC after a previous 
docetaxel regimen is of interest for 
the review as a comparator, thus 
the list was not limited 
 Comparators may include placebo, 
any chemotherapy, surgery, 
radiotherapy, and BSC 
Outcomes  OS 
 1-year survival 
 PFS 
 TTP 
 Complete response 
 Partial response 
 Overall response 
 SREs 
 PSA response 
 TTPSA 
 Time to opiate use 
 TTPP 
 Safety/AEs 
 HRQL 
 Resource utilization 
 These outcomes were chosen 
because they are well-established 
outcomes to assess efficacy and 
safety in oncology research and are 
frequently measured and reported 
in trials of mCRPC/mCRPC 
 
Study design RCTs with any blinding status in 
phases beyond Phase I  
 The design of RCTs allow for 
selection bias to be minimized and 
allow for an assessment the relative 
efficacy of interventions through 
meta-analysis and/or indirect 
treatment comparison 
 To enhance the level of evidence, 
studies with double-blind, single-
blind, and open-label design were 
included 
 
Publication 
timeframe 
 Publication timeframe: 
o From 2010 to present 
o Conference abstracts 
2011–2015 
 Publications from 2010 were 
included to identify studies not 
captured in a previous systematic 
review  
 Many congresses that took place in 
2010 were searched as part of the 
previous review and it was 
assumed that data from any 2010 
conferences that were not 
previously identified would likely be 
superseded by a full publication by 
2015 
Publication 
status 
Published, unpublished and grey 
literature (for example, conference 
To capture all published literature 
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PICOS Description  Rationale 
abstracts) were eligible for inclusion 
Language 
restrictions 
There was no language limitation To capture all published literature 
AEs, adverse events; BSC, best supportive care; HRQL, health-related quality of life; mCRPC, 
metastatic castration-resistant prostate cancer; mCRPC, metastatic hormone-refractory prostate 
cancer; OS, overall survival; PFS, progression-free survival; PSA, prostate-specific antigen; RCT, 
randomized controlled trial; SREs, skeletal-related events; TTP, time to disease progression; TTPP, 
time to pain progression; TTPSA, time to PSA progression. 
 
Table 16. Exclusion criteria checklist 
Exclusion criteria Rationale 
 Non-mCRPC/non-mCRPC populations 
o No mCRPC/mCRPC subgroup 
analysis 
o Metastatic disease unclear 
 Patients not pretreated with a docetaxel-
based regimen 
o No docetaxel-pretreated subgroup 
analysis 
o Docetaxel pretreatment unclear 
o Line of therapy unclear 
 Study population aged <18 years 
 Study does not examine an intervention of 
interest 
 Study does not include any outcomes of 
interest 
 Phase I RCTs 
 Study design is not an RCT (eg, 
nonrandomized controlled clinical trials, 
single-arm studies/uncontrolled trials, 
observational studies, letters, case reports) 
 Published before 2010 
 Studies with no subgroup data for the 
disease (mCRPC/mCRPC), disease stage 
(metastatic), and prior treatment (docetaxel-
treated) were not included to avoid 
introducing heterogeneity 
 Non-randomized evidence including case 
studies/series/reports were excluded as they 
are poor-quality evidence 
 
mCRPC, metastatic castration-resistant prostate cancer; mCRPC, metastatic hormone-refractory 
prostate cancer; RCT, randomized controlled trial. 
 
Two reviewers screened articles for inclusion; any disputes were resolved through 
discussion between reviewers or consultation with a third reviewer. All publications that met 
the inclusion criteria, based on titles and abstracts, were obtained as full documents and 
reassessed against the inclusion criteria by the same reviewers. 
Data from relevant articles were subsequently extracted in parallel by two independent 
reviewers based on the extraction grid detailed in Appendix 4. Both sets of extracted data 
were compared and combined into a final data extraction table, which was subsequently 
verified for the accuracy of all content by an independent third reviewer. 
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Where multiple publications were identified for the same trial, the novel data reported in each 
publication were extracted separately. 
4.1.4. Flow diagram of the numbers of studies included and excluded at each 
stage. 
Studies were included or excluded according to the criteria described in Table 15 and Table 
16. A flow diagram of the studies included and excluded at each stage is provided in Figure 
4. 
Figure 4. PRISMA flow diagram for the systematic literature review. 
 
 
 
 
The database searches were run on 26 February 2015 and the supplementary abstract 
search was run on 8 March 2015. 
 
In total, 935 unique records were identified for screening, which included 923 database 
search results and 12 congress abstracts. After screening 54 records were retained for full 
text review and of these 24 were excluded leaving a total of 30 articles. From this a total of 
13 studies were identified for inclusion in the systematic review. The list of all articles 
obtained for full text review is provided in Table 17. 
Table 17. List of articles retained for full text review with reason for exclusion if applicable 
No. Publication Excluded? Reason for exclusion 
Included full papers 
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No. Publication Excluded? Reason for exclusion 
1 Bahl, A., 20139 INCLUDE 
2 Cella, D., 201562 INCLUDE 
3 De Bono, J. S., 201152 INCLUDE  
4 De Bono, J. S., 20108 INCLUDE  
5 Fizazi, K., 201463 INCLUDE  
6 Fizazi, K., 201211 INCLUDE  
7 Fizazi, K., 201264 INCLUDE  
8 Fleming, M. T., 201265 INCLUDE  
9 Halabi, S., 201366 INCLUDE  
10 Harland, S., 201367 INCLUDE  
11 Hoskin, P., 201468 INCLUDE  
12 Joly, F., 201569 INCLUDE  
13 Kwon, E. D., 201470 INCLUDE  
14 Logothetis, C. , 201271 INCLUDE  
15 Ryan, C. J., 201372 INCLUDE  
16 Saad, F., 201157 INCLUDE  
17 Sartor, O., 201473 INCLUDE  
18 Scher, H. I., 201210 INCLUDE  
19 Sternberg, C. N., 201374 INCLUDE  
Included abstracts 
20 Oudard, S., 201151 INCLUDE  
21 Tombal, B., 201175 INCLUDE  
22 Hao, Y., 201376 INCLUDE  
23 Miller, K., 201377 INCLUDE  
24 Scher, H., 201378 INCLUDE  
25 Cislo, P., 201579 INCLUDE  
26 Logue, J., 201480 INCLUDE  
27 Nilsson, S., 201481 INCLUDE  
28 Fizazi, K., 201482 INCLUDE  
29 Hussain, M., 201283 INCLUDE  
30 Basch, E.M., 201584 INCLUDE  
31 Dawson, N.A., 201185 INCLUDE  
Excluded articles 
32 
No author listed. Cancer Discov. 2011 ec;1(7):OF1. 
doi: 10.1158/2159-8290.CD-NB111711OL-09. Epub 
2011 Nov 17 
EXCLUDE Incorrect study type 
33 Abraham, J., 201386 EXCLUDE Incorrect study type 
34 Aggarwal, R., 201387 EXCLUDE Incorrect intervention 
35 Amato, R., 201388 EXCLUDE Incorrect study type 
36 Beer, T. M., 201189 EXCLUDE Incorrect patient population 
37 Beer, T. M., 201390 EXCLUDE Incorrect patient population 
38 Blumenstein, B., 201391 EXCLUDE Incorrect study type 
39 Bono, J. S., 201492 EXCLUDE Outcomes not relevant 
40 Buonerba, C., 201493 EXCLUDE Incorrect study type 
41 Danila, D. C., 201194 EXCLUDE Incorrect study type 
42 Di Lorenzo, G., 201195 EXCLUDE Incorrect study type 
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No. Publication Excluded? Reason for exclusion 
43 Goodman, O. B., 201496 EXCLUDE Outcomes not relevant 
44 Jana, B. R. P., 201097 EXCLUDE Incorrect study type 
45 Kantoff, P. W., 201098 EXCLUDE Incorrect patient population 
46 Merseburger, A. S., 201599 EXCLUDE Outcomes not relevant 
47 Mulders, P. F. , 2014100 EXCLUDE Outcomes not relevant 
48 Nilsson, S., 201381 EXCLUDE Incorrect patient population 
49 Reid, A. H. M., 2010101 EXCLUDE Incorrect study type 
50 Ryan, C. J., 2013102 EXCLUDE Outcomes not relevant 
51 Ryan, C. J., 2014103 EXCLUDE Outcomes not relevant 
52 Saad, F., 2015104 EXCLUDE Outcomes not relevant 
53 Sternberg, C. N., 2014105 EXCLUDE Outcomes not relevant 
54 Thomsen, F. B., 2014106 EXCLUDE Incorrect study type 
4.1.5. Data sources for the trials considered in the analysis. 
TROPIC (cabazitaxel vs. mitoxantrone) 
In the systematic review of studies one Phase III RCT sponsored by Sanofi-Aventis 
evaluating the efficacy and safety of cabazitaxel + prednisolone vs. mitoxantrone + 
prednisolone, the TROPIC trial, was identified. The data presented in this submission have 
been drawn from the following sources: 
 
 De Bono, J.S., et al., Prednisone plus cabazitaxel or mitoxantrone for metastatic 
castration-resistant prostate cancer progressing after docetaxel treatment: A 
randomised open-label trial.8  
 Bahl, A., et al., Impact of cabazitaxel on 2-year survival and palliation of tumour-
related pain in men with metastatic castration-resistant prostate cancer treated in the 
tropic trial.9 
The 2013 paper by Bahl et al. presents the updated analysis for TROPIC which includes 
patient follow-up until March 10th 2010.9 The original publication from 2010 presented data 
until the cut-off at September 25th, 2009.8 The primary study reference is the article by Bahl, 
2013 from which data have been extracted for this appraisal; additional data were extracted 
from the clinical study report and de Bono, 2010 where necessary. 
In addition to the TROPIC study COU-AA-301 and AFFIRM are included for the purposes of 
the scenario Indirect Treatment Comparison (ITC) outlined in detail in Appendices B. The 
studies identified in the literature search are listed below. 
COU-AA-301 (abiraterone acetate vs. placebo) 
In the systematic review of studies one Phase III RCT sponsored by Jansen evaluating the 
efficacy and safety of abiraterone acetate + prednisone vs. placebo + prednisone, the COU-
AA-301 trial, was identified. The data presented in this submission have been drawn from 
the following sources: 
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 De Bono, J.S., et al., Abiraterone and increased survival in metastatic prostate cancer.52  
 Fizazi, K., et al., Abiraterone acetate for treatment of metastatic castration-resistant11 
 
AFFIRM (enzalutamide vs. placebo) 
In the systematic review of studies one Phase III RCT sponsored by Astellas evaluating the 
efficacy and safety of enzalutamide vs. placebo, the AFFIRM trial, was identified. The data 
presented in this submission have been drawn from the following source 
 Scher, H.I., et al., Increased survival with enzalutamide in prostate cancer after 
chemotherapy.10 
4.1.6. Reference list for excluded studies. 
Excluded studies have been tabulated in Section 4.1.4; Table 17 above. 
4.2 List of relevant randomised controlled trials 
TROPIC, which compared cabazitaxel to mitoxatrone was the only identified published RCT 
of and is described in detail below. In the context of the decision problem the comparison 
with mitoxantrone is valid as this is considered to be equivalent to best supportive care. 
4.2.1. List of relevant RCTs comparing cabazitaxel with other therapies 
(including placebo) in the mCRPC patients.  
The comparator, population and study reference for TROPIC are provided in Table 18. In 
addition the ongoing Phase III trial PROSELICA is listed as the results from this study may 
become available within the timeframe for this submission and if possible will form the basis 
for an addendum presented after the full dossier. PROSELICA aims to demonstrate the non-
inferiority in OS of cabazitaxel 20 mg/m² vs. 25 mg/m² in in patients with mCRPC previously 
treated with a docetaxel-containing regimen. 
Table 18. List of relevant RCTs 
Trial no. 
(acronym) 
Intervention Comparator Population Primary study 
reference 
EFC6193  
NCT00417079 
(TROPIC)  
Cabazitaxel 25 
mg/m2 plus 
prednisone or 
prednisolone 
Mitoxantrone 
plus prednisone 
or prednisolone 
 n = 755 
Patients with mCRPC and 
disease progression 
during or after treatment 
with a regimen containing 
docetaxel 
de Bono 20108 
Bahl, 20139 
NCT01308580 
PROSELICA 
Cabazitaxel 25 
mg/m2 plus 
prednisone or 
Cabazitaxel 20 
mg/m2 plus 
prednisone or 
n = ~1200 
Patients with mCRPC and 
disease progression 
TBC 
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prednisolone prednisolone during or after treatment 
with a regimen containing 
docetaxel 
The comparators outlined in the decision problem include best supportive care, abiraterone, 
enzalutamide and mitoxantrone (Section 1.1). 
Use of mitoxantrone has declined but may increase again if provision for cabazitaxel were 
not there. This was recognised in the response to the scope by the British Uro-oncology 
Group (BUG). Mitoxantrone was used as an active comparator in the TROPIC study. 
Mitoxantrone has been shown to contribute to palliation but not overall survival.2 It is 
therefore considered to be a proxy for Best Supportive Care in this submission. This was 
recognised in TA259 for abiraterone where the committee accepted the assumption that 
overall survival and progression-free survival were the same for patients taking mitoxantrone 
and patients taking prednisolone and so outcomes with mitoxatrone could be considered 
equivalent to supportive care. In this submission we compare against mitoxantrone in the 
base-case and consider this as at least equivalent to best supportive care. 
The impact of the newer hormonal therapies on pathways of care has been explored in 
Section 3.3 and, as highlighted for standard NHS practice (where abiraterone or 
enzalutamide are used in the pre-docetaxel setting), best supportive care is the only option 
available to patients.  
4.2.2 Justification for the exclusion of other RCT data.  
Radium-223 is licensed in a sub-population of mCRPC patients with two or more bone 
metastases and no visceral metastases and was evaluated in the ALSYMPCA study in 
comparison to placebo.107  Radium-223 does not currently have a NICE recommendation 
and cannot be considered to reflect established practice or the standard of care.  
Radium-223 is contraindicated in patients with liver metastases. Eleven percent of patients 
in TROPIC had liver metastases and this limits the applicability of the TROPIC dataset for 
indirect comparison with the radium-223 study ALSYMPCA. 
For these reasons we do not consider that radium-223 is a primary comparator for 
cabazitaxel and the ALSYMPCA study has been excluded. It is worth noting that within the 
NICE ongoing appraisal of radium-223 the key comparators included abiraterone which is 
considered by physicians to be a choice for patients where cytotoxic therapy post-docetaxel 
is not considered appropriate. 
The RCTs D9902B (IMPACT and supporting trials D9901A and D9901B) examining 
Sipuleucel-T have been excluded from the analysis as Sipuleucel-T has been withdrawn. 
Similarly in line with the previous submission TA255, The SPARC trial (Satraplatin + 
prednisone vs. placebo + prednisolone), satraplatin + prednisone, CNTO 328, cetuximab 
and ixabepilone are considered out with the scope for comparison with cabazitaxel. 
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4.3 Summary of methodology of the relevant randomised 
controlled trials 
Brief description of the TROPIC trial design 
The TROPIC trial was a Phase III, randomised, open label, multicentre, multinational, 
comparative study in patients with mCRPC previously treated with a docetaxel-containing 
regimen.8 
The primary objective was to determine whether cabazitaxel in combination with prednisone 
improves overall survival (OS) when compared to mitoxantrone in combination with 
prednisone. 
Figure 5. TROPIC trial: study design 
 
 
 
Inclusion criteria 
To enter the study, patients had to have: 
 Diagnosis of histologically or cytologically proven prostate adenocarcinoma, that was 
refractory to hormone therapy and previously treated with a docetaxel-containing 
regimen. Patients had documented progression of disease during or within six months 
after prior hormone therapy and disease progression during or after docetaxel-
containing therapy 
 Either measurable or non-measurable disease 
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o Patients with measurable disease had to have documented progression of 
disease by RECIST criteria demonstrating at least one visceral or soft tissue 
metastatic lesion (including new lesions). Lesions had to measure ≥10 mm in the 
longest diameter (or twice the slice thickness) on spiral CT scan or MRI (chest, 
abdomen, pelvis) or 20 mm on conventional CT or chest X-ray for biopsy proven, 
clearly defined lung lesion surrounded by aerated lung. 
o Patients with non-measurable disease had to have documented rising PSA 
levels or appearance of at least one new demonstrable radiographic lesion. 
Rising PSA was defined as at least two consecutive rises in PSA to be 
documented over a reference value measured at least a week apart.  
 Received prior castration by orchidectomy and/or luteinising hormone-releasing 
hormone (LHRH) agonist; anti-androgen withdrawal followed by progression had to 
have taken place at least four weeks (six weeks for bicalutamide) before enrolment.  
 Adequate haematological, hepatic, renal and cardiac function; and a left ventricular 
ejection fraction (LVEF) of more than 50% assessed by multi-gated radionuclide 
angiography or echocardiogram. 
 Life expectancy >2 months. 
 ECOG performance status 0 to 2 (that is, patient was to be ambulatory, capable of all 
self-care, and up and about more than 50% of waking hours).  
 Age ≥18 years.  
 Inclusion criteria amendment. The criterion to exclude patients who had received a 
cumulative dose of docetaxel <225 mg/m2 (the equivalent of three cycles of docetaxel 
= approximately 12 weeks’ treatment) was added after the trial had begun, at a point 
when 59 patients had been recruited. This amendment was made on the basis of 
emerging guidelines for patients with mCRPC from the Prostate Cancer Clinical Trials 
Working Group (PCCTWG), which recommended a protocol-specified minimum 
exposure of 12 weeks for trials in the pre-chemotherapy or first-line chemotherapy 
setting, recognising that declines in serum PSA, if they occur, may not do so for 
several weeks and that a robust PSA-based surrogate for clinical benefit has yet to be 
identified 
 
Exclusion criteria  
 Previous treatment with mitoxantrone.  
 Previous treatment with <225 mg/m2 cumulative dose of docetaxel (in response to 
emerging guidelines the study protocol was amended for this criterion after study 
initiation – in total, 59 patients who had received <225 mg/m2 were enrolled) 
 Prior radiotherapy to ≥40% of bone marrow 
 Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within four weeks 
prior to enrolment in the study.  
 Active Grade ≥2 peripheral neuropathy, stomatitis or other serious illness, including 
secondary cancer.  
 History of congestive heart failure, myocardial infarction within last six months, 
uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension.  
 History of severe hypersensitivity reaction (≥Grade 3) to polysorbate 80-containing 
drugs or prednisone.  
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 Participation in another clinical trial with any investigational drug within 30 days prior to 
study enrolment.  
 For patients enrolled in the UK, the following exclusion criterion was applicable: Patient 
with reproductive potential not implementing accepted and effective method of 
contraception, described in Protocol Amendment 3.  
Settings and locations where the data were collected. 
This was a multicentre (146 centers) study carried out in 26 countries worldwide (Argentina, 
Belgium, Brazil, Canada, Chile, Czech Republic, Denmark, Finland, France, Germany, 
Hungary, India, Italy, Korea, Mexico, Netherlands, Russia, Singapore, Slovakia, South 
Africa, Spain, Sweden, Taiwan, Turkey, UK, and the USA) 402 (53%) patients were included 
from European countries. 37 patients (5%, from six centres) were included from the UK 
Treatment was carried out in the secondary care setting in units specialising in the 
administration of cytotoxics. 
Duration of the Study 
755 patients from 146 centres in 26 countries were randomised between 2 January 2007 
and 23 October 2008.8 At the time of data cut-off (10 March 2010) for the updated analysis 
with time to death used as the duration of follow-up in patients who died before this date, 
and survival times censored for surviving patients, the median follow-up was 13.7 months. 
Alternatively, if deaths were censored and survival times were considered events, the 
median follow-up for both treatment groups combined was 25.5 months (interquartile range: 
20.7–30.0 months). Sixty (15.9%) of 378 patients in the cabazitaxel group and 31 (8.2%) of 
377 patients in the mitoxantrone group survived ≥2 years (odds ratio 2.11; 95% CI 1.33–
3.33).9 
Randomisation 
Patients were randomised to one of two treatment groups by the interactive voice response 
system (IVRS) ClinPhone in a 1:1 ratio with stratification by the following factors: 
 Measurability of disease per Response Evaluation Criteria in Solid Tumours (RECIST) 
(measurable versus non-measurable disease) 
 ECOG performance status (0 or 1 versus 2).  
A dynamic allocation method – method of minimisation – was used to avoid extreme 
imbalance of treatment assignment within a centre.  
Method of blinding 
As this was an ‘active’-controlled trial and there were differences in administration between 
treatments, this study was an open label study, so patients and treating physicians were not 
masked to treatment allocation.   The study was conducted under close monitoring from an 
Independent Data Monitoring Committee (IDMC) with the objective to review trial enrollment, 
compliance to protocol, safety of the administered treatments, quality of the data and to 
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conduct analyses on the data. The IDMC included two physicians and a statistician 
independent from the sponsor.  
The study team was blinded to treatment assignments, except for those patients with SAEs 
reported to pharmacovigilance. To maintain the blinding of the study team, an external 
contract statistician independent from the sponsor provided unblinded results to the IDMC 
with the appropriate analyses for assessment.   
The interim analyses were conducted and reviewed by the IDMC and the results not 
disclosed to the sponsor. 
Trial drugs and concomitant medications 
Cabazitaxel 25 mg/m2 intravenously (Day 1) over one hour every three weeks, and 
prednisone 10 mg orally given daily (prednisolone was allowed in countries where 
prednisone was not commercially available – including the UK). Mitoxantrone 12 mg/m2 
intravenously (Day 1) over 15 to 30 minutes every three weeks, and prednisone 10 mg orally 
given daily (prednisolone was allowed in countries where prednisone was not commercially 
available).  
Cycle length for both cabazitaxel and mitoxantrone was three weeks. Treatment was 
continued for a maximum of ten cycles. The ten-cycle maximum was imposed due to the fact 
that mitoxantrone is associated with cardiotoxicity and that this is increased with cumulative 
exposure.2 
Following progression, mitoxantrone patients were not eligible to cross over to cabazitaxel. 
However, cabazitaxel patients could receive mitoxantrone. As mitoxantrone has not been 
associated with an effect on survival, it is assumed that this crossover would not affect the 
survival curves.   
Overview of concomitant medications permitted and disallowed during 
TROPIC.8 
Premedication, consisting of single intravenous doses of an antihistamine, corticosteroid 
(dexamethasone 8 mg or equivalent), and histamine H2 antagonist (except cimetidine), was 
administered 30 minutes or more before cabazitaxel. Anti-emetic prophylaxis and other 
supportive care were given at the physician’s discretion.  
Prophylactic G-CSF was not permitted during the first cycle, but thereafter was permitted at 
physician’s discretion and was mandated for prophylaxis after first occurrence of either 
neutropenia lasting seven days or more or neutropenia complicated by fever (>38.5C or 
>38.1C x 3 observations during a 24-hour period), or infection.  
Concomitant therapy with agents known to have anticancer activity was not permitted during 
the treatment phase of the study. Treatment with radiotherapy, hormones or 
chemotherapeutic agents was also not permitted, with the exception of the following: LHRH 
agonists that were ongoing prior to study entry (without orchidectomy), steroids given for 
new adrenal failure and hormones administered for non-disease-related conditions (for 
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example, insulin for diabetes). The use of bisphosphonates was allowed; however, the dose 
had to be stable for 12 weeks prior to enrolment and during the study treatment period. 
Patients were not allowed to take part in any other investigational trials while participating in 
the treatment phase of the trial.  
Timings and assessments  
Physical examinations and blood tests were repeated before each infusion of study drug and 
at the end of treatment. Complete blood counts were performed on Days 1, 8 and 15 of each 
three-week cycle and repeated as clinically indicated. Patients who progressed or started 
another anticancer therapy were followed up every three months. Patients who withdrew 
before disease progression were followed up every six weeks for the first six months and 
every three months thereafter. Serious adverse events (SAEs) were reported from the 
signature of informed consent up to 30-days after the last dose of study drug, after which 
ongoing events were followed until resolution or stabilisation. All AEs considered related to 
the study treatment were followed until resolution at the end of the study. 
Duration of follow-up 
Patients were followed until death to the cut-off date for analysis, 25 September 2009 and in 
the extension period to March 2010. 
Patients who progressed or started another anticancer therapy were followed up every three 
months for a maximum of two years. The patients who discontinued the study treatment prior 
to documented disease progression and who had not started another anticancer therapy 
were followed up every six weeks for the first six months of the follow-up period, or until 
disease progression or start of another anticancer therapy. For the rest of the follow-up 
period patients were evaluated every three months.  
 
The predefined primary and secondary outcomes in the TROPIC trial are summarised 
below.  
Primary outcomes 
The primary efficacy endpoint was Overall Survival (OS). This was defined as the time 
interval from the date of randomisation to the date of death due to any cause. In the absence 
of confirmation of death, the survival time was censored at the last date the patient was 
known to be alive or at the data cut-off date, whichever came first.  
Secondary outcomes8 
 Progression-free survival (PFS) was evaluated from the date of randomisation to the 
date of tumour progression, PSA progression, pain progression (pain progression 
supported by clinical evidence and/or radiological evidence of disease progression), or 
death due to any cause, whichever occurred first.  
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 Tumour response rate (TRR) (in patients with measurable disease): objective 
responses (complete response (CR) and partial response (PR)) for measurable 
disease as assessed by investigator according to RECIST criteria: 
o CR = disappearance of all target lesions;  
o PR = 30% decrease in the sum of the longest diameter of target lesions;  
o PD = 20% increase in the sum of the longest diameter of target lesions; 
o Stable Disease = small changes that do not meet other criteria). 
o  Objective response had to be confirmed by repeat tumour imaging 
 Time to tumour progression (TTP): Defined as the number of months from the date 
of randomisation to evidence of progressive disease (PD) based on tumour 
measurements (RECIST criteria). Patients without PD were censored at their last 
tumour assessment.  
 PSA progression (assessed in all patients): 
o In PSA non-responders, progression was defined as a ≥25% increase over nadir 
(provided that the increase in the absolute value PSA level was at least 5 ng/ml).  
o In PSA responders and in patients not evaluable for PSA response at baseline, 
progression was defined as a ≥50% increase over the nadir (provided that the 
increase in the absolute value PSA level was at least 5ng/ml).  
 PSA response (assessed only in patients with baseline PSA ≥20 ng/ml): 
Response required a PSA decrease of ≥50% confirmed by a second PSA value at 
least three weeks later. The duration of PSA response was measured from baseline to 
the last assessment at which the above criteria were satisfied.  
 Pain progression (assessed in all patients): Pain was assessed using the Present 
Pain Intensity (PPI) scale on the McGill-Melzack pain questionnaire. Pain progression 
(cancer related) was defined as an increase of ≥1 point in the median PPI from its 
nadir noted on two consecutive three-week-apart visits, or ≥25% increase in the mean 
analgesic score (AS) compared with the baseline score and noted on two consecutive 
three-week-apart visits, or requirement for local palliative radiotherapy.  
 Pain response (assessed only in patients with median PPI ≥2 on McGill-Melzack 
scale and/or mean AS ≥10 points at baseline): Pain response was defined as a two-
point or greater reduction from baseline median PPI with no concomitant increase in 
AS, or a reduction of at least 50% in analgesic use from baseline mean AS with no 
concomitant increase in pain. Either criterion had to be maintained for two consecutive 
evaluations at least three weeks apart.  
 AEs in patients who had received at least one dose of study drug: AEs were 
graded according to the National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI-CTCAE) version 3.0,108 and summarised using Medical 
Dictionary for Regulatory Activities (MedDRA) version 12.0 terminology. For each AE 
per patient and per cycle the worst NCI grade was used. 
o In addition adverse event rates were recorded in terms of laboratory test 
results and also from the perspective of clinical presentation. The rates for 
AEs with testing positive in the laboratory, particular for the haematological 
events, were much higher than those recorded by clinicians. The former are 
reported in the original de Bono publication.  
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4.3.2. Comparative summary of the methodology of the RCTs. 
There is only one pivotal Phase III RCT for cabazitaxel which makes comparison with 
another treatment (mitoxantrone). This is the TROPIC trial described in Section 4.3.1 and 
below in Sections 4.4 to 4.8. In addition to this the Phase III RCT, PROSELICA may be 
pertinent to the decision problem.The PROSELICA methodology is described in detail 
Section 4.14. If available within the timeframe of this submission the results will form the 
basis for an addendum presented after the full dossier. 
4.4 Statistical analysis and definition of study groups in the 
relevant randomised controlled trials 
4.4.1 Trial populations8  
There were two analysis populations, ITT and per protocol, defined for the efficacy analysis. 
The ITT population included all randomised patients (755 patients [n=378 cabazitaxel; n=377 
mitoxantrone]); the per protocol population included all patients who received at least one 
dose of the study treatment (n=371 in each treatment group). The primary analysis of the 
primary efficacy endpoint was performed using the ITT population. The safety population 
was the same as the per protocol population and was used to summarise treatment 
compliance/administration and all clinical safety data.  
In general, there was no imputation of missing data. For time to event analyses, missing 
data were handled based on censoring rules. For categorical data, missing data were 
reported as missing.  
4.4.2 Statistical analysis 
Time to event analyses (OS, PFS, TTP, time to PSA progression, and time to pain 
progression), were compared between the two treatment groups using the log-rank test 
procedure in the ITT population according to the stratification factors specified at the time of 
randomisation. 
The estimates of the hazard ratio (HR) and corresponding 95% confidence intervals (CIs) 
were provided using a Cox proportional hazard model stratified by the same stratification 
factors specified at randomisation. Kaplan–Meier survival curves were generated. The chi 
square or Fischer’s exact test methods were used to compare proportions.8  
Analyses of AEs, vital signs, ECGs, LVEF and laboratory data were descriptive. For each of 
the safety parameters, a baseline value was defined as the last value or measurement taken 
up to the first dose in the study.  
In previously untreated patients with metastatic prostate cancer, OS on mitoxantrone is 12 to 
14 months.109 At the time this study was initiated, no data on OS were available for 
mitoxantrone-treated patients who progressed following docetaxel treatment in the first-line 
setting; therefore, a median survival of eight months was assumed for the purpose of sample 
size calculation in this study.8  
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Assuming the median OS time in the comparator group was eight months, a total of at least 
511 deaths in two treatment groups were needed to detect a 25% reduction in hazard rate in 
the cabazitaxel group relative to the comparator with a power of 90% at a two-sided 5% 
alpha level. To achieve the targeted number of events, approximately 720 (360 per group) 
patients needed to be randomised within 24 months for the study and 511 deaths had to be 
reached after 30 months from the first patient enrolment.8 
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4.5 Participant flow in the relevant randomised controlled trials  
4.5.1. Patient numbers in TROPIC 
Figure 6. CONSORT participant flow diagram 
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4.5.2.  Baseline patient demographics. 
Table 19. Characteristics of participants in the studies across treatment groups in the TROPIC 
trial. 
TROPIC trial 
Baseline characteristic 
Mitoxantrone + 
prednisone 
Cabazitaxel + 
prednisone 
(n=755) (n=377) (n=378) 
Age, in years 
Median 
75 and above  
 
67.0 
70 (18.6%) 
 
68.0 
69 (18.3%) 
Race 
Caucasian/White 
Black 
Asian/Oriental 
Other 
 
314 (83.3%) 
20 (5.3%) 
32 (8.5%) 
11 (2.9%) 
 
317 (83.9%) 
20 (5.3%) 
26 (6.9%) 
15 (4.0%) 
ECOG performance status* 
0 or 1 
2 
 
344 (91.2%) 
33 (8.8%) 
 
350 (92.6%) 
28 (7.4%) 
Extent of disease 
Metastatic 
Bone metastases 
Visceral metastases 
Loco regional recurrence 
Unknown 
 
356 (94.4%) 
328 (87%) 
94(25%) 
20 (5.3%) 
1 (0.3%) 
 
364 (96.3%) 
303 (80%) 
94 (25%) 
14 (3.7%) 
0 
PSA (in ng/ml) 
Number of patients 
Median (IQR) serum PSA µg/l 
Serum PSA ≥20 µg/l 
 
370 
127.5 (44.0–419.0) 
325 (86%) 
 
371 
143.9 (51.1–416.0) 
329 (87%) 
Measurable disease 
Measurable disease 
Not measurable disease 
 
204 (54.1%) 
173 (45.9%) 
 
201 (53.2%) 
177 (46.8%) 
Pain at baseline† 168 (45%) 174 (46%) 
Previous treatment 
Hormone‡ 
1 chemotherapy regimen  
2 chemotherapy regimens 
>2 chemotherapy regimens 
Radiation 
Surgery 
Biological agent 
 
375 (99%) 
268 (71%) 
79 (21%) 
30 (8%) 
222 (59%) 
205 (54%) 
36 (10%) 
 
375 (99%) 
260 (69%) 
94 (25%) 
24 (6%) 
232 (61%) 
198 (52%) 
26 (7%) 
Previous docetaxel regimens 
1 
2 
>2 
 
327 (87%) 
43 (11%) 
7 (2%) 
 
316 (84%) 
53 (14%) 
9 (2%) 
Median (IQR) total previous docetaxel dose 
mg/m2 
529.2 (380.9, 787.2) 576.6 (408.4, 761.2) 
Median (IQR) months from last dose of 
docetaxel to disease progression 
0.8 (0.0, 3.1) 0.7 (0.0, 2.9) 
Disease progression relative to docetaxel   
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TROPIC trial 
Baseline characteristic 
Mitoxantrone + 
prednisone 
Cabazitaxel + 
prednisone 
(n=755) (n=377) (n=378) 
treatment 
During 
<3 months from last dose 
≥3 months from last dose 
Unknown 
104 (28% 
181 (48%) 
90 (24%) 
2 (1%) 
115 (30%) 
158 (42%) 
102 (27%) 
3 (1%) 
Key: ECG = echocardiogram; ECOG = Eastern Cooperative Oncology Group; IQR = interquartile range; PSA = prostate-
specific antigen 
* According to the protocol patients were stratified according to ECOG performance status 0 1, versus 2 
† Pain was assessed using the McGill-Melzack PPI scale; analgesic score was derived from analgesic consumption 
(morphine equivalents) 
‡ Two patients in the cabazitaxel group did not receive prior castration by orchidectomy or hormone therapy 
There were no significant differences in baseline patient characteristics between the two 
arms in the TROPIC trial.  
4.6 Quality assessment of the relevant randomised controlled 
trials  
Critical appraisal of the TROPIC RCT was carried out for TA 255.  An updated summary of 
that appraisal is presented below.  
4.6.1. Critical appraisal of TROPIC 
The appraisal was conducted by one reviewer and checked independently by a second 
reviewer. 
The trialists employed appropriate methods to generate the random allocation sequence and 
to ensure allocation concealment to minimise selection bias. A dynamic allocation method 
was also used to avoid extreme imbalance of treatment allocation within each study centre.  
The care providers, participants and outcome assessors were not blind to treatment 
allocation. The lack of blinding could have introduced the potential for ascertainment bias in 
the subjective assessment of pain, symptom deterioration (both of which were included in 
the definition of PFS) and clinical (although not laboratory) assessment of AEs. In the ERG 
report accompanying TA255 the lack of justification for the unblinded nature of the trial was 
criticized. However the ERGs clinical advisors indicated that a double dummy procedure 
would have been difficult to implement due to the nature of the treatments and the 
requirement for premedication of patients receiving cabazitaxel. Outcome assessors were 
not blinded to treatment allocation and although this is unlikely to have introduced bias into 
the assessment of the primary outcome, overall survival, or objective assessments of tumour 
response or biochemical measurements such as PSA this could be a source of bias. 
The patients in each treatment group were well balanced with regard to demographic and 
disease parameters, and previous treatment history. A protocol amendment was made after 
the start of the trial to exclude patients who had received a cumulative dose of docetaxel 
<225 mg/m2. Eight per cent of cabazitaxel patients and 7.7% of mitoxantrone patients 
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received cumulative docetaxel doses below that threshold, indicating that no imbalance 
between arms was introduced by this amendment. 
Other than the required cabazitaxel premedication, there were no systematic differences in 
concomitant therapies allowed in both the comparator groups. G-CSF prophylaxis was 
permitted after Cycle 1 and usage was higher in the cabazitaxel arm due to the higher rate of 
neutropenia. Anti-emetic prophylaxis was also given at the physicians’ discretion in both 
treatment groups.  
The level of dropouts was low in both treatment groups and there were no unexpected 
imbalances between the groups (see CONSORT participant flow diagram, Figure 6. Only 
two patients, both in the mitoxantrone group, were lost to follow-up. A similar number of 
patients in each group (n=10 cabazitaxel, n=7 mitoxantrone) discontinued treatment due to 
events ‘other’ than disease progression or AEs. 
Scrutiny of the published journal articles and the unpublished clinical trial report found no 
evidence to suggest bias in the reporting of study outcomes. The primary analysis of the 
primary outcome, OS, and all other time-to-event outcomes (PFS, tumour progression, PSA 
progression, and pain progression) was by intention-to-treat (ITT). Missing data were 
handled appropriately according to censoring rules (see Section 4.4.2). Where available 
case analyses were conducted, the number of patients analysed in each group was clearly 
stated.  
4.6.2. Methods used for assessing risk of bias and generalizability.  
A quality assessment of the TROPIC study is provided in Table 20 below. 
Table 20. Quality assessment of the TROPIC study.8 
Appraisal question How addressed in the study Adequate or not 
Internal validity 
Was randomisation 
carried out 
appropriately? 
Computer-generated random number 
sequence; stratified by prespecified 
criteria. 
Yes 
Was the concealment of 
treatment allocation 
adequate? 
Central randomisation was 
performed using an interactive voice 
response system. 
Yes 
Were the groups similar 
at the outset of the 
study in terms of 
prognostic factors?  
Baseline demographic, disease and 
previous treatment characteristics 
were balanced. Yes 
Were the care 
providers, participants 
and outcome assessors 
blind to treatment 
allocation?  
Providers, participants and outcome 
assessors were not blind to treatment 
allocation; unlikely to bias 
assessment of OS, PFS, or objective 
assessments of tumour response; 
potential for ascertainment bias in the 
subjective assessment of PPI and 
clinical (not laboratory) assessment 
No, but unlikely to impact on the 
main outcomes. Outcome 
assessors should probably have 
been blinded to avoid the 
possibility of bias. 
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of AEs. 
Were there any 
unexpected imbalances 
in dropouts between 
groups? 
No - only two patients, both in the 
mitoxantrone group, were lost to 
follow-up; a similar number of 
patients in each group (n=10 
cabazitaxel, n=7 mitroxantrone) 
discontinued treatment due to events 
other than disease progression or 
adverse events; only one patient, in 
the cabazitaxel group, discontinued 
due to poor protocol compliance. 
Yes 
Is there any evidence to 
suggest that the authors 
measured more 
outcomes than they 
reported? 
There is no suggestion information 
was omitted 
Yes 
Was follow-up 
adequate?  
Patients were followed until death or 
the cut-off date for analysis. Yes 
Did the analysis include 
an ITT analysis? If so, 
was this appropriate 
and were appropriate 
methods used to 
account for missing 
data? 
The primary outcome was analysed 
by ITT. Missing data were accounted 
for appropriately according to 
censoring rules for survival data. Yes 
External validity 
Was the RCT 
conducted in the UK, or 
were one or more 
centres of a 
multinational RCT 
located in the UK 
International multicentre trial; 4.9% 
(37/755) of participants were 
recruited in the UK, 53% (402/755) in 
Europe. Yes 
How do the participants 
included in the RCT 
compare with patients 
who are likely to receive 
the intervention in the 
UK? 
Demographics, disease and prior 
treatment are likely to be similar 
Yes, data from the UK EAP is 
available (described in Section 
4.11) and this shows cabazitaxel 
use in a very similar patient 
population to the TROPIC study 
with improved adverse event 
profiles. 
What dosage regimens 
were used in the RCT? 
Are they within those 
detailed in the summary 
of product 
characteristics? 
Cabazitaxel 25 mg/m2 one-hour IV 
infusion every three weeks (as in the 
summary of product characteristics) 
  
Mitoxantrone 12 mg/m2 one-hour IV 
infusion every three weeks; 
recommended dosage for HRPC 12–
14 mg/m² IV every three weeks. 
Mitoxantrone is not licensed for this 
indication in the UK but is licensed in 
the USA. 
Yes 
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4.6.3 If there is more than 1 RCT, tabulate a summary of the responses applied 
to each of the quality assessment criteria. 
There is only one completed pivotal Phase III RCT for cabazitaxel. This is the TROPIC trial8 
described above and below in Sections 4.7 and 4.8. A quality assessment of the 
PROSELICA study will be provided if the data becomes available for consideration by the 
committee.  
4.7 Clinical effectiveness results of the relevant randomised 
controlled trials 
Data from the ITT population are discussed in the following section. The subgroup of 
patients with ECOG PS 0 -1 and who have received at least 225 mg/m2 docetaxel (See 
section 4.8 for results) are used in the base-case analysis presented in Section 5. 
 
The treatment received by the participants in the TROPIC trial is summarised in Table 21. 
Table 21. Treatment received in the TROPIC trial8 
Treatment Mitoxantrone Cabazitaxel 
Number of patients who received treatment 371 (98%) 371 (98%) 
Number of treatment cycles (median) 4 (IQR 2, 7) 6 (IQR 3, 10) 
Relative dose intensity (median) 97.3% (IQR 92.0, 99.3) 96.1% (IQR 90.1, 98.9) 
Treatment delays (number of patients)* 56 (15%) 104 (28%) 
Treatment delays (number of cycles) † 
≥4 days 
≤9 days 
>9 days 
 
(7.9%) 
110 (6.3%) 
28 (1.6%) 
 
(9.3%) 
157 (7.0%) 
51 (2.2%) 
Dose reductions (number of patients)‡ 15 (4%) 45 (12%) 
Dose reductions (number of cycles) 88 (5.1%) 221 (9.8%) 
* Delays of ≤2 weeks were allowed 
† Percentages are of total number of treatment cycles (2,251 for the cabazitaxel group and 1,736 in the mitoxantrone 
group 
‡ One dose reduction was allowed per patient, 20 mg/m2 for cabazitaxel or 10 mg/m2 mitoxantrone 
Primary outcome: overall survival 
The updated analysis indicates a median study follow-up of 25.5 months. Overall 277 deaths 
occurred in the cabazitaxel group and 308 in the mitoxantrone group.  
ITT analysis of the primary outcome showed an OS benefit in favour of cabazitaxel (see 
Table 22 and Figure 7). Median survival was 15.1 months in the cabazitaxel group and 12.7 
months in the mitoxantrone group. The treatment difference for OS was statistically 
significant in favour of the cabazitaxel group (p = 0.0002), which is less than the target 
statistical significance level of p= 0.0452. The hazard ratio (HR) was 0.72 (0.61 - 0.84) in 
favour of cabazitaxel corresponding to a 28% reduction in risk of death.  At 12 months, 64% 
of patients were alive in the cabazitaxel group compared with 53% in the mitoxantrone 
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group. The probability of surviving ≥2 years was 27% (95% CI 23% to 32%) with cabazitaxel 
versus 16% (95% CI 12% to 20%) with mitoxantrone. 
Table 22. Overall survival – ITT population 
 Mitoxantrone + 
prednisone 
(n=377) 
Cabazitaxel + 
prednisone 
(n=378) 
Number of patients with deaths (%) 308 (81.7%) 277 (73.3%) 
Number of patients censored (%) 69 (18.3%) 101 (26.7%) 
Median survival in months (95%CI) 12.78 (11.53-13.73) 15.08 (13.96-16.49) 
Hazard ratio (95% CI)* 0.72 (0.61 - 0.84) 
P value† 0.000 
Key: CI = confidence interval  
* P value from stratified log rank test, stratifying for ECOG performance status and measurable disease at baseline 
† Hazard ratio is estimated using a Cox proportional hazards regression model, HR <1 indicates a lower risk with 
cabazitaxel plus prednisone with respect to mitoxantrone plus prednisone 
The Kaplan–Meier plots of OS are shown in Figure 7. The disparity in excess early TEAE 
deaths on cabazitaxel (18 deaths on cabazitaxel versus 7 on mitoxantrone) within 30 days 
explains the early inflection in the Kaplan-Maier curve for overall survival. The IDMC, in an 
ad hoc IDMC meeting, reviewed these deaths and was of the opinion that in the cabazitaxel 
group, seven deaths were due to neutropenic complications, most of them during Cycle 1 of 
study treatment, and two were due to renal failure secondary to dehydration. Based on 
IDMC recommendations the investigators were advised to follow the protocol strictly 
regarding dose delay and modifications and to treat neutropenia per ASCO guidelines. 
These recommendations were instituted and no new neutropenic deaths were reported. 
Company evidence submission template for Cabazitaxel for hormone-relapsed 
metastatic prostate cancer previously treated with a docetaxel-containing regimen 
 Page 79 of 211 
 
Figure 7. Overall survival and number of patients at risk by study month (ITT population) 
 
In addition to the median OS data presented above (Table 22), mean OS was estimated 
using patient level data from the TROPIC trial. A number of parametric functions were fitted 
to the Kaplan–Meier data from TROPIC and the goodness-of-fit tested. This identified a 
Weibull function as the best fit to the OS data for both arms. Details of the curve-fitting 
method are provided in Section 5.6.1. For the ITT population, based on the Weibull 
extrapolations, mean OS was estimated as 14.53 months the mitoxantrone arm versus 
18.55 months in the cabazitaxel arm, a difference of 4.02 months in favour of cabazitaxel. 
The range of incremental OS extrapolations depending on the parameterisation used is 
between 3.6 months (Gompertz) to 8.1 months (Lognormal). 
Secondary outcome: progression-free survival 
The first secondary outcome in TROPIC was PFS defined as a composite endpoint, as the 
time between randomisation and the first date of progression as measured by PSA 
progression, tumour progression, pain progression or death. Median PFS (ITT population) 
was 2.8 months in the cabazitaxel group and 1.4 months in the mitoxantrone group (see 
Table 23). The difference in overall PFS was statistically significant in favour of the 
cabazitaxel group (p = 0.0002). The HR was 0.75 (95%CI, 0.65 - 0.87) in favour of 
cabazitaxel, corresponding to a 25% reduction in risk of progression (see Table 23). The 
Kaplan–Meier plots for PFS are presented in  
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Figure 8.The definition of PFS in TROPIC was conservative, including biochemical (PSA 
progression), which frequently precedes symptomatic or radiologic progression. As can be 
seen in Table 24, 40–50% of progression events were due to PSA progression, with 
symptom deterioration recorded in only 2–4% of patients. Patients were withdrawn from 
study treatment on the first sign of progression, including confirmed PSA progression. Hence 
the relatively short PFS duration shown in Table 23 (in comparison with other cancer types 
and other trials in this setting) reflects this definition of PFS.  
Table 23. Progression-free survival – ITT population 
 Mitoxantrone + prednisone (n=377) 
Cabazitaxel + 
prednisone (n=378) 
Number of patients with PFS events (%) 370 (98.1) 367 (97.1) 
Median PFS in months (95%CI) 1.41 (1.35-1.77) 2.76 (2.43-3.12) 
Hazard ratio (95% CI) 0.75 (95%CI, 0.65 - 0.87) 
p value 0.0002 
Key: CI = confidence interval; PFS = progression-free survival 
PFS was defined as a composite endpoint evaluated from the date of randomisation to the date of 
tumour progression, PSA progression, pain progression, or death due to any cause, whichever 
occurred first 
Table 24. Descriptive analysis of progression-free events – ITT population 
 Mitoxantrone + 
prednisone (n=377) 
Cabazitaxel + 
prednisone (n=378) 
Number of patients with PFS events (%) 370 (98.1) 367 (97.1) 
Death  33 (8.8) 41 (10.8) 
Tumour progression  68 (18.0) 67 (17.7) 
PSA progression  186 (49.3) 163 (43.1) 
Pain progression  69 (18.3) 86 (22.8) 
Symptom deterioration 14 (3.7) 10 (2.6) 
Key: PSA = prostate-specific antigen; PFS = progression-free survival 
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Figure 8. Kaplan–Meier curves of PFS and number of patients at risk by study month (ITT 
population) 
 
4.8 Subgroup analysis 
4.8.1  Details for the subgroup of patients with ECOG PS 0 -1 and having 
received at least 225 mg/m2 docetaxel 
A post-hoc subgroup analysis, previously considered by NICE as reflective of the population 
likely to be treated with cabazitaxel, was conducted following the outline for the ITT 
population.  This subgroup represented patients with mCRPC previously treated with a 
docetaxel-containing regimen, with ECOG PS 0 -1 and who have received at least 225 
mg/m2 docetaxel.  
Cabazitaxel is licensed for use in the post-docetaxel setting and in line with NICE guidance it 
is expected that all UK patients would receive sufficient exposure to docetaxel before 
consideration for cabazitaxel. The exclusion of patients receiving <225 mg/m2 docetaxel 
(approximately 3 cycles) is consistent with an amendment introduced to the TROPIC 
protocol after the recruitment of 59 patients.  
In TROPIC 61 (8.1%) patients had ECOG PS of 2. Clinical opinion, which was endorsed by 
the clinical advisors to the ERG in TA255, is that it is extremely unlikely those patients with 
an ECOG PS value of 2 would be treated with cabazitaxel in UK practice. 
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The subgroup analysis was conducted on the updated TROPIC dataset and represents 632 
(83.7%) patients out of the ITT population of 755. 
4.8.2  Characteristics of the participants in the subgroup. 
The baseline patient characteristics for the patients with mCRPC previously treated with a 
docetaxel-containing regimen, with ECOG PS 0 -1 and who have received at least 225 
mg/m2 docetaxel are presented in Table 25 below. 
The validity of this subgroup was accepted by the ERG in TA255 and the appropriateness to 
the UK setting is discussed above (Section 4.8.1). 
Table 25. Characteristics of participants in the subgroup with ECOG PS 0 -1 and who have 
received at least 225 mg/m2 docetaxel across treatment groups in the TROPIC trial. 
TROPIC trial 
Baseline characteristic – subgroup 
cohort 
Mitoxantrone + 
prednisone 
Cabazitaxel + 
prednisone 
(n=362) (n=313) (n=319) 
Age, in years 
Median 
75 and above  
 
66.0 
77 (24.6%) 
 
68.0 
77 (24.1%) 
Race 
Caucasian/White 
Black 
Asian/Oriental 
Other 
 
261 (83.4%) 
19 (6.1%) 
23 (7.3%) 
10 (3.2%) 
 
270 (84.6%) 
15 (4.7%) 
22 (6.9%) 
12 (3.8%) 
ECOG performance status* 
0 or 1 
2 
 
313 (100%) 
0 (0%) 
 
319 (100%) 
0 (0%) 
Measurable disease 
Measurable disease 
Not measurable disease 
 
166 (53.1%) 
147 (47.0%) 
 
168 (52.7%) 
151 (47.3%) 
ECOG = Eastern Cooperative Oncology Group;* According to the protocol patients were stratified according to ECOG 
performance status 0 1, versus 2 
4.8.3 Details of the statistical tests used in the primary analysis of the 
subgroups, including any tests for interaction. 
No statistical test has been applied to evaluate a difference for the treatment effect in the 
group excluded from the subgroup population and the subgroup with ECOG PS 0 -1 who 
have received at least 225 mg/m2 docetaxel. This subgroup of interest represents 84% of the 
patients in the study and according to clinical opinion, is expected to be most representative 
of patients likely to be treated with cabazitaxel in clinical practice. This was also a view 
expressed by the clinical advisors to the ERG in TA255 who stated that it would be 
extremely unlikely for patients with an ECOG PS of 2 or more to be treated with cabazitaxel. 
The clinical advisors felt that ‘it is plausible that the efficacy of cabazitaxel would be lower in 
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patients who had received insufficient docetaxel’ and the ERG report notes that ‘the a priori 
belief for this subgroup is also supported by the amendment in the TROPIC protocol (after 
the recruitment of 59 patients) to exclude patients who had not received sufficient docetaxel.’ 
This subgroup was accepted as an appropriate cohort for analysis in TA255. 
4.8.4 Summary of the results for the subgroup: patients with ECOG PS 0 -1 
who have received at least 225 mg/m2 docetaxel 
For the subgroup with ECOG PS 0 -1 who have received at least 225 mg/m2 docetaxel 
Median survival was 15.61 (13.96 - 17.28) months in the cabazitaxel group and13.37 (11.99 
- 14.52) months in the mitoxantrone group. The treatment difference for OS was statistically 
significant in favour of the cabazitaxel group (p = 0.000) and the hazard ratio (HR) was 0.69 
(0.57 - 0.82) in favour of cabazitaxel. The Kaplan–Meier plots for PFS are presented in 
Company evidence submission template for Cabazitaxel for hormone-relapsed 
metastatic prostate cancer previously treated with a docetaxel-containing regimen 
 Page 85 of 211 
 
Figure 9. 
Table 26. Overall survival in the subgroup of patients with ECOG PS 0 -1 who have received at 
least 225 mg/m2 docetaxel. 
 Mitoxantrone + 
prednisone (n=313) 
Cabazitaxel + 
prednisone (n=319) 
Number of patients censored (%) 253 (80.83) 228 (71.47) 
Median survival in months (95%CI) 13.37 (11.99-14.52) 15.61 (13.96-17.28) 
Hazard ratio (95% CI)* 0.69 (0.57-0.82) 
P value† <0.001 
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Figure 9. Kaplan–Meier curves of overall survival in the subgroup with ECOG PS 0 -1 who have 
received at least 225 mg/m2 docetaxel. 
  
Median PFS in the subgroup was 2.76 (2.43-3.12) months in the cabazitaxel group and 1.41 
(1.35-1.84) months in the mitoxantrone group (Table 27). The difference in overall PFS was 
statistically significant in favour of the cabazitaxel group (p = 0.001). The HR was 0.76 (0.65-
0.89) in favour of cabazitaxel (Table 27). The Kaplan–Meier plots for PFS are presented in 
Figure 10. 
Table 27. Progression-free survival in the subgroup with ECOG PS 0 -1 who have received at 
least 225 mg/m2 docetaxel. 
 Mitoxantrone + prednisone (n=377) 
Cabazitaxel + 
prednisone (n=378) 
Number of patients with PFS events (%) 304 (97.12) 305 (95.61) 
Median PFS in months (95%CI) 1.41 (1.35-1.84) 2.76 (2.43-3.12) 
Hazard ratio (95% CI) 0.76 (0.65-0.89) 
p value 0.001 
Key: CI = confidence interval; PFS = progression-free survival 
PFS was defined as a composite endpoint evaluated from the date of randomisation to the 
date of tumour progression, PSA progression, pain progression, or death due to any cause, 
whichever occurred first Source 
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Figure 10. Kaplan–Meier curves of PFS survival in the subgroup with ECOG PS 0 -1 who have 
received at least 225 mg/m2 docetaxel. 
 
4.9 Meta-analysis 
Meta-Analyses were not conducted as only one study per relevant treatment was found in 
the systematic review described in Section 4.1.  
4.10 Indirect and mixed treatment comparisons 
The base-case analysis presented in this dossier is for cabazitaxel versus mitoxantrone 
(which may be considered equivalent to Best Supportive Care (BSC)). We have established 
this to be the most relevant comparator for the treatment of mCRPC in the post docetaxel 
setting with cabazitaxel. This is on the basis that the NHS Standard Practice pathway 
precludes other comparators and the disease characteristics of a subset of the patients who 
follow the Alternative Practice Pathway mean cytotoxic therapy is the only active option. 
Nonetheless as required by the scope, we have carried out a scenario analysis to compare 
the clinical evidence from TROPIC with the outcomes in the COU-AA-301(abiraterone)11 and 
AFFIRM (enzalutamide)10 studies via their control arms using a Bayesian Indirect Treatment 
Comparison (ITC). These studies were identified in the systematic review and the latest data 
from each study was used to inform the ITC. This ITC analysis was then used in the 
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scenario comparative economic evaluations. The network diagrams are provided in Figure 
11. Full details can be found in Appendices B.  
Figure 11. Network diagrams for the included trials 
 
* 45.6% of patients were exposed to prednisone in the placebo arm of AFFIRM. 
 
  
Such comparisons rely on the strong assumptions that the study designs and trial 
populations are sufficiently alike, and that the respective control-arms of the trials deliver 
equivalent levels of efficacy with a similar safety profile. It is questionable whether these 
assumptions hold true and the results from the ITC and economic analysis should be treated 
with caution.  
Whilst in terms of overall survival, the three control arms from these trials have previously 
been considered equivalent for the purposes of indirect comparison (TA255, TA259 and 
TA316), the definition of Progression Free Survival (PFS) is markedly different between trials 
and represents a problem for the present indirect comparison, and by extension the use of 
indirect PFS data in the economic model.  
The main PFS definitions from the three trials are described elsewhere (Appendices B), but 
it is important to note that the principal definition of PFS in the TROPIC trial (main secondary 
endpoint), and which directly affected patients discontinuation of treatment, was more 
conservative than similar endpoints reported in the other trials.  Consideration was therefore 
given to using measures of PFS with differing definitions for the indirect comparisons. 
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In order to facilitate a more coherent comparison for progression free time, radiographic PFS 
(rPFS) was derived from the patient level data from TROPIC. The aim of this was to reflect 
the end point was reported in both the COU-AA-301 and AFFIRM trial papers. Examination 
of the median time to rPFS in the three trials however, indicates the values of rPFS for the 
control arms are substantially different, indicating that for the purposes of the ITC they 
should not be considered equivalent. 
Whilst cabazitaxel and enzalutamide reported similar median rPFS  values of academic in 
confidence information removed months and 8.2 months respectively, patients receiving 
mitoxantrone had a median rPFS of academic in confidence information removed months, 
substantially larger than the control arm in AFFIRM trial; rPFS 2.9 months.  The control arm 
of the COU-AA-301 trial was similar to that in AFFIRM with a median rPFS of 3.6 months. 
The relatively poor performance of the control arms the AFFIRM and COU-AA-301 trial, 
compared to the almost double median rPFS for mitoxantrone in the TROPIC trial raises 
questions about the comparability of the control arms and comparability of measurements for 
the indirect comparison. Hazard ratios for rPFS from both AFFIRM and COU-AA-301 are 
lower compared to those from TROPIC, and as such bias against cabazitaxel when 
combined in the indirect comparison.  As will be seen in Appendicies B, the application of 
these indirect comparisons for rPFS produce spurious results in the economic model 
As well as possible differences in the effect of the control treatments on rPFS, examination 
of the trial participants themselves may also be a reason for the difference in performance 
observed. The patients entering the studies had different disease characteristics. For 
example in the COU-AA-301 trial11 only 30% of patients were refractory to docetaxel whilst 
70% in TROPIC had progressed whilst on docetaxel or within 3 months of receiving it. In the 
AFFIRM study the mean time to start of enzalutamide therapy from last docetaxel exposure 
was 9 months.These data are indicative of more aggressive disease in the TROPIC 
population but despite this similar OS was observed between the studies. These issues are 
discussed fully in Appendices B. 
The methodology and complete set of results can be found in Appendices B. Key results 
from the scenario ITC are summarized in Table 28. 
Table 28. Key results from the mixed treatment comparisons – ITT population 
   Overall survival 
Radiographic progression 
free survival 
HR Credible intervals HR Credible intervals 
Cabazitaxel vs mitoxantrone (≡BSC 
to facilitate NMA)  0.72 0.61 0.85 0.75 0.65 0.88 
Cabazitaxel vs Abiraterone  0.97 0.78 1.21 0.97 0.76 1.22 
Cabazitaxel vs Enzalutamide  1.14 0.90 1.45 1.88 1.54 2.29 
Abbreviations. HR: Hazard Ratio; BSC: Best Supportive Care. 
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4.11 Non-randomised and non-controlled evidence 
An update to the systematic literature search described in Section 4.1 and Appendix 5, was 
carried out to identify non-randomised evidence pertinent to the decision problem for the 
period January 2010 to February 2015. A brief description of the original search carried out 
for TA255 is provided in Appendix 6. 
The following databases were searched according to the search strategies provided in 
Appendix 6. 
 Embase 
 MEDLINE (via the Embase interface) 
 MEDLINE In-Process (via PubMed) 
In addition to the published literature search, key conference proceedings were screened. 
The following conference proceedings were hand searched over the past 4 years: 
 American Society of Clinical Oncology (ASCO) 
 ASCO-Genitourinary (ASCO-GU) 
 European Society for Medical Oncology (ESMO) 
 American Urological Association (AUA) 
 American Association for Cancer Research (AACR) 
 European Association of Urology (EAU) 
 Société Internationale d'Urologie (SIU) 
English and non-English language studies were included. 
Studies were selected on the basis of the following inclusion and exclusion criteria Table 29 
and Table 30 respectively. 
Table 29. Inclusion criteria (PICOS framework) used in the search strategies 
PICOS Description  Rationale 
Population 
 
 mHRPC/mCRPC patients 
 Age: Adults (≥18 years) 
 Race: Any 
 Line of therapy: Second-line or later 
 Prior therapy: Previously treated 
with docetaxel-based regimen 
 The patient population has been 
restricted to match the stated 
decision problem for the treatment 
of mHRPC/mCRPC in patients who 
have been treated with docetaxel in 
any previous regimen 
 Because prostate cancer is a 
disease affecting older adult men, 
studies including children or 
adolescents were excluded 
Interventions 
 
The following treatments for mHRPC 
and mCRPC administered in the 
 Investigational agents used for the 
treatment of mHRPC/mCRPC 
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PICOS Description  Rationale 
second line or later: 
 Jevtana (cabazitaxel) 
 Zytiga (abiraterone) 
 Xtandi (enzalutamide) 
 Novantrone (mitoxantrone) 
 Yervoy (ipilimumab) 
 Xofigo (radium-223) 
 Provenge (sipuleucel-T) 
 Emcyt (estramustine) 
following a previous docetaxel 
regimen are of interest for the 
review 
 The list was limited to interventions 
that have been approved in the 
European Union, are currently 
seeking approval, or are otherwise 
known to be used in the European 
Union in clinical practice within this 
patient population 
Comparator  No limitation on comparator  Any agent used for the treatment of 
mHRPC/mCRPC after a previous 
docetaxel regimen is of interest for 
the review as a comparator, thus 
the list was not limited 
 Comparators may include placebo, 
any chemotherapy, surgery, 
radiotherapy, BSC, or no 
comparator 
Outcomes 
 
 OS 
 1-year survival 
 PFS 
 TTP 
 Complete response 
 Partial response 
 Overall response 
 SREs 
 PSA response 
 TTPSA 
 Time to opiate use 
 TTPP 
 Safety/AEs (eg, anaemia and 
neutropenia) 
 HRQoL 
 Resource utilization 
 These outcomes were chosen 
because they are well-established 
outcomes to assess efficacy and 
safety in oncology research and are 
frequently measured and reported 
in trials of mHRPC/mCRPC 
 
Study design  Nonrandomized controlled clinical 
trials 
 Single-arm interventional 
studies/uncontrolled trials 
 Observational studies, including: 
o Cohort studies/longitudinal 
studies (prospective or 
retrospective) 
o Case-control studies 
o Cross-sectional study/survey 
o Hospital records and database 
studies 
 A previous review in this area 
suggested a limited evidence base 
available from RCTs; therefore, 
other study designs including 
observational studies were included 
in this review 
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PICOS Description  Rationale 
Limits 
 
 Publication timeframe: 
o From 2010 to present 
o Conference abstracts from 
2011−2015 
 Publications from 2010 were 
included to identify studies not 
captured in a previous systematic 
review 
 Many congresses that took place in 
2010 were searched as part of the 
previous review and it was 
assumed that data from any 2010 
conferences that were not 
previously identified would likely be 
superseded by a full publication by 
2015 
AEs, adverse events; BSC, best supportive care; HRQoL, health-related quality of life; mCRPC, 
metastatic castration-resistant prostate cancer; mHRPC, metastatic hormone-refractory prostate 
cancer; OS, overall survival; PFS, progression-free survival; PICOS, population, intervention, 
comparators, outcomes, and study design; PSA, prostate-specific antigen; SREs, skeletal-related 
events; RCT, randomized controlled trial; TTP, time to disease progression; TTPP, time to pain 
progression; TTPSA, time to PSA progression. 
Table 30. Exclusion criteria checklist 
Exclusion criteria Rationale 
 Non-mHRPC and non-mCRPC populations 
o No mHRPC or mCRPC subgroup 
analysis 
o Metastatic disease unclear 
 Patients not pretreated with a docetaxel-
based regime 
o No docetaxel-pretreated subgroup 
analysis 
o Docetaxel pretreatment unclear 
o Line of therapy unclear 
 Study population aged <18 years 
 Study does not examine an intervention of 
interest 
 Study does not include any outcomes of 
interest 
 Study design is an RCT 
 Study design is a case study, case series, or 
case report 
 Published before 2010 
 Studies with no subgroup data for the 
disease (mHRPC/mCRPC), disease stage 
(metastatic), and prior treatment (docetaxel-
treated) were excluded 
 A previous review including RCTs was 
available, therefore RCTs were excluded 
from this review 
 Nonrandomized evidence including case 
studies/series/reports were excluded as they 
are poor-quality evidence 
 Studies in which the patient population of 
interest was not clearly identified were 
excluded from this review 
mCRPC, metastatic castration-resistant prostate cancer; mCRPC, metastatic hormone-refractory 
prostate cancer; RCT, randomized controlled trial. 
 
Two reviewers screened articles for inclusion; any disputes were resolved through 
discussion between reviewers or consultation with a third reviewer. All publications that met 
the inclusion criteria, based on titles and abstracts, were obtained as full documents and 
reassessed against the inclusion criteria by the same reviewers. 
Data from relevant articles were subsequently extracted in parallel by two independent 
reviewers based on the extraction grid detailed in Appendix 6. Both sets of extracted data 
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were compared and combined into a final data extraction table, which was subsequently 
verified for the accuracy of all content by an independent third reviewer. 
Where multiple publications were identified for the same trial, the novel data reported in each 
publication were extracted separately. 
The database searches were run on 26 February 2015 and the supplementary abstract 
search was run on 8 March 2015. The additional searches for non-English studies were run 
on 3 May 2015; however, these searches were restricted to a cut-off date of 26 February 
2015 to match the original search period and were integrated with the original search results. 
In total, 1046 unique records were identified for screening, which included 1006 database 
search results and 39 congress abstracts. A total of 103 studies from 107 references (51 full 
publications and 56 congress abstracts) were identified for inclusion in the systematic 
review. 
A flow diagram of the studies included and excluded at each stage is provided in Figure 12 
overleaf. The outcomes included in the analysis, along with a description of their reliability, 
validity, and/or clinical relevance based on recent guidelines from the European Medicines 
Agency (EMA).110 
 
 
Company evidence submission template for Cabazitaxel for hormone-relapsed 
metastatic prostate cancer previously treated with a docetaxel-containing regimen 
 Page 94 of 211 
 
Figure 12. PRISMA flow diagram for the literature review of non-randomised evidence 
 
4.11.1 Results from the non-randomised and non-controlled evidence literature 
survey. 
A full list of the 107 included non-randomised, non-controlled articles is provided in Appendix 
6. A list of the excluded articles along with the reason is also provided in Appendix 6. The 
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discussion below will focus on those articles directly relevant to the decision problem which 
fall into the two categories:  
 Safety of cabazitaxel in clinical practice 
 Efficacy of cabazitaxel used in sequence with abiraterone or enzalutamide. 
 
Safety reported in the Compassionate Use and Early Access Programs. 
Key evidence pertinent to the decision problem which provides data to support the safety of 
cabazitaxel in clinical practice comes from the Compassionate Use Programs (CUP) and 
Early Access Programs (EAP) for cabazitaxel. These studies identified in the non-
randomised and non-controlled evidence search are presented below. 
Results from the TROPIC trial stimulated the CUP/EAPs which allowed access to 
cabazitaxel ahead of commercial availability. These were initiated in 33 countries worldwide 
(Australia; Austria; Belgium; Bosnia And Herzegovina; Bulgaria; Canada; Croatia; Czech 
Republic; Denmark; Finland; France; Hungary; India; Ireland; Israel; Italy; Kazakhstan; 
Luxembourg; Malaysia; Mexico; Philippines; Poland; Portugal; Romania; Serbia; Singapore; 
Slovakia; Spain; Sweden; Taiwan, Thailand; Province Of China; United Kingdom). In all 
cases a safety awareness program for health care professionals was implemented in each 
center to encourage the proactive management of adverse events. The objective of the 
CUP/EAP was to focus on aspects of safety during treatment with cabazitaxel and so 
efficacy outcomes were not collected centrally. Nonetheless in some cases these are 
reported on a country by country basis. 
Pan-European and individual country results and have been published for several of these 
programs. In all reported cases the population considered was patients with mCRPC who 
had progressed on or after docetaxel and who had a ECOG performance status of 0 – 2 with 
90% or more patients at ECOG 0-1 (with the exception of the Korean EAP where 19% of 
patients were ECOG 2). (See Table 33 for a summary of baseline patient characteristics). In 
general the populations in the CUP/EAP match the TROPIC population although in some 
cases patients are slightly older than in TROPIC.111 A list of the interim and complete 
evidence presented in full publications is tabulated below Table 31. A poster detailing the UK 
experience of the EAP was identified in the evidence review (Table 34) but since this was 
carried out a full paper has been published.12 This is included in Table 33 alongside the full 
publications from the review.  
Table 31. Published evidence from the CUP/EAP 
Country Patients 
included 
Objectives as stated in the publication Primary study 
reference 
Europe 746 This paper describes preliminary results 
synthesized from 20 from European 
CUPs/EAPs and focuses on the safety 
results in adults aged 70 years and over. In 
agreement with national regulations, no 
efficacy data were collected. 
Heidenreich 
2014111 
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Country Patients 
included 
Objectives as stated in the publication Primary study 
reference 
Korea 26 The primary objective was to assess safety, 
and the secondary objective was to 
document PSA response, time to PSA 
progression, time to treatment failure, time 
to composite progression, and OS. 
Lee, 2014112 
Germany 111 The primary objective was to document the 
safety according to the US 
National Cancer Institute’s Common 
Terminology Criteria for Adverse 
Events v.4.0. The secondary objective was 
to  document prostate-specific antigen 
(PSA) response rates, PFS and OS. 
Heidenreich 
2014113 
Italy 218 Safety results are reported for the Italian 
program which represents the largest cohort 
within the CUP/EAP. 
Bracarda 2014114 
Netherlands 49 Safety and efficacy (OS and PFS) data are 
reported. 
Wissing 2014115 
Spain 153 The primary objective was to document the 
overall safety of cabazitaxel in mCRPC 
patients who had progressed during or 
after treatment with a docetaxel-containing 
regimen in Spain. Additionally, the efficacy 
(prostate-specific antigen [PSA] response 
and biochemical progression free 
survival) was analyzed however these 
patients were selected from the sites with 
higher recruitment rate and no formal 
selection was used. 
Castellano, 
2014116 
UK 112 The objective was to compile the safety 
profile and quality of life (HRQL) data for 
patients with mCRPC treated with 
cabazitaxel in the UK 
Bahl, 201512 
 
In addition to the full publications listed in Table 31 several posters have been presented at 
conferences more recently. These are described in Table 32 below. 
Table 32. Additional CUP/EAP studies presented at conferences. 
Country Patients 
included 
Objectives as stated in the abstract or 
poster 
Primary study 
reference 
Multiple (37) 1301 To assess real-world safety of cabazitaxel Malik 2013 (ASCO)117 
Multiple (12 
countries) 451 
To assess real-world safety of cabazitaxel Heidenreich 2014 
(ESMO)118 
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Canada 61 
To collect safety, HRQL and efficacy data in 
patients from the global Expanded Access 
Program for cabazitaxel 
Sridhar 2013 
(ASCO)119 
France 184 To assess real-world safety of cabazitaxel Houede 2012 (ASCO)120 
Thailand 40 To document overall safety of cabazitaxel in the real world. 
Pripatnanont 
2014 (SIU)121 
UK 108 
Safety profile and quality of life (HRQL) data 
for patients with mCRPC treated with 
cabazitaxel in the UK 
Bahl, 2013 
(ASCO-GU)122 
4.11.2 Provide a comparative summary of the methodology of the studies in a 
table.  
The primary objective of the CUP/EAP studies was to allow early access for patients in 
clinical practice and similar to those evaluated in the TROPIC trial (for which the licence was 
to be granted), access to cabazitaxel for the management of metastatic Hormone Refractory 
Prostate Cancer (mHRPC) The secondary objective was to document the overall safety of 
cabazitaxel in these patients. 
The methodology of the studies was common across the programs.The CUP/EAPs were 
prospective, single arm, open label, observational studies. Each patient was treated with 
cabazitaxel 25 mg/m² intravenously every 3 weeks, in combination with oral prednisone or 
prednisolone 10 mg daily until disease progression, death, unacceptable toxicity, 
investigator’s decision or up to 10 cycles. This is in accordance with the SmPC.15 Patients 
were followed-up during treatment with cabazitaxel and for 30 days after last administration. 
The main inclusion criteria were: 
 Age ≥18 years 
 Metastatic Hormone Refractory Prostate Cancer previously treated with a docetaxel-
containing regimen 
 Disease Progression during or after docetaxel containing regimen for mCRPC 
 Surgical or medical castration 
 Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0-2 
 Life-expectancy ≥3 months 
 Adequate bone marrow, liver, and renal function: Neutrophils> 1500 /mm3; 
Hemoglobin > 10 g/dL; Platelets > 100 x109/L; Bilirubin < ULN; SGOT (AST) < 
1.5xULN; SGPT (ALT) < 1.5xULN; Creatinine < 1.5xULN 
 Signed written informed consent obtained prior to Enrolment 
 
The main exclusion criteria were: 
 Prior radiotherapy to ≥ 40% of bone marrow 
 Prior radionuclide therapy (samarium-153, strontium-89, P-32…)  
 Prior surgery, radiation, chemotherapy, or otheranti-cancer therapy within 4 weeks 
prior to enrollment 
 Active grade ≥2 peripheral neuropathy 
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 Active grade ≥2 stomatitis 
 Active infection requiring systemic antibiotic or antifungal medication 
 Active cancer (other than mCRPC) including prior malignancy from which the patient 
has been disease-free for ≤5 years (except superficial nonmelanoma skin cancer) 
 Known brain or leptomeningeal involvement 
 History of severe hypersensitivity reaction (≥grade 3) to docetaxel 
 History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing 
drugs 
 History of severe hypersensitivity reaction (≥grade 3) or intolerance to prednisone or 
prendnisolone 
 Uncontrolled severe illness or medical condition (including uncontrolled diabetes 
mellitus) 
 Concurrent or planned treatment with potent inhibitors or inducers of cytochrome 
P450 3A4/5 (a one week wash-out period is necessary for patients who are already 
on these treatments) 
 Participation in a clinical trial with any investigational drug 
 Patient with reproductive potential not implementing accepted and effective method 
of contraception  
The outcomes measured in the CUP/EAP were based around safety, not efficacy. These 
were described by the incidence of clinically significant adverse events (AEs) including 
serious adverse events (SAEs). AEs were collected from the time the first dose of study 
treatment (cabazitaxel and prednisone or prednisolone) until 30 days after the administration 
of the last administration of cabazitaxel. Toxicity was graded according to the National 
Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE 
v 4.0) and summarized using MedDRA terminology. The number of cycles, cumulative dose 
received, and reason for End of Treatment (EOT) were also evaluated. In some cases 
efficacy data was collected, although this was on a country by country basis. (Table 31) 
In the UK a specific amendment was agreed allowing for the collection of HRQL.12 
The study started in the third quarter of 2010 in Europe and at the time of submission of 
cabazitaxel to local Regulatory Bodies in other participating countries. 
Statistical analysis of the non-randomised and non-controlled evidence 
4.11.3 Potential biases in the non-randomised evidence. 
The CUP/EAPs were observational studies and no formal sample size calculation was 
performed. The safety population comprised all enrolled patients who received at least part 
of one dose of cabazitaxel in order to document safety. Only descriptive summaries were 
provided in most cases as per protocol although analysis of the influence of selected 
variables was reported in the results for the European CUP/EAP. A Generalised Estimating 
Equations (GEE) model which adjusts for the clustering of treatment cycles within a patient 
was used in order to reassess the risk of grade ≥3 neutropenia and/or neutropenic  
complications before each chemotherapy cycle.123  
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There is inherent selection bias in the CUP/EAP due to the non-randomised, observational 
nature of the study and enrolment of patients into self-selecting participating centres. In 
addition there may be imperfect data collected by retrospective review which is necessary to 
capture the previous history of the patients. Similarly efficacy data, where collected, was not 
systematic. For example in the Spanish CUP efficacy data was only collected from patients 
at sites with higher recruitment rates and no formal selection was used.  
The UK EAP is unique in that it provides the first formal HRQL data specific to cabazitaxel in 
mCRPC. It was conducted as a trial but in a setting as close to real-world UK practice as 
possible. It provides for the first time evidence to suggest that cabazitaxel therapy is not 
associated with a worsening of HRQL, and, indeed, appears to be stable with a trend 
towards improved HRQL with increasing cycle number.12 See Section 5.4.1 for more details. 
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Participant flow in the CUP/EAP studies 
4.11.4 Description of the characteristics of the participants at baseline for each of the studies by country.  
Table 33. Selected baseline patient characteristics for the CUP/EAP studies reported in full publications. 
Country 
 
Baseline characteristic 
TROPIC: 
(cabazitaxel 
arm) 
European 
EAP Korea Germany Italy Netherlands Spain UK 
Number of patients 378 746 26 111 218 49 153 112 
Median age, in years 
Range  
68 
(62 – 73) 
67.7  
(SD: 7.5) 
66.5 
(53 -82) 
67.9 
(49 – 81) 
70 
(49 – 87) 
64.6 
(58.6 – 70.0) 
70.0 
(65-75) 
67 
(63.0–72.5) 
ECOG performance status (%) 
 
0 
1 
2 
0 – 1: 93% 
 
38.7 
50.9 
10.5 
 
12 
69 
19 
 
45 
49.5 
5.5 
 
67.4 
31.2 
1.4 
 
6.1 
71.4 
24.5 
 
30.7 
58.2 
11.1 
 
42.0 
51.8 
6.3 
Sites of metastases (%) 
Bone 
Lung 
Liver 
Regional lymph 
Distant lymph 
Visceral 
 
80 
NR 
NR 
NR 
NR 
25 
 
91.7 
NR 
NR 
31.6 
30.1 
25.3 
 
42 
19 
19 
NR 
NR 
31 
 
91 
10.8 
10.8 
42.3 
31.5 
NR 
 
88.0 
22.6 
13.8 
33.6 
44.7 
NR 
 
95.9 
12.2 
14.3 
34.7 
49.0 
NR 
 
94.1 
9.2 
13.1 
26.1 
22.9 
26.8 
 
92.0 
14.3 
8.0 
41.1 
27.7 
NR 
Baseline PSA, ng/mL, median 
(IQR) 
143.9 
(51.1−416.0) NR 
95.3 (9.1–
297.7) 
733.3 
(56.2–
7679) 
NR 355.5 (123.0-1515.4) NR NR 
Time from last docetaxel dose 
to inclusion, months (IQR 
unless otherwise stated) 6.2 (SD: 6.7) 
5.3 
(2.4–10.6) 
6.6 
(0.6–44.4) 
4.07  
(2.04–8.67 NR 
3.22  
(1.36 – 6.87) 
6.5  
(2.5; 12.1)
33% (within 3 
mths post 
doc.) 
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Table 34. Selected baseline patient characteristics for the CUP/EAP studies reported in 
conferences abstracts. 
Country 
 
Baseline characteristic 
Multiple 
(37 
countries)
Multiple 
(12 
countries)
Canada France Thailand 
Number of patients 1301 451 61 184 40 
Median age, in years 
Range  68 68 (43–84) 65 
67.2 (46–
92) 72 (50–83) 
ECOG performance status (%) 
 
0 
1 
2 
 0 – 1: 90 0 – 1: 92 0 – 1: 85 0 – 1: 95 
Sites of metastases (%) 
Bone 
Lung 
Liver 
Regional lymph 
Distant lymph 
Visceral 
 
91 
NR 
NR 
30 
27 
NR 
NR 
 
82 
NR 
NR 
NR 
NR 
21 
 
88 
NR 
NR 
NR 
NR 
21 
 
92 
NR 
NR 
NR 
NR 
NR 
 
In general the populations reported in the CUP/EAP publications are similar with the 
exception of the Korean study which has a higher proportion of patients with ECOG 
performance score 2 and lower proportion of patients with bone metastases. In addition 
more patients had received exposure to cytotoxic agents other than docetaxel (62 vs. 33% in 
TROPIC) and the average baseline PSA measure was much lower than the other studies 
(where reported), but closer to the TROPIC population. Taxane metabolism is affected by 
ethnicity and grade 3–4 neutropenia is much higher in Asian patients124 However here is little 
evidence in this group for the safety and efficacy of cabazitaxel beyond two Phase I studies 
which have examined pharmacokinetics and dose escalation.125, 126 In TROPIC 7% of 
subjects were Asian so this is an important study for this population.The higher rate of grade 
≥3 neutropenia may also translate in a higher survival benefit as suggested by a recent 
Phase II study with docetaxel127 and a post-hoc analysis of TROPIC study128 A relationship 
between overall survival and the occurrence of grade ≥3 neutropenia has also been reported 
in many other solud tumor types, both in adjuvant and metastatic settings.129 
4.11.5 The quality assessment for the EAP 
The UK Early Access Programme (EAP) which was part of the wider international studyis of 
particular relevance to the decision problem. This is because as well as being a UK 
population, it incorporated an amendment allowing for an evaluation of Health related QOL.12 
One hundred and twelve patients participated in the UK EAP at 12 UK Cancer Centres. All 
had mCRPC with disease progression during or after docetaxel and were similar in baseline 
patient characteristics to the population in TROPIC. In the study (as in TROPIC) patients 
received cabazitaxel 25mg/m2 every 3 weeks with prednisolone 10mg daily for up to 10 
cycles. As documented in TROPIC, UK EAP patients received a median of 6 cycles of 
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cabazitaxel.   Safety assessments were performed prior to each cycle and HRQL recorded 
at alternate cycles using the EQ-5D-3L questionnaire and visual analogue scale (VAS). 
These results are presented in detail in Section 5.4. 
The other published studies discussed above report the safety (and to a certain extent 
efficacy) of cabazitaxel in clinical practice but the results are not synthesized for use in the 
modelling. A discussion of the issues around comparison with the TROPIC data is included 
in Section 4.12.1. The study by Bahl describing the UK EAP is used to inform utilities of 
health states in the economic model presented in Section 5 The assessment of quality 
presented below in Section 4.11.7 is for Bahl study only.12 
4.11.6 Assessment of the risk of bias in the UK EAP. 
The Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies 
available from the National Institutes of Health (NIH)130 was used to assess the quality of the 
study by Bahl.12This is reproduced along with answers in Table 35 below. 
Table 35. Quality assessment of the UK EAP study entitled: Final quality of life and safety data 
for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the 
UK Early Access Programme (EAP) (NCT01254279).12 
 
Criteria  YES/
NO 
Comment
1. Was the research question 
or objective in this paper 
clearly stated? 
Yes To compile the safety profile and quality of life 
(HRQL) data for patients with metastatic castration-
resistant prostate cancer (mCRPC) treated with 
cabazitaxel in the UK Early Access Programme (UK 
EAP). 
2. Was the study population 
clearly specified and defined? 
Yes Patients were included if they had confirmed 
mCRPC 
previously treated with a docetaxel-containing 
regimen and had experienced disease 
progression during or after docetaxel. 
Other inclusion criteria were defined. Exclusion 
criteria were not specified but a reference is 
given to the TROPIC study where these are 
defined. 
3. Was the participation rate 
of eligible persons at least 
50%? 
Uncl
ear, 
but 
likely
The study recruited patients in 12 centres but it 
is not specified what proportion of patients 
presenting were recruited. However the rate of 
recruitment was higher than expected. 
Approximately 20% more patients were 
recruited than planned. Given the existence of 
alternative therapies such as the advanced 
hormonal drugs, the authors suggest this 
indicates clinician and patient enthusiasm for 
Company evidence submission template for Cabazitaxel for hormone-relapsed 
metastatic prostate cancer previously treated with a docetaxel-containing regimen 
 Page 103 of 211 
 
Criteria  YES/
NO 
Comment
the use of second-line chemotherapy. 
4. Were all the subjects 
selected or recruited from the 
same or similar populations 
(including the same time 
period)? Were inclusion and 
exclusion criteria for being in 
the study prespecified and 
applied uniformly to all 
participants? 
Yes See question 2 above 
5. Was a sample size 
justification, power 
description, or variance and 
effect estimates provided? 
No The study was not powered to deliver on an 
end point; rather this was an observational 
study seeking to provide descriptive statistics.  
6. For the analyses in this 
paper, were the exposure(s) 
of interest measured prior to 
the outcome(s) being 
measured? 
Yes The number of cycles of cabazitaxel treatment 
received was recorded. 
7. Was the timeframe 
sufficient so that one could 
reasonably expect to see an 
association between exposure 
and outcome if it existed? 
Yes The study observed adverse events due to 
cabazitaxel treatment and measured quality of 
life. Both of these outcomes are 
contemporaneous with study drug 
administration. 
8. For exposures that can 
vary in amount or level, did 
the study examine different 
levels of the exposure as 
related to the outcome (e.g., 
categories of exposure, or 
exposure measured as 
continuous variable)? 
No As this was an observational study within the 
bounds of clinical practice, intervention to 
examine different levels of exposure to the 
study drug was not implemented. 
As might be expected for a chemotherapy, 
exposure may have varied as a result of 
treatment discontinuation, dose reductions or 
treatment delays due to adverse events or 
disease progression. 
9. Were the exposure 
measures (independent 
variables) clearly defined, 
valid, reliable, and 
implemented consistently 
across all study participants? 
Yes Exposure of participants to cabazitaxel is 
reported in detail. The study was conducted 
across 12 separate centres but there is no 
reason to consider that exposure was different 
across the centres. 
10. Was the exposure(s) 
assessed more than once 
over time? 
Yes Safety assessments were made before each 
cycle and peripheral blood tests were 
performed before each treatment and within 3 
weeks of treatment, weekly blood counts were 
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Criteria  YES/
NO 
Comment
performed after cycle 1 to detect early signs of 
neutropenia. HRQL assessment was 
performed at baseline and before alternate 
cycles. 
11. Were the outcome 
measures (dependent 
variables) clearly defined, 
valid, reliable, and 
implemented consistently 
across all study participants? 
Yes Safety and HRQL outcomes were 
predetermined. There is no indication that 
implementation varied across study centers 
12. Were the outcome 
assessors blinded to the 
exposure status of 
participants?  
No This is a single arm observational study. 
13. Was loss to follow-up after 
baseline 20% or less? 
Not 
state
d 
Loss to follow-up is not stated. 
14. Were key potential 
confounding variables 
measured and adjusted 
statistically for their impact on 
the relationship between 
exposure(s) and outcome(s)? 
No The study did not control for different baseline 
patient characteristics or adjust for other 
variables which might impact the results.  
However within-patient analysis was employed 
to explore whether the results observed for the 
stable (and rising) mean HRQL scores across 
all patients was, in fact, due to selection bias. 
No bias is reported. 
4.11.7 If there is more than 1 non-randomised or non-controlled study, tabulate 
a summary of the responses applied to each of the quality assessment criteria. 
Only the UK EAP12 has been assessed since HRQL results from this study are directly 
included in the economic model. The assessment is provided above in Section 4.11.6. 
4.11.8 Quality assessment for each study should be included. 
The assessment for Bahl, 201512 is provided above in Section 4.11.6. 
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Clinical effectiveness results of the relevant non-randomised and 
non-controlled evidence 
4.11.9 Data from trial analyses should be presented whenever possible and a 
definition of the included participants provided.  
Evidence from the CUP/EAP studies is presented in Section 4.11.11 below. In addition a 
discussion of the literature on the efficacy of cabazitaxel in the post abiraterone or 
enzalutamide setting is included. 
4.11.10 The information may be presented graphically to supplement text and 
tabulated data. 
Evidence from the CUP/EAP studies is presented in Section 4.11.11 below. 
4.11.11 Evidence from the CUP/EAP and other studies 
The safety and, where available, efficacy results from the CUP/EAPs which have reported 
interim and complete results in full publications to date are presented in Table 36. Abstracts 
with details of further country specific and aggregate CUP/EAPs are presented in Table 37. 
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Table 36. Summary of the safety and efficacy results from the full publications for the CUP/EAPs for cabazitaxel 
 
Primary 
Reference Country 
Cabazit
axel 
cycles 
OS 
Months, 
(95% CI) 
PFS* 
 Months, 
(95% CI) 
Deaths 
n, (%) 
Percentage of patients with adverse events 
All grades, (≥3) 
Any Neutro-penia 
Febrile 
neutro-
penia 
Anaemia Diarrhoea Nausea Fatigue 
TROPIC: de 
Bono 20108 Mulitiple 6 
Median:15.
1 (14.0 – 
16.5) 
Median:  
2.8 (2.4- 
3.0) 
277 (61) 95.7 94 (82)† 8 (8) 97 (11) 47 (6) 34 (2) 37 (5) 
Heidenreich 
2014111 
Europe 
(20 
countries) 
4.0 
(1–16) NR NR 
16 
(21.5) 
<70 
years: 88 
(47) 
70–74 
years: 
90.5 (50)
≥75 
years: 
88.3 
(56.6) 
19.8 
(17.0) 5.5 (5.4) 21.6 (4.7) 34.6 (2.8) 
22.1 
(0.8) 
25.2 
(4.2) 
Lee 2014112 Korea 5 (1 –23) 
Median: 
16.5 (12.1 
–20.9) 
Median: 
8.5 (3.0 –
13.1) 
3 (12) 96 (77) 31 (31) 31 (31) 35 (4) 42 (0) 31 (0) 35 (4) 
Heidenreich 
2013113 Germany 
6 
(3 – 10) 
Mean: 13.9 
(0.7–35.8) 
Mean: 3.78 
(0.7–31.47) 6 (5.4) 64 (46.8) 
NR 
(7.2) NR (2) NR (4.5) NR (0.9) NR NR 
Bracarda 
2014114 Italy 6 (NR) NR NR 4 (1.8) NR (NR) 
NR 
(33.9) NR (5.0) NR (6.0) NR (2.8) NR (NR) NR (3.7) 
Wissing 
2014115 
Nether-
lands 
6  
(1 – 21) 
Median: 8.7 
(6.0 – 15.9) 
Median: 2.8 
(1.7 – 4.9) NR 100 (51) 6.1 (4.1) 4.1 (4.1) 28.6 (4.1) 40.8 (2.0) 
44.9 
(2.0) 
61.2 
(10.2) 
Castellano 
2014116 Spain 
6 
(4 – 8) NR 
Median: 4.4 
(2.7 –6.1) 5 (3.3) 
93.5 
(43.1) 
22.2 
(16.3) 5.2 (5.2) 37.9 (5.9) 45.8 (5.2) 
22.2 
(1.3) 4.6 (1.3) 
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Bahl 201512 UK 6 (3 – 10) NR NR 4 (3.6) NR (NR) 
12.5 
(9.8) 1.8 (1.8) NR 64.3 (4.5) 
46.4 
(1.8) 
54.5 
(13.4) 
* Mean or Median time to composite progression as stated in the publication (defined as the time between randomisation and the first date of progression as 
measured by PSA progression, tumour progression, pain progression or death).  †In the EAP neutropenia was based on AE declaration, whereas in TROPIC 
data for haematogical adverse events were based on laboratory assessments. Routine FBC was performed prior to every cycle; for cycle 1 further FBCs were 
performed in weeks 2 and 3. NR: Not reported.NR: Not reported. 
 
No survival data was presented in the conference abstracts identified in the literature search (Table 37). 
 
Table 37. Summary of the safety results from the conference abstracts for the CUP/EAPs for cabazitaxel 
Primary 
Reference Country 
Cabazitaxel 
cycles 
Deaths n, 
(%) 
Percentage of patients with adverse events All grades ≥3 
Any Neutropenia Febrile neutropenia Anaemia Diarrhoea Vomiting Fatigue 
Malik 2013 
(ASCO)117  Multiple (37)  6 (1–22)  39 (3.0)  43%  18%  7%  NR  4%  NR  NR 
Heidenreich 
2014 
(ESMO)118 
Multiple (12 
countries)  5 (1–34)  30 (6.7)  41.2%  16.9%  8.9%  6.0%      4.0% 
Sridhar 2013 
(ASCO)119  Canada  6  1* (1.6)  NR  NR  6.6%  9.8%  8.2%  NR  8.2% 
Houede 2012 
(ASCO)120  France  3 (1–6)  0*  NR  4%  3%  NR  2.7%  0.5%  0.5% 
Pripatnanont 
2014 (SIU)121  Thailand  7 (1–13)  5* (12.5) 
87.5% 
(all 
grades) 
45%  12.5%  15%  10%  5%  7.5% 
*Cabazitaxel treatment related deaths 
 
In addition the review of the non-randomised, non-controlled evidence found several conference abstracts have been published which consider 
the safety of weekly and bi-weekly cabazitaxel regimens. The list and results from these are collected in Table 42 in Section 4.12.1 below.
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4.11.12 Efficacy of cabazitaxel in the post abiraterone or enzalutamide setting. 
Resistance to advanced hormonal therapies 
The mechanisms of resistance to advanced hormonal therapy are now becoming better 
characterised, in particular ARv7+ve tumours typically show limited response to abiraterone 
or enzalutamide. Patients progressing rapidly to castration with ADT are also unlikely to 
respond to abiraterone or enzalutamide. Resistance can be characterised as primary or 
adaptive and it has long been established that as tumours progress and become more 
aggressive hormone therapy becomes ineffective.131 
Because they target the same signalling pathway, clinical cross-resistance between 
abiraterone and enzalutamide is possible. Retrospective studies of abiraterone in patients 
previously treated with both docetaxel and enzalutamide have been reported 132, 133 These 
show a decrease in the activity of abiraterone compared to that expected.52 (Table 38). 
Table 38. Studies examining the cross resistance in the sequence abiraterone : enzalutamide. 
Author n Median abiraterone duration 
Pts with ≥50% 
PSA decline Median PFS 
No prior enzalutamide 
De Bono 201152 797 8 months 29% 5.6 months 
Prior enzalutamide 
Loriot 2013132 38 3 months 8% 2.7 months 
Noonan 2013133 30 3 months 3% 3.6 months 
Similarly, enzalutamide treatment as third line therapy after docetaxel and after abiraterone 
has been evaluated and indication of cross resistance is emerging. (Table 39). 
Table 39. Studies examining the cross resistance in the sequence enzalutamide: abiraterone. 
Author n Median abiraterone duration 
Pts with ≥50% 
PSA decline Median PFS 
No prior abiraterone 
Scher 201210 800 8.3 months 54% 8.3 months 
Prior abiraterone 
Schrader 
2013134 35 4.9 months 29% 2.8 months 
Thomsen 
2013106 24 4.0 months 17% 2.8 months 
Badrising 
2014135 61 3.0 months 21% 2.8 months 
Bianchini 
2014136 39 2.9 months 23% 3.1 months 
Schmid 2014137 35 2.8 months 10% 4.6 months 
Azad 2015138 68 4.1 months 22% - 
Brasso 2014139 137 3.2 months 18% - 
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Author n Median abiraterone duration 
Pts with ≥50% 
PSA decline Median PFS 
Joshua 2015140 507 2.6 months - - 
Reviews of the literature suggest that there is no clear evidence of a clinical benefit of 
sequential therapy with these agents141, 142 Indeed a very recent systematic review of 
published studies suggested that patients treated with 2 advanced hormonal therapies in 
sequence post-docetaxel may have shorter OS than those sequences containing 
cabazitaxel143  
In the literature review carried out for this submission three full papers and 11 conference 
abstracts were identified with evidence for abiraterone or enzalutamide in the post-docetaxel 
setting. Since the review was carried out four further papers have been published which 
contain similar evidence. These studies are summarized in Table 40. All of these studies 
were retrospective cohort studies with the exception of the study by Onstek which 
considered biomarkers assayed before the start of the first and the third cycle of cabazitaxel 
during the randomized, Phase 2, open-label, multicenter study in mCRPC on the 
pharmacodynamic effects of budesonide on cabazitaxel (Jevtana) (CABARESC). A further 
poster presentation by Oudard on the updated results from the FLAC database of mCRPC 
patients has become available after presentation at ECC 2015 (European Cancer 
Congress).144 
In addition to the articles above, a review by Maines of all the available evidence on the use 
of cabazitaxel, abiraterone and enzalutamide in the post docetaxel setting was published just 
prior to this submission.143 
These articles provide evidence to support the continuing efficacy of cabazitaxel after 
treatment with advanced hormonal therapy (post-docetaxel setting) and are listed in Table 
40 overleaf and are discussed further in appendix 20. 
Taken as a whole the available evidence suggests that cabazitaxel remains potent in 
patients previously treated with the advanced hormonal agents abiraterone and 
enzalutamide. This could be due, at least in part, to the differing modes of action for the 
chemotherapeutic and the androgen-axis targeted agents and these have been discussed 
earlier in Section 3.3.  
These articles provide evidence to support the continuing efficacy of cabazitaxel after 
treatment with advanced hormonal therapy (post-docetaxel setting) and are listed in Table 
40 overleaf and discussed below 
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Table 40. Studies with evidence on the effect of pre-treatment with abiraterone or enzalutamide on cabazitaxel efficacy. 
Reference Country Outcome Objective 
Full papers 
Caffo, 2015145 Italy 
OS (primary), PFS, PSA 
response (biochemical RR), 
ORR 
To provide an estimate on the clinical outcomes relating to a large cohort 
of patients with mCRPC who received a third-line new agent after the 
failure of docetaxel and another new agent. 
Pezaro, 2014146 UK 
PSA response, PFS, OS, 
symptomatic benefit 
(reported here as pain) 
To describe the antitumour activity of cabazitaxel after docetaxel and next 
generation endocrine agents 
Sella, 2014147 Israel PSA response, radiographic response, OS 
To review the experience with cabazitaxel given to mCRPC patients 
whose disease had progressed after docetaxel-based chemotherapy and 
abiraterone. 
Nakouzi, 2015148 Not reported 
PFS (radiographic or PSA), 
OS 
To evaluate the antitumour activity of cabazitaxel in mCRPC pretreated 
with abiraterone or enzalutamide. 
Onsteck, 2015149 Netherlands 
Primary end point was the 
association between the 
AR-V7 status and the 
circulating tumour cells 
Secondary end points: PSA 
response rate, OS 
To investigate the association between AR-V7 expression in circulating 
tumour cells and resistance to cabazitaxel. 
Van Soest, 
2015150 Netherlands 
OS (primary), PFS, PSA 
response 
The primary objective was to explore the influence of prior abiraterone or 
enzalutamide use on the efficacy of cabazitaxel in patients with mCRPC 
Sponvade, 
2105151 US 
OS and Time to Treatment 
Failure (TTF) 
Objective 1: To characterize patients receiving different sequences of 
cabazitaxel and abiraterone after docetaxel. 
Objective 2: To estimate and compare clinical outcomes in patients 
receiving these different sequences of therapy. 
Company evidence submission template for Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a 
docetaxel-containing regimen 
 Page 111 of 211 
 
Reference Country Outcome Objective 
Maines, 2015143 Multicountry OS 
To explore the clinical outcomes of mCRPC patients who were treated with 
third-line cabazitaxel, abiraterone or enzalutamide after having previously 
received docetaxel in order to determine if treatment sequence is 
important in terms of overall survival. 
Conference abstracts 
Wissing, 2013152 Netherlands 
OS (primary), PFS, 
biochemical PFS, best 
clinical and PSA response, 
safety 
To report the clinical outcome of Dutch mCRPC patients treated with both 
cabazitaxel and abiraterone after receiving docetaxel as first-line therapy, 
evaluating antitumor activity and safety of both agents. 
Bracarda 2013 
(ASCO)153 Italy PFS 
To analyse patients treated with both abiraterone and cabazitaxel in terms 
of best sequencing evaluation and potential predictive and prognostic 
factors for different treatment sequences in a real world scenario. 
Caffo 2015 
(ASCO-GU)154 Italy 
PFS, OS, ORR, PSA 
response 
To assess the activity of new agents in patients who previously 
experienced a primary resistance to another new agent administered after 
docetaxel 
Clement-Zhao 
2015 (ASCO-
GU)155 
France Safety, PSA response, TTP (biochemical), rPFS, OS To evaluate safety and efficacy of a 2-weekly cabazitaxel schedule 
Houts 2013 
(ASCO's Quality 
Care 
Symposium)156 
US OS, PFS 
To examine whether mCRPC patients progressing on docetaxel received 
cabazitaxel and/or abiraterone, in which sequence, and how they 
compared with patients not receiving cabazitaxel or abiraterone 
Kellokumpu-
Lehtinen 2015 
(ASCO-GU)157 
Finland Safety (primary) To evaluate the safety of 2-weekly cabazitaxel as post-docetaxel treatment for mCRPC 
Oudard 2014 France, PSA response, OS, PFS To evaluate the impact of prognostic factors and sequencing on OS 
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Reference Country Outcome Objective 
(ESMO)158 Spain, 
Turkey 
calculated from the first therapy post-docetaxel. 
Pezaro 2013 
(ASCO-GU)159 
UK and 
France 
Radiological response, PSA 
response, symptomatic 
benefit 
To evaluate the antitumor activity of cabazitaxel after abiraterone 
Pfister 2012 
(ASCO-GU)160 Germany 
PSA response rate, PSA 
stabilization, safety 
To compare the PSA response and complication rate of these three 
different second-line treatment options: cabazitaxel, abiraterone and 
docetaxel re-challenge. 
Saad 2014 
(ASCO)161 Canada PSA response, HRQL 
To better understand the impact of prior abiraterone treatment on 
cabazitaxel efficacy and HRQL. 
Sonpavde 2013 
(ESMO)162 US OS, TTF 
To evaluate treatment patterns, OS, and TTF among post-docetaxel 
mCRPC patients receiving both abiraterone and cabazitaxel 
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4.12 Adverse reactions 
4.12.1 Evidence from sources other than TROPIC.  
The adverse event profile from the TROPIC study is presented Section 4.12.2 below. 
The systematic review of the literature for non-RCT evidence described in section 4.11 
above identified a number of studies which included safety of cabazitaxel as the primary end 
point. In particular the Compassionate Use Program / Early Access programmes (CUP/EAP) 
provide key data to supplement the results from TROPIC with data collected in clinical 
practice. The published interim results from these observational studies have been 
presented in Section 4.11.9 above (Table 36) for key adverse events and are discussed 
below in Section 4.12.3 
In addition to these published data several registries are being conducted by Sanofi around 
the world and one in particular, the prospective product registry in Belgium (CABAZL06515: 
HRQLANA), has provided results not yet published. (09/02/2015) The aim of this study was 
to describe the use of cabazitaxel in combination with oral prednisone (or prednisolone) for 
the treatment of patients with mCRPC. This is also discussed below in Section 4.12.3.  
 
In the UK the ECLIPSE study, described in Appendix 20, which aimed to describe the anti-
cancer treatment pathways, clinical outcomes and patient characteristics for patients who 
have received cabazitaxel following prior docetaxel treatment has reported OS results. 
Analysis of adverse events is ongoing and may be available within the timeframe of this 
submission. Furthermore the period risk benefit evaluation report is presented in brief in 
Section 4.12.3. 
4.12.2. Summary of adverse reactions. 
Adverse events in TROPIC were collected from the time the first dose of the study drug until 
30 days after the administration of the last cycle of study treatment. Toxicity was graded 
according to the National Cancer Institute Common Terminology Criteria for Adverse Events, 
Version 3.0 (NCI CTCAE v. 3.0) and summarized using Medical Dictionary for Regulatory 
Activities (MedDRA) terminology Version 12.0. 
Serious adverse events were reported from the signature of informed consent up to 30 days 
after the last dose of study medication. After the 30 day follow-up visit, ongoing SAEs were 
followed until resolution or stabilization. At the end of study treatment, all AEs and SAEs 
considered related to study treatment were followed until resolution.  
Patients in the cabazitaxel group received a median of 6 cycles of treatment and patients in 
the mitoxantrone group received a median of 4 cycles of treatment (range: 1 to 10 cycles in 
both arms). The cumulative doses were consistent with the number of cycles received.  
 
The median relative dose intensity (RDI) was 96.12% with a range of 49.0% to 108.2% for 
the cabazitaxel group and 97.25% with a range of 42.5% to 106.0% for the mitoxantrone 
group. This indicates that the intended dose of cabazitaxel and mitoxantrone could be 
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delivered. In the cabazitaxel group, 9.8% of cycles were administered with a dose reduction 
of ≥20% and 9.3% of cycles were delayed by ≥4 days compared with 5.1% of cycles dose 
reduced and 7.9% cycles delayed, respectively, in the mitoxantrone group. 
 
Treatment emergent adverse events of Grade ≥3 occurred in 57.4% of patients in the 
cabazitaxel group and 39.4% of patients in the mitoxantrone group. Serious TEAEs were 
reported in 39.1% of patients in the cabazitaxel group and 20.8% of patients in the 
mitoxantrone group. The proportion of patients withdrawing from study treatment due to any 
TEAE (including disease progression reported as a TEAE) was 18.3% in the 
cabazitaxel group compared with 8.4% in the mitoxantrone group. The incidence of TEAEs 
(not coded as disease progression) leading to death was 4.9% in the cabazitaxel group and 
1.9% in the mitoxantrone group. 
 
The most common AEs (Grade 3 events occurring in 5% of patients in either treatment 
group) are summarised in Table 42. The most common events were neutropenia and its 
complications (febrile neutropenia and infections), asthenic conditions (asthenia and fatigue), 
and gastrointestinal toxicity (diarrhoea, nausea and vomiting).8 
The most important AE associated with cabazitaxel is neutropenia, due to the potential for 
serious clinical complications. Neutropenia is to be expected when treating with taxane-
based chemotherapy and is not necessarily difficult to manage for experienced centres 163 
However, complications of neutropenia such as neutropenic sepsis and febrile neutropenia 
are serious clinical events. As can be seen in Table 42, patients treated with cabazitaxel had 
higher rates of neutropenia, (7.3% vs. 21.0% of patients based on adverse event 
declaration) and higher rates of infections and febrile neutropenia (1.6% vs. 7.3% of patients 
based on adverse event declaration). 
The clinical consequences of neutropenia were the most frequent cause of adverse event 
related death in the cabazitaxel group, with seven neutropenia-related deaths in comparison 
with one in the mitoxantrone group. The occurrence of these deaths prompted advice to the 
TROPIC investigators to manage neutropenia by strictly following the protocol regarding 
dose modification and delay and treating neutropenia as per ASCO guidelines.41 Following 
this, no new neutropaenic deaths were reported. This shows that it is critically important that, 
as with other similar chemotherapies, neutropenia is appropriately managed, particularly 
when patients are newly started on cabazitaxel treatment. 
With the exception of the haematological adverse events the side effects (grades 3 and 
over) in both treatment arms were generally well balanced. The exceptions were grade ≥3 
diarrhoea and fatigue which were more common for patients taking cabazitaxel (6.2% and 
4.9%) compared with mitoxantrone (0.3% and 3.0%)  Table 42. 
The number of deaths in TROPIC are summarised in Table 41.  Eighteen (5%) patients 
treated with cabazitaxel and nine (2%) treated with mitoxantrone died within 30 days of the 
last infusion. All of these deaths in the cabazitaxel group were considered related to TEAEs, 
whereas six in the mitoxantrone group were related to disease progression.8  
Company evidence submission template for Cabazitaxel for hormone-relapsed 
metastatic prostate cancer previously treated with a docetaxel-containing regimen 
 Page 115 of 211 
 
Table 41. Deaths reported in the TROPIC trial – ITT population. 
Outcome Mitoxantrone + prednisone (n=377) 
Cabazitaxel + prednisone 
(n=378) 
Total deaths during the study (%) 308 (81.7) 277 (73.3) 
Number of patients censored (%) 69 (18.3) 101 (26.7) 
A total of 68 patients (18.3%) in the cabazitaxel group and 31 patients (8.4%) in the 
mitoxantrone group withdrew from the study due to AEs. The most common TEAEs leading 
to treatment discontinuation in the cabazitaxel group were neutropenia (2.4%), hematuria 
(1.3%), diarrhoea, fatigue, renal failure acute (1.1% each), and abdominal pain, febrile 
neutropenia, sepsis, and renal failure (0.8% each). In the mitoxantrone group the most 
common TEAEs leading to treatment discontinuation were asthenia, back pain, pulmonary 
embolism, cardiotoxicity, and ejection fraction decreased (0.5% each). 
Table 42. Adverse events grade 3 or above reported in patients in TROPIC who received at 
least one dose of study treatment*. Subgroup ECOG-PS 0-1 with 225mg/m2 prior docetaxel 
exposure and ITT populations. 
  
Proportion of patients – ECOG-PS 
0-1 with 225mg/m2 prior docetaxel Proportion of Patients - ITT 
Adverse Event Cabazitaxel Mitoxantrone Cabazitaxel Mitoxantrone 
Neutropenia 0.201 0.081 0.210 0.073 
Febrile neutropenia 0.080 0.019 0.073 0.016 
Diarrhoea 0.064 0.003 0.062 0.003 
Fatigue 0.051 0.023 0.049 0.030 
Asthenia 0.042 0.019 0.046 0.024 
Leukopenia 0.032 0.013 0.038 0.013 
Back pain 0.038 0.032 0.038 0.030 
Anaemia 0.032 0.006 0.035 0.013 
Thrombocytopenia 0.022 0.000 0.024 0.003 
Pulmonary embolism 0.019 0.026 0.019 0.022 
Dehydration 0.016 0.006 0.022 0.008 
Nausea 0.019 0.003 0.019 0.003 
Bone pain 0.010 0.026 0.008 0.024 
Deep vein thrombosis 0.016 0.010 0.019 0.008 
Neuropathy  0.006 0.003 0.005 0.003 
*AEs reported by the investigator. (These do not include abnormal laboratory values). 
4.12.3 Details of the additional studies that report additional adverse reactions. 
A summary of the safety and efficacy results from the full publications for the CUP/EAPs for 
cabazitaxel which includes safety as a primary end point or reports adverse events as 
secondary outcomes has been presented in Section 4.11.11. The methodology used to 
identify these published articles and conference abstracts has been described in Section 
4.11 and Appendix 6. In the following section adverse events in the CUP/EAP are described. 
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Further conference abstracts for ongoing studies are presented in brief and the results from 
the prospective cabazitaxel product registry in Belgium are discussed. In addition a brief 
summary of the Cabazitaxel Periodic Benefit Risk Evaluation Report is presented. 
Adverse events in the CUP/EAP 
The results of the EAP extend the knowledge of the safety profile reported in TROPIC to 
settings more reflective of everyday clinical practice. The first entry in Table 36 above 
contains the equivalent data from the TROPIC study. Note that the safety results reported in 
the original paper are associated with lab values for the hematological events.8 Any 
comparison must be treated with some caution113 for the following reasons:  
 It is possible that the patients included in the TROPIC trial and CUP/EAP had a 
different disease burden. 
 TROPIC was conducted in 26 countries in Europe, North America, Latin America, 
India, Asia and South Africa, and it appears that some centres were not sufficiently 
experienced in monitoring and managing the toxicities of chemotherapy.  
 Haematology was monitored on a weekly basis in TROPIC while it was collected 
before each injection in the European CUP/EAP in order to reflect real-life practice. 
 Prophylactic G-CSF at the first cabazitaxel cycle was not allowed in TROPIC (it was 
allowed at physicians’ discretion after first occurrence of either neutropenia lasting 7 
days or more or neutropenia complicated by fever or infection) while in the European 
CUP/EAP, prophylactic G-CSF was allowed from the first cycle, as per ASCO and 
EORTC guidelines. 
With these caveats in mind the results from these interim analyses of the EAP shown in 
Table 36 above, suggest cabazitaxel to be a well-tolerated agent in clinical practice. This is 
despite concerns raised over the high incidence of neutropenia and neutropenic sepsis in 
the TROPIC trial.3 Indeed there were comparatively low rates of neutropenia (7 to 34% vs. 
82%8 in TROPIC) and febrile neutropenia in the EAP cohorts (2 to 6 % vs. 8% in TROPIC: 
note the results from Lee (31%) are discussed below).112 The lower incidence data may be 
partially due to a more rigorous application of the ASCO guidelines for prophylaxis with G-
CSF and the general management of febrile neutropenia, as well as improved preventative 
(proactive) patient education regarding possible treatment-related adverse events. Note that 
prophylactic G-CSF was not permitted during the first cycle in TROPIC, but thereafter was 
permitted at physician’s discretion and was mandated for prophylaxis after first occurrence of 
neutropenia.  
Whilst other adverse events were of similar or lower incidence, febrile neutropenia was 
higher in the Korean population (n = 26) studied in the EAP than in TROPIC (31% vs. 
7.3%).112 In a previous Japanese Phase I study, grade 3–4 neutropenia developed in Whilst 
both of these studies were carried out in small numbers of patients and only 60% of patients 
in the Korean EAP received G-CSF prophylaxis these results could suggest that cabazitaxel 
maypossibly have a lower clearance than in caucasians resulting in higher circulating 
concentrations.. This is reminiscent of pharmacoethnicity effects on toxicities associated with 
docetaxel.124 However, higher circulating concentrations may also results in a higher efficacy 
as suggested by a recent Phase II study comparing docetaxel (75mg/m2) plus prednisone 
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versus mitoxantrone plus prednisone in Chinese mCRPC patients. Docetaxel was 
associated with a higher rate of grade ≥3 neutropenia than in TAX327 (57.7% versus 32%) 
but the survival benefit was much higher (21.9 versus 13.7 months, HR 0.63) than in 
TAX327 (18.9 versus 16.5, HR 0.76).127 Similar findings have been observed in a post-hoc 
analysis of TROPIC study suggesting that patients experiencing grade ≥3 have an improved 
OS, PFS and PSA response.128 It is noteworthy that with the exception of one patient in the 
Korean EAP, no patients who received prophylactic G-CSF developed febrile neutropenia 
throughout the entire chemotherapy course. Nonetheless Lee et al. suggest that based on 
patient characteristics and efficacy results cabazitaxel demonstrates at least a comparable 
efficacy in Korean mCRPC patients and Western patients.112 
 
In addition to the EAP there are a number of other studies seeking to evaluate the efficacy 
and safety of cabazitaxel as a weekly or bi-weekly infusion (the current label indicates 
dosing at 3 weekly intervals). Several conference abstracts have been published that include 
some results from these programs. (Table 43). 
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Table 43. Conference abstracts with safety information 
Reference  Country Dose  Regimen n  Age 
ECOG/WHO 
performance 
status, n (%) 
Deaths
AEs grades ≥3 % 
0  1 ‐ 2 
Any 
grade 
3/4 
Neutro‐
penia 
Febrile 
neutro‐
penia 
Anaemia 
Diarrhoea Nausea 
Calvo 2015 
(ASCO‐
GU)164 
Spain  10 
mg/m2 
IV 
weekly  70 
73 
(54–84)  33%  67%  NR  NR  12.1  7.6  71.2  27.3  18.2 
Clement‐
Zhao 2015 
(ASCO‐
GU)155 
France  16 
mg/m2 
IV every 
2 weeks  26  66.5  69%  31%  NR  NR  23.8  NR  33.3  0.0  NR 
Kellokumpu‐
Lehtinen 
2015 (ASCO‐
GU)157 
Finland  16 
mg/m2 
IV every 
2 weeks  40  NR  33%  67%  NR 
18 
(45)  15.0  NR  5.0  NR  NR 
Gonzalez 
2014 
(ASCO)165 
Spain  NR  NR  99  70  77%  23%  NR  17 
(17.2)  5.0  0.0  2.0  2.0  NR 
Nicacio 
2012 
(ESMO)166 
US  NR  NR  373 (45–88)  NR  NR  57  NR  7.2  NR  2.4  5.6  3.8 
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Safety results from the prospective product registry in Belgium 
This study has reported internally. 
This was a national, multicenter, observational (non-interventional on the therapeutic 
strategy) prospective product registry to assess the use of cabazitaxel in combination with 
oral prednisone (or prednisolone) in real-life for the treatment of mCRPC patients 
(HRQLana). Registry number:  CABAZL06515. Data collection lasted until death or until 
registry cut-off, whichever came first. There was no protocol defined visit schedule and visits 
took place according to the clinical practice. The study population consisted of all patients 
eligible for a treatment with cabazitaxel for their prostate cancer, according to the Belgian 
reimbursement criteria and who presenting none of the contraindications listed in the SmPC 
and for whom the decision to start a cabazitaxel treatment had already been taken. 
Demographic data is provided in Table 44  below. 
Table 44. Baseline patient characteristics for the patients enrolled in HRQLANA 
Number of patients 
Academic in confidence information removed 
Mean age, years (SD) 
Median age, years (range) 
Median time since 
diagnosis 
median time since 
castration-resistant 
disease diagnosis 
Gleason score 
Baseline PSA 
ECOG performance score 
 
The most frequent first line therapies were chemotherapy alone for Academic in confidence 
information removed  of the patients and together with other targeted therapies for Academic 
in confidence information removed, and hormono-targeted therapy alone (Academic in 
confidence information removed ).  About Academic in confidence information removed had 
a second line therapy, among which hormono-targeted therapy only was the most frequent 
(Academic in confidence information removed of the patients treated in second line), 
followed by chemotherapy only Academic in confidence information removed were treated in 
third line, Academic in confidence information removed of whom received chemotherapy and 
Academic in confidence information removed hormono-targeted therapy.  Academic in 
confidence information removed were treated in fourth line, among which Academic in 
confidence information removed received chemotherapy and Academic in confidence 
information removed hormono-targeted therapy. 
All Academic in confidence information removed patients only treated in first line received 
chemotherapy.  Among the Academic in confidence information removed patients having 
received two lines of treatment most Academic in confidence information removed were 
treated with chemotherapy (docetaxel) followed by hormono-targeted therapy (abiraterone).  
Among the Academic in confidence information removed having received three lines of 
treatment Academic in confidence information removed were first treated with 
chemotherapy, followed by hormono-targeted therapy, and chemotherapy again. 
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Treatment-emergent adverse events (TEAEs) were reported for Academic in confidence 
information removed, SAEs for Academic in confidence information removed), AEs 
considered related to the study medication for Academic in confidence information removed , 
AEs with NCI CTCAE grade of at least Academic in confidence information removed . AEs 
causing premature drug discontinuation for Academic in confidence information removed 
and AEs with fatal outcome for Academic in confidence information removed 
 
The System Organ Class for which the occurrence of related AEs with NCI CTCAE grade at 
least 3 was the most frequent was blood and lymphatic system disorders (Academic in 
confidence information removed) followed by general disorders and administration site 
conditions (Academic in confidence information removed) and infections and infestations 
(Academic in confidence information removed). The most frequent Preferred Terms for 
related AEs with NCI CTCAE grade at least 3 were febrile neutropenia (Academic in 
confidence information removed), neutropenia (Academic in confidence information 
removed), anaemia (Academic in confidence information removed) and fatigue (Academic in 
confidence information removed). 
The HRQLANA study population is more heterogeneous in terms of baseline patient, 
disease characteristics, and tumour heterogeneity than the TROPIC cohort and the changing 
treatment landscape in mCRPC with the emergence of new therapies since TROPIC mean 
that therapeutic pathways are now different. This means that direct comparisons are not 
possible.  
However despite this heterogeneity the results suggest that cabazitaxel in the real-life setting 
has a similar safety profile to that seen in the CUP/EAP results discussed earlier. At the time 
of this interim analysis, Academic in confidence information removed patients discontinued 
treatment, from which Academic in confidence information removed presented disease 
progression.  The median PFS at this stage is of Academic in confidence information 
removed  days (Academic in confidence information removed  months) for the entire study 
group. (In the TROPIC study, the median PFS for patients treated with cabazitaxel was 
Academic in confidence information removed months). For the OS results, the data at 
interim analysis are still immature with only Academic in confidence information removed 
deaths reported. Longer follow-up is needed to provide OS data. 
Cabazitaxel Periodic Benefit Risk Evaluation Report 
 
Cabazitaxel received marketing authorisation in all 27 countries of the European Union 
(EU) in March 2011 and so has been in use in clinical practice for approximately four years. 
An annual periodic safety update report is compiled by Sanofi which summarizes the 
information received from worldwide sources by the Sanofi Global Pharmacovigilance and 
Epidemiology department. The latest issue of this report covers the period from 17th June 
2013 to 17th June 2014. 
To date approximately 36 550 patients have been exposed to cabazitaxel around the world 
including 11 800 patients during the reference period covered by the latest report (17th June 
2013 to 17th June 2014). Approximately 4502 cumulative subjects/patients were exposed to 
cabazitaxel in clinical trials up-to the data lock point of the report (17th June 2014). 
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The safety information presented in the Periodic Benefit Risk Evaluation Report is consistent 
with the known safety profile of cabazitaxel. The observed adverse reactions or any other 
safety data does not suggest a change in the benefit-risk profile of cabazitaxel. In 
conclusion, the extensive clinical and post-marketing experience with cabazitaxel is 
considered to have demonstrated the therapeutic value of the compound. The safety profile 
of cabazitaxel is comparable to that of other products in this therapeutic class. Overall, 
based on the review of safety and efficacy data, Sanofi considers that the benefit-risk 
balance of cabazitaxel in the treatment of mCRPC in patients previously treated with a 
docetaxel-containing regimen is favourable and in line with the findings in the EPAR, that 
routine pharmacovigilance is sufficient to monitor the safety profile of cabazitaxel. 
Although subject to the limitations of the post-marketing voluntary adverse event reporting 
systems, the emerging safety profile of cabazitaxel is consistent with and indeed may be 
better than that observed in the TROPIC clinical trial setting. 
Other studies  
Published Phase III safety evidence for cabazitaxel is limited to the TROPIC study as 
discussed in Section 4.2 and the Early Access Program (EAP) (Section 4.11.9).  No 
additional Phase III RCT evidence is currently available for cabazitaxel beyond the updated 
TROPIC analysis for which the safety and adverse event data has been described earlier in 
Section 4.12.2. At the time of writing (21/09/2015) there are 12 Phase III studies listed on 
ClinicalTrials.gov, completed or ongoing, examining the efficacy and/or safety of cabazitaxel, 
some of which are sponsored by Sanofi. (Table 45). 
TROPIC and the EAP have been discussed earlier but amongst the other studies 
PROSELICA (NCT01308580), may provide additional information about the safety of 
cabazitaxel in mCRPC which could supplement the original TROPIC data within the 
timeframe of this submission. PROSELICA is discussed in more detail below in Section 4.14.
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Table 45. Phase III cabazitaxel RCTs listed on clinicaltrials.gov (23/07/2015). 
NCT Number Acronym Title n  Completion 
Date  Sponsor/Collaborators 
NCT00417079 TROPIC XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer 755  01/09/2009  Sanofi 
NCT01083615  
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to 
Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With 
Metastatic Castrate Resistant Prostate Cancer (mCRPC) 
14  01/03/2013 
OncoGenex 
Technologies|Teva 
Pharmaceuticals USA 
NCT01254279 EAP Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen 984  01/12/2014  Sanofi 
NCT01308580 PROSELICA Cabazitaxel at 20 mg/mÂ² Compared to 25 mg/mÂ² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer 1200  01/07/2015  Sanofi 
NCT01308567 FIRSTANA Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer 1170  01/08/2015  Sanofi 
NCT01578655 AFFINITY Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer 630  01/12/2015 
OncoGenex 
Technologies|Teva  
NCT02044354 CABA-DOC Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer 174  01/02/2016 
Gustave Roussy, 
Cancer Campus, Sanofi 
NCT02074137  
Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic 
Hormone Refractory Prostate Cancer 10  01/02/2016  Sanofi 
NCT01649635 PROSPECTA 
Study of Cabazitaxel Combined With Prednisone and Prophylaxis of 
Neutropenia Complications in the Treatment of Patients With Metastatic 
Castration-resistant Prostate Cancer 
45  01/03/2016  Sanofi 
NCT02441894 PEGAZUS Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer 25  01/12/2016  Sanofi 
NCT01978873 SensiCab Efficacy Study Evaluating Chemotherapy in Prostate Cancer 400  01/11/2019  Ã–rebro University, 
Sweden 
NCT01952223 PEACE2 A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse 1048  01/09/2026  UNICANCER 
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PROSELICA is a Randomized, Open Label Multi-Centre Study designed to demonstrate 
non-inferiority in terms of overall survival (OS) for patients with mCRPC previously treated 
with a docetaxel-containing regimen taking cabazitaxel 20 mg/m² versus cabazitaxel 25 
mg/m² in combination with prednisone. Secondary objectives include a comparative 
assessment of the tolerability and safety of the 20 mg/m² dose versus 25 mg/m².  
PROSELICA is expected to achieve database lock in August/September 2015 and so 
adverse event data from PROSELICA is not presented here. However should this become 
available within the timeframe of this submission an addendum may be presented at the 
earliest appropriate opportunity.  A description of the study is provided in  
 
Table 47 along with further discussion about the relevance of the data to the decision 
problem. 
The FIRSTANA (NCT01308567) study may also provide preliminary outputs within the 
timeframe of this appraisal; however this study is in patients who are chemotherapy naïve 
and so falls outside the indication discussed in this submission. 
Other studies listed in Table 45 are not due to report until 2016 or later, or are not sponsored 
by Sanofi. Further description of ongoing studies is provided in Section 4.14. 
4.12.4 Overview of the safety of the technology in relation to the decision 
problem. 
The most common AEs observed in the cabazitaxel arm in TROPIC were neutropenia and 
its complications (febrile neutropenia and infections), asthenic conditions (asthenia and 
fatigue), and gastrointestinal toxicity (diarrhoea, nausea and vomiting) (Table 42). These are 
common to cytotoxic agents and the taxanes as a class.18 
The emerging evidence from the EAP (Table 31 and Table 32) and other sources discussed 
above suggests that these AEs are managed well in clinical practice. Treatment with 
granulocyte colony-stimulating factor (G-CSF) may mitigate haematologic adverse events, 
whereas supportive treatment with antiemetic and antidiarrhoeal agents may ameliorate 
gastrointestinal symptoms as per ASCO guidelines.41 A Phase III study is ongoing to 
investigate the prophylaxis of neutropenia complications in the treatment of mCRPC 
(POSTECTA, NCT01649635) Table 45, but this will not report within the timeframe of this 
submission.  In addition patient education and close monitoring for development of 
neutropenia all contribute to this improved AE event profile in clinical practice. 
European regulatory opinion, as reported in the EPAR, was that cabazitaxel had a positive 
risk-benefit profile, with no requirement for a specific risk management plan.3 This reflects 
the fact that the side-effects of cabazitaxel are predictable and manageable. Further, the 
higher risk of AEs is outweighed by the efficacy of cabazitaxel, which results overall in 
increased survival. In the economic evaluation, the costs and disutilities associated with AEs 
(≥ Grade 3) are fully considered.   
The safety information presented in the Periodic Benefit Risk Evaluation Report (Section 
4.12.1) suggests that the safety profile of cabazitaxel in clinical practice is comparable to that 
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of other products in this therapeutic class and that routine pharmacovigilance is sufficient to 
monitor the safety profile of cabazitaxel. 
4.13 Interpretation of clinical effectiveness and safety evidence  
4.13.1 A statement of principal findings from the clinical evidence highlighting 
the clinical benefits and harms of the technology. 
The TROPIC trial in mCRPC patients who have progressed after docetaxel, directly 
compared cabazitaxel with mitoxantrone. The primary outcome was Overall Survival (OS), 
which is clinically relevant and not susceptible to bias or limitations in assessment. The 
results of this study show a statistically and clinically meaningful prolongation in OS for the 
ITT population as measured by both median (difference of 2.3 months) and mean OS 
(difference of 4.02 months). Mean OS difference represents an increase in survival of 
approximately 30% for this patient group.  
The most common adverse effects due to cabazitaxel observed in the TROPIC study were 
haematological, in particular neutropenia, leukopenia, and anaemia.8 The most common 
nonhaematological grade 3 or higher adverse event was diarrhoea. (Table 42).  Neutropenia 
in particular occurred at a high rate in the TROPIC trial population but it was shown to be 
less prevalent in the CUP/EAP where cabazitaxel was used in clinical practice (Overall 
results for the EU EAP, n= 746: 17% EAP vs. 21% in TROPIC111) (82% is reported in the 
original publication and in Heidenreich, 2014,111 but this result is higher as it captures all 
positive laboratory results for neutropenia and not only those identified in clinical practice) 
(See also Section 4.12.1). Accumulating evidence from the CUP/EAPs around the world 
indicates that real-world toxicity of cabazitaxel is less than that experienced in the TROPIC 
trial and is manageable with appropriate prophylactic and supportive care measures.111 The 
UK EAP has shown that cabazitaxel in combination with prednisolone is generally well 
tolerated after prior docetaxel chemotherapy. Patients treated with cabazitaxel also showed 
stable HRQL scores with a trend towards improvement and reduction in the incidence and 
severity of pain.12 This suggests that cabazitaxel is not associated with a significant negative 
effect on utility, and may improve utility through stabilising disease and controlling 
symptoms. The EQ-5D results for the UK EAP are presented in Section 5.4.1.  
It is important to consider how cabazitaxel and other therapies should be used at each point 
in disease and to reflect when the drug’s mode of action is most appropriate for tackling the 
properties the prostate cancer is expressing and the particular patients’ needs.   Recently 
the underlying cellular and molecular mechanisms responsible for the heterogeneity 
observed within and between individual prostate cancers has become more clearly 
understood. 
4.13.2 Discussion of the strengths, limitations, validity and relevance of the 
clinical evidence base for the technology. 
TROPIC was a large (755 patients) multicentre trial. The study was well conducted and 
adequately powered and this was recognised in the ERG report to TA255.4 Analysis of time-
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to-event efficacy outcomes, including the primary outcome, was conducted on the ITT 
population providing internal validity. The interim analyses were conducted by an external 
contract statistician and reviewed by an IDMC and the results were not disclosed to the trial 
sponsor. The number of patients lost to follow-up was low.  
Over 80% of the patients included in the TROPIC study had an ECOG PS of 0–1 and prior 
use of docetaxel of at least 225 mg/m2 which is reflective of the population in whom 
cabazitaxel is used in clinical practice in the UK. 
The dosing schedule used in the TROPIC trial was consistent with the dosing schedule 
detailed in the summary of product characteristics,15 consisting of 25 mg/m2 (Day 1) 
intravenous infusion over 60 minutes every three weeks, and prednisone 10 mg orally given 
daily. In clinical practice the median number of cycles of treatment observed is 6117 and this 
was also the number observed in TROPIC. Not all patients who have progressed after 
docetaxel receive cabazitaxel rather; cabazitaxel is best used in a subset of patients with 
good performance status who are able and willing to tolerate further chemotherapy.19 The 
patients included in TROPIC are representative of this group. 
A criticism cited by the ERG in the report to TA255 was that the age of the population in 
TROPIC may have been ‘younger than is typical of patients with docetaxel-resistant mHRPC 
who are generally seen in the UK’.  However the baseline patient characteristics from the UK 
EAP12 and also the ECLIPSE study (see Appendix 20) indicate that patients treated in 
clinical practice with cabazitaxel in the UK are of a similar age to the TROPIC population 
(Mean age in years: UK EAP: 67.0 (IQR: 63 – 72.5); ECLIPSE: 69.4 (SD: 6.69); TROPIC: 68 
(IQR: 62 – 73)). Similarly it was speculated that there may be fewer co-morbidities amongst 
the TROPIC population than would be expected in clinical practice. ECLIPSE provides an 
estimate of the co-morbid status of UK cabazitaxel patients in clinical practice. In this study 
47% of patients had no co-morbidity, 40% had 1 and 9.6% had two or more co-morbidities 
with 0.4% of patients unknown.  
The TROPIC trial directly compares cabazitaxel and mitoxantrone (both with prednisolone), 
in this population. Mitoxantrone is the most valid comparator for cabazitaxel in the pathways 
described (Figure 3) due to the established place of cabazitaxel in current practice and the 
likelihood that if cabazitaxel were to be removed, mitoxantrone, although a retrograde step, 
is likely to be its replacement.   The nature of mCRPC and the requirement for different 
options (Section 3.1) and the changing needs of patients means that cabazitaxel, 
abiraterone, and enzalutamide must all be available for use at the physicians discretion as 
the patient’s circumstances demand.  
Indirect comparisons to abiraterone and enzalutamide, whilst technically possible, are of 
limited validity for several reasons.  The data has significant limitations for comparison, 
including differences in the patient populations, variations in the endpoints reported, and 
indeed variations in the conduct of the trials particularly in relation to treatment continuations.  
Therefore whilst the results of the network meta-analysis highlight the similarity in the 
results, their respective roles are complimentary, rather than alternatives. (Appendices B). 
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The lack of a standard deﬁnition for PFS in mCRPC trials has proved problematic notably in 
the comparison with the COU-AA-301 and AFFIRM studies summarised in scenario analysis 
in Section 4.10 and Appendices B. TROPIC study was designed before the development of 
a standardised definition of PFS for prostate cancer trials. Disease progression was defined 
as the time between randomisation and the first date of progression as measured by PSA 
progression, tumour progression using RECIST criteria, pain progression or death. Although 
time to PSA progression is associated with PFS,167 time to PSA progression usually 
precedes symptomatic or radiologic progression. Patients were withdrawn from study 
treatment on the first sign of progression, including confirmed PSA progression. The 
relatively short PFS duration (in comparison with other cancer types) reflects the definition of 
PFS used in TROPIC. This means that patients may have been withdrawn from the study 
drug earlier than might be expected from later studies and the main measure of PFS could 
therefore be somewhat truncated. 
QoL data were not collected in the TROPIC trial. However, EQ-5D data have been collected 
from UK patients included in the cabazitaxel EAP and an interim analysis was presented in 
the original submission (TA255). The final analysis is now available and has been utilised for 
the purposes of this submission. (See Table 55 for the utility values used in the analysis). 
Summary 
In conclusion, cabazitaxel has robust evidence to demonstrate OS and PFS benefits versus 
a relevant comparator. Within the evolving treatment paradigm of mCRPC, cabazitaxel 
provides an important treatment option for patients who have acquired or innate resistance 
to the hormonal based therapies abiraterone or enzalutamide.  
End of Life criteria 
Life expectancy in people with mCRPC varies according to the nature of their disease. In a 
recent review of the literature West et al. estimated worst-case, typical and best-case 
scenarios for survival in patients starting systemic therapies for castration resistant prostate 
cancer (CRPC).13 23 trials (13,909 patients) were reviewed with 48 treatment groups 
including 28 of chemotherapy, and three of novel hormonal agents. In the 11 treatment 
groups treated with first-line docetaxel, median OS was 19 months (IQR: 17–20). Observed 
median OS for patients in the control arms of: TROPIC, 12.7 months, COU-AA-301 
(abiraterone): 11.2 months, AFFIRM (enzalutamide): 13.6 months and ALSYMPCA  
(Radium-223): 11.3 months. 
On the basis of the information above, the importance of optionality in the provision of 
therapies for patients with mCRPC and consideration of the pathways which have been 
discussed in Section 4 delimiting the use of abiraterone and enzalutamide, we believe that 
cabazitaxel meets the criteria for consideration as 'life-extending treatment at the end of life'. 
These data are summarised in Table 46 below. 
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Table 46  End-of-life criteria. 
Criterion Data available  
The treatment is indicated for patients 
with a short life expectancy, normally 
less than 24 months  
Recent estimates suggest median OS of around 
19 months for patients starting docetaxel based 
regimens.13 Median OS in the control arms of 
TROPIC, COU-AA-301 AFFIRM and ALSYMPCA 
varied between 11.2 and 13.6 months. 
There is sufficient evidence to indicate 
that the treatment offers an extension 
to life, normally of at least an additional 
3 months, compared with current NHS 
treatment  
See Section 4.7. Mean survival for the ITT 
population in TROPIC for the mitoxantrone arm 
was 14.53 months and 18.55 months in the 
cabazitaxel arm. The difference in mean survival 
was 4.02 months. The difference in median 
survival was 2.4 months. 
The treatment is licensed or otherwise 
indicated for small patient populations  
See section 3.4, Table 10. It is estimated that 
there are 6,147 patients with mCRPC in England 
in 2015. Of these around 1690 will be eligible to 
receive second line chemotherapy. 
4.14 Ongoing studies 
Since the granting of marketing authorisation for cabazitaxel in March 2011 there have been 
a number of studies which have completed or are ongoing in a number of different 
indications. 
Studies that are likely to complete or report in the next 12 months are tabulated in Appendix 
7. 
The key studies which may provide evidence within the timeframe of this submission are 
PROSELICA, ECLIPSE and FIRSTANA. These are discussed below and in appendix 20. 
The PROSELICA study is likely to provide key additional information pertinent to the 
decision problem about the efficacy and safety of cabazitaxel which will supplement the 
original TROPIC data. It was a large Randomized, Open Label Multi-Center Study 
comparing cabazitaxel at 20 mg/m² and at 25 mg/m² every 3 weeks in combination with 
prednisone for the treatment of metastatic castration resistant prostate cancer previously 
treated with a docetaxel-containing regimen. A description of the study is provided in Table 
47. 
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Table 47. PROSELICA study description. 
 Study description 
Title Randomized, Open Label Multi-Center Study comparing cabazitaxel at 20 mg/m² and 
at 25 mg/m² every 3 weeks in combination with prednisone for the treatment of 
metastatic castration resistant prostate cancer previously treated with a docetaxel-
containing regimen. 
Study 
numbers Sanofi internal: XRP6258-EFC11785 Clincinaltrials.gov:  NCT01308580 
Primary 
objective 
To demonstrate the non-inferiority in terms of overall survival (OS) of cabazitaxel 20 
mg/m² (Arm A) versus cabazitaxel 25 mg/m² (Arm B) in combination with prednisone 
in patients with metastatic castration resistant prostate cancer (MCRPC) previously 
treated with a docetaxel-containing regimen. 
Secondary 
objectives 
• To evaluate safety in the 2 treatment arms and to assess if cabazitaxel 20 mg/m² is 
better tolerated than cabazitaxel 25 mg/m². 
• To compare efficacy of cabazitaxel at 20 mg/m² and 25 mg/m² for: 
− Progression Free Survival (PFS) defined as the first occurrence of any of the 
following events: tumor progression per Response Evaluation Criteria In Solid Tumors 
(RECIST), PSA progression, pain progression or death due to any cause 
− Prostate-Specific Antigen (PSA)-Progression 
− Pain progression 
− Tumor response in patients with measurable disease (RECIST 1.1). 
− PSA response 
− Pain response in patients with stable pain at baseline. 
• To compare Health-related Quality of Life (HRQL) using the FACT-P tool 
• To assess the pharmacokinetics and pharmacogenomics of cabazitaxel 
Study 
design Phase III, randomized, open-label, multi-center, multinational study comparing cabazitaxel 20 mg/m² plus prednisone (Arm A) and cabazitaxel 25 mg/m² plus 
prednisone (Arm B) in patient with metastatic castration resistant prostate cancer 
(MCRPC) previously treated with a docetaxel-containing regimen. 
Study 
location 
Multinational, multicentre. Planned recruitment is from approximately 200 sites within 
60 months. 
Study 
population 
Expected 1200 mCRPC patients with similar baseline characteristics to the TROPIC 
population. See Appendix 8 for main selection criteria. 
Study 
duration 
Cabazitaxel administered every 3 weeks. Patients treated until progressive disease, 
unacceptable toxicity, patient’s refusal of further study treatment or for a maximum of 
10 cycles. 
After study treatment discontinuation patients followed until death or cut-off date, 
whichever comes first. In patients that progressed the follow up was performed every 
12 weeks, in patient not progressed the follow up was performed every 6 weeks for 
the first 6 months and then every 12 weeks. 
A graphical representation of the study is provided in Figure 13 overleaf. 
We expect the data from PROSELICA to become available in late September and it is our 
intention to provide this as supplementary material as soon as we are able. 
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Figure 13. Graphical representation of the PROSELICA study design. 
 
 
 
 
 
 
 
 
 
 
 
Academic in confidence information removed 
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5. Cost effectiveness 
 In order to evaluate the incremental cost-effectiveness of cabazitaxel a 
markov model with 3 health states (stable disease, progressive disease and 
dead) was developed. 
 The evaluation had a 10 year time horizon and was conducted from an NHS 
perspective. 
 For the base-case the population considered is the subgroup of patients with 
ECOG PS 0-1 who have received at least 225mmg/m2 docetaxel. 
 The base case compares cabazitaxel to mitoxantrone (considered equivalent 
to BSC in terms of overall survival and is reflective of standard NHS practice)  
 Scenario analyses comparing cabazitaxel to the hormonal agents abiraterone 
and enzalutamide were also performed, however these are limited by the 
significant weakness in the indirect treatment comparisons. 
 The model was populated with updated clinical data from the TROPIC Phase 
III clinical trial and HRQL data from the EAP for cabazitaxel. 
 The ICER for cabazitaxel versus mitoxantrone in the base case analysis is 
£49,327 per QALY. 
 Deterministic sensitivity analyses demonstrate that the base case results are 
robust with ICERs varying from £44,290 to £56,656 per QALY 
 The probability of cabazitaxel being cost-effective versus mitoxantrone was 
46% at a WTP threshold of £50,000 per QALY 
 
5.1 Published cost-effectiveness studies 
5.1.1. Description of the strategies used to retrieve cost-effectiveness studies 
relevant to decision-making in England. 
A systematic literature review was conducted for the original submission for cabazitaxel 
TA255.4 No relevant studies were identified. The search strategy is provided in detail 
Appendix 9. 
Since this search was carried out there have been a number of publications in this area and 
so we have updated this search to identify all relevant cost-effectiveness studies from the 
published literature. The PICOS framework is included below in Table 48. 
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Table 48. PICOS Framework 
PICOS Description  
Population 
 
 mHRPC and mCRPC patients 
 Age: Adults (≥18 years) 
 Race: Any 
 Line of therapy: Second-line or later 
 Prior therapy: Previously treated with docetaxel-based regimen 
Interventions 
 
The following treatments for mHRPC and mCRPC administered in the second 
line or later: 
 Jevtana (cabazitaxel) 
 Zytiga (abiraterone) 
 Xtandi (enzalutamide) 
 Novantrone (mitoxantrone) 
 Yervoy (ipilimumab) 
 Xofigo (radium-223) 
 Provenge (sipuleucel-T) 
 Emcyt (estramustine) 
Comparators No limitation on comparator 
Outcomes  Model description 
 Patient age 
 Life years gained 
 QALYs 
 Costs 
 ICER 
Study design Economic evaluations (CEA, CUA, CBA) 
Limits  Publication from 2010 to present 
 Conference abstracts from 2012 to present 
The following data sources were searched: 
Databases 
Embase 
MEDLINE (via the Embase interface) 
MEDLINE in Process (via PubMed) 
Cochrane (Technology Assessments and Economic Evaluations databases) 
NHS EED 
EconLit 
NICE 
Conferences 
New conferences to search/screen (2012 to present) 
Health Technology Assessment international (HTAi)1 
International Health Economics Association (iHEA)2 
International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 
Previously screened – no additional searching required (2012 to present) 
                                                 
1	Only	searchable	abstracts	from	HTAi	2012	and	2014	were	identified	
2	Only	searchable	abstracts	from	iHEA	2015	were	identified	
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American Association for Cancer Research (AACR) 
American Society of Clinical Oncology (ASCO)  
American Society of Clinical Oncology-Genitourinary (ASCO-GU)  
American Urological Association (AUA)  
European Association of Urology (EAU) 
European Society for Medical Oncology (ESMO)  
Société Internationale d'Urologie (SIU)  
The search strategies are provided in Appendix 10. 
The PRISMA figure is provided overleaf in Figure 14. 
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Figure 14. PRISMA figure for the cost effectiveness searches. 
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Table 49. List of published articles retained for full text review with reasons for 
exclusion 
Publication Excluded at full text review? Reason for exclusion 
HTA database Project record for cabazitaxel, 2011 Yes Superseded by Kearns (see below) 
HTA database Project record for enzalutamide, 2013 Yes Superseded by TA316 (see below) 
HTA database structured abstract for abiraterone, 
2012 Yes 
Superseded by TA259 
(See below) 
Adams, E., 2010168 Yes Outcomes not relevant 
Bergman, J., 2010169 Yes Incorrect intervention 
Breuer, J., 2013170 Yes Outcomes not relevant 
Connock, M., 2011171 No 
Dyer, M., 2012172 Yes Duplicate 
Grabner, M., 2011173 Yes Incorrect intervention 
Hayes, 2013174 Yes Unavailable abstract (Radium-223) 
Holko, P., 2014175 Yes Incorrect patient population 
Horizon Scanning Centre, 2014176 Yes Outcomes not relevant 
Kearns, B., 2013177 Yes Duplicate 
Nachtnebel, A., 2011178 Yes Outcomes not relevant 
Nachtnebel, A., 2011179 Yes Outcomes not relevant 
NHSC, 2011180 Yes Outcomes not relevant 
NICE TA259, 20126 No  
NICE TA255, 20124 No  
NICE TA316, 20147 No  
NICE TA332, 2015181 Yes Outcomes not relevant 
Simpson, E. L., 2015182 Yes Incorrect patient population 
Zhong, L., 2013 183 No  
 
In addition to the articles cited above a further 20 congress abstracts were identified and 
included at full text review. 
5.1.2. Overview of the included reports 
The review identified 25 economic reports. These are detailed in Table 50 overleaf. These 
were supplemented by a hand search of the Scottish and Irish HTA agency databases. An 
additional 6 reports were identified and are listed in Table 51. The ongoing assessment by 
NICE of Radium-223 was not identified in the searches but is included in as the last entry in 
Table 50 overleaf for completeness.
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Table 50. Cost-effectiveness evidence from economic analyses of post-docetaxel treatments for mHRPC and mCRPC (ICER per QALY gained) 
Study Summary of model Patient age
(avg.) Interventions 
Costs 
(currency, year) QALYs 
ICER 
(per QALY gained) 
Chopra 
ASCO 2012184 
A decision analytical model using clinical data from the COU-AA-301 pivotal 
Phase III trial designed to assess the cost-effectiveness of abiraterone in the 
treatment of advanced CRPC patients from a US payer perspective. Health 
utilities were derived from the available literature, while costs for drug 
acquisition, physician visits and laboratory tests were obtained from the 
Center for Medicare Services Drug Payment Table and Physician Fee 
Schedule and are represented in 2011 US dollars. 
NR Abiraterone + prednisone NR (USD, 2011) 0.30a,b $129,000a 
He 
ISPOR 
2013185 
A survival-based Markov cohort model consisting of 3 health states 
(progression-free, progressed, and dead) to project cost-effectiveness from 
a US payer perspective over 10 year period. Progression between states 
was determined by OS and radiographic PFS. An indirect treatment 
comparison was conducted to determine the relative efficacy of abiraterone 
acetate and enzalutamide. Utilities were mapped from FACT-P to EQ-5D 
based on a review of the literature. Drug acquisition costs in the US were 
used since enzalutamide was approved only in the US at the time of 
analysis. Costs of scheduled and unscheduled follow-up visits were obtained 
from the Centers for Medicare Services Drug Payment Table and Physician 
Fee Schedule and represented in 2013 US dollars. 
NR 
Abiraterone $115,531 (USD, 2013) 1.033 Dominates 
Enzalutamide $128,852 (USD, 2013) 1.008 Dominated 
Joulain 
ISPOR 
2013186 
A Markov cohort based cost-effectiveness model from the Swedish 
healthcare perspective using a lifetime horizon (~15 years) and 3% discount 
rate. The population included a TROPIC trial subgroup consisting of patients 
who initially responded to docetaxel but experienced disease progression <3 
months since last docetaxel dose. Health state transitions that represented 
mCRPC disease progression (stable, progression, death) were estimated 
based on progression of disease and survival rates from the TROPIC trial. 
Resource inputs were obtained from literature, hospital data and key opinion 
leaders. 
18% under 
65 years 
Cabazitaxel SEK 699,176 (SEK, NR) 1.121 
vs mitoxantrone + prednisolone: 
   SEK 943,270 
vs prednisolone alone: 
   SEK 990,903 
vs prednisolone alone: 
   SEK 999,299 (subgroup) 
Mitoxantrone + 
prednisolone 
SEK 320,491 (SEK, 
NR) 0.719 Reference 
Prednisolone SEK 302,726 (SEK, NR) 0.721 Reference 
TA2596 A survival-based decision model with three health states (pre-progression, 
post progression and dead) from the perspective of the NHS and personal 
social services with a time horizon of 10 years. The number of people 
remaining in each health state after each cycle of the model (3 weeks) was 
calculated directly from the OS and PFS curves from the one prior 
chemotherapy subgroup of the COU-AA-301 trial. The model used a time 
horizon of 10 years and discounted costs and benefits at 3.5%.  
NR 
Abiraterone + 
prednisolone NR (GBP, NR) NR 
Base-case: £52,851 
Whole trial: £63,233 
Mitoxantrone + 
prednisolone NR (GBP, NR) NR 
Base-case: Dominated 
Whole trial: Dominated 
Prednisolone NR (GBP, NR) NR Reference 
TA2554 A cohort Markov model including three health states (stable disease, 
progressive disease and death) and comparing two treatment regimens. All 
patients entered the model in the stable disease state, from which transitions 
NR Cabazitaxel + prednisolone NR (GBP, NR) 
Initial model:
   0.298b 
Second 
Initial model: £74,908 
First revision: £74,938 
Second revision: £78,016 
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Study Summary of model Patient age
(avg.) Interventions 
Costs 
(currency, year) QALYs 
ICER 
(per QALY gained) 
to progressive disease and death were possible. Once patients entered the 
progressive disease state, they would remain there until death. The model's 
perspective was that of the UK NHS and personal social services, where all 
future costs and benefits were discounted at a rate of 3.56% and treatment 
was modelled over a lifetime (14.4 years) with a cycle length of 3 weeks.  
revision: 
   0.290b 
 
Population groups (initial/revised) 
1) All patients in TROPIC with 
ECOG performance score of 0 or 1 
who had received ≥ 225 mg/m2 prior 
docetaxel therapy: £87,684/£86,008  
2) European patients regardless of 
ECOG performance status and 
previous docetaxel therapy: 
£84,540/£87,348  
3) All patients in TROPIC: 
£82,538/£91,134 
Mitoxantrone + 
prednisolone NR (GBP, NR) Reference Reference 
TA3167 A state-transition Markov cohort model simulating 3 states (stable disease, 
progressive disease and death) from the perspective of the UK NHS and 
personal social services with a time horizon of 10 years. The cycle length of 
the model was 3 weeks, in line with previous models for this indication, and 
applied a half-cycle correction except for direct drug costs. Costs and health 
effects were discounted at an annual rate of 3.5%. All patients entered the 
model in the stable-disease state and received enzalutamide, abiraterone or 
best supportive care. They could then remain in this state, move to the 
progressive-disease state or die.  
NR 
Enzalutamide NR (GBP, NR) NR vs abiraterone: £14,795 vs BSC: £43,587 
Abiraterone NR (GBP, NR) NR vs enzaluatmide: Dominated vs BSC: £102,751 
BSC NR (GBP, NR) NR Reference 
Obando 
ISPOR 
2014a187 
A three-health state cohort simulation Markov model (progression-free, post-
progression and death) with a time frame of 10 years and a discount rate of 
5% was developed based on overall and progression free survival data from 
COU-AA-301 and TROPIC.  The perspective was that of the Public System 
of Health of Costa Rica, where all costs were presented in Costa Rican 
currency (CRC). 
NR 
Cabazitaxel + 
prednisone 
CRC 41,981,207 
(CRC, 2012) 0.71 Dominated 
Abiraterone + 
prednisone 
CRC 33,881,184 
(CRC, 2012) 0.79 Dominates 
Obando 
ISPOR 
2014b188 
A three-health state cohort simulation Markov model (progression-free, post-
progression and death) with a time frame of 10 years and a discount rate of 
5% was developed based on overall and progression free survival data from 
COU-AA-301 and TROPIC.  The perspective was that of the Public System 
of Health of the Dominican Republic, where all costs were presented in 
Dominican Republic currency (DOP). 
NR 
Cabazitaxel + 
prednisone 
RD$ 2,732,365 
(DOP, 2012) 0.71 Dominated 
Abiraterone + 
prednisone 
RD$ 2,204,289 
(DOP, 2012) 0.79 Dominates 
Obando 
ISPOR 
2014c189 
A three-health state cohort simulation Markov model (progression-free, post-
progression and death) with a time frame of 10 years and a discount rate of 
5% was developed based on overall and progression free survival data from 
COU-AA-301 and TROPIC.  The perspective was that of the Public System 
of Health of Panama, where all costs were presented in USD. 
NR 
Cabazitaxel + 
prednisone 
$86,286 (USD, 
2012) 0.71 Dominated 
Abiraterone + 
prednisone 
$76,179 (USD, 
2012) 0.79 Dominates 
Pereira 
ISPOR 
A cost-effectiveness Markov model that simulates disease progression and 
patient mortality from the Brazilian Private Health System perspective. NR Abiraterone 
BRL 79,974 (BRL, 
NR) 0.7977 Dominates 
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Study Summary of model Patient age
(avg.) Interventions 
Costs 
(currency, year) QALYs 
ICER 
(per QALY gained) 
2012190 Efficacy data is informed by Phase III trials and is combined/adjusted via a 
mixed treatment comparison network meta-analysis to determine the relative 
efficacy of each comparator. Only direct medical costs were considered, 
while costs and outcomes were discounted at 5% yearly. 
Cabazitaxel BRL 90,025 (BRL, NR) 0.7329 Dominated 
Persson 
ISPOR 
2012191 
A survival-based decision analysis model was developed incorporating 3 
health states (PFS, post-progression survival, and OS) and populated using 
data from two placebo-controlled randomized clinical trials. Resource 
utilization and costs reflected Swedish treatment conditions within a broad 
societal perspective. 
NR 
Abiraterone $103,100/€74,400 (USD/EUR, NR) 0.94 Dominates 
Cabazitaxel $104,600/€75,500 (USD/EUR, NR) 0.83 Dominated 
Persson 
ISPOR 
2013192 
A survival-based decision analysis model was developed incorporating 3 
health states (PFS, post-progression survival, and OS) and populated using 
data from one placebo-controlled randomized clinical trial and from the 
name-patient-program in Sweden. Resource utilization and costs reflected 
Swedish treatment conditions within a broad societal perspective. The model 
incorporated a lifetime time horizon (10 years) and a 3% discount rate. 
69.2 years 
Abiraterone $85,270/€67,300 (USD/EUR, 2012) 1.24 $69,800/€55,000 
Prednisone $52,700/€41,600 (USD/EUR, 2012) 0.77 Reference 
Shibahara 
ISPOR 
2013193 
A cost-effectiveness Markov model based on data from the COU-AA-301 
trial and literature review conducted from the Japanese public healthcare 
payer’s perspective. The base-case was assumed to be a 69 year-old man 
with metastatic CRPC. The model used a time horizon of 10 years and drug 
cost was estimated based on prices in the UK and the US. Both cost and 
outcomes were discounted at a 2% annual rate based on Japanese 
guidelines for economic evaluation.  
69 years 
Abiraterone + 
prednisolone NR (JPY/EUR, NR) NRc Exceeded JPY 10 million (€80,000) 
Placebo + 
prednisolone NR (JPY/EUR, NR) NR Reference 
Shibahara 
ISPOR 
2014194 
A cost-effectiveness Markov model based on data from the COU-AA-301 
trial and literature review conducted from the Japanese public healthcare 
payer’s perspective. The base-case was assumed to be a 72 year-old man 
with metastatic CRPC. The model used a time horizon of 10 years and drug 
cost was estimated based on prices in four other countries. Resource use 
was estimated using a Japanese claims data set with 2000 claim data of 
prostate cancer patients from January 2005 to March 2013. Both cost and 
outcomes were discounted at a 2% annual rate. 
72 years 
Abiraterone + 
prednisolone NR (JPY/EUR, NR) NRc Exceeded JPY 17 million (€120,000)  
Placebo + 
prednisolone NR (JPY/EUR, NR) NR Reference 
Vicente 
ISPOR 
2015195 
A cost-effectiveness Markov model from the Canadian perspective was 
developed to capture time spent by patients in various health states 
(progression, progression free survival and death). Transition probabilities 
were derived from patient-level data from AFFIRM and an indirect treatment 
comparison from available published literature. Direct medical costs were 
selected from the perspective of the Canadian Ministry of Health, with the 
second analysis focusing on the societal perspective. A 5% discount rate 
was applied to both costs and patient outcomes over a 10-year period. 
NR 
Enzalutamide NR (CAD, 2013) NR vs abiraterone: $42,325 vs cabazitaxel: $43,105 
Abiraterone NR (CAD, 2013) NR Reference 
Cabazitaxel NR (CAD, 2013) NR Reference 
Yeung 
ISPOR 
2012196 
A Markov model from a limited societal perspective using a lifetime horizon 
with 3 health states (pre-progression, post-progression, and death) and 1 
month transitions. Transition probabilities for all health states were derived 
from the pivotal Phase III clinical trials (AFFIRM and COU-AA-301). A 3% 
NR 
Enzalutamide $84,465 (NR, NR) 1.24 $55,070 
Abiraterone $74,119 (NR, NR) 1.05 Reference 
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Study Summary of model Patient age
(avg.) Interventions 
Costs 
(currency, year) QALYs 
ICER 
(per QALY gained) 
discount was applied to all costs and outcomes, where costs included drug 
acquisition costs, laboratory tests associated with treatment, as well as costs 
for grade 3/4 side effects management. 
Zhong 2013183 A decision-tree model to compare the cost-effectiveness of two mCRPC 
treatments versus two placebos over 18 months from a US societal 
perspective. Chance nodes include baseline pain as a severity indicator, 
grade III/IV side-effects, and survival at 18 months. Probabilities, survival 
and health utilities were from published Phase III studies. Model cost inputs 
included drug treatment, side-effect management and prevention, radiation 
for pain, and death associated costs in 2010 US dollars. 
NR 
Placebo $75,366 (USD, 2010) 0.43 Reference 
Mitoxantrone $83,171 (USD, 2010) 0.51 $100,675 
Abiraterone $101,050 (USD, 2010) 0.70 $91,188 
Cabazitaxel $156,140 (USD, 2010) 0.76 $955,863 
NICE:ID576197 
A semi-Markov model with time-dependent transition probabilities was 
developed based on survival analysis: the number of patients remaining in 
each of the health states is calculated in a per model cycle basis based on 
survival curves from the clinical trial. 
N/A 
Radium 223 
£24,240 (av. Course 
of treatment taken 
from ERG report) 
Redacted 
Basecase ICER: £47,697 
Placebo Unclear Redacted 
aReference group = not specified 
bIncremental QALY 
cDescribed as "higher than prednisolone alone"  
AE, adverse events; CAD, Canadian Dollar; CRC, Costa Rican Colón; DOP, Dominican Peso; EUR, Euro; GBP, British Pound; ICER, incremental cost-effectiveness ratio; JPY, Japanese Yen; LYG, 
life year gained; mCRPC, metastatic castration-resistant prostate cancer; mHRPC, metastatic hormone-resistant prostate cancer; OS, overall survival; PFS, progression-free survival; QALY, quality-
adjusted life year, NR, not reported; SEK, Swedish Krona; USD, United States dollars 
 
In a separate hand search the reports from the SMC (Scotland) and NCPE (Ireland) were reviewed and are summarised in Table 51 below. 
Table 51. Additional summary of HTA reports in mCRPC in Scotland and Ireland. 
Country (HTA 
body, HTA id 
no.) 
Study 
(Intervention) Year 
Summary of 
model Patient population 
QALYs 
(intervention 
comparator) 
Costs (Based on 
list price) ICER (per QALY gained) Status 
Ireland (NCPE) AFFIRM (Enzalutamide) 2014 
Three-state 
Markov model with 
a 10 year time 
horizon. 
Patients with 
mCRPC whose 
disease has 
progressed on or 
after docetaxel 
therapy 
Not available Not available 
 
Enzalutamide vs.  
 
BSC: €98,949 
Cabazitaxel: €75,311 
Abiraterone: €60,738 
Not recommended 
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Country (HTA 
body, HTA id 
no.) 
Study 
(Intervention) Year 
Summary of 
model Patient population 
QALYs 
(intervention 
comparator) 
Costs (Based on 
list price) ICER (per QALY gained) Status 
Scotland (SMC, 
911/13) 
AFFIRM 
(Enzalutamide) 2013 Not available 
Cost per course: 
Enzalutamide: 
£n/a 
Cabazitaxel: 
£36,980 
Docetaxel: 
£10,240 
Mitoxantrone: 
£1,539 
 Enzalutamide vs.  
 
BSC: N/A 
 
Cabazitaxel: N/A 
Abiraterone: £15,696 (with 
PAS) 
Accepted for use 
Ireland (NCPE) 
COU-AA-301 
(Abiraterone 
acetate) 
2012 
Three-state 
survival based 
decision analysis 
model 
mCRPC in adult 
patients whose 
disease has 
progressed on or 
after docetaxel 
based 
chemotherapy 
Not available 
Cost per course: 
Abiraterone: £n/a 
(£2,054 per cycle) 
Cabazitaxel: 
£36,980 
Docetaxel: £9.026 
Mitoxantrone: 
£1,549 
Abiraterone + prednisone 
vs.  
 
placebo + pred.: €135,454 
Mitoxantrone + pred.: 
€160,388 
Not recommended 
Scotland (SMC, 
764/12) 2012 
Abiraterone + prednisone 
vs. 
 
Placebo + pred.: £46,421 
Mitoxantrone + pred.: 
£41,222 
Accepted for 
restricted use 
Ireland (NCPE) TROPIC (Cabazitaxel) 2012 
Three-state 
Markov model 
Patients with  
mCRPC previously 
treated with a 
docetaxel-containing 
regimen 
Not available Not available Cabazitaxel vs.  Mitoxantrone: €120,084 
Following HTA, 
recommendation 
was not to 
reimburse. 
Subsequently full 
reimbursement was 
approved for 
hospitals with 
prescribing protocol 
implemented by the 
NCCP as per 
licence. 
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Country (HTA 
body, HTA id 
no.) 
Study 
(Intervention) Year 
Summary of 
model Patient population 
QALYs 
(intervention 
comparator) 
Costs (Based on 
list price) ICER (per QALY gained) Status 
Scotland (SMC, 
753/11) 2011 Not available 
Cost per course: 
Cabazitaxel: 
£36,975 
Docetaxel: £9,662 
Mitoxantrone: 
£1,539 
Cabazitaxel vs.  
Mitoxantrone: £76,670 Not recommended 
HTA, Health Technology Assessment; NICE, National Institute for health and Care Excellence; NCPE, National Center for Pharmacoeconomics; SMC, Scottish Medicines Consortium; mCRPC 
metastatic Castrate Resistant Prostate Cancer; QALY, Quality Adjusted Life Year; ICER, Incremental Cost Effectiveness Ratio; NCCP, National Cancer Control Program. 
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5.1.3. Provide a complete quality assessment for each relevant cost-
effectiveness study identified.  
The review identified abstracts, HTA reports and one full article containing data on cost-
effectiveness studies for products in the post-docetaxel 2nd line setting. Cabazitaxel is 
directly compared with mitoxantrone using the TROPIC data in the report for TA255 and in 
an abstract from the Swedish perspective. In both cases cabazitaxel is associated with a 
higher QALY gain but also higher cost than the mitoxantrone arm. A quality assessment is 
not provided for these reports as this dossier provides an update of the analysis presented in 
TA255. Cabazitaxel also features in TA259 for abiraterone, however in this analysis, 
cabazitaxel is only implemented as part of the post-treatment 2nd line treatment mix and so 
the results are not relevant here. 
 
Of the remaining reports, several abstracts report comparisons of abiraterone with 
cabazitaxel carried out for populations in South and Central America, Sweden and 
Canada.187-191 Whilst these are structured abstracts there is no detailed discussion of the 
methodology used to arrive at the conclusions beyond headline figures for costs and 
outcomes. Nonetheless these abstracts report higher QALY gains for the abiraterone arms 
in the comparisons and lower costs with the conclusion that abiraterone is the dominant 
strategy in most cases. We have argued that the comparisons between cabazitaxel and the 
advanced hormonal agents are limited by the heterogeneous definitions of survival 
outcomes in the trials, the patient populations included, and by the differing trial protocols not 
least around discontinuation rules. In our indirect comparisons we found no statistically 
significant increased survival for any of the agents. (Section 4.10). From the published 
information it is not possible to provide detailed commentary on these evaluations. 
The review of the literature identified one published article by Zhong in which cabazitaxel 
was compared against standard of care and also versus abiraterone from a US societal 
perspective.183 In this article a decision tree approach was taken to evaluate the various 
different comparisons and cabazitaxel was found not to be a cost-effective option.  The 
approach taken differs in many respects to the methodology used to make the comparison 
reported in this dossier and indeed to that used for other comparisons more generally in 
oncology submissions. More usually a Markov model is implemented using hazard ratios 
derived from survival analysis and utilities and costs assigned to the Markov states. However 
it is interesting to reflect that in the study by Zhong, unlike those discussed above, there is a 
QALY gain associated with cabazitaxel treatment versus abiraterone of 0.06. The much 
higher cost in the cabazitaxel arm is reflective of the very high treatment cost for neutropenia 
in the US. Given the very different methodologies and perspective used for this analysis to 
the one presented here a quality assessment has not been carried out. 
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5.2 De novo analysis 
5.2.1 Patient groups are included in the economic evaluation. 
The base-case population considered in the model is the subgroup of patients with ECOG 
PS 0 -1 who have received at least 225 mg/m2 docetaxel. The clinical outcomes observed in 
these patients along with the rationale for the choice of this group as the base-case 
population has been provided in Section 4.8 above. Amongst the participants in TROPIC, 
this cohort represents those patients most likely to be treated with cabazitaxel in UK clinical 
practice and therefore is the most relevant group to inform the decision problem. The ITT 
population from TROPIC is considered in scenario analysis. 
5.2.2 Model structure. 
In order to evaluate the cost-effectiveness cabazitaxel, a health economic state-transition 
model (i.e. Markov model) was developed. The model comprises a set of different health 
states each associated with costs, health effects and the probability of moving to any other 
state (Figure 15). When simulating a scenario, a cohort of defined patients progress through 
the model during the time period of choice, and it is assumed that transitions between states 
only occurs at equidistant time-points (cycles). The cycle length in the model is 3 weeks, 
corresponding to the length of one chemotherapy administration cycle. Transition rates 
between different states representing mCRPC disease progression were estimated based 
on progression of disease and survival estimates from the TROPIC trial. 
The health states in a Markov model are typically defined based on a patient’s possible 
health states specific to the disease. The states are mutually exclusive and collectively 
exhaustive, i.e. patients can only be in one single state at any one time, and the set of states 
should cover all relevant possibilities. The most important assumption of a Markov model is 
that future events only depend on the current health state of the patient, and not on prior 
events. 
The following health states were chosen for use in the model to mirror the likely disease 
history of the patient population: 
• Patients who have not progressed on 2nd line mCRPC therapy (stable disease) 
• Patients who have progressed while on 2nd line mCRPC therapy (progressive disease) 
• Patients who have died (dead) 
All patients begin in the “Stable disease” health state and are either treated with cabazitaxel 
or mitoxantrone. In each cycle, patients have a probability of remaining in their current state 
(“Stable disease” or “Progressive disease” states), moving to the other state (“Progressive 
disease” state) or dying (move to the absorbing “Dead” state) (see Figure 15) As this is a 
cohort model, patients are not followed individually. Costs and health utilities are assigned 
for each Markov health state.  
Adverse events were not implemented as separate health states but were rather taken into 
consideration by assigning a cost and utility reduction in each cycle during the stable 
disease health state. 
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To account for the uncertainty of the underlying parameter estimates, second-order 
stochastic sensitivity analysis was performed. A detailed discussion is provided in Appendix 
19.  
Figure 15. Schematic model structure 
 
5.2.3. Features of the de novo analysis.  
A summary of the de-novo analysis is provided in Table 52 below. 
Table 52. Features of the de novo analysis 
Factor Chosen values Justification Reference 
Time horizon 10 years To reflect all relevant costs 
and outcomes associated 
with treatment. 
NICE MTA 
method guide 
Cycle length Three weeks Because of the relatively 
short survival time of 
mCRPC patients, the cycle 
lengths in the model was set 
at 3 weeks, to get high 
precision in the model and to 
reflect the duration of 
treatment cycles 
TROPIC 
Half-cycle correction Included The method of half-cycle 
correction was used, by 
adding one extra cycle and 
assuming that the first and 
final cycles in the model are 
half as long as the cycles in 
between. This way, the over-
estimation will be corrected. 
Half-cycle correction was not 
undertaken on the cost of 
therapy, since this would be 
incurred at the start of each 
cycle, regardless of the 
patient’s movement 
thereafter. 
NICE MTA 
method guide 
Were health effects Yes, health effects As recommended in the NICE MTA 
Stable disease
Dead
Progressive disease
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Factor Chosen values Justification Reference 
measured in QALYs; 
if not, what was 
used? 
measured in QALYs Reference Case. method guide 
Discount of 3.5% for 
utilities and costs 
Costs and benefits were 
discounted at 3.5%. 
 
Continuous discounting is 
applied within the model 
rather than the more 
traditional discounting year 
on year.  
As recommended by the UK 
Treasury. Discount rates 
were varied in the sensitivity 
analysis.  
Continuous discounting 
avoids the ‘stepped’ 
changes in discount rate that 
occur due to the 
compounding effect of 
cycles discounted at discrete 
intervals.  Continuous 
discounting provides a truer 
estimate of the value, since 
this offers a greater degree 
of granularity (i.e. infinite 
granularity, as opposed to 
the discrete three-weekly 
compounding).198, 199  
NICE MTA 
method guide 
Perspective 
(NHS/PSS) 
The perspective of the 
analysis in that of the NHS in 
England. 
As recommended in the 
Reference Case. 
NICE MTA 
method guide 
Key: mCRPC = metastatic hormone-refractory prostate cancer; NHS = National Health Service; PSS = Personal Social 
Services; QALYs = quality-adjusted life years 
5.2.4. Implementation of cabazitaxel and comparators in the model. 
Cabazitaxel is compared to mitoxantrone in the model in line with the decision problem 
depicted in Table 5. 
In line with the scope we, consider mitoxantrone to be a valid comparator and equivalent to 
best supportive care for comparisons within the ITC. 
Cabazitaxel is implemented as per its marketing authorisation in the post docetaxel setting 
and the relative effect sizes for each therapy are taken from the survival analysis presented 
in Section 5.6.  
The model arms for the comparison based on TROPIC are, therefore: 
• Mitoxantrone, 12 mg/m2 every three weeks in combination with 10 mg/day of 
prednisolone 
• Cabazitaxel, 25 mg/m2 every three weeks in combination with 10 mg/day of 
prednisolone. 
For the base-case comparison with mitoxantrone, updated data from the TROPIC trial are 
modelled directly.  For scenarios examining other comparisons, hazard ratios for OS and 
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rPFS derived from the ITC summarised in section 4.10 and Appendices B are applied to the 
TROPIC data.  
Treatments are implemented in the model according to their marketing authorisations. 
The model arms for the comparisons with TROPIC based on COU-AA-301 and AFFIRM 
therefore include the therapies at the cost and dose presented in the BNF as requested by 
NICE18 
• Abiraterone, 1.0 g daily in combination with 10 mg/day of prednisolone. Pack price: 
£2930; 120 x 250 mg tablets. 
• Enzalutamide, 120 mg daily. Pack price: £2734; 112 x 40 mg tablets. 
5.2.5 Treatment continuation and discontinuation rules  
In line with the SPC and the dosing regimen from the TROPIC trial, patients continue 
treatment from the start of the model until one or more of the following events occur: 
 The patient progresses 
 The patient dies 
 The patient has received ten cycles of chemotherapy.  
In TROPIC, 23% of patients in the cabazitaxel arm and 16% in the mitoxantrone arm 
discontinued for other reasons than progression. In order to reflect this, the rate of 
discontinuation was accounted for in the economic modelling. From the proportion of 
patients that discontinue treatment, a discontinuation rate (over 10 cycles) was derived and 
applied to patients on treatment: 2.6% in the cabazitaxel arm and 1.7% in the mitoxantrone 
arm. In sensitive analysis these discontinuation rates were excluded. 
5.3 Clinical parameters and variables 
5.3.1. Description of how the clinical data were incorporated into the model. 
The key clinical data used to populate this model were informed by the updated cut-off data 
TROPIC trial. These data include PFS and OS of cabazitaxel and mitoxantrone, along with 
the risk of adverse events associated with each treatment.  
Overall survival 
In the updated TROPIC trial, patients receiving cabazitaxel in the subgroup population 
demonstrated significantly longer overall survival (OS) compared to patients receiving 
mitoxantrone in the subgroup (HR: 0.69 [0.57 – 0.82], P-value <0.0001). The median 
survival for patients in the cabazitaxel group was 15.61 months in comparison to 13.37 
months in the mitoxantrone group. The overall survival Kaplan-Meier (KM) curve from 
TROPIC for the sub-group population is shown below.  KM curves for the ITT population are 
presented in Appendix 18.  
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Figure 16 Kaplan-Meier estimates of overall survival probability in TROPIC (subgroup 
population) 
 
Extrapolation of OS and PFS data for the duration of the trial period and beyond was 
evaluated using five different parametric models: Weibull, exponential, Log-logistic, 
Gompertz and Log-Normal. The selection of the most appropriate model was based on 
Akaike’s Information Criteria (AIC) and Bayesian Information Criterion (BIC) for each 
parametric distribution method. The AIC and BIC are criteria for selecting a model based on 
goodness of fit. Both can be described as a measure of fit, based on the likelihood function, 
with a complexity penalty. It is this complexity penalty that differs between the two, as well as 
some underlying assumptions. AIC’s complexity penalty is an increasing function of the 
number of estimated parameters. BIC’s complexity penalty is an increasing function of the 
number of estimated parameters and sample size. Which criterion to choose depends on the 
context, although both are often reported. When using these criteria for model section, one 
should choose the model with the lowest value.  
As seen in Table 53 the Weibull model provides the lowest AIC and BIC for Cabazitaxel OS, 
and the Log-logistic gives the minimum AIC and BIC for mitoxantrone OS. Ideally, the same 
parametric model type should be chosen for the two treatment arms unless there is a 
specific expectation that they should be different. To assess which parametric model to use 
when no specific justification exists for different functions to be applied, the AIC and BIC can 
be assessed for both arms; the sum of the AICs and BICs across the two treatment arms 
then informs the parametric model choice. The sum of the AICs and BICs, respectively, 
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supports the use of the Weibull extrapolation. For the base-case analysis, the Weibull 
extrapolation of the data was selected for the OS curves for both treatment arms. 
Table 53.  AICs and BICs for different parametric models for overall survival probability 
extrapolation 
Parametric 
Model 
Exponential 
Cabazitaxel Mitoxantrone Combination 
AIC BIC AIC BIC AIC BIC 
801.62 805.38 771.59 775.33 1573.21 1580.71 
Weibull 757.69 765.22 699.30 706.78 1456.99 1472.00 
Gompertz 772.80 780.33 725.61 733.10 1498.41 1513.43 
Log-logistic 758.91 766.44 699.13 706.62 1458.04 1473.06 
Log-Normal 788.59 796.12 705.92 713.41 1494.51 1509.52 
 
Figure 17. Weibull model for overall survival – subgroup population (compared to the TROPIC 
Kaplan-Meier data) 
 
 
 
  
Company evidence submission template for Cabazitaxel for hormone-relapsed 
metastatic prostate cancer previously treated with a docetaxel-containing regimen 
 Page 148 of 211 
 
For OS, the following parameters were obtained for the Weibull distribution for the subgroup 
cohort: 
 Mitoxantrone arm: λ and σ Commercial in confidence information removed 
 Cabazitaxel arm: µ and σ Commercial in confidence information removed 
The full survival analysis is available in Appendix 18.  
In sensitivity analyses, the actual Kaplan Meier (KM) survival data from the TROPIC trial is 
also used in the model. The KM data for OS were used up 37.52 months. Thereafter, the 
parametric Weibull survival curves were used in order to extrapolate the KM data up to the 
lifetime of all patients.   
Progression-free survival 
PFS was also statistically significantly longer for patients receiving cabazitaxel compared to 
patients receiving mitoxantrone (HR: 0.76 [0.65– 0.89 ], P-value<0.0001). The progression-
free survival KM curve from TROPIC for the sub-group population is shown in Figure 18. KM 
curves for the ITT population are presented in Appendix 18. 
Figure 18. Kaplan-Meier estimates of progression-free survival in TROPIC (subgroup 
population) 
 
Table 54 presents the AICs and BICs for the extrapolations of the PFS data. The Log-
Logistic model gives the minimum AIC and BIC for the Cabazitaxel PFS. The Log-Normal 
model gives the minimum AIC and BIC for the mitoxantrone arm. When assessing the most 
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appropriate fit for the PFS curve, the sum of the AICs and BICs for mitoxantrone and 
Cabazitaxel suggest the most appropriate fit is the Log-Normal model. 
Table 54. AICs and BICs for different parametric models for progression-free probability 
extrapolation 
Cabazitaxel Mitoxantrone Combination 
Parametric 
Model AIC BIC AIC BIC AIC BIC 
Exponential 907.07 910.82 935.93 939.66 1843.01 1850.48 
Weibull 903.14 910.63 937.72 945.17 1840.86 1855.81 
Gompertz 908.11 915.61 926.82 934.28 1834.93 1849.89 
Log-logistic 900.25 907.74 874.94 882.39 1775.18 1790.14 
Log-Normal 900.88 908.67 869.05 876.82 1769.93 1785.49 
 
Figure 19. Lognormal model for progression-free survival - subgroup population (compared to 
the TROPIC Kaplan-Meier data) 
 
For PFS, the following parameters were obtained for the Lognormal distribution for the 
subgroup cohort: 
 Mitoxantrone arm: µ and σ Commercial in confidence information removed 
 Cabazitaxel arm: µ and σ Commercial in confidence information removed 
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In sensitivity analyses, the actual KM for progression-free survival data from the TROPIC 
trial is also used in the model. The KM data for PFS were used up 25.43 months. Thereafter, 
the parametric Log-Normal survival curves were used in order to extrapolate the KM data up 
to the lifetime of all patients 
The model assumes only patients in the stable state receive second-line treatment with 
cabazitaxel or mitoxantrone, and that patients can receive up to a maximum of ten cycles of 
second-line treatment.  
Following progression, for standard NHS practice the use of follow on chemotherapy is very 
limited. However, in the base-case, the post-second-line treatment mix is taken from the 
post-second-line treatments received by patients in the TROPIC trial. As a scenario analysis, 
the post-second-line treatment mix is based on those received by patients in an observation 
study of five major UK cancer centres (See Appendix 14). It is assumed that post-second-
line treatment offers no differential effect between arms. Post-second-line treatment is only 
received for a relatively short duration (as shown by both TROPIC and the UK observational 
study) and the cost of these drugs is applied as a transition cost.  
Typically, high costs are incurred at the end of life, when patients may require frequent 
hospitalisations and palliative care. Therefore, a specific cost for end-of-life care is 
calculated and applied as a transition cost on death. This is calculated based on the 
hospitalisations occurring in the last month as reported in the UK observational study and 
expert opinion on frequency of hospice care provision.  
Adverse events 
As mentioned in Section 5.5.7 Grade ≥3 AEs are incorporated into this model as costs and 
disutilities rather than separate events or states. Patients having an AE during the time they 
spend in a state also incur the associated cost and disutility. The AEs were only included in 
the stable disease state and not in the progressive disease health state because in the 
TROPIC trial there is only data for AEs occurring during treatment with cabazitaxel or 
mitoxantrone and up to 30 days after last cycle.  
This approach of incorporating AEs is taken for several reasons. First, it is simpler and 
clearer to include the AEs in this manner. The alternative would be to have a greater number 
of health states, defined by a combination of disease stage and AE (for example, stable 
disease with deep vein thrombosis). This would make the model more complex and less 
transparent. Second, the available data on resource use, cost and utility associated with 
each AE are defined as the cost and disutility per event. This means that the data can be 
applied without unnecessary adjustment. The incidence of each AE per three-week cycle 
was included in the model along with the appropriate resource use, unit cost and disutility 
value.  
AEs included in the model are listed in Table 70 in Section 5.5.7 together with AE rates in 
patients who experienced these events in each arm of the TROPIC trial. These AEs were 
chosen on the grounds that they were the most frequent treatment-emergent Grade ≥3 AEs. 
In addition, deep vein thrombosis and neuropathy according to clinical presentation were 
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added to the list of AEs, as they were classified as important based on clinical expert 
opinion.  
5.3.2. Demonstrate how the transition probabilities were calculated from the 
clinical data. If appropriate, provide the transition matrix and describe the 
details of the transformation of clinical outcomes or any other relevant details 
here. 
As is generally the case in oncology models the probability of transitioning between states is 
not based on a transition probability matrix.  Instead, the percentage of time spent in each 
health state, is determined as the probability of survival, or progression at each time point.  
Effectively, average time spent in each health state is represented as the area-under-the-
curve, or between the curves in the case of the progressive disease state.  
5.3.3. If there is evidence that (transition) probabilities may change over time 
for the treatment effect, condition or disease, confirm whether this has been 
included in the evaluation. 
The use of the Kaplan–Meier data and the fitted curves ensures that time dependent 
transitions between states are captured correctly. 
5.3.4. Assessment of the applicability of the clinical parameters or 
approximations. 
As part of initial model development, an advisory board was held with four oncologists on 30 
November 2009. The criteria for selection were   
 Specialism in prostate cancer 
 UK-based (from different parts of the UK)  
 Considered to be at least regional experts on the disease.  
A number of follow-up conversations were held to seek further clinical opinion and validation 
of assumptions. Clinicians were asked to provide their opinion on the clinical validity of the 
key model assumptions, including UK-specific resource use data. (See Section 5.5 for 
further details). 
This expert advice was used to estimate the UK-specific value for the BSA to be 1.9 m2 and 
so the model base-case assumes a BSA of 1.9 m2. The experts also reviewed the AEs in the 
model and deep vein thrombosis and neuropathy were added to the list of AEs based on 
their input. They also provided input on drug dosages related to AE treatment.  
5.4 Measurement and valuation of health effects 
5.4.1 Health-related quality-of-life (HRQL) data collected in the clinical trials 
The Early Access Programme (EAP) for cabazitaxel (NCT01254279) evaluated utility in UK 
patients treated with cabazitaxel in the post docetaxel setting.12 
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Overall the mean (SD) EQ-5D-3L index score at baseline was 0.6821 (0.2571; n = 103) with 
a trend towards increased HRQL with increasing cycle number (utility at cycle 10 = 0.8185 
(0.1870; n = 32). At Cycle 6 which was the median number of cycles received in both 
TROPIC and the UK EAP, the mean (SD) utility was 0.7518 (0.1925). As would be expected, 
as the number of cycles increased fewer patients remained on treatment (n = 103 at 
baseline vs. n = 32 at cycle 10). In order to explore selection bias ‘within patient’ analysis 
was conducted and this showed that for those patients completing 10 cycles of treatment the 
values and observed trends are consistent with those observed for the trial group as a 
whole.12. The overall utility value at 30 days post discontinuation was 0.6946 (SD: 0.2406). 
Full details are provided in Table 55.  
As time passes in each health state average HRQL might be expected to worsen, however 
this was not observed. Indeed there was a non-significant trend towards increased HRQL 
with increasing cycle number (base line utility was 0.6821 (0.2571) and utility at cycle 10 was 
0.8185 (0.1870)).12 This is consistent with anecdotal evidence from clinicians treating 
patients with cabazitaxel (see Appendix 17 for representative opinion). 
The cohort with utility values was also analysed according to evidence of disease 
progression by the end of the study. 39 patients were identified with progressive disease by 
the end of the study and 71 remained in the stable state. Of the patients with evidence of 
progression 25 had a recorded utility value 30 days after their last cycle of treatment.  
The mean (SD) utility value recorded for progressive patients 30 days after their last 
treatment was 0.6266 (0.2978). As these were patients no longer on treatment and had 
documented evidence of progression this is assumed to accurately reflect utility for the 
progressed disease state. Progressive disease will lead to decreased utility due to the 
worsening symptoms. However, the definition of progression used in TROPIC included 
biochemical (PSA) progression as well as symptomatic or pain progression. It is unlikely that 
patients who only have PSA progression will experience a decline in utility until they also 
show symptomatic progression. Therefore, the constant utility assumption in the model may 
underestimate the health benefits of both treatments. 
Table 55. Utility results from EAP 
Baseline N 103 Cycle 6 N 64 
 Mean (SD) 0.6821 (0.2571)  Mean (SD) 0.7518 (0.1925) 
 Min;Max -0.594;1.000  Min;Max 0.208;1.000 
Cycle 2 N 98 Cycle 8 N 39 
 Mean (SD) 0.7284 (0.2038)  Mean (SD) 0.7892 (0.2142) 
 Min;Max 0.159;1.000  Min;Max 0.055;1.000 
Cycle 4 N 77 Cycle 10 N 32 
 Mean (SD) 0.7495 (0.2262)  Mean (SD) 0.8185 (0.1870) 
 Min;Max -0.113;1.000  Min;Max 0.260;1.000 
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5.4.2. Mapping of HRQL data 
Mapping was not undertaken as the utility data used in the modelling were collected 
directed.  
5.4.3. Description of the systematic searches for HRQL data. 
The search for studies reporting HRQL for mHRPC/mCRPC carried out for the original 
submission to NICE for cabazitaxel in 2011 (TA255) identified 59 reports of which 57 reports 
were rejected, either because no HRQL or EQ5D data were reported, the data related to 
early, or locally advanced disease.   
Of the two studies retained, Sandblom30 and Sullivan200 provided estimates for utility 
decrements of 0.070 and 0.085 respectively which were applied to the estimated value for 
the stable disease state, itself derived from the interim analysis of the utility data from the UK 
EAP. 
The updated clinical search for RCTs (discussed in Section 4.1.1 – 4.1.4) included search 
terms relevant to HRQL. This search identified five articles which included HRQL data for 
data extraction. These were associated with the included studies COU-AA-301 and AFFIRM. 
Both studies assessed HRQL using the Functional Assessment of Cancer Therapy-Prostate 
(FACT-P) questionnaire and also assessed patient-reported fatigue using the Brief Fatigue 
Inventory (BFI). A summary of the articles identified in the updated clinical literature review, 
including key results is provided in Section 5.4.4. 
HRQL in mCRPC has been reviewed in several recent submissions to NICE, most recently 
by Bayer for radium-223. Only a handful of papers were identified by the updated review 
described above for the time period following the original cabazitaxel search and these 
included studies are summarised in Appendix 16.  
Given the relatively short time period between the end of the HRQL search in the radium-
223 submission (22nd February 2013) and the timeframe for the submission of this current 
dossier we have taken a pragmatic approach to updating the HRQL review. In order to 
capture the most recently published studies the PubMed database was searched on 26th 
August 2015. This was also a supplementary strategy adopted for the radium-223 
submission where the authors note that PubMed captures e-publications ahead of journal 
publication and so is likely to provide the most up to date overview of the literature. 
The search terms used for the PubMed search are reproduced in Table 56 below. These 
have been simplified and developed from the original search terms for TA255 reproduced in 
Appendix 13. The search term ("2013"[PDAT]: "3000"[PDAT]) is included to capture only 
those studies published since the beginning of 2013. 
Table 56. PubMed search terms for HRQL in mCRPC 
Search term No. hits 
Search ((((castration resistant prostate cancer OR hormone refractory prostate 
cancer OR mCRPC OR mHRPC) AND (health-related quality of life OR QoL or 74 
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HRQoL OR HRQL OR utility OR utilities OR EQ-5D OR EQ5D OR EuroQol 
OR sf thirtysix OR sf thirty six OR shortform thirtysix OR shortform thirty six OR 
short form thirtysix OR short form thirty six OR sf12 OR sf 12 OR short form 12 
OR shortform 12 OR sf twelve OR short form twelve OR sf 6d OR sf6d OR 
short form 6d OR shortform 6d OR sf six OR shortform six OR short form six))) 
AND ("2013"[Date - Publication] : "3000"[Date - Publication])) 
The inclusion and exclusion criteria applied to the results from the HRQL search conducted 
in PubMed are shown in Table 57  below. 
Table 57. Inclusion and exclusion criteria applied to the search results from the HRQL PubMed 
search. 
PICOS Inclusion Exclusion 
Population 
mCRPC/mCRPC patients 
Adults (≥18 years) 
Race: Any 
 
Non-human populations 
Non-mCRPC / non-mCRPC 
populations 
No mCRPC / mCRPC subgroup 
analysis 
Metastatic disease unclear 
Study population aged <18 years 
Interventions All None 
Comparator  All None 
Outcomes 
Health related quality of life (HRQL) 
Reported utility and disutility in mCRPC 
/ mHRPC patients 
Outcomes not relevant to HRQL 
Study design 
Reports of utility validation or elicitation 
exercises OR  
Reports of economic evaluations using 
utility measures gathered during the 
studies  
None 
Publication 
timeframe 
From 1st January 2013 to 26th August 
2015 Publications prior to 2013 
Publication 
status 
Published 
e-publication ahead of print 
Editorials 
Notes 
Comments 
Letters 
Systematic reviews of EE 
Language 
restrictions English language Non-English studies 
EE, economic evaluations; HRQL, health-related quality of life; mCRPC, metastatic castration-
resistant prostate cancer; mHRPC, metastatic hormone-refractory prostate cancer 
 
A flow diagram of the search is included in Figure 20 overleaf. 
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Figure 20. Flow diagram of the included studies from the PubMed search 
 
A list of the articles retained for full text review with reasons for exclusion is provided in 
Table 58. 
Table 58. List of articles retained for full text review from the PubMed search with reasons for 
exclusion 
Publication Excluded at full text review ? Reason for exclusion 
Cameron MG, 2015201 Yes Wrong population 
Loriot Y, 2015132 No N/A 
Bahl A, 201512 No N/A 
Zhou T, 2015127 No N/A 
Cella D, 2015202 Yes Included in the Clinical Searches 
Diels J, 2015203 No N/A 
Fizazi K, 201463 Yes Included in the Clinical Searches 
Records identified from 
PubMed 
(n = 74) 
Records after duplicates 
removed (none found) 
(n = 75) 
Records included based 
on title/abstract review 
(n = 16) 
Records included based 
on full text review 
 (n = 8) 
Records excluded based on title / 
abstract review 
(n = 59) 
Reasons for exclusion 
Literature review (n=15) 
No utility values reported (n=25) 
Wrong type of study (n=16) 
Wrong population (n=5) 
Non‐English study (n=1) 
Records excluded based on full text 
review 
(n = 8) 
Reasons for exclusion 
Not a source paper (n = 1) 
Already included in clinical search (n = 3) 
Wrong population (2) 
No utility values reported (n=2) 
Ide
nti
fic
ati
on
 
Sc
ree
nin
g 
Eli
gib
ility
 
Inc
lud
ed
 
Additional studies identified through 
hand search 
(n = 1) 
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Publication Excluded at full text review ? Reason for exclusion 
Clark MJ, 2014204 Yes No utility values reported 
Skaltsa K, 2014205  Yes Not a source paper  
Basch E, 201384 No N/A 
von Moos R, 2013206 Yes Wrong population 
Harland S, 201367 Yes Included in the Clinical Searches 
Li YF, 2013207 No N/A 
Fizazi K, 2013208 Yes No utility values reported 
Organ M, 2013209 No N/A 
Torvinen S, 2013210 No N/A 
5.4.4. Details of the included studies in which HRQL was measured. 
Summaries of the studies identified in the clinical and PubMed searches are provided in 
Appendix 16. 
5.4.5 Highlight any key differences between the values derived from the 
literature search and those reported in or mapped from the clinical trials. 
The results from the FACT-P studies reported in the literature were mapped to EQ-5D for 
use in their respective submissions (for example TA259 and TA316). This data is generally 
redacted in the submissions and has not been used for the purposes of this submission due 
to the availability of directly measured utility data from the UK EAP.  
EQ-5D utility values collected from the literature reviews (including the studies identified in 
Appendices 18 and 19 are tabulated below (Table 59). In most cases the assignment to the 
‘stable’ and ‘progressed’ disease states is based on assumption and this is explored in the 
comments sections. 
Utility values identified in the literature search relevant to the health states in the model are 
tabulated below. Table 59 
Table 59. Utility values from the literature for the stable and progressive disease states 
 Stable utility* (SD) 
Progressed 
utility* (SD) Comment 
Bahl, 201512 0.7281 (0.238) to 0.8185 (0.187) 
0.6266 
(0.298) 
Data collected in the UK EAP for 
cabazitaxel. First utility reported here  is 
for cycle 2. Interpolated utility at cycle 1 
is used in the modelling.  Discussed in 
Section 5.4.1, Table 55 
Loriot, 2015211 0.85 (0.15)  
Data collected in chemotherapy naïve 
patients in the Prevail study 
Diels, 2015203 0.66 (0.02) 0.60 (0.03) 
For the purposes of this table the ‘stable’ 
state is assumed to be for patients 
undergoing chemotherapy and the 
progressed utility is assumed for patients 
characterised as ‘post chemotherapy’. 
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 Stable utility* (SD) 
Progressed 
utility* (SD) Comment 
Torvinen, 
2013212 
0.74 (95% CI: 0.69 – 
0.80) 
0.59 
(95% CI: 
0.48 – 0.70) 
For the purposes of this table the ‘stable’ 
state is assumed to be for metastatic 
patients on active treatment and the 
progressed utility is assumed for patients 
characterised as receiving palliative care. 
Wolff, 2012213 
Mean (SD) EQ-5D: 0.72 (0.30)  
No chemo: 0.81 (0.27)  
Post-chemo:0.66 (0.30)  
Ongoing chemo: 0.64 (0.31) 
Published in conference proceedings in 
German patients. 
Diels 2012214 0.67 Updated above in Diels 2015. Mean utility for all patients recorded. 
James 2012215 - 0.63 (0.26) 
Published in conference proceedings 
only. Utility is for mCRPC patients 
progressed after docetaxel.  
Sullivan, 2007200 0.715 -0.07 decrement 
Baseline utility recorded for the UK 
population studied with decrement for 
progression at -0.07 
Sandblom, 
200430 - 
0.538 
(0.077) 
Utility value recorded in the last year 
before death in patients who died of 
prostate cancer.  
*Uncertainty is described as standard deviation unless otherwise noted. 
In the ERG report to TA 255 the interim utility values which were taken from the UK EAP 
(Bahl, 2015) were highlighted as an area of key uncertainty due to their premature nature 
(only the first 4 cycles in the UK EAP had been collected at the time by the early recruiting 
patients). 
We have implemented the mature utility values from the UK EAP which we believe represent 
the most reliable source for estimates of utility in both the stable and progressive states and 
are treatment specific to cabazitaxel. The use of these values from the EAP for both states 
provides consistency in the analysis. The magnitude of these utility estimates is generally in 
line with the values reported in the literature and summarised in Table 59 above, which 
range from 0.66 to 0.85 for the stable state and from 0.54 to 0.66 for progressive disease. 
Health-related quality-of-life data used in cost-effectiveness analysis  
5.4.6. The effect of adverse reactions on HRQL 
AEs will impact on HRQL and, as discussed in Section 4.12 earlier, cabazitaxel has a higher 
AE rate than mitoxantrone.  
 
Disutility values for adverse events were not collected in the UK EAP or in TROPIC. In line 
with the approach taken in TA255 disutility values associated with experiencing each AE 
presented in the model were derived from literature data. When disutilities were found in two 
different sources, an average value was used in the model. The studies from which the 
disutility values were retrieved were not specific to prostate cancer patients. Instead, the 
studies described utility losses due to AEs for breast cancer patients and non-small cell lung 
cancer (NSCLC) patients. This is due to the lack of data specific to prostate cancer and 
because it was assumed that treatment-induced AEs would confer corresponding utility 
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losses irrespective of cancer type. For some of the AEs no disutility values were found. 
Disutility values used in the model are reported in Table 60.  
The disutilities associated with neutropenia and diarrhoea were taken from a study eliciting 
health state utilities in patients with metastatic NSCLC, where members of the general public 
estimated the disutilities.216 The disutilities for leukopenia and thrombocytopenia were 
assumed to be equal to the utility loss for neutropenia. The disutility of pulmonary embolism 
was estimated as an average from Gould et al217 and Treasure et al218 and the disutility of 
deep vein thrombosis was taken from Gould et al.217 The disutility associated with febrile 
neutropenia, fatigue and nausea/vomiting were averages of disutilities retrieved from the 
studies by Nafees et al216 and Lloyd et al. 219 The latter was a study eliciting health state 
utilities in patients with breast cancer, where members of the general public estimated the 
disutilities. From the same study, the utility loss determined for stomatitis was used for 
dehydration (based on clinical expert opinion that stomatitis cases are often filed under 
dehydration). The disutility for asthenia was assumed to be equal to the utility loss for 
fatigue. 
For patients experiencing back and bone pain, the disutility value was based on the disutility 
associated with experiencing pain as estimated by Doyle et al.220 The disutility values 
associated with anaemia were taken from a study of standard gamble interviews in members 
of the general public. The utility value for patients experiencing severe anaemia (patients 
with 7.0–8.0 g/dl which corresponds to Grade 3 and above) was estimated to 0.583, while 
the utility value for patients experiencing no anaemia was estimated at 0.708, whereby a 
disutility of -0.125 was included in the model. 
Finally, the disutility for neuropathy was derived from another study on patients with 
metastatic NSCLC, where members of the general public estimated the disutilities (Lewis et 
al) and was estimated to -0.116.221 
Table 60. Disutility due to treatment related adverse events used in the model* 
State Utility 
value SE 
Reference in 
submission 
Justification 
Neutropenia -0.090 0.0157 Nafees et al (2008)216  
Only available evidence 
Febrile 
neutropenia -0.120 0.0209
Lloyd et al (2006)219 
and Nafees et al 
(2008)216  
Average of the two available 
studies. 
Diarrhoea -0.047 0.0082 Nafees et al (2008)216 
Only available evidence 
Fatigue 
-0.094 0.0163
Lloyd et al (2006)219 
and Nafees et al 
(2008)216  
Average of the two available 
studies 
Asthenia 
(weakness) -0.094 0.0163
Assumption No data available – assumed 
to be equal to fatigue 
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State Utility 
value SE 
Reference in 
submission 
Justification 
Leucopaenia 
-0.090 0.0157
Assumption No specific data available – 
assumed to be equal to 
neutropenia 
Back pain -0.069 0.0120 Doyle et al (2008)220 Only available evidence 
Anaemia -0.125 0.0217 Lloyd et al (2008)222  Only available evidence 
Thrombocytopenia 
-0.090 0.0157
Assumption No specific data available – 
assumed to be equal to 
neutropenia 
Pulmonary 
embolism -0.145 0.0252
Gould et al (1999)217 
and Treasure et al 
(2009)218 
Average of the two available 
studies 
Dehydration 
-0.151 0.0263
Lloyd et al (2006)219  Based on clinical expert 
opinion that stomatitis cases 
are often filed under 
dehydration 
Nausea/vomiting 
-0.076 0.0131
Lloyd et al (2006)219 
and Nafees et al 
(2008)216  
Average of the two available 
studies 
Bone pain -0.069 0.0120 Doyle et al (2008)220 Only available evidence 
Deep vein 
thrombosis -0.160 0.0278
Gould et al (1999)217 Only available evidence 
Neuropathy -0.116 0.0202 Lewis et al (2010)221 Only available evidence 
*Where more than one reference is available in the literature the average of the values has been 
used. 
5.4.7 Patient experience of HRQL in the health states described by the model 
The EAP provides EQ-5D based utility data for UK patients treated with cabazitaxel and 
prospectively followed up. These data are therefore considered to be consistent with the 
reference case. The UK EAP is described in detail in Sections 4.11.3 to 4.11.12 above. 
EQ-5D responses were recorded in the UK EAP at every other cycle and so utility data is 
available for baseline and cycles 2,4,6,8 and 10. Utilities for cycles 1,3,5,7 and 9 have been 
interpolated. These values are implemented in the model at each cycle up to cycle 10 and 
then held constant thereafter for patients who do not progress. Patients progressing on an 
earlier line of therapy (baseline) experience increases to their initial health-related quality of 
life (albeit not statistically significant)  and maintain this over time whilst  on treatment in the 
stable disease. The list of values implemented in the model is provided in Table 61 below.  
The utility value for the progressive disease state is captured from the UK EAP as the last 
recorded utility value 30 days after final cabazitaxel treatment in those patients with 
documented evidence of progression. As these were patients no longer on treatment and 
had documented evidence of progression this is assumed to accurately reflect utility for the 
progressed disease state. As might be expected this is lower than observed in the stable 
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disease state. In the absence of other evidence and in order to reflect later deteriorations 
and a terminal period a utility value of 0 is implemented in the last 3 months of life.  
The EAP only considers patients treated with cabazitaxel however, the clinical advisors to 
the ERG for TA255 had no reason to believe that the utility for patients would be affected by 
the type of second-line chemotherapy used (i.e. cabazitaxel or mitoxantrone). Therefore 
these data are applied within the model regardless of the treatment administered, provided 
that they are in the same disease state.  
We consider that the use of the updated, mature UK EAP data reduces uncertainty and 
provides the most appropriate figures to use for both the stable and progressed states 
Treatment related adverse reactions 
Whilst application of different values for stable and progressive disease state utilities allows 
for the differential effect on disease control to be captured, this approach does not account 
for effects of increased rates of AEs. To account for the potential for adverse events to affect 
utility, disutilities are applied as they are experienced in the model.  
Fifteen AEs were included in the model. These are listed in above in Table 60 together with 
AE rates in patients who experienced these events in each arm of the TROPIC trial. These 
AEs were chosen on the grounds that they were the most frequent treatment-emergent 
Grade ≥3 AEs (occurring in more than 2% of the patients in any treatment arm of the 
TROPIC trial). In addition, deep vein thrombosis and neuropathy were added to the list of 
AEs, as they were classified as important based on clinical expert opinion. 
Although early-stage disease may be asymptomatic, metastatic prostate cancer is 
associated with a range of symptoms that substantially affect HRQL (Section 3.2). 
Symptoms include lymphoedema, weight loss, pain, and Skeletal related Events (SREs) 
associated with bone metastases. Pain associated with bone metastases is considered one 
of the most important factors affecting HRQL in mCRPC. The patient’s HRQL is also likely to 
be directly affected by various other factors, including fatigue and anxiety. Mitoxantrone was 
licensed in the first-line setting principally for its palliative benefits, including its impact on 
pain,223 and its historic use in second line therapy illustrates the importance of effective 
symptom control in mCRPC.  
In addition to the impact of the disease, AEs and general fatigue/ malaise associated with 
chemotherapy are also likely to affect HRQL. However, the use of active chemotherapy such 
as mitoxantrone even in the absence of a proven survival benefit suggests that clinicians 
perceive the benefits of chemotherapy in terms of symptom control to outweigh the negative 
impact of the therapy. 
5.4.8 Clarify whether HRQL is assumed to be constant over time in the cost-
effectiveness analysis. If not, provide details of how HRQL changes over the 
course of the disease or condition. 
There is limited published data available to describe HRQL in mHRPC/mCRPC over time. 
Generally it is assumed that HRQL would remain reasonably constant while patients are in 
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the stable state and receiving regular chemotherapy, and that HRQL would decrease 
towards the last months of life, when patients have very advanced, progressing cancer. In 
fact the UK EAP has shown that HRQL in the stable state may increase with time on therapy 
and although not a statistically significant trend this is an observation supported by clinical 
opinion (see Appendix 17). Therefore in the stable disease state we have implemented the 
observed values from the UK EAP for cycles 1 to 10 and then made the assumption that 
after cycle 10 utility remains constant until progression (see Table 55 for the full utility data 
and Table 61 for a summary). 
The usual approach taken to modelling progression in metastatic cancer is to assume lower 
HRQL in the progressed disease state compared with the stable disease state. This is the 
approach taken here informed by the last utility value measured 30 days after cabazitaxel 
cessation in patients with evidence of progression from the UK EAP. In reality this is unlikely 
to be a stepwise transition to a lower value as it is probable that a number of factors will 
affect HRQL, including presence of painful bone metastases, efficacy of pain control, receipt 
and type of further chemotherapy/BSC, and disease history as time in state continues.. 
There is no literature evidence for the evolution of utility over time in this state and so to 
account for the assumed decrease in utility the value is held constant until the last three 
months of life (four cycles in then model) whereupon it is set to 0.  
5.4.9 Describe whether the baseline HRQL assumed in the cost-effectiveness 
analysis is different from the utility values used for each of the health states. 
State whether quality-of-life events were taken from this baseline. 
There are three health states in the model: stable, progressive disease and dead. (Section 
5.2.2). As discussed in Section 5.4.8 above, in the base-case for the cost-effectiveness 
analysis, baseline utility is taken from the UK EAP for the stable disease state (See section 
5.4.1 above) and successive on treatment cycles are assumed to follow the values for each 
cycle observed in the UK EAP. Unlike the values used for the progressive state in the 
previous submission (TA255) where decrements were assumed from literature precedent to 
inform this state30, 200 values from the UK EAP are now available. Hence a directly measured 
progressive disease utility value from a similar population to the TROPIC study is applied 
with no requirement for adjustment. 
5.4.10 Adjustment of the health state utility values 
The health state utilities derived from the UK EAP have not been adjusted. 
5.4.11 Health effects found in the literature or clinical trials that were excluded 
from the cost effectiveness analysis  
No additional health effects were found in the trials or literature. 
5.4.12 Summary of the utility values for the disease states in the model. 
A summary of the utility values implemented in the base-case for the three health states 
modelled is provided in Table 61 
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Table 61. Summary of utility values for cost-effectiveness analysis 
State Utility value Reference 
in 
submission 
Justification 
Stable 
disease  Cycle 
Stable 
Disease 
  
1 0.704 
2 0.728 
3 0.728 
4 0.750 
5 0.753 
6 0.752 
7 0.778 
8 0.789 
9 0.803 
10 and 
therafter 0.819 
 
UK EAP 
(Section 
5.4.1) 
[Bahl 2015]12 
The UK EAP provides utility data 
for the stable disease state in a 
UK specific population treated 
with cabazitaxel. It is not 
expected that patients treated 
with mitoxantrone would 
experience different utility in this 
state. 
Odd cycles are interpolated data 
as utility values were collected 
at baseline (0.682) and then 
even cycles thereafter. 
Progressive 
disease 
0.6266
until last 3 months of life 
which are set to  0 
UK EAP 
(Section 
5.4.1) 
The UK EAP also provides a 
utility value for the progressive 
disease state. The 
measurement used is the value 
recorded 30 days (last record) 
after the last cycle of treatment 
received for patients with 
evidence of progression. This 
provides an estimate lower than 
that employed in TA255  
There are no data in the 
literature (or from the UK EAP) 
which provide a time dependent 
estimate of utility post 
progression. In lieu of this, utility 
in the progressive disease state 
is maintained after progression 
until the last 4 cycles (3 months) 
whereupon it is set to 0 in the 
model. This estimate, albeit a 
step change, attempts to reflect 
the expected HRQL reduction 
across the health state 
 
 Dead 0.000 Assumption Standard approach  
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In addition there is variation in HRQL for patients due to disutilities arising from AEs. To 
account for this, the disutility estimated from the literature for a specific AE is multiplied by 
the average duration of the AE as experienced in TROPIC and by the risk per cycle as 
experienced in TROPIC to give the per cycle disutility for that AE. The disutility for all AEs is 
then summed and incorporated within the calculation of QALYs for each cycle.  Disutilities 
are only applied in the stable disease state, as AE rates are only available for this period. 
Disutility due to adverse events used in the model are summarised in Table 60 above.  
5.5 Cost and healthcare resource use identification, measurement 
and valuation 
5.5.1 All parameters used to estimate cost effectiveness should be presented 
clearly in a table with details of data sources. 
Tables detailing costs and estimates for resource usage along with sources are presented in 
the following sections. 
5.5.2 Describe how relevant cost and healthcare resource use data for England 
were identified.  
On the basis that there were limited published data available on resource use in second-line 
mCRPC a full literature search was not carried out for the original submission TA255. Rather 
service evaluations were undertaken at five major UK centres to provide relevant and robust 
data for the model. The service evaluations included patients who received docetaxel for 
first-line treatment of mCRPC on or after 1 June 2007 and for whom records were available. 
Approximately 20–25 patients were included from each of the five centres. The study 
provided resource use estimates for patients on second-line cytotoxic chemotherapy, and on 
post-second-line chemotherapy and post-second-line BSC, which are applied as appropriate 
in the model. Full methods are reported in Appendix 14.  
The literature review carried out for this submission described in Section 4.1 included terms 
for health resource utilisation. A list of the studies identified in the review along with 
abstracted cost and hospital resource utilisation information is provided in Appendix 15. No 
UK studies were found and little information relevant to this submission was available in 
these reports. Hospital resource utilization data for adverse events were available in the 
CAST study in 63 patients in Dutch hospitals152 This study looked at sequences including 
cabazitaxel and abiraterone. Regardless of treatment or sequence, median length of stay 
(for the aggregate of all adverse events) was consistently 5 days in CAST. These results are 
comparable to those identified in the UK treatment audit. For example costly events such as 
febrile neutropenia resulted in 6 to 10 days in hospital on cabazitaxel treatment (depending 
on line of therapy) in the CAST study and 5.4 in the UK treatment audit. Neutropenia in 
CAST was observed at 1 to 2 days but in the UK treatment audit was longer at 4.5 days (see 
Table 70 for the average length of stay from the UK treatment audit). Other events reported 
in the CAST study are generally in line with observed UK rates. 
Treatment cost data were provided in nine studies identified by the review (See Appendix 
21) however no studies reported UK cost of treatment.	
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The large observational study described above provided an estimate for resource use at the 
time of the last submission for cabazitaxel (TA255). As there continues to be a dearth of UK 
evidence we believe these data remain the most robust source available for resource use 
information for second-line mCRPC in UK clinical practice and the findings have been 
applied in the modelling for this submission. Costings from standard sources (such as NHS 
reference costs, BNF drug costs) were updated from TA255 and applied to these resource 
use estimates in the model. 
5.5.3 When describing how relevant unit costs were identified, comment on 
whether NHS reference costs or payment-by-results (PbR) tariffs are 
appropriate for costing the intervention being appraised.  
Because the treatment is likely to have a number of consequences on the resource usage by 
patients, it is appropriate to consider NHS reference costs in this analysis. 
5.5.4 Clinical expert assessment of the applicability of the cost and healthcare 
resource use values 
For the purposes of the previous submission (TA255) an advisory board was held to obtain 
advice from four oncologists on UK-specific resource use data. The estimates of resource 
use which were elicited were used to supplement missing values from the UK-based 
retrospective observational study of five major cancer centres described above (Section 
5.5.2). These included rates of use of liver function test, PSA test and ECG, and the rates of 
secondary G-CSF prophylaxis. In addition, clinicians made estimates around palliative care 
requirements in the last month of life. This was necessary as the observational study was 
based on hospital records and did not estimate directly palliative care received elsewhere 
(e.g. in a hospice). (Data on inpatient hospitalisations occurring in the last month of life were 
available from the study and were used.) 
5.5.5. Summary of the cost and associated healthcare resource use of each 
treatment. 
A summary of the unit costs used in the model is provided in Table 62. 
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Table 62. Unit costs associated with the technology in the economic model 
Items Cabazitaxel  Ref. in 
submn 
Mitoxantrone Ref. in 
submn 
Abiraterone Ref. in 
submn 
Enzalutamide Ref. in 
submn 
Drug cost (unit) Commercial in 
confidence information 
removed 
Section 
2.3.3 
£100 per vial Section 
2.3.2  
£2930.00 per 120 
tablet pack 
Section 
2.3.1 
£2734.67 per 112 
capsule pack 
Section 
2.3.1 
Administration cost / 
per cycle 
Commercial in 
confidence information 
removed 
Section 
5.5.6 
Commercial in 
confidence 
information removed 
Section 
5.5.6 
n.a. Section 
5.5.6 
n.a. Section 
5.5.6 
Pre- & Concomitant 
medication / cycle 
Commercial in 
confidence information 
removed 
Section 
5.5.6 
Commercial in 
confidence 
information removed 
Section 
5.5.6 
Commercial in 
confidence 
information removed 
Section 
5.5.6 
Commercial in 
confidence 
information removed 
Section 
5.5.6 
Adverse event 
management costs 
(total / risk adjusted 
for length of AE 
episodes) 
£105.18 (total) Section 
5.5.7 
£53.78 (total) Section 
5.5.7 
£5.15 Section 
5.5.7 
£5.05 Section 
5.5.7 
Progressive disease : 
active treatment / per 
cycle 
Commercial in 
confidence information 
removed 
Section 
5.5.6 
Commercial in 
confidence 
information removed 
Section 
5.5.6 
Commercial in 
confidence 
information removed 
Section 
5.5.6 
Commercial in 
confidence 
information removed 
Section 
5.5.6 
Progressive disease: 
BSC treatment cost / 
per cycle 
Commercial in 
confidence information 
removed 
Section 
5.5.6 
Commercial in 
confidence 
information removed 
Section 
5.5.6 
 Section 
5.5.6 
 Section 
5.5.6 
End of life cost – one 
off cost applied when 
patients transition to 
the dead state 
£1952.15 Section 
5.5.6 
£1952.15 Section 
5.5.6 
£1952.15 Section 
5.5.6 
£1952.15 Section 
5.5.6 
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5.5.6 Summary of the costs included in each health state.  
Costs in the stable disease state comprise acquisition costs for active treatment, 
acquisition costs for pre-medications and concomitant medications, costs of 
chemotherapy administration, cost of disease management including hospitalisations 
and testing, and adverse event costs. Resource use data are summarised in Table 
63, and unit costs in Table 64. Adverse event costs are summarised separately 
below in section 5.5.7. 
Drug acquisition costs were sourced from the BNF and the cost of cabazitaxel was 
modified by the PAS discount. (See Section 2.3.2).  
Down titration of the cabazitaxel dose is recommended according to the SPC if there 
are adverse reactions or if patients have compromised liver function (Table 8). This 
is captured in the model according to the mean dose intensity received in TROPIC 
(0.9259 and 0.9398 for cabazitaxel and mitoxantrone respectively). 
Assumptions around pre- and concomitant medications are summarised in Table 63 
below. The most complex is granulocyte-colony stimulating factor (G-CSF) 
prophylaxis, which is discussed separately below. 
In the stable disease state, costs for active treatment, pre-medications and 
chemotherapy administration are applied for ten cycles, corresponding to the 
maximum number of cycles allowed in TROPIC. Concomitant LHRH agonist therapy 
and disease management costs (hospitalisations and so forth) are applied for the 
entire duration of stable disease. In most cases estimates for the resource use are 
derived from the UK treatment audit which provided values for a 3 month period. 
These values are presented in the tables below where appropriate. (Table 63 and 
Table 67). The model calculates the per cycle usage. 
Table 63. Resource use estimates for stable disease state 
Resource use 
item 
Resource use estimate per 3 
weekly cycle Source/ justification 
Arm-specific resource use 
Active intervention: 
cabazitaxel 
47.50 mg per 3 weekly cycle plus 
daily 10 mg prednisolone 
Based on dose of 25 mg/m2, BSA 
of 1.9 m2 assuming no wastage. 
Comparator: 
mitoxantrone 
1 or 2 vials of 20 mg plus daily 10 
mg prednisolone 
Based on dose of 12 mg/m2, BSA 
of 1.9 m2 and assumption of no 
vial sharing 
Comparator: 
abiraterone 1g once daily plus daily 10 mg prednisolone BNF September 2015 
Comparator: 
enzalutamide 160 mg once daily BNF September 2015 
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Resource use 
item 
Resource use estimate per 3 
weekly cycle Source/ justification 
Premedications – 
cabazitaxel arm 
100% patients receive 
premedication with antihistamine, 
H2-antagonist, anti-emetic, and 
corticosteroid once per 3-week 
cycle 
25% patients receive primary 
prophylaxis with G-CSF per cycle 
Mandated premedication regimen 
TROPIC data showed 100% 
patients received anti-emetics 
(based on proportion of patients 
who received the four most 
common anti-emetics 
ondansetron, ondansetron-HCl, 
granisetron and granisetron-HCl).  
Premedications – 
mitoxantrone arm 
Premedications as follows: 
antihistamine (9%), H2 antagonist 
(25%), anti-emetics (100%), 
corticosteroids (56%), G-CSF as 
primary prophylaxis (10%) per 
cycle.   
Data from TROPIC for treatments 
received 
TROPIC data showed 100% 
patients received anti-emetics 
(based on proportion of patients 
who received the four most 
common anti-emetics 
ondansetron, ondansetron-HCl, 
granisetron and granisetron-HCl) 
Premedications – 
abiraterone arm 
Assumption – same as 
mitoxantrone arm in TROPIC, not 
including G-CSF 
As above 
Premedications – 
enzalutamide arm 
Assumption – same as 
mitoxantrone arm in TROPIC, not 
including G-CSF 
As above 
General resource use per 3 weeks 
Concomitant 
medications 
100% patients receive 
concomitant LHRH agonist 
therapy 
Based on data from TROPIC and 
confirmed by clinical opinion. In 
absence of further data assume 
50-50 split between leuprorelin 
and goserelin 
Chemotherapy 
administration  
One visit per 3 weeks, plus cost 
of pharmacist time 
In line with treatment regimen. 
Pharmacist time required to 
prepare drug for infusion 
Oncology ward 
(ALoS, Inpatient 
care) 
8.17 0.681 
UK observational study General ward 
(ALoS, Inpatient 
care) 
8.17 0.681 
Resource use estimate per 3 months 
Description Value SD* Source/ justification 
Visit to Clinical oncologist/ 3 weeks - caba 4.3 0.358 
UK observational 
study 
Visit to nurse/3 weeks 0 0.000 
Visit to Clinical oncologist/week 4.3 0.358 
Visit to nurse/week 0 0.000 
Urologist (Outpatient care) 0.07 0.006 
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GP (Outpatient care) 0 0.000 
Nurse (Outpatient care) 0 0.000 
A & E (Outpatient care) 0 0.000 
Oncology ward (Inpatient care) 0.030 0.003 
General ward (Inpatient care) 0.04 0.003 
Hospice home 0 0.000 
CT scan 0.15 0.013 
MRI 0.04 0.003 
Bone scan 0.09 0.008 
Ultrasound 0.04 0.003 
Conventional X-ray 0.13 0.011 
Complete blood count 4.96 0.413 
Chemistry panel 6.06 0.505 
Liver function test 2 0.167 
PSA 2 0.167 
ECG 1 0.083 
Echocardiography 0 0.000 
*PERT approximation for standard deviation [Max-Min]/6 with Min/Max of distribution 
assumed : mean +-25% SD = [1,25*Mean - 0,75*Mean]/6 = Mean / 12 
Table 64. Unit cost inputs for stable disease state 
Cost Cost (£) / unit Unit Comment 
Active treatment 
Mitoxantrone 5.00 Mg Cost per vial; £100 (2 mg/ml; 10 ml vial) – Online BNF June 2015 
Cabazitaxel 
Commercial 
in confidence 
information 
removed 
Mg 
Commercial in confidence information 
removed per 60 mg vial according to PAS 
discount  
Abiraterone acetate 0.10 Mg Based on 250 mg tablet, net price 120-tab pack = £2930.00 
Enzalutamide 0.61 mg Based on 40 mg capsule, net price 112-cap pack = £2734.67 
Premedication 
Antihistamines 0.45 Mg Based on cost for chlorphenamine - Online BNF June 2015 
H2 inhibitors 0.01 Mg Based on cost for ranitidine – Online BNF June 2015 
Anti-emetics 0.58 Mg Based on cost for ondansetron – Online BNF June 2015 
Corticosteroids 0.52 Mg Based on cost for dexamethasone – Online BNF June 2015 
G-CSF 175.67 Mg Based on cost for filgrastim - Online BNF June 2015 
Concomitant medication 
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Prednisolone 0.01 Mg Online BNF June 2015 
Goserelin 18.06 Mg Online BNF June 2015 (based on price of Zolodex) 
Leuprorelin 20.06 Mg Online BNF June 2015 (based on price of Prostap) 
Chemotherapy administration 
Clinical oncologist 
(chemotherapy 
admin.) 
320 Per administration
Total HRG tab - Currency code SB15Z - 
NHS Ref Cost 2013-2014 
Pharmacist cost per 
cabazitaxel 
administration 
10.50 Per administration
Table 13.6 - (PSSRU 2014). No 
preparation prior to administration is 
required.  Based on 15 minutes of 
pharmacist time required to order the 
appropriate dose of cabazitaxel. 
Pharmacist cost per 
other chemotherapy 
administration 
42 Per administration
Table 13.6 - (PSSRU 2014). Based on 1 
hour of pharmacist time including 
chemotherapy preparation prior to 
administration. 
Supportive care costs 
Clinical Oncologist 
(regular visit) 143 Per visit 
Out-patients consultant led tab - Currency 
code WF01A - Service code 370 - (NHS 
Ref Cost 2013-2014) 
Urologist 92 Per visit 
Out-patients consultant led tab - Currency 
code WF01A - Service code 101 - (NHS 
Ref Cost 2013-2014) 
Inpatient care: 
oncology ward 537 Per 24 h 
Non elective inpatients short stay tab - 
average of currency codes LB06H, 
LB06J, LB06K, LB06L, LB06N, LB06P, 
LB06Q, LB06R, LB06S (NHS Ref Cost 
2013-2014) 
Inpatient care: 
general ward 537 Per 24 h 
Non elective inpatients short stay tab - 
average of currency codes LB06H, 
LB06J, LB06K, LB06L, LB06N, LB06P, 
LB06Q, LB06R, LB06S (NHS Ref Cost 
2013-2014) 
Imaging: CT scan 124 Per scan 
Diagnostic imaging tab - service code 
(DIAGIMOP) - service description 
(outpatient) - RA10Z (NHS Ref Cost 
2013-2014) 
Imaging: MRI 212 Per scan 
Diagnostic imaging tab - service code 
(DIAGIMOP) - service description 
(outpatient) - RA03Z (NHS Ref Cost 
2013-2014) 
Imaging: bone scan 204 Per scan 
Diagnostic imaging tab - service code 
(DIAGIMOP) - service description 
(outpatient) - RA36Z  (NHS Ref Cost 
2013-2014) 
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Imaging: ultrasound 57 Per scan 
Diagnostic imaging tab - service code 
(DIAGIMOP) - service description 
(outpatient) - Average of RA23Z-RA24Z 
(NHS Ref Cost 2013-2014) 
Imaging: X-ray 204 Per scan 
Diagnostic imaging tab - service code 
(DIAGIMOP) - service description 
(outpatient)  - RA36Z  (NHS Ref Cost 
2013-2014) 
Lab tests: complete 
blood count 3 Per test 
DAPS tab - DAPS05 (NHS Ref Cost 
2013-2014) 
Chemistry panel 1 Per test DAPS tab - DAPS04 (NHS Ref Cost 2013-2014) 
Liver function test 3 Per test DAPS tab - DAPS08 (NHS Ref Cost 2013-2014) 
PSA 1 Per test DAPS tab - DAPS04 (NHS Ref Cost 2013-2014) 
ECG 121 Per test Total HRGs tab, code EA47Z, NHS Reference costs 2013-2014 
Echocardiogram 72 Per test IMAG tab - DIAGIMOP RA60A - Direct Access (NHS Ref Cost 2013-2014) 
G-CSF prophylaxis 
In the base-case scenario for the comparison of cabazitaxel and mitoxantrone, the 
proportion of patients receiving G-CSF as primary prophylaxis (before any clinical 
event of neutropenia Grade ≥ 3 or febrile neutropenia) was derived from TROPIC. G-
CSF usage in the TROPIC trial was analysed to give an average rate per cycle of 
25% for cabazitaxel and 10% for mitoxantrone. The average length of G-CSF 
treatment as primary prophylaxis per cycle (4.1 days) was also derived from the 
TROPIC trial and was based on the mean duration of G-CSF treatment for all treated 
patients. 
In the model, there is a possibility to change the proportion of patients receiving G-
CSF treatment as primary prophylaxis, to reflect country-specific treatment practice. 
In general UK clinicians follow EORTC guidelines and apply primary G-CSF 
prophylaxis. Around 20 – 25% of patients are managed in this way, however this is 
variable and may be lower; for example in a recent audit of patients treated in 
Preston and Lancashire, Academic in confidence information removed % of patients 
received prophylactic G-CSF. If the proportion of patients that receive G-CSF as 
primary prophylaxis is increased, the risk of having neutropenia or febrile 
neutropenia will consequently decrease. The rate per cycle of G-CSF prophylaxis is 
varied in sensitivity analysis (see Table 79 for the one-way sensitivity analyses). The 
risk of having neutropenia and febrile neutropenia after primary prophylaxis 
treatment with G-CSF is adjusted by applying the relative risk presented in a 
publication on breast cancer224 When applying the relative risk derived from this 
paper, the predicted risks of having neutropenia or febrile neutropenia without any 
G-CSF prophylaxis coincides with the observed risks of having neutropenia or febrile 
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neutropenia without any G-CSF prophylaxis in the TROPIC trial, thus validating the 
use of the relative risk from Vogel et al.224 The varying use of G-CSF as primary 
prophylaxis is added as a sensitivity analysis.  
It is recommended that patients who experience febrile neutropenia should be 
treated with G-CSF as secondary prophylaxis in every remaining cycle after the 
event. However, as this is a cohort model, the prophylaxis use cannot be modelled 
for each patient individually. Rather, the proportion of patients in the cohort treated 
with G-CSF as secondary prophylaxis in each cycle was estimated by clinical 
expertise and is used in the model. 
For the comparisons with abitraterone and enzalutamide no G-CSF prophylaxis is 
assumed in the abitraterone or enzalutamide arms. 
Progressed disease state 
Costs in the progressed disease state comprise acquisition costs for post-second-
line active chemotherapy and BSC treatments, costs of chemotherapy 
administration, and cost of disease management including hospitalisations and 
testing. Resource use data are shown in Table 67 and unit costs for items not 
already covered within the stable disease state are shown in Table 68. 
Post-progression treatment 
It is assumed a proportion of patients will receive active post-second-line 
chemotherapy, while a proportion will receive BSC only. In the base-case, this 
proportion comes from TROPIC and is 44% for the base-case population. The mix of 
post-second-line chemotherapies received also is taken from TROPIC. The 
proportion of UK patients receiving BSC (80%) and a UK-specific treatment mix, both 
taken from the treatment audit, are applied as a sensitivity analysis.  
The use of abiraterone or enzalutamide in this mix is not considered due to the 
pathway arguments put forward earlier. Where patients have received abiraterone or 
enzalutamide before docetaxel (standard NHS practice) they are prohibited under 
the current guidelines from receiving a second course of treatment. (For the case 
where they have not received these treatments ahead of cabazitaxel a scenario 
comparison is presented in Section 5.7 based on the Indirect Treatment 
Comparison).  
Post-second-line chemotherapy is applied as a transition cost on transition from 
stable to progressive disease. No separate survival advantage is attributed to the 
post-second-line treatment whether with BSC or post-second-line chemotherapy: the 
post-second-line treatment will solely add to the total cost in each cycle. The 
TROPIC post-second-line treatment mix is based on the ten most commonly 
prescribed drugs after patients had progressed on their study treatment in the trial, 
and which more than 2% of patients in any of the treatment arms received. To define 
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the top ten post-second-line treatment mixes, the following post-second-line 
treatment / antineoplastic off label agents were grouped together: 
 Cisplatin and cisplatin W 
 Estramustine and estramustine phosphate sodium (latter not in top ten on its 
own) 
 Gemcitabine and gemcitabine hydrochloride 
 Mitoxantrone and mitoxantrone hydrochloride 
 Vinorelbine and vinorelbine tartrate. 
The frequencies presented in Table 65 represent the proportion of patients in each 
arm receiving the respective types of chemotherapeutic agents post-second-line.  
Table 65. Frequency of post-second-line chemo for the base-case population 
Treatment  Frequency 
 Cabazitaxel (n=142) 
Mitoxantrone 
(n=142) 
Carboplatin 0.04 0.08 
Cyclophosphamide 0.07 0.09 
Docetaxel 0.11 0.17 
Estramustine 0.10 0.08 
Etoposide 0.08 0.08 
Mitoxantrone 0.35 0.11 
Paclitaxel 0.06 0.07 
Vinorelbine 0.04 0.09 
Cisplatin 0.02 0.01 
Gemcitabine 0.00 0.03 
The assumption is made that the mitoxantrone treatment mix is received in the 
abiraterone and enzalutamide comparisons. 
The UK-specific post-second-line treatment mix obtained from the clinical audit is 
presented in Table 66. It should be noted that carboplatin was used in a mixture of 
regimens, with no one regimen used in more than one patient.  
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Table 66. The treatments that constitute the UK-specific post-second-line treatment 
mix42  
Treatment Frequency (n): Mitoxantrone and cabazitaxel arm Source 
Docetaxel 0.54 (6) 
UK observational study Mitoxantrone 0.18 (2) Carboplatin-based 
regimens 0.27 (3) 
BSC treatment 
BSC is comprised of analgesics, steroids, palliative radiotherapy and 
bisphosphonates. These were selected as being the most important types of 
treatment, although clearly, other treatments are likely to be used as supportive 
medications throughout mCRPC. BSC medications are assumed to be received 
throughout the progressive disease state on an ongoing per cycle basis. 
Concomitant medications 
LHRH agonists are applied on an ongoing basis until death. 
Additional care costs 
Additional care costs, such as lab tests and hospitalisations, are applied on an 
ongoing per cycle basis. Resource use estimates for these come from the UK 
observational study.(Appendix The per-cycle cost for patients receiving post-second-
line chemotherapy was higher than that for BSC. As discussed above, post-second-
line chemotherapy is only applied for a relatively short time, and therefore the cost 
for BSC is applied to all patients on an ongoing basis, with the incremental cost for 
post-second-line chemotherapy applied as a transition cost (as is done for the drug 
costs).  
End-of-life care costs 
Costs are higher towards the end of life, and based on advice from the clinical 
experts at the advisory board, a separate ‘end-of-life’ cost is incorporated in the 
model to account for this. This is applied as a transition cost on death.  
It was not possible to break down all the resource use data from the audit to provide 
specific estimates for resource use in the last month of life. This was done, however, 
for hospitalisations. The audit showed a notably higher rate of hospitalisations in the 
last month of life. It would have been inaccurate to apply a hospitalisation rate 
including these hospitalisations on an ongoing per-cycle basis throughout the 
progressive disease state. Therefore, the hospitalisations occurring during the last 
month of life were applied as a separate end-of-life transition cost. Expert opinion 
was used to provide estimates for other resource use items during the last month of 
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life, including hospice care and palliative care at home; these were not available from 
the audit as this was based on hospital records. 
Resource use estimates for the progressive disease state used in the model are 
provided in Table 67 below. 
Table 67. Resource use estimates for progressive disease state 
Resource use 
item Resource use estimate per 3 months (SD*) 
Source/justific
ation 
Post-second-line 
chemotherapy mix As detailed in Table 65 and Table 66 
TROPIC and UK 
observational 
study 
BSC treatment: 
analgesics 
Received by 43% (SD: 0.0358) patients – assumed 
50-50 split between diclofenac and co-codamol 
UK 
observational 
study 
BSC treatment: 
palliative 
radiotherapy 
Received by 43% (SD: 0.0358) patients – assumed 
50-50 split between strontium-89 and external beam 
radiotherapy 
BSC treatment: 
corticosteroids 
Received by 51% (SD: 0.0425) patients – assumed 
50-50 split between prednisolone and 
dexamethasone 
BSC treatment: 
bisphosphonates 
Received by 17% (SD: 0.0142) patients – assumed 
all patients receive zoledronate 
Chemotherapy 
administration  
Once every 3 weeks for post-second-line 
chemotherapy for duration of chemotherapy 
In line with 
treatment 
regimen. 
Pharmacist time 
required to 
prepare drug for 
infusion 
(mitoxantrone) 
or ordering 
(cabazitaxel) 
Resource use (visits) by post second  line mix 
 Receiving post-second-line chemotherapy mix 
Receiving post-second-
line BSC  
 Value SD* Value SD*  
Urologist 
(outpatient) 0.000 0.000 0.050 0.004 UK 
observational 
study 
GP(outpatient) 0.000 0.000 0.000 0.000 
Nurse (outpatient) 0.000 0.000 0.000 0.000 
A & E (outpatient) 0.000 0.000 0.000 0.000 
Oncology ward  
(Inpatient care) 0.200 0.017 0.130 0.011 Average LOS 
6.5 days: 
UK treatment 
audit 
General ward 
(Inpatient care) 0.060 0.005 0.090 0.008 
Urology ward  
(Inpatient care) 0.000 0.000 0.020 0.002 
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Resource use 
item Resource use estimate per 3 months (SD*) 
Source/justific
ation 
Urologist  
(Inpatient care) 0.400 0.033 0.000 0.000 
UK 
observational 
study 
CT scan 0.090 0.008 0.470 0.039 
MRI 0.130 0.011 0.150 0.013 
Bone scan 0.000 0.000 0.140 0.012 
Ultrasound 0.050 0.004 0.000 0.000 
Conventional X-ray 0.050 0.004 0.840 0.070 
Complete blood 
count 3.470 0.289 4.120 0.343 
Chemistry panel 4.440 0.370 3.890 0.324 
Liver function test 2.000 0.167 2.000 0.167 
PSA 2.000 0.167 2.000 0.167 
ECG 1.000 0.083 0.000 0.000 
Echocardiography 0.000 0.000 0.020 0.002 
End-of-life resource use 
 Value SD* 
Expert estimate 
Hospice home 2 0.167 
Palliative care at home 6 0.500 
Palliative hospital outpatients visits 0.8 0.067 
Palliative care - hospital inpatient 0.32 0.027 
Hospice home:  ALoS per episode 5 0.417 
Palliative care - hospital inpatient ALoS per 
episode 8 0.667 
*PERT approximation for SDs: [Max-Min]/6 with Min/Max of distribution assumed : mean +-
25% SD = [1,25*Mean - 0,75*Mean]/6 = Mean / 12 
Unit costs for the progressive disease state are provided in Table 68 below. 
Table 68. Unit costs for progressive disease cost items 
Cost Cost/un
it 
Unit Comment 
BSC 
Analgesics – co-codamol 0.058 Tablet Cost per tablet 30/500 – Online BNF June 2015 
Analgesics – diclofenac 0.004414286 Tablet 
Cost per tablet – Online BNF June 
2015 
Strontium-89 234 Dose NHS Ref Cost  (Currency SC29Z) 
External beam radiation 103 Fraction NHS Ref Cost  (Currency SC22Z) 
Bisphosphonate – zoledronic 
acid 50.676 mg Online BNF June 2015 
Company evidence submission template for Cabazitaxel for hormone-relapsed 
metastatic prostate cancer previously treated with a docetaxel-containing 
regimen 
 Page 176 of 211 
 
Post-second-line chemotherapy mix drugs 
Etoposide 0.12 mg Online BNF June 2015 
Estramustine 1.71 Tablet Online BNF June 2015 
Cyclophosphamide 0.02 mg Online BNF June 2015 
Paclitaxel 2.23 mg Online BNF June 2015 
Vinorelbine (tartrate) 2.90 mg Online BNF June 2015 
Carboplatin 0.40 mg Online BNF June 2015 
Cisplatin 0.59 mg Online BNF June 2015 
Gemcitabine 0.15 mg Online BNF June 2015 
Docetaxel 6.68 mg Online BNF June 2015 
Palliative care 
Palliative homecare (nurse) 66 Per home visit 
Section 10.1 - Community nurse 
per hour of patient-related work with 
qualifications (PSSRU 2014) 
Palliative homecare (GP) 114 Per home visit 
Table 10.8b - PSSRU (2013) - 
inflated to 2014 cost 
Palliative hospital outpatients 
visits 139 Per visit 
Specialist Palliative Care Tab - 
(service description - outpatient ) - 
SD04A (NHS Ref Cost 2013-2014) 
Hospital inpatient 537 Per 24 h 
Non elective inpatients short stay 
tab - average of currency codes 
LB06H, LB06J, LB06K, LB06L, 
LB06N, LB06P, LB06Q, LB06R, 
LB06S (NHS Ref Cost 2013-2014) 
5.5.7 Summary of adverse reaction unit costs and resource use 
included in the de novo cost-effectiveness analysis.  
Costs for drugs used to treat AEs were retrieved from the BNF (Table 69). Costs per 
inpatient bed-day (24 h) were based on NHS Trusts Non-Elective Inpatient (Short 
Stay) HRG Data from the National Schedule of Reference Costs and are shown in 
Table 70.  
Table 69. Cost for drugs used to treat AEs* 
AE treatment drug Cost/unit Unit Comment 
Gentamicin £0.04 Mg Based on injection 
Teicoplanin £0.02 Mg   
Imodium £0.04 Mg Based on tablet formulation (generic form - loperamide) 
Blood transfusion £147 Unit 
The estimated cost of a unit of 
red blood cells including the 
laboratory services in our 
hospital is £132 (2008) - inflated 
to 2014 cost 
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AE treatment drug Cost/unit Unit Comment 
Platelet transfusion £241 Pool 
Approximately £200 per adult 
dose (2005) - inflated to 2014 
cost 
Intravenous drip £63 Day Calculated as £60 from 2010 source and inflated to 2014 cost 
Warfarin £0.04 Mg Tablet form 
Domperidone £0.01 Mg Tablet form 
Metoclopramide £0.004 Mg Tablet form 
Cyclizine £0.002 Mg Tablet form 
Amitryptiline £0.004 Mg Tablet form 
*Unless otherwise stated costs are taken from the BNF June 2015. 
Table 70. Costs of adverse events 
Reason for 
hospitalisation 
Unit cost 
(per 24 h) 
Average 
length of stay 
(days) 
SD: average 
length of 
stay 
HRG currency code 
Neutropenia £493 4.65 0.3875 Weighted average SA08G, SA08H, SA08J 
Febrile 
neutropenia £999 5.4 0.4500 
Weighted average PM45A, 
PM45B, PM45C, PM45D 
Diarrhoea £477 4.32 0.3600 
Weighted average: FZ91A,  
FZ91B,  FZ91C,  FZ91D,  
FZ91E,  FZ91F,  FZ91G,  
FZ91H,  FZ91J,  FZ91K,  
FZ91L,  FZ91M 
Fatigue £413 1.61 0.1342 Weighted average: AA31C, AA31d, AA31E, DZ38Z 
Asthenia 
(weakness) £413 1.61 0.1342 
Weighted average: AA31C, 
AA31d, AA31E, DZ38Z 
Leucopenia £493 4.65 0.3875 Weighted average: SA08G, SA08H, SA08J 
Back pain £425 9.55 0.7958 Weighted average: HD26D, HD26E, HD26F, HD26G 
Anaemia £517 6.46 0.5383 
Weighted average: SA04G,  
SA04H,  SA04J,  SA04K,  
SA04L 
Thrombocytope
nia £571 5.88 0.4900 
Weighted average: SA12G, 
SA12H, SA12J, SA12K 
Pulmonary 
embolism £494 6.32 0.5267 
Weighted average: DZ09D, 
DZ09E, DZ09F, DZ09G, 
DZ09H 
Dehydration £449 7.37 0.6142 
Weighted average: KC05G, 
KC05H, KC05J, KC05K, 
KC05L, KC05M, KC05N 
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Reason for 
hospitalisation 
Unit cost 
(per 24 h) 
Average 
length of stay 
(days) 
SD: average 
length of 
stay 
HRG currency code 
Nausea / 
vomiting £477 4.32 0.3600 
Weighted average: FZ91A,  
FZ91B,  FZ91C,  FZ91D,  
FZ91E,  FZ91F,  FZ91G,  
FZ91H,  FZ91J,  FZ91K,  
FZ91L,  FZ91M 
Bone pain £425 9.55 0.7958 Weighted average: HD26D, HD26E, HD26F, HD26G 
Deep vein 
thrombosis £405 4.65 0.3875 
Weighted average: YQ51A, 
YQ51B, YQ51C, YQ51D, 
YQ51E 
Neuropathy £590 2.77 0.2308  
*PERT approximation for SDs: [Max-Min]/6 with Min/Max of distribution assumed: 
mean +-25% SD = [1,25*Mean - 0,75*Mean]/6 = Mean / 12 
The AE rate is equal to the cumulative risk of the AE over the follow-up time in 
TROPIC. This risk was transformed to a probability per three-week cycle, which was 
implemented in the model.  
Since drugs filed in the TROPIC database cannot easily be correctly assigned to 
every AE, treatment of every specific AE was based on UK clinical expert opinion. It 
was assumed that treatment of all AEs requires no extra outpatient visits apart from 
the regular visits patients make for the purpose of therapy administration, an 
assumption that was supported by clinical expert opinion. The rate of hospitalisation 
for every SAE was available in the TROPIC trial and was collected in the case report 
form (CRF). As hospitalisation for SAE in TROPIC was defined as new 
hospitalisations or a prolongation of an ongoing hospitalisation, the rates of 
hospitalisation estimated in TROPIC may overestimate the rate of hospitalisations in 
clinical practice (since patients may already be hospitalised, and if the box is 
checked in the CRF, it could just be because the hospitalisation was prolonged). The 
TROPIC-derived SAE hospitalisation rates were, therefore, validated by UK clinical 
expertise to make sure that the rates applied in the model are appropriate estimates 
and reflect the clinical practice. The rates validated and adjusted by clinical expertise 
were then used to populate the model. The hospitalisation rate for every SAE used 
in the model was based on an average of all hospitalisations for this SAE, 
irrespective of treatment arm (Table 71). The average length of stay for each 
hospitalisation episode was based on HRG data, using appropriate currency 
codes.50 
Table 71. Hospitalisation rates by severe adverse event (Grade ≥3) 
Severe adverse event (Grade 
≥3) 
Rate of 
hospitalisation 
SD*: rate of 
hospitalisation 
Neutropenia 0.02 0.0051 
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Severe adverse event (Grade 
≥3) 
Rate of 
hospitalisation 
SD*: rate of 
hospitalisation 
Febrile neutropenia 0.75 0.0158 
Diarrhoea 0.10 0.0109 
Fatigue 0.01 0.0036 
Asthenia (weakness) 0.01 0.0036 
Leucopenia 0.02 0.0051 
Back pain 0.15 0.0130 
Anaemia 0.15 0.0130 
Thrombocytopenia 0.05 0.0079 
Pulmonary embolism 0.80 0.0146 
Dehydration 0.25 0.0158 
Nausea 0.00 0.0000 
Bone pain 0.02 0.0051 
Deep vein thrombosis 0.30 0.0167 
Neuropathy 0.00 0.0000 
*PERT approximation for SD: [Max-Min]/6 with Min/Max of distribution assumed: mean +-
25% SE = [1,25*Mean - 0,75*Mean]/6 = Mean / 12 
5.5.8 Additional costs and healthcare resource not been covered 
elsewhere. 
There are no additional costs or healthcare resource use. 
5.6 Summary of base-case de novo analysis inputs and 
assumptions 
5.6.1 Summary of base-case de novo analysis inputs 
Efficacy and safety inputs were derived from the patient level data of the TROPIC 
trial.  
Parametric functions fitted to patient-level data were used to describe PFS and OS. 
The statistical analyses and selection of functions for the model were performed in 
accordance with best practice guidelines. 
Extrapolation was made using different parametric distributions (exponential, 
Weibull, Lognormal, Log-logistic and Gompertz distributions). 
The choice of the parametric distribution that best fit the data is done using the 
Akaike’s Information criteria (AIC), the Bayesian Information Criteria (BIC) and 
graphical method to evaluate the goodness-of-fit of the distributions. The preferred 
model is the one with the lowest AIC and BIC value, i.e. the model that best explains 
the data with a minimum of parameters. 
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Patients receiving cabazitaxel demonstrated statistically significant longer overall 
survival (OS) compared to mitoxantrone (p<0.0001). The hazard ratio was 0.72 
(95%CI, 0.61, 0.84) corresponding to a 28% reduction in risk of death. The median 
survival for patients in the cabazitaxel group was 15.1 months in comparison to 12.7 
months in the mitoxantrone group. 
Progression-free survival (PFS) defined as the earliest progression in tumour, PSA 
or pain or death was also statistically significantly longer in the cabazitaxel group 
compared to the mitoxantrone group (hazard ratio was 0.75 (95%CI, 0.65, 0.87); 
median progression-free survival was 2.8 months versus 1.4 months. 
The economic model was populated with updated (cut-off date on 10th March, 2010) 
efficacy and safety inputs derived from the patient level data of the TROPIC trial. 
Extensive survival analyses were conducted in order to determine the best fitting 
parametric functions to inform extrapolation. These statistical analyses and selection 
of functions for the model were performed in accordance with best practice 
guidelines. 
Extrapolation was made using different parametric distributions (Exponential, 
Weibull, Log-Normal, Log-logistic and Gompertz distributions). 
The choice of the parametric distributions that best fit the data was done using the 
Akaike’s Information criteria (AIC) and the Bayesian Information Criteria (BIC) to 
evaluate the goodness-of-fit of the distributions; eyeballing of survival curves was 
also conducted. The preferred model is the one with the lowest AIC and BIC value, 
i.e. the model that best explains the data with a minimum of parameters. Tables 
reporting AIC and BIC for all parametric functions and respective survival curves are 
presented at the end of this section. 
The parametric functions used in the economic model, based on the criteria above, 
are tabulated in Table 72 below and presented graphically in Appendix . For the 
comparisons with abiraterone and enzalutamide hazard ratios (HR) derived from a 
network meta-analysis were applied to the function that best fit the cabazitaxel 
parametric function. Note that the function that best fits cabazitaxel PFS is the Log-
Normal. As the proportionality of the hazard does not hold for this function the HRs 
for PFS were applied to the Weibull distribution, which is the function that has the 
second best fit.  
Table 72. Best fit Parametric Functions used in the CEA vs mitoxantrone 
 Overall Survival Progression Free Survival ITT SG ITT SG 
Cabazitaxel vs Mitoxantrone - 
SG Weibull Weibull  Log-Normal Log-Normal 
Cabazitaxel vs Mitoxantrone - 
ITT Weibull Weibull  Log-Normal Log-Normal 
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Table 73. Summary of key variables applied in the economic model 
Variable  Value CI (distribution) 
Ref in 
submission 
Model settings  
Cycle length (weeks) 3.00 NA Section 5.2.3 
Time horizon (years) 10.00 1 – 10 Section 5.2.3 
Discount rate: costs 3.5% 0.0% – 6.5% Section 5.2.3 
Discount rate: Outcomes 3.5% 0.0% – 6.5% Section 5.2.3 
Effectiveness 
Median OS – cabazitaxel (months) 15.1 14.0 – 16.5 Section 4.7 
Median OS – mitoxantrone 12.8 11.5 – 13.7 Section 4.7 
Median PFS – cabazitaxel 2.8  2.4 – 3.1 Section 4.7 
Median PFS – mitoxantrone 1.4 1.4 – 1.8 Section 4.7 
Drug costs: cabazitaxel 
Cabazitaxel (£/mg) 
Commercial in 
confidence 
information removed 
NA Section 2.3.1 
Dose (mg / m2) 25 NA Section 2.3.1 
Body surface area (m2) 1.9  Section 2.3.1 
Frequency Per cycle NA Section 2.3.1 
Cost of administration (£) Commercial in 
confidence 
information removed 
Calculated from multiple 
variables. Section 2.3.1 Premedication and concomitant drugs (£) 
Drug costs: mitioxantrone 
Mitoxantrone (£/mg) 5.00 NA Section 2.3.1 
Dose (mg / m2) 12.0 NA Section 2.3.1 
Body surface area (m2) 1.9  Section 2.3.1 
Frequency Per cycle NA Section 2.3.1 
Cost of administration per cycle (£) Commercial in 
confidence 
information removed 
Calculated from multiple 
variables. See  Section 2.3.1 Premedication and concomitant drugs per cycle (£) 
Other drug costs: progressive disease state 
Cost per cycle: chemotherapy drugs 
and administration, premedication 
and concomitant medication 
70.93 Calculated from multiple variables. See Section 5.5.6 
Share of patients receiving BSC. 
The balance receive chemotherapy 
mix 
0.44 (TROPIC) 
0.8 (UK 
treatment 
audit) 
Section 5.5.6 
Cost per cycle - other non-chemotherapy or AE-related health care 
Stable disease state (£) Commercial in 
confidence 
information removed 
Calculated from multiple 
variables. See Section 5.5.6 Progressive disease state (£) Dead (£) 
Adverse event costs (Stable disease state) 
Cabazitaxel (£) Commercial in 
confidence 
information removed 
Calculated from multiple 
variables. Section 5.5.7 Mitoxantrone (£) 
Utility 
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Stable disease 
state 
 Point estimate SD 
Section 5.4.1 
 
Cycle 1 0.704 0.033 
Cycle 2 0.728 0.021 
Cycle 3 0.728 0.033 
Cycle 4 0.750 0.026 
Cycle 5 0.753 0.035 
Cycle 6 0.752 0.024 
Cycle 7 0.778 0.042 
Cycle 8 0.789 0.034 
Cycle 9 0.803 0.048 
Cycle 10 0.819 0.033 
Progressive 
disease state 
Per cycle 
followed by last 
4 cycles at 0 
0.6266 0.0187 
Dead  0  NA Usual practice 
SD: standard deviation; CI: confidence interval
Table 74. Assumptions used in the modelling. 
Assumption Justification 
It was assumed that patients would receive 
‘second-line’ treatment only while they were 
in the stable disease state. Once 
progressed, patients would discontinue 
treatment. 
Reflects the protocol of the TROPIC trial. 
Patients cannot return to the ‘stable 
disease’ state from the ‘progressive 
disease’ state. 
Assumption made to minimise the 
complexity of the model and the 
available data. 
After failing second-line treatment, patients 
receive a mix of third-line treatments (with 
some patients receiving BSC alone).  
Reflects clinical management of mCRPC 
patients in TROPIC and in the UK 
Patients receiving post-progression 
treatment incur the cost but do not derive 
benefits beyond those observed in the trial. 
There are no data showing a survival 
benefit with any of the treatments used in 
this setting and it is expected OS data 
reported from TROPIC would capture all 
of these benefits. 
Utility values change over time for the first 
10 cycles on treatment in the stable state 
and then remain stable thereafter. Utility is 
constant in the progressive state until the 
last 3 months of life whereupon it is set to 0. 
Reflects available utility data from the UK 
EAP up to the point of progression and 
just beyond. There is no data available to 
describe utility as a function of time in the 
progressed disease state so a constant 
value is applied until the last 3 months 
whereupon it is set to 0.. 
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5.7 Base-case results 
5.7.1 Base-case incremental cost effectiveness analysis results 
The base-case results are presented in Table 75 below. Cabazitaxel is a more 
effective treatment option than mitoxantrone in the treatment of mHRPC. The 
expected incremental life expectancy (discounted) is 0.338 Life Years Gained or 
4.02 months (4.37 months undiscounted, 95% CI: 2.12 to 5.95). This additional 
survival translates into an incremental QALY gain of 0.232 (or 2.78 months 
discounted (2.99 undiscounted)). 
Cabazitaxel is also a more costly treatment option. The expected incremental cost of 
treating patients is £11,450. This increment is not only driven by the cost of 
treatment, including administration, pre- and concomitant medication and the 
management of AEs, but also by the costs associated with increased survival. This 
granularity is provided in Table 76 and Table 77 below.  
The Incremental Cost-Effectiveness Ratio (ICER) is £49,327 per QALY, when 
compared to mitoxantrone.  
Table 75.  Base-case results: cabazitaxel vs. mitoxantrone - SG: ECOG PS 0-1, tottax 
≥225. 
Technologies Cabazitaxel Mitoxantrone 
Total costs (£) 
Commercial in confidence information removed Total LYG 
Total QALYs 
Incremental costs (£) £11,450 - 
Incremental LYG 0.338 - 
Incremental QALYs 0.232 - 
ICER (£) versus baseline 
(QALYs) £49,327 - 
ICER, incremental cost‐effectiveness ratio; LYG, life years gained; QALYs, quality‐adjusted 
life years 
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5.7.2 Disaggregated results of the base-case incremental cost 
effectiveness analysis 
Table 76. Summary of QALY gain by health state for the comparison versus 
mitoxantrone - SG: ECOG PS 0-1, tottax≥225. 
Health 
state 
QALY 
intervention 
(cabazitaxel) 
QALY 
comparator 
(Mitoxantrone) 
Increment Absolute increment 
% absolute 
increment 
Stable  
Commercial in confidence information removed Progressive 
Total  Commercial in confidence information 
removed 0.232 100% 
QALY, quality-adjusted life year 
Adapted from Pharmaceutical Benefits Advisory Committee (2008) Guidelines for preparing 
submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). Canberra: 
Pharmaceutical Benefits Advisory Committee 
 
5.7.3 Summary of costs by health state 
Table 77. Summary of costs by health state for the comparison versus mitoxantrone - 
SG: ECOG PS 0-1, tottax≥225. 
Health 
state 
Cost 
intervention 
(Cabazitaxel) 
Cost 
comparator 
(Mitoxantrone)
Increment Absolute increment 
% absolute 
increment 
Stable  
Commercial in confidence information removed Progressive 
End-of-life 
costs 
Total  Commercial in confidence 
information removed £11,450 £11,450 100% 
Adapted from Pharmaceutical Benefits Advisory Committee (2008) Guidelines for preparing 
submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). Canberra: 
Pharmaceutical Benefits Advisory Committee 
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Note that Commercial in confidence information removed % of the incremental costs 
are associated with the progressive disease state which is by definition post-
treatment. By removing the costs in both treatment arms associated with additional 
survival (post-progression), the base-case ICER is reduced to £ Commercial in 
confidence information removed / QALY. 
5.8 Sensitivity analyses 
5.8.1 Probabilistic sensitivity analysis 
Results for the probabilistic sensitivity analysis 
The results of the probabilistic sensitivity analysis (PSA) are presented in Figure 21 
below. These are based on 2,000 simulations. 
Figure 21. Cost-effectiveness plane based on 2000 probabilistic simulations  
 
The cost effectiveness acceptability curve derived from the PSA is shown in Figure 
22. 
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Figure 22. Cost-effectiveness Acceptability Curve (CEAC) 
 
At a Willingness to Pay (WTP) threshold of £50,000/QALY the probability of 
cabazitaxel being a cost-effective treatment when compared to mitoxantrone is 46%. 
5.8.2 Deterministic sensitivity analysis 
All variables subjected to one-way sensitivity analysis are shown below. These 
analyses were conducted to demonstrate the relative impact of changes in each of 
these parameters on results. 
Table 78. One-way sensitivity analyses implemented in the model 
One-way sensitivity 
analysis variable 
Variation Rationale 
State utility values ±20% To investigate the relative impact 
of utility values (both SD and PD) 
on results 
Time horizon 3 and 5 years The time horizon is typically 
important in economic evaluations 
Discount rates 0, 3.5 and 6% rates applied to 
costs and effects 
Varied between 0% and 6%, in 
line with NICE guidelines 
BSC as post-2nd line 
treatment for all arms 
0, 20, 40, 60, 80 and 100% 
proportions applied 
Variations may occur in clinical 
practice; important to investigate 
the impact of such variations 
Key: BSC = best supportive care; G-CSF = granulyte colony-stimulating factor; NICE = National Institute for Health 
and Clinical Excellence 
The one way sensitivity analyses in the population of patients with ECOG PS 0 -1 
and who have received at least 225 mg/m2 docetaxel are presented in Table 79  and 
below. 
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Table 79. One-way sensitivity analyses for the comparison versus mitoxantrone - SG: 
ECOG PS 0-1, tottax≥225. 
Sensitivity analysis Incremental 
cost 
Incremental 
QALYs 
Incremental 
LYs 
ICER per 
QALY 
ICER per 
LY 
  
Base-case 11,450 0.232 0.338 49,327 33,917 
Utilities 
AE disutilities excluded  11,450 0.233 0.338 49,138 33,917 
SD utility +20% 11,450 0.240 0.338 47,655 33,917 
SD utility -20% 11,450 0.224 0.338 51,121 33,917 
PD utility +20% 11,450 0.259 0.338 44,232 33,917 
PD utility -20% 11,450 0.206 0.338 55,749 33,917 
  
Time horizon 
3 years 10,600 0.192 0.274 55,291 38,672 
5 years 11,396 0.229 0.334 49,666 34,163 
  
Discount rates 
Costs: 0%, Effects: 0% 11,817 0.249 0.364 47,711 32,444 
Costs: 3.5%, Effects: 
0% 11,474 0.249 0.364 46,323 31,500 
Costs: 0%, Effects: 
3.5% 11,794 0.232 0.338 50,807 34,934 
Costs: 6%, Effects: 6% 11,207 0.221 0.320 50,527 35,018 
  
BSC as post-2nd line 
treatment for all arms      
Share of patients: 0% 11,683 0.232 0.338 50,327 34,604 
Share of patients: 20% 11,577 0.232 0.338 49,873 34,291 
Share of patients: 40% 11,472 0.232 0.338 49,418 33,979 
Share of patients: 60% 11,366 0.232 0.338 48,964 33,666 
Share of patients: 80% 11,261 0.232 0.338 48,509 33,354 
Share of patients: 100% 11,155 0.232 0.338 48,055 33,041 
The one-way sensitivity analyses indicates that the results are robust for the majority 
of the parameters tested. The impact of adverse events on the overall results is 
marginal. Also, in the unlikely scenario of a 5-year time horizon the ICER is still 
below £50,000/QALY. 
The model is most sensitive to variations in the Progressive Disease utility values, 
which is consistent with the base-case results as the majority of the QALY gain 
(Commercial in confidence information removed) is obtained in this health state. 
5.8.3 Scenario analysis – cabazitaxel versus mitoxantrone 
The scenarios tested around the different OS and PFS distributions are presented 
here only for completeness as the most appropriate distributions were used in the 
base-case. Note that, as expected, the choice of the distribution used for OS 
extrapolation impacts the cost-effectiveness results. For example, using the Log-
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logistic distribution, which is the second-best fit distribution (with very similar AIC and 
BIC estimates) produces an ICER of £41,920/QALY. The Log-logistic distribution is, 
however, characterised by having a long tail which may produce unrealistic survival 
results. Interestingly, truncating the model to a 5-year time-horizon the resulting 
ICER is £46,865/QALY. The same logic applies when the Log-Normal distribution is 
tested: truncating the model to a 5-year time-horizon the resulting ICER is 
£42,696/QALY. 
We note that the use of KM data and extrapolation thereafter increases the ICER to 
above £50,000/QALY but this analysis has to be interpreted with caution as the point 
from which the extrapolation starts is arbitrary and difficult to justify. 
Table 80. Additional Sensitivity analyses for the comparison versus mitoxantrone 
Parameter/Assumption Base-Case Scenario tested 
Incremental 
Costs 
Incremental 
QALYs ICER 
Base-Case £11,450 0.232 £49,327 
Overall Survival OS 2yrs IPD-Weibull 
OS 2yrs IPD- 
Exponential £12,631 0.295 £42,838 
OS 2yrs IPD-
Gompertz £11,155 0.215 £51,967 
OS 2yrs IPD-
Log logistic £12,724 0.304 £41,920 
OS 2yrs IPD-
Lognormal £13,969 0.373 £37,496 
Progression Free 
Survival 
PFS Cab 2yrs 
IPD-Lognormal 
 
PFS 2yrs IPD-
Exponential £11,587 0.226 £51,229 
PFS 2yrs IPD-
Weibull £11,985 0.225 £53,283 
PFS 2yrs IPD-
Gompertz £11,950 0.222 £53,764 
PFS 2yrs IPD-
Log logistic £11,356 0.237 £47,921 
Extrapolation Entirely parametric 
KM data and 
extrapolation 
(2yrs IPD-
Weibull – OS 
and 2yrs IPD-
Lognormal - 
PFS) 
£12,016 0.235 £51,168 
BSA 1.9 2 £11,852 0.232 £50.985 
Pharmacist cost per 
cabazitaxel 
administration 
15 minutes of 
pharmacist 
time required 
to order the 
appropriate 
dose of 
cabazitaxel 
30 minutes of 
pharmacist 
time required 
to order the 
appropriate 
dose of 
cabazitaxel 
£11,504 0.232 £49,556 
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Discontinuation 
Inclusion of 
discontinuation 
for other 
reasons than 
progression 
(23% in 
cabazitaxel 
arm; 16% in 
mitoxantrone 
arm) 
Exclusion of 
discontinuation 
for other 
reasons than 
progression 
(0% in 
cabazitaxel 
arm; 0% in 
mitoxantrone 
arm) 
£11,693 0.232 £50,370 
Population SG (ECOG 0-1, tottax≥225) ITT £11,141 0.215 £51,833 
Proportion with G-CSF 
as primary prophylaxis 
Caba 25% & 
Mitox: 10% 
Caba 25% & 
Mitox: 0% £11,549 0.232 £49,749 
Share of BSC as post 
second line treatment 
44% BSC 
66% chemo. 
mix 
80% BSC, 
20% chemo. 
mix 
£11,261 0.232 £48,509 
 
5.8.4 Scenario analysis – Comparison with abiraterone and 
enzalutamide 
The aggregate comparisons vs. abiraterone and enzalutamide are presented as 
scenario analysis in Table 81 and Table 82 overleaf 
At the request of NICE we have modelled the cost-effectiveness results for the 
comparisons versus abiraterone and enzalutamide using the PAS adjusted cost of 
cabazitaxel and the list prices for the comparators. However interpretation of these 
results is problematic on the basis of the unrealistic prices used for the comparators. 
Further results including sensitivity analysis can be found in Appendices B. 
The ITT population is implemented in these analyses and the definition of PFS used 
is radiographic PFS. See Appendices B for a discussion of the differing definitions of 
PFS used in the TROPIC, COU-AA-301 and AFFIRM studies. In order to fulfil the 
requirement for proportional hazards the Weibull distribution was used to fit rPFS 
and OS for both abiraterone and enzalutamide.  
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Abiraterone  
Table 81 Scenario results vs abiraterone 
Cabazitaxel Abiraterone 
Total costs (£) 
Commercial in confidence information 
removed Total LYG Total QALYs 
Incremental costs (£) -£17,430 - 
Incremental LYG 0.029 - 
Incremental QALYs 0.022 - 
ICER (£) versus baseline (QALYS) -£808,425 - 
Under the limitations of the analysis described in previous sections and Appendices 
B, cabazitaxel is the dominant strategy as it is less costly and more effective 
although these results should be treated with caution. 
Enzalutamide  
Table 82 Scenario results vs enzalutamide 
Cabazitaxel Enzalutamide 
Total costs (£) 
Commercial in confidence information removed Total LYG 
Total QALYs 
Incremental costs (£) ‐£37,850  ‐ 
Incremental LYG ‐0.132  ‐ 
Incremental QALYs ‐0.179  ‐ 
ICER (£) versus baseline (QALYs) £212,038  ‐ 
As for the comparison with abiraterone, these results need to be interpreted with 
caution. Cabazitaxel is less effective but at the same time less costly than 
enzalutamide and so the point estimate for the ICER is located in the south west 
quadrant of the cost-effectiveness plane. This presents a challenge in the 
interpretation of the results that is discussed in section 5.11 below. 
5.9 Subgroup analysis 
There are no further subgroups considered in the analysis.  
5.10 Validation 
Before conducting the final analyses, validation analyses were carried out to verify 
the technical validity of the model. The model was run under a variety of settings of 
the input parameters to see if the results appeared to be reasonable. The validation 
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analyses included setting inputs to extreme values and verifying the results for 
logical consistency.  
5.11 Interpretation and conclusions of economic evidence  
The analysis presented is based on a good quality head-to-head randomised 
controlled trial that directly compared cabazitaxel with mitoxantrone and in scenario 
analysis, on the indirect comparisons with abiraterone and enzalutamide. As 
previously discussed these comparisons should be treated with caution. 
Base-case: Results for comparison with mitoxantrone 
No indirect comparison was required to derive the relative treatment effects between 
cabazitaxel and mitoxantrone. This allows the analysis to be more sound and robust 
given that the number of assumptions made around treatment effects are minimised. 
The PFS and OS data from the TROPIC trial are relatively mature; almost all 
patients had reached the PFS endpoint and the majority had reached the OS 
endpoint within the trial follow-up period. Nevertheless, extrapolation was necessary 
to characterise OS but the extent of this extrapolation in the model was small. In 
order to validate this extrapolation, multiple alternative parametric functions were 
assessed according to best practice using statistical and visual tests to find the best 
fitting functions to the data. Structural uncertainty arising from alternative possible 
parametric survival functions has been fully explored in sensitivity analysis.  
The cost-effectiveness analysis shows that cabazitaxel is associated with a QALY 
gain over mitoxantrone (∆QALY of 0.232). This is driven by the increase in OS (∆LY 
of 0.338) and PFS; this finding is consistent with the demonstrated statistically 
significant benefits observed in the TROPIC trial. On the other hand, cabazitaxel is a 
more costly strategy than mitoxantrone in the second line treatment of prostate 
cancer patients. This is caused not only by the costs associated with cabazitaxel 
(drug and administration) but also by the increased post-progression costs as a 
result of increasing patient survival. The ICER presented in the base-case analysis is 
£49.327 per QALY. 
The sensitivity analyses conducted revealed that the base-case results are robust. 
The base-case ICER varied between £44,290 and £55,656 per QALY for the 
parameters tested in the deterministic sensitivity analyses. 
The probability of cabazitaxel being cost-effective versus mitoxantrone was 46% at a 
WTP threshold of £50,000 per QALY.. 
Interpretation and conclusions 
We have argued that the nature of mCRPC is such that a wide range of treatments is 
required by patients and clinicians and that a single therapeutic choice is not 
appropriate for everybody. Consideration of the pathways of care in which 
abiraterone or enzalutamide feature in the pre- or post-docetaxel setting preclude 
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their use in many patients. Indeed standard NHS practice renders cytotoxic therapy 
the only active option for most patients in the post-docetaxel setting. In the 
alternative practice pathway clinicians will identify the ‘chemotherapy patient’ using 
clinical judgement based on prognostic characteristics. This means that for these 
patients the choice of the advanced hormone therapies is not a relevant one. These 
considerations have led us to present the evaluation versus mitoxantrone in the 
base-case. 
The results from the economic analysis show that cabazitaxel is an effective use of 
NHS resources in the second line treatment of mCPRC in England. In our analysis, 
the most plausible ICER estimate does exceed £30,000 per QALY gained. 
Nevertheless, the cost per QALY is only part of a wider judgment of the value of a 
new medicine and a number of factors that can be applied to medicines with a cost 
per QALY above £30,000 to allow their approval. 
We consider that cabazitaxel falls within the End of Life (EoL) criteria, which allows 
greater flexibility in the appraisal of life-extending medicines used at the end of life. 
These criteria require an extension to life of at least an additional 3 months, 
compared to current NHS treatment. In the TROPIC trial the reported median OS 
was 2.4 months. However, the mean survival times are recognised by NICE as being 
more relevant than the median statistic for estimating cost-effectiveness as they 
takes into account the entire survival curve including continued divergence beyond 
the median. Cabazitaxel not only improved mean OS but also produced significant 
and clinically meaningful improvements in PFS and overall response rate in patients.  
Mean OS was increased by an estimated 4.02 months. The 95% confidence interval 
estimated from the PSA is 2.17 to 5.91 months. 
As cabazitaxel has become, through its use via the CDF, the established 2nd line 
chemotherapy in mCRPC patients previously treated with docetaxel, it is logical to 
consider what would replace it were it no-longer available on the NHS. Mitoxantrone 
use is currently very limited due to the availability of newer treatment options. 
However if provision for cabazitaxel is withdrawn then it is likely that, through 
necessity, mitoxantrone use would increase. This is the expectation of the British 
Uro-oncology Group as highlighted in their response to the draft scope;  ‘the 
likelihood is that if provision for cabazitaxel is not there then mitoxantrone use would 
increase’.  
Consequently, the NHS would be in the position of funding a treatment which 
delivered less health to patients, but at the same time achieving some cost savings.  
In this situation, health economists might look at the net-monetary benefit of such a 
decision. 
Mitoxantrone would on average, deliver 0.232 less QALYs, at a cost saving of 
approximately £11,500 per patient.  In Net Monetary Benefit terms (NMB), assuming 
the NHS would accept to ‘sell QALYs’ at a higher rate than it ‘buys’ them (in our 
example doubling the typical upper threshold for purchase of QALYs from £30,000 to 
£60,000/QALY) then the NMB of a move from cabazitaxel back to mitoxantrone 
Company evidence submission template for Cabazitaxel for hormone-relapsed 
metastatic prostate cancer previously treated with a docetaxel-containing 
regimen 
 Page 193 of 211 
 
would equate to a negative net monetary benefit of -£2,469 (-0.232*£60,000) [value 
of QALYs foregone] less £11,500 [cost savings realised]. In other words, moving 
back to mitoxantrone would sacrifice more QALYs than would be warranted by the 
savings released.  
 
Scenario analysis: Results for comparisons with abiraterone and enzalutamide 
There is limited value in the comparison between cabazitaxel and abiraterone or 
enzalutamide on the basis of current treatment pathways and also because the trial 
designs, outcomes and patients in TROPIC are not directly comparable to the COU-
AA-301 and AFFIRM studies. Nonetheless in line with the stated requirements in the 
scope the indirect treatment comparison summarised in Section 4.10 and described 
in detail in Appendices B was used to examine these competing strategies. 
Fully parametric Weibull fits were used in the analysis for all strategies for both OS 
and rPFS. The cost of cabazitaxel was set at the PAS adjusted cost  and as directed 
by NICE the unit costs for abiraterone and enzalutamide were set at list price. 
These analyses shows that cabazitaxel is associated with a QALY gain over 
abiraterone (∆QALY of Commercial in confidence information removed; OS: ∆LY of 
Commercial in confidence information removed) and a QALY loss versus 
enzalutamide (∆QALY of Commercial in confidence information removed; OS: ∆LY 
of Commercial in confidence information removed). In both cases the incremental 
costs were lower in the cabazitaxel arms (abiraterone arm: Commercial in 
confidence information removed; enzalutamide arm: Commercial in confidence 
information removed). These differences were principally driven by drug costs. The 
larger cost differential in the enzalutamide arm reflects increased rPFS for 
enzalutamide and as a consequence increased duration of therapy in the stable 
state. The ICER presented for the comparison versus abiraterone indicates that 
cabazitaxel dominates and for enzalutamide that cabazitaxel is in the South West 
Quadrant (SWQ) of the cost-effectiveness plain. 
In line with advice received from the secretariat we have not presented multiple 
incremental scenarios examining different levels for the manufacturer discounts for 
the advanced hormone therapies. However we have modelled discounts of 50% to 
the list price for each therapy. Cabazitaxel continues to dominate abiraterone at this 
discount (incremental cost = Commercial in confidence information removed) and 
whilst the point estimate for the ICER is still in the south west quadrant versus 
enzalutamide, the ICER is Commercial in confidence information removed. 
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6. Assessment of factors relevant to the NHS and 
other parties 
6.1 Estimation of patient numbers 
The number of patients who may be eligible for cabazitaxel in 2015 has been 
described in Section 3.4. and is reproduced below for clarity. 
Table 83. Estimation of mCPRC patients eligible for second-line chemotherapy in 
England 
 Percentage 
Number of 
patients 
Estimated number of patients diagnosed 
with prostate cancer - England 2015  40,980 
Of these, mCRPC patients37 15% 6,147 
Of these, patients receiving  first-line 
treatment with docetaxel.38 50% 3,073 
Of these, patients eligible to receive 
second-line chemotherapy.38 55% 1,690 
In discussion with their clinicians a proportion of patients may elect not to receive 
further treatment or may not receive it for other reasons and so this estimate of 
eligible patients is likely to be higher than the expected number of patients treated. 
Cabazitaxel has been available under the CDF since April 2013. The total number of 
notifications (patients) received was 352 in 2013 and 531 in 2014. Note that the data 
available for 2013 covers the period from April do December.14 
Should positive opinion be received from NICE, the estimated number of patients 
receiving cabazitaxel has been calculated on the basis of the CDF figures and a 
10% year-to-year growth for the uptake of cabazitaxel (calculated from the 2014 
figure) assumed for the first three years following this appraisal (2016 – 2018). 
Thereafter no growth is expected. Table 84.  
Table 84. Estimated number of patients receiving cabazitaxel 
  CDF figures Estimated figures 
Year 2013 2014 2015 2016 2017 2018 2019 2020 
Number of patients 352 531 584 643 707 777 777 777 
6.2 Estimation of pharmacy cost 
An average patient is expected to consume 1 vial of cabazitaxel during each course 
of therapy. This is calculated on the basis of a patient with body surface area of 
1.9m2 receiving 47.5mg of cabazitaxel taken from a 60 mg vial with no vial sharing. 
The list price of a vial is £3696.  
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On the assumption that each patient will receive 6 courses of cabazitaxel according 
to usage in TROPIC and the observational data from the real world setting described 
in Section 4, the estimated cost of cabazitaxel to the NHS per year could rise from 
£12.95M in 2015 to £17.24M.  
Table 85. Estimated pharmacy cost of cabazitaxel. 
Year  2015 2016 2017 2018 2019 2020 
Cost of 
cabazitaxel  £12.95M £14.25M £15.67M £17.24M £17.24M £17.24M 
6.3 Net budget impact to the NHS 
A Patient Access Scheme is proposed in this appraisal which will be a simple 
confidential reduction off the list price at the point of invoice. Therefore the pharmacy 
cost to the NHS of cabazitaxel is anticipated to be less than shown in Table 85. 
Cabazitaxel is an established medicine in clinical practice and has received funding 
through the Cancer Drugs Fund. This arrangement is expected to continue should 
positive opinion be received and as such there is no expectation of a net budget 
impact. 
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 Single Technology Appraisal (STA) 
Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with 
a docetaxel-containing regimen (review of TA255) [ID 889] 
 
Dear xxxxxxx, 
 
The Evidence Review Group, Sheffield School of Health and Related Research, and the 
technical team at NICE have now had an opportunity to take a look at the submission 
received from Sanofi on the 30th September. In general terms they felt that it is well 
presented and clear. However, the ERG and the NICE technical team would like further 
clarification relating to the clinical and cost effectiveness data.    
 
Both the ERG and the technical team at NICE will be addressing these issues in their 
reports.  
 
We request you to provide a written response to this letter to the Institute by 5 pm on 6th 
November. Two versions of this written response should be submitted; one with 
academic/commercial in confidence information clearly marked and one from which this 
information is removed. 
 
Please underline all confidential information, and separately highlight information that is 
submitted under ‘commercial in confidence’ in turquoise, and all information submitted under 
‘academic in confidence’ in yellow. 
 
If you present data that is not already referenced in the main body of your submission and 
that data is seen to be academic/commercial in confidence information, please complete the 
attached checklist for in confidence information. 
 
Please do not ‘embed’ documents (i.e. PDFs, spreadsheets) within your response as this 
may result in your information being displaced or unreadable. Any supporting documents 
should be uploaded to NICE Docs/Appraisals. 
 
If you have any further queries on the technical issues raised in this letter then please 
contact Victoria Kelly, Technical Lead (victoria.kelly@nice.org.uk). Any procedural questions 
should be addressed to Jeremy Powell, Project Manager (Jeremy.powell@nice.org.uk  in the 
first instance.  
 
Yours sincerely  
 
Melinda Goodall 
Associate Director – Appraisals 
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Centre for Health Technology Evaluation 
 
Encl. checklist for in confidence information 
 
Section A: Clarification on effectiveness data 
 
      
A1.Priority Question: The final scope states that radium-223 is a comparator for one of the 
subgroups that should be considered. Additionally our clinical advisors and the expert 
submissions indicate that radium-223 is a viable treatment option in some people with 
symptomatic bone-only disease. As we expect that the Appraisal Committee would want an 
estimate of the relative effectiveness of cabazitaxel and radium-223 in the appropriate 
patient group, please re-run the network meta-analysis incorporating radium-223, 
highlighting the limitations of such an analysis.  
A2.Priority Question: Please clarify what evidence is available to support the assertion on 
page 39 that use of abiraterone or enzalutamide in the pre-chemotherapy is ‘standard NHS 
practice’. As part of this clarification please provide details on the validity and robustness of 
the Sanofi data (page 14, reference 5) and how these data were collated. It is noted that 
neither abiraterone nor enzalutamide have been recommended by NICE in the pre-
chemotherapy setting and that data from the Cancer Drugs Fund 
(http://www.england.nhs.uk/ourwork/pe/cdf/  - report: April - March 2014/15) indicates that 
the most common setting for notifications of enzalutamide is in the post-chemotherapy 
setting (1164/1971 notifications).  
A3.Please justify why the estimate (Table 10, page 41) of second line chemotherapy eligible 
patients in England (n=1690) is substantially different to the estimates reported in the 
Evidence Review Group evaluation report on enzalutamide for metastatic hormone-relapsed 
prostate cancer previously treated with a docetaxel-containing regimen in table 2.1, page 24 
(http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0004/82579/ERGReport-10-49-01.pdf) 
which suggest that approximately 3000 patients would be eligible for second line 
chemotherapy.  
A4.Please clarify if the marketing authorisation for Cabazitaxel limits its use to 10 cycles. If it 
does not, please comment on the potential implications for UK clinical practice. 
A5.Please clarify why abnormal laboratory values were excluded when calculating the 
proportion of adverse events in TROPIC (Table 42, page 113). 
A6.Please report rates of hospitalisation in TROPIC by arm in Table 71 (page 177).  
A7.Please explain what the relative risks refer to in Table 45 (Appendix A, page 117) and 
please could you provide the full bibliographic details of the two references that do not have 
superscript links to the references section (that is, Doyle et al. and Vogel et al.). 
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Literature searching 
 
A8.Please clarify the discrepancy in Figure 4 (page 59) which states that 30 studies met the 
inclusion criteria and 24 studies were excluded, whereas Table 17 (page 59) states that 31 
studies were included and 23 studies were excluded.  
A9.Please clarify and explain why the systematic review includes studies of interventions 
(Figure 4 and Table 17; pages 59-61) which are not discussed further in the submission 
(such as mitoxantrone containing regimens [Fizazi 2012, Fleming 2012, Joly 2015, Ryan 
2013, Saad 2011, Hussain 2012, Basch 2015] and ipilimumab [Kwon 2014; Fizazi 2014]). 
Further, please provide an evidence network for all the included studies similar to Figure 1, 
page 48 of the ERG report for TA255 
(http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0004/82579/ERGReport-10-49-01.pdf).  
A10.In the original submission (TA255) a search was conducted to identify all studies 
relating to cabazitaxel in any context. Please clarify why the same search strategy was not 
used for the latest submission.  
A11.Please provide details (including sources and details of any alterations made) for the 
validated filter that was used to identify RCTs (Appendices pages 25). Please also clarify 
whether validated filters were employed for the non-RCT and economic studies searches, 
providing details of sources if so and justifying if not.  
Systematic review process 
 
A12.Please confirm if study selection, data extraction and quality assessment were 
undertaken independently by a minimum of two reviewers for each systematic review in the 
clinical and cost section. If not, please justify.  
A13.Please clarify/define what is meant by best supportive care in the systematic reviews of 
the clinical evidence (Table 15, pages 56-58; Section 4.10, page 85; table 29, pages 88-90) 
Quality assessment, data synthesis and analysis 
 
A14.Please confirm whether there is any overlap in data across studies reported within 
Table 31 and between studies in Table 31 and 32 (pages 93-4). For example, does the study 
by Heindrich 2014 (reference 87), which includes preliminary results from 20 European 
Compassionate Use and Early Access Programs, include data from the other European 
studies reported in Table 31?  
A15.Please provide further details on the effect of cabazitaxel on cardiac and renal 
complications in the TROPIC trial including any additional supporting evidence from post-
marketing surveillance data and other sources, if applicable.  
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A16.Please provide details on dose modification (including relative dose intensity) in the 
Compassionate Use and Early Access Programs detailed in Tables 33 and 34 (pages 83-
84). If dose modifications due to adverse events have been made in the Compassionate Use 
and Early Access Programs, what is the likely or expected impact (even if not recorded in 
the individual programs) on efficacy and health related quality of life. In addition, how many 
patients discontinued treatment in each of the programs (of these, how many presented 
disease progression)?  
A17.Please provide further comments (page 97 company submission) on the strength, 
robustness and limitation of the data from the Compassionate Use and Early Access 
Programs from around the world including variation in practice.  
A18.Please provide a summary table listing the proportion of patients that suffered adverse 
events across the four pivotal trials for cabazitaxel, abiraterone, enzalutamide and radium-
223.  
Indirect treatment comparison (ITC) 
 
A19.Priority Question: Please clarify why the ITC and associated modelling are based on 
hazard ratios (which assume proportional hazards), and why this approach was selected 
over methods that allow the relative treatment effects to vary over time. For the abiraterone 
pivotal trial Fizazi (2012) noted that the proportional hazards assumption is not met. Please 
clarify the likely impact on the results.  
A20.Priority Question: Please clarify why the random effects ITC used an uninformative 
prior despite the fact that there was insufficient data to update the prior distribution.  Please 
undertake  an analysis with a weakly informative prior that reflects reasonable prior beliefs, 
as recommended in Spiegelhalter, Abrams and Myles (2004) Bayesian approaches to 
clinical trials and health-care evaluation. Wiley, New York (doi: 10.1002/0470092602), in 
order to provide confidence intervals that better reflect the observed heterogeneity between 
trials.  
Section B: Clarification on cost-effectiveness data 
B1.Priority Question. Please clarify why the use of piecewise curves to represent overall 
survival and progression-free survival was not considered. It is noted within TA255 that the 
Committee considered the use of piecewise curves to be the most appropriate approach. 
B2.Priority Question. Please provide an amended version of the economic model that 
allows for a fully incremental analysis (including cabazitaxel, best supportive care 
[mitoxantrone], abiraterone and enzalutamide) based on the results of the probabilistic 
sensitivity analyses. 
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B3.Priority Question: Please clarify what supporting evidence is available for vial sharing of 
cabazitaxel in clinical practice, as the base-case analysis assumes that there is no wastage 
for cabazitaxel, but there is for mitoxantrone. 
B4.Priority Question: Please provide an estimate of the ICER for cabazitaxel versus 
mitoxantrone based on the probabilistic sensitivity analysis. 
B5.Priority Question. We believe that transition probabilities that add up to greater than one 
are used in the model when the estimated proportion of patients in the stable disease in the 
following cycle is fewer than the proportion alive. This will reduce the estimated number in 
the progressed state. Please comment on how amending the model to address this issue 
would affect the ICER. 
B6.Priority Question: We believe that the following problems exist in relation to patients 
who discontinue:  
a. Underestimated drug costs in the base-case. Assuming that the patients 
discontinue after the dosage of drug has been received, the drug costs should 
not be reduced in that cycle 
b. Overestimation of the utility in the base-case. Patients who have discontinued 
are assumed to still be associated with the increased utility related to 
additional treatment cycles 
c. Overestimation of drug costs. Currently only a non-cumulative proportion of 
drug costs are removed due to discontinuations rather than cumulative rates 
which should be adjusted for the proportion of patients who discontinue that 
subsequently progress. 
If these problems exist, please comment on how amending the model to address 
these issues would affect the ICER. It is unlikely that the points could be completely 
resolved without explicitly defining patients who discontinue with stable disease as a 
separate health state. 
B7.Please provide a sensitivity analysis using the electronic market information tool (eMIT) 
price for all generic drugs in the model, including mitoxantrone.  
B8.Please clarify why the proportion of patients experiencing an adverse event (for 
cabazitaxel and mitoxantrone) and the odds ratios for the rates of adverse events (for 
abiraterone and enzalutamide) were not varied within the probabilistic sensitivity analyses. 
B9.Please provide a sensitivity analysis that uses a single utility value (the mean of the 
observed utility values in the UK EAP) at all times for the stable disease state. 
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B10.Within the economic model, hazard ratios are used to derive rates of adverse events for 
abiraterone / enzalutamide (tab 'Hazard Ratios') - please provide details regarding the 
derivation of these values. 
B11.An assumption of zero utility for the last three months spent in the progressive disease 
(PD) health state is used in the model. This is implemented as a disutility. The current 
disutility appears to be calculated based on all patients who die (not the subgroup of patients 
who die from the PD health state). Please confirm that this is as intended. If not, please 
amend. In addition, the disutility incurred should be constrained by the time spent in the PD 
health state (for example, if it is two months, then at most only two months will be spent with 
a disutility of zero). Please comment on how amending the model to address these issues 
would affect the ICER.  
B12.Please clarify why the proportions of patients receiving 10 cycles of cabazitaxel differ 
between the modelled estimate (17%) and those observed in the TROPIC ITT population 
and the Early Access Programme (approximately 30%). Please confirm the proportion of 
patients who received 10 cycles in the population of interest within the TROPIC trial. 
B13.Please justify why data from the TROPIC trial (page 171, Table 65) were used in 
preference to those from the UK audit (page 171, Table 66) for post second line treatment in 
the economic model.  
B14.On page 171 it states that ’The assumption is made that the mitoxantrone treatment mix 
is received in the abiraterone and enzalutamide comparisons.’ However, in the economic 
model, abiraterone values are taken from the UK audit, whilst the enzalutamide values are 
taken from the post-cabazitaxel arm. Please comment on this discrepancy.  
B15.Please clarify if the proportion of patients receiving best supportive care as post second 
line treatment should be varied in the probabilistic sensitivity analysis. Currently, this is 
varied, but only for enzalutamide. Please amend as appropriate.  
B16.Please clarify why the value of body surface area used in the model (1.9, based on 
clinical opinion) has changed from the value used in TA255 (2.01 from the TROPIC trial),.  
B17.Please clarify why the quality of life data (section 5.4, page 150) from the EAP is 
different to that reported in reference 12 (http://www.ncbi.nlm.nih.gov/pubmed/25639506). 
Please confirm that the data used in the submission is the most up-to-date.  
B18.Please clarify how secondary G-CSF use is implemented in the company’s model (table 
63, page 166).  
B19.When adverse event treatment is costed in the Model, (tab 'AE Care') some grade 3+ 
events receive neither inpatient care nor drugs (for example, for neutropenia 2% require 
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inpatient care and 50% receive filgastrim, so at least 48% receive neither). Please confirm 
that this is as intended and justify why.  
B20.Please provide further details about the evidence used for the rates of drug use for 
adverse events.  
B21.The submission states (Table 61, page 161 - Utility in the stable disease state) that odd 
cycles are interpolated. Please provide details about how these interpolated values were 
derived, and justify this method over linear interpolation between cycles (for example, the 
cycle 3 value would be the mean of the values observed for cycles 2 and 4).  
B22.Please provide information (with references) about the proportion of patients requiring 
each end-of-life resource component (Table 67 and 68, pages 172-175): Please also provide 
a cost (with reference) for a hospice home stay.  
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Section A: Clarification on effectiveness data 
 
      
A1.Priority Question: The final scope states that radium-223 is a comparator for one of 
the subgroups that should be considered. Additionally our clinical advisors and the 
expert submissions indicate that radium-223 is a viable treatment option in some 
people with symptomatic bone-only disease. As we expect that the Appraisal 
Committee would want an estimate of the relative effectiveness of cabazitaxel and 
radium-223 in the appropriate patient group, please re-run the network meta-analysis 
incorporating radium-223, highlighting the limitations of such an analysis.  
The inclusion of radium-223 as a comparator for cabazitaxel was discussed at the decision-
problem meeting held with NICE and representatives of the ERG in July. During this meeting 
we expressed our concerns about the applicability and feasibility of this comparison. We 
recognise that radium-223, in time, may become a relevant comparator for part of the 
population, but have not included radium-223 in the NMA and subsequent economic 
analysis for the reasons that we put forward in our response to the draft scope and at the 
decision-problem meeting.  
We would like to take this opportunity to highlight again the reasons that we do not to 
consider the comparison to be valid and the limitations and difficulties of such an analysis 
were it to be performed. 
Radium-223 is licensed in a sub-population of mCRPC patients with two or more bone 
metastases and no visceral metastases; the TROPIC trial did not have the same inclusion 
criteria. In addition radium-223 is contraindicated in patients with liver metastases and 
eleven percent of patients in TROPIC had liver metastases. This raises questions over the 
suitability of indirect comparison of the population within the ALSYMPCA study. 
More importantly, technical difficulties also arise when considering inclusion of radium in the 
network of evidence. We have discussed the definitions of progression free survival (PFS) 
used in the NMA for the TROPIC, COU-AA-301 and AFFIRM studies at length in the dossier 
and commented on the issues around comparability between studies. In order to estimate a 
comparable value of rPFS for the TROPIC and the COU-AA-301 and AFFIRM populations it 
was necessary to synthesize a measure of radiographic PFS from the TROPIC data. A 
comparable measure of rPFS is not available from the ALSYMPCA study.  
Given these anticipated issues with the different RCT populations, study endpoints coupled 
with the characteristics of patients in whom the different drugs are likely to be used, it 
remains a concern that inclusion of ALSYMPCA in the existing NMA is problematic and we 
have not done this analysis. 
Notwithstanding the comments above we appreciate that the committee might wish to be 
reminded of the efficacy of radium-223 when considering their views on cabazitaxel. The 
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table below reports the summary statistics for overall survival in the cohort of patients with 
previous docetaxel use from ALSYMPCA and the TROPIC ITT population. We present these 
here side by side but with no further analysis. 
 
Active therapy 
(cabazitaxel, 
radium-223) 
Placebo 
(mitoxantrone 
for cabazitaxel) 
Difference Hazard ratio 
TROPIC (ITT) 15.1  (14.0 – 16.5) 
12.8 
(11.5 – 13.7) 2.3 months 
0.72  
(0.61 - 0.85) 
ALSYMPCA(1) 
(patients with previous 
docetaxel use) 
14.4 months 
(12.5 – 15.5) 
11.3 months  
(10.0 – 12.9) 3.1 months 
0.70 
(0.56 – 0.88) 
 
A2.Priority Question: Please clarify what evidence is available to support the 
assertion on page 39 that use of abiraterone or enzalutamide in the pre-chemotherapy 
is ‘standard NHS practice’. As part of this clarification please provide details on the 
validity and robustness of the Sanofi data (page 14, reference 5) and how these data 
were collated. It is noted that neither abiraterone nor enzalutamide have been 
recommended by NICE in the pre-chemotherapy setting and that data from the Cancer 
Drugs Fund (http://www.england.nhs.uk/ourwork/pe/cdf/  - report: April - March 
2014/15) indicates that the most common setting for notifications of enzalutamide is 
in the post-chemotherapy setting (1164/1971 notifications).  
The information referred to on page 14 (reference 5) is a summary of market research 
undertaken on behalf of Sanofi by Kantar Health between 14th April 2015 and 26th May 
2015. Data was collected via online surveys completed by 55 Oncologists managing 795 
mCRPC patients that had recently been treated in clinic. Three-hundred and twenty-seven of 
these patients were on 1st line therapy. Forty-seven percent of patients had received 
Abiraterone 1st line, 21% had received Enzalutamide 1st line and 30% had received 
Docetaxel 1st line.  
This market research was repeated between 26th June 2015 and 4th August 2015 with 56 
oncologists looking at 896 patients. Three-hundred and forty patients were on 1st line 
therapy which comprised 44% Abiraterone, 31% Docetaxel and 22% Enzalutamide. 
The sample overlap between these waves was 36 (65%). 
Hence two thirds of patients in England were receiving abiraterone and enzalutamide in the 
chemotherapy naïve setting. We believe that these therapies, which are funded by the CDF 
in the pre-docetaxel setting pending NICE decisions, represent current established practice 
this setting. 
Table 1 shows the CDF data referenced in the question. 
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Table 1. CDF notifications for abiraterone and enzalutamide*  
Year 2014 2015 Total 
Apr 14 : 
Mar 15 Month Apr May Jun Jul Aug Sept Oct Nov Dec Jan Feb Mar 
Abiraterone 
Pre-
chemo 
setting 
193 258 253 211 205 157 148 122 73 92 120 80 1912 
Enzalutamide 
Post 
doc. 
setting 
68 57 81 65 77 94 145 154 74 94 167 88 
1971 Pre-
chemo 
setting 
0 0 0 0 0 82 72 90 141 128 138 156 
*https://www.england.nhs.uk/ourwork/pe/cdf/ accessed 02/11/2015. 
Enzalutamide received positive guidance from NICE in July 2014 and so should have been available 
for baseline commissioning 90 days thereafter. Therefore it is surprising to see any notifications for 
enzalutamide on the CDF in the post-docetaxel setting in late 2014 and early 2015. 
We have queried this with the CDF and they have informed us that the figures are published as 
reported to them. However they did look into this apparent anomaly as post docetaxel use came off 
the CDF in September 2014, three months after publication of the final TAG. 
The CDF have confirmed that there were errors in reporting and that one region was incorrectly 
notifying that all their pre-docetaxel notifications were post-docetaxel. The other regions reported use 
switching in Sept/Oct 14. 
Therefore the CDF have advised that the majority of notifications reported as post-docetaxel should 
be counted as pre-docetaxel from Sep/Oct 2014 onwards. 
The CDF reiterated to us that the criteria are very clear that sequencing of these agents is not 
allowed. 
A3.Please justify why the estimate (Table 10, page 41) of second line chemotherapy 
eligible patients in England (n=1690) is substantially different to the estimates 
reported in the Evidence Review Group evaluation report on enzalutamide for 
metastatic hormone-relapsed prostate cancer previously treated with a 
docetaxel-containing regimen in table 2.1, page 24 
(http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0004/82579/ERGReport-10-49-
01.pdf) which suggest that approximately 3000 patients would be eligible for second 
line chemotherapy.  
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The link provided in the question points to the original ScHARR report for TA255 cabazitaxel. 
We have located the ERG report on enzalutamide for metastatic hormone-relapsed prostate 
cancer previously treated with a docetaxel-containing regimen by Kleijnen Systematic 
Reviews Ltd at http://www.nice.org.uk/guidance/TA316/documents/prostate-cancer-
hormone-relapsed-metastatic-enzalutamide-after-docetaxel-evaluation-report4 and assume 
that this is the document referred to in the question. 
 
Table 2.1 from the ERG report above is reproduced below along with details of the estimate 
from the current submitted cabazitaxel dossier and the radium-223 dossier for comparative 
purposes. 
Table 2. Estimates of the eligible population. 
 
Enzalutamide 
submission 
Abiraterone 
submission 
Radium‐223 
submission  Current submission  
Prevalence 
of mCRPC in 
England and 
Wales 
12,029 (No valid 
reference in the 
MS estimate in 
2013) 
10,448 
(NICE 
estimate in 
2006) 
6,142 (based on 
40,948 pts diagnosed 
in 2010 assuming 
0.75% inflation 
according to ONS of 
whom 15% are 
castrate resistant) 
6,147 (based on 
40,980 pts diagnosed 
diagnosed in 2011 
assuming 0.75% 
inflation according to 
ONS of whom 15% are 
castrate resistant) 
Eligible for 
docetaxel 
33% eligible 
(3,969 patients) 
40% eligible 
(4,400 
patients) 
N/A 50% eligible (3,073) 
Eligible for 
second-line 
treatment of 
interest 
75% of 3, 969 
mCRPC 
patients eligible 
(2,977patients) 
75% of 4,400 
mCRPC 
patients 
eligible 
(3,300 
patients) 
N/A 55% eligible (1,690) 
 
The estimate of between 10,488 and 12,029 mCRPC patients in the enzalutamide and 
abiraterone dossiers is higher than the one accepted by the committee during the radium-
223 submission (6,142). We have updated our figure based on the latest available evidence 
for the number of diagnosed patients from the ONS and implemented an estimate of  the 
percentage of these who are castrate resistant taken from a review of the literature by 
Kirby(2). These data indicate that 10–20% of prostate cancer patients develop mCRPC 
within approximately 5 years of follow-up.  We have taken the mid-point of this range, 15% 
and applied it to the number of patients diagnosed. The number implemented in the 
abiraterone submission was 19.5%, in the radium submission 15% was used. 
Our market research indicated that 50% of patients will be eligible for docetaxel and we have 
applied that figure in the calculations. 
The manufacturers of abiraterone or enzalutamide estimate that 75% of patients who 
become refractory to docetaxel will be eligible for second line treatment. As these drugs are 
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administered orally, and may be suited particularly for patients not fit enough or willing to 
embark on second line chemotherapy, it is not unreasonable to expect more patients might 
be expected to be eligible for enzalutamide.  Our estimate of 55% eligibility for a second line 
chemotherapy has been obtained from market research. 
The estimates for enzalutamide and abiraterone are for England and Wales. In line with 
NICE requirements we have presented the figures for England only. In Wales according to 
the latest figures available from the Welsh Cancer Intelligence and Surveillance Unit from 
2013 there were 2,634 people diagnosed with prostate cancer.(3) Assuming 15% of these 
are castrate resistant patients there may be 401 mCRPC patients in Wales and applying the 
proportions above around 110 of these would be eligible for second line treatment.  
In TA255 the ERG estimated that there would be 1,823 patients eligible in England and 
Wales. According to the estimates above the combined number presented here would 
therefore be 1800 (1,690 +110). 
For these reasons we believe that the estimate presented above is robust. 
 
A4.Please clarify if the marketing authorisation for Cabazitaxel limits its use to 10 
cycles. If it does not, please comment on the potential implications for UK clinical 
practice. 
The license has never limited cabazitaxel usage to a maximum of 10 cycles nor has this 
been mandated by the Cancer Drug Fund.    
In TROPIC the maximum number of cycles given was 10 but this was a trial protocol 
decision to balance the arms of the study; mitoxantrone has dose limiting cardiotoxicity 
meaning it cannot be given for more than 10 cycles. During treatment in TROPIC the median 
number of cycles received by patients was 6.   
In the UK EAP, a protocol amendment was implemented to enable clinicians to continue 
treating patients with cabazitaxel beyond 10 cycles if further clinical benefit was anticipated; 
bring the design in line with the license, rather than mirroring the pivotal trial. Similar to the 
TROPIC trial, the median number of cycles received was 6. 
The economic evaluation evaluates up to 10 cycles of treatment in order to be consistent 
with the trial evidence base, however based on UK experience (UK EAP and the number of 
cycles recorded on the CDF), it is reasonable to assume most patients will receive less than 
10 cycles. 
A5.Please clarify why abnormal laboratory values were excluded when calculating the 
proportion of adverse events in TROPIC (Table 42, page 113). 
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In examining the safety and tolerability of a new medicine, the regulatory authorities require 
assessment of both clinical and subclinical changes to body systems and physiological 
processes.   Whilst abnormal laboratory findings are important to their assessment, in real 
practice such departures may not be observed - where tests are not performed as per 
clinical trial protocol – or may not manifest as clinical symptoms requiring intervention.   
Adverse events that manifested as clinically significant issues  requiring medical intervention 
by the investigator, (such as dose reductions, dose modifications, use of supportive 
treatment, or treatment discontinuation) were captured as part of the trial case-report-forms, 
and were considered the most appropriate information to include in  the economic model.  
Clinical manifestations requiring intervention will clearly incur a cost and a disutility, whereas 
laboratory anomalies alone are more likely to be asymptomatic in nature and less likely to be 
‘observed’ or ‘felt’ by patients in real world clinical practice compared to a protocol driven trial 
with heightened measurement frequency. 
For example in TROPIC if both laboratory and symptomatic events (‘patient felt’) are 
included neutropenia (grade 3 and above) was observed in 82% of people in the cabazitaxel 
arm. However the proportion of people experiencing events that required intervention of 
some kind was far less at 21%. 
A6.Please report rates of hospitalisation in TROPIC by arm in Table 71 (page 177).  
The rates of hospitalisation observed in both arms in TROPIC for grade 3 and above AEs 
are presented in Table 3. The rates used in the model are also tabulated for comparative 
purposes. 
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Table 3. Hospitalisation rates in TROPIC 
Severe adverse 
event (Grade ≥3) 
Rate of hospitalisation in TROPIC Hospitalisation 
rate used in the 
model Cabazitaxel Mitoxantrone 
Neutropenia 0.18 0.00 0.02 
Febrile neutropenia 0.86 0.80 0.75 
Diarrhoea 0.26 0.00 0.10 
Fatigue 0.06 0.00 0.01 
Asthenia (weakness) 0.12 0.00 0.01 
Leucopenia 0.21 0.00 0.02 
Back pain 0.14 0.40 0.15 
Anaemia 0.08 0.40 0.15 
Thrombocytopenia 0.11 0.00 0.05 
Pulmonary embolism 0.57 0.40 0.80 
Dehydration 0.50 0.00 0.25 
Nausea 0.14 0.00 0.00 
Bone pain 0.00 0.00 0.02 
Deep vein 
thrombosis 0.29 0.30 0.30 
Neuropathy 0.00 0.30 0.02 
 
 
 
The rates used in the model differ from those observed in TROPIC. This is explained below. 
 
As hospitalization for SAE in TROPIC was defined as new hospitalisations or a prolongation 
of an ongoing hospitalization, the rates of hospitalisation estimated in TROPIC may 
overestimate the rate of hospitalisations in clinical practice (since patients may already be 
hospitalised, and if the box is checked in the CRF, it could just be because the 
hospitalisation was prolonged).  
The TROPIC-derived SAE hospitalisation rates were therefore validated by UK clinical 
experts to make sure that the rates applied in the model are appropriate estimates and 
reflect UK clinical practice. The rates were subsequently adjusted before use and are 
applied according to AE type in the model. 
Therefore the modelled rates reported in table 71 of the dossier and reproduced in Table 3 
above do not reflect arm specific treatments. 
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These rates are used to calculate costs. Hence the general rate for adverse events 
described above is applied to the cost of an inpatient spell for that particular event type. 
In order to calculate arm specific costs, the risk per cycle of experiencing the adverse event 
in each arm is then multiplied by this total cost to find the cost per patient per adverse event. 
A7.Please explain what the relative risks refer to in Table 45 (Appendix A, page 117) 
and please could you provide the full bibliographic details of the two references that 
do not have superscript links to the references section (that is, Doyle et al. and Vogel 
et al.). 
Relative risk refers to the calculation of relative risk of the proportion of patients requiring 
GCSF prophylaxis. 
The relevant tables in the model can be found on the ‘Risk AEs’ worksheet encompassed by 
cells AD45:AT86. 
We will amend this entry in the redacted version of the dossier to be supplied by 11th 
December 2015 as per the Procedure note. 
 
We apologise for the minor technical issues we experienced in the automatic referencing of 
both the appendices and the main dossier prior to submission. We provided updated 
documents which contained full lists of references via NICE docs a few days after the 
submission deadline which addressed these issues.  To confirm, the Doyle and Vogel 
references omitted from the first submission are again provided below.  
 
Doyle, S. et al., Health State utility scores in advanced non-small cell lung cancer. Lung 
Cancer 2008, 63, 374-380. 
Vogel, C.L. et al. First and subsequent cycle use of pegfilgrastim prevents febrile 
neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled 
phase III study. J Clin Oncol 2005; 23: 1178-1184.  
 
Literature searching 
 
A8.Please clarify the discrepancy in Figure 4 (page 59) which states that 30 studies 
met the inclusion criteria and 24 studies were excluded, whereas Table 17 (page 59) 
states that 31 studies were included and 23 studies were excluded.  
Thank you for pointing out this typological discrepancy. The error is in Figure 4. 
 
We provide an updated PRISMA diagram (Figure 1 overleaf) which includes the correct 
number of records included and excluded. The number of studies and detail contained in 
Table 17 is correct. . 
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Figure 1. PRISMA flow diagram for the systematic literature review of RCT studies. 
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A9.Please clarify and explain why the systematic review includes studies of 
interventions (Figure 4 and Table 17; pages 59-61) which are not discussed further in 
the submission (such as mitoxantrone containing regimens [Fizazi 2012, Fleming 
2012, Joly 2015, Ryan 2013, Saad 2011, Hussain 2012, Basch 2015] and ipilimumab 
[Kwon 2014; Fizazi 2014]). Further, please provide an evidence network for all the 
included studies similar to Figure 1, page 48 of the ERG report for TA255 
(http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0004/82579/ERGReport-10-49-
01.pdf).  
The systematic review of RCTs in mCRPC was carried out with a wide remit. This was 
because we are aware that since the original SLRs were conducted there have been a large 
number of interventions and major studies approved and published. We felt that it would be 
prudent to capture the entire evidence base within the inclusion criteria and to focus on 
those studies with direct relevance to the decision problem in the document. In fact it was 
noted during the decision problem meeting that focus would be needed due to the extensive 
literature base. 
The final scope for this appraisal identified abiraterone, enzalutamide, mitoxantrone and best 
supportive care as the key comparators. In addition Radium-223 dichloride was included for 
people with bone metastasis only.  
The advanced hormonal agents have been studied in the COU-AA-301(4) and AFIRM(5) 
studies and these were identified in the SLR. Mitoxantrone was the control arm in the pivotal 
cabazitaxel study TROPIC(6) which was also identified. Therefore we have based our 
analyses on these three studies and the relevant key papers have been critically reviewed 
within the submission document.  
We have argued that Radium-223 is not a valid comparator both in the submission and also 
in question 1A above. Hence we have not discussed the ALSYMPCA study at length. 
We recognise that we should have provided a rationale for not discussing further the 
remaining therapies that were identified. 
These interventions and studies were not included in the review for a number of reasons. 
Siproleucel-T has been withdrawn. All but one of the other therapies do not have licences for 
the treatment of mCRPC and are either not used in UK clinical practice or are experimental 
technologies in this space. Beyond cabazitaxel, docetaxel is the only other licensed 
chemotherapy agent for the treatment mHRPC but the CUOG Trial P-06c study was not 
discussed further as this is, by definition in the wrong patient group. (The licence for 
cabazitaxel is in the post-docetaxel setting). None of the therapies identified would be 
considered to be best supportive care in clinical practice. 
We note that mitoxantrone is not licensed in mCRPC but at the time of the TROPIC trial was 
considered to be standard of care and we have argued that it may be considered at least 
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equivalent to best supportive care today. Many of the studies shown in the evidence network 
below included mitoxantrone in the control arm. However we judged that it would not be 
informative to discuss this evidence further as it is not clear how these studies could 
increase the robustness of the NMA. 
The requested the evidence network from the SLR is provided in Figure 2 below and 
summary information including references for each publication related to the 13 studies and 
the study Phase is presented in Table 4. 
 
Figure 2 Evidence network. 
 
 
 
Table 4. Summary information of the included RCTs		
	
Trial name 
(citations) N Intervention arm Comparator arm Phase 
COU-AA-301 study 
2013(4;7-10) 1195 
Abiraterone acetate + 
prednisone Placebo + prednisone Phase III 
TROPIC study 
2013(6;11-14)  755 Cabazitaxel + prednisone 
Mitoxantrone + 
prednisone Phase III 
Fizazi 2012(15) 97 Siltuximab + mitoxantrone + Mitoxantrone + Phase II 
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prednisone prednisone 
Fleming 2012(16) 115 
Cetuximab + 
mitoxantrone + 
prednisone 
Mitoxantrone + 
prednisone Phase II 
ALSYMPCA study 
2015(1;17-20) 526
a Radium-223 + BSC Placebo + BSC Phase III 
GETUG P02 study 
2015(21) 92 
Etoposide + prednisone Mitoxantrone + 
prednisone Phase II Vinorelbine + prednisone 
CA184-043 study 
2014(22;23) 799 
Radiotherapy + 
ipilimumab Radiotherapy + placebo Phase III 
Ryan 2013(24) 142 
Rilotumumab + 
mitoxantrone + 
prednisone 
Placebo + mitoxantrone 
+ prednisone Phase II 
CUOG Trial P-06c 
study 2011(25) 45 
Docetaxel + prednisone + 
custirsen 
Mitoxantrone + 
prednisone + custirsen Phase II 
AFFIRM study 
2015(5;26-29) 1199 Enzalutamide Placebo Phase III 
Hussain 2012(30) 132 
Cixutumumab + 
mitoxantrone + 
prednisone 
Ramucirumab + 
mitoxantrone + 
prednisone 
Phase II 
COMET-2 study 
2015(31) 119 Cabozantinib 
Mitoxantrone + 
prednisone Phase III 
IMPACT study 
2011(32) 512 Sipuleucel-T Placebo Phase III 
 
 
A10.In the original submission (TA255) a search was conducted to identify all studies 
relating to cabazitaxel in any context. Please clarify why the same search strategy 
was not used for the latest submission.  
At the time of TA255 there was far less published literature in the area of castrate resistant 
prostate cancer and few studies relating to cabazitaxel directly. The original search strategy 
was conducted in three distinct parts: 
1. The objective of the first search was to identify all studies of cabazitaxel versus any 
comparator, to identify the complete evidence base for cabazitaxel.  
2. The objective of the second search was to identify all randomised controlled trials 
(RCTs) in second-line metastatic hormone-resistant prostate cancer (mCRPC) 
(patients progressed after first-line docetaxel). This was done to identify any 
additional RCT evidence for comparators within the NICE scope that were not picked 
up by the first search (which would only pick up head-to-head evidence versus 
cabazitaxel).  
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3. The objective of the third search was to identify all non-randomised studies in 
second-line mCRPC (post-docetaxel). This was done to identify any non-randomised 
evidence for cabazitaxel or comparators within the NICE scope that could potentially 
be relevant to the decision problem. 
Given the changed landscape and the anticipated increase in the number of studies (that 
may not be relevant, for example cabazitaxel in head and neck cancer) a slightly different 
strategy was adopted for the current submission. Four literature reviews were carried out 
and these are presented in the latest submission.  
Three were fully systematic literature reviews covering the RCT and non-RCT evidence in 
mHRPC/mCRPC, and one examining cost-effectiveness literature. The fourth review was a 
pragmatic review of the very recent literature for HRQL carried out as a PubMed search. 
 The new searches for clinical data in mHRPC/mCRPC were not conducted exclusively to 
address the NICE decision-problem and as such had broader search terms to include 
interventions in use or under investigation across the European Union: Jevtana 
(cabazitaxel) 
 Zytiga (abiraterone) 
 Xtandi (enzalutamide) 
 Novantrone (mitoxantrone) 
 Yervoy (ipilimumab) 
 Xofigo (radium-223) 
 Provenge (sipuleucel-T) 
 Emcyt (estramustine) 
 
Hence this search amalgamated search terms from the reviews described as 1 and 2 from 
the original TA 255 above. 
 
A11.Please provide details (including sources and details of any alterations made) for 
the validated filter that was used to identify RCTs (Appendices pages 25). Please also 
clarify whether validated filters were employed for the non-RCT and economic studies 
searches, providing details of sources if so and justifying if not.  
We employed the EMBASE versions of the Scottish Intercollegiate Guidelines Network 
(SIGN) search filters within our RCTs, non-RCT, and economic study searches. Additional 
indexed and free-text synonyms were added to the SIGN filters within all of our searches to 
increase the sensitivity of our search results. The citation for the SIGN search filters is: 
Scottish Intercollegiate Guidelines Network. Search Filters. 2014  [cited 2015 March 25]; 
Available from: http://www.sign.ac.uk/methodology/filters.html. 
We chose the SIGN filters as these have a good balance of sensitivity and specificity (see 
McKibbon 2009 for an example of balance(33)). This balance allows for an effective and 
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efficient review. In addition, before using these terms we confirmed they were included in the 
the InterTASC Information Specialists' Sub-Group Search Filter Resource (cite:  InterTASC 
Information Specialists’ Sub-Group. Search Filter Resource. Accessible at: 
http://www.york.ac.uk/inst/crd/intertasc/), which is referenced in the York CRD systematic 
review guidelines as resource for identifying search filters.  
 
Systematic review process 
 
A12.Please confirm if study selection, data extraction and quality assessment were 
undertaken independently by a minimum of two reviewers for each systematic review 
in the clinical and cost section. If not, please justify.  
For the RCT, non-RCT and Cost-effectiveness reviews two reviewers screened articles for 
inclusion first based on titles and abstracts, and subsequently by full text. Any disputes were 
resolved through discussion between reviewers or consultation with a third reviewer.  
Data from relevant articles were subsequently extracted in parallel by two independent 
reviewers, and studies were critically appraised using both a qualitative appraisal and a 
study grade. Both sets of extracted data were compared and combined into a final data 
extraction table, which was subsequently verified for the accuracy of all content by an 
independent third reviewer. 
Where multiple publications were identified for the same trial, the novel data reported in each 
publication were initially extracted separately and then grouped together to create the most 
complete data extraction while avoiding double counting of the patients.  
 
For the pragmatic review of HRQL data carried out using Pubmed two reviewers screened 
articles for inclusion first based on titles and abstracts, and subsequently by full text. Data 
from relevant articles were subsequently extracted and tabulated by one reviewer, with 
verification by the second reviewer. A quality assessment of the study by Bahl which 
presented the results from the UK EAP was carried out as the HRQL data contained therein 
were used in the modelling.(34) No quality assessments of the other HRQL studies identified 
in the review described above were carried out. This was because the data from these 
studies were not used in the evaluation directly, rather they provided supportive information 
to validate the magnitude of the utility values from Bahl 2015.(34) 
A13.Please clarify/define what is meant by best supportive care in the systematic 
reviews of the clinical evidence (Table 15, pages 56-58; Section 4.10, page 85; table 
29, pages 88-90) 
Best supportive care (BSC) is a blanket term used within clinical studies to describe the 
routine standard of care taking place at whatever centre is involved in the trial of interest. For 
mCRPC this can include analgesics, local external beam radiotherapy, glucocorticoids, 
antiandrogens, ketoconazole, bisphosphonates or oestrogens such as diethylstilbestrol or 
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estramustine. The mix and sequencing of these treatments is likely to vary between patients 
and between centres according to individual patient disease characteristics and local 
preferences. BSC is expected to provide symptomatic relief but not to extend survival. 
For the purposes of the literature review BSC has no definition beyond that stated above and 
is cited in the aggregate in the outputs of the literature review. 
For the economic modelling, BSC in the base-case is defined as the treatment mix received 
by patients in the TROPIC study once they had progressed and were no longer taking active 
chemotherapy treatments.  
Table 5. Best supportive care in TROPIC 
Therapeutic class Proportion of patients on therapy Therapy 
Analgesics 
 0.43 
Co-codamol 
Diclofenac 
Steroids 
 0.51 
Dexamethasone  
Prednisone 
Palliative Radiotherapy 
 0.43 
Strontium-89  
External beam RT 
Bisphosphonates 0.17 Zoledronic acid 
 
 
Quality assessment, data synthesis and analysis 
 
A14.Please confirm whether there is any overlap in data across studies reported 
within Table 31 and between studies in Table 31 and 32 (pages 93-4). For example, 
does the study by Heindrich 2014 (reference 87), which includes preliminary results 
from 20 European Compassionate Use and Early Access Programs, include data from 
the other European studies reported in Table 31?  
Data from the EAP/CUP programmes has been reported at the country, regional (including 
EU) and worldwide levels.  
Full papers are available for the following countries: Germany,(35) UK,(34) Korea,(36) 
Netherlands,(37) Spain(38) and Italy.(39) Conference abstracts have been published for 
Canada,(40) France(41) and Thailand.(42) 
Patients from all European CUP/EAPs were included in the study reported in full by 
Heidenreich(43) cited above so there is overlap in terms of some of the European data, 
however this paper focuses on safety in senior (>70 years) patients. 
Heidenreich also presented a poster at ESMO 2014 in which data on 451 patients from 12 
countries from around the world (Bangladesh, Korea, Lebanon, Thailand, Turkey, Germany, 
Greece, Netherlands, Norway, Slovenia, Brazil and Peru) were pooled.(44) 
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Malik has presented an interim analysis in poster form in which the data from all the 37 
countries taking part in the programmes has been pooled.(45) As yet there is no full 
publication which discusses this analysis. As this abstract presents interim analysis and is 
not a full paper this was not the focus of the discussion in the dossier. 
 
A15.Please provide further details on the effect of cabazitaxel on cardiac and renal 
complications in the TROPIC trial including any additional supporting evidence from 
post-marketing surveillance data and other sources, if applicable.  
The committee reflected at there was uncertainty about the effects of cabazitaxel on renal 
and cardiovascular safety during the evaluation of cabazitaxel for TA255. In our response to 
the ACD we were able to take the opportunity to address these concerns. (Our response can 
be found in the committee papers here: 
http://www.nice.org.uk/guidance/TA255/documents/prostate-cancer-cabazitaxel-sanofi2) and 
is reproduced as part of the answer below. 
We noted that these data have already been explored in detail with the regulatory bodies 
and agencies. Indeed, the UK regulatory agency, the MHRA, was the co-rapporteur of the 
EMA review of cabazitaxel. Both the FDA and EMA concluded that there was a positive 
benefit-risk profile for cabazitaxel, with no need for a further risk-management plan beyond 
that proposed. 
Cardiac disorders in TROPIC 
 There were five cardiac-related deaths in TROPIC in the cabazitaxel arm, and none 
in the mitoxantrone arm (noted by the EMA and De Bono 2010(6); the FDA deemed 
four deaths to be cardiac-related).(46) None of these were considered by the 
investigators to be related to the study drug – this fact was highlighted by one of the 
clinical experts at the Appraisal Committee meeting, referring to the letter published 
by De Bono et al in the Lancet.(47)  
 In their analysis, the FDA commented that three patients also had confounding 
factors including diabetes, hypertension, atrial fibrillation, prior warfarin use, and 
history of pulmonary embolism, and stated that: “Hence, there is no clear relationship 
between cabazitaxel exposure and fatal cardiotoxicity”.  
 In TROPIC, all Grade cardiac events were more common on cabazitaxel of which 6 
patients (1.6%) had Grade ≥3 cardiac arrhythmias, compared with 1 patient (0.3%) 
on mitoxantrone. The incidence of tachycardia on cabazitaxel was 1.6%, none of 
which were Grade ≥3. The incidence of atrial fibrillation was 1.1% in the cabazitaxel 
group. Cardiac failure events were more common on cabazitaxel, the event term 
being reported for 2 patients (0.5%), versus none on mitoxantrone (EPAR 2011; 
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TROPIC clinical study report). As expected, more events of LV dysfunction and EF 
decrease occurred on the mitoxantrone arm (all grades - 3 patients versus 1 patient) 
(TROPIC CSR). As stated in the EPAR, there is a lack of clear evidence to suggest 
that cabazitaxel contributed to these cardiac events. In light of the unknown aetiology 
of the increased incidence of cardiac deaths and arrhythmias, the potential risk for 
cardiac conduction disorders was included in the SmPC 
 An evaluation of the effect of cabazitaxel on the QT/Qc interval in cancer patients has 
been undertaken in study TES10884. This study has been designed to meet the 
current ICH E14 guidance (standard FDA guidance applicable to all drugs). The 
results of this were reviewed and interpreted by an external cardiology expert who 
concluded that cabazitaxel does not affect the ventricular repolarisation in humans to 
an extent that would require substantial risk-benefit considerations. The overall 
conclusion was that cabazitaxel at a dose of 25 mg/m2 was well tolerated, with QTc 
changes from baseline below the level of regulatory concern and not clinically 
meaningful. 
Maison-Blanche also conducted an open-label study assessing the cardiovascular safety of 
cabazitaxel, based on thorough evaluation of QT and non-QT variables, and the relationship 
between pharmacokinetic and pharmacodynamic ECG profiles and the occurrence of Grade 
≥3 cardiovascular adverse events.(48) The authors concluded that cabazitaxel had no 
clinically significant cardiovascular adverse effects in the 94 patients with advanced solid 
tumours.  
Renal effects in TROPIC 
 The EMA and the De Bono study reported 3 renal deaths, although the FDA 
attributed 4 deaths to renal failure, on the cabazitaxel arm, versus none in the 
mitoxantrone arm.  
 After considering the available data, the CHMP commented: “Renal failure was often 
multi-factorial in origin and a direct causal relationship with cabazitaxel cannot be 
determined. Haematuria is very common in patients with prostate cancer. Although 
more frequent in the cabazitaxel group, a possible explanation for the observed 
haematuria was found in most cases. Haematuria should be closely monitored”.  
 In response to the FDA review, an expert advisory board was convened to evaluate 
renal events occurring in the seven completed cabazitaxel studies (TROPIC, the 
Phase II breast cancer study, and the Phase I studies). This board concluded that, 
for the vast majority of the patients with an AE renal failure, at least one concomitant 
risk has been identified, such as an AE (e.g. diarrhoea, dehydration, severe infection 
plus or minus septic shock), local obstruction/progression, medications (eg, NSAID, 
zoledronic acid, vancomycin, aminosides), contrast given for repeated CT scans, or 
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co-morbidity (e.g. diabetes) and stated: “It is difficult to assess retrospectively the 
exact level of implication of each of these risk factors of renal failure in the completed 
studies.” 
 With regards to the pharmacokinetics of cabazitaxel, cabazitaxel is minimally 
excreted via the kidney (2.3% of the dose) (EPAR). No formal pharmacokinetic 
studies were conducted with cabazitaxel in patients with renal impairment. However, 
the population pharmacokinetic analysis carried out in 170 patients that included 14 
patients with moderate renal impairment (creatinine clearance in the range of 30 to 
50 ml/min) and 59 patients with mild renal impairment (creatinine clearance in the 
range of 50 to 80 ml/min) showed that mild to moderate renal impairment did not 
have meaningful effects on the pharmacokinetics of cabazitaxel. To further 
investigate the pharmacokinetics in patients with moderate and severe renal 
impairment, a study (POP12251) was undertaken. This is described below. 
 POP12251: An open-label pharmacokinetic and safety study of cabazitaxel in 
patients with solid tumors with moderately and severely impaired and with normal 
renal function. This study has been completed and the clinical study report (CSR) 
preparation is in progress. The primary objective of this study was to study the effect 
of moderate and severe renal impairment on the pharmacokinetics (PK) of 
cabazitaxel (CBZ).  
  
 
 
 
Periodic safety update 
The latest periodic safety update covering the period 17th June 2013 to 17th June 2014 
states that approximately 36 550 patients were exposed cumulatively to cabazitaxel in 
marketing experience including 11 800 patients during the reference period, and 
approximately 4502 cumulative subjects/patients were exposed to cabazitaxel in clinical 
trials up-to the data lock point of this report. 
Cardiovascular safety in the Periodic safety update 
Cardiac arrhythmia, Torsade de pointes/QT prolongation, cardiac arrhythmia terms (incl. 
bradyarrhythmias and tachyarrhythmia’s are listed as important potential risk of JEVTANA in 
the EU-RMP and specified for review in each periodic safety update. A search was 
performed in AWARETM using MedDRA version 16.1 to detect all cases involving diagnoses 
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of arrhythmia related investigations for cabazitaxel for the time period of 17 June 2013 to 17 
June 2014. No new information that would indicate a new safety signal for cabazitaxel was 
identified. 
 
Renal safety in the Periodic safety update 
In the latest periodic safety update the results from the analysis of studies EFC11784* and 
EFC11785** are presented. This was analysis was carried out in response to the US FDA 
post marketing requirement to submit integrated analyses of renal toxicity from these two 
trials every 6 months for 3 years from the initiation of the clinical trial. The 6th and final 
integrated renal safety analysis from these 2 ongoing randomized Phase 3 studies has been 
completed for the cut-off date of 27 February 2014.  
Analyses were performed on 2,321 treated patients with at least 1 cycle of study treatment 
completed at the cut-off date of 27 February 2014, including 1,934 patients treated with 
cabazitaxel and 387 patients treated with docetaxel. The covered period was from 04 May 
2011 to 27 February 2014. 
Based on the information presented in this 6th integrated renal report, no new findings have 
been identified in the 2 ongoing Phase 3 studies that would require a change in the study 
monitoring or in the current assessment of the potential impact of cabazitaxel on renal 
function. This was the sixth and last integrated renal safety report. On 3 July 2014, the US 
FDA confirmed that the corresponding Post-Marketing Requirement was duly fulfilled. 
The advice remains in the SPC that for patients with renal impairment No dose adjustment is 
necessary in patients with mild renal impairment (creatinine clearance (CLCR): 50 to 80 
mL/min). Data in patients with moderate (CLCR: 30 to 50 mL/min) and severe renal 
impairment (CLCR<30 mL/min) or end-stage renal disease is limited; therefore these 
patients should be treated with caution and monitored carefully during treatment 
 
 
*EFC11784: A Phase 3 randomized, open label, multicenter study comparing cabazitaxel at 
25 mg/m2 and at 20 mg/m2 (CBZ25 and CBZ20, respectively) in combination with 
prednisone every 3 weeks to docetaxel in combination with prednisone in patients with 
metastatic castrati on resistant prostate cancer not pretreated with chemotherapy. 
 
**EFC11785: A Phase 3 randomized, open label, multicenter study comparing cabazitaxel at 
20 mg/m2 and at 25 mg/m2 (CBZ20 and CBZ25, respectively) every 3 weeks in combination 
with prednisone for the treatment of metastatic castration resistant prostate cancer 
previously treated with a docetaxel-containing regimen. 
 
 
A16.        Please provide details on dose modification (including relative dose 
intensity) in the Compassionate Use and Early Access Programs detailed in Tables 33 
and 34 (pages 83-84).  
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- If dose modifications due to adverse events have been made in the Compassionate 
Use and Early Access Programs, what is the likely or expected impact (even if not 
recorded in the individual programs) on efficacy and health related quality of life.  
- In addition, how many patients discontinued treatment in each of the programs (of 
these, how many presented disease progression)?  
The relative dose intensity, discontinuation and dose reductions are reported in the full 
papers which have been published for the EAP/CUP programmes. These data are provided 
in Table 6. 
Table 6. Relative dose intensity, discontinuation and dose reductions reported for the 
EAP/CUP 
Country 
Median 
Relative dose 
intensity 
Discontin’n for 
disease 
progression 
Dose 
reduction due 
to any cause 
Dose 
reduction due 
to AEs 
Italy(39) 98.3% 44.9% 21% 17% 
Spain(38) 99.7% 48.5% 18.2% 15.2% 
Germany(35) 99.3% 14.5% NR 10% 
Korea(36) 99.6% 58% 43% 39% 
UK(34) 97.8% (mean) 27.7% 30.4% 29.5% 
Netherlands(37
) N/A N/A 26.5% NR 
EU pooled 
results in elder 
populations(44) 
98.9 38.4% 17.4% NR 
Discontinuation for any cause in the EAP/CUP programs was near to 100% in all cases 
since patients either die whilst on treatment (not a discontinuation event), reach the end of 
the number of cycles allotted or discontinue due to other reasons. In Germany 
discontinuation was also recorded at the point cabazitaxel became commercially available 
((n = 71, 64.5% of patients). 
The results in the Korean EAP stand out from the European studies with a greater proportion 
of patients discontinuing for reasons of disease progression and experiencing a higher rate 
of dose reductions. We have commented in the submission document that it is widely 
accepted that taxane metabolism is effected by ethnicity and that the results from this study 
suggest that caution should be exercised when treating Asian patients, especially those 
prone to cabazitaxel-induced complicated febrile neutropenia, such as patients >65 years, or 
with a poor performance status, extensive prior radiotherapy, or poor nutritional status. 
We are unable to speculate on the effect on HRQL and efficacy due to dose reduction. 
However the PROSELICA study which is evaluating the safety and efficacy for the 25mg/m2 
and 20mg/m2 doses of cabazitaxel may provide evidence to support this. We indicated in the 
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dossier that if these results become available within the timeframe of the NICE process we 
would endeavour to provide these data in an addendum. 
A17.Please provide further comments (page 97 company submission) on the strength, 
robustness and limitation of the data from the Compassionate Use and Early Access 
Programs from around the world including variation in practice.  
We will follow up with a quality assessment of the EAP/CUP studies using the quality 
assessment tool that was used for the UK EAP in the submission. 
A18.Please provide a summary table listing the proportion of patients that suffered 
adverse events across the four pivotal trials for cabazitaxel, abiraterone, enzalutamide 
and radium-223.  
The table with the adverse events from TROPIC, COU-301-AA and AFFIRM used to inform 
the ITC is provided as part of the answer to Question B10 below. 
The table of adverse events from the ALSYMPCA study for radium-223 taken from Hoskin 
2014(1) is reproduced below: 
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Table 7. Adverse events in the ALSYMPCA study(1) 
 
Indirect treatment comparison (ITC) 
 
A19.Priority Question: Please clarify why the ITC and associated modelling are based 
on hazard ratios (which assume proportional hazards), and why this approach was 
selected over methods that allow the relative treatment effects to vary over time. For 
the abiraterone pivotal trial Fizazi (2012) noted that the proportional hazards 
assumption is not met. Please clarify the likely impact on the results.  
Of the modelling approaches considered, adapting and updating the model presented to the 
Appraisal Committee in TA255 represented significant advantages of simplicity and 
continuity, not least because we believe the main comparator of interest is that of 
mitoxantrone.  Application of Hazard ratios to the modelled treatment effects from 
cabazitaxel within this modelling framework is also easy to implement transparently and 
robustly, and lends itself to full examination in probabilistic sensitivity analyses. 
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The issues arising from the examination of the trial design, populations and results of the 
NMA as discussed at the decision-problem meeting, in the dossier, and elsewhere, raised 
significant concerns about the reliability of the ITC results.  
We are aware that the Fizazzi et al comment that the hazard ratios are not proportional in 
the updated COU-AA-301study for abiraterone vs. placebo and inspection of the KM data 
(from figure 2 in Fizzazi 2012) shows that the placebo OS line crosses the abiraterone line at 
24 months.   
The proportional hazards assumption was the approach taken for the primary endpoint 
analysis reported in Table 14, page 53 of the Janssen submission to NICE for TA259 and in 
the Fizzazi paper and no detailed characterisation of how the hazards change over time has 
been reported to our knowledge.     
Modelling these results as proportional is however a conservative approach since we make 
the assumption that the beneficial treatment effect for abiraterone vs. placebo holds over 
time; thus favouring abiraterone in comparison with cabazitaxel.  
This was seen as a reasonable approach given the limitations with the data and the 
comparisons in general. 
A20.Priority Question: Please clarify why the random effects ITC used an 
uninformative prior despite the fact that there was insufficient data to update the prior 
distribution.  Please undertake  an analysis with a weakly informative prior that 
reflects reasonable prior beliefs, as recommended in Spiegelhalter, Abrams and Myles 
(2004) Bayesian approaches to clinical trials and health-care evaluation. Wiley, New 
York (doi: 10.1002/0470092602), in order to provide confidence intervals that better 
reflect the observed heterogeneity between trials.  
In the DSU Technical Support Document 2 (A generalised linear modelling framework for 
pairwise and network meta-analysis of randomised controlled trials, 2011), NICE 
recommends that vague or flat priors, such as N (0, 1002) be used for Bayesian analyses. 
This specifies that informative priors for relative effect measures require special justification.  
For example if there are multiple clinical trials with large numbers of subjects, the standard 
deviation around the variance can be estimated for the meta-analysis using these posterior 
distributions.  
When we were considering the evidence for the ITC we identified only three RCTs to inform 
the network. These were TROPIC (cabazitaxel), COU-AA-301 (abiraterone) and AFFIRM 
(enzalutamide). We based our approach to priors in the Bayesian analysis on the fact that no 
other RCT data was available and so there was no evidence upon which to base prior 
beliefs. Moreover we felt that using the identified studies to inform the priors would be 
inappropriate. 
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Hence, we followed the NICE recommended approach and used vague priors.  Details can 
be found in the WinBugs code provided in Appendices B. 
In considering our answer to this question we have reflected upon the fact that there are a 
number of observational studies and treatment audits that have been published in which the 
sequencing of abiraterone or enzalutamide with docetaxel or cabazitaxel has been 
examined. Many of these studies were summarised in Appendices A. The general finding 
has been that the efficacy of cabazitaxel is undiminished before or after the use of the 
advanced hormonal agents. These results should be treated with caution as they are often in 
small uncontrolled studies and as none of these are controlled head-to-head studies there is 
no robust data upon which to determine the relative treatment effect of the agents at the 
same point in the treatment pathway. The null hypothesis, that there is no difference, 
therefore stands and the use of vague priors remains justified. 
Rather than attempting to define arbitrary weakly informative priors we would welcome 
guidance from the ERG to help us specify these distributions so that sensitivity analysis may 
be run. 
 
Section B: Clarification on cost-effectiveness data 
B1.Priority Question. Please clarify why the use of piecewise curves to represent 
overall survival and progression-free survival was not considered. It is noted within 
TA255 that the Committee considered the use of piecewise curves to be the most 
appropriate approach. 
As discussed at the Decision Problem meeting, Sanofi raised several concerns and 
considerations in the approach to data extrapolation methodologies, particularly in light of 
the strong request for Sanofi to undertake indirect comparisons with abiraterone and 
enzalutamide despite issues with data limitations and apparent key differences in the 
underlying nature of the data – e.g. lack of a common underlying proportionality in hazards. 
It was noted that in 2011 the Appraisal Committee considered a piece-wise modelling of the 
TROPIC data represented the preferred modelling approach – of those options presented at 
the time – and we understand this was in part following advice from the ERG that the piece-
wise approach might minimise the impact of early deaths from cabazitaxel-induced 
neutropenia.  However whilst such an approach may well offer a better characterisation of 
the TROPIC data in and of itself, it creates challenges of interpretation when using hazard 
ratios derived from indirect comparison methods.   
 
Arguably, the application of a single Hazard Ratios derived from indirect comparisons that 
rely on the published primary endpoints, to an underlying cabazitaxel survival curve that 
reflected varying hazards across its individual ‘pieces’ would create questionable derived 
curves for the comparator arms and by extension significantly increase the complexity of, 
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and confound the interpretation of the result outputs.  In particular, examining alternative 
assumptions about the interplay of these hazards would add additional complexity and 
create excessive computational challenges of implementation, particularly in regards to the 
execution of probabilistic sensitivity analyses. 
 
In the ERG report to TA255 highlighted that fact that the ERG felt the use of parametric 
curves throughout is preferable compared with directly using the Kaplan-Meier curves 
followed by the transition proportions from the curves. This is primarily for two reasons: firstly 
the Kaplan-Meier curves are likely to overfit the data and be less generalisable; secondly the 
choice of time point at which the data from the Kaplan-Meier curves are considered 
unreliable has a marked effect on the ICER. These concerns expressed during TA255 on, 
for example, the point of transition between KM data and parametric extrapolation were 
‘heeded’ and as a result the base-case model applies a parametric function derived from the 
underlying data throughout the entire period of follow-up. However, the approach adopted for 
curve fitting is ultimately parsimonious in nature, seeking instead to maintain an inherent 
continuity between the curve-fitting approach and the hazard ratios derived from the indirect 
comparisons.  
 
Whilst we may, in hindsight have settled on an alternative approach to fitting survival curves 
had the comparison between limited to mitoxantrone alone, and could be based exclusively 
on data which could be accessed at the individual patient level, we considered it would be 
more appropriate to apply a consistent approach to all comparisons. 
In recognition that the OS data to 2.1 months in the cabazitaxel arm of TROPIC presents a 
visual ‘kink’ in the KM plot we have refitted the Weibull distribution from a cut-off point of 2.1 
months onwards as was discussed in section 3.32 in TA255. We present this as a scenario 
analysis below for the comparison with mitoxantrone only. The issue of proportional hazards 
discussed above prevents such an analysis being applied to the comparisons with 
abiraterone or enzalutamide. 
In this analysis the KM data is used for OS in the cabazitaxel arm until 2.1 months and from 
there onwards the newly fitted Weibull extrapolation is implemented. The mitoxantrone arm 
utilises the previously fitted Weibull curve. 
Table 8. Results (using KM followed by Weibull using 2.1 months cut-off point) 
Cabazitaxel Mitoxantrone Increment
2nd line chemotherapy (includes administration, pre- & 
concomitant medication)    
Costs associated with treating Adverse events during 2nd line 
chemotherapy    
Total health care cost during 2nd line chemotherapy (=SD)    
Total health care cost during progressive disease (=PD)    
End-of-life costs    
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Total life-time cost per patient £29,666 £18,098 £11,568 
        
QALYs 0.884 0.647 0.238 
Life-years 1.550 1.203 0.347 
Progression-free life years 0.361 0.969 0.127 
Cost per QALY gained (ICER) £48,543 
Cost per Life-year gained £33,303 
 
 
 
B2.Priority Question. Please provide an amended version of the economic model that 
allows for a fully incremental analysis (including cabazitaxel, best supportive care 
[mitoxantrone], abiraterone and enzalutamide) based on the results of the 
probabilistic sensitivity analyses. 
A fully incremental analysis is technically possible and as requested by the ERG would need 
to be accommodated through changes to the company model. For example the model does 
not currently provide an estimate of costs in each arm when the PSA is run; rather it 
presents the incremental costs.  
However we are not comfortable with providing this analysis as we have concerns about the 
fundamental nature of such a set of comparisons. We have discussed in the submission that 
differences in the definitions of PFS between the studies led us to create a highbred 
definition of rPFS that was applied to the TROPIC data for use in the ITC. We also reflected 
that this definition provided counterintuitive results in the enzalutamide comparison. 
The base-case versus mitoxantrone does not use this rPFS definition. So in order to 
undertake a fully incremental analysis it would be necessary to either, use two definitions 
(PFS from TROPIC (the base-case) for the cabazitaxel vs. mitoxantrone comparison and 
then the synthesised rPFS metric used in the ITC) or to use only the rPFS definition for all 
analyses. The use of the rPFS definition for the mitoxantrone comparison is nonsensical 
particularly as discontinuation in TROPIC was linked to PFS and so patients came off 
treatment earlier than they might have done in the COU-AA-301 and AFFIRM studies. This 
might be expected to have an effect on overall survival and also on costs. Such an analysis 
would be sub-optimal. 
In addition to the issues around PFS the populations used for the base-case and the 
analyses versus abiraterone and enzalutamide were different (SG and ITT). Moreover the 
design of the trials and the baseline patient characteristics were also different and so for all 
these reasons we believe that to combine the outputs from the PSA for each comparison 
into a fully incremental analysis is not advisable. 
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From the deterministic analyses we would expect the rank order to be mitoxantrone followed 
by cabazitaxel, abiraterone and then enzalutamide and that abiraterone would be extendedly 
dominated but we are uncomfortable about providing figures to support this assumption. We 
would prefer to maintain the more credible comparison of cabazitaxel versus mitoxantrone 
using the base-case settings. 
We would welcome comment from the ERG if they are able to provide a solution or make 
recommendations to accomplish the incremental analysis without the compounding effect of 
these issues.  
B3.Priority Question: Please clarify what supporting evidence is available for vial 
sharing of cabazitaxel in clinical practice, as the base-case analysis assumes that 
there is no wastage for cabazitaxel, but there is for mitoxantrone. 
Sanofi believe there will be no wastage of active ingredient because patient specific doses in 
the form of compounded IV bags of cabazitaxel can be supplied direct to NHS hospitals. 
Such a supply mechanism, is a practice already in very common usage in NHS cancer 
centres across a range of products and diseases, and therefore supports the assumption of 
zero wastage.  As Sanofi does not supply mitoxantrone, the zero wastage assumption 
cannot be addressed in this way. 
B4.Priority Question: Please provide an estimate of the ICER for cabazitaxel versus 
mitoxantrone based on the probabilistic sensitivity analysis. 
Using the base case settings in the model and 2000 simulations the probabilistic ICER is 
estimated to be £50,659. In the submitted model v12  the proportion of patients receiving 
best supportive care as post second line treatment were not varied in the probabilistic 
sensitivity analysis. The analysis presented here has been performed using an updated 
version of the model amended to correct errors highlighted by the ERG (See also question 
B15 to clarify model settings and update). 
 
B5.Priority Question. We believe that transition probabilities that add up to greater 
than one are used in the model when the estimated proportion of patients in the 
stable disease in the following cycle is fewer than the proportion alive. This will 
reduce the estimated number in the progressed state. Please comment on how 
amending the model to address this issue would affect the ICER. 
The proportions of patients in each health state are driven by the survival curves for PFS 
and OS. The proportion in the PD state is determined by the delta between those curves. 
The calculation of the proportion in the PD state (see below, third bullet point) protects 
against these values becoming more than 1. However as a consequence of this it is possible 
at the very end of the tails in the model for the PD proportion to become negative. In order to 
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prevent this happening there an IF statement is implemented in the SD calculations. 
(Second bullet point below). 
 The proportion in the dead state (e.g. cycle 3; H7) is calculated by multiplying the 
transition probability of death at cycle 3 (E7) by the proportion of patients in the 
stable and progressed disease states in cycle 2 (F6+G6) and then adding this ‘new 
deaths’ figure to accumulated proportion of deaths up to and including cycle 2 (H6). 
o H7 = H6+E7*(F6+G6) 
 The proportion in the stable disease state (cycle 3; F7) is then calculated by 
multiplying the proportion in the stable disease state in cycle 2 (F6), by the probability 
of remaining in the state (D7). However at this stage there is a check in place (IF 
statement) such that if this value is greater than the proportion alive (i.e. one minus 
the proportion in the dead state; H7) it is set equal to one minus the proportion in the 
dead state. 
o F7 = IF((F6*D7)>(1-H7),(1-H7),(F6*D7)) 
 The proportion in the progressed disease state at cycle 3 (G7) is then equal to one 
minus the proportion in the dead (H7) or stable disease states (F7). 
o G7 =1-F7-H7 
Inspection of the calculations sheet indicates that this ‘correction’ (implementation of the 
alternative in the IF statement discussed above) occurs at cycle 126 (week 378) in the base-
case for cabazitaxel and at cycle 89 (week 267) in the mitoxantrone arm where the 
proportion in the PD state falls to 0. If the IF statement is removed then the values in the PD 
state go negative from these points onwards. The ICER is unaffected by this change as 
patient numbers alive, albeit all now in the SD state are so small by this point. 
 
The process described in the bullet points above ensures that the total proportion of patients 
across all states cannot exceed one. We concede that this may ‘sacrifice’ patients in the PD 
state in keeping the proportion to one but the numbers are so small that there is no 
substantive effect on the outcomes. 
 
B6.Priority Question: We believe that the following problems exist in relation to 
patients who discontinue:  
a. Underestimated drug costs in the base-case. Assuming that the patients 
discontinue after the dosage of drug has been received, the drug costs 
should not be reduced in that cycle 
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Patients labelled as discontinuing in cycle n actually discontinue between the beginning of 
cycle n-1 and the beginning of cycle n. For example, the 1.59% of patients in SD who are 
labelled as discontinuing in cycle 1 incur the cost of treatment at the beginning of cycle 0 and 
discontinue between the beginning of cycle 0 and the beginning of cycle 1. Therefore, no 
drug cost is incurred for these patients in cycle 1 as they are never treated at the beginning 
of cycle 1. 
Further to that we have applied the proportion of patients on treatment to incur drug costs in 
the stable disease state, leaving the proportion of patients off treatment in the stable disease 
state (discontinued) without a cost for drugs for that cycle. 
For the following 2 questions we have made some amendments to the model according to 
the proportion of patients who are on and off treatment but still in the stable disease state. 
The amendments are described in these sections and the effect on the ICER is presented 
after question B6c. 
b. Overestimation of the utility in the base-case. Patients who have 
discontinued are assumed to still be associated with the increased 
utility related to additional treatment cycles 
We have considered this issue and agree that there are patients who discontinue but remain 
in the SD state thus continuing to accrue utility at the SD levels.  
 
We have performed a quick and crude analysis (still to be verified) of the patient level data 
from TROPIC from which we have retrieved those patients who were on cabazitaxel 
treatment without progressing and those patients who were off cabazitaxel treatment 
(discontinued) without progressing for the first 10 cycles. These proportions are shown 
below along with the overall proportion of patients in the SD state for completeness.  
Table 9. Proportion of patients on and off treatment in the stable disease state for the first 10 
cycles-  SG population. 
Patients in SD state Proportion in the SD in the model 
Proportion off Tx 
in the SD state 
Proportion on Tx 
in the SD state 
cycle 0 1.000000   
cycle 1 0.917866   
cycle 2 0.753990   
cycle 3 0.608505   
cycle 4 0.493353   
cycle 5 0.403917   
cycle 6 0.334204   
cycle 7 0.279326   
cycle 8 0.235633   
cycle 9 0.200452   
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In order to calculate the associated QALYs for the SD state we have applied the varying 
utilities observed in the early access programme (EAP) for the first 10 cycles to the 
proportion of patients on treatment without progressing in the normal way. Those patients off 
treatment without progressing (discontinued) but who are still in the SD state have been 
assigned the progressive disease utility (0.627) as a conservative assumption. 
 
c. Overestimation of drug costs. Currently only a non-cumulative 
proportion of drug costs are removed due to discontinuations rather 
than cumulative rates which should be adjusted for the proportion of 
patients who discontinue that subsequently progress. 
Further to that we have applied the proportion of patients on treatment to incur drug costs in 
the stable disease state, leaving the proportion of patients off treatment in the stable disease 
state (discontinued) without a cost for active drug for that cycle. 
 
If these problems exist, please comment on how amending the model to 
address these issues would affect the ICER. It is unlikely that the points could 
be completely resolved without explicitly defining patients who discontinue 
with stable disease as a separate health state. 
The results based on the updated estimates described above for the proportion of patients 
on and off treatment in the model are presented below in Table 10. This has a minimal 
increasing effect on the ICER from £49,327 to £49,420. 
Table 10. Results based on proportion of patients on and off treatment for the first 10 cycles 
Cabazitaxel Mitoxantrone Increment 
Total life-time cost per patient £29,513 £18,098 £11,415 
        
QALYs 0.876 0.645 0.231 
Life-years 1.541 1.203 0.338 
Progression-free life years 0.361 0.969 0.127 
Cost per QALY gained (ICER) £49,420 
 
 
B7.Please provide a sensitivity analysis using the electronic market information tool 
(eMIT) price for all generic drugs in the model, including mitoxantrone.  
All costs for generic drugs in the model have been replaced with the current eMIT prices 
taken from the https://www.gov.uk/government/publications/drugs-and-pharmaceutical-
electronic-market-information-emit accessed 26/10/2015. A table showing the changes 
made to the model default values (BNF) and the eMIT costs replacing these is presented 
overleaf. (Table 11). 
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Table 11. Model default costs for generic drugs and eMIT costs 
BNF Prices in V12 model. Prices taken from eMIT (https://www.gov.uk/government/publications/drugs-and-
pharmaceutical-electronic-market-information-emit accessed 26/10/2015) 
Drug Pack price Cost/mg Drug description in eMIT Pack price Cost/ mg 
Mitoxantrone £100 £5.00 Mitoxantrone 20mg/10ml solution for infusion vials  /  Packsize 1 £29.37 £1.47 
Docetaxel £1069.50 £6.68 Docetaxel 140mg/7ml solution for infusion vials  /  Packsize 1 £54.60 £0.39 
etoposide £12.15 £0.12 N/A 
estramustine £171.28 £1.71 N/A 
cyclophosphamide £9.20 £0.02 Cyclophosphamide 500mg powder for solution for injection vials  /  Packsize 1 £8.87 £0.02 
paclitaxel £66.85 £2.23 Paclitaxel 30mg/5ml solution for infusion vials  /  Packsize 1 £3.78 £0.13 
vinorelbine (tartrate) £29.00 £2.90 Vinorelbine 10mg/1ml solution for injection vials  /  Packsize 1 £4.51 £0.45 
carboplatin £20.00 £0.40 Carboplatin 50mg/5ml solution for infusion vials  /  Packsize 1 £3.43 £0.07 
cisplatin £5.85 £0.59 Cisplatin 10mg/10ml solution for infusion vials  /  Packsize 1 £3.71 £0.37 
gemcitabine 
£29.80 £0.15 Gemcitabine 2g/20ml (100mg/ml) concentrate for solution for infusion vials  /  
Packsize 1 
£29.03 £0.01 
chlorphenamine £4.47 £0.45 Chlorphenamine 10mg/1ml solution for injection ampoules  /  Packsize 5 £14.47 £0.29 
ranitidine £0.54 £0.01 Ranitidine 150mg tablets  /  Packsize 60 £0.50 £0.0001 
ondansetron £46.58 £0.58 Ondansetron 8mg orodispersible tablets  /  Packsize 10 £15.88 £0.20 
dexamethasone £1.99 £0.52 Dexamethasone 3.3mg/1ml solution for injection ampoules  /  Packsize 10 £3.70 £0.11 
Filgrastim £52.70 £175.67 N/A 
Goserelin £65.00 £18.06 N/A 
Leuprorelin £75.24 £20.06 N/A 
Co-codamol £5.80 £0.06 Co-codamol 30mg/500mg capsules  /  Packsize 100 £3.01 £0.001 
Diclofenac £6.18 £0.00 Diclofenac sodium 50mg gastro-resistant tablets  /  Packsize 28 £0.56 £0.0004 
Dexamethasone £1.99 £0.52 Dexamethasone 3.3mg/1ml solution for injection ampoules  /  Packsize 10 £3.70 £0.11 
Prednisone £1.29 £0.01 Prednisolone 5mg tablets  /  Packsize 28 £0.37 £0.003 
Zoledronic acid £253.38 £50.68 Zoledronic acid 5mg/100ml solution for injection bottles  /  Packsize 1 £67.79 £13.56 
Genatmicin £1.40 £0.04 Gentamicin 80mg/2ml solution for injection ampoules  /  Packsize 5 £4.21 £0.01 
Imodium £2.15 £0.04 N/A 
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BNF Prices in V12 model. Prices taken from eMIT (https://www.gov.uk/government/publications/drugs-and-
pharmaceutical-electronic-market-information-emit accessed 26/10/2015) 
Drug Pack price Cost/mg Drug description in eMIT Pack price Cost/ mg 
Warfarin £1.04 £0.04 Warfarin 5mg tablets  /  Packsize 28 £0.25 £0.002 
Domperidone £1.75 £0.01 Domperidone 10mg tablets  /  Packsize 30 £0.58 £0.002 
Amitryptylline £1.05 £0.004 Amitriptyline 10mg tablets  /  Packsize 28 £0.34 £0.001 
Teicoplanin £3.57 £0.02 N/A 
Metoclopramide £0.97 £0.035 Metoclopramide 10mg tablets  /  Packsize 28 £0.22 £0.001 
Cyclizine £10.97 £0.002 Cyclizine 50mg tablets  /  Packsize 100 £6.17 £0.001 
N/A: not available in eMIT 
 
The effect on the ICER due to sensitivity analysis around the eMIT prices is provided in Table 12. The base-case results are also included for 
comparative purposes along with the differences to the incremental costs. 
 
Table 12. Costs, outcomes and Incremental differences for the sensitivity analysis using eMIT prices. 
  
Base-case (MIMS costs) Sensitivity analysis (eMIT costs) Difference in incremental 
costs Cabazitaxel Mitoxantrone Increment Cabazitaxel Mitoxantrone Increment 
2nd line chemotherapy (includes administration, 
pre- & concomitant medication)        
Costs associated with treating Adverse events 
during 2nd line chemotherapy        
Total health care cost during 2nd line 
chemotherapy (=SD)        
Total health care cost during progressive 
disease (=PD)        
End-of-life costs        
Total life-time cost per patient £29,548 £18,098 £11,450 £28,902 £16,906 £11,995 £545 
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Base-case (MIMS costs) Sensitivity analysis (eMIT costs) Difference in incremental 
costs Cabazitaxel Mitoxantrone Increment Cabazitaxel Mitoxantrone Increment 
QALYs 0.878 0.645 0.232 0.878 0.645 0.232 
Life-years 1.541 1.203 0.338 1.541 1.203 0.338 
Progression-free life years 0.361 0.234 0.127 0.361 0.234 0.127 
Cost per QALY gained (ICER) £49,327 £51,675 
Cost per Life-year gained £33,917 £35,530 
 
As might be expected the lower drug costs have reduced the cost in both arms. The small overall difference in the costs of £545 results in an 
increase in the ICER from £49,327 to £51,675. The difference in the costs is evenly split between the stable and progressive disease states 
(£263 and £282 respectively). The additional incremental cost in the stable disease state comes from the reduction in the cost of mitoxantrone 
and in the progressive disease state from the survival benefit due to cabazitaxel.  If the incremental cost due to survivorship is removed from 
the calculation and costs in the progressive disease state are not considered then the ICER is £41,446.
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B8.Please clarify why the proportion of patients experiencing an adverse event (for 
cabazitaxel and mitoxantrone) and the odds ratios for the rates of adverse events (for 
abiraterone and enzalutamide) were not varied within the probabilistic sensitivity 
analyses. 
This was an oversight and these inputs have been varied in PSA in the analyses below.  
To vary the proportion of patients experiencing adverse events in the PSA, a beta 
distribution has been applied. Based on the number of patients experiencing the event (r) 
and patients at risk (n), the alpha and beta parameters were calculated as follows: 
α = r 
β = n - r  
To vary the odds ratios derived in the ITC for abiraterone and enzalutamide in the PSA, a 
lognormal distribution has been applied. The odds ratios and associated credible intervals 
were transformed to the log scale and samples taken from a normal distribution with median 
equal to the median log odds ratio and SE calculated from the log of the upper and lower 
95% credible intervals assuming a normal distribution. For those odds ratios where the lower 
credible interval was 0, the upper credible interval was used as it was assumed that the 95% 
credible intervals were symmetric about the mean on the log scale. 
The impact of including the proportion of patients experiencing an adverse event in the PSA 
as well as the odds ratios of adverse events for abiraterone and enzalutamide were minimal.  
Table 13 Probabilistic ICER for cabazitaxel versus mitoxantrone 
Mean difference in costs: £ 11,781 
Mean difference in effects: 0.2323 QALYs 
Incremental cost-effectiveness ratio £50,708  per QALY gained 
 
The probability of being cost-effective at a willingness to pay of £50,000 is £45.8%. At a 
WTP of £51,000 the probability of being cost-effective is 51%. 
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Figure 3. Scatterplot for cabazitaxel vs. mitoxantrone (After inclusion of additional inputs  in 
PSA) 
 
Figure 4. Cost-effectiveness acceptability curve (cabazitaxel vs. mitoxantrone) - After inclusion 
of additional inputs in PSA 
 
The PSA results for abiraterone and enzalutamide are summarised in  
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Table 14. Updated PSA results for abiraterone and enzalutamide 
 Cab vs. Enzalutamide 
Cab vs. 
Abiraterone 
Mean difference in costs: -£38.230 -£17,723 
Mean difference in effects: -0.1793 0.0228 
Incremental cost-effectiveness ratio: £213,256 -£776,567 
 
B9.Please provide a sensitivity analysis that uses a single utility value (the mean of 
the observed utility values in the UK EAP) at all times for the stable disease state. 
In the base-case we have implemented the observed utilities from the UK EAP at each cycle 
in order to reflect as accurately as possible what might be expected for UK patients 
remaining on treatment. This study suggested that for those patients who persist on 
treatment utility may increase. We have made an assumption that patients who reach 10 
cycles and who do not show evidence of progression remain at the utility observed at the 
last cycle (cycle 10) in the UK EAP.  
The mean of the observed utility values in the UK EAP for the stable disease state is 0.7533. 
Sensitivity analysis under the assumption that patients remain at this utility for the whole of 
the stable state is provided in Table 15 below. 
Table 15. Sensitivity analysis using the mean of the utility values observed in the UK EAP. 
Base-case (MIMS costs) 
Cabazitaxel Mitoxantrone Increment
2nd line chemotherapy (includes administration, pre- & concomitant 
medication)    
Costs associated with treating Adverse events during 2nd line 
chemotherapy    
Total health care cost during 2nd line chemotherapy (=SD)    
Total health care cost during progressive disease (=PD)    
End-of-life costs    
Total life-time cost per patient £29,548 £18,098 £11,450 
        
QALYs 0.879 0.647 0.232 
Life-years 1.541 1.203 0.338 
Progression-free life years 0.361 0.969 0.127 
Cost per QALY gained (ICER) £49,423 
Cost per Life-year gained £33,917 
 
The median number of cycles received in TROPIC was 6. This was also the median number 
of cycles observed in the EAP programs conducted internationally. On this basis further 
sensitivity analysis is provided for the utility observed at the average number of cycles 
received (SD utility = 0.7518). (Table 16). 
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Table 16 Sensitivity analysis using the mean of the utility values observed in the UK EAP. 
Base-case (MIMS costs) 
Cabazitaxel Mitoxantrone Increment
2nd line chemotherapy (includes administration, pre- & concomitant 
medication)    
Costs associated with treating Adverse events during 2nd line 
chemotherapy    
Total health care cost during 2nd line chemotherapy (=SD)    
Total health care cost during progressive disease (=PD)    
End-of-life costs    
Total life-time cost per patient £29,548 £18,098 £11,450 
        
QALYs 0.879 0.647 0.232 
Life-years 1.541 1.203 0.338 
Progression-free life years 0.361 0.969 0.127 
Cost per QALY gained (ICER) £49,447 
Cost per Life-year gained £33,917 
 
The base-case ICER is £49,327. Changes to the utility described above do materially not 
impact this. (£49,423 and £49,447 respectively). 
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B10.Within the economic model, hazard ratios are used to derive rates of adverse events for abiraterone / enzalutamide (tab 'Hazard 
Ratios') - please provide details regarding the derivation of these values. 
Adverse events were extracted from the primary papers for the COU-AA-301 and AFFIRM studies(4;5). These are presented below in Table 
17. 
Table 17. Adverse events in TROPIC, COU-AA-301 and AFFIRM studies. 
Grade ≥3 Mitoxantrone Cabazitaxel % Abiraterone Placebo plus prednisone % Enzalutamide Placebo % 
Haematological† 
Neutropenia 215 303 81.67% 1 1 0.13% nr nr nr 
Febrile neutropenia 5 28 7.55% 0 0 0.00% nr nr nr 
Leukopenia 157 253 68.19% nr nr nr nr nr nr 
Anaemia 18 39 10.51% 62 32 7.84% 62 38 7.75% 
Thrombocytopenia 6 15 4.04% 11 2 1.39% 8 3 1.00% 
Non-
haematological  
Diarrhoea 1 23 6.20% 9 5 1.14% 9 1 1.13% 
Fatigue 11 18 4.85% 72 41 9.10% 50 29 6.25% 
Asthenia 9 17 4.58% 26 8 3.29% 20 10 2.50% 
Back pain 11 14 3.77% 56 40 7.08% 40 16 5.00% 
Nausea 1 7 1.89% 17 11 2.15% 12 13 1.50% 
Vomiting 0 7 1.89% 21 12 2.65% 9 10 1.13% 
Haematuria 2 7 1.89% 12 9 1.52% 12 4 1.50% 
Abdominal pain 0 7 1.89% 18 8 2.28% 0.00% 
Pain in extremity 4 6 1.62% 24 20 3.03% 14 14 1.75% 
Dyspnoea 3 5 1.35% 14 9 1.77% 5 6 0.63% 
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Grade ≥3 Mitoxantrone Cabazitaxel % Abiraterone Placebo plus prednisone % Enzalutamide Placebo % 
Constipation 2 4 1.08% 10 4 1.26% 6 5 0.75% 
Pyrexia 1 4 1.08% 3 5 0.38% 0.00% 
Arthralgia 4 4 1.08% 40 17 5.06% 20 7 2.50% 
Urinary-tract 
infection 3 4 1.08% 12 3 1.52% 10 3 1.25% 
Pain 7 4 1.08% 7 8 0.88% 0.00% 
Bone pain 9 3 0.81% 51 31 6.45% 18 13 2.25% 
OTHER 
Cardiac disorders 3 7 1.89% 41 9 5.18% 7 8 0.88% 
Abnormalities in liver 
function tests nr nr nr! 30 14 3.79% 3 3 0.38% 
Hypertension 1 1 0.27% 10 1 1.26% 16 5 2.00% 
Hypokalaemia 0 2 0.54% 35 3 4.42% 0.00% 
Fluid retention or 
oedema 1 2 0.54% 20 4 2.53% 8 3 1.00% 
Seizure 0 1 0.27% 0.00% 5 0 0.63% 
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The hazard ratios for adverse events utilised in the model were calculated in the indirect 
treatment comparison.  
For these safety analyses, given the low number of studies and events in most of the trial 
arms, only fixed effects models were used; using random effects models under these 
circumstances would produce unstable results associated with credible intervals which were 
excessively wide. 
The odds ratios were calculated from the number of events in the studies tabulated above. 
For example the data for anaemia that was used in the WinBugs code was derived in the 
following way – see Table 18. 
Table 18 Derivation of odds ratios for use in the ITC for anemia 
r[,1] n[,1] r[,2] n[,2] STUDY ID ODDS c ODDS t OR 
18 371 39 371 TROPIC 0.05 0.12 2.30 
32 394 62 791 COU-AA-301 0.09 0.09 0.96 
38 399 62 800 AFFIRM 0.11 0.08 0.80 
Where r = number of events in arm 1 or arm 2, n = number of subjects in arm 1 or arm 2 
The odds ratios were implemented in the Winbugs code presented in Appendices B. 
The results are tabulated below. (Error! Not a valid bookmark self-reference. to Table 27). 
Table 19. Hazard ratios for neutropenia. 
Neutropenia FE  OR  lCr.Int.  u.Cr.Int 
BSC vs Cabazitaxel  0.31  0.22  0.43 
BSC vs Abiraterone  2  0.05  77.5 
Cabazitaxel vs BSC  3.24  2.33  4.53 
Cabazitaxel vs Abiraterone  6.54  0.16  251 
Abiraterone vs BSC  0.5  0.01  20 
Abiraterone vs Cabazitaxel  0.15  0  6.29 
Table 20. Hazard ratios for anaemia 
Anaemia FE  OR  lCr.Int.  u.Cr.Int 
BSC vs Cabazitaxel  0.43  0.23  0.76 
BSC vs Abiraterone  1.03  0.66  1.61 
BSC vs Enzalutamide  1.25  0.81  1.91 
Cabazitaxel vs BSC  2.33  1.31  4.29 
Cabazitaxel vs Abiraterone  2.42  1.16  5.09 
Cabazitaxel vs Enzalutamide  2.91  1.42  6.14 
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Anaemia FE  OR  lCr.Int.  u.Cr.Int 
Abiraterone vs BSC  0.97  0.62  1.52 
Abiraterone vs Cabazitaxel  0.41  0.2  0.86 
Abiraterone vs Enzalutamide  1.21  0.65  2.24 
Enzalutamide vs BSC  0.8  0.52  1.23 
Enzalutamide vs Cabazitaxel  0.34  0.16  0.71 
Enzalutamide vs Abiraterone  0.83  0.45  1.53 
Table 21. Hazard ratios for anaemia 
Thrombocytopenia FE  OR  lCr.Int.  u.Cr.Int 
BSC vs Cabazitaxel  0.38  0.13  0.96 
BSC vs Abiraterone  0.32  0.04  1.27 
BSC vs Enzalutamide  0.69  0.14  2.49 
Cabazitaxel vs BSC  2.66  1.04  7.74 
Cabazitaxel vs Abiraterone  0.85  0.1  4.91 
Cabazitaxel vs Enzalutamide  1.83  0.29  9.82 
Abiraterone vs BSC  3.11  0.79  23.7 
Abiraterone vs Cabazitaxel  1.18  0.2  10.4 
Abiraterone vs Enzalutamide  2.16  0.26  22.6 
Enzalutamide vs BSC  1.45  0.4  7.28 
Enzalutamide vs Cabazitaxel  0.55  0.1  3.51 
Enzalutamide vs Abiraterone  0.46  0.04  3.85 
Table 22. Hazard ratios for diarrhoea 
Diarrhoea FE  OR  lCr.Int.  u.Cr.Int 
BSC vs Cabazitaxel  0.03  0  0.18 
BSC vs Abiraterone  1.08  0.32  3.21 
BSC vs Enzalutamide  0.16  0.01  1.05 
Cabazitaxel vs BSC  33.4  5.66  1070 
Cabazitaxel vs Abiraterone  36.7  4.16  1370 
Cabazitaxel vs Enzalutamide  5.59  0.12  306 
Abiraterone vs BSC  0.92  0.31  3.14 
Abiraterone vs Cabazitaxel  0.03  0  0.24 
Abiraterone vs Enzalutamide  0.15  0.01  1.42 
Enzalutamide vs BSC  6.1  0.95  155 
Enzalutamide vs Cabazitaxel  0.18  0  8.23 
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Diarrhoea FE  OR  lCr.Int.  u.Cr.Int 
Enzalutamide vs Abiraterone  6.73  0.7  189 
Table 23. Hazard ratios for fatigue 
Fatigue FE  OR  lCr.Int.  u.Cr.Int 
BSC vs Cabazitaxel  0.59  0.26  1.27 
BSC vs Abiraterone  1.16  0.77  1.74 
BSC vs Enzalutamide  1.17  0.73  1.87 
Cabazitaxel vs BSC  1.7  0.79  3.82 
Cabazitaxel vs Abiraterone  1.96  0.83  4.86 
Cabazitaxel vs Enzalutamide  1.98  0.8  5.08 
Abiraterone vs BSC  0.87  0.58  1.3 
Abiraterone vs Cabazitaxel  0.51  0.21  1.21 
Abiraterone vs Enzalutamide  1.01  0.54  1.88 
Enzalutamide vs BSC  0.85  0.54  1.38 
Enzalutamide vs Cabazitaxel  0.5  0.2  1.24 
Enzalutamide vs Abiraterone  0.99  0.53  1.84 
Table 24. Hazard ratios for fatigue 
Asthenia FE  OR  lCr.Int.  u.Cr.Int 
BSC vs Cabazitaxel  0.51  0.21  1.14 
BSC vs Abiraterone  1.16  0.76  1.73 
BSC vs Enzalutamide  0.99  0.43  2.09 
Cabazitaxel vs BSC  1.98  0.88  4.74 
Cabazitaxel vs Abiraterone  2.28  0.93  5.99 
Cabazitaxel vs Enzalutamide  1.94  0.61  6.15 
Abiraterone vs BSC  0.87  0.58  1.31 
Abiraterone vs Cabazitaxel  0.44  0.17  1.08 
Abiraterone vs Enzalutamide  0.85  0.34  2.01 
Enzalutamide vs BSC  1.01  0.48  2.33 
Enzalutamide vs Cabazitaxel  0.52  0.16  1.63 
Enzalutamide vs Abiraterone  1.18  0.5  2.93 
Table 25. Hazard ratios for back pain 
Back pain FE  OR  lCr.Int.  u.Cr.Int 
BSC vs Cabazitaxel  0.77  0.33  1.74 
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Back pain FE  OR  lCr.Int.  u.Cr.Int 
BSC vs Abiraterone  1.48  0.97  2.27 
BSC vs Enzalutamide  0.79  0.42  1.39 
Cabazitaxel vs BSC  1.29  0.57  3.01 
Cabazitaxel vs Abiraterone  1.92  0.77  4.89 
Cabazitaxel vs Enzalutamide  1.01  0.36  2.81 
Abiraterone vs BSC  0.68  0.44  1.03 
Abiraterone vs Cabazitaxel  0.52  0.2  1.3 
Abiraterone vs Enzalutamide  0.53  0.25  1.08 
Enzalutamide vs BSC  1.27  0.72  2.39 
Enzalutamide vs Cabazitaxel  0.99  0.36  2.76 
Enzalutamide vs Abiraterone  1.9  0.92  4.01 
Table 26. Hazard ratios for nausea 
Nausea FE  OR  lCr.Int.  u.Cr.Int 
BSC vs Cabazitaxel  0.1  0  0.68 
BSC vs Abiraterone  1.29  0.57  2.79 
BSC vs Enzalutamide  2.23  1.01  5.04 
Cabazitaxel vs BSC  9.69  1.47  252 
Cabazitaxel vs Abiraterone  12.6  1.6  355 
Cabazitaxel vs Enzalutamide  22  2.74  618 
Abiraterone vs BSC  0.78  0.36  1.76 
Abiraterone vs Cabazitaxel  0.08  0  0.63 
Abiraterone vs Enzalutamide  1.73  0.57  5.49 
Enzalutamide vs BSC  0.45  0.2  0.99 
Enzalutamide vs Cabazitaxel  0.05  0  0.37 
Enzalutamide vs Abiraterone  0.58  0.18  1.74 
Table 27. Hazard ratios for bone pain 
Bone pain FE  OR  lCr.Int.  u.Cr.Int 
BSC vs Cabazitaxel  3.31  0.93  15.8 
BSC vs Abiraterone  1.24  0.77  1.97 
BSC vs Enzalutamide  1.45  0.69  2.98 
Cabazitaxel vs BSC  0.3  0.06  1.07 
Cabazitaxel vs Abiraterone  0.37  0.07  1.43 
Cabazitaxel vs Enzalutamide  0.43  0.08  1.89 
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Bone pain FE  OR  lCr.Int.  u.Cr.Int 
Abiraterone vs BSC  0.81  0.51  1.3 
Abiraterone vs Cabazitaxel  2.68  0.7  13.7 
Abiraterone vs Enzalutamide  1.17  0.49  2.78 
Enzalutamide vs BSC  0.69  0.34  1.45 
Enzalutamide vs Cabazitaxel  2.3  0.53  12.8 
Enzalutamide vs Abiraterone  0.85  0.36  2.03 
 
 
B11.An assumption of zero utility for the last three months spent in the progressive 
disease (PD) health state is used in the model. This is implemented as a disutility. The 
current disutility appears to be calculated based on all patients who die (not the 
subgroup of patients who die from the PD health state). Please confirm that this is as 
intended. If not, please amend. In addition, the disutility incurred should be 
constrained by the time spent in the PD health state (for example, if it is two months, 
then at most only two months will be spent with a disutility of zero). Please comment 
on how amending the model to address these issues would affect the ICER.  
To apply the disutility to the deaths attributed to the PD state only is appealing, as the 
implementation of this penalty is indeed intended to address the concern often raised that 
the PD health states in oncology models carry a constant utility, despite an expectation that 
patient quality of life might deteriorate over time.      However, the disutility is applied in the 
model to all patients who die, irrespective of the state they previously occupied.  This is as 
intended and was chosen because it is computationally simple since deaths from the PD 
state are not separately tracked in the model on a cycle by cycle basis.  Applying the penalty 
to all deaths, from where ever they originate has the effect of reducing the overall utility 
gains achieved within the model and is therefore considered to be more conservative.  
Whilst the second part of the question relating to the duration in the PD is not relevant in the 
context of the implementation of the penalty to all deaths, it is noted that an amendment 
should be made to implement a reduced penalty in the first few cycles commensurate with 
the time experienced to date.  That is to say, a patient who dies in cycle 2 can only incur a 
penalty of two cycles, not four.  Amending the model to include 0, 1, 2 and 3 months’ worth 
of disutility at the start of the model increases the ICER from £49,327 to £49,362. This is due 
to a marginal decrease in incremental utility from 0.23213 to 0.23197. 
Table 28. Base-case results amended to incorporate the appropriate number of disutility 
cycles at the start of the model. 
Cabazitaxel Mitoxantrone Increment
2nd line chemotherapy (includes administration, pre- & concomitant 
medication)    
Costs associated with treating Adverse events during 2nd line    
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chemotherapy 
Total health care cost during 2nd line chemotherapy (=SD)    
Total health care cost during progressive disease (=PD)    
End-of-life costs    
Total life-time cost per patient £29,548 £18,098 £11,450 
        
QALYs 0.87934 0.64737 0.23197 
Life-years 1.54064 1.20303 0.33761 
Progression-free life years 0.36104 0.23408 0.12696 
Cost per QALY gained (ICER) £49,362.15 
Cost per Life-year gained £33,916.50 
 
B12.Please clarify why the proportions of patients receiving 10 cycles of cabazitaxel 
differ between the modelled estimate (17%) and those observed in the TROPIC ITT 
population and the Early Access Programme (approximately 30%). Please confirm the 
proportion of patients who received 10 cycles in the population of interest within the 
TROPIC trial. 
The proportion of patients in the subgroup population receiving 10 cycles is 20.04% (we 
have retrieved these figures from the model engine ‘calculations’ sheet from the row 
referring to the cycle 9 as patients receive cabazitaxel start treatment at cycle 0). The 
relevant figure for the ITT population is 20.17%. These are the figures that were derived by 
fitting the lognormal parametric distribution to the KM data.  
The observed data from the TROPIC trial, when deriving the Kaplan Meier data indicates 
that the proportion of patients in the subgroup population receiving 10 cycles is 25% (please 
refer to cell EU106, “KM new” tab in the company’s model) and 24.6% for the ITT population 
(please see cell AO115 in the same sheet). 
The small discrepancy between the model and trial estimates of patients receiving 10 cycles 
noted above occur because the parametric distribution and the Kaplan Meier data from the 
trial after 10 treatment cycles are not identical. Please see below the lognormal and KM 
curves for the SG base case population plotted on the same graph. Please note that cycle 9 
takes place at 6.21 months (or 27 weeks), where a divergence between the Kaplan Meier 
and lognormal parametric distribution curves can be observed. 
In addition to these considerations the model does not capture other issues such as dose 
delay that may contribute to this discrepancy. Hence whilst we have chosen the most robust 
way to model the KM data we recognise that the calculations for PFS and OS to derive 
populations on treatment may not be absolutely reflective of trial reality. 
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Figure 5. Comparison of lognormal distribution and KM data 
 
B13.Please justify why data from the TROPIC trial (page 171, Table 65) were used in 
preference to those from the UK audit (page 171, Table 66) for post second line 
treatment in the economic model.  
The data from the TROPIC study was used to maintain consistency with what was done in 
the trial and so when this treatment mix is costed it provides the most robust estimate for the 
post-second line setting. 
The UK information was provided as part of a sensitivity analysis, but only recognising costs. 
B14.On page 171 it states that ’The assumption is made that the mitoxantrone 
treatment mix is received in the abiraterone and enzalutamide comparisons.’ 
However, in the economic model, abiraterone values are taken from the UK audit, 
whilst the enzalutamide values are taken from the post-cabazitaxel arm. Please 
comment on this discrepancy.  
Thank you for pointing out this discrepancy in the abiraterone and enzalutamide Markov 
traces. This has now been fixed by including the variable ‘transRewMitoxTropic’ on both 
sheets in place of ‘transRewGeneralCountry’ and ‘transRewCabaTropic’ in column X. 
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The updated results are provided in Table 30. For comparative purposes the original results 
are presented in Table 29. 
Table 29. Results for the incremental analysis versus abiraterone and enzalutamide presented 
in the dossier 
  Cabazitaxel Abiraterone  Difference Enzalutamide Difference 
2nd line chemotherapy (includes 
administration, pre- & concomitant 
medication) 
     
Costs associated with treating Adverse 
events during 2nd line chemotherapy      
Total health care cost during 2nd line 
chemotherapy (=SD)      
Total health care cost during progressive 
disease (=PD)      
End-of-life costs      
Total life-time cost per patient £31,734 £49,165 -£17,430 £69,585 -£37,850 
        
QALYs 0.922 0.901 0.022 1.101 -0.179 
Life-years 1.485 1.456 0.029 1.617 -0.132 
Progression-free life years 0.817 0.793 0.024 1.316 -0.499 
Post-progression survival 0.668 0.663 0.005 0.301 0.367 
  
Cost per QALY gained (ICER) -£808,425 £212,038 
Cost per Life-year gained -£601,379 £287,115 
 
Table 30. Updated incremental results for abiraterone and enzalutamide. 
  Cabazitaxel Abiraterone  Difference Enzalutamide Difference 
2nd line chemotherapy (includes 
administration, pre- & concomitant 
medication) 
     
Costs associated with treating Adverse 
events during 2nd line chemotherapy      
Total health care cost during 2nd line 
chemotherapy (=SD)      
Total health care cost during progressive 
disease (=PD)      
End-of-life costs      
Total life-time cost per patient £31,734 £56,466 -£24,731 £73,796 -£42,061 
        
QALYs 0.922 0.901 0.022 1.101 -0.179 
Life-years 1.485 1.456 0.029 1.617 -0.132 
Progression-free life years 0.817 0.793 0.024 1.316 -0.499 
Post-progression survival 0.668 0.663 0.005 0.301 0.367 
  
Cost per QALY gained (ICER) -£1,147,038 £235,630 
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  Cabazitaxel Abiraterone  Difference Enzalutamide Difference 
Cost per Life-year gained -£853,269 £319,060 
 
The total lifetime cost for patients in the abiraterone and enzalutamide arms is increased. In 
scenario analysis in section 5.11 we presented the deterministic ICERs for abiraterone and 
enzalutamide at modelled    % discounts. In this analysis cabazitaxel continued to dominate 
abiraterone at this discount (incremental cost =        ) and whilst the point estimate for the 
ICER is still in the south west quadrant versus enzalutamide, the ICER is         . The updated 
analysis suggest the incremental cost versus abiraterone is much larger at          and the 
ICER versus enzalutamide is           in the southwest quadrant (incremental cost of         ).  In 
other words, this correction improves the results for cabazitaxel, but the concerns expressed 
in the main submission about the relevance of these analyses still remain. 
B15.Please clarify if the proportion of patients receiving best supportive care as post 
second line treatment should be varied in the probabilistic sensitivity analysis. 
Currently, this is varied, but only for enzalutamide. Please amend as appropriate.  
Thank you for highlighting this issue. The formula required which points to the PSA sheet 
had not been replaced in cells E29:E32 on the ‘Resource input’ sheet in the model submitted 
to the ERG after final testing of the model. During this testing absolute values were included. 
The PSA has been re-run to check that the results presented in the submission dossier 
remain substantively unchanged. The probabilistic results, after re-running the analysis 
versus mitoxantrone with the correct formula in cells E29:E32, are presented in the response 
to Question B4 above. Whilst there will always be slight differences in the figures obtained 
from each PSA run, these match the submitted results and do not change the interpretation. 
B16.Please clarify why the value of body surface area used in the model (1.9, based 
on clinical opinion) has changed from the value used in TA255 (2.01 from the TROPIC 
trial). 
The UK-specific base-case value for the body surface area (BSA) was estimated by UK 
clinical experts during advisory boards held at the time of TA255 to be 1.9 m2. The average 
BSA of patients included in the TROPIC trial was 2.01 m2, however, the TROPIC population 
was drawn from many different countries with varying average BSAs. Thus, in the base-
case, it has since been deemed more appropriate to use am estimated UK-specific average 
BSA.  
Sensitivity analysis is provided for BSA 2.01 m2 in table 80 on page 188 of the submission 
document. 
B17.Please clarify why the quality of life data (section 5.4, page 150) from the EAP is 
different to that reported in reference 12 
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(http://www.ncbi.nlm.nih.gov/pubmed/25639506). Please confirm that the data used in 
the submission is the most up-to-date.  
The quality of life data published in graphical form in the paper by Bahl(34) is described as 
the final cut of the data. However in the time since publication several more questionnaires 
have been returned and so the numbers of patients at each cycle have increased slightly 
and the utility values have changed marginally as a consequence. We were able to provide 
this more complete dataset for the analysis presented in the dossier. This was available to 
us in numerical form and included measures of variance. 
Question B21 explores the effect of small differences in the utility values for the stable 
disease state and as can be seen there is no substantive difference to the ICER. 
 
 
B18.Please clarify how secondary G-CSF use is implemented in the company’s model 
(table 63, page 166).  
Secondary G-CSF is implemented in the model separately to primary G-CSF prophylaxis. 
Table 63, page 166 refers to primary prophylaxis which is incorporated into the model as 
part of the total cost of pre-medication and concomitant drugs and is then included as part of 
the total cost of the SD state. Secondary G-CSF has been incorporated as part of treatment 
of adverse events because patients receiving secondary G-CSF experience higher rates of 
febrile neutropenia. Frequencies of neutropenia and febrile neutropenia for patients that did 
not receive any G-CSF as primary prophylaxis are then used in the model. 
 
It is recommended that patients that experience febrile neutropenia should be treated with 
G-CSF as secondary prophylaxis in every remaining cycle after the event if they did not 
receive previously a primary prophylaxis. However, as this is a cohort model, the prophylaxis 
use cannot be modelled for each patient individually. Instead of modelling the proportion of 
patients in the cohort treated with G-CSF as secondary prophylaxis in each cycle, the 
proportion of patients treated with G-CSF as secondary prophylaxis or with curative intent 
was estimated by clinical experts and then used in the model. 
 
On the ‘Resource Input’ tab in the Adverse Event section, the model includes drug treatment 
used for neutropenia and febrile neutropenia (as well as others).  50% of patients 
experiencing Neutropenia receive a total dose of 3 units of Filgastrim and 20% of patients 
experiencing Febrile Neutropenia receive a total dose of 0.9 units (as per expert opinion). 
 
Although the ASCO guidelines advise that secondary prophylaxis is only recommended for 
patients who did not receive it as primary prophylaxis, the percentage of patients that 
received G-CSF as primary prophylaxis was not subtracted from the percentage of patients 
that received G-CSF as secondary prophylaxis. This approach was taken since the UK 
clinical expert panel estimated the proportion of patients receiving G-CSF as secondary 
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prophylaxis or with curative intent irrespective of any known proportions of primary 
prophylaxis. This implies that the proportion of patients receiving G-CSF as secondary 
prophylaxis or with curative intent may be overestimated in the model, but this can be 
regarded as a conservative assumption.   
 
B19.When adverse event treatment is costed in the Model, (tab 'AE Care') some grade 
3+ events receive neither inpatient care nor drugs (for example, for neutropenia 2% 
require inpatient care and 50% receive filgastrim, so at least 48% receive neither). 
Please confirm that this is as intended and justify why.  
The rates of drug use implemented in the base-case were validated with clinical experts at 
the time of the original submission.  
We recognise that the face validity of these rates could be challenged and so have 
performed an extreme sensitivity analysis in which the rates of drug use for all adverse 
events are set to 1. This ensures all patients receive a therapeutic intervention. The 
incremental results from this analysis are presented in Table 31.  
Table 31. Incremental analysis with rates of drug use set to 1 for all adverse event therapies. 
  Cabazitaxel Mitoxantrone Difference 
2nd line chemotherapy (includes 
administration, pre- & concomitant 
medication) 
   
Costs associated with treating Adverse 
events during 2nd line chemotherapy    
Total health care cost during 2nd line 
chemotherapy (=SD)    
Total health care cost during progressive 
disease (=PD)    
End-of-life costs    
Total life-time cost per patient £29,639 £18,128 £11,511 
        
QALYs 0.878 0.645 0.232 
Life-years 1.541 1.203 0.338 
Progression-free life years 0.361 0.234 0.127 
Post-progression survival 1.180 0.969 0.211 
        
Cost per QALY gained (ICER) £49,587 
Cost per Life-year gained £34,095 
The ICER is marginally increased from £49,327 in the base-case to £49,587. This is due to 
an increase of         in the cabazitaxel arm and         in the mitoxantrone arm for the cost of 
treating adverse events during 2nd line chemotherapy. A small increase only is expected 
given the limited impact of adverse events on the overall analysis. 
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This represents the extreme case and it is expected that in real world practice, rates of 
therapeutic intervention would be lower. 
B20.Please provide further details about the evidence used for the rates of drug use 
for adverse events.  
Since drugs filed in the TROPIC database cannot easily be assigned to every AE, treatment 
of every specific AE was based on UK clinical expert opinion. This is described in the 
submission document in Section 5.3.4.  
Extreme sensitivity analysis around the rates of drug use is provided above in question 19. 
 
B21.The submission states (Table 61, page 161 - Utility in the stable disease state) 
that odd cycles are interpolated. Please provide details about how these interpolated 
values were derived, and justify this method over linear interpolation between cycles 
(for example, the cycle 3 value would be the mean of the values observed for cycles 2 
and 4).  
The odd cycle utilities were interpolated using the TREND function in excel. (Table 32). 
 
Table 32. Interpolation method used to obtain utilities for the odd cycles. 
Cycle Utility Value from UK EAP TREND function* Trend result 
Baseline 0.6821 
1 TREND(W11:W16,V11:V16,1) 0.703724 
2 0.7284 
3 TREND(W11:W16,V11:V16,3) 0.728487 
4 0.7495 
5 TREND(W11:W16,V11:V16,5) 0.75325 
6 0.7518 
7 TREND(W11:W16,V11:V16,7) 0.778013 
8 0.7892 
9 TREND(W11:W16,V11:V16,9) 0.802776 
10 0.8185 
 
*The range W11:W16 refers to the range of utility values from the UK EAP and the range 
V11:V16 refers to the cycle number. 
 
This method was chosen because it takes into account the entire dataset and not just 
adjacent values as would be the case by taking a simple average. 
 
B22.Please provide information (with references) about the proportion of patients 
requiring each end-of-life resource component (Table 67 and 68, pages 172-175): 
Please also provide a cost (with reference) for a hospice home stay.  
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Costs are higher towards the end of life, and based on advice from clinical experts, a 
separate ‘end-of-life’ cost is incorporated in the model to account for this. This is applied as a 
transition cost on death.  
It was estimated by clinical experts that end-of-life care, defined as the time period from 
interruption of active treatment until death, has an average duration of 1 month.  
In the model, it was assumed that patients do not receive any post-second line treatment mix 
or BSC during their last month of life.  
All resources use that occurred during the last month of life was not available in the UK 
observational study. This was available, however, for hospitalisations. Expert opinion was 
used to provide estimates for other resource use items during the last month of life, including 
hospice care and palliative care at home. A summary of the estimates received from UK 
clinical experts and the UK observational study regarding end-of-life care is outlined in Table 
33 below. 
 
Table 33. Resource estimates for end-of-life care 
Type of end-of-life care Share of patients 
Average number 
of episodes / 
visits per month 
Average 
length of stay 
per episode 
Source 
Hospice home 0.2 2 5 UK clinical expert 
Palliative care at home 0.5 6  UK clinical expert 
Nurse visits 0.8   UK clinical expert 
Physician (GP) visits 0.2   UK clinical expert 
Palliative hospital outpatients visits 0.5 0.8  UK clinical expert 
Palliative care - hospital inpatient 1 0.32 8 UK observational study 
 
The cost for Hospice care comes from the National Audit Office, End of Life report from 2008 
which can be found here: https://www.nao.org.uk/wp-
content/uploads/2008/11/07081043.pdf). This figure has been inflated to 2013-14 costs 
using the GDP deflator which can be found here: 
https://www.gov.uk/government/statistics/gdp-deflators-at-market-prices-and-money-gdp-
march-2015-quarterly-national-accounts 
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NATIONAL INSTITUTE FOR HEALTH AND CARE 
EXCELLENCE 
Patient/carer organisation submission (STA) 
Cabazitaxel for hormone-relapsed metastatic prostate 
cancer previously treated with a docetaxel-containing 
regimen (review of TA255) [ID889] 
Thank you for agreeing to give us your views on this treatment that is being 
appraised by NICE and how it could be used in the NHS. Patients, carers and 
patient organisations can provide a unique perspective on conditions and their 
treatment that is not typically available from other sources. We are interested 
in hearing about: 
 the experience of having the condition or caring for someone with the 
condition 
 the experience of receiving NHS care for the condition  
 the experience of having specific treatments for the condition  
 the outcomes of treatment that are important to patients or carers (which 
might differ from those measured in clinical studies, and including health-
related quality of life) 
 the acceptability of different treatments and how they are given 
 expectations about the risks and benefits of the treatment. 
To help you give your views, we have provided a questionnaire. You do not 
have to answer every question — the questions are there as prompts to guide 
you. The length of your response should not normally exceed 10 pages. 
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1. About you and your organisation 
Your name: xxxxxxxxxxxxxxxxxx 
Name of your organisation: xxxxxxxxxxxxxxxxxx 
Your position in the organisation: xxxxxxxxxxxxxxxxxxxxxx 
Brief description of the organisation: Prostate Cancer UK is the UK’s 
leading charity for men with prostate cancer and prostate problems. We 
support men and provide information, find answers through funding research 
and lead change to raise awareness and improve care. The charity is 
committed to ensuring the voice of people affected by prostate disease is at 
the heart of all we do. 
The following pharmaceutical companies sponsored and/or supported 
activities carried out by Prostate Cancer UK from April 2014 – March 2015: 
 Astellas Pharma UK 
 Lilly UK 
Prostate Cancer UK has a policy that funding from pharmaceutical and 
medical device companies will not exceed 5% of its total annual income. 
During the financial year 2014/2015 donations from such organisations, 
expressed as a percentage of our total annual income, were less than 0.1%. 
2. Living with the condition 
What is it like to live with the condition or what do carers experience 
when caring for someone with the condition? 
Men with advanced prostate cancer tell us that they are often bed-ridden and 
unable to perform day-to-day activities, many experiencing significant pain 
and fatigue. Other symptoms associated with advanced disease include 
hypercalcaemia, urinary problems, swollen and uncomfortable lymph nodes 
and, occasionally, metastatic spinal cord compression causing weakness and 
numbness in the legs. 
Living with prostate cancer can also have a strong emotional impact on the 
lives of men and those close to them. Men with prostate cancer have an 
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increased risk of depression and anxiety. Anxiety has been identified in 10–
36% of short- and long-term prostate cancer survivors (1). Between 13% and 
27% of prostate cancer patients are thought to have major depressive 
disorder or clinically significant levels of depression (2). 
Men with prostate cancer can experience significant side effects following 
treatment. Depending on the treatment type, physiological side effects can 
include: osteoporosis, breast swelling and tenderness, chills/fever, nausea, 
headaches, hot flushes, difficulty having or maintaining an erection, infertility, 
loss of libido, muscle aches, pain, bowel and urinary incontinence, problems 
passing urine, fatigue, weight gain, and weight and muscle loss. Psychological 
side effects, such as anxiety and depression, have also been observed (3–6).  
Many side effects are experienced by a high proportion of people living with 
prostate cancer. An English PROMs (Patient Reported Outcome Measures) 
study involving 866 prostate cancer patients found 58.4% of patients reported 
being unable to have an erection, 38.5% reported some degree of urinary 
leakage, and 12.9% reported difficulty controlling their bowels (7). Our own 
survey carried out with 610 men between October 2011 and January 2012 
found 52% experienced anxiety as a side effect of treatment, 60% of whom 
rated this as bad or very bad. In addition to this, 67% experienced fatigue 
(59% of whom rated this bad or very bad) and 57% experienced problems 
passing urine (33% of whom rated this bad or very bad) (8).   
3. Current practice in treating the condition 
Which treatment outcomes are important to patients or carers? (That is, 
what would patients or carers like treatment to achieve?) Which of these 
are most important? If possible, please explain why. 
Our research shows that people affected by cancer place a high value on 
treatments that can prolong life. An opinion survey we commissioned with 412 
people affected by cancer showed 98% of respondents placed a high value on 
treatments that can give people approaching the end of their lives extra time 
(9). Our most recent survey, conducted in 2014 with 267 people affected by 
prostate cancer on the availability of the enzalutamide, showed a large 
number of men living with prostate cancer place value on extending life as a 
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means to spend extra time with loved ones. Life extending treatments are also 
valued by some men as a means to achieve closure and to prepare for the 
end of life (10). Men see this as important, even when the extra time given is 
relatively short.   
A part of this survey, we asked men and their loved ones to describe what life 
extension would mean to them (10): 
“It is quite hard to imagine how much even two extra months can mean 
until you face being given or denied that time” – man diagnosed with 
prostate cancer. 
“Two months longer on your life is priceless; family moments are 
precious” – family member of a man who has died from prostate cancer. 
99% of respondents to our opinion survey also indicated that priority should 
also be given to the ability of a drug to improve quality of life (QOL) with the 
highest priority given to pain relief (9). One man said: 
“Life is precious and if treatment can extend it while retaining a moderate 
quality of life this will be important to me and my dependents” – man 
diagnosed with prostate cancer. 
Other men place value on treatments that would enable them to continue to 
participate as a full member of society, while others highlighted personal 
fulfilment benefits to be gained from life extending treatment (10). 
What is your organisation’s experience of currently available NHS care 
and of specific treatments for the condition? How acceptable are these 
treatments and which are preferred and why? 
Men with advanced prostate cancer are currently able to access enzalutamide 
and abiraterone after chemotherapy routinely on the NHS. Both these drugs 
significantly increase overall survival when taken after chemotherapy (11,12). 
Cabazitaxel, currently available through the Cancer Drugs Fund (CDF) in 
England, offers an important additional option after chemotherapy for men 
with advanced prostate cancer, and has been shown to improve overall 
survival by 2.4 months in patients with hormone-relapsed prostate cancer 
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(13). Data published in September 2014 have also shown a 2.1 month 
increase in overall survival for patients with metastatic hormone-relapsed 
prostate cancer previously treated with docetaxel if they had cabazitaxel then 
abiraterone, compared to abiraterone then cabazitaxel (14). In addition to this, 
extended follow-up data from the TROPIC trial also demonstrated significantly 
reduced tumour-related pain for men treated with the drug (15). Findings from 
the UK Early Access Programme indicate cabazitaxel could improve QOL in 
men with metastatic hormone-relapsed prostate cancer (16).  
Treatments that can extend life and improve QOL are of upmost importance to 
men living with prostate cancer and their loved ones (10). Clinicians should 
have the maximum number of treatments at their disposal so they can tailor 
the optimum treatment pathway for their individual patients. Cabazitaxel is 
regularly used to treat advanced prostate cancer and recent figures show 
1270 men have accessed cabazitaxel through the CDF in the two years 
between April 2013 and March 2015 (17,18). This has been for use as a 
second line treatment following docetaxel chemotherapy, or a third line 
treatment following docetaxel and abiraterone. 
A recent study conducted at the Institute of Cancer Research (ICR) indicated 
that, for some men, cabazitaxel was active when given after abiraterone or 
enzalutamide (19). The only other effective treatment that we are aware of at 
this point in the pathway is radium-223 dichloride. However, this is 
contraindicated in patients with liver metastases (20). Cabazitaxel could 
therefore be the only active treatment option for men whose prostate cancer 
has metastasised to the liver following endocrine treatment and docetaxel. 
Furthermore, radium-223 dichloride has been marked for delisting from the 
CDF on 4 November 2015 (21), which means that cabazitaxel will be the only 
active treatment option available to men in England whose prostate cancer 
has progressed following endocrine treatment and docetaxel.  
 
 
Appendix G – patient/carer organisation submission template 
National Institute for Health and Care Excellence    Page 6 of 17 
Patient/carer organisation submission template (STA) 
4. What do patients or carers consider to be the advantages of 
the treatment being appraised? 
Benefits of a treatment might include its effect on: 
 the course and/or outcome of the condition 
 physical symptoms 
 pain 
 level of disability 
 mental health 
 quality of life (such as lifestyle and work) 
 other people (for example, family, friends and employers) 
 ease of use (for example, tablets rather than injection) 
 where the treatment has to be used (for example, at home rather than in 
hospital) 
 any other issues not listed above 
Please list the benefits that patients or carers expect to gain from using 
the treatment being appraised. 
Improved overall survival is seen by people affected by prostate cancer as a 
major benefit of using cabazitaxel. In a survey we carried out in 2011 on the 
availability of cabazitaxel with 30 people affected by prostate cancer, 19 
respondents identified that the possibility of extended life that cabazitaxel 
offers was its most important benefit, particularly when no other treatment 
options are available. The survival benefit was seen by some as an 
opportunity for these patients to be able to spend more time with family and 
friends. Comments from respondents suggested another benefit was the 
increase in hope the availability of such a drug could give, which would have a 
positive impact on QOL and potentially reduce distress (22).  
In a recent survey conducted with 267 people affected by prostate cancer on 
the availability of enzalutamide, men described hope where treatments 
prolong life, and stressed how valuable it is to be able to spend extra time with 
loved ones. Patients have also highlighted the importance of treatment choice 
(10). The availability of cabazitaxel would mean more clinically effective 
options are available to men after chemotherapy, allowing men more options 
when deciding on the best treatment for them.   
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Please explain any advantages that patients or carers think this 
treatment has over other NHS treatments in England. 
Cabazitaxel is an important option for men whose prostate cancer has 
metastasised to the liver following novel endocrine treatments and docetaxel.  
There is evidence that the use of cabazitaxel after docetaxel is becoming part 
of routine clinical practice. NHS England’s National Chemotherapy Algorithm 
for advanced hormone-relapsed prostate cancer recommends cabazitaxel as 
an option for men whose cancer has progressed after docetaxel or after the 
use of abiraterone or enzalutamide and docetaxel (23). Between April 2013 
and March 2015, 707 men accessed cabazitaxel as a third line treatment for 
advanced hormone-relapsed prostate cancer following docetaxel and 
abiraterone via the CDF. A further 563 accessed it as a second line treatment 
for advanced hormone-relapsed prostate cancer following a docetaxel based 
regimen (17,18). 
Without cabazitaxel there are no active treatment options for men with 
advanced hormone-relapsed prostate cancer that has metastasised to the 
liver following novel endocrine treatments and docetaxel. Evidence that 
indicates cabazitaxel might still be active when used after enzalutamide and 
abiraterone (19) will therefore be important to patients as it suggests 
cabazitaxel can provide hope of extending life beyond what is possible with 
the treatments that are currently routinely available.  
Evidence showing cabazitaxel can increase overall survival when used before 
abiraterone (14) also makes it an increasingly desirable treatment option for 
men as it again offers hope of extending life beyond what is possible with the 
treatments that are currently routinely available. 
If you know of any differences in opinion between patients or carers 
about the benefits of the treatment being appraised, please tell us about 
them. 
None known. 
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5. What do patients and/or carers consider to be the 
disadvantages of the treatment being appraised? 
Disadvantages of a treatment might include: 
 aspects of the condition that the treatment cannot help with or might 
make worse 
 difficulties in taking or using the treatment (for example, injection rather 
than tablets) 
 side effects (for example, type or number of problems, how often, for 
how long, how severe. Please describe which side effects patients might 
be willing to accept or tolerate and which would be difficult to accept or 
tolerate)  
 where the treatment has to be used (for example, in hospital rather than 
at home) 
 impact on others (for example, family, friends and employers) 
 financial impact on the patient and/or their family (for example, the cost 
of travel to hospital or paying a carer) 
 any other issues not listed above 
Please list any concerns patients or carers have about current NHS 
treatments in England. 
Many patients and their loved ones have concerns about the side effects of 
chemotherapy. Delaying or avoiding chemotherapy, or having a treatment 
option where chemotherapy is not an option, came through as a key theme in 
our previous survey (10). 
Please list any concerns patients or carers have about the treatment 
being appraised. 
Trial findings show the most common clinically significant grade 3 or higher 
adverse events associated with cabazitaxel were neutropenia and diarrhoea 
(13). Another study into the safety profile and QOL data for patients with 
metastatic hormone-relapsed prostate cancer treated with cabazitaxel found 
that the most frequent grade 3 or 4 treatment-emergent adverse events were 
fatigue, diarrhoea and neutropenic sepsis (16). These side effects will be a 
concern to some patients, depending on their own personal circumstances 
and attitudes to the effects of treatment. However, our survey on cabazitaxel 
found that many patients accept that all treatments have some side effects, 
and will want balanced information on the potential risks and benefits of a 
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treatment so they can make an informed decision themselves as to whether to 
have it (22).  
Cabazitaxel is administered in combination with prednisone or prednisolone. 
These corticosteroids may be unsuitable for some patients due to the severity 
of associated side effects (24).  
If you know of any differences in opinion between patients or carers 
about the disadvantages of the treatment being appraised, please tell us 
about them. 
Most of the people affected by prostate cancer who we surveyed about 
cabazitaxel agreed that its main benefit was increased survival and that there 
were very few concerns about its side effects. Of the 30 respondents, only 1 
thought that the disadvantages of the drug outweighed the advantages (22). 
6. Patient population 
Are there any groups of patients who might benefit more from the 
treatment than others? If so, please describe them and explain why. 
Men with advanced, hormone-relapsed prostate cancer who have already had 
abiraterone or enzalutamide and docetaxel, and whose cancer has 
progressed, might benefit from the availability of this treatment (19) (see 
sections 3 and 4).  
The only other treatment option at this stage is radium-223 dichloride. While 
radium-223 dichloride can be used following treatment with either abiraterone 
or enzalutamide and docetaxel, it is contraindicated in patients with liver 
metastases (20,25). Therefore, cabazitaxel may be the only active treatment 
option for men whose prostate cancer has metastasised to the liver following 
novel endocrine treatments and docetaxel. Furthermore, radium-223 
dichloride has been marked for delisting from the CDF on 4 November 2015 
(21), which means that cabazitaxel is set to become the only active treatment 
option available to men in England whose prostate cancer has progressed 
following endocrine treatment and docetaxel.   
Cabazitaxel, therefore, addresses an important unmet need for a sub-
population of patients who are not served by alternative active therapies.  
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Are there any groups of patients who might benefit less from the 
treatment than others? If so, please describe them and explain why. 
Cabazitaxel is administered in combination with prednisone or prednisolone. 
These corticosteroids may be unsuitable for some patients because of severe 
side effects (24).  
Cabazitaxel is also unsuitable for patients with a low neutrophil count due to 
the chance it can cause further neutropenia (16,26). 
7. Research evidence on patient or carer views of the 
treatment 
Is your organisation familiar with the published research literature for 
the treatment? 
 Yes  ☐ No 
If you answered ‘no’, please skip the rest of section 7 and move on to 
section 8. 
 
Please comment on whether patients’ experience of using the treatment 
as part of their routine NHS care reflects the experiences of patients in 
the clinical trials. 
Unfortunately we have been unable to gather patient’s real-world experience 
of using this treatment.  
Do you think the clinical trials have captured outcomes that are 
important to patients? Are you aware of any limitations in how the 
treatment has been assessed in clinical trials? 
The original TROPIC clinical trial captured overall survival and QOL data, 
measured by Present Pain Intensity (PPI) and analgesic score and ECOG PS 
(a measure of quality of life) (15). Cabazitaxel was shown to provide similar 
palliation of pain to mitoxantrone and ECOG PS deterioration was similar 
between treatment groups. However patients in the cabazitaxel group 
received a greater number of treatment cycles versus those in the 
mitoxantrone group (15).  
The subsequent publication of QOL and safety data from metastatic hormone-
relapsed prostate cancer patients treated with cabazitaxel in the UK EAP 
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included QOL data measured by the Visual Analogue Scale (VAS), which is a 
quantitative measure of health status, and EQ-5D-3L questionnaires. The 
study showed improvements in VAS and EQ-5D-3L pain scores as patients 
received more cycles of treatment. The UK EAP experience indicates that 
cabazitaxel might improve QOL in men with metastatic hormone-relapsed 
prostate cancer and represents a useful addition to the armamentarium of 
treatment for patients whose disease has progressed during or after docetaxel 
(16).  
Overall, whilst the original trial was limited in its scope of measuring QOL, 
when taken with the UK EAP experience data we believe it gives a good 
picture of the outcomes that are important to patients (overall survival and 
QOL data).    
If the treatment being appraised is already available in the NHS, are 
there any side effects that were not apparent in the clinical trials but 
have emerged during routine NHS care? 
N/A 
Are you aware of any relevant research on patient or carer views of the 
condition or existing treatments (for example, qualitative studies, 
surveys and polls)? 
 Yes  ☐ No 
If yes, please provide references to the relevant studies. 
1. Prostate Cancer UK. ‘A survey of people affected by cancers’ views on 
cabazitaxel becoming a treatment option for men with advanced 
prostate cancer’. 30 people responded to an online and paper survey. 
90% of respondents had been diagnosed with prostate cancer (the 
others were relatives or friends of someone with the disease) and 33% 
of respondents had advanced cancer. None had any experience of 
cabazitaxel. Fieldwork was undertaken between 24th May and 3rd 
June 2011. 2011.  
2. Prostate Cancer UK. ‘A survey of the public’s views on Xtandi® 
(enzalutamide) becoming a treatment option for men with advanced 
prostate cancer, who have not previously received chemotherapy’.  
Total sample size was 267 UK adults which included men with prostate 
cancer and friends/family of men with prostate cancer. Fieldwork was 
undertaken between 7th January and 1st February 2015. The survey 
was carried out online. 2015.  
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3. Prostate Cancer UK. Hampered by Hormones [Internet]. [cited 2013 
Jun 21]. Available from: 
http://prostatecanceruk.org/media/49198/htcampaignreport.pdf 
4. Prostate Cancer UK. Value-based pricing: Getting it right for people 
with cancer [Internet]. 2012 [cited 2013 May 10]. Available from: 
http://prostatecanceruk.org/media/1633387/1513_value-
based_pricing_report_for_print.pdf 
5. Ream E, Quennell A, Fincham L, Faithfull S, Khoo V, Wilson-Barnett J, 
et al. Supportive care needs of men living with prostate cancer in 
England: a survey. Br J Cancer. 2008 Jun 17;98(12):1903–9.  
8. Equality 
NICE is committed to promoting equality of opportunity, eliminating unlawful 
discrimination and fostering good relations between people with particular 
protected characteristics and others. Protected characteristics are: age; being 
or becoming a transsexual person; being married or in a civil partnership; 
being pregnant or having a child; disability; race including colour, nationality, 
ethnic or national origin; religion, belief or lack of religion/belief; sex; sexual 
orientation. 
Please let us know if you think that recommendations from this appraisal 
could have an adverse impact on any particular groups of people, such as:   
 excluding from full consideration any people protected by the equality 
legislation who fall within the patient population for which the treatment 
is/will be licensed;  
 having a different impact on people protected by the equality legislation 
than on the wider population, e.g. by making it more difficult in practice 
for a specific group to access the treatment;  
 any adverse impact on people with a particular disability or disabilities.   
Please let us know if you think that there are any potential equality 
issues that should be considered in this appraisal. 
None. 
Are there groups of patients who would have difficulties using the 
treatment or currently available treatments? Please tell us what evidence 
you think would help the Committee to identify and consider such 
impacts. 
Cabazitaxel is administered in combination with prednisone or prednisolone. 
These corticosteroids may be unsuitable for some patients because of severe 
side effects (24). 
Cabazitaxel is also unsuitable for patients with a low neutrophil count due to 
the chance it can cause further neutropenia (16,26). 
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9. Other issues 
Do you consider the treatment to be innovative? 
 Yes  ☒ No 
If yes, please explain what makes it significantly different from other 
treatments for the condition. 
N/A 
Are there any other issues that you would like the Appraisal Committee 
to consider? 
None. 
10. Key messages 
In no more than 5 bullet points, please summarise the key messages of 
your submission. 
 People affected by prostate cancer place high value on treatments that can 
extend life. A large number of men living with prostate cancer place value 
on extending life as a means to spend extra time with loved ones. It is also 
valued by some men as a means to achieve closure and to prepare for the 
end of life (10). Men see this as important even when the extra time given 
is relatively short.   
 Cabazitaxel has been shown to improve overall survival by 2.4 months in 
patients with hormone relapsed prostate cancer (13). Data published in 
September 2014 have also shown a 2.1 month increase in overall survival 
for patients with metastatic hormone-relapsed prostate cancer previously 
treated with docetaxel if they had cabazitaxel then abiraterone, compared 
to abiraterone then cabazitaxel (14).  
 There is evidence that the use of cabazitaxel after chemotherapy is 
becoming part of routine clinical practice. NHS England’s National 
Chemotherapy Algorithm for advanced hormone-relapsed prostate cancer 
recommends cabazitaxel as an option for men whose cancer has 
progressed after docetaxel or after the use of abiraterone or enzalutamide 
and docetaxel (23). Between April 2013 and March 2015, 1270 men 
accessed cabazitaxel through the Cancer Drugs Fund (17,18).  
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 Cabazitaxel has the potential to address an important unmet need for 
patients whose prostate cancer has progressed after novel endocrine 
treatments and docetaxel chemotherapy. A recent study conducted at the 
Institute of Cancer Research (ICR) suggested that cabazitaxel is active 
when given after docetaxel followed by abiraterone and enzalutamide (19). 
 Without cabazitaxel there are no active treatment options for men with 
advanced hormone-relapsed prostate cancer that has metastasised to the 
liver following novel endocrine treatment and docetaxel.  
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NATIONAL INSTITUTE FOR HEALTH AND CARE 
EXCELLENCE 
Patient/carer organisation submission (STA) 
Cabazitaxel for hormone-relapsed metastatic prostate 
cancer previously treated with a docetaxel-containing 
regimen (review of TA255) [ID889] 
Thank you for agreeing to give us your views on this treatment that is being 
appraised by NICE and how it could be used in the NHS. Patients, carers and 
patient organisations can provide a unique perspective on conditions and their 
treatment that is not typically available from other sources. We are interested 
in hearing about: 
 the experience of having the condition or caring for someone with the 
condition 
 the experience of receiving NHS care for the condition  
 the experience of having specific treatments for the condition  
 the outcomes of treatment that are important to patients or carers (which 
might differ from those measured in clinical studies, and including health-
related quality of life) 
 the acceptability of different treatments and how they are given 
 expectations about the risks and benefits of the treatment. 
To help you give your views, we have provided a questionnaire. You do not 
have to answer every question — the questions are there as prompts to guide 
you. The length of your response should not normally exceed 10 pages. 
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1. About you and your organisation 
Your name: xxxxxxxxxxxxx 
Name of your organisation: Tackle Prostate Cancer 
Your position in the organisation: xxxxxxxxxxxxxx 
Brief description of the organisation: Tackle Prostate Cancer is the only 
patient led prostate cancer charity. It provides help, support and advice to 
individual prostate cancer support groups in the whole of the UK. It works hard 
to raise awareness of prostate cancer and runs a national 24/7 help line for 
anybody who needs help or advice. 
We have  some 7500 members plus partners and we rely donations from our 
members, private trusts and some Pharma Companies. The donations from 
Pharma Companies follow the strict guidelines set down by the industry and 
Tackle is a completely independent charity. 
(For example: who funds the organisation? How many members does the 
organisation have?) 
We are asking for your collective view as an organisation and will be asking 
patient experts for their individual input separately. If you have the condition, 
or care for someone with the condition, you may wish to complete a patient 
expert questionnaire to give your individual views as well. 
2. Living with the condition 
What is it like to live with the condition or what do carers experience 
when caring for someone with the condition? 
Advanced prostate cancer is a progressive disease. For some years, life can 
carry on as normal. As the disease progresses, the patient is likely to suffer 
from bone pain, fractures immobility and eventually death. This causes 
problems for patients and carers both in practical ways and emotional and 
psychological ways as well. 
3. Current practice in treating the condition 
Which treatment outcomes are important to patients or carers? (That is, 
what would patients or carers like treatment to achieve?) Which of these 
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are most important? If possible, please explain why. 
As cabazitaxel has proven to perform much better in the clinical setting than in 
trials, both patients and carers would like to see: 
• A decrease in levels of pain 
• A longer survival time 
• An increase of mobility due to the decrease in pain. 
What is your organisation’s experience of currently available NHS care 
and of specific treatments for the condition? How acceptable are these 
treatments and which are preferred and why? 
At the moment, the end of life drugs being used are Abiraterone and 
Enzalutamide. Both are very successful, but both have a limited life. When 
either of these drugs stop working, there is very little else in the armoury to 
fight this disease and death will surely follow. Cabazitaxel is the final 
treatment which will give any hope of survival after the failure of Abiraterone 
or Enzalutamide. There are also patients for whom hormone treatment and 
docetaxel have not been very successful. Cabazitaxel has been shown to be 
remarkably successful within this group. In the clinical setting, it has been 
shown to be highly successful, much better than in trials, with few side affects.  
It is therefore of the utmost importance that it is recommended by NICE for 
use in the NHS 
4. What do patients or carers consider to be the 
advantages of the treatment being appraised? 
Benefits of a treatment might include its effect on: 
 the course and/or outcome of the condition 
 physical symptoms 
 pain 
 level of disability 
 mental health 
 quality of life (such as lifestyle and work) 
 other people (for example, family, friends and employers) 
 ease of use (for example, tablets rather than injection) 
 where the treatment has to be used (for example, at home rather than in 
hospital) 
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 any other issues not listed above 
Please list the benefits that patients or carers expect to gain from using 
the treatment being appraised. 
It would be realistic to expect a positive benefit on physical symptoms, less 
pain and increased mobility. A longer survival time and a general increase in 
the quality of life. Cabazitaxel has proven to be a very successful treatment for 
controlling advanced prostate cancer after Abiraterone or Enzalutamide have 
failed.  
Please explain any advantages that patients or carers think this 
treatment has over other NHS treatments in England. 
At the moment, this is the final treatment which will help to control advanced 
prostate cancer, after all of the other treatments have failed. There is nothing 
else which can take its place and nothing to compare it with. 
If you know of any differences in opinion between patients or carers 
about the benefits of the treatment being appraised, please tell us about 
them. 
None that I know of 
5. What do patients and/or carers consider to be the 
disadvantages of the treatment being appraised? 
Disadvantages of a treatment might include: 
 aspects of the condition that the treatment cannot help with or might 
make worse 
 difficulties in taking or using the treatment (for example, injection rather 
than tablets) 
 side effects (for example, type or number of problems, how often, for 
how long, how severe. Please describe which side effects patients might 
be willing to accept or tolerate and which would be difficult to accept or 
tolerate)  
 where the treatment has to be used (for example, in hospital rather than 
at home) 
 impact on others (for example, family, friends and employers) 
 financial impact on the patient and/or their family (for example, the cost 
of travel to hospital or paying a carer) 
 any other issues not listed above 
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Please list any concerns patients or carers have about current NHS 
treatments in England. 
This is a chemotherapy treatment with all of the rigours that this implies. 
However, It seems that side affects are few and the quality of life whilst it is 
being given is good. Therefore, any disadvantages are far out weighed by the 
advantages. 
Please list any concerns patients or carers have about the treatment 
being appraised. 
None that I know of 
If you know of any differences in opinion between patients or carers 
about the disadvantages of the treatment being appraised, please tell us 
about them. 
None that I know of 
6. Patient population 
Are there any groups of patients who might benefit more from the 
treatment than others? If so, please describe them and explain why. 
None that I know of 
Are there any groups of patients who might benefit less from the 
treatment than others? If so, please describe them and explain why. 
None that I know of 
 
7. Research evidence on patient or carer views of the 
treatment 
Is your organisation familiar with the published research literature for 
the treatment? 
x Yes  ☐ No 
If you answered ‘no’, please skip the rest of section 7 and move on to 
section 8. 
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Please comment on whether patients’ experience of using the treatment 
as part of their routine NHS care reflects the experiences of patients in 
the clinical trials. 
Cabazitaxel has been shown to far exceed the trial results. It has the 
endorsement of the leading oncologists in the country. 
Do you think the clinical trials have captured outcomes that are 
important to patients? Are you aware of any limitations in how the 
treatment has been assessed in clinical trials? 
The clinical trials did not demonstrate the full potential of this treatment 
If the treatment being appraised is already available in the NHS, are 
there any side effects that were not apparent in the clinical trials but 
have emerged during routine NHS care? 
Cabazitaxel is available from the CDF and is performing much better than the 
clinical trials would have suggested. 
Are you aware of any relevant research on patient or carer views of the 
condition or existing treatments (for example, qualitative studies, 
surveys and polls)? 
☐ Yes  ☐x No 
If yes, please provide references to the relevant studies. 
      
8. Equality 
NICE is committed to promoting equality of opportunity, eliminating unlawful 
discrimination and fostering good relations between people with particular 
protected characteristics and others. Protected characteristics are: age; being 
or becoming a transsexual person; being married or in a civil partnership; 
being pregnant or having a child; disability; race including colour, nationality, 
ethnic or national origin; religion, belief or lack of religion/belief; sex; sexual 
orientation. 
Please let us know if you think that recommendations from this appraisal 
could have an adverse impact on any particular groups of people, such as:   
 excluding from full consideration any people protected by the equality 
legislation who fall within the patient population for which the treatment 
is/will be licensed;  
 having a different impact on people protected by the equality legislation 
than on the wider population, e.g. by making it more difficult in practice 
for a specific group to access the treatment;  
 any adverse impact on people with a particular disability or disabilities.   
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Please let us know if you think that there are any potential equality 
issues that should be considered in this appraisal. 
None 
Are there groups of patients who would have difficulties using the 
treatment or currently available treatments? Please tell us what evidence 
you think would help the Committee to identify and consider such 
impacts. 
None 
9. Other issues 
Do you consider the treatment to be innovative? 
☐X Yes  ☐ No 
If yes, please explain what makes it significantly different from other 
treatments for the condition. 
There are no other treatments, This is the last treatment available which will 
keep patients not only alive, but alive with a good quality of life. 
Are there any other issues that you would like the Appraisal Committee 
to consider? 
No 
10. Key messages 
In no more than 5 bullet points, please summarise the key messages of 
your submission. 
 This is the last available treatment to control advanced prostate cancer 
 Cabazitaxel will reduce pain and increase mobility 
 Cabazitaxel will increase survival time 
 Cabazitaxel will give hope to patients and carers 
 Cabazitaxel will enable patients to continue with a normal life and 
contribute to society, enjoy time with family and friends and in some cases, 
continue working. 
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Single Technology Appraisal (STA) 
 
Cabazitaxel for the second line treatment of hormone refractory, metastatic 
prostate cancer 
 
 1
Thank you for agreeing to give us a statement on your organisation’s view of the 
technology and the way it should be used in the NHS. 
 
Healthcare professionals can provide a unique perspective on the technology within 
the context of current clinical practice which is not typically available from the 
published literature. 
 
To help you in making your statement, we have provided a template. The questions 
are there as prompts to guide you. It is not essential that you answer all of them.  
 
Please do not exceed the 8-page limit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
About you 
 
Your name: xxxxxxxxxxxxx 
 
 
Name of your organisation : British Uro-Oncology Group (BUG) 
 
 
 
Are you (tick all that apply): 
 
- a specialist in the treatment of people with the condition for which NICE is 
considering this technology? Yes 
 
- a specialist in the clinical evidence base that is to support the technology (e.g. 
involved in clinical trials for the technology)? Yes 
 
 
- an employee of a healthcare professional organisation that represents 
clinicians treating the condition for which NICE is considering the technology? 
If so, what is your position in the organisation where appropriate (e.g. policy 
officer, trustee, member etc.)? Executive Committee member and Trustee 
of British Uro-Oncology Group 
 
- other? (please specify) 
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NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 
 
Single Technology Appraisal (STA) 
 
Cabazitaxel for the second line treatment of hormone refractory, metastatic 
prostate cancer 
 
 2
 
 
What is the expected place of the technology in current practice? 
How is thecondition currently treated in the NHS? Is there significant geographical variation in current 
practice? Are there differences of opinion between professionals as to what current practice should be? 
What are the current alternatives (if any) to the technology, and what are their respective advantages 
and disadvantages? 
Are there any subgroups of patients with the condition who have a different prognosis from the typical 
patient? Are there differences in the capacity of different subgroups to benefit from or to be put at risk by 
the technology? 
In what setting should/could the technology be used – for example, primary or secondary care, specialist 
clinics? Would there be any requirements for additional professional input (for example, community 
care, specialist nursing, other healthcare professionals)? 
If the technology is already available, is there variation in how it is being used in the NHS? Is it always 
used within its licensed indications? If not, under what circumstances does this occur? 
Please tell us about any relevant clinical guidelines and comment on the appropriateness of the 
methodology used in developing the guideline and the specific evidence that underpinned the various 
recommendations. 
 
The condition under consideration is metastatic castration-resistant prostate 
cancer which is progressing post-docetaxel. National clinical guidelines are 
currently under development for prostate cancer. Local practice is governed by 
locally developed guidelines and local implementation of NICE guidance. 
Current treatment options for management include: 
1. Abiraterone or enzalutamide in the post-docetaxel setting if not already used 
in the patient in the pre-docetaxel setting (NICE approved) 
2. Radium 223 in the appropriate patient with bone only metastases (NCDF in 
England) 
3. Alternative chemotherapy regimens- paucity of evidence, based on local 
expertise 
4. Best supportive care 
 
Docetaxel is recommended by NICE for the treatment of metastatic hormone-
refractory prostate cancer in men of KPS 60% and is widely used for this 
indication with no geographical variation.  
 
Abiraterone acetate or enzalutamide is recommended by NICE for patients with 
metastatic castration resistant prostate cancer that has progressed after 
docetaxel-containing chemotherapy regimens.  
Abiraterone and enzalutamide also have marketing authorisation for patients 
with metastatic castration resistant prostate cancer who are asymptomatic or 
mildly symptomatic in whom docetaxel chemotherapy is not yet indicated. 
However they are not approved by NICE for this indication. It is available in 
England through the Cancer Drugs Fund (CDF) but is not available in Wales. In 
England it is widely used for this indication with high uptake through the CDF. 
There is no significant geographic or clinical variation in this practice.     
 
Best supportive care alone is not a relevant comparator as any patient who is 
fit for cabazitaxel would be keen on further treatment and there is a high 
likelihood of use of other chemotherapy regimens.  
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As well as clear improvements in median overall survival in the reported 
randomised trial (TROPIC), the UK Expanded Access Programme showed a 
significant improvement in pain with treatment with cabazitaxel with no 
detriment to QOL of individuals treated with cabazitaxel. 
 
In England, the uptake of cabazitaxel through NCDF shows the unmet need for 
this group of patients and the use is across the country with no significant 
geographical variation.  
 
 
The advantages and disadvantages of the technology 
 
NICE is particularly interested in your views on how the technology, when it becomes available, will 
compare with current alternatives used in the UK. Will the technology be easier or more difficult to use, 
and are there any practical implications (for example, concomitant treatments, other additional clinical 
requirements, patient acceptability/ease of use or the need for additional tests) surrounding its future 
use? 
If appropriate, please give your view on the nature of any rules, informal or formal, for starting and 
stopping the use of the technology; this might include any requirements for additional testing to identify 
appropriate subgroups for treatment or to assess response and the potential for discontinuation. 
If you are familiar with the evidence base for the technology, please comment on whether the use of the 
technology under clinical trial conditions reflects that observed in clinical practice. Do the circumstances 
in which the trials were conducted reflect current UK practice, and if not, how could the results be 
extrapolated to a UK setting? What, in your view, are the most important outcomes, and were they 
measured in the trials? If surrogate measures of outcome were used, do they adequately predict long-
term outcomes? 
What is the relative significance of any side effects or adverse reactions? In what ways do these affect 
the management of the condition and the patient’s quality of life? Are there any adverse effects that 
were not apparent in clinical trials but have come to light subsequently during routine clinical practice? 
 
 
Cabazitaxel chemotherapy was given as part of the TROPIC trial which was 
done in 26 countries including UK. It reflects the ‘real-life’ setting of treating 
these patients. The most important outcome was improvement in overall 
survival which previous to this trial was never seen with any other intervention 
in this group. 
 
The published evidence of the UK Expanded Access Programme shows the 
significant benefit in terms of pain control and no detriment to QOL with 
treatment with cabazitaxel.(Final quality of life and safety data for patients with 
metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early 
Access Programme (EAP) (NCT01254279). 
Bahl A, Masson S, Malik Z, Birtle AJ, Sundar S, Jones RJ, James ND, Mason MD, Kumar S, 
Bottomley D, Lydon A, Chowdhury S, Wylie J, de Bono JS. 
BJU Int. 2015 Jan 30. 
 
There are no robust randomised trials to address the optimum sequencing of 
treatments for mCRPC (metastatic castration resistant prostate cancer). The 
meta-analysis of 10 published sequencing studies shows that overall survival 
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is significantly better in patients with mCRPC who receive 3 agents (docetaxel, 
abiraterone and cabazitaxel) compared to those who receive 2 agents 
(docetaxel and abiraterone). (Maines F et al. ASCO GU 2015 (abstract  258) 
 
Recent evidence indicates that Cabazitaxel is active in mCRPC in both AR-V7 
positive and negative cases whilst abiraterone/enzalutamide are unlikely to be 
of benefit in AR-V7 positive MCRPC cases. (Cabazitaxel Remains Active in Patients 
Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. Al 
Nakouzi N. Eur Urol. 2014 May 2) 
 
Any additional sources of evidence 
Can you provide information about any relevant evidence that might not be found by a technology-
focused systematic review of the available trial evidence? This could be information on recent and 
informal unpublished evidence, or information from registries and other nationally coordinated clinical 
audits. Any such information must include sufficient detail to allow a judgement to be made as to the 
quality of the evidence and to allow potential sources of bias to be determined. 
 
British Uro-oncology Group conducted a survey of specialist oncologists who 
treat prostate cancer to look at their views regarding the forthcoming 
developments in systemic therapy of prostate cancer. This has been submitted 
for publication to BJUI. 
 
The views of British Ur-oncologists are similar to the European and St Gallen 
consensus guidelines which advocate cabazitaxel as an option for mCRPC 
cases post-docetaxel. This is also reflected in the NCCN guidelines. 
 
 
Implementation issues 
 
The NHS is required by the Department of Health and the Welsh Assembly Government to provide 
funding and resources for medicines and treatments that have been recommended by NICE technology 
appraisal guidance. This provision has to be made within 3 months from the date of publication of the 
guidance. 
 
If the technology is unlikely to be available in sufficient quantity, or the staff and facilities to fulfil the 
general nature of the guidance cannot be put in place within 
3 months, NICE may advise the Department of Health and the Welsh Assembly Government to vary this 
direction. 
 
Please note that NICE cannot suggest such a variation on the basis of budgetary constraints alone. 
 
How would possible NICE guidance on this technology affect the delivery of care for patients with this 
condition? Would NHS staff need extra education and training? Would any additional resources be 
required (for example, facilities or equipment)? 
 
All chemotherapy units are equipped to provide chemotherapy. Cabazitaxel 
chemotherapy is already provided in established units through access to the 
drug from NCDF. 
 
 
 
Appendix I -Professional organisation statement template 
 
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 
 
Single Technology Appraisal (STA) 
 
Cabazitaxel for the second line treatment of hormone refractory, metastatic 
prostate cancer 
 
 5
 
 Equality  
 
Are there any issues that require special attention in light of the NICE’s duties to have due regard to the 
need to eliminate unlawful discrimination and promote equality and foster good relations between 
people with a characteristic protected by the equalities legislation and others? 
 
No comment 
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Thank you for agreeing to make a submission on your organisation’s view of the 
technology and the way it should be used in the NHS. 
 
Healthcare professionals can provide a unique perspective on the technology within 
the context of current clinical practice which is not typically available from the 
published literature. 
 
To help you in making your submission, we have provided a template. The questions 
are there as prompts to guide you. It is not essential that you answer all of them.  
 
Please do not exceed the 8-page limit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
About you 
 
Your name: xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
Name of your organisation: xxxxxxxxxxxxxxxxxxx 
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What is the expected place of the technology in current practice? 
 
How is the condition currently treated in the NHS? Is there significant geographical 
variation in current practice? Are there differences of opinion between professionals 
as to what current practice should be? What are the current alternatives (if any) to 
the technology, and what are their respective advantages and disadvantages? 
 
For most men the main alternative to cabazitaxel will be Best Supportive Care (BSC), 
or in some cases, Radium-223. Not all patients with metastatic castration resistant 
prostate cancer (mCRPC; ‘hormone-relapsing prostate cancer’) are treated in the 
same way. Until 2010, docetaxel was only one proven life-prolonging therapy and in 
excess of 50% of patients were, for one reason or another, unsuitable. In addition to 
docetaxel we now have multiple life-prolonging options for these men including one 
of either abiraterone or enzalutamide, Radium-223 (for men with symptomatic bone-
only disease) and cabazitaxel. Whilst most patients are suitable for at least one of 
these options, some men may be suitable for all of them, although there is no 
evidence to guide the optimal sequencing of these therapies. Increasingly, these men 
will have already received docetaxel prior to becoming castration resistant, and so 
docetaxel will not be a recognised option of these men when they relapse. In 
England, as in most other high-income countries, it is reasonably clear that the first 
treatment most men receive will be either abiraterone or enzalutamide, irrespective of 
whether or not they are suitable for chemotherapy in the future. On failure of this 
treatment it is likely that most men will receive docetaxel (if not previously given), 
Radium-223 (if symptomatic bone-only disease) or cabazitaxel (if previously given 
docetaxel). For those that are not suitable for any of these options, the only likely 
treatment will be Best Supportive Care. Although mitoxantrone has no marketing 
authorisation in UK, it is not a life-prolonging therapy and is now only rarely used as 
part of Best Supportive Care in patients who are symptomatic and who have no life-
prolonging therapies available to them. There is no evidence to support the use of 
sequential abiraterone/enzalutamide therapy and, as these two drugs are highly 
cross-resistant, such sequential use is not generally permitted or desired, particularly 
if other life-prolonging therapies are available.  
 
Within England there is little evidence of significant geographical variation in practice. 
Although there are differences of opinion, particularly with regards to the most 
appropriate timing of docetaxel (some advocate giving early in the course of the 
illness, others would not consider it until a patient becomes symptomatic), by and 
large most clinicians would offer abiraterone or enzalutamide as a first treatment at 
the point of diagnosis with mCRPC, the first manifestation of which is usually an 
asymptomatic rise in prostate-specific antigen (PSA). 
 
By and large, most men who are being considered for cabazitaxel will, therefore, 
have had either abiraterone or enzalutamide before considering cabazitaxel, either 
before or after prior docetaxel. Only in very rare circumstances would a patient be 
considered for cabazitaxel in preference to one or other of these hormonal agents if 
they had no prior exposure to one of them. No clinician would routinely recommend 
cabazitaxel in preference to one or other of abiraterone or enzalutamide where the 
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patient had no prior exposure to one of these drugs. Therefore, the great majority (in 
excess of 90% by my estimate) of the men who are being considered of cabazitaxel 
will have previously had docetaxel and one of abiraterone or enzalutamide. As 
sequential enza/abi therapy is not considered, the only alternatives available to these 
men would be Radium-223 (where indicated) or Best Supportive Care (which, rarely, 
may include mitoxantrone). Best Supportive Care may also include radiotherapy, 
corticosteroids, palliative care measures, bisphosphonates and, occasionally, bone-
seeking radioisotopes other than Radium. 
 
The review should take into account that NICE guidance covers Wales, but that the 
CDF does not operate in Wales, hence patients do not receive pre-chemotherapy 
Aberaterone or Enzalutamide. 
 
Are there any subgroups of patients with the condition who have a different prognosis 
from the typical patient? Are there differences in the capacity of different subgroups 
to benefit from or to be put at risk by the technology? 
 
There are no subgroups of patients who are specifically more likely to benefit from 
cabazitaxel as opposed to any alternative treatments. mCRPC covers a spectrum of 
disease, from men with slow-growing disease which may never cause problems in 
the remainder of that patient’s life, to highly aggressive forms of the disease which 
rapidly causes debilitating symptoms and death. There are various factors which 
independently predict prognosis: these include baseline performance status, the 
presence of visceral disease and various biochemical and haematological 
parameters. Although patients with poor prognostic feature, by and large, gain less 
benefit from all systemic therapies, there are no widely accepted predictors of 
efficacy of cabazitaxel specifically. In particular there are no known markers which 
enable clinicians to choose between cytotoxics (such as cabazitaxel) and hormonal 
therapies (such as abiraterone and enzalutamide). 
 
In what setting should/could the technology be used – for example, primary or 
secondary care, specialist clinics? Would there be any requirements for additional 
professional input (for example, community care, specialist nursing, other healthcare 
professionals)? 
 
Cabazitaxel is only ever likely to be prescribed by specialist oncologists and 
administered in secondary care specialist clinics. These clinics are likely to be 
hospital based and will require input from specialist oncology nurses and oncology 
pharmacists. These facilities are no different from those required to give most 
commonly used intravenous cytotoxic drugs. In some cases, patients suffering from 
the acute toxicities of cabazitaxel, most notably complications of neutropenia such as 
sepsis will require emergency medical care as an inpatient.  
 
If the technology is already available, is there variation in how it is being used in the 
NHS? Is it always used within its licensed indications? If not, under what 
circumstances does this occur? 
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Although uptake of cabazitaxel varies across the English NHS, this is assumed to be 
more due to variations in clinician preferences and experience rather than differences 
in the patient population. Within prostate cancer it is unlikely that it is being used 
outside of its licensed indication. 
 
Please tell us about any relevant clinical guidelines and comment on the 
appropriateness of the methodology used in developing the guideline and the specific 
evidence that underpinned the various recommendations. 
 
Among others, guidelines from the European Association of Urologists, the National 
Comprehensive Cancer Network, and the American Society for Clinical Oncology all 
recommend the use of cabazitaxel within its licensed indication. Although the specific 
methodologies employed by these organisations differ, the primary evidence is 
derived from the TROPIC trial (de Bono et al. Lancet 2010; 376: 1147–54) which was 
a phase III trial comparing predisone with either cabazitaxel or mitoxantrone in men 
with metastatic castration resistant prostate cancer who had had prior docetaxel. This 
trial demonstrated a significant survival advantage among the men receiving 
cabazitaxel. Subsequent retrospective studies suggest the activity of cabazitaxel is 
preserved in men who have also received prior abiraterone or enzalutamide (eg. 
Pezaro et al. Eur Urol. 2014 Sep;66(3):459–65). 
 
 
The advantages and disadvantages of the technology 
 
NICE is particularly interested in your views on how the technology, when it becomes 
available, will compare with current alternatives used in the UK. Will the technology 
be easier or more difficult to use, and are there any practical implications (for 
example, concomitant treatments, other additional clinical requirements, patient 
acceptability/ease of use or the need for additional tests) surrounding its future use? 
 
As described previously, the main alternative to this technology is BSC, the nature 
and complexity of which will differ greatly from one patient to the next. The 
appropriate use of cabazitaxel has the potential to displace some of these BSC 
requirements, such as the requirement for complex analgesia or the use of external 
beam radiotherapy. Cabazitaxel does require resources for the administration of 
infusional chemotherapy and also requires the patient to attend a hospital-based 
infusion unit every 3 weeks during treatment. In addition it is advisable for the patient 
to have a full blood count on days 8 and 15 of the first cycle and prior to each cycle of 
treatment. In most areas, these blood tests can be delivered in conjunction with 
primary care, and so the patient need only attend their local surgery. If the patient is 
receiving Radium-223, the main alternative after BSC, then the patient would still 
require a blood test prior to each 4-weekly infusion which is infused in secondary 
care. Patients receiving BSC are unlikely to require regular blood tests. For patients 
receiving abiraterone (as outlined above, this is unlikely to be an alternative), blood 
tests are required every 15 days for the first 16 weeks and 4-weekly thereafter. For 
patients receiving enzalutamide (again, rarely an alternative to cabazitaxel), blood 
tests are not mandated. Both abiraterone and enzalutamide are usually prescribed in 
secondary care, although prescription intervals vary. 
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Granulocyte colony stimulating factors (G-CSF) are recommended as secondary 
prophylaxis for prolonged or complicated neutropenia. These may be given daily, 
subcutaneously, for up to 10 days per cycle, or as a single dose of pegylated G-CSF 
on day 2. Some recommend the use of primary prophylactic G-CSF (ie. With the first 
dose of cabazitaxel without the ‘need’ to have observed prolonged or complicated 
neutropenia). Most patients requiring G-CSF would be able to self-administer, but 
sometimes community nurses are called upon to give them. G-CSF would not be 
required with any of the alternative treatments. 
 
If appropriate, please give your view on the nature of any rules, informal or formal, for 
starting and stopping the use of the technology; this might include any requirements 
for additional testing to identify appropriate subgroups for treatment or to assess 
response and the potential for discontinuation. 
 
Patients would not commence cabazitaxel without evidence of disease progression 
on prior therapy. By and large this is indicated by a rising PSA blood test, but may 
include evidence from worsening bone and CT scans and / or symptoms. 
Cabazitaxel is given for a maximum of 10 3-weekly cycles, but should be 
discontinued prior to this if there is clear evidence of intolerance which cannot be 
managed without cessation of therapy, or disease progression. The former requires 
no specific testing, but the latter can be complex and the decision to stop treatment 
on the basis of disease progression will often be taken in the context of a rising PSA 
in combination with symptomatic progression and / or worsening disease on bone or 
CT scans. It is therefore good practice to perform one or both such scans prior to 
starting cabazitaxel. If one or both of these scans demonstrates metastatic disease at 
baseline, it is often necessary to repeat that / those scans to confirm disease 
progression (for example where the PSA is continuing to rise 12 weeks after 
commencing cabazitaxel). The precise number and nature of these scans will vary 
greatly from one patient to the next and between clinicians. 
 
If you are familiar with the evidence base for the technology, please comment on 
whether the use of the technology under clinical trial conditions reflects that observed 
in clinical practice. Do the circumstances in which the trials were conducted reflect 
current UK practice, and if not, how could the results be extrapolated to a UK setting? 
What, in your view, are the most important outcomes, and were they measured in the 
trials? If surrogate measures of outcome were used, do they adequately predict long-
term outcomes? 
 
I have prescribed cabazitaxel within its licensed indication to around 40 patients, 
mainly under clinical trial conditions, including participation in the TROPIC trial. In my 
experience, and in consultation with colleagues in England and elsewhere, patients 
are more carefully selected for cabazitaxel in routine practice than seemed to be the 
case in TROPIC such that the incidence of severe toxicity is lower in routine use than 
was observed in TROPIC.  
 
The TROPIC trial was conducted globally but there were several UK centres 
involved, including that of the chief investigator (Royal Marsden / Institute of Cancer 
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Research). The findings have equal relevance in England as any other high income 
country. 
 
There are two outcomes of major importance for men with mCRPC: first, overall 
survival and second, overall quality of life (QoL). Overall survival was robustly 
measured in TROPIC, but QoL was not. Improvement in pain control was assessed, 
but this is, in my opinion, only a week surrogate of QoL as it fails to encompass other 
symptoms of the disease or the toxicities of the treatment. Subsequent, non-
randomized, prospective studies performed in the UK do suggest that QoL is at least 
maintained in patients receiving cabazitaxel (Sanofi, data on file).  
 
What is the relative significance of any side effects or adverse reactions? In what 
ways do these affect the management of the condition and the patient’s quality of 
life? Are there any adverse effects that were not apparent in clinical trials but have 
come to light subsequently during routine clinical practice? 
 
The most significant toxicity of cabazitaxel is neutropenia. Asymptomatic, 
uncomplicated neutropenia, even at high grade, is common but of no direct clinical 
significance and does not adversely affect the patient. Complicated neutropenia 
(neutropenic fever, neutropenic sepsis) is potentially life-threatening and requires 
hospitalisation, intravenous antibiotics and intensive monitoring with escalation of 
care if required. Patients suffering severe complications will suffer considerably and 
may not fully recover from the effects. Fortunately, with post marketing experience, 
such severe complications appear rare (probably due to better patient selection than 
was applied in the TROPIC trial along with judicious use of G-CSF). Other 
complications such as diarrhoea and cardiac dysrhythmias are also fortunately rare 
and usually occur simultaneously with complicated neutropenia. Clinically significant 
neuropathy is rare in patients who are appropriately managed with cabazitaxel in 
routine practice. The overall implications for QoL have not been formally assessed in 
TROPIC, but the non-randomized data available suggest that there is not an overall 
detrimental effect on QoL. 
 
There are no major or significantly common adverse effects which have come to light 
post-marketing. 
 
 
 
Any additional sources of evidence 
 
Can you provide information about any relevant evidence that might not be found by 
a technology-focused systematic review of the available trial evidence? This could be 
information on recent and informal unpublished evidence, or information from 
registries and other nationally coordinated clinical audits. Any such information must 
include sufficient detail to allow a judgement to be made as to the quality of the 
evidence and to allow potential sources of bias to be determined. 
 
Bahl et al. BJU Int. 2015 Jan 30. UK prospective study of QoL (measured by EQ5D) 
among men receiving cabazitaxel within the expanded access programme. This 
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paper can be accessed by usual library sources. This suggested a trend towards 
improved QoL and lower incidence of neutropenic sepsis than seen in the TROPIC 
trial.  
 
 
 
Implementation issues 
 
The NHS is required by the Department of Health to provide funding and resources 
for medicines and treatments that have been recommended by NICE technology 
appraisal guidance. This provision has to be made within 3 months from the date of 
publication of the guidance. 
 
If the technology is unlikely to be available in sufficient quantity, or the staff and 
facilities to fulfil the general nature of the guidance cannot be put in place within 
3 months, NICE may advise the Department of Health to vary this direction. 
 
Please note that NICE cannot suggest such a variation on the basis of budgetary 
constraints alone. 
 
How would possible NICE guidance on this technology affect the delivery of care for 
patients with this condition? Would NHS staff need extra education and training? 
Would any additional resources be required (for example, facilities or equipment)? 
 
As cabazitaxel is currently available within its licensed indication on the Cancer 
Drugs Fund, it is unlikely that a NICE recommendation in favour of its use will 
significantly increase the amount of drug or other resources/facilities/equipment. 
 
 
 
Equality 
NICE is committed to promoting equality of opportunity, eliminating unlawful 
discrimination and fostering good relations between people with particular protected 
characteristics and others.  Please let us know if you think that this appraisal:   
 
 - could exclude from full consideration any people protected by the equality 
legislation who fall within the patient population for which [the treatment(s)] is/are/will 
be licensed;  
 - could lead to recommendations that have a different impact on people protected by 
the equality legislation than on the wider population, e.g. by making it more difficult in 
practice for a specific group to access the technology;  
 - could lead to recommendations that have any adverse impact on people with a 
particular disability or disabilities.   
 
Please tell us what evidence should be obtained to enable the Committee to identify 
and consider such impacts. 
 
I do not believe there are any equality issues. 
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Cabazitaxel for treating hormone-relapsed metastatic prostate cancer 
after a docetaxel-containing regimen (review of TA255) [ID889] 
 
Thank you for agreeing to give us a statement on your view of the technology and the 
way it should be used in the NHS. 
 
Healthcare professionals can provide a unique perspective on the technology within 
the context of current clinical practice which is not typically available from the 
published literature. 
 
To help you in making your statement, we have provided a template. The questions 
are there as prompts to guide you. It is not essential that you answer all of them.  
 
Please do not exceed the 8-page limit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
About you 
 
Your name: Dr Zafar Malik. 
 
 
Name of your organisation  
The Clatterbridge Cancer Centre Liverpool 
 
xxxxxxxxxxxxxxxxxxxx 
xxxxxxxxxxx 
xxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
Are you (tick all that apply): 
 
X   a specialist in the treatment of people with the condition for which NICE is 
considering this technology? 
 
X a specialist in the clinical evidence base that is to support the technology (e.g. 
involved in clinical trials for the technology)? 
 
X an employee of a healthcare professional organisation that represents clinicians 
treating the condition for which NICE is considering the technology? If so, what is 
your position in the organisation where appropriate (e.g. policy officer, trustee, 
member etc.)? 
 
- other? (please specify) 
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What is the expected place of the technology in current practice? 
 
How the condition is currently treated in the NHS? Is there significant geographical 
variation in current practice? Are there differences of opinion between professionals 
as to what current practice should be? What are the current alternatives (if any) to 
the technology, and what are their respective advantages and disadvantages? 
 
Are there any subgroups of patients with the condition who have a different prognosis 
from the typical patient? Are there differences in the capacity of different subgroups 
to benefit from or to be put at risk by the technology? 
 
In what setting should/could the technology be used – for example, primary or 
secondary care, specialist clinics? Would there be any requirements for additional 
professional input (for example, community care, specialist nursing, other healthcare 
professionals)? 
 
If the technology is already available, is there variation in how it is being used in the 
NHS? Is it always used within its licensed indications? If not, under what 
circumstances does this occur? 
 
Please tell us about any relevant clinical guidelines and comment on the 
appropriateness of the methodology used in developing the guideline and the specific 
evidence that underpinned the various recommendations. 
 
 
 
 
How is the condition currently treated in the NHS? 
 
 Metastatic castrate resistant prostate cancer (mCRPC) is a heterogeneous disease. 
Currently the options available on diagnosis are LHRH therapy plus docetaxel or 
novel anti andogen therapy (abiraterone or enzalutamide) through the CDF. On 
relapse cabazitaxel is available through the CDF or for those patients who haven’t 
received novel anti androgens in the chemo naïve setting. Abiraterone or 
enzalutamide are options available through the NICE adoption process. 
The main advantage for cabazitaxel treatment is that it offers chance of response 
and survival benefit in a group of patients who have the most aggressive prostate 
cancer e.g. high tumour burden, visceral disease, poor response to hormonal therapy 
or docetaxel resistant disease. In these patients pursuing novel hormonal treatment 
offers no realistic prospect of response. Moreover it is likely to result in the patients’ 
condition deteriorating and missing the window of opportunity where cabazitaxel may 
deliver clinical benefit. 
 
 Is there significant geographical variation in current practice? 
 
 It is difficult to comment on geographic variation, however within cancer centres 
variation does occur on treatments. This is dependent on patient characteristics: - 
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medical co morbidity, Performance Status, tumour characteristics, disease burden, 
Gleason grade, response to pervious hormonal therapy and biochemistry e.g. LDH, 
ALP N: L ratio, patient preference or indeed clinician choice.  However, in the more 
aggressive prostate cancer patients mentioned above most clinicians would 
recommend chemotherapy treatment utilising cabazitaxel. 
 
 Are there differences of opinion between professionals as to what current practice 
should be? 
 
 Yes there are as no randomised data exists to guide optimal sequence for treatment. 
Also as this disease is heterogeneous in certain situations there may be advantages 
in pursuing further chemotherapy with cabazitaxel. Conversely in other settings for 
the aforementioned reasons there may be advantages for novel hormonal therapy. 
 
 What are the current alternatives (if any) to the technology, and what are their 
respective advantages and disadvantages?  
 
The alternative to cabazitaxel would be either abiraterone or enzalutamide treatment 
if this has not been administered in the chemo naive setting. The advantage of these 
treatments is that they are oral and often well tolerated. The main disadvantage is 
that for patients with aggressive prostate cancer who have responded poorly to 
previous hormonal treatment or those patients who have docetaxel resistant disease 
the chance of response to these hormonal treatments is extremely low. 
Radium 223 treatment is an alternative available on the CDF for those patients who 
have nodal disease restricted to the pelvis and no evidence of visceral/ extra pelvic 
nodal disease.  This represents a subgroup with relatively indolent metastatic 
disease in whom cabazitaxel would not be best treatment option 
 
Are there any subgroups of patients with the condition who have a different prognosis 
from the typical patient? 
 
 Yes, as mentioned earlier metastatic castrate resistant prostate cancer is a 
heterogeneous disease.   Treatment decisions are based on a whole range of factors 
including patient characteristics:- medical co morbidity, Performance Status, tumour 
characteristics, disease burden, Gleason grade, response to pervious hormonal 
therapy and biochemistry e.g. LDH,ALP N:L ratio, availability of medications on CDF 
and patient preference or indeed clinician choice. 
All of these factors are considered by clinicians in making treatment 
recommendations. However no randomised controlled evidence exists to guide 
practice at present.     
 
 
Are there differences in the capacity of different subgroups to benefit from or to be 
put at risk by the technology? 
 
 All the above treatments carry with them potential disadvantages and none of the 
treatment options offer 100% chance of response. However, in the more aggressive 
mCRPC cabazitaxel appears to offer therapeutic advantages especially if patients 
have responded poorly to prior hormonal treatment or have a significant disease 
burden. 
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In what setting should/could the technology be used – for example, primary or 
secondary care, specialist clinics?  
 
 This treatment can only be delivered in a special cancer centre /unit.  
 
Would there be any requirements for additional professional input (for example, 
community care, specialist nursing, other healthcare professionals)?  
 
There is no extra provision required for this technology to be administered that is not 
already in place. Docetaxel chemotherapy treatment which is already approved by 
NICE has been offered for many years for metastatic prostate cancer and is available 
in all Cancer Centres throughout the UK. With this framework in place the necessary 
infrastructure exists to implement this technology as evidenced by usage within CDF.  
 
If the technology is already available, is there variation in how it is being used in the 
NHS?  
 
Is it always used within its licensed indications? If not, under what circumstances 
does this occur? Currently this technology is being utilised within its licence indication 
through the CDF. I do not see it being considered outside its current licence.  
 
 
The advantages and disadvantages of the technology 
 
NICE is particularly interested in your views on how the technology, when it becomes 
available, will compare with current alternatives used in the UK. Will the technology 
be easier or more difficult to use, and are there any practical implications (for 
example, concomitant treatments, other additional clinical requirements, patient 
acceptability/ease of use or the need for additional tests) surrounding its future use? 
 
If appropriate, please give your view on the nature of any rules, informal or formal, for 
starting and stopping the use of the technology; this might include any requirements 
for additional testing to identify appropriate subgroups for treatment or to assess 
response and the potential for discontinuation. 
 
If you are familiar with the evidence base for the technology, please comment on 
whether the use of the technology under clinical trial conditions reflects that observed 
in clinical practice. Do the circumstances in which the trials were conducted reflect 
current UK practice, and if not, how could the results be extrapolated to a UK setting? 
What, in your view, are the most important outcomes, and were they measured in the 
trials? If surrogate measures of outcome were used, do they adequately predict long-
term outcomes? 
 
What is the relative significance of any side effects or adverse reactions? In what 
ways do these affect the management of the condition and the patient’s quality of 
life? Are there any adverse effects that were not apparent in clinical trials but have 
come to light subsequently during routine clinical practice? 
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This technology is a chemotherapy agent that offers survival benefits in patients with 
aggressive prostate cancer. In particular it offers a chance of response to treatment 
in patients that have responded poorly to previous hormonal or chemotherapy 
treatment. Often these patients have a poor prognosis and little chance of response 
to novel antiandrogen therapy and a narrow therapeutic window where the 
technology can be considered and applied. 
This therapy has a side effect profile similar to docetaxel treatment which is NICE 
approved in the first line setting. With appropriate selection of patients and support 
this chemotherapy treatment can be safely delivered. It carries with it all the risks 
associated of chemotherapy treatment including febrile neutropenia and death. 
 As with all chemotherapy treatment 30 day mortality is collected and reported and 
this would be the case with this technology. 
  Many centres in the UK have undertaken audits and have reported a toxicity profile 
that is comparable with published registry data. However, one would expect further 
audits to be undertaken should this technology be approved to check that patients 
have received the treatment appropriately (starting and stopping treatment) and to 
monitor the toxicity profile. 
In my clinical experience as well as published experience from other centres I have 
found that cabazitaxel is well tolerated in appropriately selected patients with a 
manageable side effect profile that is comparable with published data.  Moreover it is 
no more difficult to use than NICE approved docetaxel treatment. In fact this regimen 
requires less steroid use and is better tolerated.  
No randomised control trial evidence exists to show optimal sequencing of the 
available agents. No predictive biomarker tests are currently available to determine 
treatment recommendations in this mCRPC setting.  None of the agents currently 
being prescribed in the mCRPC setting have directly been compared to each other in 
a trial setting.  
 mCRPC is an area of rapid change with many clinical trials being undertaken. This 
technology does have an important role to play in the mCRPC offering clinical benefit 
for patients where alternative treatment options are unlikely to be successful.  
 
 
 
 
Equality and Diversity 
 
NICE is committed to promoting equality of opportunity, eliminating unlawful 
discrimination and fostering good relations between people with particular protected 
characteristics and others.  Please let us know if you think that this appraisal: 
 
 - Could exclude from full consideration any people protected by the equality 
legislation who fall within the patient population for which [the treatment(s)] is/are/will 
be licensed;  
- Could lead to recommendations that have a different impact on people 
protected by the equality legislation than on the wider population, e.g. by making it 
more difficult in practice for a specific group to access the technology; 
- Could lead to recommendations that have any adverse impact on people with 
a particular disability or disabilities 
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Please tell us what evidence should be obtained to enable the Committee to identify 
and consider such impacts  
 
This technology will not exclude or have any negative impact on any patients from 
the equality, diversity position. 
 
Any additional sources of evidence 
 
Can you provide information about any relevant evidence that might not be found by 
a technology-focused systematic review of the available trial evidence? This could be 
information on recent and informal unpublished evidence, or information from 
registries and other nationally coordinated clinical audits. Any such information must 
include sufficient detail to allow a judgement to be made as to the quality of the 
evidence and to allow potential sources of bias to be determined. 
 
The recent STAMPEDE study in hormone sensitive prostate cancer showed that the 
utilisation of early chemotherapy significantly improved overall survival, ASCO 2015 
LBA5001. The data are compelling and support finding from the CHAARTED study.  
  
There is ongoing work to identify predictive biomarkers. However, currently none 
have been approved for clinical practice.  Note the work published by Small in ASCO 
2015. Abstract 5003.  
 
 
 
Implementation issues 
 
The NHS is required by the Department of Health and the Welsh Assembly 
Government to provide funding and resources for medicines and treatments that 
have been recommended by NICE technology appraisal guidance. This provision has 
to be made within 3 months from the date of publication of the guidance. 
 
If the technology is unlikely to be available in sufficient quantity or the staff and 
facilities to fulfil the general nature of the guidance cannot be put in place within 
3 months, NICE may advise the Department of Health and the Welsh Assembly 
Government to vary this direction. 
 
Please note that NICE cannot suggest such a variation on the basis of budgetary 
constraints alone. 
 
How would possible NICE guidance on this technology affect the delivery of care for 
patients with this condition? Would NHS staff need extra education and training? 
Would any additional resources be required (for example, facilities or equipment)? 
 
 
Currently this technology is available for treatment on the CDF. Therefore all 
necessary support structures are in place to implement treatment should it receive 
positive NICE appraisal.   
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EXCELLENCE 
Patient/carer expert statement (STA) 
 Cabazitaxel for treating hormone-relapsed metastatic 
prostate cancer after a docetaxel-containing regimen 
(review of TA255) [ID889] 
Thank you for agreeing to give us your views on this treatment that is being 
appraised by NICE and how it could be used in the NHS. Patients, carers and 
patient organisations can provide a unique perspective on conditions and their 
treatment that is not typically available from other sources. We are interested 
in hearing about: 
 the experience of having the condition or caring for someone with the 
condition 
 the experience of receiving NHS care for the condition  
 the experience of having specific treatments for the condition  
 the outcomes of treatment that are important to patients or carers (which 
might differ from those measured in clinical studies, including health-
related quality of life) 
 preferences for different treatments and how they are given 
 expectations about the risks and benefits of the treatment. 
 
We have already asked your nominating organisation to provide an 
organisation’s view. We are asking you to give your views as an individual 
whether you are: 
 a patient 
 a carer (who may be voicing views for a patient who is unable to) or 
 somebody who works or volunteers for a patient organisation. 
 
To help you give your views, we have provided a questionnaire. You do not 
have to answer every question — the questions are there as prompts to guide 
you. The response area will expand as you type. The length of your response 
should not normally exceed 10 pages. 
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1. About you 
Your name: Allan Higgin 
Name of your nominating organisation: Prostate Cancer Support 
Organisation (PCaSO) 
Do you know if your nominating organisation has submitted a 
statement? 
 
x Yes  ☐ No 
Do you wish to agree with your nominating organisation’s statement? 
 
x Yes  ☐ No 
(We would encourage you to complete this form even if you agree with your 
nominating organisation’s statement.) 
Are you: 
 a patient with the condition?  
 
☐ Yes  X No 
 
 a carer of a patient with the condition? 
 
☐ Yes  X No 
 
 a patient organisation employee or volunteer? 
  
X Yes  ☐ No 
 
Do you have experience of the treatment being appraised? 
☐ Yes  X No 
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If you wrote the organisation submission and do not have anything to add, tick 
here  (If you tick this box, the rest of this form will be deleted after 
submission.) 
2. Living with the condition 
What is your experience of living with the condition as a patient or 
carer? 
I am prostate cancer patient who has been living with the disease for 6 years. 
I was on active surveillance for 3 years before electing to have a radical 
prostatectomy. 
I am now involved with various PC charities, a member of PCUK’s Grant 
Application Panel, involved in PSA testing across Dorset, including helping to 
run a counselling service. I am working with Surrey University on a mental 
health initiative aimed at PC suffers and I often lecture to various groups on 
prostate cancer awareness. Though these activities, I meet and talk to many 
men and their families who are living with the disease and it’s varying 
symptoms and treatments. 
3. Current practice in treating the condition 
Which treatment outcomes are important to you? (That is, what would 
you like treatment to achieve?) Which of these are most important? If 
possible, please explain why. 
A longer survival time 
Increased quality of life 
Reduction of pain and other side effects 
What is your experience of currently available NHS care and of specific 
treatments? How acceptable are these treatments – which did you prefer 
and why? 
It is very haphazard, the CDF creates unacceptable degrees of uncertainty. A 
sure knowledge that an agreed treatment regime will continue as long as 
necessary/effective is essential for both the patient and carer’s mental 
wellbeing and quality of life.  
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4. What do you consider to be the advantages of the 
treatment being appraised? 
Benefits of a treatment might include its effect on: 
 the course and/or outcome of the condition 
 physical symptoms 
 pain 
 level of disability 
 mental health 
 quality of life (such as lifestyle and work) 
 other people (for example, family, friends and employers) 
 ease of use (for example, tablets rather than injection) 
 where the treatment has to be used (for example, at home rather than in 
hospital) 
 any other issues not listed above 
Please list the benefits that you expect to gain from using the treatment 
being appraised. 
None personally but others should benefit from a relief of physical symptoms 
and a more stable approach to mental welfare. 
Please explain any advantages that you think this treatment has over 
other NHS treatments in England. 
I believe it is currently the final drug treatment available to sustain life after all 
other treatments have ceased to be effective, 
If you know of any differences in opinion between you and other 
patients or carers about the benefits of the treatment being appraised, 
please tell us about them. 
None that I am aware of. 
5. What do you consider to be the disadvantages of the 
treatment being appraised? 
Disadvantages of a treatment might include: 
 aspects of the condition that the treatment cannot help with or might 
make worse 
 difficulties in taking or using the treatment (for example, injection rather 
than tablets) 
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 side effects (for example, type or number of problems, how often, for 
how long, how severe. Please describe which side effects patients might 
be willing to accept or tolerate and which would be difficult to accept or 
tolerate)  
 where the treatment has to be used (for example, in hospital rather than 
at home) 
 impact on others (for example, family, friends and employers) 
 financial impact on the patient and/or their family (for example, the cost 
of travel to hospital or paying a carer) 
 any other issues not listed above 
Please list any concerns you have about current NHS treatments in 
England. 
Some treatments only seem to be available to the few whilst others are 
rationed by CCG’s. 
Please list any concerns you have about the treatment being appraised. 
Only those that would apply to any chemotherapy treatment and the possibility 
that unrealistic expectations may be assumed by the patient. 
If you know of any differences in opinion between you and other 
patients or carers about the disadvantages of the treatment being 
appraised, please tell us about them. 
None that I am aware of. 
6. Patient population 
Do you think some patients might benefit more from the treatment than 
others? If so, please describe them and explain why. 
None that I am aware of. 
Do you think some patients might benefit less from the treatment than 
others? If so, please describe them and explain why. 
None that I am aware of. 
7. Research evidence on patient or carer views of the 
treatment  
Are you familiar with the published research literature for the treatment? 
☐ Yes  x No 
If you answered ‘no’, please skip the rest of section 7 and move on to 
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section 8. 
Please comment on whether your experience of using the treatment as 
part of routine NHS care reflects the experience of patients in the clinical 
trials. 
      
Do you think the clinical trials have captured outcomes that are 
important to patients? Are you aware of any limitations in how the 
treatment has been assessed in clinical trials? 
      
If the treatment being appraised is already available in the NHS, are 
there any side effects that were not apparent in the clinical trials but 
have emerged during routine NHS care? 
      
Are you aware of any relevant research on patient or carer views of the 
condition or existing treatments? 
☐ Yes  ☐ No 
If yes, please provide references to the relevant studies. 
      
8. Equality 
NICE is committed to promoting equality of opportunity and eliminating 
discrimination. Please let us know if you think that recommendations 
from this appraisal could have an adverse impact on any particular 
groups of people, who they are and why. 
None 
9. Other issues 
Do you consider the treatment to be innovative? 
x Yes  ☐ No 
If yes, please explain what makes it significantly different from other 
treatments for the condition. 
It is the final treatment available to prolong a reasonable quality of life. 
Is there anything else that you would like the Appraisal Committee to 
consider? 
Nothing 
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10. Key messages 
In no more than 5 bullet points, please summarise the key messages of 
your submission. 
 Men need to know it will continue to be available 
 It’s the last ‘port-of-call’ for those who have run out of options 
 It will give hope to men, their families and carers 
 It will enable men to live a longer ‘normal’ useful life 
 It will reduce pain and other undesirable symptoms and increase and 
prolong a better quality of life 
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1 SUMMARY 
1.1 Critique of the decision problem in the company’s submission  
The company’s submission (CS) to the National Institute for Health and Care Excellence (NICE) 
aimed to provide evidence relating to the clinical and cost effectiveness of cabazitaxel used within its 
licensed indication in combination with prednisolone or prednisone for the treatment of metastatic 
hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing regimen. 
The CS represents an update to a previous submission (TA255), for which the final appraisal 
determination was issued in January 2012. This determination did not recommend cabazitaxel (in 
combination with prednisone or prednisolone) for the treatment of hormone-refractory metastatic 
prostate cancer previously treated with a docetaxel-containing regimen.  The Appraisal Committee 
agreed that cabazitaxel was an effective, life-extending treatment but that the most plausible 
incremental cost effectiveness ratio (ICER) was likely to be above £87,500 per quality-adjusted life 
years (QALYs) gained.  Nevertheless, cabazitaxel was made available via the Cancer Drugs Fund 
(CDF) until its removal in January 2015.  After an agreement had been reached with NHS England, it 
was later re-instated on the CDF in May 2015 as an interim measure pending NICE re-review. 
Following TA255, the terminology for the population for which cabazitaxel is suitable has evolved. A 
distinction has been made between people with mHRPC and metastatic castrate resistant prostate 
cancer (mCRPC), with the latter more likely to respond to subsequent hormonal therapy than the 
former. The main focus of the CS was mCRPC, and the ERG shall refer to the population of interest 
as people with mCRPC. 
 
The NICE final scope identified five relevant comparators: abiraterone in combination with 
prednisone or prednisolone; enzalutamide; mitoxantrone in combination with prednisolone; best 
supportive care (BSC); and radium-223 dichloride for the subgroup of people with bone metastasis 
only (no visceral metastasis). However, the CS only formally considered three comparators omitting 
BSC and radium-223 dichloride. It was assumed by the company that mitoxantrone could be 
considered to be at least equivalent to BSC as there was no demonstrable survival advantage 
associated with using mitoxantrone instead of BSC. The clinical advisors to the Evidence Review 
Group (ERG) concurred with this view. The company did not include radium-223 dichloride as a 
comparator for two main reasons. Firstly, evidence on the clinical effectiveness of cabazitaxel and 
radium-223 dichloride came from different patient populations as radium-223 dichloride is only 
licensed for use in a sub-population of adults who have mCRPC with symptomatic bone metastases 
and no known visceral metastases, and radium-223 dichloride is contra-indicated in people with liver 
metastases.  Secondly, it was not possible to compare radium-223 dichloride with either abiraterone or 
enzalutamide due to differences in the definitions of progression-free survival (PFS) used. However, 
the ERG notes that whilst the reasons provided make comparisons of clinical and cost effectiveness 
difficult, they are not a sufficient rationale for excluding radium-223 dichloride as a comparator. The 
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potential cost-effectiveness of cabazitaxel when compared with radium-223 dichloride is discussed in 
Section 1.7. 
 
The CS addressed the outcomes specified within the NICE final scope. However, one of the outcomes 
was PFS. Whilst the comparison between cabazitaxel and mitoxantrone used the same definition of 
PFS, an alternative definition was required for comparisons with abiraterone and enzalutamide. The 
company noted that analyses using this alternative definition, (radiographic PFS (rPFS)) should be 
interpreted with caution. The ERG agreed with this view. 
 
1.2 Summary of clinical effectiveness evidence submitted by the company 
The CS included a systematic review of the clinical effectiveness literature. The TROPIC trial, which 
forms the main supporting evidence for the intervention, was a phase III, manufacturer-sponsored, 
multi-centre (146 centres in 26 countries including the UK), randomised, open-label, active-controlled 
trial. TROPIC was designed to evaluate the efficacy and safety of cabazitaxel (25mg/m2 intravenously 
over 1 hour, n=378) with mitoxantrone (12mg/m2 intravenously over 15 to 30 minutes, n=377) in 755 
men aged over 18 years with mHRPC, with an Eastern Cooperative Oncology Group (ECOG) 
performance score of 0–2, and with evidence of disease progression during or after treatment with a 
docetaxel-containing regimen.  All patients received oral prednisone 10mg daily (or prednisolone 
where prednisone was unavailable).  Exposure to the study treatment varied between the groups. In 
the cabazitaxel group, patients received a median of six cycles of treatment, of which 10% of cycles 
required a dose reduction, with a median relative dose intensity of 96.1%.  In contrast, patients in the 
mitoxantrone group completed a median of four cycles of treatment, of which 5% of cycles required a 
dose reduction, with a median relative dose intensity of 97.3%.   
 
The CS provided updated results from the TROPIC study.  The results for the whole trial population 
were originally published after a median follow-up of 12.8 months, at which point 513 deaths had 
occurred (final analyses had been planned after 511 deaths). An updated analysis, with extended 
follow-up, was carried out when 585 deaths had occurred.  In this analysis, after a median follow-up 
of 20.5 months, 277 (73.3%) deaths had occurred in the cabazitaxel group compared with 308 
(81.7%) in the mitoxantrone group.  Median overall survival (OS) (a primary efficacy endpoint) was 
15.1 months in the cabazitaxel group and 12.8 months in the mitoxantrone group, thus, cabazitaxel 
plus prednisone or prednisolone was associated with an estimated median OS gain of 2.3 months 
relative to mitoxantrone plus prednisone or prednisolone.  The hazard ratio (HR) was 0.72 (95% 
confidence interval [CI] 0.61 to 0.84, p<0.0001). Median PFS (a composite endpoint defined as time 
to progression as measured by a rise in prostate-specific antigen (PSA) level, tumour progression, 
pain progression or death) was significantly greater statistically in the cabazitaxel group (2.8 months) 
than in the mitoxantrone group (1.4 months) with an estimated 25% reduction in the risk of 
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progression (HR 0.75, 95% CI: 0.65 to 0.87, p=0.0002).  The CS did not report any results for the 
following secondary outcomes and no explanations were provided for these omissions: tumour 
response; time to tumour progression; PSA response; PSA progression; pain response; and pain 
progression.  Data on health related quality-of-life were not collected in the TROPIC study.   
 
In NICE TA255, the Appraisal Committee considered a subgroup of patients with an ECOG 
performance score of 0 or 1 and who had received at least 225 mg/m2 of prior docetaxel to be the most 
appropriate population to receive cabazitaxel in UK clinical practice. Patients with an ECOG 
performance score of 2 would not be deemed not fit enough to tolerate further chemotherapy and 
patients would need to receive at least 225 mg/m2 of docetaxel to gain the full benefit of first-line 
treatment before going on to receive cabazitaxel.  In this post-hoc subgroup analysis (representing 
83.7% [632/755] of the total TROPIC trial population), the median OS was 15.6 months in the 
cabazitaxel group and 13.4 months in the mitoxantrone group with a HR of 0.69 (95% CI 0.57 to 0.82, 
p<0.001) corresponding to a 31% reduction in the risk of death. Thus, cabazitaxel plus prednisone or 
prednisolone was associated with an estimated median OS gain of 2.2 months relative to mitoxantrone 
plus prednisone or prednisolone.  A statistically significant improvement in median PFS was also 
observed.  PFS was 2.8 months in the cabazitaxel group and 1.4 months in the mitoxantrone group 
(HR 0.76, 95% CI: 0.65 to 0.89, p=0.001) corresponding to a 24% reduction in the risk of 
progression.  
 
In the TROPIC study, treatment emergent adverse events (AEs) of grade ≥3 occurred in 213/371 
(57.4%) patients in the cabazitaxel group and 146/371 (39.4%) patients in the mitoxantrone group.  
The proportion of patients withdrawing from study treatment permanently due to any treatment 
emergent AE was higher in the cabazitaxel group (18.3%) compared with the mitoxantrone group 
(8.4%).  The most common AEs associated with cabazitaxel of grade ≥3 requiring medical 
intervention (i.e. dose reduction, dose modifications, use of supportive treatment or treatment 
discontinuation) compared with mitoxantrone were: neutropenia and its complications (neutropenia: 
21% versus 7.3%; febrile neutropenia, 7.3% versus 1.6%); asthenic conditions (asthenia: 4.6% versus 
2.4%; fatigue: 4.9% versus 3.0%); and gastrointestinal toxicity (diarrhoea: 6.2% versus 0.3%; nausea: 
1.9% versus 0.3%), respectively.  A similar frequency of AEs were also observed in the subgroup of 
patients with an ECOG performance score of 0 or 1 and who had received at least 225 mg/m2 of prior 
docetaxel.   
 
Deaths within 30 days of the last dose of study drug in the TROPIC study were more common with 
cabazitaxel (5%) than mitoxantrone (2%).  The most common causes of such deaths were neutropenia 
and its complication in patients receiving cabazitaxel (accounting for seven deaths in the cabazitaxel 
group compared with one death in the mitoxantrone group), and disease progression in patients 
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receiving mitoxantrone (accounting for six deaths in the mitoxantrone group compared with zero 
deaths in the cabazitaxel group).  Additional safety data, in the post-docetaxel setting, from 112 
patients with mCRPC treated with cabazitaxel in the UK Early Access Programme (EAP) (which is 
part of an international phase IIIB/IV study with participants from 12 UK cancer centres) indicate 
lower rates of grade 3 or 4 treatment-emergent AEs: neutropenia, 9.8%; diarrhoea, 4.5%; and cardiac 
toxicity (0%), and that cabazitaxel is generally well tolerated with manageable toxicity.  Seven 
patients (6.3%) experienced neutropenic sepsis during treatment in the UK EAP; however, none of 
these patients had received prophylactic granulocyte-colony stimulating factor. 
 
In the absence of any direct head-to-head randomised controlled trials (RCTs) comparing cabazitaxel 
and other second-line agents for the treatment of mCRPC, a network meta-analysis (NMA) was 
conducted (termed as an indirect treatment comparison by the company).  The NMA conducted by the 
company compared cabazitaxel, abiraterone, enzalutamide, mitoxantrone and BSC for the following 
outcomes: OS; rPFS; and selected AEs.  The company only considered three studies relevant to the 
decision problem and these were included in the NMA.  The TROPIC study compared cabazitaxel 
plus prednisone or prednisolone with mitoxantrone plus prednisone or prednisolone; the AFFIRM 
study compared enzalutamide plus placebo with placebo with or without prednisone; and the COU-
AA-301 study compared abiraterone plus prednisone with prednisone plus placebo.  For the purpose 
of this analysis, the CS noted that the three control arms from these trials were considered equivalent 
for the OS endpoint in the previous NICE Single Technology Appraisals (STAs) for cabazitaxel 
(TA255), abiraterone (TA259) and enzalutamide (TA316).  The CS provided evidence to suggest that 
mitoxantrone does not improve survival and therefore a regimen comprising mitoxantrone plus 
prednisone together with BSC can be considered equivalent to BSC alone. The ERG’s clinical 
advisors concurred with this view.  As no consistent definition of PFS was employed across the 
pivotal trials for cabazitaxel, abiraterone and enzalutamide, the rPFS endpoint (defined as the time 
from randomisation to the first occurrence of: tumour progression [based on RECIST criteria] or 
death due to any cause) was analysed to facilitate a more coherent comparison across the three 
studies.  Based on results from the fixed effects NMA, the CS showed that the treatment effects for 
cabazitaxel, abiraterone and enzalutamide are broadly similar for OS. With regards to rPFS the results 
of the fixed effects NMA indicate that the disease appears to progress more slowly when patients are 
treated with enzalutamide rather than when patients are treated with cabazitaxel or abiraterone. For 
AE outcomes, the fixed effect NMA indicates a significant increase in occurrences of anaemia and 
nausea for cabazitaxel compared with BSC, abiraterone and enzalutamide. For diarrhoea there is a 
statistically significantly increase in AEs for cabazitaxel compared with BSC and abiraterone. 
 
86 
 
1.3 Summary of the ERG’s critique of clinical effectiveness evidence submitted 
The systematic review process followed by the company was reasonably comprehensive. Despite 
minor limitations in the company’s search strategy, the ERG is confident that all relevant studies of 
cabazitaxel in combination with prednisone or prednisolone were included in the CS, including data 
from ongoing or planned studies.  The specified inclusion and exclusion criteria were (mostly) 
appropriate and generally reflect the decision problem.  However, studies that included radium-223 
dichloride were excluded in the CS for the reasons described in Section 1.1.  Nevertheless, the ERG’s 
clinical advisors and the expert submissions indicate that radium-223 dichloride is a valid treatment 
option for people with symptomatic bone metastases and no known visceral metastases.  Moreover, 
preliminary NICE guidance recommends radium-223 dichloride as an option for treating adults with 
hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, 
only if: they have had treatment with docetaxel, and the company provides radium-223 dichloride 
with the discount agreed in the confidential patient access scheme.  The validity assessment tool used 
to appraise the included studies was considered appropriate by the ERG. 
 
The CS includes the only RCT of cabazitaxel plus prednisone or prednisolone which is known to have 
been undertaken in the relevant population. This study, the TROPIC study, is an open-label study and 
is therefore susceptible to bias.  In the guidance issued by NICE for cabazitaxel in 2011 (TA255) the 
Appraisal Committee accepted that, ‘as an open-label study, TROPIC was susceptible to bias in the 
subjective outcomes included in progression-free survival, such as pain and deterioration in 
symptoms’.  In addition, the assessment of clinical AEs is susceptible to bias because of lack of 
blinding, although the assessment of laboratory AEs is unlikely to have been affected. In the TROPIC 
trial, cabazitaxel was associated with higher rates of neutropenic complications (febrile neutropenia 
and infection), renal failure, and cardiac toxicity compared with mitoxantrone, however, after 
consideration of additional evidence (provided by the company during the consultation process) for 
TA255, the Appraisal Committee concluded that ‘…there is no evidence of additional risk other than 
that included in the SPC [Summary of Product Characteristics]’.  Moreover, as noted earlier, 
additional safety data from post-docetaxel patients with mCRPC treated with cabazitaxel in the UK 
EAP suggest that cabazitaxel is generally well tolerated with manageable toxicity. 
 
In the company’s NMA, the ERG considered that the results presented may have underestimated the 
uncertainty in treatment effects since fixed effects models were used, despite clear evidence of 
heterogeneity amongst the trials included in the network. Results from an amended random effects 
model, conducted by the ERG, confirm the finding of broadly similar treatment effects for OS but 
also indicate that no active treatments are significantly more effective than other active treatments for 
rPFS. Furthermore, given the use of HRs, the relative treatment effects are assumed to be constant 
over time, with no justification for this assumption. The ERG consider that the NMA results presented 
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by the company should be interpreted with caution since they were based on an assumption of no 
between-study variance (using a fixed effects model) and because of concerns related to differences in 
patient populations between the trials and in the assumption that control treatments are exchangeable. 
 
1.4 Summary of cost effectiveness submitted evidence by the company 
The manufacturer supplied a de novo cohort Markov model constructed in Microsoft Excel©. Three 
states are modelled: stable disease; progressive disease; and death. All patients begin in the stable 
disease state, from which transitions to progressive disease or death are possible. Following 
progression the only transition possible is to death, which is an absorbing state. 
 
The main comparison considered by the company was between cabazitaxel and mitoxantrone. 
Effectiveness data for the main comparison came from the subgroup of the TROPIC trial, as described 
in Section 1.2. In scenario analyses the manufacturer compared cabazitaxel with abiraterone and 
separately with enzalutamide. As there were no trials comparing cabazitaxel with abiraterone or 
enzalutamide, effectiveness data for the two scenario analyses was taken from an NMA performed by 
the company, which used the entire trial populations. Health-related quality of life was incorporated 
by attaching utility values to each of the health states; evidence from these was taken from the 
company’s UK EAP. Evidence on resource use came from the TROPIC trial, supplemented by both 
expert clinical opinion and a UK clinical audit. Unit costs came from standard national sources. List 
prices were used for mitoxantrone, abiraterone and enzalutamide as directed by NICE, although 
commercial in confidence PASs are in place for abiraterone and enzalutamide. 
 
In their base-case analysis the company estimated a probabilistic cost per QALY gained of £50,682 
when comparing cabazitaxel with mitoxantrone. Based on scenario analyses, use of cabazitaxel was 
estimated to be both cheaper and more effective than use of abiraterone. Compared with 
enzalutamide, cabazitaxel was estimated to be cheaper but less effective, resulting in an ICER of 
£212,038 for enzalutamide compared with cabazitaxel. 
 
1.5 Summary of the ERG’s critique of cost effectiveness evidence submitted 
The ERG notes that the company did not consider radium-223 dichloride as a comparator despite its 
inclusion in the NICE final scope. However, for people with mCRPC, symptomatic bone metastases 
and no known visceral metastases, radium-223 dichloride is a valid treatment option. Hence excluding 
it leads to uncertainty regarding the cost-effectiveness of cabazitaxel. The comparison between 
cabazitaxel and mitoxantrone is relevant when either abiraterone or enzalutamide are used in the pre-
chemotherapy setting (as neither would then be a comparator for cabazitaxel). The ERG notes that for 
the alternative setting of using either abiraterone or enzalutamide post-chemotherapy the company did 
not perform a fully incremental analysis: such an analysis should also include BSC. Radium-223 
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dichloride is a valid comparator (for the indicated sub-group) in both settings. The ERG notes that due 
to these omissions there is uncertainty in the cost effectiveness of cabazitaxel in both settings, and that 
it is unclear which setting represents standard National Health Service practice. 
 
The ERG agrees with the company that the results of the NMA (and hence the cost-effectiveness 
results when cabazitaxel is compared with enzalutamide or abiraterone) should be viewed with 
caution.  
 
1.6 ERG commentary on the robustness of evidence submitted by the company  
1.6.1 Strengths 
The company undertook a reasonably comprehensive systematic review (no major limitations were 
noted) of cabazitaxel (in combination with prednisone or prednisolone) in patients with mCRPC 
previously treated with a docetaxel-containing regimen.  The TROPIC study was a large, multicentre 
RCT of reasonable methodological quality (with some limitations, as noted in Section 1.3) that 
measured a range of clinically relevant outcomes.  
 
The conceptual model used appears robust and transparent and contained the functionality to assess 
the impact of changing parameters and structural uncertainties on the ICER. A number of built-in 
alternative scenarios were included. 
 
1.6.2 Weaknesses and areas of uncertainty 
The key area of uncertainty in the clinical evidence concerned the absence of any head-to-head RCTs 
comparing cabazitaxel with other second-line agents such as abiraterone or enzalutamide for the 
treatment of mCRPC post docetaxel.  In addition, there is no high quality evidence from prospective 
controlled trials to guide optimum sequencing of these agents after docetaxel treatment in patients 
with mCRPC and there is uncertainty over the optimal dose and frequency of cabazitaxel 
administration in men with mCRPC.  Results from the PROSELICA trial (a study examining the 
dosage of cabazitaxel [either 25 or 20 mg/m2] to optimise treatment benefits in relation to potential 
toxicity) are expected to be reported within the next 12 months. 
 
Indirect comparisons between the treatments are subject to increased uncertainty due to concerns over 
differences between patient populations and exchangeability of control treatments. Results of the 
fixed effects NMA conducted by the company are likely to underestimate the uncertainty in treatment 
effects. Furthermore, the relative treatment effects are assumed to be constant over time, with no 
justification for this assumption. 
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Within the CS the clinical effectiveness of radium-223 dichloride and its cost effectiveness when 
compared with cabazitaxel were not formally considered. As radium-223 dichloride is a comparator 
for the subgroup of people with bone metastasis and no known visceral metastases, this exclusion 
leads to uncertainty regarding the cost-effectiveness of cabazitaxel. 
 
Cost-effectiveness results were sensitive to the utility values that should be assigned to progressive 
disease, and to the choice of parametric model used for extrapolating the clinical effectiveness data. It 
is unclear how resolving these uncertainties would impact on the cost-effectiveness of cabazitaxel. 
 
1.7 Summary of exploratory and sensitivity analyses undertaken by the ERG 
The probabilistic base-case ICER presented in the CS comparing cabazitaxel with mitoxantrone was 
£50,682. The ERG made six changes to the company’s base case. These were: the use of Electronic 
market information tool prices in preference to British National Formulary prices for generic drug 
costs (including mitoxantrone); modelling vial wastage; not modelling discontinuation for reasons 
other than disease progression; not modelling a reduced disutility in the last three months of 
progressive disease; basing post-second line treatment resource use from a UK audit for all 
treatments; and using results from the NMA adjusted by the ERG. When taken in isolation each of 
these changes led to an increase in the ICER, with the largest increase attributable to the modelling of 
vial wastage. The combined effect of these changes was to increase the probabilistic ICER from 
£50,682 to XXX. If vial wastage is not modelled then the probabilistic ICER is £54,126. 
 
The ERG also performed exploratory analyses regarding the long-term modelling of effectiveness 
data and using different utility values for progressive disease. It was noted that these uncertainties led 
to both increases and decreases in the base-case ICER depending on the assumptions made. 
 
The ERG used the results from the NMA adjusted by the ERG to assess the cost-effectiveness of 
cabazitaxel when compared to BSC, abiraterone and enzalutamide. The ICER comparing 
enzalutamide with cabazitaxel was £141,363 when vial wastage was modelled and £155,014 when it 
was not modelled. Clinical advice given to the ERG suggests that vial wastage would be likely. 
Abiraterone was extendedly dominated by enzalutamide irrespective of how vial wastage was 
modelled. The ICER comparing cabazitaxel with BSC was £109,325 when vial wastage was modelled 
and £88,766 when it was not modelled: this was greater than estimated from the direct comparison 
with mitoxantrone and may indicate the inappropriateness of assuming proportional hazards. Analyses 
using the PAS-adjusted prices of abiraterone and enzalutamide, along with sensitivity analyses, are 
provided in a confidential appendix prepared for the Appraisal Committee only. 
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The ERG noted that, whilst it was not possible to include radium-223 dichloride in the cost-
effectiveness analyses within the timelines of an STA, this comparator appeared to have similar 
clinical efficacy to cabazitaxel.xxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxx. A comparison with the PAS price of radium-223 dichloride is provided in a 
confidential appendix. 
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2 BACKGROUND  
This report provides a review of the evidence submitted by the company for cabazitaxel for hormone-
relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen. 
Cabazitaxel is licensed within the EU for use in combination with prednisone or prednisolone for the 
treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated 
with a docetaxel-containing regimen.1  
 
Cabazitaxel was previously appraised as part of the NICE Single Technology Appraisal (STA) 
process (TA255), with the final appraisal determination issued in January 2012.2 The Committee 
considered that the most plausible ICER was likely to be above £87,500 per quality-adjusted life years 
(QALYs) gained, and so did not recommend treatment with cabazitaxel. The Committee noted that 
key uncertainties related to the company's modelling of clinical effectiveness data and the utility 
values used. Cabazitaxel was available via the National Cancer Drugs Fund (CDF) until its removal in 
January 2015. It was later re-instated on the CDF in May 2015. 
 
2.1 Critique of the company’s description of underlying health problem 
The company’s submission (CS3) provides an appropriate overview of prostate cancer noting that 
prostate cancer can be heterogeneous with regards to both treatment response and the types of disease 
progression observed. Prostate cancer is the most common form of cancer in men in the UK, and the 
second most common cause of cancer death. There were 41,736 incident cases, and 10,837 deaths 
from prostate cancer in the UK in 2012, the most recent year for which data are available.4 
 
For metastatic prostate cancer (cancer that has spread to other parts of the body), there is a distinction 
between mHRPC and metastatic castrate resistant prostate cancer (mCRPC).5 Tumours that progress 
with castrate levels of testosterone (typically taken to be lower than 50 ng per deciliter6) are classified 
as mCRPC; tumours that progress after conventional luteinising hormone-releasing hormone (LHRH) 
and newer hormone therapies such as abiraterone and enzalutamide are classified as mHRPC.  First 
line therapy is typically androgen deprivation therapy or LHRH with patients with mCRPC more 
likely to respond to further hormonal therapies than people with mHRPC.5 As the advanced hormonal 
therapies abiraterone and enzalutamide were not available at the time of the company’s original 
submission, the terminology used for TA255 was people with mHRPC. As terminology has 
subsequently evolved, for the purposes of this report, the ERG shall refer to the population of interest 
as people with mCRPC. 
 
There are no published data for the incidence of mCRPC. However, a report from the National Cancer 
Intelligence Network7 reveals that of the 36,287 diagnoses in England in 2013, 5836 (16%) were 
classified as Stage 4 (or metastatic) cancers, with a further 6661 diagnoses (18%) having an unknown 
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stage. As mCRPC represents a sub-group of stage 4 cancers, the incidence of mCRPC will be less 
than 12,497 (if all of the unknown stages were stage 4). Both clinical advisors to the ERG and the 
company noted that a large proportion of prostate cancer deaths will be amongst people with mCRPC 
– in England there were 9133 deaths attributable to prostate cancer in 2012.4 
 
The company estimates that there are 6,147 people with mCRPC, a value that appears plausible given 
the calculations previously detailed. The company further estimate that, of people with mCRPC, 50% 
would receive first-line treatment with docetaxel, and of this group, and further 55% (therefore 27.5% 
of the mCRPC group) would be eligible to receive second-line chemotherapy. These two proportions 
are based on market research performed by the company, and result in an estimated 3073 people 
receiving docetaxel of whom 1690 people who would be eligible for cabazitaxel. In comparison, data 
from the CDF reveal that there were 805 notifications for cabazitaxel in 2014/158, whilst data from 
the Systemic Anti-Cancer Therapy Dataset for the calendar year 2014 record that (excluding clinical 
trials) 1,920 people received docetaxel and 551 people received cabazitaxel.9  
 
The company considered life expectancy for people with mCRPC for both people receiving first line 
docetaxel and for people receiving post-docetaxel treatment. In the former case, the company cite a 
systematic review which calculated a median overall survival (OS) of 19 months (inter-quartile range: 
17 to 20 months) based on 11 trials.10 In the post-docetaxel setting, control-arm data from the pivotal 
trials for cabazitaxel, abiraterone, enzalutamide and radium-223 dichloride showed that median OS 
ranged from 11.2 months to 13.6 months.11, 12,13, 14 
 
2.2 Critique of the company’s overview of current service provision  
A description of the company’s overview of current service provision is provided below, followed by 
the ERG’s critique of this overview.  
 
For people with mCRPC, the company detailed two possible clinical care pathways under which 
patients may be eligible for cabazitaxel in England. These two pathways are re-produced from the CS 
in   
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Figure 1. The key difference between the two pathways is where abiraterone or enzalutamide is used: 
either in the pre- chemotherapy setting (left-hand side of   
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Figure 1) or post- chemotherapy (right-hand side). In both instances the chemotherapy was assumed 
to be docetaxel. At the time of the CS, use of either abiraterone or enzalutamide in the pre-
chemotherapy setting was not approved by the National Institute for Health and Care Excellence 
(NICE), and was instead funded by the CDF. The two advanced hormonal therapies both had 
however, NICE approval in the post-chemotherapy setting. The company noted that sequential use of 
abiraterone and enzalutamide is not allowed in the CDF, and that due to concerns about cross-
resistance only one of the two therapies is likely to be used in clinical practice. 
 
Cabazitaxel is licensed only following the use of a docetaxel containing regimen. In the pathway 
where abiraterone and enzalutamide are used in the pre-chemotherapy setting this would mean that 
only best supportive care (BSC) is an alternative treatment option to cabazitaxel. Where abiraterone 
and enzalutamide are used in the post-chemotherapy setting these interventions are also comparators 
in addition to BSC. 
 
The company denote the use of abiraterone or enzalutamide in the pre-chemotherapy as standard 
(established) National Health Service (NHS) practice. In response to clarification question A2, the 
company justified this definition of standard NHS practice based on market research undertaken on 
behalf of Sanofi by Kantar Health. The most recent figures from this market research were for the 
time period 26th June 2015 to 4th August 2015. There were 345 people with mCRPC receiving 1st 
line therapy. Abiraterone and enzalutamide together accounted for 66% of these therapies, with 
docetaxel comprising 31%. 
 
For the purposes of their submission, the company assumed that use of mitoxantrone was equivalent 
to BSC. In the previous submission to the NICE for cabazitaxel (TA255), this assumption was 
deemed by the ERG to have clinical validity as mitoxantrone does not provide a proven extension to 
life for people with mCRPC.15 For this submission, based on the advice provided by the clinical 
advisors to the ERG, the ERG believes this assumption to be reasonable. 
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Figure 1: Clinical pathways of care for mCRPC (reproduced from Figure 3, p40, CS)a 
 
 
 
a The CS does not provide a footnote for ‘*’ in the figure 
 
The ERG is satisfied with the company’s argument that sequential use of abiraterone and 
enzalutamide would not occur in clinical practice. However, there are a number of concerns with the 
company’s description of existing NHS care pathways. These concerns are described below. 
 
Is use of abiraterone and enzalutamide in the pre-chemotherapy setting standard NHS practice? 
The company use the results of market research, which shows that 66% of patients receive either 
abiraterone or enzalutamide in the pre-chemotherapy setting, to justify denoting this as standard NHS 
practice. However, the ERG does not believe that this evidence represents suitable justification for the 
purposes of this appraisal. 
 
This appraisal is concerned with potential clinical pathways that include the use of cabazitaxel. The 
market research provided by the company does not include evidence about the number of people 
treated with first-line abiraterone or enzalutamide who are also eligible to receive docetaxel and then 
cabazitaxel. In other words, an unknown proportion of the people receiving first line therapy with 
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abiraterone or enzalutamide will be receiving these because they are unsuitable for chemotherapeutic 
treatment. 
 
The ERG also notes that there are ongoing NICE appraisals of both abiraterone and enzalutamide in 
the pre-docetaxel setting. The results of these appraisals may influence which of the two pathways 
described in the CS becomes NHS standard practice in the future. 
 
Would patients be treated with cabazitaxel before they are treated with abiraterone or enzalutamide? 
When abiraterone or enzalutamide are used in the post-chemotherapy setting, the company suggests 
that these are potential treatment alternatives to cabazitaxel. However, clinical advisors to the ERG, 
along with the expert submission submitted by Dr Andrew Goddard on behalf of the 
NCRI/RCP/RCR/ACP suggested that, for the majority of patients, cabazitaxel would only be 
considered following treatment with one of the advanced hormonal therapies.16 This view is also 
supported by the recommendations of the St Gallen Advanced Prostate Cancer Consensus 
Conference.17 
 
However, the ERG also acknowledges that whilst use of either advanced hormonal therapy may result 
in fewer side effects (and so be preferred to cabazitaxel), there is uncertainty with regards to whether 
abiraterone and enzalutamide are more clinically effective and more cost-effective than cabazitaxel. 
These considerations of effectiveness and cost-effectiveness are discussed further in sections 4.3 and 
5.2 respectively. 
 
What is the role of radium-223 dichloride?   
The company did not include radium-223 dichloride in their clinical pathways of care, nor did it 
include it in their economic evaluation. However, radium-223 dichloride was included in the final 
scope issued by NICE as a comparator. Radium-223 dichloride has European Union approval for 
people with mCRPC with symptomatic bone metastases and no known visceral metastases. An 
analysis for this subgroup was also included in the final scope, conditional on the available evidence. 
Clinical advisors to the ERG, along with the expert submission submitted by Dr Andrew Goddard on 
behalf of the NCRI/RCP/RCR/ACP suggested that radium-223 dichloride is a valid treatment option 
for people with mCRPC who had previously received docetaxel.16 
 
In response to clarification question A1, the company defended their decision to exclude radium-223 
dichloride on the basis that there was not sufficient evidence to perform a comparison. This is 
discussed in further detail in Section 3.3. However, irrespective of whether or not there is available 
evidence to conduct a meaningful comparison with radium-223 dichloride, this technology represents 
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a valid treatment option for people with mCRPC, and should have been included in the company’s 
overview of current service provision. 
 
Given the above considerations, an alternative overview of current clinical care pathways provided by 
clinical input is depicted in Figure 2. The ERG believes that there is insufficient available evidence to 
denote which use of the advanced hormonal agents (either pre-chemotherapy or post-chemotherapy) 
represents standard NHS practice. Further, whilst cabazitaxel is likely to be currently used after either 
of abiraterone or enzalutamide (in the post-chemotherapy setting) due to its worse side-effect profile, 
the clinical effectiveness and cost-effectiveness of this pathway need to be established.  
 
Figure 2: Simplified clinical pathway of care illustrating the comparators for cabazitaxel 
 
ADT: androgen deprivation therapy. LHRH: Luteinising hormone-releasing hormone 
 
It is noted that treatment for mCRPC is an area of active research, and so the current clinical pathways 
may change in the future. For example, clinical advisors to the ERG noted that results from the 
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy 
(STAMPEDE) trial had been presented at a recent conference, with results suggesting that use of 
docetaxel (in addition to current standards of care) should become routine amongst men with newly-
diagnosed metastatic prostate cancer.18 
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3 CRITIQUE OF THE COMPANY’S DEFINITION OF DECISION PROBLEM 
 
Table 1 summarises the population, intervention, comparators and outcomes specified within the 
company’s decision problem. These are discussed and critiqued in the following sections. 
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Table 1: The company’s decision problem (based on Table 5, p23-26, CS) 
 Final scope issued by NICE Decision problem addressed in 
the CS 
ERG comments 
Population People with hormone-relapsed metastatic 
prostate cancer previously treated with a 
docetaxel-containing regimen. 
People with hormone refractory 
relapsed metastatic prostate cancer 
previously treated with a docetaxel-
containing regimen with or without 
prior treatment with abiraterone or 
enzalutamide. 
The company included additional wording to 
emphasise that cabazitaxel has two different sets of 
comparators, depending on where in the clinical 
pathway of care abiraterone or enzalutamide are 
used. This is discussed further in Section 2.2 of the 
ERG report. 
There is also a potential difference between people 
with hormone refractory and castrate resistant 
prostate cancer, as discussed in Section 2.1 of the 
ERG report. 
Intervention Cabazitaxel in combination with prednisone or 
prednisolone 
Cabazitaxel in combination with 
prednisolone (or prednisone) 10 
mg/day up to a maximum of ten 
cycles 
In the TROPIC trial11 , which provides evidence on 
the effectiveness of cabazitaxel, cabazitaxel was 
limited to a maximum of ten cycles, for consistency 
with mitoxantrone. However, the licence for 
cabazitaxel does not restrict its use in clinical 
practice. 
Comparators  Abiraterone in combination with 
prednisone or prednisolone 
 Enzalutamide 
 Mitoxantrone in combination with 
Best supportive care represented by 
mitoxantrone. 
 
Abiraterone and enzalutamide in 
The company assumes that use of mitoxantrone 
may be considered as equivalent to best supportive 
care. The ERG believes that this claim has clinical 
validity. 
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prednisolone (not licensed in the UK for 
this indication) 
 Best supportive care (this may include 
radiotherapy, radiopharmaceuticals [apart 
from radium-223 dichloride], analgesics, 
bisphosphonates, and corticosteroids) 
For people with bone metastasis only (no 
visceral metastasis) 
 Radium-223 dichloride (NICE guidance is 
in development, funded by the CDF in the 
interim) 
the context where these agents were 
not used prior to docetaxel. This 
was deemed alternative practice in 
the NHS. 
 
 
The company notes that abiraterone and 
enzalutamide are only valid when they are used in 
the post-chemotherapy setting. However, the ERG 
does not believe that there is sufficient evidence to 
justify labelling this as ‘alternative practice’. 
 
The company did not consider radium-223 
dichloride as a comparator for its indicated sub-
group. This was primarily justified by a lack of 
comparative evidence. This is discussed further in 
Section 3.3 of the ERG report. 
Outcomes The outcome measures to be considered 
include: 
 Overall survival (OS) 
 Progression-free survival (PFS) 
 Response rate 
 Adverse effects of treatment 
 Health-related quality of life. 
 Primary outcome: OS 
 Secondary outcomes:  
o PFS 
o Radiographic PFS (rPFS) 
o Adverse effects of treatment 
o Health-related quality of life 
o Response rate. 
No comments 
 
Economic 
analysis 
The reference case stipulates that the cost 
effectiveness of treatments should be 
expressed in terms of incremental cost per 
quality-adjusted life year. 
As the final scope issued by NICE.  
The availability of a Patient Access 
Scheme (PAS) for cabazitaxel was 
included in the analysis. 
The ERG provides analyses based on the PAS 
prices for abiraterone and enzalutamide in a 
confidential appendix.  
The ERG provides exploratory analyses comparing 
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The reference case stipulates that the time 
horizon for estimating clinical and cost 
effectiveness should be sufficiently long to 
reflect any differences in costs or outcomes 
between the technologies being compared. 
Costs will be considered from an NHS and 
Personal Social Services perspective. 
The availability of any patient access schemes 
for the intervention or comparator technologies 
should be taken into account. 
The scenario analysis including 
abiraterone and enzalutamide were 
based on NHS list prices, as 
requested by NICE, as the PAS 
arrangements are confidential. 
cabazitaxel with radium-223 dichloride (at list 
price) in this report, and compared with radium-223 
dichloride (at a PAS price in a confidential 
appendix). 
Other 
considerations 
If evidence allows the following subgroups 
will be considered. 
 People who have received abiraterone 
or enzalutamide 
 People with bone metastasis only (no 
visceral metastasis). 
 
The subgroup of people who have 
received abiraterone or 
enzalutamide was considered by the 
company. 
 
The subgroup of people with bone 
metastasis only (no visceral 
metastasis) was not considered by 
the company. 
For the subgroup of people with bone metastasis 
only (no visceral metastasis) one of the relevant 
comparators is radium-223 dichloride. The 
exclusion of this comparator is discussed further in 
Section 3.3 of the ERG report. Exploratory analyses 
consider the cost-effectiveness of cabazitaxel 
compared with radium-223 dichloride. 
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3.1 Population 
The patient population described in the final scope19 is “People with hormone-relapsed metastatic 
prostate cancer previously treated with a docetaxel-containing regimen”. The main source of clinical 
evidence used by the company is the TROPIC trial.11 A sub-population of this trial is considered in 
the CS with people who received an insufficient prior dose of docetaxel (less than 225mg/m2) or who 
had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 were excluded. 
These exclusions were justified by the company on the basis that the sub-population better reflects 
patients who are likely to be treated in clinical practice. The ERG believes that this is an appropriate 
population, although it is noted that data from the company’s UK Early Access Programme (EAP) 
indicate that a small proportion of people who receive cabazitaxel had a PS of 2 (7/112; 6.3%). 
 
3.2 Intervention 
The intervention under consideration in the CS is cabazitaxel, which matches the intervention 
described in the final scope. Cabazitaxel is licensed within the EU for use in combination with 
prednisone or prednisolone for the treatment of patients with mHRPC previously treated with a 
docetaxel-containing regimen.20 
 
It is marketed in the UK by Sanofi under the trade name Jevtana® and supplied as a pack containing 
one 1.5 ml vial of liquid cabazitaxel concentrate (60mg of cabazitaxel diluted in polysorbate 80 and 
citric acid), and one vial containing 4.5 ml of solvent. Dosing is by body surface area (BSA); the 
recommended dose is 25 mg/m2, and some patients may require more than one pack per cycle of 
treatment. Unopened vials of cabazitaxel have a shelf-life of two years but, after opening, the 
concentrate and solvent should be used immediately.  
 
Cabazitaxel is administered as a 60-minute intravenous infusion every three weeks. Patients should be 
observed closely for infusion-related hypersensitivity reactions, especially during the first and second 
infusions. Dose modifications should be made if patients experience specified adverse reactions, and 
treatment should be discontinued if the patient continues to experience any of those reactions at a dose 
of 20 mg/m2 (for details, see   
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Table 2).  
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Table 2: Recommended dose modifications for adverse reactions in patients treated with 
cabazitaxel20 
Adverse reaction Dose modification 
Prolonged (longer than 1 week) grade >3 
neutropenia despite appropriate treatment 
including Granulocyte-Colony Stimulating 
Factors 
Delay treatment until neutrophil count is >1,500 
cells/mm3, then reduce cabazitaxel dose from 25 
mg/m2 to 20 mg/m2 
Febrile neutropenia or neutropenic infection Delay treatment until improvement or resolution, 
and until neutrophil count is >1,500 cells/mm3, 
then reduce cabazitaxel dose from 25 mg/m2 to 
20 mg/m2 
Grade >3 diarrhoea or persisting diarrhoea 
despite appropriate treatment, including fluid and 
electrolytes replacement 
Delay treatment until improvement or resolution, 
then reduce cabazitaxel dose from 25 mg/m2 to 
20 mg/m2 
Grade >2 peripheral neuropathy Delay treatment until improvement, then reduce 
cabazitaxel dose from 25 mg/m2 to 20 mg/m2 
 
 
To minimise the risk and severity of infusion-related hypersensitivity reactions, the following 
premedication regimen should be administered at least 30 minutes prior to each dose of cabazitaxel: 
 antihistamine (dexchlorpheniramine 5 mg or diphenhydramine 25 mg or equivalent) 
 corticosteroid (dexamethasone 8 mg or equivalent) 
 H2 antagonist (ranitidine or equivalent).  
 
To minimise the risk of neutropenia and its complications, complete blood counts should be 
monitored on a weekly basis during the first cycle of cabazitaxel, and before each subsequent cycle, 
so that if necessary the dose can be adjusted.  
 
Anti-emetic prophylaxis is recommended and can be given orally or intravenously as needed. Primary 
prophylaxis with Granulocyte-Colony Stimulating Factors (G-CSF) should be considered in patients 
with clinical features which put them at high risk of increased complications from prolonged 
neutropenia (these include being older than 65 years, poor PS, previous episodes of febrile 
neutropenia, extensive prior radiation ports, poor nutritional status, or other serious comorbidities). 
  
Cabazitaxel should not be given to patients with hepatic impairment. Patients with moderate or severe 
renal impairment or end stage renal disease should be treated with caution and monitored carefully 
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during treatment. Co-administration with strong CYP3A inhibitors or strong CYP3A inducers should 
be avoided.  
 
Oral prednisone or prednisolone, at a dose of 10 mg/day, should be taken throughout the course of 
treatment with cabazitaxel. Prednisone is a synthetic corticosteroid which is converted in the liver into 
the corticosteroid prednisolone. In the UK, prednisone is only licensed for use in moderate to severe 
rheumatoid arthritis, whereas prednisolone is licensed for use in a range of conditions. Patients who 
are medically castrated may also require ongoing therapy with LHRH agonists.  
 
The licensed indication states that the use of cabazitaxel should be limited to units specialised in the 
administration of cytotoxic drugs, and that it should only be administered under the supervision of a 
qualified physician experienced in the use of anti-cancer chemotherapy and with facilities and 
equipment available to treat serious hypersensitivity reactions. 
 
3.3 Comparators 
The NICE final scope19 listed five comparators for cabazitaxel in combination with prednisone or 
prednisolone. These were: 
 Abiraterone in combination with prednisone or prednisolone 
 Enzalutamide 
 Mitoxantrone in combination with prednisolone 
 Best supportive care (this may include radiotherapy, radiopharmaceuticals [apart from 
radium-223 dichloride], analgesics, bisphosphonates, and corticosteroids) 
 Radium-223 dichloride for people with bone metastasis only (no visceral metastasis) 
 
Of these comparators, mitoxantrone is not licensed in the UK for this indication, whilst NICE 
guidance is in development for radium-223 dichloride. 
 
Within their submission the company argued that mitoxantrone could be considered equivalent to 
BSC, as there is no available evidence that it has any additional impact on survival. The ERG’s 
clinical advisors concurred with this view. 
 
The company did not consider radium-223 dichloride to be a valid comparator, and hence excluded it 
from their economic evaluation (nor did they discuss its clinical effectiveness). In response to 
clarification question A1, the company defended their decision to exclude radium-223 dichloride on 
the basis that there was not sufficient evidence to perform a comparison. The reasons provided by the 
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company for not being able to compare the pivotal trials for cabazitaxel and radium-223 dichloride 
(TROPIC11 and ALSYMPCA14, respectively) were: 
 The two trials considered different patient populations: of the 755 people in the TROPIC trial 
16% did not have bone-metastases, 25% had visceral metastases and 11% had liver 
metastases, for which radium-223 dichloride is contraindicated (these numbers are not 
mutually exclusive).  
 It was not possible to derive a measure of progression-free survival from the ALSYMPCA 
trial that was consistent with the measures used in the pivotal trials for abiraterone and 
enzalutamide. 
 
However, the ERG notes that these limitations would not have stopped the company performing a 
separate comparison between cabazitaxel and radium-223 dichloride, using data from the relevant 
sub-group of the TROPIC randomised controlled trial (RCT). In response to clarification question A1, 
the company did provide summary statistics from the ALSYMPCA trial for OS in the cohort of 
patients with previous docetaxel use. The potential impact of including radium-223 dichloride in the 
economic evaluation is discussed in Section 6. 
 
3.4 Outcomes  
The outcomes considered in the CS match those described in the final scope. The outcomes are 
discussed in turn. 
 
 Overall survival (OS) 
OS is taken as the primary outcome measure. The pivotal trials for cabazitaxel11, abiraterone12, 
enzalutamide13 and radium-223 dichloride14 all defined OS as the time from the date of randomisation 
to death from any cause. Data on OS were censored at the last date the patient was known to be alive, 
or at the data cut-off date, whichever was earlier.  
 
 Progression-free survival (PFS) 
There was no standard definition of PFS employed across the pivotal trials for cabazitaxel, abiraterone 
and enzalutamide. Within the TROPIC study11 PFS was defined as the time from randomisation to the 
first occurrence of: tumour progression (based on Response Evaluation Criteria in Solid Tumours 
(RECIST) criteria); prostate specific antigen (PSA) progression; pain progression; or death due to any 
cause. Median time to progression using this definition was 1.4 months for mitoxantrone and 2.8 
months for cabazitaxel. Treatment was discontinued following the identification of disease 
progression. 
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To allow for inclusion in a network meta-analysis (NMA) (also termed an indirect treatment 
comparison (ITC) by the company), an alternative definition of PFS, radiographic PFS (rPFS) was 
used. This was defined as the time from randomisation to the first occurrence of: tumour progression 
(based on RECIST criteria) or death due to any cause. Median time to progression using this 
definition was 5.9 months for mitoxantrone and 8.8 months for cabazitaxel. 
 
Progression-free survival was not measured in the radium-223 dichloride study.14 However, time to 
PSA progression was measured. Both the abiraterone and enzalutamide trials12, 13 defined progression-
free survival as the time from randomisation to the first occurrence of: tumour progression (based on 
RECIST criteria), bone scans showing two or more new lesions not consistent with tumour flare, or 
death. 
 
 Tumour response rate (assessed only in patients with measurable disease at baseline) 
Tumour response rate was only assessed in patients with measurable disease at baseline, and based on 
RECIST criteria.21 These criteria define measurable disease as the presence of at least one lesion 
which can be accurately measured and whose longest dimension is >20 mm using conventional 
techniques or >10 mm using spiral CT scan. The RECIST criteria define tumour responses as follows: 
o Complete response: disappearance of all target lesions 
o Partial response : decrease of at least 30% in the sum of the longest diameter of target 
lesions 
o Progressive disease: increase of at least 20% in the sum of the longest diameter of target 
lesions 
o Stable disease: neither sufficient decrease to qualify as partial response nor sufficient 
increase to qualify as progressive disease. 
 
 Health-related quality of life (HRQoL) 
The TROPIC study did not collect data relating to HRQoL. For this outcome, the CS therefore utilised 
interim UK results from the EAP for cabazitaxel, a global study which includes nine active sites in the 
UK. In the UK sites only, Euro-QoL 5 Dimension (EQ-5D) questionnaires were administered to all 
patients at baseline, cycle 2, cycle 4, cycle 6, cycle 8, cycle 10, and 30 days after withdrawal from or 
completion of treatment; utility was also assessed using a visual analogue scale. Utility data from the 
EAP are limited by not being comparative (utility values for patients receiving mitoxantrone or BSC 
are not collected), and by not being blinded, which may cause some bias due the subjective nature of 
the EQ-5D questionnaire. 
 
HRQoL values for abiraterone and enzalutamide were collected in their respective pivotal trials, using 
the Functional Assessment of Cancer Therapy – Prostate (FACT-P) tool. These were not considered 
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in the CS, as they contend that EQ-5D data from the EAP are of greater relevance. The radium-223 
dichloride trial collected EQ-5D data; however details on this are not available in the public domain. 
In the AFFIRM study comparing enzalutamide with placebo, EQ-5D data were collected at some sites 
but only for a limited number of patients.22 In the STA submission for enzalutamide EQ-5D data were 
used; in the abiraterone submission FACT-P data were mapped to EQ-5D However, these data were 
commonly redacted. 
 
 Adverse effects of treatment 
Adverse events (AEs) in TROPIC were recorded in patients who had received at least one dose of 
study drug. Grading of AEs was based on National Cancer Institute Common Terminology Criteria 
for Adverse Events version 3.0. These criteria classify severe AEs as grade 3, life-threatening or 
disabling AEs as grade 4, while grade 5 is used for deaths related to AEs.23 If patients experienced 
multiple AEs within a treatment cycle then the worst (highest) NCI grade was used.  
 
Rates of AEs may be based on either laboratory test results or be investigator reported. The former are 
reported in the key publication for TROPIC11 with both being reported in the CS. 
 
3.5 Other relevant factors 
Cabazitaxel, abiraterone, enzalutamide and radium-223 dichloride are all subject to confidential 
Patient Access Schemes (PASs). In addition, abiraterone and enzalutamide are subject to ongoing 
NICE appraisals, which may affect their PASs. Mitoxantrone is available as a generic drug, and so is 
not subject to a PAS. 
 
Within their submission, the company argued that cabazitaxel fulfilled the NICE criteria for a life-
extending, end-of-life treatment. These NICE criteria are that: 
 The treatment is indicated for patients with a short life expectancy, normally less than 24 
months and; 
 There is sufficient evidence to indicate that the treatment offers an extension to life, normally 
of at least an additional three months, compared to current NHS treatment, and; 
 The treatment is licensed or otherwise indicated, for small patient populations. 
 
The company's justification for why they believe that cabazitaxel fulfils these criteria, along with the 
ERG's critique of this, are described in Section 7. 
 
In the CS (section 3.8, p50-51) it was noted that the prevalence of prostate cancer varied with 
ethnicity, with an estimated 29% of black men being diagnosed with prostate cancer during their 
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lifetime compared to 13.3% for white men and 7.9% for Asian men. The company further noted that 
black men are more likely to die from prostate cancer.  
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4 CLINICAL EFFECTIVENESS 
This chapter presents a review of evidence relating to the clinical effectiveness of cabazitaxel in 
combination with prednisone or prednisolone for the treatment of patients with mCRPC previously 
treated with a docetaxel-containing regimen.  Section 4.1 presents a critique of the company’s 
systematic review and Section 4.2 provides a summary of the clinical effectiveness results (efficacy 
and safety) and critique of included cabazitaxel trials.  Sections 4.3 and 4.4 provide a critique of the 
trials within the NMA and of the NMA respectively.  Section 4.5 presents additional work on clinical 
effectiveness undertaken by the ERG.  Finally, Section 4.6 provides the conclusions of the clinical 
effectiveness section. 
 
4.1  Critique of the methods of review(s) 
As part of the original submission, which informed TA255 for cabazitaxel in 2011,15  the company 
performed three systematic searches with the following aims and objectives (which also apply to the 
current submission): 
1. To identify all studies of cabazitaxel versus any comparator, in order to identify the complete 
evidence base for cabazitaxel.  
2. To identify all RCTs in the second-line treatment of patients with mCRPC which had 
progressed after first-line docetaxel, in order to identify any RCT evidence that would allow 
indirect comparisons with the comparators specified in the NICE final scope19 which had not 
been directly compared with cabazitaxel. 
3. To identify all non-randomised studies of second-line therapy in patients with mCRPC which 
had progressed after first-line docetaxel, in order to identify any non-randomised evidence for 
cabazitaxel or its comparators which might potentially be relevant to the decision problem.  
 
All searches were initially undertaken between September to November 2010 (as part of the original 
submission which informed TA255)15 with updated searches undertaken in February 2015.   
 
For the current submission, the company adopted a slightly different approach to that of the original 
submission in that two broad clinical effectiveness searches were undertaken to identify all RCT and 
non-RCT evidence on the use of cabazitaxel or its comparators in the context of mCRPC previously 
treated with docetaxel instead of separate searches for each of the reviews. However, the presentation 
of these sections in the CS is made somewhat confusing due to extensive cross-referencing between 
the main document and appendices.    
 
In brief, for the original search of cabazitaxel versus any comparator and for RCTs of second-line 
therapy in mCRPC, several electronic bibliographic databases (including MEDLINE, MEDLINE in 
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Process, EMBASE, and the Cochrane Library) and research registers (ClinicalTrials.gov and the 
International Clinical Trials Platform) were searched covering the period from January 2000 to 
August/September 2010. Supplementary searches such as scanning of bibliographies of included 
studies, clinical study reports, regulatory agency websites and various conference proceedings were 
also undertaken. For the update searches, similar sources appear to have been searched and covered 
the period from January 2010 to February 2015. However, it is unclear why the Health Technology 
Assessment database and the Cochrane Database of Systematic reviews and the Database of Abstracts 
of Reviews of Effects, which forms part of the Cochrane Library, were not searched, as additional 
studies may have been identified from the reviews of primary studies. Nevertheless, the ERG 
considers the chosen electronic databases and internet sources to be appropriate. The company’s 
second set of systematic searches were undertaken to identify all non-randomised studies in second-
line therapy in mCRPC.  In the original searches undertaken for NICE TA255,15 three electronic 
bibliographic databases (MEDLINE, MEDLINE in Process, and EMBASE) and several conference 
proceedings were searched from January 2000 to March 2010. No additional searches, such as 
searches of company databases, were undertaken. For the update searches, similar sources appear to 
have been searched from January 2010 to February 2015.    
 
In general, all searches in the CS were conducted in a systematic fashion and to a clear protocol based 
on an explicit PICOS question. However, Tables 8-10 (p35-39) and 15-16 (p49-51) of the appendices 
in the CS do not include numbers of results. This, combined with the fact that the ERG do not have 
access to the Embase.com platform for MEDLINE and EMBASE, made it difficult to recreate the 
searches exactly as the company had run them to verify the numbers of results against those given in 
the PRISMA flowchart.24 In a systematic literature search it is customary to search each database 
separately in order (a) to indicate how many records were returned from each, and (b) to allow for the 
optimisation of the search strategy for each database by choosing the most appropriate subject 
headings, field codes and limits. Every database has a different thesaurus and indexing hierarchy 
(although there is some overlap between those of MEDLINE (MeSH) and EMBASE (Emtree)).  
Records imported from MEDLINE into EMBASE are automatically re-indexed to Emtree but the 
process is unmediated and can result in sub-headings losing their original context and treated as free-
standing subject headings.  For this reason, the ERG believes that searching EMBASE and 
MEDLINE together is not optimal. 
 
When attempting to replicate the company’s search on the OVID platform, numerous error messages 
were encountered due to the inclusion of subject headings which were not recognised by one or both 
of the databases being searched. Similarly, there is some redundant explosion of subject headings 
where this has no effect (e.g. Placebo/).  The records of the searches are also confused by referring to 
PubMed as “MEDLINE In Process” in the tables of searches but as “MEDLINE” in the PRISMA 
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flowcharts.  PubMed does indeed have the advantage of including “Pre-MEDLINE” (records to be 
added to Medline but not yet indexed with subject headings) and “Publisher supplied” records (see 
https://www.nlm.nih.gov/pubs/techbull/jf99/jf99_subset.html for more details) but the searches have 
not been restricted to these subsets and therefore there is likely to be substantial duplication with the 
EMBASE/MEDLINE searches. 
 
There appears to be some errors in the subject headings chosen for the RCT search - for example, the 
correct Emtree heading is “Prostate tumor” (not “tumour”, as used in the RCT search (Appendix 4, 
Table 8, CS) – though the ERG notes that this error was corrected for the non-RCT and cost-
effectiveness searches) and the equivalent MeSH term is “Prostatic Neoplasms” (which in fact has a 
narrower heading, “Prostatic Neoplasms, Castration Resistant”).  However, since free text searches 
for spelling variations have been included, the ERG is confident all relevant results will have been 
found.     
 
Finally, the ERG also noticed a logic error in the combination of terms in the EMBASE/MEDLINE 
search: due to the way line 17 has been combined with the other search strings, it is likely to retrieve 
results related to other types of hormone-refractory cancer (not just prostate). However, since this 
error increases rather than reduces the sensitivity of the search, the only effect will have been to 
increase the number of articles requiring screening. 
 
Despite the noted limitations, the ERG considers all the search strategies to be sufficiently 
comprehensive to retrieve important citations relating to all eligible studies of which the ERG and its 
clinical advisors are aware. No relevant published studies are likely to have been missed. 
 
4.1.2  Inclusion criteria 
The CS describes appropriate methods of identifying and screening references for inclusion in the 
systematic reviews of clinical effectiveness.  Two independent reviewers applied pre-specified 
inclusion and exclusion criteria (via a two-stage sifting process) to citations identified by the searches. 
Any differences in selection were resolved through discussion between reviewers or consultation with 
a third reviewer (p58 and p90-91, CS).  A summary of the inclusion and exclusion criteria, as reported 
in the CS (p56-58 and p88-90; data re-tabulated and adapted in a consistent and more transparent 
format), for each of the systematic reviews is summarised in Table 3.   
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Table 3: Inclusion/exclusion criteria used to select studies in the reviews conducted by the company (p56-58 and p88-90, CS) 
Criteria Review type 
1. Systematic review of RCTs of cabazitaxel 2. Systematic review of all RCTs 
in second-line for mCRPC 
3. Systematic review of non-
randomised studies in second-line 
for mCRPC 
 Inclusion criteria   
Population  mCRPC patients 
 Age: Adults (≥18 years) 
 Race: Any 
 Line of therapy: Second-line or later 
 Prior therapy: Previously treated with 
docetaxel-based regimen 
 As per review 1  As per review 1 
Interventions The following treatments for mCRPC used in the 
second line or later a: 
 
 Jevtana (cabazitaxel) 
 Zytiga (abiraterone) 
 Xtandi (enzalutamide) 
 Novantrone (mitoxantrone) 
 Yervoy (ipilimumab) 
 Xofigo (radium-223 dichloride) 
 Provenge (sipuleucel-T) 
 Emcyt (estramustine) 
 As per review 1  As per review 1 
Comparator   Any (e.g. placebo, any chemotherapy, surgery, 
radiotherapy and/or best supportive care) 
 As per review 1  As per review 1 
Outcomes  Overall survival 
 1-year survival 
 Progression-free survival  
 Time to disease progression  
 Complete response 
 Partial response 
 Overall response 
 Skeletal-related events  
 As per review 1  As per review 1 
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 Prostate-specific antigen (PSA) response 
 Time to PSA progression  
 Time to opiate use 
 Time to pain progression 
 Safety and adverse events 
 Health-related quality of life  
 Resource utilisation 
Study design  RCTs with any blinding status in phases 
beyond Phase I  
 As per review 1  Non - RCTs 
 Single-arm interventional 
studies/uncontrolled trials 
 Observational studies, including: 
o Cohort studies/longitudinal 
studies (prospective or 
retrospective) 
o Case-control studies 
o Cross-sectional study/survey 
o Hospital records and 
database studies 
Publication timeframe  From January 2010 to February 2015 as earlier 
studies would have been identified in a 
previous systematic review which  informed 
TA255 for cabazitaxel in 201115  
 As per review 1  As per review 1 
Publication status  Published, unpublished and grey literature (e.g. 
conference abstracts) 
 As per review 1  As per review 1 
Language restrictions  None  As per review 1  As per review 1 
 Exclusion criteria   
General  Studies with no subgroup data for the disease 
(mCRPC), disease stage (metastatic or unclear), 
and prior treatment (docetaxel-treated or 
unclear) were not included to avoid introducing 
heterogeneity 
 Study population aged <18 years 
 Study does not examine an intervention of 
 As per review 1  As per review 1 
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interest 
 Study does not include any outcomes of interest 
 For review 1 and 2 the following study designs 
were excluded: Phase I RCTs, non RCTs 
single-arm studies/uncontrolled trials, 
observational studies, letters and case reports as 
these were considered as poor quality evidence 
 For review 3 the following study designs were 
excluded:  RCTs as these were included in 
review 1 and 2 and non-randomised evidence 
including case studies/series/reports as these 
were considered as poor quality evidence. 
 Studies published before 2010 as earlier studies 
would have been identified in a previous 
systematic review which  informed TA255 for 
cabazitaxel in 201115 
mCRPC, metastatic castration-resistant prostate cancer; RCT, randomised controlled trial 
 
a The list was limited to interventions that have been approved in the European Union, are currently seeking approval, or are otherwise known to be used in the European Union in clinical 
practice within this patient population 
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The specified inclusion and exclusion criteria were appropriate and generally reflect the information 
given in the decision problem; however, there appeared to be some irregularities in the CS.   
 
Firstly, the statement of the decision problem proposed that the following treatments be considered as 
comparators: abiraterone (in combination with prednisone or prednisolone), enzalutamide, 
mitoxantrone in combination with prednisolone, BSC and radium-223 dichloride (for people with 
bone metastasis only).  Initially, it was unclear to the ERG why other comparators such ipilimumab, 
sipuleucel-T, estramustine and other mitoxantrone containing regimens were included in the 
systematic reviews conducted by the company as no explicit details were provided in the CS. 25  
Following a clarification response to question A9 (p10-12), the company noted that it initially 
considered a wider remit to capture the entire evidence base as part of the inclusion criteria (a 
summary table of all potential included studies was provided in the CS (Table 17, p59-61) and 
clarification response (Table 4, p11-12)), but then focused the systematic reviews to those studies 
directly relevant to the decision problem.  As a result, the systematic reviews of RCT evidence 
(review 1 and 2) excluded interventions that were not listed in the decision problem after the study 
selection stage and thus were not discussed further in the CS.  
 
Secondly, the company did not consider radium-223 dichloride to be a valid comparator as it is only 
licensed for use in a sub-population of adults who have mCRPC with symptomatic bone metastases 
and no known visceral metastases.  It is also contra-indicated in people with liver metastases.  
Nevertheless, the ERG’s clinical advisors and the expert submissions submitted by Dr Andrew 
Goddard on behalf of the NCRI/RCP/RCR/ACP16 and Dr Amit Bahl on behalf of the British Uro-
Oncology Group26 indicate that radium-223 dichloride is a viable treatment option in some people 
with symptomatic bone-only disease.  Moreover, preliminary NICE guidance recommends27 radium-
223 dichloride as an option for treating adults with hormone-relapsed prostate cancer, symptomatic 
bone metastases and no known visceral metastases, only if: they have had treatment with docetaxel, 
and the company provides radium-223 dichloride with the discount agreed in the confidential patient 
access scheme.  Following an ERG request (company’s clarification response to question A1, p1-2), 
the company re-expressed their concerns about the applicability and feasibility of including radium-
223 dichloride as a comparator but provided a summary of the efficacy results for OS in the cohort of 
patients with previous docetaxel use from the ALSYMPCA study.14  However, the company provided 
no further analysis (further details are provided in Section 4.3). 
 
For the systematic review of non-randomised and non-controlled evidence, the company undertook a 
similar approach and initially identified all relevant studies (a summary of all potential included 
studies was provided in Appendix 6 of the CS), but focused the systematic review in the CS to those 
studies directly relevant to the decision problem, that is, on the safety of cabazitaxel in clinical 
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practice and the efficacy of cabazitaxel in sequence with abiraterone or enzalutamide (p93, CS). Three 
sequences were determined: (1) all-hormonal sequences such as abiraterone followed by 
enzalutamide, or enzalutamide followed by abiraterone; (2) cabazitaxel-hormonal such as cabazitaxel 
followed by abiraterone or enzalutamide; and (3) hormonal- cabazitaxel such as abiraterone or 
enzalutamide followed by cabazitaxel. 
 
Whilst these approaches seem acceptable to the ERG, ideally, systematic reviews should have clearly 
focused research questions and inclusion/exclusion criteria at the outset. 
 
4.1.3  Critique of data extraction 
The data extracted and presented in the clinical Section of the CS appear appropriate and 
comprehensive.  As noted in the CS (p58, 90-91) all relevant data for each of the reviews was 
extracted by two independent reviewers into a pre-defined data extraction table.  All extractions were 
then checked for accuracy by a third independent reviewer.    
 
4.1.4  Quality assessment 
The validity assessment tools used to appraise the relevant included studies in the CS differed 
between the reviews undertaken.  For the systematic review of cabazitaxel (review 1), the validity 
assessment tool was based on the quality assessment criteria for RCTs, as suggested in the NICE 
guideline template for evidence submissions by a company.28   For the review of second-line therapies 
in mCRPC (review 2), the same template was used; however, no explicit consideration was given on 
how closely the included RCTs reflected routine clinical practice in England.  For the review of non-
randomised studies in second-line treatments for mCRPC (review 3) the National Institutes of Health 
National Heart, Lung, and Blood Institute Quality Assessment Tool for Cross-Sectional Studies29 was 
used.  As noted in the company’s clarification response to question A12, methodological quality 
assessment of included studies for each of the reviews was performed by one researcher and checked 
independently by a second.  The ERG considers the validity assessment tools used in the CS to be 
appropriate. 
 
4.1.5  Evidence synthesis 
The company undertook a narrative synthesis of the evidence for cabazitaxel; however, no explicit 
details were provided in the CS on how this approach was undertaken.25 Ideally, a narrative synthesis 
approach should be justified, rigorous (i.e. describe results without being selective or emphasising 
some findings over others) and transparent to reduce potential bias.30,31  Despite the lack of 
transparency regarding the methods adopted, the ERG acknowledges that the narrative synthesis 
approach undertaken by the company was acceptable.  In the absence of any direct head-to-head 
RCTs comparing cabazitaxel and other second-line agents such as abiraterone or enzalutamide for the 
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treatment of mCRPC post-docetaxel, the company conducted a NMA.  Further details on the studies 
included and a critique of the NMA can be found in Sections 4.3 and 4.4 respectively. 
 
4.2 Critique of trials of the technology of interest, their analysis and interpretation (and any 
standard meta-analyses of these)  
4.2.1   Studies included in/excluded from the submission  
The company’s Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
flow diagram relating to the literature searches does not conform exactly to the PRISMA statement 
flow diagram (http://www.prisma-statement.org/).  Despite this, the flow diagrams presented by the 
company represent the identification and selection of all relevant RCTs (see the company’s 
clarification response to question A8, p9) and non-randomised studies (see CS, p92) of second-line 
therapies in mHRPC/ mCRPC post-docetaxel and appear to be an adequate record of the literature 
searching and screening process.  However, for clarity, a separate PRISMA flow diagram for each of 
the reviews would have been beneficial (including details of the final set of studies that were included 
in the CS which were directly relevant to the decision problem) as it would aid the transparency of the 
identification and selection processes for each of the reviews. 
 
The company’s systematic review of RCTs of cabazitaxel identified and included only one relevant 
study.  This was the TROPIC study,11, 32 which compared cabazitaxel plus prednisone or prednisolone 
with mitoxantrone plus prednisone or prednisolone in patients with mHRPC which had progressed 
during or after previous treatment with docetaxel.  Further details of the TROPIC study are provided 
in this section.  
 
The company’s broader systematic review of RCTs of all second-line agents in mHRPC/ mCRPC 
post-docetaxel (which was conducted to allow a NMA to be conducted with the comparator 
interventions listed in the decision problem i.e. abiraterone (in combination with prednisone or 
prednisolone), enzalutamide, mitoxantrone in combination with prednisolone, BSC and radium-223 
dichloride (for people with bone metastasis only)) initially identified 13 potential studies (see 
company’s clarification response to question A9, Table 4, p11).  Of these, only two studies (the 
AFFIRM trial13 which compared enzalutamide with placebo and the COU-AA-301 trial12,33 which 
compared abiraterone acetate plus prednisone with placebo plus prednisone) in addition to the 
TROPIC study11,32 were considered to be relevant to the decision problem.  Further details of the 
AFFIRM13 and COU-AA-30112,33 trials are presented in Section 4.3.  As noted in Section 4.1.2, the 
company did not consider radium-223 dichloride (as investigated in the ALSYMPCA study)14 to be a 
valid comparator, whereas the remaining studies investigated other treatments that (isiltuximab,34 
cetuximab,35 etoposide or vinorelbine,36 ipilimumab,37, 38 rilotumumab,39 custirsen,40 cixutumumab,41 
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cabozantinib42 or sipuleucel-T43 [which has been withdrawn from use in the EU]) either do not hold 
licenses for the treatment of mCRPC post-docetaxel use or are not used in UK clinical practice. 
 
The company’s systematic review of non-randomised and non-controlled evidence initially identified 
103 studies from 107 citations (see p92 and Appendix A6, CS).  However, despite minor 
discrepancies between the main text and appendices of the CS, it was not explicitly clear to the ERG 
how many studies (non-randomised and non-controlled) were included in the systematic review that 
directly provided evidence relevant to the decision problem. Nevertheless, it appears that 12 studies44-
55 from the Compassionate Use Programme (CUP) and EAPs for cabazitaxel provided data on the 
safety of cabazitaxel in post-docetaxel treatment for mCRPC in clinical practice (p93-95 and 
Appendix A6, CS). 
 
For the efficacy sequencing review, 12 studies (3 studies on enzalutamide33,56,57 and 9 studies on 
abiraterone)13,58-65 provided data on cross-resistance in mCRPC patients who were treated with third 
line advanced hormonal therapies (enzalutamide or abiraterone) after having previously received 
docetaxel and another advanced hormonal therapy compared with studies of no prior hormonal 
therapy.  In addition, 17 studies (7 full papers66-72 and 10 abstracts73-82 (the CS suggests that 11 
abstracts were identified; however, one abstract83 was recently published and included as a full 
paper72) provided data on the efficacy of cabazitaxel in sequence with abiraterone or enzalutamide 
post-docetaxel (p106-110 and Appendix A20, CS).  The CS also provided brief details of a recent 
systematic review84 on sequencing of abiraterone, enzalutamide and cabazitaxel after docetaxel) in 
patients with mCRPC, which was published just prior to the CS to NICE.  Further details of the 
systematic review of non-randomised and non-controlled evidence are presented in Section 4.2.4.3.   
 
 The main evidence (pivotal study: TROPIC trial)11,32   
The CS (p64-74) included one phase III, manufacturer-sponsored, randomised, open-label, active-
controlled, multicentre (146 centres in 26 countries including the UK) study designed to evaluate the 
efficacy and safety of cabazitaxel (plus prednisone or prednisolone) in 755 men aged over 18 years 
(median age 68 years and 84% were Caucasian) with mHRPC whose disease had progressed during 
(about 30% of patients) or after (about 70% of patients) treatment with a docetaxel-containing 
regimen.  Eligible patients needed to have an ECOG PS score of 0 or 1 (n=694, 92%) or 2 (n=61, 8%) 
and documented disease progression according to the RECIST criteria21 (measurable disease) with ≥1 
visceral or soft-tissue metastatic lesion or based on a rising PSA level or the appearance of new 
lesions (non-measurable disease).  A summary of the study design and population characteristics is 
provided in Table 4. 
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Table 4: Characteristics of the TROPIC study (see CS, p64-74 and de Bono et al.11, 32)  
Study Location 
(sites) 
Design Population Interventions Comparator Primary 
outcome 
measures 
Duration 
TROPIC 
(NCT 
00417079)11, 32  
 
 
 
 
146 centres in 
26 countries 
(including 6 
sites [n=37, 
5%] in the 
UK)   
 
Phase III, 
randomised, 
open-label, 
active drug 
controlled 
trial 
Men aged ≥18 
years with 
mHRPC post-
docetaxel 
(n=755) 
 
Cabazitaxel 25 mg/m2 
intravenously over 1 
hour on day 1 of each 
21-day cycle plus oral 
prednisone 10 mg/day 
or similar doses of 
prednisolone in 
countries in which 
prednisone was 
unavailablea (n=378)  
 
Mitoxantrone 12 
mg/m2 intravenously 
over 15-30 minutes on 
day 1 of each 21-day 
cycle plus oral 
prednisone 10 mg/day 
or similar doses of 
prednisolone where 
prednisone was 
unavailableb (n=377) 
Overall survival 
(calculated from 
date of 
randomisation to 
death) 
 
 
 
 
Until death or the 
cut-off date for 
analysis (25 
September 2009 
[median follow-up 
was 12.8 months] 
and in the extension 
period to 10 March 
2010 [median follow 
up was 20.5 months]) 
mHRPC, metastatic hormone-refractory prostate cancer 
a Premedication, consisting of single intravenous doses of an antihistamine, corticosteroid (dexamethasone 8 mg or equivalent), and histamine H2-antagonist (except cimetidine) was administered 30 
minutes or more before cabazitaxel 
b Premedication with an anti-emetic only, with other premedication at the physician’s discretion  
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The key exclusion criteria included active grade 2 or higher peripheral neuropathy or stomatitis, other 
serious illness (including secondary cancer) or a history of hypersensitivity to polysorbate 80-
containing drugs and prednisone.  In addition, a protocol amendment mandated that study subjects 
who received a cumulative dose of docetaxel less than 225 mg/m2 (n=59, 8%) were excluded from the 
study.  This amendment was made in light of guidelines suggesting that docetaxel treatment be 
maintained for a period of at least three cycles prior to instituting any change in order to obtain a true 
‘docetaxel-refractory’ population. 
 
All patients received oral prednisone 10mg daily (or prednisolone where prednisone was unavailable) 
and were randomised to receive cabazitaxel 25mg/m2 intravenously over 1 hour (n=378) or 
mitoxantrone 12mg/m2 intravenously over 15 to 30 minutes (n=377).  Treatments were given on day 1 
of each 21-day cycle and could be given for a maximum of ten cycles to minimise risk of 
mitoxantrone-induced cardiac toxicity. As noted in the company’s clarification response to question 
A4, the license for cabazitaxel does not limit its usage to 10 cycles.  Treatment delays up to two 
weeks were permitted, with one dose reduction per patient permitted if the initial dose was not 
tolerated: cabazitaxel from 25 to 20mg/m2; and mitoxantrone from 12 to 10mg/m2.  The ERG notes 
that in the European Medicines Agency assessment report for cabazitaxel1 it states that ‘No dose 
escalation is mentioned in the protocol.’  Prophylactic treatment with G-CSFs was not allowed during 
the first cycle, but thereafter was allowed at the physician's discretion and was mandated for patients 
with neutropenia lasting longer than seven days or neutropenia complicated by fever or infection.  
Patients in the cabazitaxel arm were given premedication consisting of antihistamine, corticosteroid 
and histamine-2 antagonists to reduce the risk of hypersensitivity reactions. Anti-emetic prophylaxis 
and other supportive care were given at the physician's discretion. 
 
Exposure to the study treatment varied between the groups. In the cabazitaxel group, patients 
completed a median of six cycles of treatment, of which 10% of cycles required a dose reduction, with 
a median relative dose intensity of 96.1%.  In contrast, patients in the mitoxantrone group completed a 
median of four cycles of treatment, of which 5% of cycles required a dose reduction, with a median 
relative dose intensity of 97.3%.  The protocol prohibited crossover to cabazitaxel for patients 
randomised to the mitoxantrone group, although 44 (12%) patients in this group received treatment 
with tubulin-binding drugs at the time of disease progression. 
 
The primary efficacy endpoint was OS (defined as the time from date of randomisation to death due to 
any cause or the study cut-off date, whichever came first) and the main secondary endpoint was PFS 
(a composite endpoint defined as the time between randomisation and the first date of progression as 
measured by a: rise in PSA levels; tumour progression; pain progression; or death, whichever 
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occurred first).  Other secondary endpoints included: time to tumour progression; overall response 
rate; PSA progression; pain response measures; and safety. 
 
 Ongoing studies of cabazitaxel for mCRPC post-docetaxel 
Several ongoing studies on the use of cabazitaxel in patients with mCRPC after docetaxel-based 
therapy were noted in the CS; however, full and clear explicit details on study characteristics 
including expected completion dates were lacking (see Appendix 7, CS for further details). A 
summary of two key studies (PROSELICA, a phase III study comparing the efficacy and tolerability 
of cabazitaxel 25 mg/m2 with cabazitaxel 20 mg/m2 and ECLIPSE, an observational retrospective 
study on treatment sequencing of anti-cancer agents in mCRPC) that may provide evidence within the 
timeframe of this submission is provided in Table 5.  In addition, the CS (p122) also notes that the 
FIRSTANA (NCT01308567) study may also provide preliminary outputs within the timeframe of this 
appraisal; however, this study is in mCRPC patients who are chemotherapy naïve and so falls outside 
the indication discussed in this submission. 
 
Table 5: List of key ongoing studies of cabazitaxel for mCRPC post-docetaxel (p127 and 
Appendix 20, CS) 
Criteria PROSELICA study ECLIPSE study 
Title Randomized, open label multi-centre study 
comparing cabazitaxel at 20 mg/m² and at 25 
mg/m² every 3 weeks in combination with 
prednisone for the treatment of mCRPC previously 
treated with a docetaxel-containing regimen 
Real Life treatment sequences and survival 
of men with mCRPC receiving cabazitaxel 
in UK clinical practice 
Study ID 
number 
Sanofi internal: XRP6258-EFC11785 
Clincinaltrials.gov:  NCT01308580 
Sanofi internal: CABAZL07485 
Primary 
objective 
To demonstrate the non-inferiority in terms of 
overall survival of cabazitaxel 20 mg/m² (Arm A) 
versus cabazitaxel 25 mg/m² (Arm B) in 
combination with prednisone in patients with 
mCRPC previously treated with a docetaxel-
containing regimen. 
To describe anti-cancer treatment 
sequences and treatment outcomes in 
patients receiving cabazitaxel in England. 
Secondary 
objectives 
 To evaluate safety in the 2 treatment arms and 
to assess if cabazitaxel 20 mg/m² is better 
tolerated than cabazitaxel 25 mg/m² 
 To compare efficacy of cabazitaxel at 20 
mg/m² and 25 mg/m² for: 
o Progression Free Survival   
o Prostate-Specific Antigen (PSA)-
 To describe the clinical outcomes of 
patients who have received cabazitaxel 
following prior docetaxel treatment 
(according to the treatment sequencing 
received post-docetaxel) 
 To describe the characteristics of 
patients receiving cabazitaxel treatment 
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Progression 
o Pain progression 
o Tumour response in patients with 
measurable disease  
o PSA response 
o Pain response in patients with stable 
pain at baseline 
 To compare Health-related Quality of Life 
using the FACT-P tool 
 To assess the pharmacokinetics and 
pharmacogenomics of cabazitaxel 
 To describe side effects associated with 
cabazitaxel use 
Study 
design 
Phase III, randomised, open-label, multi-centre, 
multinational study comparing cabazitaxel 20 
mg/m² plus prednisone (Arm A) and cabazitaxel 25 
mg/m² plus prednisone (Arm B) in patients with 
mCRPC post-docetaxel. 
A multi-centre, observational, retrospective 
research study of patients with mCRPC 
who have received cabazitaxel in England. 
Study 
location 
Multinational, multicentre. Planned recruitment is 
from approximately 200 sites within 60 months. 
5 centres in England 
Study 
population 
Expected 1200 mCRPC patients with similar 
baseline characteristics to the TROPIC population 
115 patients with mCRPC treated with 
cabazitaxel following docetaxel failure and 
who started cabazitaxel treatment ≥1 year 
before data collection. 
Study 
duration 
Cabazitaxel administered every 3 weeks. Patients 
treated until progressive disease, unacceptable 
toxicity, patient’s refusal of further study treatment 
or for a maximum of 10 cycles.  After study 
treatment discontinuation patients followed until 
death or cut-off date, whichever comes first. In 
patients that progressed the follow up was 
performed every 12 weeks, in patient not 
progressed the follow up was performed every 6 
weeks for the first 6 months and then every 12 
weeks. 
Data relating to patients’ demographic and 
clinical characteristics and cancer treatment 
pathways (including life-prolonging anti-
cancer treatments and clinical outcomes) 
were collected from electronic and paper-
based hospital records between March 2015 
and August 2015. 
Expected 
completion 
date 
August / September 2015 with full results expected  
within the next 12 months 
Not reported but interim results available in 
Appendix A20, CS (p127-130) 
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4.2.2 Details of relevant studies not included in the submission 
The ERG is confident that all relevant studies were included in the CS and details of ongoing trials 
that are likely to be reporting additional evidence within 12 months were reported. 
 
4.2.3  Summary and critique of the company’s analysis of validity assessment 
The company provided a formal appraisal of the validity of the included cabazitaxel RCT using 
standard and appropriate criteria.  The completed validity assessment tool for the TROPIC trial, as 
reported in the CS, is reproduced (with minor changes) in Table 6.   
 
Table 6: Quality assessment results for the TROPIC study as assessed by the company 
Quality assessment criteria Trial 
TROPIC 
How addressed in the study Adequate or not 
Internal validity 
Was randomisation carried out 
appropriately? 
Computer-generated random number 
sequence; stratified by pre-specified 
criteria. 
Yes 
Was the concealment of treatment 
allocation adequate? 
Central randomisation was 
performed using an interactive voice 
response system. 
Yes 
Were the groups similar at the 
outset of the study in terms of 
prognostic factors?  
Baseline demographic, disease and 
previous treatment characteristics 
were balanced. 
Yes 
Were the care providers, 
participants and outcome 
assessors blind to treatment 
allocation?  
Providers, participants and outcome 
assessors were not blind to treatment 
allocation; unlikely to bias 
assessment of overall survival, 
progression free survival or objective 
assessments of tumour response; 
potential for ascertainment bias in the 
subjective assessment of present pain 
intensity and clinical (not laboratory) 
assessment of adverse events. 
No, but unlikely to 
impact on the main 
outcomes. Outcome 
assessors should 
probably have been 
blinded to avoid the 
possibility of bias. 
 
(See text for ERG 
comment on this) 
Were there any unexpected 
imbalances in dropouts between 
groups? 
No - only two patients, both in the 
mitoxantrone group, were lost to 
follow-up; a similar number of 
Yes 
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patients in each group (n=10 
cabazitaxel, n=7 mitoxantrone) 
discontinued treatment due to events 
other than disease progression or 
adverse events; only one patient, in 
the cabazitaxel group, discontinued 
due to poor protocol compliance. 
Is there any evidence to suggest 
that the authors measured more 
outcomes than they reported? 
There is no suggestion information 
was omitted 
Yes 
Was follow-up adequate?  Patients were followed until death or 
the cut-off date for analysis. 
Yes 
Did the analysis include an ITT 
analysis? If so, was this 
appropriate and were appropriate 
methods used to account for 
missing data? 
The primary outcome was analysed 
by intention to treat. Missing data 
were accounted for appropriately 
according to censoring rules for 
survival data. 
Yes 
External validity 
Was the RCT conducted in the 
UK, or were one or more centres 
of a multinational RCT located in 
the UK 
International multicentre trial; 5% 
(37/755) of participants were 
recruited in the UK, 53% (402/755) 
in Europe. 
Yes 
How do the participants included 
in the RCT compare with patients 
who are likely to receive the 
intervention in the UK? 
Demographics, disease and prior 
treatment are likely to be similar 
Yes, data from the UK 
Early Access 
Programme50 is 
available and this 
shows cabazitaxel use 
in a very similar 
patient population to 
the TROPIC study11, 32 
with improved adverse 
event profiles. 
What dosage regimens were used 
in the RCT? Are they within 
those detailed in the summary of 
product characteristics? 
Cabazitaxel 25 mg/m2 one-hour 
intravenous infusion every three 
weeks (as in the summary of product 
characteristics) 
Yes 
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Mitoxantrone 12 mg/m2 one-hour 
intravenous infusion every three 
weeks; recommended dosage for 
HRPC 12–14 mg/m² intravenous 
every three weeks. Mitoxantrone is 
not licensed for this indication in the 
UK but is licensed in the USA. 
ERG, Evidence Review Group; HRPC, hormone refractory prostate cancer; RCT, randomised controlled trial 
 
 
The CS considered the TROPIC study to be adequate in relation to all of these criteria with the 
exception of the criterion relating to the blinding of patients, care providers, and outcome assessors. 
The CS considered that the fact that the trial was open-label was unlikely to have introduced bias into 
the assessment of OS (primary outcome), or into objective assessments of tumour response or 
biochemical measurements such as PSA, but recognised that it might have introduced bias into the 
subjective assessment of pain and symptom deterioration (both of which were included in the 
definition of PFS) and of clinical (although not laboratory) assessment of AEs.  In the guidance issued 
by NICE for cabazitaxel in 2011,15 the Appraisal Committee accepted that, ‘as an open-label study, 
TROPIC was susceptible to bias in the subjective outcomes included in progression-free survival, 
such as pain and deterioration in symptoms’.  In addition, whilst a clear reason for the study being 
open label was lacking in the CS, NICE TA25515 notes that ‘The Committee heard from the 
manufacturer that blinding was not possible because of differences in the rate of infusion and colour 
of the drugs being compared’.   Nevertheless, the ERG notes that there appears to be no reason why 
outcome assessors should not have been blinded to treatment allocation. 
 
The CS states that the investigators used appropriate methods to generate the random allocation 
sequence and ensure allocation concealment, using a dynamic allocation method – a form of 
minimisation – to avoid extreme imbalance of treatment allocation within each study centre. 
However, it should be noted that such allocation is not truly random, and can potentially be subverted 
because of difficulties in concealing the allocation sequence. It is therefore theoretically possible that 
some patients may have been deliberately allocated to one or other treatment group on the basis of 
prognostic factors; however, the ERG has no reason to believe that this was the case. 
 
The CS considered all the external validity criteria to be adequately met.  However, the ERG notes 
that only 5% (37/755) of participants were recruited from the UK.  Nevertheless, in NICE TA255,15 
the Appraisal Committee concluded that the results from the TROPIC trial would be generalisable to 
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clinical practice in the UK.  Moreover, recent data presented in the CS (p124 and Appendix 20) from 
the UK EAP (n=112)50 and the unpublished data from the ongoing UK ECLIPSE study (n=115) 
suggest that patients treated in clinical practice with cabazitaxel in the UK are of similar age to the 
TROPIC population (UK EAP26: median age 67.0 years (IQR: 63 – 72.5); ECLIPSE: mean age 69.4 
years (standard deviation [SD]: 6.69); TROPIC:11 median age 68 years (IQR: 62 – 73)) with a median 
of six cycles of treatment, with mean dose intensity of 97.82%.50 
 
4.2.4  Summary and critique of results 
This section presents the results (as reported by the company) from the TROPIC trial,11,32 which forms 
the pivotal evidence in the CS for the efficacy and safety of cabazitaxel (plus prednisone or 
prednisolone) in people with mHRPC whose disease had progressed during or after treatment with a 
docetaxel-containing regimen.  In the original TROPIC study, final analyses had been planned after 
511 death events had occurred using the intention to treat (ITT) principle.  The results for the whole 
trial population were first published by de Bono et al. in 201011 after a median follow-up of 12.8 
months (study cut-off date: 25 September 2009), at which point 513 deaths had occurred.  Although a 
summary of these data is not reported in Section 4.7 of the CS (p77-81), the ERG reports this data for 
completeness in Appendix 1.  The CS does provide data from an updated analysis (OS data published 
by Bahl et al. in 2013)32 after a median follow-up of 20.5 months (study cut-off date: 10 March 2010), 
at which point 585 deaths (77.5%) had occurred.  All efficacy analyses were by ITT and estimates of 
the hazard ratio (HR) and corresponding 95% confidence intervals (CI) were provided using a Cox 
proportional hazard model stratified by factors specified at randomisation.  Additional information, 
not reported in the CS, was provided by the company in their response to the clarification questions 
raised by the ERG.  Where applicable, data have been re-tabulated by the ERG to provide further 
clarity.   
 
4.2.4.1   Efficacy 
 OS 
In an updated analysis, with a median follow-up of 20.5 months, 277 (73.3%) deaths had occurred in 
the cabazitaxel group compared with 308 (81.7%) in the mitoxantrone group.  Median survival values 
(HR for death 0.72, 95% CI: 0.61 to 0.84, p<0.0001) were similar to the ‘final efficacy analysis’ (HR 
for death 0.70, 95% CI: 0.59 to 0.83, p<0.0001), with a median gain of 2.3 months.   As noted in the 
CS (p79), the mean OS was estimated using individual patient level data from the TROPIC trial.  For 
the ITT population, based on Weibull extrapolations, OS was estimated to be 18.55 months in the 
cabazitaxel group compared with 14.53 months in the mitoxantrone group, with a mean survival gain 
of 4.02 months. A summary of the OS results are provided in Table 7. 
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Table 7: Summary of OS in the TROPIC study - updated efficacy analysis 
 Cabazitaxel 
(n=378) 
Mitoxantrone 
(n=377) 
Hazard ratio 
(95% CI) 
p value 
Analysis at 10.3.10 (updated efficacy analysis) (p77-79, CS and Bahl et al.)32 
Total deaths, ITT population 277 (73.3%) 308 (81.7%) NR NR 
Number of patients censored 101 (26.7%) 69 (18.3%) NR NR 
Median overall survival, 
months (95% CI) a 
15.08 
(13.96 to 16.49) 
12.78 
(11.53 to 13.73) 
0.72 c 
(0.61 to 0.84) 
<0.0001 c 
Estimated mean overall 
survival (extrapolated), 
months (95% CI) b 
18.55 
(NR) 
14.53 
(NR) 
NR NR 
Additional data from CS (p77-78) and Bahl et al.32 
Patients alive at 12 months 
(95% CI) 
64%  
(NR) 
53%  
(NR) 
NR NR 
Patients alive ≥ 24 months 
(95% CI) 
27% 
(23 to 32) 
16% 
(12 to 20) 
NR NR 
CI, confidence interval; ITT, intention-to-treat; NR, not reported 
a Median difference in overall survival, 2.3 months 
b Mean difference in overall survival, 4.02 months (estimated using Weibull extrapolations to the Kaplan-Meier data from 
the TROPIC trial) 
c Data discrepancy in CS: Table 2 (p18, CS) reports corresponding data as follows: HR 0.72, 95%CI: 0.61 to 0.85; p=0.0002 
and Table 22 (p78, CS) reports corresponding data as follows: HR 0.72, 95%CI: 0.61 to 0.84; p=0.000 
 
 
 PFS 
Despite the lack of clarity and minor data discrepancies, the ERG assumes that the PFS data reported 
in the CS (Section 4.7, p79-81) are based on the updated analysis as the CS (p144) states that ‘The 
key clinical data used to populate this model were informed by the updated cut-off data TROPIC trial. 
These data include PFS and OS of cabazitaxel and mitoxantrone, along with the risk of AEs 
associated with each treatment.’   
 
In an updated analysis, cabazitaxel was associated with a statistically significant improvement in 
median PFS (a composite endpoint defined as the time between randomisation and first date of 
progression as measured by PSA progression, tumour progression, pain progression or death).   PFS 
was 2.76 months in the cabazitaxel group and 1.41 months in the mitoxantrone group (HR 0.75, 95% 
CI: 0.65 to 0.87, p=0.0002) corresponding to a 25% reduction in the risk of progression.  These results 
appear to be very similar to the final efficacy analysis data reported by de Bono et al.11 (HR 0.74, 95% 
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CI: 0.64 to 0.86, p<0.0001).  As discussed in the CS (p80) the observed PFS duration was somewhat 
shorter than other cancer types and other trials in this setting.  A contributing factor to this difference 
was the conservative definition of PFS, including biochemical (PSA progression), which frequently 
precedes symptomatic or radiologic progression.  The CS states that ‘40-50% of progression events 
were due to PSA progression, with symptom deterioration recorded in only 2-4% of patients.  Patients 
were withdrawn from study treatment on first sign of progression, including confirmed PSA 
progression.  Hence, the relatively short PFS duration.’  A summary of the PFS results are provided in 
Table 8. 
 
Table 8: Progression-free survival in the TROPIC study - updated efficacy analysis 
 Cabazitaxel  
(n=378) 
Mitoxantrone 
(n=377) 
Hazard ratio  
(95% CI) 
p value 
Analysis at 10.3.10 (updated efficacy analysis as reported in CS, p79-81) 
Number of patients with 
progression-free survival events (%) 
367 (97.1%) a 370 (98.1%) a NR NR 
Median progression-free survival 
(months)  
2.76  
(2.43 to 3.12) 
1.41  
(1.35 to 1.77) 
0.75  
(0.65 to 0.87) b 
0.0002 
 Death 41 (10.8%) 33 (8.8%) NR NR 
 Tumour progression 67 (17.7%) 68 (18.0%) NR NR 
 PSA progression 163 (43.1%) 186 (49.3%) NR NR 
 Pain progression 86 (22.8%) 69 (18.3%) NR NR 
 Symptom deterioration 10 (2.6%) 14 (3.7%) NR NR 
Censored (calculated by the 
ERG) 
11 (2.9%) 7 (1.9%) NR NR 
CI, confidence interval; ITT, intention-to-treat; NR, not reported; PSA, prostate specific antigen 
a Data discrepancy in CS: Table 23 (p80, CS) reports corresponding data as follows: cabazitaxel, n=364 (96.30%); 
mitoxantrone, n=366 (97.08) - this appears to be similar to the data reported for the final efficacy analysis 
b Data discrepancy in CS: Table 2 (p18, CS) reports corresponding data as follows: 0.76 (0.65 to 0.89) - this appears to be 
the data reported for the subgroup analysis 
 
 
 Other secondary outcomes 
The CS did not report any results for the following secondary outcomes and no explanations were 
provided: tumour response; time to tumour progression; PSA response; PSA progression; pain 
response; and pain progression.  In brief, the published final efficacy analysis results reported by de 
Bono et al.11 found that cabazitaxel was associated with statistically significant improvements in: PSA 
response (p=0.0002); time to PSA progression (p=0.001); objective tumour response (p=0.0005); and 
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time to tumour progression (p<0.0001).  However, it was not associated with statistically significant 
differences in pain response (p=0.63) or pain progression (p=0.52).  A comprehensive summary and 
evaluation of the results is reported in NICE TA255.15  Moreover, data on HRQoL were not collected 
in the TROPIC study.  
 
 Subgroup analyses 
A post-hoc subgroup analysis was performed in mCRPC patients previously treated with a docetaxel 
containing regimen (at least 225 mg/m2) with an ECOG performance score of 0 or 1 (representing 
83.7% [632/755] of the TROPIC trial population).  In NICE TA25515  the Appraisal Committee 
considered this group of people to be the most appropriate population to receive cabazitaxel in UK 
clinical practice as patients with an ECOG performance score of 2 would not be fit enough to tolerate 
further chemotherapy and patients would need to receive at least 225 mg/m2 of docetaxel to gain the 
full benefit of first-line treatment before going on to second-line treatment with cabazitaxel.   
 
In the subgroup of mCRPC patients with an ECOG performance score of 0 or 1 and who had received 
at least 225 mg/m2 of prior docetaxel, the median OS was 15.61 months in the cabazitaxel group and 
13.37 months in the mitoxantrone group and the HR was 0.69 (95% CI 0.57 to 0.82, p<0.001) 
corresponding to a 31% reduction in the risk of death. Thus, cabazitaxel plus prednisone/prednisolone 
was associated with a median survival gain of 2.24 months relative to mitoxantrone plus 
prednisone/prednisolone.  A statistically significant improvement in median PFS was also observed.  
PFS was 2.76 months in the cabazitaxel group and 1.41 months in the mitoxantrone group (HR 0.76, 
95% CI: 0.65 to 0.89, p=0.001) corresponding to a 24% reduction in the risk of progression.  A 
summary of the OS and PFS results are provided in Table 9. 
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Table 9: Summary of the OS and PFS in patients with ECOG performance score of 0 or 1 
and who had received >225mg/m2 of docetaxel 
 Cabazitaxel  
(n=319) 
Mitoxantrone 
(n=313) 
Hazard ratio  
(95% CI) 
p value 
Analysis at 10.3.10 (updated efficacy analysis as reported in CS, p83-84) 
Overall survival 
Number of patients with 
deaths a 
228 (71.47 %) 253 (80.83%) NR NR 
Number of patients censored 91 (28.53 %) 60 (19.17 %) NR NR 
Median overall survival, 
months (95% CI)  
15.61  
(13.96 to 17.28) 
13.37  
(11.99 to 14.52) 
0.69  
(0.57 to 0.82) 
 
<0.001 
Progression-free survival 
Number of patients with 
progression-free survival 
events (%) 
305 (95.61%) 304 (97.12%) NR NR 
Median progression-free 
survival,b months (95% CI)  
2.76  
(2.43 to 3.12) 
1.41  
(1.35 to 1.84) 
0.76  
(0.65 to 0.89) 
0.001 
CI, confidence interval; NR, not reported; PSA, prostate specific antigen 
a These figures were incorrectly presented in the CS Table 26 as number of patients censored, rather than number of deaths 
b Progression-free survival was defined as a composite endpoint evaluated from the date of randomisation to the date of 
tumour progression, PSA progression, pain progression, or death due to any cause, whichever occurred first  
 
 
4.2.4.2  Safety and tolerability 
This section provides the main safety evidence for the use of cabazitaxel (plus prednisone or 
prednisolone) in people with mCRPC whose disease had progressed during or after treatment with a 
docetaxel-containing regimen from the TROPIC trial.11  The CS (including the company’s 
clarification response) also provided supplementary evidence based on a systematic review of non-
randomised studies, on the safety of cabazitaxel in routine clinical practice.  Further details of this 
review are provided in the supplementary evidence section.   
 
In the TROPIC trial,11 the median number of treatment cycles administered, and the number of 
patients completing the planned 10 cycles of treatment, were both higher in the cabazitaxel group 
than in the mitoxantrone group.  Disease progression was the most common reason for 
discontinuation of study treatment, and was more common in the mitoxantrone group than in patients 
receiving cabazitaxel, whereas discontinuations because of unacceptable adverse effects or patient 
request were both more common in the cabazitaxel group.  In addition, more patients in the 
59 
 
cabazitaxel group than in the mitoxantrone group required dose reductions and treatment delays, 
suggesting that cabazitaxel was less well tolerated than mitoxantrone.  A summary of the treatments 
received and reasons for discontinuation (no statistical comparisons were reported in the CS for any 
of these outcomes) are provided in  
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Table 10. 
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Table 10: Treatment received and reasons for discontinuation in the TROPIC study11 
 Cabazitaxel 
(n=378) 
Mitoxantrone 
(n=377) 
Patients who received study treatment, 371 (98%) 371 (98%) 
Median number of treatment cycles (IQR) 6 
(3 to 10) 
4 
(2 to 7) 
Number of patients completing planned 10 cycles of 
study treatment 
105 (28%) 46 (12%) 
Median relative dose intensity (IQR) 96.1% 
(90.1 to 98.9) a,b 
97.3% 
(92.0 to 99.3) a,b 
Discontinuation of study treatment 266 (70%) 325 (86%) 
Reasons for discontinuation of study treatment   
Disease progression 180 (48%) 267 (71%) 
Adverse event 67 (18%) 32 (8%) 
Non-compliance with protocol 1 (<1%) 0 
Lost to follow-up 0 2 (1%) 
Patient request 8 (2%) 17 (5%) 
Other  10 (3%) 7 (2%) 
Dose reductions   
Number of patients c 45 (12%) 15 (4%) 
Number of cycles d 221 (9.8%) 88 (5.1%) 
Treatment delays   
Number of patients e 104 (28%) 56 (15%) 
Number of cycles d   
≥4 days NR (9.3%) NR (7.9%) 
≤9 days 157 (7.0%) 110 (6.3%) 
>9 days 
 
51 (2.2%) 28 (1.6%) 
IQR, interquartile range 
a Data discrepancy in CS - p111 (CS) suggest a range (unit not specified) of 49.0% to 108.2% for cabazitaxel and 42.5% to 
106% for mitoxantrone 
b Data from de Bono et al.11 and CS (p77, Table 26) 
c One dose reduction was allowed per patient, 20 mg/m2 for cabazitaxel or 10 mg/m2 mitoxantrone 
d Percentages are of total number of treatment cycles: 2251 for cabazitaxel and 1736 for mitoxantrone  
e Delays of ≤2 weeks were allowed 
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All AEs in the TROPIC trial11 were recorded from the time of first dose until 30 days after the cycle 
of treatment.  General and serious AEs were assessed and graded according to National Cancer 
Institute Common Terminology Criteria for AE, version 3.23 and were followed until resolution.  
Treatment emergent AEs of grade ≥3 occurred in 213/371 (57.4%) patients in the cabazitaxel group 
and 146/371 (39.4%) patients in the mitoxantrone group.  Serious treatment emergent AEs were 
reported in 145 (39.1%) patients in the cabazitaxel group and 77 (20.8%) patients in the mitoxantrone 
group.   The proportion of patients withdrawing from study treatment permanently due to any 
treatment emergent AE (including disease progression reported as a treatment emergent AE) was 
18.3% (68/371) in the cabazitaxel group compared with 8.4% (31/371) in the mitoxantrone group.  
The most common treatment emergent  AEs leading to treatment discontinuation in the cabazitaxel 
group compared with the mitoxantrone group were neutropenia (2.4% versus 0%), renal failure 
including acute renal failure (1.9% versus 0%) haematuria (1.3% versus 0.3%), sepsis including 
neutropenic sepsis, pneumococcal sepsis and septic shock (1.3%% versus 0.3%), diarrhoea (1.1% 
versus 0.3%), fatigue (1.1% versus 0.3%), and abdominal pain (0.8% versus 0%) and febrile 
neutropenia (0.8% versus 0%), respectively.85 
 
The most common AEs in the TROPIC trial11 (≥ grade 3 occurring in ≥5% of patients in either 
treatment group) were: neutropenia and its complications (febrile neutropenia and infections); 
asthenic conditions (asthenia and fatigue); and gastrointestinal toxicity (diarrhoea, nausea and 
vomiting), which were noticeably higher in the cabazitaxel group than in the mitoxantrone group.  As 
stated in the company’s clarification response to question A5 (p5-6), ‘regulatory authorities require an 
assessment of both clinical and subclinical changes to body systems and physiological processes.  
Whilst abnormal laboratory findings are important to their assessment, in real practice such departures 
may not be observed…For example in TROPIC if both laboratory and symptomatic events (‘patient 
felt’) are included neutropenia (grade 3 and above) was observed in 82% of people in the cabazitaxel 
arm. However the proportion of people experiencing events that required intervention of some kind 
was far less at 21%.’  The clinical advisors to the ERG agreed with the company’s response and 
commented that high levels of monitoring in a trial setting would result in abnormal laboratory 
measurements being recorded as AEs despite the fact that these may not cause any problems for the 
patient.   Whilst a detailed summary of all AEs from the TROPIC study is provided in Section 4.5 (so 
that a comparison can be made with studies included in the NMA), Table 11provides a brief summary 
of AEs requiring medical intervention (e.g. dose reduction, dose modifications, use of supportive 
treatment or treatment discontinuation) in all patients who received at least part of one dose of study 
drug (safety analysis) in the TROPIC trial and in the subgroup of mCRPC patients previously treated 
with a docetaxel containing regimen (at least 225 mg/m2) with an ECOG performance score of 0 or 1.  
This was considered by the company to be the most appropriate information to include in the 
economic model.    
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Table 11: AEs requiring medical interventiona (≥ grade 3 occurring in ≥5% of patients in 
either treatment group) in the TROPIC trial (reproduced with minor changes; 
p19 and 113, CS) 
Adverse Event Proportion of patients 
Safety analysis  
(all patients who received study drug) 
Subgroup with ECOG PS 0-1 
with 225mg/m2 prior docetaxel 
Cabazitaxel Mitoxantrone Cabazitaxel Mitoxantrone 
Haematological 
Neutropenia 0.210 0.073 0.201 0.081 
Febrile neutropenia 0.073 0.016 0.080 0.019 
Anaemia 0.035 0.013 0.032 0.006 
Thrombocytopenia 0.024 0.003 0.022 0.000 
Non-Haematological 
Diarrhoea 0.062 0.003 0.064 0.003 
Fatigue 0.049 0.030 0.051 0.023 
Asthenia 0.046 0.024 0.042 0.019 
Leukopenia 0.038 0.013 0.032 0.013 
Back pain 0.038 0.030 0.038 0.032 
Pulmonary embolism 0.019 0.022 0.019 0.026 
Dehydration 0.022 0.008 0.016 0.006 
Nausea 0.019 0.003 0.019 0.003 
Bone pain 0.008 0.024 0.010 0.026 
Deep vein thrombosis 0.019 0.008 0.016 0.010 
Neuropathy  0.005 0.003 0.006 0.003 
a AEs reported by the investigator and do not include abnormal laboratory values 
 
 
The number of deaths reported within 30 days of the last dose of study drug (n=27) are summarised in 
Table 12.  Such deaths were more common with cabazitaxel than with mitoxantrone. Neutropenia was 
the most common cause of such death in patients receiving cabazitaxel, compared with disease 
progression in those receiving mitoxantrone.  A FDA medical review of cabazitaxel85 considered five 
of the 18 deaths in the cabazitaxel group to be due to infections; 80% of these deaths occurred after a 
single dose of cabazitaxel, and none of the five patients had been given prophylactic G-CSF.  As 
noted in the CS (p112), neutropenia is to be expected when treating with taxane-based chemotherapy 
and is not necessarily difficult to manage for experienced centres.  Similarly, in TA255,15 the 
Appraisal Committee noted that the incidence of neutropenia was lower among participants recruited 
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at European centres than other centres and that clinicians in the UK follow best practice guidelines for 
managing neutropenia and, as a result, few patients in the UK develop febrile neutropenia or 
neutropenic sepsis.  Recent evidence from the UK EAP study suggests that cabazitaxel can be used 
safely in UK practice with manageable toxicity.  As noted by Bahl et al.50 (the authors of the UK EAP 
study) lower rates of neutropenia and sepsis were observed in the UK EAP cohort where primary 
prophylactic G-CSF use was common, whereas this was not permitted during the first cycle in the 
original TROPIC study11 but was allowed (at physicians discretion) after first occurrence of either 
neutropenia lasting ≥7 days or neutropenia complicated by fever or infection. 
 
Table 12: Deaths occurring within 30 days of last dose of study drug in the TROPIC trial11 
 Cabazitaxel 
(n=371) 
Mitoxantrone 
(n=371) 
Deaths within 30 days of last dose of study drug 18 (5%) 9 (2%) 
Causes of deaths within 30 days of last dose of study drug   
Disease progression 0 6 (2%) 
Neutropenia & clinical consequences/sepsis 7 (2%) 1 (<1%) 
Cardiac  5 (1%)a 0 
Dyspnoea (apparently related to disease progression) 0 1 (<1%) 
Dehydration/electrolyte imbalance 1 (<1%) 0 
Renal failure 3 (1%)b 0 
Cerebral haemorrhage 1 (<1%) 0 
Unknown cause 1 (<1%) 0 
Motor accident 0 1 (<1%) 
a Cardiac arrest (n=3), sudden death (n=1) and ventricular fibrillation (n=1).  None of these events were regarded as being 
related to the study drug.86 
b Data discrepancy: FDA reviewers attributed 4 deaths to renal failure,85 rather than the 3 reported by de Bono et al.11 
 
 
Moreover, none of the cardiac deaths in the TROPIC study were considered by the study investigators 
to be treatment related86 and additional evidence provided in the company’s clarification response to 
question A15, p16-19 (i.e. results of studies evaluating cardiac toxicity associated with cabazitaxel, 
the conclusions of a review by an expert panel of renal events observed with cabazitaxel and post-
marketing safety data) suggest there are no safety concerns related to cardiac or renal toxicity.   In 
TA255,15 the Appraisal Committee also concluded that ‘…there is no evidence of additional risk other 
than that included in the SPC.’ 
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4.2.4.3.  Supplementary evidence 
The CS included a review based on a systematic search of non-randomised and uncontrolled evidence 
considered relevant to the decision problem (further details are provided in Section 4.1).  The stated 
aim of the review was to identify evidence related to: 
 Safety of cabazitaxel in clinical practice 
 Efficacy of cabazitaxel used in sequence with abiraterone or enzalutamide. These sequences 
formed three broad categories: (1) all-hormonal sequences such as abiraterone followed by 
enzalutamide, or enzalutamide followed by abiraterone; (2) cabazitaxel-hormonal such as 
cabazitaxel followed by abiraterone or enzalutamide; and (3) hormonal- cabazitaxel such as 
abiraterone or enzalutamide followed by cabazitaxel. 
 
In brief, only studies of patients with mCRPC previously treated with a docetaxel-based regimen were 
eligible for inclusion but there was no limitation on comparators and broad inclusion criteria for 
outcomes and study designs. Case series and case reports were excluded but studies published only as 
conference abstracts were eligible for inclusion. 
 
The methods used for study selection and data extraction were adequate. However, the company 
stated that 107 studies met the inclusion criteria (51 full papers and 56 conference abstracts) but only 
a small proportion of these were used in the analysis. The selective inclusion of part of the evidence 
base should be kept in mind when interpreting the findings. 
 
Evidence on the safety of cabazitaxel in clinical practice was derived from the CUP and the EAPs in 
various countries and regions (see Table 13 for details of published reports). Seven published 
reports44-50 and five conference abstracts51-55 were included. As noted in the company’s clarification 
response, there is overlap in some of the European data from the CUP/EAPs, however, the extent of 
overlap is not explicitly clear within the CS. All the studies were uncontrolled, open label 
observational studies. Patients received cabazitaxel 25 mg/m2 intravenously every three weeks in 
combination with prednisone or prednisolone 10 mg daily. Treatment was stopped in the event of 
disease progression, unacceptable toxicity, investigator’s decision or after 10 cycles. The CUP/EAP 
studies were primarily designed to assess safety, although efficacy data were collected in some 
countries. 
 
The CS only included a quality (risk of bias) assessment for one of the included studies, namely the 
UK EAP.50 The assessment used the National Institutes of Health National Heart, Lung and Blood 
Institute Quality assessment Tool for Cross-Sectional Studies.29  Following a clarification response to 
question A18 (p21) the company noted that a quality assessment of the other CUP/EAP studies would 
be provided; however, these were not received prior to the completion of the ERG report.  The 
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limitations identified for the UK EAP study were lack of a sample size justification or power 
calculation; that the study did not examine effects of different levels of exposure to the study drug; 
lack of blinding and lack of adjustment for confounders. In addition, the participation rate of eligible 
patients was unclear and loss to follow-up was not reported. These limitations were in line with what 
would be expected for an uncontrolled observational study. It is likely that CUP/EAP studies from 
other countries would have the same limitations. The CS commented that studies of this kind are 
inherently susceptible to selection bias. Demographic details of the participants are summarised in 
Table 13, which also includes the cabazitaxel arm of the TROPIC study11 for comparison purposes. 
There were no dramatic differences between the trial and the CUP/EAP populations, although some 
characteristics, for example baseline PSA level, varied between countries in the CUP/EAP studies. 
The Korean study had a higher proportion of patients with an ECOG PS of 2 and a lower proportion 
with bone metastases compared with the other national studies. 
 
Table 14 summarises the efficacy and safety results from the TROPIC trial (cabazitaxel arm) and the 
fully published CUP/EAP reports. The CS noted that in the EAP reports, neutropenia was only 
recorded when it represented a clinical AE, whereas in the TROPIC study, data for haematological 
AEs were based on laboratory assessments. This would explain why levels of neutropenia recorded in 
cabazitaxel-treated patients in the TROPIC study were markedly higher than those reported from 
CUP/EAP settings. For example, neutropenia was recorded for 94% of patients in the TROPIC 
cabazitaxel arm (82% at grade 3 or above)11 compared with 12.5% (9.8% grade 3 or above) in the UK 
EAP observational study.50 Febrile neutropenia occurred in 8% of patients in the TROPIC cabazitaxel 
arm11 compared with 1.8% in the UK EAP.50  In addition, seven patients (6.3%) experienced 
neutropenic sepsis during treatment in the UK EAP, however, none of these patients had received 
prophylactic G-CSF.  Clinical advisors to the ERG considered the data from the UK EAP50 to be a 
reasonable reflection of the situation in clinical practice. 
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Table 13: Patient characteristics in TROPIC study and selected EAP/CUP reports (reproduced from CS, Table 33, p98) 
Baseline characteristic Country 
TROPIC trial: 
(cabazitaxel arm: 
multiple countries)11 
European EAP44 Korea45 Germany46 Italy47 Netherlands48 Spain49 UK50 
Number of patients 378 746 26 111 218 49 153 112 
Median age, in years 
 
68 
 
Mean 67.7  
(SD ±7.5) 
66.5 
 
67.9 
 
70 
 
64.6 
 
70.0 
 
67 
 
Age range 62 – 73 NR 53 - 82 49 – 81 49 – 87 59 – 70 65 – 75 63 – 72.5 
Eastern Cooperative Oncology Group 
performance status (%) 
0 
1 
2 
 
 
0 – 1: 93% 
 
 
38.7 
50.9 
10.5 
 
 
12 
69 
19 
 
 
45 
49.5 
5.5 
 
 
67.4 
31.2 
1.4 
 
 
6.1 
71.4 
24.5 
 
 
30.7 
58.2 
11.1 
 
 
42.0 
51.8 
6.3 
Sites of metastases (%) 
Bone 
Lung 
Liver 
Regional lymph 
Distant lymph 
Visceral 
 
80 
NR 
NR 
NR 
NR 
25 
 
91.7 
NR 
NR 
31.6 
30.1 
25.3 
 
42 
19 
19 
NR 
NR 
31 
 
91 
10.8 
10.8 
42.3 
31.5 
NR 
 
88.0 
22.6 
13.8 
33.6 
44.7 
NR 
 
95.9 
12.2 
14.3 
34.7 
49.0 
NR 
 
94.1 
9.2 
13.1 
26.1 
22.9 
26.8 
 
92.0 
14.3 
8.0 
41.1 
27.7 
NR 
Baseline Prostate Specific Antigen, 
ng/mL, median (IQR) 
143.9 
(51.1 − 416.0) 
NR 95.3 
(9.1 – 297.7) 
733.3 
(56.2 – 7679) 
NR 355.5 
(123.0 - 1515.4) 
NR NR 
Time from last docetaxel dose to 
inclusion, months (IQR unless 
otherwise stated) 
6.2  
(SD ±6.7) 
5.3 
(2.4 – 10.6) 
6.6 
(0.6 – 44.4) 
4.07 
(2.04 – 8.67 
NR 3.22 
(1.36 – 6.87) 
6.5 
(2.5 - 12.1) 
33% (within 3 
months post 
docetaxel) 
EAP, Early Access Programme; IQR, interquartile range; NR, not reported; SD, standard deviation 
68 
 
Table 14: Efficacy and safety outcomes in TROPIC study and selected EAP/CUP reports (reproduced, with minor changes from CS, Table 36, 
p104-105) 
Country Cabazitaxel 
cycles 
(median and 
IQR) 
Overall 
survival, 
months (95% 
CI) 
Progression-free 
survival,a 
months (95% 
CI) 
Deaths n, 
(%) 
Percentage of patients with adverse events. All grades (≥3) 
Any Neutro-
penia 
Febrile 
neutro-
penia 
Anaemia Diarrhoea Nausea Fatigue 
TROPIC study: 
multiple 
countries11 
6 (3–10) Median:15.1 
(14.0 – 16.5) 
Median:  2.8 (2.4- 
3.0) 
277 (61) 95.7 94 (82)b 8 (8) 97 (11) 47 (6) 34 (2) 37 (5) 
UK50 6 (3 – 10) NR NR 4 (3.6) NR (NR) 12.5 (9.8) 1.8 (1.8) NR 64.3 (4.5) 46.4 (1.8) 54.5 (13.4) 
Europe (20 
countries)44 
4.0 (1–16) NR NR 16 (21.5) <70 years: 88 
(47) 
70–74 years: 
90.5 (50) 
≥75 years: 
88.3 (56.6) 
19.8 (17.0) 5.5 (5.4) 21.6 (4.7) 34.6 (2.8) 22.1 (0.8) 25.2 (4.2) 
Germany46 6 (3 – 10) Mean: 13.9 
(0.7–35.8) 
Mean: 3.78 
(0.7–31.47) 
6 (5.4) 64 (46.8) NR (7.2) NR (2) NR (4.5) NR (0.9) NR NR 
Italy47 6 (NR) NR NR 4 (1.8) NR (NR) NR (33.9) NR (5.0) NR (6.0) NR (2.8) NR (NR) NR (3.7) 
Netherlands48 6 (1 – 21) Median: 8.7  
(6.0 – 15.9) 
Median: 2.8  
(1.7 – 4.9) 
NR 100 (51) 6.1 (4.1) 4.1 (4.1) 28.6 (4.1) 40.8 (2.0) 44.9 (2.0) 61.2 (10.2) 
Spain49 6 (4 – 8) NR Median: 4.4 
(2.7 –6.1) 
5 (3.3) 93.5 (43.1) 22.2 (16.3) 5.2 (5.2) 37.9 (5.9) 45.8 (5.2) 22.2 (1.3) 4.6 (1.3) 
Korea45 5 (1 –23) Median: 16.5 
(12.1 –20.9) 
Median: 
8.5 (3.0 –13.1) 
3 (12) 96 (77) 31 (31) 31 (31) 35 (4) 42 (0) 31 (0) 35 (4) 
CI, confidence interval; IQR, interquartile range; NR, not reported; OS, overall survival; PFS, progression-free survival; PSA, prostate-specific antigen 
a Mean or Median time to composite progression as stated in the publication (defined as the time between randomisation and the first date of progression as measured by PSA progression, tumour 
progression, pain progression or death).   
b In the EAP, neutropenia was based on adverse event declaration, whereas in TROPIC, data for haematological adverse events were based on laboratory assessments. Routine full blood count was 
performed prior to every cycle; for cycle 1 further full blood counts were performed in weeks 2 and 3. 
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The CS argued that differences in levels of neutropenia and febrile neutropenia between TROPIC and 
the CUP/EAP studies may partially reflect more rigorous application of guidance regarding 
prophylaxis with G-CSFs in clinical practice (Section 4.12.3, p114, CS). No direct evidence was 
presented to support this statement but it was noted that prophylactic G-CSF treatment was not 
permitted for the first cabazitaxel cycle in TROPIC but was allowed from the first cycle in the 
European CUP/EAP programme. The CS also noted that other AEs associated with cabazitaxel (for 
example, fatigue, diarrhoea, nausea and vomiting) are predictable and can be managed in practice by 
medication and patient education.  
 
The CS (p117-119) also included two other sources of evidence on AEs: safety results from a 
prospective product registry in Belgium and a summary of a Periodic Benefit Risk Evaluation (PBRE) 
report compiled by Sanofi. These both appear to be unpublished sources of data (results from the 
Belgian registry are designated academic in confidence) and their relationship to the systematic search 
and study selection process is unclear. 
 
The Belgian registry (HRQLana: Registry Number CABAZL06515) included 93 patients eligible for 
cabazitaxel treatment for mCRPC according to Belgian reimbursement criteria. The mean age was 
69.4 (SD 8.8) years and ECOG PS was 0 for 25 patients (26.9%) and 1 for 68 (73.1%). Treatment-
emergent AEs were reported for 81 patients (87.1%) and 43 patients (46.2%) had AEs of grade 3 or 
above. The most frequent AEs of grade 3 or above were: febrile neutropenia (8 patients, 8.6%); 
neutropenia (7 patients, 7.5%); anaemia (5 patients, 5.4%); and fatigue (3 patients, 3.2%). The CS 
(p118) noted that the population in this registry was more heterogeneous than the TROPIC trial 
population in terms of disease characteristics and had followed different therapeutic pathways so the 
two groups were not directly comparable. Furthermore, the time period of data collection was not 
reported for this registry. However, the results provide further uncontrolled evidence that the safety 
profile seen in the CUP/EAP studies is broadly representative of outcomes seen in clinical practice. 
 
The CS provided a brief summary of the PBRE report, with no detailed results (p118-119, CS). The 
latest issue of the report covers the period from the 17th of June 2013 to the 17th of June 2014. The 
company stated that approximately 36,550 patients have been exposed to cabazitaxel worldwide, 
including 11,800 patients during the period covered by this report; approximately 4500 patients were 
exposed to cabazitaxel in clinical trials up to June 2014.  The company stated that the PBRE findings 
are consistent with the known safety profile of cabazitaxel and that this is comparable with that of 
other products in this therapeutic class. 
 
The ERG considers that despite the limitations of the evidence review process and the evidence itself, 
the CS provides a reasonable summary of the safety profile of cabazitaxel and of possible differences 
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between the results seen in the TROPIC study11 and those seen in centres providing high-quality care 
in clinical practice. 
 
The CS also presented a section (4.11.12) entitled ‘Efficacy of cabazitaxel in the post abiraterone or 
enzalutamide setting. Resistance to advanced hormonal therapies’. This section included studies 
identified by the systematic search for non-randomised and non-controlled evidence together with 
other studies published since the date of that search. The section also draws on a systematic review by 
Maines et al.84 
 
The first part of Section 4.11.12 of the submission (p106-108) comprises two tables. Table 38 of the 
CS (p106) compares patients treated with abiraterone with and without prior enzalutamide while 
Table 39 of the CS (p106) compares patients treated with enzalutamide with and without prior 
abiraterone (the legends to these tables appear to be incorrect). In both of these tables the ‘no prior 
treatment’ data are taken from randomised trials (COU-AA-30133 and AFFIRM,13 respectively) and 
these are compared with data from what appear to be retrospective cohort studies. These tables in the 
CS appear to show shorter PFS and fewer patients with a ≥50% decline in PSA in the studies of 
patients with prior treatment with another hormonal agent. No data on OS were reported.  Table 15 
summarises these data. Dates of the references by Schrader et al. and Thomsen et al. were reported as 
2013 in the CS but the ERG believes 2014 to be correct. The CS identified one further study65 but this 
apparently did not report any data on PFS or decline in PSA. 
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Table 15: Studies examining cross resistance between abiraterone and enzalutamide 
(reproduced, with minor changes, from CS Tables 38 and 39, p 106) 
Reference n Median abiraterone 
duration 
Patients with ≥50% 
PSA decline 
Median PFS 
No prior enzalutamide 
De Bono 201133 797 8 months 29% 5.6 months 
Prior enzalutamide 
Loriot 201356 38 3 months 8% 2.7 months 
Noonan 201357 30 3 months 3% 3.6 months 
 
Reference n Median enzalutamide 
duration 
Patients with ≥50% 
PSA decline 
Median PFS 
No prior abiraterone 
Scher 201213 800 8.3 months 54% 8.3 months 
Prior abiraterone 
Schrader 201458 35 4.9 months 29% 2.8 months 
Thomsen 201459 24 4.0 months 17% 2.8 months 
Badrising 201460 61 3.0 months 21% 2.8 months 
Bianchini 201461 39 2.9 months 23% 3.1 months 
Schmid 201462 35 2.8 months 10% 4.6 months 
Azad 201563 68 4.1 months 22% NR 
Brasso 201464 137 3.2 months 18% NR 
PFS, progression-free survival; PSA, prostate-specific antigen; NR, not reported 
 
The CS also included details of studies supporting the continuing efficacy of cabazitaxel after 
treatment with enzalutamide or abiraterone.  Although seven full papers66-69, 71, 72, 87 and 10 conference 
abstracts73-82 were identified (Table 40, p108-110 and Appendix A20 of the CS), these were simply 
listed with no additional analyses undertaken.   
 
The ERG notes that in the absence of further details, it is unclear whether the included studies were 
designed, as stated, to examine cross resistance between abiraterone and enzalutamide and / or 
treatment sequencing.  In addition, the criteria for inclusion in the review of non-randomised and non-
controlled evidence (based on those reported in Tables 29 and 30 on p88-90 of the CS) were broad 
and no explicit details were provided on how studies were selected and included in section 4.11.12 
(p106-110) of the CS.  Although a list of relevant studies were provided, no details of study or patient 
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characteristics were reported, no quality assessment was undertaken, data synthesis was limited and 
the discussion of the findings including the strength and weaknesses of the findings was lacking.   
 
The CS (p107) also identified a systematic review by Maines et al.84 on the sequential use of agents 
(cabazitaxel, abiraterone and enzalutamide) after docetaxel treatment in patients with mCRPC.  
However, no further details were provided in the CS.  The CS states that ‘…a review by Maines of all 
the available evidence on the use of cabazitaxel, abiraterone and enzalutamide in the post docetaxel 
setting was published just prior to this submission’.  For completeness, a brief summary of the 
systematic review is provided by the ERG.  This systematic review undertook comprehensive 
searches of two electronic databases (MEDLINE and EMBASE) to identify all published studies 
between January 2012 and March 2015 (in the English language) reporting monthly OS rates of 
mCRPC patients receiving third-line new agents after having previously received docetaxel and 
another new agent.  Searches were supplemented by searching key conference websites.  For the 
descriptive analysis, the treatments were merged into three groups: (1) all-hormonal sequences i.e. 
abiraterone followed by enzalutamide, or enzalutamide followed by abiraterone; (2) cabazitaxel-
hormonal i.e. cabazitaxel followed by abiraterone or enzalutamide; and (3) hormonal- cabazitaxel i.e.  
abiraterone or enzalutamide followed by cabazitaxel.  No quality assessment was undertaken.  The 
cumulative monthly OS rates in each group were determined using a weighted-average approach. OS 
was considered to be the most reliable measure of clinical outcome as endpoints such as biochemical 
or objective response rates and PFS can be greatly influenced by different definitions and/or timings 
of follow-up between studies. The review included thirteen retrospective studies56, 57, 60, 62, 63, 66, 68, 69, 72, 
73, 88-90 including 1016 patients who received the following sequences (some were multi-arm studies): 
all-hormonal sequences (n=397 [72 patients were excluded from the analysis because they were 
chemo-naïve]), cabazitaxel-hormonal (n=229) and hormonal-cabazitaxel (n=318).  The 6-month OS 
rates were 65.4%, 94.8%, and 85.8%, whereas the 12-month OS rates were 28.5%, 76.4%, and 61.3%, 
respectively.  There were no statistically significant differences in terms of known prognostic factors 
(median age, ECOG PS 0-1 and ≥2, Gleason score ≥8, and the rate of bone, lymph nodes and visceral 
metastases).  The authors concluded that ‘The retrospective nature of included studies, the limited 
cohort size, the short follow-up of most of them as well as the heterogeneity of patient population 
across studies and the inevitable selection and methodological biases require caution in the 
interpretation of the results. Our analysis does not allow any definite conclusions to be drawn, and the 
suggestion that sequences including CABA [Cabazitaxel] may lead to better disease control needs to 
be prospectively validated in larger series, ideally head-to-head comparison trials…’ 
 
4.3  Critique of trials identified and included in NMA 
In the absence of any direct head-to-head RCTs comparing cabazitaxel and other second-line agents 
(abiraterone and enzalutamide) for the treatment of mCRPC, the company conducted an NMA. This is 
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an extension of the conventional pairwise meta-analysis, combining direct and indirect evidence from 
RCTs. This approach allows simultaneous comparisons of multiple treatments from trials comparing 
different sets of treatments (providing there is a connected network) and ensures that the estimates 
produced between the pairwise comparators are not discrepant. It is typically performed in a Bayesian 
manner to allow for all sources of uncertainty and to allow probabilistic statements to be made about 
population parameters.  
 
The company conducted a systematic review (review 2) to collate the clinical evidence from 
published RCTs which assess the efficacy of second-line agents for the treatment of mCRPC which 
had progressed after first-line docetaxel.  Full details of the inclusion and exclusion criteria of the 
systematic reviews are provided in Section 4.1.2.  In brief, the population of interest was adults with 
mCRPC who had been previously treated with docetaxel based regimens where the relevant study was 
an RCT and the outcomes included efficacy. The interventions of interest (relevant to the decision 
problem) were: cabazitaxel; abiraterone; enzalutamide; mitoxantrone; and BSC.  It is noteworthy that 
radium-223 dichloride was listed in the final scope as a comparator for the subgroup of patients with 
bone metastasis only (no visceral metastasis). However, as discussed in Section 4.1.2, the company 
expressed their concerns about the applicability and feasibility of including radium-223 dichloride as 
a comparator.  As noted in the company’s clarification response to question A1 (p1-2), the company 
states that ‘Given these anticipated issues with the different RCT populations, study endpoints 
coupled with the characteristics of patients in whom the different drugs are likely to be used, it 
remains a concern that inclusion of ALSYMPCA in the existing NMA is problematic and we have not 
done this analysis.’  Nevertheless, the company did provide a summary of the efficacy results for OS 
in the cohort of patients with previous docetaxel use from the ALSYMPCA study14 and the TROPIC 
study11 (Table 16) but with no further analysis. 
 
Table 16: Overall survival for the TROPIC and ALSYMPCA (previous docetaxel use) 
populations 
Trial Active therapy 
(cabazitaxel, 
radium-223 
dichloride ) 
Placebo 
(mitoxantrone 
for cabazitaxel) 
Difference Hazard ratio 
TROPIC (ITT)11 15.1 
(14.0 – 16.5) 
12.8 
(11.5 – 13.7) 
2.3 months 0.72 
(0.61 - 0.85) 
ALSYMPCA14 (patients 
with previous docetaxel 
use) 
14.4 months 
(12.5 – 15.5) 
11.3 months 
(10.0 – 12.9) 
3.1 months 0.70 
(0.56 – 0.88) 
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The systematic review methods undertaken for the NMA (e.g. literature searching, study selection, 
data extraction and quality assessment) were similar to those undertaken for the cabazitaxel 
systematic review.  As noted in Section 4.1, adequate methods were undertaken to identify, select and 
quality assess all relevant RCT studies. 
  
Although numerous studies were initially identified, only three studies (which were considered 
relevant to the decision problem by the company) were included in the NMA.  The TROPIC study11 
compared cabazitaxel plus prednisone with mitoxantrone plus prednisone; the AFFIRM study13 
compared enzalutamide plus placebo with placebo with or without prednisone; and the COU-AA-301 
study12 compared abiraterone plus prednisone with prednisone plus placebo.  A summary of the key 
design and study characteristics, as reported in the CS, is provided in Table 17. Inclusion and 
exclusion criteria were similar for all three studies. 
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Table 17: Characteristics of trials included in the NMA (adapted from Section 4.3 and appendices B (tables 1 and 2) of the CS) 
 TROPIC11 AFFIRM13 COU-AA-30112, 33 
Location 146 sites in 26 countries (6 UK sites) 156 sites in 15 countries (12 UK sites) 130 sites in 13 countries (12 UK sites) 
Design Phase III RCT Phase III RCT Phase III RCT 
Duration Treatment to disease progression or 
unacceptable toxicity or maximum of 
ten cycles; follow-up to death or 
study cut-off  
24 months Treatment to disease progression 
Randomisation By interactive voice response system 
stratification by measurability of 
disease and ECOG PS 
By interactive voice response system; 
stratification by ECOG PS and pain 
score 
By interactive web response system; stratification by 
baseline ECOG PS; presence or absence of pain; 1 vs. 
2 previous chemotherapy regimens; and type of 
disease progression at study entry 
Blinding Patients and treating physicians not 
blinded 
Patients, investigators, site personnel 
and sponsor’s staff involved in the study 
were blinded to study drug 
Patients and investigators blinded to study drug 
Intervention(s) 
and 
comparator(s) 
Cabazitaxel plus prednisone (n=378) 
Mitoxantrone plus prednisone 
(n=377) 
Enzalutamide (n=800) 
Placebo (n=399) 
Use of prednisone or other 
glucocorticoids was permitted but not 
required 
Abiraterone acetate plus prednisone/prednisolone 
(n=797) 
Placebo plus prednisone/prednisolone (n=398) 
Primary 
outcomes 
OS: defined as time from 
randomisation to death from any 
OS: time from randomisation to death 
from any cause 
OS: time from randomisation to death from any cause 
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cause 
Secondary 
outcomes 
PFS; tumour response rate; time to 
tumour progression; PSA 
progression; PSA response; pain 
progression; pain response; adverse 
events in patients who had received 
at least one dose of study drug 
Time to PSA progression; radiographic 
PFS; time to first skeletal-related event; 
FACT-P response rate; rate of pain 
palliation at week 13 
Time to PSA progression; PSA response rate 
Other endpoints  PSA response rate; best overall 
radiographic response; EQ-5D; ECOG 
PS; pain progression rate; time to pain 
progression; change from baseline in 
pain severity and pain interference; 
change from baseline in QoL 
Modified PFS; objective tumour response rate; pain 
palliation; time to pain progression; fatigue palliation 
and time to fatigue progression; functional status 
measured by FACT-P; AEs and clinical laboratory 
tests for safety; medical resource utilisation 
information 
Duration of 
follow-up  
Median 12.8 months in publication, 
20.5 months in updated analysis 
included in CS  
Median 14.4 months at interim analysis 
and 15 months at database lock 
Up to 60 months 
AEs, adverse events; ECOG, Eastern Co-operative Oncology Group; EQ-5D, EuroQoL-5D quality of life instrument; FACT, Functional Assessment of Cancer Therapy-Prostate; OS, overall 
survival; PFS, progression-free survival; PS, performance status; PSA’ prostate-specific antigen; QoL, quality of life; RCT, randomised controlled trial; UK, United Kingdom  
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Despite stating that ‘the populations are comparable between the trials’ included in the NMA 
(Appendices B, p6, CS), the CS also presented data indicating that ‘patients entering the studies had 
different disease characteristics’ (Appendices B, p9, CS). Firstly, the CS stated that ‘in the COU-AA-
310 trial, only 30% of patients were refractory to docetaxel whilst 70% in TROPIC had progressed 
whilst on docetaxel or within three months of receiving it’. The ERG was unable to verify the 
statement about COU-AA-301 from the publication cited.12 Secondly, the CS stated that in AFFIRM 
‘the mean time to start of enzalutamide therapy from last docetaxel exposure was 9 months’ 
(Appendices B, p9, CS). No reference was provided and the ERG was unable to verify the statement 
in the main AFFIRM trial publication13 (including supplementary appendices). For comparison, Table 
3 of the COU-AA-301 study publication12 indicates that 339/1195 patients (28%) started treatment in 
the trial within three months of their last dose of docetaxel. No mean or median value for time since 
the last dose of docetaxel was reported. In TROPIC, the median time from last docetaxel dose to 
disease progression (before entering the trial) was 0.7 months in the control group and 0.8 months in 
the cabazitaxel group.11  
 
Data indicating possible differences in disease status between trial populations need to be interpreted 
in the context of the generally similar patient characteristics presented in Table 18. Clinical advisors 
to the ERG indicated that while the TROPIC trial may involve patients with more advanced disease 
than the other two trials, the best measure for this and hence the significance of any differences was 
unclear. The ERG noted that when groups are compared for a large number of variables, it is possible 
that some potentially significant differences will be identified by chance.    
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Table 18: Characteristics of patients enrolled in the trials included in the NMA (reproduced from CS, Appendices B, Table 5) 
Baseline Characteristics TROPIC11 AFFIRM13 COU-AA-30112, 33 
  Cabazitaxel (n=378) 
Mitoxantrone 
(n=377) 
Enzalutamide 
(n=800) 
Placebo 
(n=399) 
Abiraterone + 
Prednisone (n=797)
Placebo + 
Prednisone 
(n=398) 
Age (years) 
Median (range) 68 (62−73) 67 (61−72) 69 (41, 92) 69 (49, 89) 69 (42, 95) 69 (39, 90) 
≥75 years 69 (18%) 70 (19%) 199 (24.9%) 104 (26.1%) 220/797 (28%) 111/397 (28%) 
Ethnicity 
White: 83.5% 
Asian: 7.5% 
Black: 5% 
Other: 3.5% 
White: 93.1% 
Asian: 1.7% 
Black: 3.6% 
Other: 1.6% 
White: 92.6% 
Asian: 1.1% 
Black: 4.0% 
Other: 2.2% 
Time since diagnosis (months) 
Mean ± SD NR NR 86.1 ± 54.83 81.9 ± 50.89 85.8 ± 53.6 82.5 ± 56.3 
Eastern Cooperative Oncology Group 
performance status       
0-1 350 (93%) 344 (91%) 730 (91.3%) 367 (92.0%) 715/797 (90%) 353/398 (89%) 
2 70 (8.8%) 32 (8.0%) 82/797 (10%) 45/398 (11%) 
Prostate Specific Antigen (ng/ml) 
Median 143·9 127·5 107.7 128.3 128.8 137.7 
Gleason score at initial diagnosis 
≤7 NR NR 355/726 (49%) 175/368 (48%) 341/697 (49%) 161/350 (46%) 
≥8 NR NR 366/726 (50%) 193/368 (52%) 356/697 (51%) 189/350 (54%) 
Number of previous cytotoxic 
chemotherapy regimens       
1 260 (69%) 268 (71%) 579 (72.4%) 296 (74.2%) 558/797 (70%) 275/398 (69%) 
2 94 (25%) 79 (21%) 196 (24.5%) 95 (23.8%) 239/797 (30%) 123/398 (31%) 
3 25 (3.1%) 8 (2.0%) 0 0 
>2 24 (6%) 30 (8%) 
Disease location 
Bone NR NR 730 (92.2%) 364 (91.5%) 709/797 (89%) 357/397 (90%) 
Node NR NR 92 (11.6%) 34 (8.5%) 361/797 (45%) 164/397 (41%) 
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Baseline Characteristics TROPIC11 AFFIRM13 COU-AA-30112, 33 
Liver NR NR 442 (55.8%) 219 (55.0%) 90/797 (11%) 30/397 (8%) 
Previous cancer therapy 
Surgery 198 (52%) 205 (54%) 531 (66.4%) 243 (60.9%) 429/797 (54%) 193/398 (49%) 
Radiotherapy 232 (61%) 222 (59%) 571 (71.4%) 287 (71.9%) 570/797 (72%) 285/398 (72%) 
Hormonal 375 (99%) 375 (99%) 800 (100%) 399 (100%) 796 (100%) 396 (100%) 
Number of previous docetaxel 
regimens       
1 316 (84%) 327 (87%) NR NR NR NR 
2 53 (14%) 43 (11%) NR NR NR NR 
>2 9 (2%) 7 (2%) NR NR NR NR 
NR, not reported; SD, standard deviation 
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The NMA presented by the company links cabazitaxel with abiraterone and enzalutamide via a 
comparator defined as ‘BSC’ (Figure 3). The actual interventions received by patients in the control 
group differed between trials: mitoxantrone + prednisone in TROPIC; placebo with or without 
prednisone in AFFIRM; and prednisone + placebo in COU-AA-301. In the appraisal of enzalutamide 
(TA316), it was accepted that the three control groups could be considered equivalent for the purposes 
of indirect comparison of OS.25 This was based on evidence that: 
 prednisone was unlikely to affect overall or progression-free survival given that patients 
would have already received steroids and progressed on this treatment earlier in the course of 
the disease (ERG report TA316,22 p82) 
 median times for OS in the control groups were similar across the three trials (12.7 months in 
TROPIC, 11.7 months in COU-AA-301 and 13.6 months in AFFIRM (ERG report TA316,22 
Table 4.27, p86)). 
 
In the CS for the current appraisal (Appendices B, p1), additional evidence is presented to support the 
claim that mitoxantrone does not improve survival and therefore a regimen comprising mitoxantrone 
plus prednisone together with BSC can be considered equivalent to BSC alone. A recent study91 
analysed data from the control arms of TROPIC11 and SUN1120.92 In the latter trial control group 
patients received prednisone plus placebo. Both trials enrolled men with mCRPC whose disease had 
progressed after docetaxel treatment. Propensity score matching was used to balance patient 
characteristics across the two trials, based on age and key prognostic variables for survival. The study 
found that median survival was similar between mitoxantrone plus prednisone and prednisone alone 
(385 vs. 336 days). Although this study had limitations associated with combining data from two 
different trials, taken together with other evidence it seems reasonable to consider the control arm of 
TROPIC as equivalent to BSC for the purposes of the NMA of OS. The ERG notes that if 
mitoxantrone does confer an advantage (to either OS or PFS) over BSC, then this would be 
unfavourable to cabazitaxel in indirect comparisons. 
 
The other outcome analysed in the NMA was rPFS. The CS (p86-87) pointed out that the three trials 
included in the NMA used different definitions of PFS (see   
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Table 19). TROPIC11 used a composite definition of progression so a patient’s disease was considered 
to have progressed if they met criteria for: PSA progression; tumour progression; pain progression; or 
death. By contrast, AFFIRM13 and COU-AA-30112 used a definition based solely on tumour 
progression. However, rPFS was reported in the AFFIRM and COU-AA-301 trials. To facilitate 
comparison across the trials rPFS was derived from the patient level data from TROPIC, with the aim 
of reflecting the endpoint that was reported in the AFFIRM and COU-AA-301 trials.   
Figure 3: Network diagrams for the included trials 
 
* 45.6% of patients were exposed to prednisone in the placebo arm of AFFIRM 
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Table 19: Definitions of progression-free survival in trials included in the NMA 
Study Definition of progression-free 
survival 
Type of 
endpoint 
Comments 
TROPIC11 Time from randomisation to first 
date of progression as measured by 
PSA progression, tumour 
progression, pain progression or 
death 
Secondary For use in the NMA, a 
modified definition was used: 
time from randomisation to the 
first occurrence of: tumour 
progression (based on RECIST 
criteria) or death 
AFFIRM13 Time to progression of soft-tissue 
disease according to RECIST 
version 1.1; progression of osseous 
disease according to bone scans 
showing two or more new lesions 
per PCWG2; or death from any 
cause 
Secondary Confirmed by CT or MRI 
imaging of soft tissue or 
radionuclide bone scanning 
COU-AA-
30112 
Time to radiographic progression 
defined as soft-tissue disease 
progression by modified RECIST 
criteria or progression according to 
bone scans showing two or more 
new lesions not consistent with 
tumour flare 
Secondary Also had PSA progression as 
an endpoint 
CT, computed tomography; MRI, magnetic resonance imaging; PCWG2, Prostate Cancer Working Group 2; PSA, prostate-
specific antigen; RECIST, response evaluation criteria in solid tumours 
 
 
The analysis of rPFS revealed that there were differences in this outcome between the control groups 
of the three trials. Specifically, the control group in TROPIC had a longer median rPFS (5.9 months, 
95% CI: 5.1 to 7.0) compared with the control groups in AFFIRM (2.9 months, 95% CI: 2.8 to 3.4) 
and COU-AA-301 (3.6 months, 95% CI: 2.9 to 5.5). It is noteworthy that despite the different point 
estimates there was some overlap in the 95% CI for median rPFS between TROPIC and COU-AA-
301. The company argued that: 
The relatively poor performance of the control arms [in] the AFFIRM and COU-AA-301 
trial[s], compared to the almost double median rPFS for mitoxantrone in the TROPIC trial 
raises questions about the comparability of the control arms for the indirect comparison. 
Hazard ratios for rPFS from both AFFIRM and COU-AA-301 are lower compared to those 
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from TROPIC, and as such bias against cabazitaxel when combined in the indirect 
comparison (Appendices B, p9, CS).  
 
The ERG accepts that it is questionable whether outcomes of PFS can be synthesised in a NMA when 
the definitions of the outcome are different; however, assuming that the derived measure of rPFS is 
adequate, then this concern can be considered to have been addressed in the presented analysis. 
Therefore, use of rPFS was appropriate to allow a comparison across trials. This issue is discussed in 
Section 4.4. Furthermore, the ERG notes that for the company’s economic evaluation, increased 
values of rPFS lead to worse estimates of cost-effectiveness. Hence the company’s argument that the 
results of the NMA bias against the clinical effectiveness of cabazitaxel may result in a bias in favour 
of the cost-effectiveness of cabazitaxel. 
 
Risk of bias was assessed for the three RCTs in the CS (TROPIC in Section 4.6.2 and the other RCTs 
in appendices B, Tables 3 and 4). The results are summarised in Table 20.  
 
Table 20: Quality (risk of bias) assessment for trials included in the NMA (based on data 
in the CS) 
 TROPIC11 AFFIRM13 COU-AA-30112
Was randomisation carried out appropriately?  Yes Yes Yes 
Was the concealment of treatment allocation 
adequate? 
Yes Yes Yes 
Were the groups similar at baseline in terms of 
prognostic factors? 
Yes Yes Yes 
Were care providers, participants and outcome 
assessors blind to treatment allocation? 
No Yes Yes 
Were there any unexpected imbalances in drop-
outs between groups? 
No Not clear Not clear 
Is there any evidence to suggest that the authors 
measured more outcomes than they reported? 
No Yes No 
Did the analysis include an intention-to-treat 
analysis? If so, was this appropriate and were 
appropriate methods used to account for missing 
data? 
Yes/Yes Yes/Not clear Yes/Yes 
 
The CS concluded that there was no evidence of risk of bias in the AFFIRM and COU-AA-301 trials. 
The question about selective reporting bias was answered ‘yes’ for AFFIRM because EQ-5D data 
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have not been reported but this does not suggest a major problem with selective reporting of study 
outcomes.  The major potential risk of bias in trials used for the NMA arises from the lack of blinding 
of care providers, participants and outcome assessors in TROPIC. The company acknowledged this as 
a limitation of the trial but argued that it was unlikely to impact on the main outcomes. In the previous 
appraisal of cabazitaxel, the ERG agreed that OS (the primary outcome) and tumour response were 
unlikely to have been affected by bias. However, there was some risk of bias in the assessment of 
subjective outcomes such as pain and symptomatic disease progression. PFS, a composite endpoint 
incorporating some subjective outcomes, was therefore potentially susceptible to bias. 
 
4.4  Critique of the NMA 
4.4.1 Efficacy 
A NMA was performed to compare treatment effects of cabazitaxel, enzalutamide, abiraterone and 
BSC for the outcomes of OS and rPFS using data from the following trials: TROPIC;11 AFFIRM;13 
and COU-AA-301.12 Separate NMAs were undertaken for each outcome. The results of the NMA are 
relevant for the scenario analysis (alternative treatment practice) presented in Section 5.2.9.2. 
 
It is assumed that the respective control-arms of the trials namely, mitoxantrone + prednisone 
(TROPIC), placebo + prednisone (COU-AA-301) and prednisone alone (AFFIRM) can all be 
considered equivalent to BSC. Under this assumption, the studies provide a connected network, as 
presented in Figure 3.  
 
Despite conducting the NMA, as required by the scope, the CS (p85-87) raises concerns over the 
validity of the indirect comparisons due to differences between i) patient populations and trial design 
ii) control-arm treatments and iii) definition of PFS. The described differences have been discussed in 
Section 4.3 and the effect that these have on the validity of the NMA are discussed below. 
 
Heterogeneity between studies is to be expected, but will only result in biased estimates of treatment 
effects if there is an imbalance in treatment effect modifiers across studies comparing different pairs 
of treatments. Although the CS (p87) notes concerns relating to differences in patient characteristics 
there is no discussion of whether the treatment effects are modified by these characteristics. Previous 
reports have considered potential treatment effect modifiers. For the TROPIC study11 the results 
indicated “no significant interactions between the prognostic factors of interest and treatment 
response”.15 For the AFFIRM13 study it was stated that “The overall survival benefit was consistent 
across all subgroups, including… type of disease progression at entry”.13 The COU-AA-30112 trial 
found “the test for heterogeneity of treatment effect between subgroups showed no significant 
finding”, although they note small sample sizes for some subgroups. 
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Based on the derived estimate of median rPFS for the TROPIC11 trial and the reported rPFS outcomes 
for the AFFIRM13 and COU-AA-3012 trials, the control arms of the three trials are described by the 
CS (p87) to be “substantially different, indicating that for the purposes of the NMA they should not be 
considered equivalent”. The ERG notes that variation in control effects between studies are to be 
expected, reflecting differences in patient characteristics. In an NMA it is the treatment effects (in this 
case the HR) that are assumed to be combinable across studies. The CS (p87) states that “Hazard 
ratios for rPFS from both AFFIRM and COU-AA-301 are lower compared to those from TROPIC, 
and as such bias against cabazitaxel when combined in the indirect comparison.” The ERG notes that 
the reasoning provided in the CS does not in itself imply that the resulting treatment effects will be 
biased. The treatment effects may be biased if there is an imbalance in treatment effect modifiers 
between the studies; however, no evidence has been provided to suggest that this is the case.  Validity 
of the NMAs for both OS and rPFS are dependent on the assumption that the control treatments of the 
three included trials can be considered exchangeable, and therefore provide a connected evidence 
network. If this is not the case (i.e. the control treatments are not exchangeable) then we may expect 
considerable heterogeneity. In the presence of between study heterogeneity a fixed effect model is not 
appropriate, and the ERG considers that a random effect model should be used for the analysis (as 
discussed in further detail below). 
 
The results of the company’s NMA are presented in   
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Table 21 in terms of HR for cabazitaxel versus each treatment (BSC, enzalutamide, abiraterone). The 
results are based on a fixed effects model, with results from a random effects model also provided in 
the appendix (although this has not been implemented correctly in the absence of sufficient sample 
data and the results are therefore not valid). Following a request for clarification (question A20), the 
company failed to provide updated results using a weakly informative prior to inform the random 
effects meta-analysis. When there are too few studies to estimate the between-study SD from the 
sample data alone and a fixed effect model is used, this can be viewed as asserting that the between 
study SD is zero. Although prior distributions should not be used without reasonable justification, the 
ERG considers that the assumption of zero between-study variation should also be treated with 
caution given the clear case that has been made to suggest heterogeneity. In the absence of further 
information on which to base the choice of prior, use of a half-normal prior as described in the NICE 
Technical Support Document (TSD)93 is recommended. Furthermore, in the presence of 
heterogeneity, the predictive distribution, rather than the distribution of the mean treatment effect, 
would better represent uncertainty about the treatment effect in a future study.93  In a Bayesian setting, 
the predictive distribution can be obtained by generating samples from a normal distribution with 
mean equal to the estimated mean treatment effect, and variance given by the estimated between-trial 
heterogeneity. 
 
Based on results from the fixed effects NMA, the CS (Section 8: Appendices B pg22-23) concludes 
that treatment effects for cabazitaxel, abiraterone and enzalutamide are broadly similar for OS. With 
regards to rPFS the results of the fixed effects NMA indicate that the disease appears to progress 
slower when patients are treated with enzalutamide rather than when patients are treated with 
cabazitaxel or abiraterone. The ERG considers the NMA results should be interpreted with caution 
since they were based on an assumption of no between-study variance (using a fixed effects model), 
despite the stated concerns in terms of differences between patient populations and exchangeability of 
control treatments. Results from an amended random effects model (Section 4.5) confirm this finding 
of broadly similar treatment effects for OS but, contrasting to the results presented in the CS, also 
indicate that no active treatments are significantly more effective than other active treatments for 
rPFS.  
 
The ERG also notes that HRs have been used for the synthesis. HRs are averaged estimates of 
treatment effect, ignoring any potential treatment by time interaction, and use of HR in the NMA will 
only be appropriate if the hazards are proportional.94 Alternative methods that allow the relative 
treatment effects to vary over time have been proposed, including the use of fractional polynomials95 
which could be implemented in this case using individual patient data from the trials where available, 
and reconstructed individual patient data from Kaplan-Meir curves otherwise. The company state in 
their clarification response to question A19 that they are “aware that the Fizazzi et al. comment that 
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the hazard ratios are not proportional in the updated COU-AA-301study for abiraterone vs. placebo 
and inspection of the KM data (from Figure 2 in Fizzazi 2012) shows that the placebo OS line crosses 
the abiraterone line at 24 months.” Despite this, they state that use of HR can be “seen as a reasonable 
approach given the limitations with the data and the comparisons in general.” The ERG consider that 
the results of the NMA can be used as an indication of the treatment effects between relevant 
comparators, but should be treated with caution due to the described uncertainty in the suitability of 
the effect measure, in addition the other stated concerns in terms of implementation of the NMA.  
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Table 21: Key results from the fixed effects NMA – ITT population, (reproduced, with 
minor changes, pg87, CS.) 
  
Overall survival Radiographic progression free survival 
HR Credible intervals HR 
Credible 
intervals 
Cabazitaxel vs BSCa  0.72 0.61 0.85 0.75 0.65 0.88 
Cabazitaxel vs abiraterone 0.97 0.78 1.21 0.97 0.76 1.22 
Cabazitaxel vs enzalutamide 1.14 0.90 1.45 1.88 1.54 2.29 
HR, Hazard Ratio; BSC, Best Supportive Care 
a mitoxantrone assumed equivalent to BSC 
 
 
4.4.2  Safety  
Following a clarification response to question B10, the company provided details of AEs from the 
TROPIC, COU-AA-301 and AFFIRM trials. A summary is provided in Table 22.  It should be noted 
that this table only includes AEs of grade 3 or above (see Appendix 2 for all grade AE).  The source 
of some of these data were unclear as only frequently occurring AEs were reported in the AFFIRM 
trial publication cited by the company.13 It should also be noted that the 2012 publication of the COU-
AA-301 trial12 reported three cases of febrile neutropenia (grade 4) in the abiraterone group rather 
than zero as reported in Table 22. Data from the ALSYMPCA trial of radium-223 dichloride14 have 
been added given that radium-223 dichloride was identified as a relevant comparator in the NICE 
final scope.19 These data are for patients previously treated with docetaxel who received radium-223 
dichloride in the ALSYMPCA study, and were provided in the company’s response to clarification 
(question A18). 
 
Comparison across trials is limited by differences in reporting. While TROPIC and COU-AA-301 
reported fully on AEs during treatment, the AFFIRM publication only reported events that occurred in 
more than 10% of patients in the enzalutamide group and whose rate was at least 2 percentage points 
higher with enzalutamide compared with placebo.  The ALSYMPCA publication reported 
haematological AEs that occurred in at least 5% of patients in either treatment group and non-
haematological events that occurred in at least 10% of patients.14 
 
Differences in AEs across the four trials reflect the different mechanisms of action of the agents 
involved. Cabazitaxel, which acts by blocking cell division, would be expected to have a different AE 
profile to the advanced hormonal agents abiraterone and enzalutamide. Table 22 shows that high rates 
of haematological AEs such as anaemia and neutropenia were observed in patients treated with 
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cabazitaxel plus prednisone. However, clinical advisors to the ERG commented that high levels of 
monitoring in a trial setting would result in abnormal laboratory measurements being recorded as AEs 
despite the fact that these may not cause any problems for the patient. The ERG’s clinicians agreed 
with the view expressed in the CS that rates of haematological AEs reported in the CUP and EAPs 
were likely to be more reflective of clinical practice. This evidence is discussed in Section 4.2. 
 
Among non-haematological AEs, the most common in cabazitaxel-treated patients in TROPIC11 were 
diarrhoea (47%), fatigue (37%), nausea (34%) and vomiting (23%). The most common AEs in 
patients receiving abiraterone in COU-AA-30112 were fatigue (44%), nausea (30%), back pain (30%) 
and arthralgia (27%). Comparison with the enzalutamide group of the AFFIRM trial13 was only 
possible for diarrhoea (21%) and fatigue (34%). The most common AEs in ALSYMPCA14 in the 
relevant patient subgroup (those who had previously received docetaxel) were bone pain (53%), 
nausea (40%) and fatigue (27%). 
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Table 22: Table of adverse event data used in the company’s economic model (based on company clarification response, Table 17) 
 TROPIC11 COU-AA-30112 AFFIRM13 ALSYMPCA (subgroup 
with previous docetaxel 
use)14 
Grade ≥3 Cabazitaxel 
(n=371) 
Mitoxantrone 
(n=371) 
Abiraterone 
(n=791) 
Placebo plus 
prednisone 
(n=394) 
Enzalutamide 
(n=800) 
Placebo 
(n=399) 
Radium-223 
dichloride 
(n=347) 
Placebo 
(n=171) 
Haematological         
Neutropenia 303 (82%) 215 (58%) 1 (<1%) 1 (<1%) NR NR 11 (3%) 1 (<1%) 
Febrile neutropenia 28 (8%) 5 (1%) 0 (0%) 0 (0%) NR NR NR NR 
Leukopenia 253 (68%) 157 (42%) NR NR NR NR 5 (1%) 1 (<1%) 
Anaemia 39 (11%) 18 (5%) 62 (8%) 32 (8%) 62 (8%) 38 (10%) 50 (14%) 25 (15%) 
Thrombocytopenia 15 (4%) 6 (2%) 11 (1%) 2 (<1%) 8 (1%) 3 (<1%) 31 (9%) 5 (3%) 
Non-haematological         
Diarrhoea 23 (6%) 1 (<1%) 9 (1%) 5 (1%) 9 (1%) 1 (<1%) 2 (<1%) 4 (2%) 
Fatigue 18 (5%) 11 (3%) 72 (9%) 41 (10%) 50 (6%) 29 (7%) 16 (5%) 10 (6%) 
Asthenia 17 (5%) 9 (2%) 26 (3%) 8 (2%) 20 (2.5%) 10 (2.5%) NR NR 
Back pain 14 (4%) 11 (3%) 56 (7%) 40 (10%) 40 (5%) 16 (4%) NR NR 
Nausea 7 (2%) 1 (<1%) 17 (2%) 11 (3%) 12 (1.5%) 13 (3%) 8 (2%) 3 (2%) 
Vomiting 7 (2%) 0 (0%) 21 (3%) 12 (3%) 9 (1%) 10 (2.5%) 9 (3%) 5 (3%) 
Haematuria 7 (2%) 2 (1%) 12 (2%) 9 (2%) 12 (1.5%) 4 (1%) NR NR 
Abdominal pain 7 (2%) 0 (0%) 18 (2%) 8 (2%) NR NR NR NR 
Pain in extremity 6 (2%) 4 (1%) 24 (3%) 20 (5%) 14 (2%) 14 (3.5%) NR NR 
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Dyspnoea 5 (1%) 3 (1%) 14 (2%) 9 (2%) 5 (<1%) 6 (1.5%) NR NR 
Constipation 4 (1%) 2 (1%) 10(1%) 4 (1%) 6 (<1%) 5 (1%) 3 (1%) 1 (<1%) 
Pyrexia 4 (1%) 1 (<1%) 3 (<1%) 5 (1%) NR NR NR NR 
Arthralgia 4 (1%) 4 (1%) 40 (5%) 17 (4%) 20 (2.5%) 7 (2%) NR NR 
Urinary-tract infection 4 (1%) 3 (1%) 12 (2%) 3 (<1%) 10 (1%) 3 (<1%) 3 (1%) 4 (2%) 
Pain 4 (1%) 7 (2%) 7 (1%) 8 (2%) NR NR NR NR 
Bone pain 3 (1%) 9 (2%) 51 (6%) 31 (8%) 18 (2%) 13 (3%) 74 (21%) 53 (31%) 
Other         
Cardiac disorders 7 (2%) 3 (1%) 41 (5%) 9 (2%) 7 (1%) 8 (2%) NR NR 
Abnormalities in liver 
function tests 
NR NR 30 (4%) 14 (4%) 3 (<1%) 3 (<1%) NR NR 
Hypertension 1 (<1%) 1 (<1%) 10 (1%) 1 (<1%) 16 (2%) 5 (1%) NR NR 
Hypokalaemia 2 (<1%) 0 (0%) 35 (4%) 3 (<1%) NR NR NR NR 
Fluid retention or oedema 2 (<1%) 1 (<1%) 20 (3%) 4 (1%) 8 (1%) 3 (<1%) 6 (2%) 2 (2%) 
Seizure 1 (<1%) 0 (0%) NR NR 5 (<1%) 0 (0%) NR NR 
Weight decrease NR NR NR NR NR NR 4 (1%) 5 (3%) 
Anorexia NR NR NR NR NR NR 4 (1%) 2 (1%) 
NR, not reported 
 
 
 
Confidential until published 
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Rates of withdrawal due to AEs were higher in patients treated with cabazitaxel in TROPIC11 than in 
the abiraterone and enzalutamide arms of COU-AA-30112 and AFFIRM,13 respectively. Rates of AEs 
leading to death were higher in COU-AA0301 than the other two trials, although it should be noted 
that the rates of events leading to withdrawal and those leading to death were reported as identical for 
the abiraterone group in this trial. Table 23 summarises these data. For comparison, in the 
ALSYMPCA trial of radium-223 dichloride, withdrawals due to AEs occurred in 99/600 (17%) 
patients in the radium-223 dichloride group and 62/301 (21%) in the placebo group.14 The breakdown 
of withdrawals between patients previously treated with docetaxel or untreated was not reported, 
which limits the relevance of the data to this appraisal. 
 
Clinical advisors to the ERG stated that enzalutamide or abiraterone would normally be given to 
patients with mCRPC before cabazitaxel because of the lower toxicity of the hormonal agents. 
However, the advisors recognised that this may not be the approach adopted by all clinicians. 
 
Table 23: Adverse events leading to withdrawal or death in trials included in the NMA 
 TROPIC11 AFFIRM13 COU-AA-30112 
 Cabazitaxel Mitoxantrone Enzalutamide Placebo Abiraterone 
+ 
prednisolone 
Placebo + 
prednisolone 
AEs 
leading to 
withdrawal 
67/378 
(18%) 
32/377 (8%) 61/800 (8%) 39/399 
(10%) 
105/791 
(13%) 
71/394 (18%) 
AEs 
leading to 
death 
18/378 
(5%) 
2/377 (<1%) 23/800 (3%) 14/399 
(4%) 
105/791 
(13%) 
61/394 (16%) 
AEs, adverse events 
 
 
In the clarification response, the company also reported results of the fixed effects NMA for AEs 
across the TROPIC, AFFIRM and COU-AA-301 trials (Tables 18–27, question B10). These data 
were used in the economic model but were not reported in the discussion of the NMA in the CS. The 
ERG believes that odds ratios were used and not HRs as reported in the table headings. There were 
also discrepancies in labelling of some of the tables, making it unclear to which AEs the table 
referred. Key results from the NMAs are summarised for each AE in Table 24. For anaemia and 
nausea, the estimated treatment effects indicate a statistically significantly increase AE for cabazitaxel 
compared with BSC, abiraterone and enzalutamide. For diarrhoea there is a statistically significantly 
increase in AEs for cabazitaxel compared with BSC and abiraterone, and for neutropenia there is a 
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93 
 
statistically significant increase in AEs for cabazitaxel compared with BSC.  As with the NMA of 
clinical effectiveness, the ERG considers results from the NMA for AEs should be interpreted with 
caution since they were based on an assumption of no between-study variance (using a fixed effects 
model), despite the previously stated concerns in terms of differences between patient populations, 
and an assumption that control treatments were exchangeable. The uncertainty in treatment effects is 
therefore likely to be underestimated. 
 
Table 24:  Key results from fixed effects NMAs of adverse events (summarised from Tables 
18-27, company’s clarification response to question B10) 
Adverse event Cabazitaxel vs 
  BSC a Abiraterone Enzalutamide 
Neutropenia 3.24(2.33,4.53) 6.54 (0.16,251) - 
Anaemia 2.33 (1.31.4.29) 2.42 (1.16,5.09) 2.91 (1.42,6.14) 
Thrombocytopeniab 2.66 (1.04,7.74) 0.85 (0.1,4.91) 1.83 (0.29,9.82) 
Diarrhoea 33.4 (5.66,1070) 36.7 (4.16,1370) 5.59 (0.12,306) 
Fatigue 1.7 (0.79,3.82) 1.96 (0.83,4.86) 1.98 (0.8,5.08) 
Astheniac 1.98 (0.88,4.74) 2.28 (0.93,5.99) 1.94 (0.61,6.15) 
Back pain 1.29 (0.57,3.01) 1.92 (0.77,4.89) 1.01 (0.36,2.81) 
Nausea 9.69 (1.47,252) 12.6 (1.6,355) 22 (2.74,618) 
Bone pain 0.3 (0.06,1.07) 0.37 (0.07,1.43) 0.43 (0.08,1.89) 
BSC, Best Supportive Care 
All comparisons are reported as odds ratios (OR) and 95% credible intervals 
Statistically significant OR are shown in bold 
a Mitoxantrone assumed equivalent to BSC 
b Note: original table labelled as anaemia rather than thrombocytopenia 
c Note: original table labelled as fatigue rather than asthenia 
 
 
4.5  Additional work on clinical effectiveness undertaken by the ERG 
The NMA reported in Table 28 (p87) of the CS were based on a fixed effects model with the 
assumption of no between study variance. To assess the impact of incorporating between study 
heterogeneity, the ERG conducted additional analyses using a random effects model. Since there were 
too few studies to estimate the between-study SD from the sample data alone, and in the absence of 
further information on which to base the choice of prior, a weakly informative half-normal prior with 
variance 0.32ଶ was used. Choice of this prior is discussed in more detail in the NICE TSD.93 Under 
this prior, the between-study SD has a mean of 0.26. NMA results based on this prior were used by 
the ERG when estimating the ERG base-case cost-effectiveness results, as detailed in Section 6. In 
order to demonstrate the effect of choice of prior on the sensitivity of the results, additional analyses 
were conducted with a prior that suggests a more conservative amount of between-study 
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heterogeneity; a half-normal prior with variance 0.22ଶ. Under this prior, the between-study SD has a 
mean of 0.17.  
 
Results of the random effects NMA are summarised in Table 25 and Table 26. The median HRs are 
consistent with the results presented in Table 28 of the CS (p87), but with wider credible intervals,  
suggesting that there is no statistically significant difference between the three interventions for either 
OS or rPFS.  
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Table 25:  Results of NMA using random effects model, half-normal prior with variance ૙. ૜૛૛ 
  Overall survival Radiographic progression free survival 
  HR      HR      
Cabazitaxel vs median mean 95% CrI 95% PrI median mean 95% CrI 95% PrI 
BSC 0.72 0.77 (0.35,1.47) (0.26,1.99) 0.75 0.80 (0.36,1.53) (0.28,2.07) 
Abiraterone 0.97 1.10 (0.35,2.74) (0.24,4.16) 0.96 1.09 (0.34,2.71) (0.23,4.12) 
Enzalutamide 1.14 1.29 (0.41,3.19) (0.27,4.73) 1.87 2.12 (0.66,5.22) (0.45,7.70) 
HR, Hazard Ratio; CrI, Credible Interval; PrI, Predictive Interval; BSC, Best Supportive Care 
a mitoxantrone assumed equivalent to BSC           
 
Table 26:  Results of NMA using random effects model, half-normal prior with variance ૙. ૛૛૛ 
  Overall survival Radiographic progression free survival 
  HR      HR      
Cabazitaxel vs median mean 95% CrI 95% PrI median mean 95% CrI 95% PrI 
BSC 0.72 0.74 (0.44,1.17) (0.37,1.44) 0.75 0.77 (0.46,1.22) (0.38,1.50) 
Abiraterone 0.97 1.03 (0.49,1.97) (0.37,2.57) 0.96 1.02 (0.48,1.96) (0.37,2.54) 
Enzalutamide 1.14 1.20 (0.55,2.28) (0.42,2.94) 1.87 1.97 (0.91,3.70) (0.69,4.81) 
HR, Hazard Ratio; CrI, Credible Interval; PrI, Predictive Interval; BSC, Best Supportive Care 
 a mitoxantrone assumed equivalent to BSC  
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4.6 Conclusions of the clinical effectiveness section 
4.6.1  Completeness of the CS with regard to relevant clinical studies and relevant data within those 
studies 
The clinical evidence in the CS is based on a systematic review of cabazitaxel in combination with 
prednisone or prednisolone for the treatment of patients with mCRPC previously treated with a 
docetaxel-containing regimen.  The ERG is content that all relevant studies (published and 
unpublished) of cabazitaxel were included in the CS, including data from ongoing/planned studies.  
The ERG is also confident that no published comparator studies of abiraterone and enzalutamide are 
likely to have been missed.  However, whilst the ERG acknowledges the exclusion of radium-223 
dichloride from the NMA due to differences in patient populations and variations in the definitions of 
PFS used, it should have been considered as a relevant comparator as it was specified in the NICE 
final scope.19 
 
4.6.2  Interpretation of treatment effects reported in the CS in relation to relevant population, 
interventions, comparator and outcomes 
A key issue that may limit the robustness of the efficacy and safety data reported in the CS relates to 
lack of blinding of patients, care providers, and outcome assessors in the TROPIC study.  For 
objective outcomes, such as OS (which was primary outcome), unblinded assessment is unlikely to 
bias the trial results.  However, treatment effect estimates may be exaggerated for subjective 
outcomes such as pain and symptom deterioration (both of which were included in the definition of 
PFS) and of clinical (although not laboratory) assessment of AEs, when outcome assessors are not 
blinded.96, 97  Another issue that may limit the robustness of the efficacy evidence relates to the post-
hoc subgroup analyses of participants from the TROPIC trial that had mCRPC with an ECOG 
performance score of 0 or 1 and who had received at least 225 mg/m2 of prior docetaxel.  The 
TROPIC study was not powered for this exploratory subgroup analysis and in addition to the known 
limitations of post-hoc subgroup analyses,98 Sun et al.99 also suggest that the credibility of subgroup 
effects, even when claims are strong, is usually low.  Nevertheless, for NICE TA25515  both the 
Appraisal Committee and clinical advisors to the ERG considered this group of people to be the most 
appropriate population to receive cabazitaxel in UK clinical practice. 
 
The results of the NMA, modified by the ERG using a random effects model, indicate that there 
is no statistically significant difference between cabazitaxel, abiraterone and enzalutamide in terms of 
OS or rPFS.  However, the indirect comparisons between the treatments were considered subject to 
uncertainty due to potential imbalances in treatment effect modifiers, comparability of the control 
treatments and, in the case of rPFS, definition of the outcome.  Since there was evidence of 
heterogeneity among the trials included in the NMA, the ERG considers a random effects model to be 
more appropriate so that this uncertainty is appropriately reflected in the estimated treatment effects.  
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However, due to the small number of studies in the network, and lack of replication within pairs of 
treatments, a weakly informative prior for the between-study heterogeneity was required in this 
analysis.  Further evidence (i.e. implementation of further studies) would ideally provide more precise 
treatment estimates.  The results of the NMA are further limited by the use of HRs to describe the 
treatment effects. HRs are averaged estimates of treatment effect that ignore any potential treatment 
by time interaction, and their use is only appropriate if the hazards are proportional. Evidence 
presented in the CS (including the clarification responses) suggests that the hazards are not 
proportional in the COU-AA-301 study reported by Fizazzi et al.12 
 
4.6.3 Uncertainties surrounding the reliability of the clinical effectiveness  
The main uncertainties in the clinical evidence primarily relate to the absence of any head-to-head 
RCTs comparing cabazitaxel with other second-line agents such as abiraterone or enzalutamide for 
the treatment of mCRPC following treatment with docetaxel.  In addition, there is no high quality 
evidence from prospective controlled trials to guide optimum sequencing of these agents after 
docetaxel treatment in patients with mCRPC.  Although there is uncertainty over the optimal dose and 
frequency of cabazitaxel administration in men with mCRPC, the ongoing PROSELICA trial is 
examining the dosage of cabazitaxel (either 25 or 20 mg/m2) to optimise treatment benefits in relation 
to potential toxicity.  This study was expected to achieve database lock in August/September 2015 
with full results reported within the next 12 months. 
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5 COST EFFECTIVENESS 
5.1 ERG comment on the company’s review of cost-effectiveness evidence 
5.1.1 The objective of cost effectiveness review  
Within the submission for TA25515 the company conducted a simple but highly sensitive search to 
identify the complete evidence base for cabazitaxel, looking for any instance of the drug name (or 
synonyms) across a wide range of databases including specialist databases such as the Health 
Economic Evaluations Database and the NHS Economic Evaluation Database. The ERG concluded in 
its report that this search, combined with the accompanying clinical effectiveness search, was 
sufficient to identify all relevant economic evaluations. 
 
In 2015, a more structured approach has been employed to identify publications since 2010 (and 
conference presentations since 2012). Searches again encompassed an appropriate selection of 
databases, but this time included filters to identify economic studies.  The ERG noted some minor 
errors in the filters and queried the fact that no sources were cited for these. During the clarification 
response to question A11 the company responded that all the filters used in their submission were 
based on those developed for the Scottish Intercollegiate Guidelines Network (SIGN) but that they 
had modified them slightly by introducing additional terms to increase sensitivity. Although SIGN 
filters are not necessarily validated prior to publication, the ERG recognises the reputation of the 
resource and considers the filters fit for purpose. While any modification to a published filter risks 
reducing its effectiveness, the ERG was content that on this occasion the company’s modifications 
would not have adversely affected recall. 
 
As with the clinical effectiveness searches, the ERG was unable to reproduce the company’s search 
exactly as presented due to the different platform used (Embase.com); but since the numbers of results 
retrieved by each search string had been included on this occasion, it was possible to approximate 
their work and the ERG believes that all economic studies would have been identified. 
 
HRQoL searches 
Within the submission for TA25515 the company followed the traditional process of searching a range 
of databases for studies reporting the HRQoL of mCRPC, noting that “Utilities papers may not be 
specific to a particular intervention; therefore, the search was structured to retrieve records 
mentioning prostate cancer in combination with utilities.” In its report for TA255 the ERG noted that 
fewer synonyms for the condition had been used in the HRQoL review than in the clinical 
effectiveness review.15  
 
For the 2015 submission the CS bases its quality of life review largely on another recent evidence 
submission from Bayer which had already reviewed the HRQoL evidence for mCRPC up to 22nd 
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February 2013.100  For this reason, they did not conduct a full systematic update search of all sources 
but instead searched only PubMed (including Pre-MEDLINE, also known as MEDLINE In Process) 
from 2013-2015, once again using a shorter list of synonyms for the condition than were used for 
some of the other searches. While the ERG would ideally have preferred to see a more comprehensive 
search encompassing multiple databases, it recognises that PubMed is the most appropriate single 
source for a “pragmatic” update search of this nature. 
 
5.1.2 The inclusion and exclusion criteria used in the study selection 
The review of cost-effectiveness described in the CS considered economic evaluations (cost 
effectiveness analyses, cost-utility analyses and cost benefit analyses) and identified these using a 
recognised filter.  Date limits were applied to consider published studies from 2010, when the 
coverage of the previous cabazitaxel submission to NICE (TA255) ended.15 In order to identify more 
recent research which had not yet been published, additional searches were conducted of conference 
proceedings since 2012 (where searchable abstracts were available). 
 
The review included studies of cabazitaxel or of comparators from a list of those used in second-line 
therapy (or later) for adult patients previously treated with a docetaxel-based regimen.  No restrictions 
were placed on race, but studies were only included if they addressed a defined list of outcomes (see 
Table 48, p130 of the CS for further details). This resulted in the rejection of seven studies at the full-
text review stage.     
 
Searching and sifting have been reported in accordance with PRISMA guidelines.24 The ERG believes 
that the inclusion and exclusion criteria used by the company in the submission were appropriate. 
 
HRQoL searches 
For the review of HRQoL evidence, as previously noted, the company had largely relied on the 
radium-223 dichloride submission,100 updated from 2013-2015 with a brief PubMed search. As is 
typical for a HRQoL review, this search was designed to find any studies relating to utilities or quality 
of life for people with mCRPC, without restriction to any specific intervention(s). 
 
Studies were excluded on the basis of: 
 Publication status (letters, comments, systematic reviews of economic evaluations) 
 Incorrect population (including where insufficient information was available about the nature 
of the disease) 
 Outcomes not relevant to HRQoL 
 Language (the review only included English language studies) 
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Searching and sifting have been reported in accordance with PRISMA guidelines.24 The ERG believes 
that the inclusion and exclusion criteria used by the company in the submission were appropriate. 
 
5.1.3 Findings and conclusions of the cost effectiveness review  
The systematic literature review undertaken by the company identified 319 records after removal of 
duplicates. Of these records, 277 were excluded based on their title or abstract for the following 
reasons: 
 Incorrect intervention: 83 
 Incorrect study type: 77 
 Outcomes not relevant: 65 
 Incorrect patient population: 49 
 Data superseded: 3 
Of the remaining 42 records, 17 were excluded after a sift of their full text for the following reasons: 
 Outcomes not relevant: 7 
 Data superseded or duplicated: 5 
 Incorrect patient population: 2 
 Incorrect intervention: 2 
 Full-text not available: 1 
 
Of the 25 remaining papers (from 23 studies), five were full-text publications, and 20 were conference 
abstracts. Of these 25 papers, a summary of 17 was provided in the CS (Table 50, p134). This 
summary also included the ongoing assessment by NICE of radium-223 dichloride, which was not 
identified in the searches. It is unclear why the summary did not include all 23 studies. A separate 
hand search identified reports from the Scottish Medicines Consortium and the Irish National Center 
for Pharmacoeconomics; these are summarised in Table 51 (p138) of the CS. None of the identified 
records were formally assessed for quality. 
 
No conclusion from the cost-effectiveness review was presented by the company, who argued that the 
results of the review were limited by the heterogeneous definitions of survival employed, differences 
in patient populations, and differences in the trial protocols. As such the company presented the cost-
effectiveness results from an updated version of the de novo model developed for TA255 and 
described in Section 5.2 of this report. 
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5.2 ERG summary and critique of the company’s submitted model and economic evaluation  
5.2.1 NICE reference case 
A summary of the key features of the company’s de novo model is provided in  
Table 27. 
 
Table 27: Key features of the company’s de novo model 
Population, intervention, 
comparators and outcomes. 
See Table 1. 
Time horizon 10 years 
Cycle length Three weeks 
Half-cycle correction Included 
Measure of health effects  QALYs 
Primary health economic 
outcome 
Incremental cost per QALY gained 
Discount of 3.5% for 
utilities and costs 
Costs and benefits were discounted at 3.5%, using continuous 
discounting.  
Perspective The NHS in England. 
 
The ERG is satisfied that these are consistent with the NICE reference case. 
 
5.2.2 Model structure 
The model structure employed by the company was the same as that used in the previous submission, 
TA255:15 a cohort Markov model constructed in Microsoft Excel©. Three health states were modelled, 
representing: stable disease; progressive disease; and dead. All patients begin in stable disease; during 
each model cycle they may either remain in this state, transition to progressive disease, or die. 
Following progression it was assumed that patients could not revert to stable disease, but would 
instead remain in the progressed state until death. Time-varying transition probabilities were used, as 
described in Section 5.2.6. A model schematic is presented in   
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Figure 4, taken from the CS (p142). 
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Figure 4: Model schematic 
 
  
A cycle length of three weeks was employed in the model, to reflect the timing of treatment cycles for 
cabazitaxel. Serious AEs due to treatment were included by applying an additional (treatment-
specific) cost and disutility to a proportion of the cohort in the stable disease state. 
 
One-off transition costs were applied upon transitions to the progressive disease state (to account for 
post-second-line treatment) and transitions to the death state (to account for end of life costs). These 
are described in Section 5.2.8. 
 
5.2.3 Population 
For the comparison between cabazitaxel and mitoxantrone the company used the following 
population: 
 Patients within TROPIC who received ≥ 225mg/m2 of first-line docetaxel and with an ECOG 
PS of 0 or 1 
In a scenario analysis the entire intention-to-treat TROPIC population was considered. 
 
The population used for this comparison (a sub-group of the TROPIC trial) is the same as that used by 
the ERG when calculating their most plausible incremental cost effectiveness ratio (ICER) for the 
appraisal of cabazitaxel (TA255), and was judged to have clinical validity. For this appraisal the ERG, 
following discussions with its clinical experts, believe that there are no strong reasons for changing 
this population.  
 
When comparing cabazitaxel with abiraterone and enzalutamide, the entire ITT TROPIC population 
was used for cabazitaxel. 
 
The company did not consider the sub-population of people with bone metastasis. The ERG believes 
that this sub-population was inappropriately omitted, for the reasons detailed in Section 3.3. 
 
Stable disease
Dead
Progressive disease
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5.2.4 Interventions and comparators 
The intervention modelled was cabazitaxel (25 mg/m2) plus 10 mg per day of prednisolone given 
every three weeks for a maximum of ten cycles. Three comparators were considered by the company. 
These were: 
 Mitoxantrone (12 mg/m2) plus 10 mg per day of prednisolone given every three weeks. 
 Abiraterone, 1.0 g daily in combination with 10 mg/day of prednisolone. 
 Enzalutamide, 160 mg daily. 
 
Of the comparators, mitoxantrone is a chemotherapeutic agent, whilst abiraterone and enzalutamide 
are both advanced hormonal agents. Amongst patients with stable disease, cabazitaxel and 
mitoxantrone may be taken for a maximum of ten cycles. In contrast, abiraterone and enzalutamide 
are taken until disease progression or death. The company noted that, due to cross-resistance, 
sequential use of abiraterone and enzalutamide was not permitted in the CDF.8 Clinical advisors to the 
ERG also confirmed that these two hormonal agents would not be used sequentially. The submission 
made on behalf of the NCRI/RCP/RCR/ACP stated that mitoxantrone is rarely used in clinical 
practice, with BSC used instead.16 However, the company asserted that comparison with mitoxantrone 
was expected to be similar to a comparison with BSC with regards to impact on OS; this assertion was 
supported by the ERG's clinical experts. The ERG notes that the restriction on cabazitaxel use to a 
maximum of ten cycles is consistent with the trial protocol for TROPIC11, but that the license for 
cabazitaxel does not restrict its use to ten cycles. 
 
Cabazitaxel was directly compared with mitoxantrone in the TROPIC trial.32 No head-to-head 
comparisons were available for cabazitaxel and the two hormonal agents. Instead, the effectiveness of 
these hormonal agents (relative to cabazitaxel) was estimated by the company using an NMA, as 
described in Section 4.3. 
 
The company did not include radium-223 dichloride in their economic evaluation, for the reasons 
provided in Section 3.3. However, radium-223 dichloride was in the final scope issued by NICE, and 
the ERG believes that it should have been included. Radium-223 dichloride (50 kBq/kg body weight) 
is administered by intravenous injection every four weeks, for six injections. The potential 
implications of including radium-223 dichloride in the economic evaluation are discussed in Section 
6. 
 
5.2.5 Perspective, time horizon and discounting 
The perspective of the evaluation was appropriately that of the NHS and personal social services. A 
lifetime horizon was also appropriately used to capture differential mortality rates between the 
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intervention and the comparators. This was estimated using a time horizon of 10 years. After 10 years, 
the proportion of patients alive in the company's base case was 0.0001% for cabazitaxel and less than 
0.0014% for each of the comparators.  
 
The company used discount rates of 3.5% per year for both costs and benefits, in line with the NICE 
reference case.101 It is noted that a continuous discount rate is used despite the fact that the model 
handles time as a discrete variable. However, this difference is of no material significance. A half-
cycle correction was appropriately implemented. 
 
5.2.6 Assumed treatment effectiveness 
Within the health economic model, treatment effectiveness was modelled by including treatment-
dependent transition probabilities for both OS (the probability of moving to the dead state from either 
of the other two states) and PFS (the probability of moving from the stable to the progressed health 
state). 
 
Data on the effectiveness of cabazitaxel and mitoxantrone were taken from the TROPIC trial. For 
abiraterone and enzalutamide data were taken from the COU-AA-301 and AFFIRM trials 
respectively. For the purposes of conducting an NMA between cabazitaxel, abiraterone and 
enzalutamide it was assumed that effectiveness data for the control arm of the three trials was 
interchangeable. The appropriateness of this assumption is discussed in Section 4.4. 
 
To extrapolate the effectiveness of cabazitaxel and mitoxantrone, parametric models were fitted to the 
observed data. Each parametric model was used to derive time-dependent transition probabilities for 
the cohort’s entire lifetime (and was used in preference to the Kaplan Meier curves for the observed 
time period in the company’s base case). For both OS and PFS the company considered five different 
parametric models: Exponential; Weibull; Gompertz; Log-logistic; and Log-Normal. To inform the 
choice of parametric model for extrapolation both Akaike’s information criterion (AIC) and the 
Bayesian information criterion (BIC) were considered. The choice of curve was restricted so that the 
same parametric model was used for both cabazitaxel and mitoxantrone for a given effectiveness 
measure (but different parametric models could be used for OS and PFS). Because of this restriction 
the parametric model chosen was that which minimised the sum (combination) of the information 
criteria for the two treatments. It is commented that these goodness of fit tests do not indicate a 
definite selection of a curve since information criteria cannot be formally tested for significance. An 
overview of these values is provided in Table 28, with minimum values, which highlight the best 
model fit to the data, highlighted in bold. 
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Table 28: Goodness of fit data for the parametric models  
 Combined values: overall survival Combined values: progression-
free survival 
 AIC BIC AIC BIC 
Exponential 1573.21 1580.71 1843.01 1850.48 
Weibull 1456.99 1472.00 1840.86 1855.81 
Gompertz 1498.41 1513.43 1834.93 1849.89 
Log-logistic 1458.04 1473.06 1775.18 1790.14 
Log-Normal 1494.51 1509.52 1769.93 1785.49 
AIC: Akaike’s information criteria. BIC: Bayesian information criteria 
 
Use of either the AIC or BIC led to the same parametric model being chosen. It is unclear which 
measure the company would have preferred if the two suggested different models. The company did 
not consider fitting separate parametric models to the two treatment arms (for either type of survival). 
The company justified this approach by stating (p145) that: 
“Ideally, the same parametric model type should be chosen for the two treatment arms unless there is 
a specific expectation that they should be different.” 
 
Based on the information criteria results, separate curves based on the Weibull model were fit to the 
two treatment arms to generate transition probabilities for death, and separate curves based on the 
Log-Normal model were used for transition probabilities to the progressed disease state. The use of 
separate curves based on separate parametric models (for each treatment) was considered by the ERG, 
as discussed in Section 5.3, with results in Section 6. 
 
To generate transition probabilities for abiraterone and enzalutamide, estimated HRs (as detailed in 
Section 4.3) for these two comparators were applied to the parametric models for cabazitaxel. As the 
Log-Normal model (used to model PFS) is not a proportional hazards model, a Weibull model was 
instead used to model PFS. The justification for using a Weibull model is not stated, but it is noted 
that, of the three proportional hazards models (Exponential, Weibull and Gompertz), this provides the 
lowest AIC and BIC values when considering the cabazitaxel arm which is then adjusted using HRs 
for abiraterone and enzalutamide. To use proportional hazards models requires an assumption of 
proportional hazards. The appropriateness of this assumption is discussed in Section 4.4. 
 
For both OS and PFS, the company considered the use of each of the four alternative parametric 
models in scenario analyses. The use of Kaplan Meier data for the observed time period was also 
explored in a scenario analysis. The results of these analyses are discussed in Section 5.2.10. 
 
It was noted that in TA255 the NICE Appraisal Committee considered the use of piecewise curves to 
be the most appropriate approach.15 However, this approach was not considered in the initial 
submission provided by the company. In response to clarification on this issue (question B1), the 
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company argued against using this approach for the NMA, stating that it would lead to “questionable 
derived curves for the comparator arms” and “add additional complexity and create excessive 
computational challenges of implementation”. The company further do not use piecewise curves in 
the comparison between cabazitaxel and mitoxantrone, arguing for consistency with the modelling 
approach used in the NMA. However, the ERG notes that the company assesses the results from the 
NMA separately to the comparison between cabazitaxel and mitoxantrone, so it is unclear why the 
modelling approach for the two should be consistent. One of the main drivers for considering 
piecewise curves was the observation of early deaths from cabazitaxel-induced neutropenia, which 
may have affected subsequent extrapolations. To account for this, the company present the results of 
an analysis which used the observed Kaplan-Meier curve for cabazitaxel for the first 2.1 months, 
followed by a Weibull curve fit to the remaining trial data, and used for extrapolation. No change was 
made to the modelling of the mitoxantrone arm. Use of this hybrid model led to a slight decrease in 
the ICER comparing cabazitaxel to mitoxantrone, from £49,327 to £48,543. The ERG believes that, of 
the approaches to modelling OS presented by the company, this hybrid approach is likely to be the 
most appropriate. However, the company did not present details about the Weibull curve that was 
used, and so the ERG was not able to replicate this analysis. 
 
Within the economic model base-case analysis a proportion of patients receiving cabazitaxel or 
mitoxantrone discontinued treatment but remained in the stable disease state. The ERG had three 
concerns with how this type of discontinuation was modelled. These concerns are discussed in turn. 
1. It was assumed in the model that patients who discontinued did not incur drug costs during 
the cycle of discontinuation. The ERG believed that this would under-estimate drug costs, as 
patients would discontinue after receiving the drug. 
2.  It was assumed in the model that patients who discontinued would have the increased utility 
related to additional treatment cycles. The ERG believed that this would over-estimate 
utilities. 
3. Within the model the proportion of drug costs that was removed due to discontinuation was 
not cumulative. In other words, for any given cycle, patients who discontinued during a 
previous cycle and remained with stable disease would incorrectly incur drug costs. The ERG 
believed that this would over-estimate drug costs. 
 
In response to clarification question B6, the company stated that patients who were modelled as 
discontinuing actually did so during the previous cycle, and so it was appropriate to exclude drug 
costs for their current cycle. However, this is not how discontinuation has been implemented in the 
model (as patients can discontinue during cycle zero). Hence the ERG maintains that drug costs are 
under-estimated due to this. The company agreed with points 2 and 3, and provided the results of an 
analysis which assumed that patients who discontinued (but remained in the stable disease state) had a 
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utility equal to that of patients in the progressed disease health state, and which also removed a 
cumulative proportion of drug costs. The result of these changes had a minimal impact on the ICER. 
 
People who received either abiraterone or enzalutamide were not modelled as being able to 
discontinue and remain in the stable disease state. This inconsistency of modelling approach may 
affect the validity of comparisons between cabazitaxel, abiraterone and enzalutamide. 
 
The ERG noted that within the economic model, transition probabilities that exceeded one were 
sometimes used. This appears to be because the calculated probabilities for remaining in the stable 
disease health state and for dying are not mutually exclusive: transitions to death are included in both 
the estimates of OS and of PFS. Using transition probabilities that exceed one without adjustment in 
the economic model would lead to the sum of the proportions in each health state exceeding one. To 
remedy this, the company appear to have incorporated an adjustment that reduces the proportion of 
patients in the progressive disease health state with the effect of potentially underestimating the 
number of patients in the progressive disease health state. However, in response to clarification 
question B5 the company noted that the impact of this on the ICER was likely to be small. The ERG 
agreed with this. 
 
5.2.7 Health related quality of life 
HRQoL data were not collected in the TROPIC trial. Utility values for people receiving cabazitaxel 
measured using the EQ-5D were collected in the UK EAP,50 and used in the health economic model. 
In addition, the company provided details about the results of a systematic search for data on HRQoL. 
The UK EAP is discussed first, followed by the systematic search results. 
 
The UK EAP is an open-label, single-arm study of cabazitaxel and thus does not include 
mitoxantrone. Within the UK EAP, participants were asked to complete the EQ-5D questionnaire at 
baseline, prior to cycles 2, 4, 6, 8 and 10 of chemotherapy, and after completing treatment. The ERG 
notes that the EQ-5D questionnaire asks people about their HRQoL on the day of completing the 
questionnaire. Hence it would not capture to any effects of chemotherapy that lasted for less than six 
weeks (the time-frame between completing questionnaires). 
 
Baseline data used in the health economic model were available for 103 participants, with a mean EQ-
5D summary score of 0.682. The data used in the economic model are more up-to-date than that 
reported in Bahl et al.50 Mean scores increased with each cycle of treatment (and the sample size 
decreased), with a mean score at cycle 10 of 0.819, based on 32 participants. The weighted mean EQ-
5D summary score across all 10 cycles was 0.737. Results for the sub-group of participants who 
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completed all 10 cycles of treatment produced consistent results with the full sample, which suggest 
that the observed increase in utility may not be due to selection bias.  
 
Within the UK EAP, 25 participants were identified as having both disease progression and an EQ-5D 
summary score recorded 30 days after their last treatment. The mean utility value of 0.627 for these 
participants was used within the economic model for progressed disease. 
 
There were two components to the stable disease utility values used within the economic model. The 
first was the UK EAP values, which were assumed to reflect the utility of patients with stable disease 
regardless of the treatment that they received. Cycle-specific values were used for the first 10 cycles, 
after which the cycle 10 utility value (0.819) was used for all subsequent cycles. The second 
component was a treatment-specific disutility due to AEs. Fifteen AEs were considered: neutropenia; 
febrile neutropenia; diarrhoea; fatigue; asthenia; leukopenia; back pain; anaemia; thrombocytopenia; 
pulmonary embolism; dehydration; nausea; bone pain; deep vein thrombosis; and neuropathy. The 
duration of events, and their rate of occurrence for cabazitaxel and mitoxantrone were taken from the 
TROPIC trial.11 Rates for abiraterone and enzalutamide were taken from their respective pivotal trials, 
as described in Section 4.5. Disutility values for the AEs were based on a literature review conducted 
for the submission in relation to TA255.15 In the absence of evidence for people with prostate cancer, 
values for people with breast cancer or non-small cell lung cancer were used.  
 
An overview of the utility values used in the economic model is provided in Table 29, whilst an 
overview of the adverse event data used is provided in Table 30. 
 
Table 29: Utility values used in the economic model 
 Utility 
Stable disease (weighted average UK EAP values) 0.737 
    Disutility due to treatment with cabazitaxel 0.00033 
    Disutility due to treatment with mitoxantrone 0.00022 
    Disutility due to treatment with abiraterone 0.00007 
    Disutility due to treatment with enzalutamide 0.00005 
Progressed disease 0.627 
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Table 30: Adverse event data used in the economic model 
Adverse Event Disutility Duration (days) 
Neutropenia -0.090 1.9 
Febrile neutropenia -0.120 6.2 
Diarrhoea -0.047 8.0 
Fatigue -0.094 19.3 
Asthenia -0.094 13.3 
Leukopenia -0.090 11.1 
Back pain -0.069 7.2 
Anaemia -0.125 25.4 
Thrombocytopenia -0.090 23.8 
Pulmonary embolism -0.145 27.0 
Dehydration -0.151 3.8 
Nausea -0.076 6.2 
Bone pain -0.069 9.5 
Deep vein thrombosis -0.160 24.0 
Neuropathy  -0.116 5.0 
 
 
Because the UK-EAP only measured EQ-5D during even-numbered cycles, a method of interpolation 
was required to estimate utility values for odd-numbered cycles. The company applied a linear 
regression to estimate these values. Within the economic model the company used observed values for 
even-numbered cycles and estimated values for odd-numbered. The ERG notes that this approach 
leads to potential logical inconsistencies. For example, the modelled utility for cycle six is lower than 
that for cycle five. A more consistent approach (with regards to having monotonically increasing 
utility values) would have been to use the estimated values for all 10 cycles. The ERG also requested 
that the company provide an analysis using the mean of the UK EAP utility values for all 10 cycles. In 
response, the company provided two analyses: one which used the unweighted mean of the UK EAP, 
and one which used the mean value at cycle 6 of the UK EAP (which corresponds to the median 
number of cycles received). These changes did not have a material impact on the base-case ICER. 
 
The ERG carried out additional analyses: (1) using values estimated from a linear regression for all 10 
cycles, and (2) using the weighted mean of the UK EAP utility values for all 10 cycles. The results of 
these are discussed in Section 5.3, and show that the ICER is robust to these changes. 
 
The company also assumed that people with progressive disease would have zero utility in their last 
three months of life. This assumption was used as a simplified means of incorporating any reductions 
in HRQoL as people approached the end of their life. This was incorporated within the model as a 
disutility. However, the calculation of the treatment-specific disutility was based upon all deaths, not 
upon deaths amongst people with progressive disease. In addition, this calculation assumed that 
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everybody had a zero utility for three months, even if they lived for less than three months. In 
response to clarification question B5 the company adjusted the disutility calculations so that people 
who died before three months contributed a reduced disutility. This amendment had a minimal impact 
on the ICER. However, the company did not alter the disutility calculations to be based on only 
people with progressive disease, stating that cycle-specific deaths from this health state were not 
tracked. However, the ERG notes that the company could have amended their model to track this. The 
ERG believes that applying a disutility based on all patients who die is of questionable validity.    
 
The company’s literature review identified nine studies that directly measured EQ-5D values. There 
were no studies that directly measured EQ-5D values amongst people receiving cabazitaxel. Instead, 
the company subjectively categorised the reported values as pertaining to patients with either stable or 
progressed disease. Utility values for stable disease ranged from 0.66 (patients with mCRPC 
undergoing chemotherapy)102 to 0.85 (asymptomatic and minimally symptomatic, chemotherapy-
naive patients with mCRPC).103 Utility values for progressed disease ranged from 0.54 (people with 
prostate cancer in their last year of life)104 to 0.66 (post-chemotherapy patients with mCRPC).105 The 
company noted that these ranges were consistent with their UK EAP values, and used this as an 
additional justification for use of the observational data in their submission. 
 
It has previously been noted that participants in the UK EAP may not be comparable with participants 
in the TROPIC106, as participants in TROPIC had higher levels of previous chemotherapy use (31% 
had received at least two previous chemotherapy regimens compared to 11% in the UK EAP), and 
were more likely to have progressed during or within three months of finishing treatment with 
docetaxel (72% compared to 33%). This, in combination with the non-comparative non-blinded 
nature of the UK EAP limits the applicability of the data. However, in the absence of more robust 
data, the ERG believes that use of the UK EAP within the economic model is appropriate. It is further 
noted that the company’s implementation of HRQoL values appropriately disadvantages cabazitaxel 
as this has the largest disutility due to being associated with the largest number of AEs. 
 
5.2.8 Resources and costs 
Data on unit costs were taken from standard national sources (The British National Formulary,107 
NHS reference costs108 and Personal Social Services Research Unit [PSSRU]109). The main sources 
for evidence on resource use were the TROPIC trial,11 a UK clinical audit (as described in Appendix 
14 of the CS), and expert opinion. 
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Stable disease 
Cabazitaxel and mitoxantrone are both provided in vials with the required dosage dependent on BSA 
(25 mg/m2 for cabazitaxel and 12 mg/m2 for mitoxantrone). Within the submission the company 
assumed that the mean BSA was 1.9 (with a standard error of 0.21 used to estimate the average 
number of vials required per patient), with vial sharing for cabazitaxel but not for mitoxantrone. The 
value of 1.9 was based on the clinical opinion of UK experts; the mean BSA observed in the TROPIC 
(2.01) was used in a scenario analysis. The standard error of 0.21 was based on TROPIC data. The 
ERG queried why the TROPIC-derived BSA was used in the base-case for the original submission 
(TA255), but not for this submission. The company justified this change by stating that the value of 
1.9 is more likely to reflect values observed in the UK. The ERG notes that, based on the company’s 
economic model, the threshold for an increase in vials is a BSA of xxxxx for cabazitaxel and xxxxx for 
mitoxantrone. 
 
The ERG queried why it was assumed that there was no vial wastage for cabazitaxel. The company 
responded with: 
“Sanofi believe there will be no wastage of active ingredient because patient specific doses in the 
form of compounded IV bags of cabazitaxel can be supplied direct to NHS hospitals”. 
The ERG asked their clinical advisors if they believed that there would be vial wastage for 
cabazitaxel. The following reply was obtained from a pharmacist: 
“As far as I am aware, most centres do not buy in compounded bags as this would add to the total cost 
of treatment as likewise they would need to add a compounding fee to treatment. Occasionally we 
have been able to “save” a vial where several patients are receiving treatment on one day and as a 
result vials can be ‘campaigned worked’ (i.e. shared). This can seldom be achieved however and 
certainly isn’t generally the rule.” 
 
The ERG noted that in addition vial wastage may occur, if people did not attend their appointment. 
Hence there is uncertainty over the degree of vial wastage that would occur in clinical practice. The 
ERG further noted that in the company’s base-case there appeared to be no wastage assumed for 
either cabazitaxel or mitoxantrone. 
 
Treatment with abiraterone requires 1.0g daily whilst for enzalutamide 160mg is required daily.  
Costs for cabazitaxel and all three comparators were taken from the BNF June 2015.107 A pack of 
abiraterone contains 120 tablets of 250mg, whilst a pack of enzalutamide contains 112 tablets of 
40mg. These costs, which do not include any Patient Access Scheme or any administration costs, are 
displayed in Table 31. With the exception of enzalutamide, all of the treatments are in combination 
with 10 mg/day of prednisolone, at a 3-week cycle cost of £1.94. 
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Table 31: Direct treatment costs 
Treatment Cost per unit Details Cost per 3-week cycle* 
Mitoxantrone £100.00 Cost per vial £172.87 
Cabazitaxel £3696.00 Cost per vial £3696.00 
Abiraterone £2930.00 Cost per 120-tab pack £2,051.00 
Enzalutamide £2734.67 Cost per 112-cap pack £2,051.00 
*Mitoxantrone and cabazitaxel are estimated by the company to require 1.73 and 1.00 vials per cycle, respectively 
 
It was assumed that all four treatments would require one visit to a clinical oncologist every three 
weeks, at a cost of £320 per visit.27 Treatment with cabazitaxel and mitoxantrone incurred additional 
administration costs for pharmacist time. The hourly cost for pharmacist time used was £42,109 it was 
assumed that mitoxantrone would require an hour of pharmacy time and cabazitaxel would require 15 
minutes. 
 
Pre-medication resource use for cabazitaxel and mitoxantrone were taken from the TROPIC, as 
detailed in Table 63 of the CS (p165-167). The main driver of pre-medication costs was the use of 
primary prophylaxis, with a unit cost of £175.67. This was received by 25% of patients in the 
cabazitaxel arm and 10% in the mitoxantrone arm. It was assumed that patients receiving either 
abiraterone or enzalutamide would have the same resource use as mitoxantrone, but with no primary 
prophylaxis. The resulting three-weekly pre-medication costs were £87.29 for cabazitaxel, £36.32 for 
mitoxantrone, and £7.52 for either abiraterone or enzalutamide. 
 
For patients with stable disease, the direct treatment costs (as detailed in Table 31), along with 
administration costs and pre-medication costs were incurred for either the first ten cycles of treatment 
(for cabazitaxel and mitoxantrone) or until disease progression or death (for abiraterone and 
enzalutamide). 
 
In addition, patients with stable disease also required treatment with an LHRH agonist, at a cost of 
£52.59 every three weeks. Additional costs relating to outpatient care, inpatient care, hospice care, 
imaging and laboratory tests were also incurred, at a cost of £303.65 every three weeks. These two 
additional costs were incurred by patients as long as they remained in the stable disease state. 
 
The costs of treating AEs were incorporated into the economic model as an additional treatment-
specific cost for patients with stable disease who are receiving treatment. The rates of occurrence of 
AEs as used in the economic model are described in Table 22. Costs for treating AEs were based on 
the cost of inpatient visits and drug costs. The company assumed that no additional outpatient costs 
would be required for treating AEs. Costs for inpatient visits, and the length of stay, were both taken 
from NHS reference costs.27 These were weighted by the proportion of people experiencing the AEs 
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who required an inpatient stay. These proportions were based on TROPIC data32 adjusted by expert 
opinion. The proportions applied were irrespective of treatment received. The drugs required to treat 
AEs were based on expert opinion, with unit costs from the BNF.107 
 
The two most expensive AEs to treat were febrile neutropenia (£4,077.58) and pulmonary embolism 
(£2,517.72). All other AEs cost less than £900 to treat. The average cycle costs of treating AEs were 
£105.18 (cabazitaxel), £53.78 (mitoxantrone), £5.15 (abiraterone), and £5.05 (enzalutamide). The 
main cost contributions for cabazitaxel were febrile neutropenia (£64.44) and neutropenia (£13.02). 
For mitoxantrone these were febrile neutropenia (£20.62) and pulmonary embolism (£17.07). 
 
The ERG noted that, based on the CS, some AEs received neither inpatient care nor drugs. In 
response to clarification question B19 the company provided a scenario analysis where the rates of 
drug use for all AEs were 100%. The ICER was robust to this extreme case, with an increase of 
0.53% from the base-case value. 
 
For the company’s base-case analysis, the total cost of AEs during the first ten weeks of treatment 
were £546.44 (cabazitaxel), £207.19 (mitoxantrone), £41.36 (abiraterone), and £44.84 (enzalutamide). 
For cabazitaxel and mitoxantrone these are also the lifetime costs of AEs, as treatment cannot exceed 
ten weeks in the model. For abiraterone and enzalutamide the lifetime costs were £73.60 and £118.20 
respectively. 
 
Progressed disease 
Sequencing of the four treatments was not considered by the company. Instead, if people progressed 
whilst on treatment, they received either a post-second line treatment mix or BSC. The proportion 
receiving post-second line treatment was independent of the previous treatment received, and was 
56% in the company’s base-case analysis: this proportion was taken from the TROPIC trial. An 
alternative estimate of 20% receiving post-second line treatment (and hence 80% receiving BSC), 
derived from a UK-based treatment audit, is used in a scenario analysis. Post-second line treatment 
costs had two components: the costs of chemotherapeutic drugs, and administration costs. There were 
three sources providing evidence on these costs: the two treatment arms (cabazitaxel and 
mitoxantrone) of the TROPIC trial,32 and a UK clinical audit.25 The costs of chemotherapeutic drugs 
derived from the TROPIC trial were £1192.81 for the cabazitaxel arm and £1767.02 for the 
mitoxantrone arm. The driver for the difference in these costs was the increased use of docetaxel in 
the mitoxantrone arm (17% of people, compared to 11%, increasing costs by £423.59). The drug cost 
derived from the UK clinical audit was between the middle of the two TROPIC estimates, at 
£1364.07. Costs relating to treatment administration were similar for the cabazitaxel (£1328.56) and 
mitoxantrone (£1255.26) treatment arms in TROPIC. Administration costs derived from the UK 
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clinical audit were almost half (£691.96) of the TROPIC estimates, due to an estimated shorter 
duration of treatment. 
 
For the company’s base-case analysis post-second line treatment costs for cabazitaxel and 
mitoxantrone were based on their respective TROPIC treatment arms. Costs for abiraterone and 
enzalutamide were based on the mitoxantrone arm. Post-second line treatment was incorporated 
within the economic model as a one-off cost upon transitioning from stable to progressed disease. The 
ERG queried why data from the TROPIC trial were used in preference to the UK clinical audit. The 
company’s justification was that TROPIC data “was used to maintain consistency with what was done 
in the trial”. This may be appropriate if the differences in post-second line treatment in TROPIC 
contributed to the observed differences in OS. However, if this is not the case then the ERG believes 
that the use of arm-specific post-second line treatment costs is inappropriate. The ERG notes that 
mitoxantrone has no known effect on OS, so it is unlikely that post-second line treatment will have an 
impact. Clinical advisors to the ERG agreed with this view. In addition, it is unclear why post-second 
line treatment costs for mitoxantrone (which are the most expensive of the three available estimates) 
are used for abiraterone and enzalutamide. 
 
Following post-second line treatment, people received on-gong treatment with an LHRH agonist, at a 
cost of £52.59 every three weeks. A proportion of patients received additional treatment. This 
consisted of analgesics, steroids, palliative radiotherapy and bisphosphonate, with an overall cost of 
£41.68 every three weeks, in addition to the cost of an LHRH agonist. The company labelled this 
additional treatment as BSC. Using the base-case estimate that 44% of patients received BSC, the 
average cycle cost for progressed disease was £70.93, independent of the previous treatment received 
(ignoring the one-off cost for post-second line treatment). Using the alternative estimate of 80% 
receiving BSC, the cycle cost changes to £85.93. 
 
Additional costs relating to outpatient care, inpatient care, hospice care, imaging and laboratory tests 
were also incurred, at a cost of £303.65 every three weeks for patients with progressed disease, 
irrespective of the previous treatment received. 
 
End of life costs 
End of life costs for treating prostate cancer were included within the CS. Evidence on the number of 
inpatient and outpatient hospitalisations was available from a UK clinical audit.25 Evidence on home 
visits (from nurses and GPs) along with hospice home stays was based on expert opinion. End of life 
costs were included as a one-off cost upon transition to death, from either of the other two health 
states. The estimated cost was £1952.15, independent of the previous treatments received. The main 
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cost component was inpatient visits at an overall cost of £1374.72 (based on a unit cost of £537 per 
day and an average of 2.56 days). Costs relating to end of life drugs were not included. 
 
An overview of the per-cycle costs that vary depending on the treatment received is displayed in 
Table 32. 
 
Table 32: Additional treatment-dependent costs (base-case values per three weeks unless 
otherwise specified) 
Treatment 
Administration Pre-medication Post-second line 
chemotherapeutic 
drugs* 
Post-second line 
administration* 
Adverse 
events 
Mitoxantrone £362.50 £87.29 £1767.02 £1328.56 £105.18 
Cabazitaxel £330.50 £36.22 £1192.81 £1255.26 £53.78 
Abiraterone £320.50 £  7.52 £1364.07 £691.96 £5.15 
Enzalutamide £320.50 £  7.52 £1364.07 £691.96 £5.05 
*Applied as a one-off cost and only received by a proportion of patients 
 
The costs of generic drugs (which include the cost of mitoxantrone) were taken from the BNF for the 
company’s base-case analysis. An alternative estimate of generic drug costs is available from the 
electronic market information tool (eMIT), made available by the Department of Health.110 In 
response to clarification question B7 the company used eMIT prices in place of BNF prices. The 
eMIT prices used reflect the average price paid by English trusts for the period September 2014 to 
December 2014. The cost per unit for mitoxantrone is £100 based on the BNF (June 2015) and £29.37 
based on the eMIT, resulting in a cost of £486 per cycle. Comparisons for the other generic drugs are 
provided in Table 11 of the company’s response to clarification question B7. The impact of using 
these costs within the economic evaluation is discussed in Section 5.2.10.  
 
5.2.9 Cost effectiveness results 
5.2.9.1 Cabazitaxel compared to mitoxantrone 
Within their initial submission,25 the company presented an ICER for cabazitaxel compared to 
mitoxantrone. This ICER was based on a deterministic analysis, and is displayed in Table 33. An 
estimate of the ICER based on the results of the probabilistic sensitivity analysis was not presented. In 
response to clarification question B4 the company presented a probabilistic ICER of £50,659, which 
is reported in Table 33 of this report. The ERG notes that an ICER based on the results of a 
probabilistic sensitivity analysis is more appropriate than an ICER based on a deterministic analysis 
as the former incorporates any potential non-linear relationships between model inputs and model 
results.111  
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The probabilistic ICER included a slight amendment to the originally submitted model (the proportion 
of patients who received BSC as post second-line treatment was initially fixed but was subsequently 
included in the probabilistic sensitivity analysis). The company tested a number of alternative 
scenarios, and made model adjustments in response to clarification questions, as described in Section 
5.2.10. However, in the updated model provided by the company in response to clarification 
questions, the only change that was incorporated was the afore-mentioned inclusion of the proportion 
of patients receiving BSC in the probabilistic sensitivity analysis. This suggests that the base-case 
deterministic results presented by the company did not change in response to clarification questions. 
 
At a willingness to pay value of £50,000 per QALY, the probability of cabazitaxel being a cost-
effective treatment when compared to mitoxantrone was 46.20%. At £40,000 this probability was 
6.4% whilst at £30,000 it was less than 0.001%.  
 
The economic model provided by the company did not record total costs and QALYs when saving the 
results of probabilistic sensitivity analyses. Hence for the probabilistic sensitivity analyses only the 
incremental values were reported. The mean values of the incremental costs and QALYs contained in 
the revised economic model submitted by the company following the clarification process are 
displayed in Table 33.  
 
Table 33: Cost-effectiveness results comparing cabazitaxel with mitoxantrone 
Treatment Total values Incremental values ICER (£) Costs (£) QALYs Costs (£) QALYs 
Deterministic results 
Mitoxantrone xxxxx  xxxxx - - - 
Cabazitaxel xxxxx  xxxxx £11,450 0.232 £49,327 
Probabilistic sensitivity analysis results 
Mitoxantrone NR NR - - - 
Cabazitaxel NR NR £11,829 0.233 £50,682 
ICER: Incremental cost-effectiveness ratio. NR: Not reported. QALYs: Quality adjusted life years 
 
5.2.9.2 Cabazitaxel compared to abiraterone and enzalutamide 
The company also reported the results of scenario analyses that compared cabazitaxel with abiraterone 
and enzalutamide (a fully incremental comparison including mitoxantrone was not undertaken). These 
results use the BNF list price of abiraterone and enzalutamide as the PAS for these interventions are 
commercial in confidence. The impact of using the confidential PAS prices on the cost-effectiveness 
results was explored in a confidential appendix prepared for the Appraisal Committee only. 
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The results of the company’s analyses are not directly comparable with those displayed in Table 33 in 
Section 5.2.9.1 for three main reasons: 
 A different parametric model is used for PFS because the parametric model used to compare 
mitoxantrone and cabazitaxel in 5.2.9.1 did not assume proportional hazards, and 
 A different definition of PFS is employed (rPFS, as opposed to the broader definition used in 
the TROPIC trial), and 
 The entire TROPIC population is used, as opposed to the sub-group who received at least 
225 mg/m2 of docetaxel and had an ECOG performance score of 0 or 1. 
 
When comparing cabazitaxel with the two advanced hormonal therapies the company used the 
confidential PAS price for cabazitaxel, and the BNF list prices for both abiraterone and enzalutamide. 
The results of these comparisons were presented as scenario analyses. From the CS it is unclear if 
these results are based on a deterministic analysis or a probabilistic sensitivity analysis. These results 
are presented in   
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Table 34, with the results taken from the revised economic model submitted by the company 
following the clarification process. For the probabilistic sensitivity analysis 2,000 runs were 
performed, and only the incremental values were reported. As cost-effectiveness results for BSC 
derived from the NMA are not included in the company’s economic model, these are not included and 
a fully incremental analysis is not presented. The ERG notes that the company used median hazard 
ratios when estimating the deterministic results. The ERG believes that use of means is more 
appropriate. 
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Table 34: Cost-effectiveness results comparing cabazitaxel with abiraterone and 
enzalutamide 
Treatment Total values 
Incremental values 
compared to cabazitaxel ICER compared to cabazitaxel (£) Costs (£) QALYs Costs (£) QALYs 
Deterministic results 
Cabazitaxel xxxxx  xxxxx - - - 
Abiraterone xxxxx  xxxxx 25,310 -0.017 Dominated by cabazitaxel 
Enzalutamide xxxxx  xxxxx 20,504 0.085 241,968 
Probabilistic sensitivity analysis results 
Cabazitaxel NR NR - - - 
Abiraterone NR NR 25,362 -0.018 Dominated by cabazitaxel 
Enzalutamide NR NR 20,716 0.0816 253,956 
ICER: Incremental cost-effectiveness ratio. NR: Not reported. QALYs: Quality adjusted life years. 
 
 
5.2.10 Sensitivity analyses 
The company performed a number of sensitivity analyses to test the robustness of the model to 
changes in the values of various input parameters. The results of these analyses are described in 
Tables 79 and 80 of the CS (p186-188). The key results from these analyses, along with the results of 
additional sensitivity analyses carried out by the company in response to clarification questions, are 
described in this section. All of the sensitivity analyses relate to a deterministic base-case comparison 
between cabazitaxel and mitoxantrone. An overview of the sensitivity analyses presented by the 
company, both in the CS and in response to clarification questions, is provided in Table 35. 
 
Utility values 
The base-case results were relatively robust to changes in the utility values for stable disease, with an 
increase or decrease by 20% changing the ICER by less than 10%. However, the ICER was more 
sensitive to changes in the modelled utility value for progressive disease. Decreasing the base-case 
value by 20% (from 0.627 to 0.522) increased the ICER by 13% (from £49,327 to £55,749), whilst an 
increase in the value of 20% (from 0.627 to 0.752) decreased the ICER by 13% (to £44,232). 
However, it is noted that under this latter sensitivity analysis the utility value for progressive disease 
is greater than the utility for the first four cycles with stable disease. The sensitivity of the ICER to the 
utility value for progressive disease is relevant given this value is estimated with a large degree of 
uncertainty as it is derived from 25 patients with an SD of 0.298. This provides a standard error of 
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0.060 and a 95% CI of 0.510 to 0.743 (based on the normal approximation). The CS did not vary the 
utility for progressive disease in the probabilistic sensitivity analysis, although this was only noted 
after the clarification process and therefore not amended in the model supplied post-clarification. 
 
Methods for extrapolating trial evidence 
Within the base-case analysis, OS and PFS were extrapolated using Weibull and log-normal curves 
(respectively) for both treatment arms. As described in Section 5.2.6, the company chose these curves 
as they minimised goodness-of-fit statistics when fitting to both curves simultaneously. Based on 
these statistics, the goodness of fit of the log-logistic curve to both observed OS and observed PFS is 
almost identical to the fit of the two curves used in the base-case (with maximum differences in 
information criteria of 1 [0.1%] and 5 [0.3%] units respectively – all of the alternative curves have 
differences of at least 38 [2.5%] units). 
 
Use of the log-logistic curve for OS decreased the ICER from the base-case value of £49,327 to 
£41,875 (it is believed that there is a typographical error in the CS that reports this as £41,920). Use of 
the log-logistic curve for PFS produced an ICER of £47,921. The company justified the use of the 
Weibull curve for OS by noting that use of the log-logistic curve led to longer mean survival, which 
may be “unrealistic”. The cabazitaxel treatment arm mean survival is 18.5 months using a Weibull 
curve and 21.8 months using a log-logistic curve, with mean survival gains over mitoxantrone of 4.1 
and 5.4 months respectively. The ERG notes that there is little external data to inform estimates of 
long-term (and hence mean) survival for patients with mCRPC previously treated with docetaxel. 
 
Other notable sensitivity analyses performed in the initial submission 
The inclusion of discontinuation for reasons other than disease progression in the economic model has 
been critiqued in Section 5.2.6. Not including this type of discontinuation increased the ICER by 2.1% 
to £50,370. 
 
Using the mean BSA from the TROPIC trial (in preference to the value obtained from UK clinical 
experts), increased the ICER by 3.4% to £50,985. 
 
Use of the entire TROPIC population (as is used in the NMA) increased the ICER by 5.1% to 
£51,833. 
 
Sensitivity analyses performed in response to clarification questions 
Three sensitivity analyses were performed relating to utilities (two using alternative values for stable 
disease and one which modified the calculations for the disutility due to reduced HRQoL in the last 
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three months of life); the base-case results were not materially changed under any of these analyses. 
The analyses are described further in Section 5.2.7. 
 
The company considered a change in how OS for cabazitaxel was modelled. Kaplan-Meier curves 
were used for the first 2.1 months, with a Weibull curve used for the remaining lifetime. This analysis 
was designed to account for early deaths due to cabazitaxel-induced neutropenia. Under this analysis 
the ICER reduced by 1.6% to £48,543. 
 
In the company’s base-case generic drugs were costed using the BNF. An alternative cost estimate is 
the eMIT (see Section 5.2.8 for further details). Using these costs increased the ICER by 4.8% to 
£51,675. 
 
Finally, a sensitivity analysis was performed under which all AEs were treated with drugs – this did 
not materially change the base-case ICER. 
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Table 35: Overview of deterministic sensitivity analyses presented by the company 
Scenario tested Incremental 
costs 
Incremental 
QALYs 
Incremental cost-
effectiveness ratio
Included within the company submission 
Base-case £11,450 0.232 £49,327 
Progressive disease utility +20% £11,450 0.259 £44,232 
Progressive disease utility -20% £11,450 0.206 £55,749 
Use of log-logistic curves for overall 
survival £12,724 0.304 £41,920 
Not including discontinuation for 
reasons other than disease progression £11,693 0.232 £50,370 
Mean BSA value taken from the 
TROPIC trial £11,852 0.232 £50.985 
Use of the entire TROPIC population £11,141 0.215 £51,833 
Performed in response to clarification questions*  
Use of Kaplan-Meier curves for the first 
2.1 months of overall survival for 
cabazitaxel (B1). 
£11,568 0.238 £48,543 
Using eMIT for generic drug costs (B7). £11,995 0.232 £51,675 
Rates of drug use for all adverse events 
= 1 (B19). £11,511 0.232 £49,587 
*(numbers in brackets denote the clarification question). 
QALYs: Quality-adjusted life years. 
 
 
5.2.11 Model validation and face validity check 
The company provided the following details with regards to model validation: 
“The model was run under a variety of settings of the input parameters to see if the results appeared to 
be reasonable. The validation analyses included setting inputs to extreme values and verifying the 
results for logical consistency.” No further details were provided. The ERG performed its own model 
validation checks when critiquing the company’s submitted evidence. The main issues are 
summarised in Section 5.2.12. 
 
5.2.12 Overview of the ERG’s critique of the cost-effectiveness evidence 
This section provides an overview of the critiques previously discussed, concentrating on the main 
areas of uncertainty or disagreement. 
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Exclusion of radium-223 dichloride as a comparator 
Radium-223 dichloride was included in the final NICE scope,19 but not in the company’s economic 
evaluation. The ERG believes that radium-223 dichloride should have been included. A formal 
estimate of the cost effectiveness of radium-223 dichloride relative to cabazitaxel would have required 
the ERG to both conduct an NMA and adapt the company’s model. This was not possible in the time-
frame of the assessment. However, the potential impact of including radium-223 dichloride in the 
economic evaluation is discussed in Section 5.3.  
 
Modelling of overall survival 
For the company’s base-case analysis, OS and PFS were modelled using separate Weibull and log-
normal curves (respectively) for both treatment arms. In response to clarification question B1, which 
queried why piecewise curves were not used, the company presented the results using a hybrid 
method for estimating OS following cabazitaxel treatment with the mitoxantrone OS curve 
unchanged. This method used Kaplan-Meier curves for the first 2.1 months and a Weibull curve for 
the remaining lifetime for the cabazitaxel arm. Under this method the base-case ICER reduced by 
1.6% to £48,543. The ERG believes that this hybrid method is likely to be more appropriate than the 
base-case method. However, it is noted that details regarding the Weibull curve used for the hybrid 
method were not provided, so the ERG was not able to replicate this analysis. 
 
Utility values 
Data from the UK EAP50 were used by the company to derive utility values for patients with stable 
disease and progressive disease. The UK EAP data are more mature than when used for the TA255 
submission15. While it is believed that the estimated values have face validity it is noted that the 
model results are sensitive to the utility value for progressive disease and that there is uncertainty over 
this value, as it is only based on data for 25 people. It is unclear what impact reducing uncertainty in 
the utility value for progressive disease would have on the ICER. 
 
Resource use and costs 
Two national sources are available for estimates of the costs of generic drugs: the BNF107 and the 
eMIT.112 The company used the BNF in its base-case analysis. However, the ERG feels that use of the 
eMIT is more appropriate, as this is based on the actual price paid by English trusts. Use of eMIT 
prices increased the ICER comparing cabazitaxel with mitoxantrone by 4.8% to £51,675. 
 
Three different estimates of post-second line treatment costs are available. The most expensive 
estimate (£1767.02) is for the mitoxantrone arm of the TROPIC trial. The least expensive estimate 
(£1192.81) is for the cabazitaxel arm of the TROPIC trial. The third estimate was based on a UK 
clinical audit (£1364.07). Within the economic model the cabazitaxel arm estimate was used for 
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treatment following cabazitaxel, and the mitoxantrone arm estimate was used for treatment following 
any of mitoxantrone, abiraterone or enzalutamide. The ERG believes that differences in post-second 
line treatment were unlikely to have contributed to differences in OS for the TROPIC trial. Hence the 
ERG believes that the same post-second line treatment costs should be used for cabazitaxel and each 
of the comparators. The ERG performed an analysis which used the values from the UK clinical audit 
for cabazitaxel and all of the comparators. This increased the ICER comparing cabazitaxel with 
mitoxantrone by 2.3% to £50,444. 
 
Within their base-case the company assumed that there would not be any wastage of cabazitaxel. As 
discussed in Section 5.2.8, the ERG believes that there is likely to be some vial wastage occurring in 
clinical practice, but there is uncertainty about how much vial wastage would occur. The ERG 
performed an analysis which assumed that a cycle of treatment with cabazitaxel (or mitoxantrone) 
would require the cost of a vial of cabazitaxel (or mitoxantrone). This increased the ICER by XX to 
XXXX. 
 
Modelling of discontinuation for reasons other than progression 
For cabazitaxel and mitoxantrone the company modelled discontinuation for reasons other than 
disease progression. People who discontinued this way remained in the stable disease state. The ERG 
identified three potential issues with how this approach was implemented and it believes that only two 
of these were adequately addressed by the company in their response to clarification question B6 (see 
Section 5.2.6 for a fuller discussion). In addition, the ERG believes that it is inappropriate to include 
this type of discontinuation for cabazitaxel and mitoxantrone but not for the two advanced hormonal 
therapies. Not including this type of discontinuation in the economic model increased the ICER by 
2.1% to £50,370. 
 
Disutility during the end of life period 
The company included a disutility in the QALY calculations to account for the assumed reduced 
quality of life experienced by people with progressive disease in their last three months of life. 
However, the ERG noted that this disutility was calculated based on all deaths observed, not deaths 
amongst people with progressive disease. This was not changed in response to clarification question 
B11. The ERG notes that as all patients are modelled until death, the effect of this disutility will 
cancel out except for differences in discounting due to the differential timing of deaths for the 
different treatments. The impact on the ICER of removing this disutility was tested by the ERG, as 
discussed in Section 5.3, was to increase the ICER by 0.74% to £364. 
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5.3 Exploratory and sensitivity analyses undertaken by the ERG 
The ERG undertook a number of additional sensitivity analyses using the economic model, and base-
case settings, supplied by the company (these did not change following response to clarification 
questions). Due to the requirement of following the template for ERG reports the results produced 
from key analyses undertaken by the ERG are reported in Section 6 (Table 36). 
 
The following exploratory analyses had a notable effect on the base-case ICER reported in the CS. 
 
For the company's base-case it was assumed that wastage would not occur for either cabazitaxel or 
mitoxantrone. As discussed in Section 5.2.8, the ERG believes that wastage could still occur. Hence 
an analysis was conducted that allowed for wastage. This was implemented in the company's model 
by setting the cost for mitoxantrone and cabazitaxel to be the cost per vial (instead of the cost per mg).  
 
The ERG changed the post-second line treatment mix so that it was no longer treatment-specific, with 
resource use estimates from a UK clinical audit used instead.25 The rationale for this change is 
summarised in Section 5.2.12. The change was achieved by changing the drop-down box of cell 
'Post2ndChemoMix' (sheet 'Resource input') from 'TROPIC (arm-specific)' to 'Country-specific 
(general)'. 
 
The ERG examined how sensitive the model results were to including a dose-reduction for both 
cabazitaxel and mitoxantrone. These reductions were removed by setting cells Rel_dose_int_caba and 
Rel_dose_int_mitox both equal to one. 
 
For the comparison between cabazitaxel and mitoxantrone, the choice of parametric curve for 
extrapolation was based on minimising the goodness of fit to both TROPIC arms. The ERG explored 
the impact on the ICER of minimising the goodness of fit to the TROPIC arms separately (hence 
allowing for different parametric models to be used for the two treatments). This led to modelling OS 
with the Weibull curve for cabazitaxel and the log-logistic curve for mitoxantrone. For PFS the log-
logistic curve was used for cabazitaxel and the log-normal curve was used for mitoxantrone. 
 
The ERG noted that, based on their goodness of fit to the observed data, the use of log-logistic curves 
for both OS and PFS was a plausible alternative to the curves used in the base-case, although the ERG 
notes the statements made in the CS (p187)25 that these had less face validity regarding long-term 
projection of survival. The ERG enacted these changes using the options in the 'RUN MODEL' sheet. 
 
The ERG explored the sensitivity of the model results to the choice of progressive disease. The value 
used in the base-case was 0.6266, based on data from the UK EAP. Based on the standard error of 
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0.060 derivable from the UK EAP data, a normal 95% CI for the utility value for progressive disease 
is 0.510 to 0.743. These values were used in the economic model by changing the cell 
‘utility_value_PD’ to these values. It should be noted that when using the latter estimate, the modelled 
utility will increase for people who progressed after receiving less than four cycles of treatment. 
Hence these results should be viewed with caution. 
 
The company did not consider radium-223 dichloride to be a valid comparator, and so did not include 
it within their NMA. The ERG believes that this exclusion was inappropriate, as discussed in Section 
3.3. When queried about this exclusion (clarification question A1), the company did provide summary 
statistics comparing OS amongst the TROPIC population with OS amongst the ALSYMPCA 
population with previous docetaxel use. This comparison is reproduced in Table 16 (comparable 
measures of PFS were not reported by the two trials): 
 
The ERG notes that the differences in OS (both absolute and relative) are similar for cabazitaxel and 
radium-223 dichloride. Hence, the cost-effectiveness of cabazitaxel in comparison with radium-223 
dichloride is likely to be driven mainly by the costs of the two drugs. The list price for a course of 
radium-223 dichloride (£4040) is xxxxx the PAS price for a cycle of cabazitaxel xxxxx. Radium-223 
dichloride is taken for a maximum of six courses, whereas in the company’s economic model 
cabazitaxel is taken for a maximum of ten cycles. In clinical practice there is no restriction on the 
maximum number of cycles for which cabazitaxel may be taken, although the median number of 
treatment cycles observed in both the TROPIC trial11 and the UK EAP50 was six. Data on the median 
number of treatments for radium-223 dichloride is not available. xxxxx xxxxx xxxxx xxxxx xxxxx xxxxx 
xxxxx xxxxx xxxxx xxxxx xxxxx xxxxx xxxxx xxxxx xxxxx. A consideration of the effect of the PAS for 
radium-223 dichloride on cost-effectiveness is discussed in a confidential appendix. 
 
The following analyses did not materially affect the company’s reported base-case ICER. 
The company included a disutility to HRQoL to reflect the potentially worsening HRQoL for people 
with progressive disease in their last three months of life. The ERG had concerns with how this was 
implemented in the economic model, as discussed in Section 5.2.12. Hence an analysis was performed 
that removed this disutility. This was achieved by setting cells B3 to B6 on sheet 'Utility death' each 
equal to zero. 
 
The ERG performed three sensitivity analyses concerning the stable disease utility values. These 
were: 
1. Use of the weighted mean utility from the UK EAP (0.737) for all cycles. 
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2. Use of the values estimated from the 'TREND' function for each of the 10 cycles (as opposed 
to just being used for odd cycles - see response to clarification question B21 for further 
details). 
3. Estimating the values for odd cycles as a weighted mean of the adjacent values (for example, 
the cycle 3 value would be the mean of the values observed for cycles 2 and 4). 
 
5.4 Conclusions of the cost effectiveness section  
The report was generally well written and the model was transparent with relatively few errors 
identified. The clarification process was smooth and the company responded to all of the ERG’s 
questions.  
 
Within the CS (p39)25 it was argued that there are two clinical pathways of care for mCRPC, 
depending on whether or not the advanced hormonal therapies (abiraterone and enzalutamide) are 
used in the pre-chemotherapy or post-chemotherapy setting. Their use in the pre-chemotherapy setting 
was considered by the company to represent standard NHS practice. For this setting, the CS included 
a comparison between cabazitaxel and mitoxantrone. For the alternative pathway (post-chemotherapy 
use of the advanced hormonal therapies) the CS included comparisons between cabazitaxel and 
abiraterone and between cabazitaxel and enzalutamide although there was not an intention to perform 
a fully incremental analysis and BSC was not considered. The ERG notes that the exclusion of 
radium-223 dichloride from both pathways will lead to uncertainty in the cost-effectiveness results. 
However, given the results in Table 16 it did not seem unreasonable to explore the potential cost-
effectiveness of radium-223 dichloride and cabazitaxel assuming equal efficacy of the interventions. 
This is detailed in Section 5.3, whilst an analysis using the PAS prices for cabazitaxel and radium-223 
dichloride is provided in a confidential appendix. The ERG does not believe that the company 
provided sufficient justification for denoting the use of abiraterone and enzalutamide in the pre-
chemotherapy setting as standard NHS practice. It is noted that both of these advanced hormonal 
therapies have NICE approval in the post-chemotherapy setting, and both are subject to on-going 
NICE appraisals in the pre-chemotherapy setting. 
 
There was uncertainty relating to the amount of vial wastage that would occur for cabazitaxel in 
clinical practice. The base-case analysis assumed no wastage. If wastage does occur, this would 
increase the ICER. 
 
Additional uncertainties related to the estimate of utility for patients with progressive disease, and 
how effectiveness data should be extrapolated. It is unclear if resolving these uncertainties would 
increase or decrease the base-case ICER. 
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6 IMPACT ON THE ICER OF ADDITIONAL CLINICAL AND ECONOMIC 
ANALYSES UNDERTAKEN BY THE ERG 
An overview of the ERG changes to the company’s model is displayed in Table 36, along with 
estimates from the ERG base-case. The results presented in Table 36 are for the comparison between 
cabazitaxel and mitoxantrone. As discussed in Section 5.2.12, the ERG believes that the hybrid 
method for modelling the effectiveness of cabazitaxel is more appropriate than the company’s base-
case method. However, the ERG was not able to replicate this hybrid method. Use of the hybrid 
method decreased the company’s base-case ICER by 1.6%, hence including the hybrid method is 
likely to reduce the ERG base-case ICER. In addition, as discussed in Section 5.2.8 there is 
uncertainty about the extent to which vial wastage occurs in clinical practice. Hence, two ERG base-
cases are presented: one for which cabazitaxel treatment is based on the vial price (assuming that 
there will be some wastage of the vial), and one which assumes no wastage, with the clinical advisors 
to the ERG believing the scenario with vial wastage to be more realistic. It is noted that there will be 
some unavoidable wastage if people fail to attend their appointments for treatment. All probabilistic 
sensitivity analyses used 2,000 iterations. 
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Table 36: Overview of ERG changes to the model 
Individual changes made 
Cabazitaxel Mitoxantrone Incremental values 
ICER (£) Total costs
(£) 
Total 
QALYs 
Total costs 
(£) 
Total 
QALYs Costs (£) QALYS 
Company deterministic base-case xxxxx xxxxx xxxxx xxxxx 11,450 0.232 49,327 
Company probabilistic base-case NR NR NR NR 11,829 0.233 50,682 
Changes made        
A1) Use eMIT prices* xxxxx xxxxx xxxxx xxxxx 11,994 0.232 51,667 
A2) Discontinuation for reasons other than 
disease progression not modelled 
xxxxx xxxxx xxxxx xxxxx 11,693 0.232 50,370 
A3) Reduced disutility in the last 3 months 
of progressive disease not modelled 
xxxxx xxxxx xxxxx xxxxx 11,450 0.230 49,691 
A4) Post-second line treatment resource use 
from UK audit for all treatments. 
xxxxx xxxxx xxxxx xxxxx 11,710 0.232 50,444 
A5) Network meta-analysis results using a 
weakly informative prior (does not affect 
the comparison with mitoxantrone). 
xxxxx xxxxx xxxxx xxxxx 
11,450 0.232 49,327 
A6) Cost of cabazitaxel and mitoxantrone 
based on vial cost (assuming wastage). 
xxxxx xxxxx xxxxx xxxxx 
xxxxx 0.232 xxxxx 
A7) Use of log-logistic curves for both 
overall and progression-free survival. 
xxxxx xxxxx xxxxx xxxxx 12,627 0.309 40,887 
A8) Parametric curves for OS and PFS 
based on lowest AIC value (no requirement 
xxxxx xxxxx xxxxx xxxxx 9,347 0.137 68,168 
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for same parametric form for both arms)** 
A9) Use of the 95% low confidence interval 
value for progressive disease (0.510). 
xxxxx xxxxx xxxxx xxxxx 11,450 0.207 55,248 
A10) Use of the 95% high confidence 
interval value for progressive disease 
(0.743). 
xxxxx xxxxx xxxxx xxxxx 
11,450 0.257 44,560 
ERG Deterministic base-case 1 (changes 
A1 to A6) 
xxxxx xxxxx xxxxx xxxxx XXX 0.230 XXX 
ERG Probabilistic base-case 1 (changes 
A1 to A6) 
xxxxx xxxxx xxxxx xxxxx XXX 0.231 XXX 
ERG Deterministic base-case 2 (changes 
A1 to A5) 
xxxxx xxxxx xxxxx xxxxx 12,218 0.230 53,021 
ERG Probabilistic base-case 2 (changes 
A1 to A5) 
xxxxx xxxxx xxxxx xxxxx 12,654 0.234 54,126 
ICER: Incremental cost-effectiveness ratio. NR: Not reported. OS: Overall survival. PFS: Progression-free survival. QALYS: Quality-adjusted life-years. 
*Note: when the company used eMIT prices (in response to clarification question B7), the reported total costs for cabazitaxel and mitoxantrone were £28,902 and £16,906 respectively, resulting 
in an ICER of £51,675. The ERG was unable to replicate these values. 
** For cabazitaxel the Weibull curve is used for OS and the log-logistic curve for PFS. For mitoxantrone the curves are the log-logistic and the log-normal, respectively. 
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Under the ERG base-cases (using the results of probabilistic sensitivity analyses), the ICER 
comparing cabazitaxel with mitoxantrone was XXX if vial wastage occurs and £54,126 in the absence 
of vial wastage. Clinical advice given to the ERG suggests that vial wastage would be likely. The 
sensitivity analyses performed (A7 to A10) showed that the ICER was also sensitive to the methods 
employed for extrapolating clinical effectiveness data, and the utility value used for progressive 
disease. In addition, the ERG noted that when choosing the parametric form to extrapolate OS (and 
allowing cabazitaxel and mitoxantrone to have different parametric forms), the difference in goodness 
of fit statistics were less than 0.2% for both treatments. The models with the lowest goodness of fit 
statistics provided estimated mean survival times of 1.54 and 1.36 years for cabazitaxel and 
mitoxantrone respectively (ICER: £73,592). The models with the second lowest goodness of fit 
statistics provided estimated mean survival times of 1.82 and 1.20 years for cabazitaxel and 
mitoxantrone respectively (ICER: £35,947). 
 
Based on the ERG base-cases, the cost-effectiveness of cabazitaxel when compared with abiraterone, 
enzalutamide or BSC is displayed in Table 37 (assuming vial wastage) and Table 38 (with no vial 
wastage). The company’s model was amended to include BSC as a comparator. It was assumed that 
BSC was represented by mitoxantrone with respect to per-cycle costs and utility values. The 
effectiveness of BSC was modelled in the same manner as for abiraterone and enzalutamide by using 
HRs for BSC derived from the NMA as updated by the ERG (see Section 4.5 for more details). 
 
Table 37: Cost-effectiveness results comparing cabazitaxel with BSC, abiraterone and 
enzalutamide (ERG base-case assuming vial wastage) 
Treatment Total values Incremental cost-effectiveness ratio (£) Costs (£) QALYs 
Deterministic results 
BSC xxxxx  xxxxx - 
Cabazitaxel xxxxx  xxxxx £112,800 compared with best-supportive care 
Abiraterone xxxxx  xxxxx Extendedly dominated by enzalutamide 
Enzalutamide xxxxx  xxxxx £134,326 compared with cabazitaxel 
Probabilistic sensitivity analysis results 
BSC xxxxx  xxxxx - 
Cabazitaxel xxxxx  xxxxx £109,325 compared with best-supportive care 
Abiraterone xxxxx  xxxxx Extendedly dominated by enzalutamide 
Enzalutamide xxxxx  xxxxx £141,363 compared with cabazitaxel 
BSC: Best supportive care. QALYs: Quality adjusted life years. 
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Table 38: Cost-effectiveness results comparing cabazitaxel with BSC, abiraterone and 
enzalutamide (ERG base-case assuming no vial wastage) 
Treatment Total values Incremental cost-effectiveness ratio (£) Costs (£) QALYs 
Deterministic results 
BSC xxxxx  xxxxx - 
Cabazitaxel xxxxx  xxxxx £87,191 compared with best-supportive care 
Abiraterone xxxxx  xxxxx Extendedly dominated by enzalutamide 
Enzalutamide xxxxx  xxxxx £150,338 compared with cabazitaxel 
Probabilistic sensitivity analysis results 
BSC xxxxx  xxxxx - 
Cabazitaxel xxxxx  xxxxx £88,766 compared with best-supportive care 
Abiraterone xxxxx  xxxxx Extendedly dominated by enzalutamide 
Enzalutamide xxxxx  xxxxx £155,014 compared with cabazitaxel 
BSC: Best supportive care. QALYs: Quality adjusted life years. 
 
Based on the ERG base-case assumptions (using the results of probabilistic sensitivity analyses) the 
ICER for cabazitaxel compared with BSC is estimated to be £109,325 with vial wastage and £88,766 
without vial wastage.. Abiraterone does not lie on the efficiency frontier, as the ICER comparing 
abiraterone with cabazitaxel is greater than that comparing enzalutamide with abiraterone regardless 
of the assumption made concerning vial wastage, and hence abiraterone is extendedly dominated by 
enzalutamide. Compared with cabazitaxel, the ICER for enzalutamide is £141,363 with vial wastage 
and £155,014 without vial wastage. 
 
It should be noted that the ICERs comparing cabazitaxel with BSC are substantively greater than 
those comparing cabazitaxel with mitoxantrone, as reported in Table 35. This shows that the 
estimated cost-effectiveness results are sensitive to the modelling approach employed for 
extrapolating clinical effectiveness data. For the NMA results (which are used when comparing 
cabazitaxel with BSC and the two advanced hormonal therapies), an assumption of proportional 
hazards is required. The ERG has already noted that this assumption is questionable, and that the 
NMA results should be treated with caution, as discussed in Section 4.4. 
 
Sensitivity analyses for the comparison between cabazitaxel, BSC, abiraterone and enzalutamide were 
not performed as the list prices used for abiraterone and enzalutamide do not reflect the true cost to 
the NHS. Cost-effectiveness results and sensitivity analysis based on the PAS for abiraterone and 
enzalutamide are reported in a confidential appendix. 
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There are two important uncertainties that are not captured within the ERG base-case. Firstly, it is 
noted that clinical use is not restricted to a maximum of ten cycles. However, this restriction was used 
in the TROPIC trial, to enable comparison with mitoxantrone, which is restricted to ten cycles of use. 
The TROPIC trial provides estimates for the effectiveness of cabazitaxel as used in the economic 
model. Using cabazitaxel for more than ten cycles would increase the lifetime costs associated with 
cabazitaxel, although it would be anticipated that this could also increase OS and utility and thus the 
impact on the ICER is unknown. In response to clarification question A4 the company stated that: 
“The economic evaluation evaluates up to 10 cycles of treatment in order to be consistent with the 
trial evidence base, however based on UK experience (UK EAP and the number of cycles recorded on 
the CDF), it is reasonable to assume most patients will receive less than 10 cycles.” Data from the UK 
EAP50 show that 30.4% (34/112) of people received ten or more cycles of cabazitaxel. The maximum 
number of cycles received was 16, experienced by one person. It is further unclear what impact 
receiving more than ten cycles of cabazitaxel would have on HRQoL. Data from the UK EAP are 
only provided for the first ten cycles. They show that HRQoL improves as more cycles of cabazitaxel 
are received, although this improvement is not statistically significant. It is unclear if this 
improvement would be maintained beyond ten cycles. 
 
The second important uncertainty relates to the results of the NMA. Both the ERG and the company 
believe that the results should be treated with caution. In addition, the ERG notes the uncertainty in 
using rPFS, which the company believes may bias against cabazitaxel when compared with 
abiraterone or enzalutamide. Within the economic model lower estimates of rPFS compared with a 
constant OS are associated with improved cost-effectiveness, as less drug costs are incurred, which 
may produce a favourable ICER for cabazitaxel. 
 
The company did not consider the cost-effectiveness of cabazitaxel when compared to radium-223 
dichloride. Whilst it was not possible within the timescales of the STA to include radium-223 
dichloride within the existing cost-effectiveness analyses, a discussion of the potential consequences 
of including radium-223 dichloride as a comparator (for the sub-group for which it is indicated) is 
provided in both Section 5.3 and a confidential appendix.  
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7 END OF LIFE 
To satisfy the NICE criteria for a life-extending, end-of-life treatment, three separate criteria must be 
met. These criteria, along with the company's justification for why they are met and the ERG's 
critique of this justification, are discussed in turn. It is noted that the decision of whether cabazitaxel 
meets end of life criteria may depend on the treatments to which it is being compared. These 
treatments may be BSC (including mitoxantrone), or an active comparator (abiraterone, enzalutamide 
and radium-223 dichloride), which do have a proven impact on OS when compared with BSC.   
 
1. The treatment is indicated for patients with a short life expectancy, normally less than 24 
months. 
 
The company refer to a recent review of the literature by West et al,10 who showed that median OS for 
patients treated first-line with docetaxel was 19 months. As cabazitaxel has marketing authorisation 
for treatment following prior adequate treatment with docetaxel, it is expected that OS in this group 
will be less than 19 months. The company also note that median OS for the control arms of the pivotal 
trials for cabazitaxel, abiraterone, enzalutamide and radium-223 dichloride varied from 11.2 months 
to 13.6 months. The ERG notes that OS for the active treatment arms (not including cabazitaxel) were 
15.8 months (abiraterone), 18.4 months (enzalutamide) and 14.4 months (radium-223 dichloride). 
 
2. There is sufficient evidence to indicate that the treatment offers an extension to life, normally 
of at least an additional three months, compared to current NHS treatment, and; 
 
When compared to mitoxantrone, cabazitaxel offered an estimated extension to median OS of 2.4 
months (based on the full TROPIC population), and an estimated extension to mean OS of 4.1 months 
(based on the company's base-case analysis where OS is modelled using Weibull curves). In Section 
5.2.10 the ERG noted that the fit to the observed data using log-logistic curves was similar to the fit 
produced using Weibull curves. Use of log-logistic curves led to an estimated mean extension to OS 
of 5.4 months.  
 
The company did not consider if cabazitaxel met this criteria when compared to other treatments. The 
ERG notes that within the company's NMA, no statistically significant difference was found in OS 
between cabazitaxel and either abiraterone or enzalutamide. This lack of difference is based on the 
95% credible interval for the estimated HR including one in both comparisons, based on the results 
from a fixed effects model. The ERG further notes that use of a random effects model would be likely 
to lead to an increase in the width of the 95% credible interval (and so still include one). A 
comparison with radium-223 dichloride was not performed. However, as discussed in Section 5.3, the 
Confidential until published 
136 
 
available evidence suggests that cabazitaxel and radium-223 dichloride potentially have similar 
effects on OS. 
 
3. The treatment is licensed or otherwise indicated, for small patient populations. 
 
The company provided details of a calculation which estimated that 1,690 people would be eligible 
for cabazitaxel. The ERG believes that this estimate is appropriate, although it is noted that there is 
uncertainty in the values used to derive this estimate. Further details are provided in Section 2.1. The 
ERG notes that the CSs for abiraterone and enzalutamide estimated that the number of patients 
eligible for treatment following docetaxel would be 3,300 and 2,977 respectively. 
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8 OVERALL CONCLUSIONS 
The ERG did not identify any issues relating to the company’s systematic review which appeared 
likely to influence the size of the ICER, with the possible exception of the subgroup analyses which 
are discussed below. 
 
The company reported the results of an NMA using a fixed effects model. The ERG believes that by 
not using a random effects model the uncertainty in the effectiveness of treatments will be 
underestimated. The ERG updated the NMA results using a random effects model. The findings 
confirmed that there were broadly similar treatment effects for OS. They also indicate that no active 
treatments are significantly more effective than any of the other active treatments for rPFS. However, 
there is uncertainty in the results of the NMA due to concerns over differences between patient 
populations and exchangeability of control treatments. In addition, the relative treatment effects are 
assumed to be constant over time, which may not be realistic. 
 
Within the CS a probabilistic base-case ICER of £50,682 comparing cabazitaxel with mitoxantrone 
was presented. In scenario analyses the company presented cost-effectiveness results, based on their 
NMA, to suggest that use of cabazitaxel dominated use of abiraterone (being associated with both 
reduced lifetime costs and improved overall HRQoL), and was cheaper but less effective than 
enzalutamide with an ICER of £212,038 for enzalutamide compared with cabazitaxel. 
 
The company noted that there were two clinical pathways of care for people with mCRPC. Use of 
abiraterone or enzalutamide in the pre-chemotherapy setting was taken by the company to represent 
standard NHS practice, whilst use of abiraterone or enzalutamide in the post-chemotherapy setting 
was taken to be alternative practice. For standard NHS practice the company presented a probabilistic 
base-case ICER of £50,682 comparing cabazitaxel with mitoxantrone. For alternative practice the 
company presented cost-effectiveness results, using results from their NMA, to suggest that use of 
cabazitaxel dominated use of abiraterone (being associated with both reduced lifetime costs and 
improved overall health-related quality of life), and was cheaper but less effective than enzalutamide 
with enzalutamide having an ICER of £253,956 per QALY gained compared with cabazitaxel. The 
comparisons against abiraterone and enzalutamide were both undertaken using the list price of these 
drugs. 
 
The ERG does not believe that there is sufficient justification for denoting either clinical pathway as 
standard NHS practice. It is noted that both of these advanced hormonal therapies have NICE 
approval in the post-chemotherapy setting, and both are subject to on-going NICE appraisals in the 
pre-chemotherapy setting. For the sub-group of people with symptomatic bone metastases and no 
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known visceral metastases radium-223 dichloride is a comparator in the NICE final scope, so 
excluding it will lead to uncertainty in the cost-effectiveness of cabazitaxel for both clinical pathways. 
In addition, not including BSC in the alternative practice pathway also leads to uncertainty about the 
cost-effectiveness of cabazitaxel. 
 
The ERG’s estimate of the ICER comparing cabazitaxel with mitoxantrone was XXX when modelling 
vial wastage and £54,126 when this was not modelled. The ERG also considered the cost-
effectiveness of cabazitaxel when compared with BSC, abiraterone and enzalutamide. Effectiveness 
data were taken from the NMA adjusted by the ERG. The ICER comparing cabazitaxel with BSC was 
£109,325 when vial wastage was modelled and £88,766 when it was not modelled. Abiraterone was 
extendedly dominated by enzalutamide irrespective of how vial wastage was modelled. The ICER 
comparing enzalutamide with cabazitaxel was £141,363 when vial wastage was modelled and 
£155,014 when it was not modelled. 
 
8.1 Implications for research 
There are no direct comparisons of the clinical and cost effectiveness of cabazitaxel and any of 
abiraterone, enzalutamide or radium-223 dichloride. Hence there is a need for RCTs that directly 
compare these treatments, collects sufficient evidence on resource use and costs, and is powered to 
detect clinically meaningful changes in both OS and PFS. Trials comparing different sequences of 
treatment involving cabazitaxel and the advanced hormonal agents would also be beneficial. 
 
Further research into the utility of people with mCRPC, particularly for people with progressed 
disease and how this utility varies over time, would help to reduce the uncertainty in the cost-
effectiveness results. Uncertainty would also be reduced if longer-term data concerning the 
effectiveness of cabazitaxel (and each of the comparators) were available.  
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10 APPENDICES 
Appendix 1: Summary of TROPIC results (final analyses) as published by de Bono et al.11 
In the TROPIC study, final efficacy analyses were planned after 511 death events had occurred using 
the ITT principle.  The results for the whole trial population were first published by de Bono et al. in 
201011 after a median follow-up of 12.8 months (study cut-off date: 25 September 2009), at which 
point 513 deaths had occurred.  All efficacy analysis were by ITT and estimates of the HR and 
corresponding 95% CI were provided using a Cox proportional hazard model stratified by factors 
specified at randomisation.  A brief summary of the key results is provided below. 
 
 OS 
Following a median follow-up of 12.8 months, 234 patients in the cabazitaxel group and 279 patients 
in the mitoxantrone group had died.  Median OS (calculated using Kaplan-Meier methodology) was 
15.1 months in the cabazitaxel group and 12.7 months in the mitoxantrone group and the HR was 0.70 
(95% CI 0.59 to 0.83, p<0.0001, Table 39). Thus, cabazitaxel plus prednisone/prednisolone was 
associated with an estimated median survival gain of 2.4 months relative to mitoxantrone plus 
prednisone/prednisolone. The estimated modelled mean survival gain, reported in NICE TA255,15 was 
4.2 months.   
 
Table 39: Summary of OS in the TROPIC study – final efficacy analysis 
 Cabazitaxel 
(n=378) 
Mitoxantrone 
(n=377) 
Hazard ratio 
(95% CI) 
p value 
Analysis at 25.9.2009 (final efficacy analysis)11 
Total deaths, ITT population 234 (61.9%) 279 (74.0%) NR NR 
Number of patients censored 144 98 NR NR 
Median overall survival,  
months (95% CI) a 
15.1 
(14.1 to 16.3) 
12.7 
(11.6 to 13.7) 
0.70 
(0.59 to 0.83) 
<0.0001 
CI, confidence interval; ITT, intention-to-treat 
a Median difference in overall survival, 2.4 months 
 
 
 PFS 
In the final analysis, as reported by de Bono et al.11 cabazitaxel was associated with a statistically 
significant improvement in median PFS (a composite endpoint defined as the time between 
randomisation and first date of progression as measured by PSA progression, tumour progression, 
pain progression or death).   Median PFS was 2.8 months in the cabazitaxel group and 1.4 months in 
the mitoxantrone group (HR: 0.74, 95% CI 0.64 to 0.86, p<0.0001).  Additional data from a FDA 
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reviewers’ report85 indicated that the majority (43-49%) of progression events were related to PSA 
progression.  A summary of the PFS results are provided in Table 40. 
 
Table 40: Progression-free survival in the TROPIC study – final efficacy analysis 
 Cabazitaxel  
(n=378) 
Mitoxantrone 
(n=377) 
Hazard ratio  
(95% CI) 
p value 
Analysis at 25.9.2009 (final efficacy analysis)  
Number of patients with 
progression-free survival events 
(%)85 
364 (96.3%) 367 (97.3%) NR NR 
Median progression-free survival, 
months (95% CI)11  
2.8  
(2.4 to 3.0) 
1.4  
(1.4 to 1.7) 
0.74  
(0.64 to 0.86) 
<0.0001 
 Death 38 (10.1%) 29 (7.7%) NR NR 
 Tumour progression 67 (17.7%) 68 (18.0%) NR NR 
 PSA progression 163 (43.1%) 186 (49.3%) NR NR 
 Pain progression 86 (22.8%) 70 (18.6%) a NR NR 
 Symptom deterioration 10 (2.6%) 14 (3.7%) NR NR 
 Censored 14 (3.7%) 10 (2.7%) NR NR 
CI, confidence interval 
a Data discrepancy in CS: updated efficacy analysis had fewer number of patients (n=69) 
 
 
 Other secondary outcomes 
In general, as reported by de Bono et al.11 cabazitaxel was associated with statistically significant 
improvements in PSA response (p = 0.0002), time to PSA progression (p = 0.001), objective tumour 
response (p = 0.0005) and time to tumour progression p < 0.0001.  However, it was not associated 
with statistically significant differences in pain response (p=0.63) or pain progression (p = 0.52).  
Data on HRQoL were not collected in the TROPIC study.  
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Appendix 2:  Additional data on adverse events 
 
A comparison of the adverse events observed in the trials included in the NMA are provided in Table 41. 
Table 41: Comparison of adverse events in trials included in the NMA 
 TROPIC (cabazitaxel + 
prednisone arm, n=371)11 
AFFIRM (enzalutamide 
arm, n=800)13 
COU-AA-301 (abiraterone + 
prednisone arm, n=791)12 
ALSYMPCA (radium-223 dichloride 
arm with previous docetaxel use, 
n=347)14 
 All grades Grades ≥ 3 All grades Grades ≥ 3 All grades Grades ≥ 3 All grades Grades ≥ 3 
Haematological         
Anaemia 361 (97%) 39 (11%) NR NR 178 (23%) 59 (7%) 120 (35%) 50 (14%) 
Thrombocytopenia 176 (47%) 15 (4%) NR NR 28 (4%) 11 (1%) 53 (15%) 31 (9%) 
Leukopenia 355 (96%) 253 (68%) NR NR   21 (6%) 5 (1%) 
Neutropenia 347 (94%) 303 (82%) NR NR 7 (1%) 1 (<1%) 24 (7%) 11 (3%) 
Febrile neutropenia  28 (8%) NR NR 0 (0%) 0 (0%) NR NR 
Non-haematological         
Abdominal pain 43 (12%) 7 (2%) NR NR 95 (12%) 16 (2%) NR NR 
Anorexia NR NR NR NR NR NR 58 (17%) 4 (1%) 
Arthralgia 39 (11%) 4 (1%) NR NR 215 (27%) 33 (4%) NR NR 
Asthenia 76 (20%) 17 (5%) NR NR 104 (13%) 18 (2%) NR NR 
Back pain 60 (16%) 14 (4%) NR NR 233 (30%) 47 (6%) NR NR 
Bone pain 19 (5%) 3 (1%) NR NR 194 (25%) 44 (6%) 185 (53%) 74 (21%) 
Cardiac disorder NR NR 49 (6%) 7(1%) 106 (13%) 33(4%) NR NR 
Constipation 76 (20%) 4 (1%) NR NR 206 (26%) 8 (1%) 62 (18%) 3 (1%) 
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Diarrhoea 173 (47%) 23 (6%) 171 (21%) 9 (1%) 139 (18%) 5 (<1%) 85 (25%) 2 (1%) 
Dyspnoea 44 (12%) 5 (1%) NR NR 102 (13%) 10 (1%) NR NR 
Fatigue 136 (37%) 18 (5%) 269 (34%) 50 (6%) 346 (44%) 66 (8%) 94 (27%) 16 (5%) 
Fluid retention and 
oedema 
NR NR NR NR 241 (31%) 18 (2%) 39 (11%) 6 (2%) 
Haematuria 62 (17%) 7 (2%) NR NR 65 (8%) 11 (1%) NR NR 
Headache NR NR 93 (12%) 6 (<1%) NR NR NR NR 
Hot flash NR NR 162 (20%) 0 NR NR NR NR 
Hypertension NR NR NR NR 77 (10%) 10 (1%) NR NR 
Hypokalaemia NR NR NR NR 135 (17%) 30 (4%) NR NR 
Liver function 
abnormality 
NR NR 8 (1%) 3 (<1%) 81 (10%) 27 (3%) NR NR 
Musculoskeletal pain NR NR 109 (14%) 8 (1%) NR NR NR NR 
Nausea 127 (34%) 7 (2%) NR NR 233 (30%) 13 (2%) 137 (40%) 8 (2%) 
Pain 20 (5%) 4(1%) NR NR 13 (2%) 5 (1%) NR NR 
Pain in extremity 30 (8%) 6 (2%) NR NR 134 (17%) 19 (2%) NR NR 
Pyrexia 45 (12%) 4 (1%) NR NR 71 (9%) 3 (<1%) NR NR 
Seizure NR NR 5 (<1%) 5 (<1%) NR NR NR NR 
Urinary tract 
infection 
27 (7%) 4 (1%) NR NR 91 (12%) 17 (2%) 26 (8%) 3 (1%) 
Vomiting 84 (23%) 7 (2%) NR NR 168 (21%) 14 (2%) 83 (24%) 9 (3%) 
Weight loss NR NR NR NR NR NR 48 (14%) 4 (1%) 
NR, not reported 
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Within the CS the clinical effectiveness of radium-223 dichloride and its cost effectiveness when 
compared with cabazitaxel were not formally considered. As radium-223 dichloride is a comparator 
for the subgroup of people with bone metastasis and no known visceral metastases, this exclusion 
leads to uncertainty regarding the cost-effectiveness of cabazitaxel. 
 
Cost-effectiveness results were sensitive to the utility values that should be assigned to progressive 
disease, and to the choice of parametric model used for extrapolating the clinical effectiveness data. It 
is unclear how resolving these uncertainties would impact on the cost-effectiveness of cabazitaxel. 
 
1.7 Summary of exploratory and sensitivity analyses undertaken by the ERG 
The probabilistic base-case ICER presented in the CS comparing cabazitaxel with mitoxantrone was 
£50,682. The ERG made six changes to the company’s base case. These were: the use of Electronic 
market information tool prices in preference to British National Formulary prices for generic drug 
costs (including mitoxantrone); modelling vial wastage; not modelling discontinuation for reasons 
other than disease progression; not modelling a reduced disutility in the last three months of 
progressive disease; basing post-second line treatment resource use from a UK audit for all 
treatments; and using results from the NMA adjusted by the ERG. When taken in isolation each of 
these changes led to an increase in the ICER, with the largest increase attributable to the modelling of 
vial wastage. The combined effect of these changes was to increase the probabilistic ICER from 
£50,682 to XXX. If vial wastage is not modelled then the probabilistic ICER is £51,849. 
 
The ERG also performed exploratory analyses regarding the long-term modelling of effectiveness 
data and using different utility values for progressive disease. It was noted that these uncertainties led 
to both increases and decreases in the base-case ICER depending on the assumptions made. 
 
The ERG used the results from the NMA adjusted by the ERG to assess the cost-effectiveness of 
cabazitaxel when compared to BSC, abiraterone and enzalutamide. The ICER comparing 
enzalutamide with cabazitaxel was £142,180 when vial wastage was modelled and £158,873 when it 
was not modelled. Clinical advice given to the ERG suggests that vial wastage would be likely. 
Abiraterone was extendedly dominated by enzalutamide irrespective of how vial wastage was 
modelled. The ICER comparing cabazitaxel with BSC was £107,604 when vial wastage was 
modelled and £86,888 when it was not modelled: this was greater than estimated from the direct 
comparison with mitoxantrone and may indicate the inappropriateness of assuming proportional 
hazards. Analyses using the PAS-adjusted prices of abiraterone and enzalutamide, along with 
sensitivity analyses, are provided in a confidential appendix prepared for the Appraisal Committee 
only. 
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2 BACKGROUND  
This report provides a review of the evidence submitted by the company for cabazitaxel for hormone-
relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen. 
Cabazitaxel is licensed within the EU for use in combination with prednisone or prednisolone for the 
treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated 
with a docetaxel-containing regimen.1  
 
Cabazitaxel was previously appraised as part of the NICE Single Technology Appraisal (STA) process 
(TA255), with the final appraisal determination issued in January 2012.2 The Committee considered 
that the most plausible ICER was likely to be above £87,500 per quality-adjusted life years (QALYs) 
gained, and so did not recommend treatment with cabazitaxel. The Committee noted that key 
uncertainties related to the company's modelling of clinical effectiveness data and the utility values 
used. Cabazitaxel was available via the National Cancer Drugs Fund (CDF) until its removal in 
January 2015. It was later re-instated on the CDF in May 2015. 
 
2.1 Critique of the company’s description of underlying health problem 
The company’s submission (CS3) provides an appropriate overview of prostate cancer noting that 
prostate cancer is heterogeneous with regards to both treatment response and the types of disease 
progression observed. Prostate cancer is the most common form of cancer in men in the UK, and the 
second most common cause of cancer death. There were 41,736 incident cases, and 10,837 deaths from 
prostate cancer in the UK in 2012, the most recent year for which data are available.4 
 
For metastatic prostate cancer (cancer that has spread to other parts of the body), there is a distinction 
between mHRPC and metastatic castrate resistant prostate cancer (mCRPC).5 Tumours that progress 
with castrate levels of testosterone (typically taken to be lower than 50 ng per deciliter6) are classified 
as mCRPC; tumours that progress after conventional luteinising hormone-releasing hormone (LHRH) 
and newer hormone therapies such as abiraterone and enzalutamide are classified as mHRPC.  First 
line therapy is typically androgen deprivation therapy or LHRH with patients with mCRPC more likely 
to respond to further hormonal therapies than people with mHRPC.5 As the advanced hormonal 
therapies abiraterone and enzalutamide were not available at the time of the company’s original 
submission, the terminology used for TA255 was people with mHRPC. As terminology has 
subsequently evolved, for the purposes of this report, the ERG shall refer to the population of interest 
as people with mCRPC. 
 
There are no published data for the incidence of mCRPC. However, a report from the National Cancer 
Intelligence Network7 reveals that of the 36,287 diagnoses in England in 2013, 5836 (16%) were 
classified as Stage 4 (or metastatic) cancers, with a further 6661 diagnoses (18%) having an unknown
57 
 
Table 1: Treatment received and reasons for discontinuation in the TROPIC study11 
 Cabazitaxel 
(n=378) 
Mitoxantrone 
(n=377) 
Patients who received study treatment, 371 (98%) 371 (98%) 
Median number of treatment cycles (IQR) 6 
(3 to 10) 
4 
(2 to 7) 
Number of patients completing planned 10 cycles of 
study treatment 
109 (29.4%) 50 (13.5%) 
Median relative dose intensity (IQR) 96.1% 
(90.1 to 98.9) a,b 
97.3% 
(92.0 to 99.3) a,b 
Discontinuation of study treatment 266 (70%) 325 (86%) 
Reasons for discontinuation of study treatment   
Disease progression 180 (48%) 267 (71%) 
Adverse event 67 (18%) 32 (8%) 
Non-compliance with protocol 1 (<1%) 0 
Lost to follow-up 0 2 (1%) 
Patient request 8 (2%) 17 (5%) 
Other  10 (3%) 7 (2%) 
Dose reductions   
Number of patients c 45 (12%) 15 (4%) 
Number of cycles d 221 (9.8%) 88 (5.1%) 
Treatment delays   
Number of patients e 104 (28%) 56 (15%) 
Number of cycles d   
≥4 days NR (9.3%) NR (7.9%) 
≤9 days 157 (7.0%) 110 (6.3%) 
>9 days 
 
51 (2.2%) 28 (1.6%) 
IQR, interquartile range 
a Data discrepancy in CS - p111 (CS) suggest a range (unit not specified) of 49.0% to 108.2% for cabazitaxel and 42.5% to 
106% for mitoxantrone 
b Data from de Bono et al.11 and CS (p77, Error! Reference source not found.) 
c One dose reduction was allowed per patient, 20 mg/m2 for cabazitaxel or 10 mg/m2 mitoxantrone 
d Percentages are of total number of treatment cycles: 2251 for cabazitaxel and 1736 for mitoxantrone  
e Delays of ≤2 weeks were allowed 
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cabazitaxel plus prednisone. However, clinical advisors to the ERG commented that high levels of 
monitoring in a trial setting would result in abnormal laboratory measurements being recorded as AEs 
despite the fact that these may not cause any problems for the patient. The ERG’s clinicians agreed 
with the view expressed in the CS that rates of haematological AEs reported in the CUP and EAPs 
were likely to be more reflective of clinical practice. This evidence is discussed in Section 4.2. 
 
Among non-haematological AEs, the most common in cabazitaxel-treated patients in TROPIC11 were 
diarrhoea (47%), fatigue (37%), nausea (34%) and vomiting (23%). The most common AEs in patients 
receiving abiraterone in COU-AA-30112 were fatigue (44%), nausea (30%), back pain (30%) and 
arthralgia (27%). Comparison with the enzalutamide group of the AFFIRM trial13 was only possible for 
diarrhoea (21%) and fatigue (34%). The most common AEs in ALSYMPCA14 in the relevant patient 
subgroup (those who had previously received docetaxel) were bone pain (53%), nausea (40%), fatigue 
(27%) and diarrhoea (25%). 
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Stable disease 
Cabazitaxel and mitoxantrone are both provided in vials with the required dosage dependent on BSA 
(25 mg/m2 for cabazitaxel and 12 mg/m2 for mitoxantrone). Within the submission the company 
assumed that the mean BSA was 1.9 m2 (with a standard error of 0.21 used to estimate the average 
number of vials required per patient), with vial sharing for cabazitaxel but not for mitoxantrone. The 
value of 1.9 m2 was based on the clinical opinion of UK experts; the mean BSA observed in the 
TROPIC (2.01 m2) was used in a scenario analysis. The standard error of 0.21 was based on TROPIC 
data. The ERG queried why the TROPIC-derived BSA was used in the base-case for the original 
submission (TA255), but not for this submission. The company justified this change by stating that the 
value of 1.9 m2 is more likely to reflect values observed in the UK. The ERG notes that, based on the 
company’s economic model, the threshold for an increase in vials is a BSA of xxxxx for cabazitaxel 
and xxxxx for mitoxantrone. 
 
The ERG queried why it was assumed that there was no vial wastage for cabazitaxel. The company 
responded with: 
“Sanofi believe there will be no wastage of active ingredient because patient specific doses in the form 
of compounded IV bags of cabazitaxel can be supplied direct to NHS hospitals”. 
The ERG asked their clinical advisors if they believed that there would be vial wastage for cabazitaxel. 
The following reply was obtained from a pharmacist: 
“As far as I am aware, most centres do not buy in compounded bags as this would add to the total cost 
of treatment as likewise they would need to add a compounding fee to treatment. Occasionally we have 
been able to “save” a vial where several patients are receiving treatment on one day and as a result 
vials can be ‘campaigned worked’ (i.e. shared). This can seldom be achieved however and certainly 
isn’t generally the rule.” 
 
The ERG noted that in addition vial wastage may occur, if people did not attend their appointment. 
Hence there is uncertainty over the degree of vial wastage that would occur in clinical practice. The 
ERG further noted that in the company’s base-case there appeared to be no wastage assumed for either 
cabazitaxel or mitoxantrone. 
 
Treatment with abiraterone requires 1.0g daily whilst for enzalutamide 160mg is required daily.  
Costs for cabazitaxel and all three comparators were taken from the BNF June 2015.107 A pack of 
abiraterone contains 120 tablets of 250mg, whilst a pack of enzalutamide contains 112 tablets of 40mg. 
These costs, which do not include any Patient Access Scheme or any administration costs, are 
displayed in Table 2. With the exception of enzalutamide, all of the treatments are in combination with 
10 mg/day of prednisolone, at a 3-week cycle cost of £1.94. 
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Table 2: Direct treatment costs based on list prices. 
Treatment Cost per unit Details Cost per 3-week cycle* 
Mitoxantrone £100.00 Cost per vial £172.87 
Cabazitaxel £3696.00 Cost per vial £3696.00 
Abiraterone £2930.00 Cost per 120-tab pack £2,051.00 
Enzalutamide £2734.67 Cost per 112-cap pack £2,051.00 
*Mitoxantrone and cabazitaxel are estimated by the company to require 1.73 and 1.00 vials per cycle, respectively. The PAS 
price is used for cabazitaxel in the main analyses. The PAS prices for abiraterone and enzalutamide are used in the 
confidential appendix. 
 
It was assumed that all four treatments would require one visit to a clinical oncologist every three 
weeks, at a cost of £320 per visit.27 Treatment with cabazitaxel and mitoxantrone incurred additional 
administration costs for pharmacist time. The hourly cost for pharmacist time used was £42,109 it was 
assumed that mitoxantrone would require an hour of pharmacy time and cabazitaxel would require 15 
minutes. The shorter pharmacist time required for cabazitaxel reflects the fact that cabazitaxel will be 
provided in prefilled bags with a tailored dose appropriate for specific patients. Hence no time is 
needed to make up the IV infusions. This additional time is required for mitoxantrone delivery. 
 
Pre-medication resource use for cabazitaxel and mitoxantrone were taken from the TROPIC, as 
detailed in Table 63 of the CS (p165-167). The main driver of pre-medication costs was the use of 
primary prophylaxis, with a unit cost of £175.67. This was received by 25% of patients in the 
cabazitaxel arm and 10% in the mitoxantrone arm. It was assumed that patients receiving either 
abiraterone or enzalutamide would have the same resource use as mitoxantrone, but with no primary 
prophylaxis. The resulting three-weekly pre-medication costs were £87.29 for cabazitaxel, £36.32 for 
mitoxantrone, and £7.52 for either abiraterone or enzalutamide. 
 
For patients with stable disease, the direct treatment costs (as detailed in Table 2), along with 
administration costs and pre-medication costs were incurred for either ten cycles of treatment or until 
disease progression or death for cabazitaxel and mitoxantrone. Patients persist on treatment until 
progression or death for abiraterone and enzalutamide. 
 
In addition, patients with stable disease also required treatment with an LHRH agonist, at a cost of 
£52.59 every three weeks. Additional costs relating to outpatient care, inpatient care, hospice care, 
imaging and laboratory tests were also incurred, at a cost of £303.65 every three weeks. These two 
additional costs were incurred by patients as long as they remained in the stable disease state. 
 
The costs of treating AEs were incorporated into the economic model as an additional treatment-
specific cost for patients with stable disease who are receiving treatment. The rates of occurrence of 
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AEs as used in the economic model are described in Error! Reference source not found.. Costs for 
treating AEs were based on
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5.3 Exploratory and sensitivity analyses undertaken by the ERG 
The ERG undertook a number of additional sensitivity analyses using the economic model, and base-
case settings, supplied by the company (these did not change following response to clarification 
questions). Due to the requirement of following the template for ERG reports the results produced from 
key analyses undertaken by the ERG are reported in Section 6 (Table 3). 
 
The following exploratory analyses had a notable effect on the base-case ICER reported in the CS. 
 
For the company's base-case it was assumed that wastage would not occur for either cabazitaxel or 
mitoxantrone. As discussed in Section 5.2.8, the ERG believes that wastage could still occur. Hence an 
analysis was conducted that allowed for wastage. This was implemented in the company's model by 
setting the cost for mitoxantrone and cabazitaxel to be the cost per vial (instead of the cost per mg).  
 
The ERG changed the post-second line treatment mix so that it was no longer treatment-specific, with 
both resource use estimates and the proportion receiving BSC taken from a UK clinical audit used 
instead.25 The rationale for this change is summarised in Section 5.2.12. The change was achieved by 
changing the drop-down box of cell 'Post2ndChemoMix' (sheet 'Resource input') from 'TROPIC (arm-
specific)' to 'Country-specific (general)', and by setting the proportion receiving BSC for all treatments 
to be 0.80 (sheet ‘Cost treatment’). 
 
The ERG examined how sensitive the model results were to including a dose-reduction for both 
cabazitaxel and mitoxantrone. These reductions were removed by setting cells Rel_dose_int_caba and 
Rel_dose_int_mitox both equal to one. 
 
For the comparison between cabazitaxel and mitoxantrone, the choice of parametric curve for 
extrapolation was based on minimising the goodness of fit to both TROPIC arms. The ERG explored 
the impact on the ICER of minimising the goodness of fit to the TROPIC arms separately (hence 
allowing for different parametric models to be used for the two treatments). This led to modelling OS 
with the Weibull curve for cabazitaxel and the log-logistic curve for mitoxantrone. For PFS the log-
logistic curve was used for cabazitaxel and the log-normal curve was used for mitoxantrone. 
 
The ERG noted that, based on their goodness of fit to the observed data, the use of log-logistic curves 
for both OS and PFS was a plausible alternative to the curves used in the base-case, although the ERG 
notes the statements made in the CS (p187)25 that these had less face validity regarding long-term 
projection of survival. The ERG enacted these changes using the options in the 'RUN MODEL' sheet. 
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The ERG explored the sensitivity of the model results to the choice of progressive disease. The utility 
value used in the base-case was 0.6266, based on data from the UK EAP. Based on the standard error 
of 0.060 derivable from the UK EAP data, a normal 95% CI for the utility value for progressive disease 
is 0.510 to 0.743. These values were used in the economic model by changing the cell 
‘utility_value_PD’ to these values. It should be noted that when using the latter estimate, the modelled 
utility will increase for people who progressed after receiving less than four cycles of treatment. Hence 
these results should be viewed with caution. 
 
The company did not consider radium-223 dichloride to be a valid comparator, and so did not include 
it within their NMA. The ERG believes that this exclusion was inappropriate, as discussed in Section 
3.3. When queried about this exclusion (clarification question A1), the company did provide summary 
statistics comparing OS amongst the TROPIC population with OS amongst the ALSYMPCA 
population with previous docetaxel use. This comparison is reproduced in Error! Reference source 
not found. (comparable measures of PFS were not reported by the two trials): 
 
The ERG notes that the differences in OS (both absolute and relative) are similar for cabazitaxel and 
radium-223 dichloride. Hence, the cost-effectiveness of cabazitaxel in comparison with radium-223 
dichloride is likely to be driven mainly by the costs of the two drugs. The list price for a course of 
radium-223 dichloride (£4040) is xxxxx the PAS price for a cycle of cabazitaxel (xxxxxxxxxx). Radium-
223 dichloride is taken for a maximum of six courses, whereas in the company’s economic model 
cabazitaxel is taken for a maximum of ten cycles. In clinical practice there is no restriction on the 
maximum number of cycles for which cabazitaxel may be taken, although the median number of 
treatment cycles observed in both the TROPIC trial11 and the UK EAP50 was six. Data on the median 
number of treatments for radium-223 dichloride is not available. xxxxx xxxxx xxxxx xxxxx xxxxx xxxxx 
xxxxx xxxxx xxxxx xxxxx xxxxx. A consideration of the effect of the PAS for radium-223 dichloride on 
cost-effectiveness is discussed in a confidential appendix. 
 
The following analyses did not materially affect the company’s reported base-case ICER. 
The company included a disutility to HRQoL to reflect the potentially worsening HRQoL for people 
with progressive disease in their last three months of life. The ERG had concerns with how this was 
implemented in the economic model, as discussed in Section 5.2.12. Hence an analysis was performed 
that removed this disutility. This was achieved by setting cells B3 to B6 on sheet 'Utility death' each 
equal to zero. 
 
The ERG performed three sensitivity analyses concerning the stable disease utility values. These were: 
1. Use of the weighted mean utility from the UK EAP (0.737) for all cycles.
123 
 
 
Table 3: Overview of ERG changes to the model 
Individual changes made 
Cabazitaxel Mitoxantrone Incremental values 
ICER (£) Total costs
(£) 
Total 
QALYs 
Total costs 
(£) 
Total 
QALYs Costs (£) QALYS 
Company deterministic base-case xxxxx xxxxx xxxxx xxxxx 11,450 0.232 49,327 
Company probabilistic base-case NR NR NR NR 11,829 0.233 50,682 
Changes made        
A1) Use eMIT prices* xxxxx xxxxx xxxxx xxxxx 11,994 0.232 51,667 
A2) Discontinuation for reasons other than 
disease progression not modelled 
xxxxx xxxxx xxxxx xxxxx 11,693 0.232 50,370 
A3) Reduced disutility in the last 3 months 
of progressive disease not modelled 
xxxxx xxxxx xxxxx xxxxx 11,450 0.230 49,691 
A4) Post-second line treatment resource use 
and proportion receiving BSC both from 
UK audit for all treatments. 
xxxxx xxxxx xxxxx xxxxx 
11,353 0.232 48,908 
A5) Network meta-analysis results using a 
weakly informative prior (does not affect 
the comparison with mitoxantrone). 
xxxxx xxxxx xxxxx xxxxx 
11,450 0.232 49,327 
A6) Cost of cabazitaxel and mitoxantrone 
based on vial cost (assuming wastage). 
xxxxx xxxxx xxxxx xxxxx XXX 0.232 XXX 
A7) Use of log-logistic curves for both 
overall and progression-free survival. 
xxxxx xxxxx xxxxx xxxxx 12,627 0.309 40,887 
A8) Parametric curves for OS and PFS xxxxx xxxxx xxxxx xxxxx 9,347 0.137 68,168 
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based on lowest AIC value (no requirement 
for same parametric form for both arms)** 
A9) Use of the 95% low confidence interval 
value for progressive disease (0.510). 
xxxxx xxxxx xxxxx xxxxx 11,450 0.207 55,248 
A10) Use of the 95% high confidence 
interval value for progressive disease 
(0.743). 
xxxxx xxxxx xxxxx xxxxx 
11,450 0.257 44,560 
ERG Deterministic base-case 1 (changes 
A1 to A6) 
xxxxx xxxxx xxxxx xxxxx XXX 0.230 XXX 
ERG Probabilistic base-case 1 (changes 
A1 to A6) 
xxxxx xxxxx xxxxx xxxxx XXX 0.231 XXX 
ERG Deterministic base-case 2 (changes 
A1 to A5) 
xxxxx xxxxx xxxxx xxxxx 11,823 0.230 51,308 
ERG Probabilistic base-case 2 (changes 
A1 to A5) 
xxxxx xxxxx xxxxx xxxxx 12,133 0.234 51,849 
BSC: Best supportive care. ICER: Incremental cost-effectiveness ratio. NR: Not reported. OS: Overall survival. PFS: Progression-free survival. QALYS: Quality-adjusted life-years. 
*Note: when the company used eMIT prices (in response to clarification question B7), the reported total costs for cabazitaxel and mitoxantrone were £28,902 and £16,906 respectively, resulting 
in an ICER of £51,675. The ERG was unable to replicate these values. 
** For cabazitaxel the Weibull curve is used for OS and the log-logistic curve for PFS. For mitoxantrone the curves are the log-logistic and the log-normal, respectively. 
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Under the ERG base-cases (using the results of probabilistic sensitivity analyses), the ICER comparing 
cabazitaxel with mitoxantrone was XXX if vial wastage occurs and £51,849 in the absence of vial 
wastage. Clinical advice given to the ERG suggests that vial wastage would be likely. The sensitivity 
analyses performed (A7 to A10) showed that the ICER was also sensitive to the methods employed for 
extrapolating clinical effectiveness data, and the utility value used for progressive disease. In addition, 
the ERG noted that when choosing the parametric form to extrapolate OS (and allowing cabazitaxel 
and mitoxantrone to have different parametric forms), the difference in goodness of fit statistics were 
less than 0.2% for both treatments. The models with the lowest goodness of fit statistics provided 
estimated mean survival times of 1.54 and 1.36 years for cabazitaxel and mitoxantrone respectively 
(ICER: £73,592). The models with the second lowest goodness of fit statistics provided estimated 
mean survival times of 1.82 and 1.20 years for cabazitaxel and mitoxantrone respectively (ICER: 
£35,947). 
 
Based on the ERG base-cases, the cost-effectiveness of cabazitaxel when compared with abiraterone, 
enzalutamide or BSC is displayed in Table 4 (assuming vial wastage) and Table 5 (with no vial 
wastage). The company’s model was amended to include BSC as a comparator. It was assumed that 
BSC was represented by mitoxantrone with respect to per-cycle costs and utility values. The 
effectiveness of BSC was modelled in the same manner as for abiraterone and enzalutamide by using 
HRs for BSC derived from the NMA as updated by the ERG (see Section 4.5 for more details). 
 
Table 4: Cost-effectiveness results comparing cabazitaxel with BSC, abiraterone and 
enzalutamide (ERG base-case assuming vial wastage) 
Treatment Total values Incremental cost-effectiveness ratio (£) Costs (£) QALYs 
Deterministic results 
BSC xxxxx  xxxxx - 
Cabazitaxel xxxxx  xxxxx £111,543 compared with best-supportive care 
Abiraterone xxxxx  xxxxx Extendedly dominated by enzalutamide 
Enzalutamide xxxxx  xxxxx £136,902 compared with cabazitaxel 
Probabilistic sensitivity analysis results 
BSC xxxxx  xxxxx - 
Cabazitaxel xxxxx  xxxxx £107,604 compared with best-supportive care 
Abiraterone xxxxx  xxxxx Extendedly dominated by enzalutamide 
Enzalutamide xxxxx  xxxxx £142,180 compared with cabazitaxel 
BSC: Best supportive care. QALYs: Quality adjusted life years. 
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Table 5: Cost-effectiveness results comparing cabazitaxel with BSC, abiraterone and 
enzalutamide (ERG base-case assuming no vial wastage) 
Treatment Total values Incremental cost-effectiveness ratio (£) Costs (£) QALYs 
Deterministic results 
BSC xxxxx  xxxxx - 
Cabazitaxel xxxxx  xxxxx £85,934 compared with best-supportive care 
Abiraterone xxxxx  xxxxx Extendedly dominated by enzalutamide 
Enzalutamide xxxxx  xxxxx £152,914 compared with cabazitaxel 
Probabilistic sensitivity analysis results 
BSC xxxxx  xxxxx - 
Cabazitaxel xxxxx  xxxxx £86,888 compared with best-supportive care 
Abiraterone xxxxx  xxxxx Extendedly dominated by enzalutamide 
Enzalutamide xxxxx  xxxxx £158,873 compared with cabazitaxel 
BSC: Best supportive care. QALYs: Quality adjusted life years. 
 
Based on the ERG base-case assumptions (using the results of probabilistic sensitivity analyses) the 
ICER for cabazitaxel compared with BSC is estimated to be £107,604 with vial wastage and £86,888 
without vial wastage.. Abiraterone does not lie on the efficiency frontier, as the ICER comparing 
abiraterone with cabazitaxel is greater than that comparing enzalutamide with abiraterone regardless of 
the assumption made concerning vial wastage, and hence abiraterone is extendedly dominated by 
enzalutamide. Compared with cabazitaxel, the ICER for enzalutamide is £142,180 with vial wastage 
and £158,873 without vial wastage. 
 
It should be noted that the ICERs comparing cabazitaxel with BSC are substantively greater than those 
comparing cabazitaxel with mitoxantrone, as reported in Error! Reference source not found.. This 
shows that the estimated cost-effectiveness results are sensitive to the modelling approach employed 
for extrapolating clinical effectiveness data. For the NMA results (which are used when comparing 
cabazitaxel with BSC and the two advanced hormonal therapies), an assumption of proportional 
hazards is required. The ERG has already noted that this assumption is questionable, and that the NMA 
results should be treated with caution, as discussed in Section 4.4. 
 
Sensitivity analyses for the comparison between cabazitaxel, BSC, abiraterone and enzalutamide were 
not performed as the list prices used for abiraterone and enzalutamide do not reflect the true cost to the 
NHS. Cost-effectiveness results and sensitivity analysis based on the PAS for abiraterone and 
enzalutamide are reported in a confidential appendix. 
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known visceral metastases radium-223 dichloride is a comparator in the NICE final scope, so 
excluding it will lead to uncertainty in the cost-effectiveness of cabazitaxel for both clinical pathways. 
In addition, not including BSC in the alternative practice pathway also leads to uncertainty about the 
cost-effectiveness of cabazitaxel. 
 
The ERG’s estimate of the ICER comparing cabazitaxel with mitoxantrone was XXX when modelling 
vial wastage and £51,849 when this was not modelled. The ERG also considered the cost-effectiveness 
of cabazitaxel when compared with BSC, abiraterone and enzalutamide. Effectiveness data were taken 
from the NMA adjusted by the ERG. The ICER comparing cabazitaxel with BSC was £107,604 when 
vial wastage was modelled and £86,888 when it was not modelled. Abiraterone was extendedly 
dominated by enzalutamide irrespective of how vial wastage was modelled. The ICER comparing 
enzalutamide with cabazitaxel was £142,180 when vial wastage was modelled and £158,873 when it 
was not modelled. 
 
8.1 Implications for research 
There are no direct comparisons of the clinical and cost effectiveness of cabazitaxel and any of 
abiraterone, enzalutamide or radium-223 dichloride. Hence there is a need for RCTs that directly 
compare these treatments, collects sufficient evidence on resource use and costs, and is powered to 
detect clinically meaningful changes in both OS and PFS. Trials comparing different sequences of 
treatment involving cabazitaxel and the advanced hormonal agents would also be beneficial. 
 
Further research into the utility of people with mCRPC, particularly for people with progressed disease 
and how this utility varies over time, would help to reduce the uncertainty in the cost-effectiveness 
results. Uncertainty would also be reduced if longer-term data concerning the effectiveness of 
cabazitaxel (and each of the comparators) were available. 
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Pro-forma Response  
 
ERG report 
 
Cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing 
regimen (review of TA255) [ID889] 
 
 
You are asked to check the ERG report from the School of Health and Related Research (ScHARR) to ensure there are no factual 
inaccuracies contained within it. 
 
If you do identify any factual inaccuracies you must inform NICE by 5pm, 15 December using the below proforma comments table. 
All factual errors will be highlighted in a report and presented to the Appraisal Committee and will subsequently be published on the 
NICE website with the Evaluation report. 
 
The proforma document should act as a method of detailing any inaccuracies found and how and why they should be corrected. 
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 Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
Issue 1 Page 11 paragraph 2 
 ‘the AFFIRM study compared 
enzalutamide plus placebo with placebo 
with or without prednisone’ 
We believe the reader may be confused 
by, or misunderstand the two treatment 
arms 
Suggested text change – include a 
comma after the first use of the word 
placebo: 
 
‘the AFFIRM study compared 
enzalutamide plus placebo, with 
placebo with or without prednisone’ 
Clarity on the therapies used in the 
enzalutamide arm in the AFFIRM 
study 
 
The ERG believe that 
it can be argued 
whether or not this 
represents a factual 
error. The ERG have 
not made any 
changes, the 
company can make 
this issue clear if 
necessary during the 
Appraisal Committee 
 Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
Issue 2 Page 17 paragraph 3 
Footnote … ‘The company’s submission 
(CS) provides an appropriate overview of 
prostate cancer noting that prostate 
cancer can be heterogeneous with 
regards to both treatment response and 
the types of disease progression 
observed.’ 
Prostate cancer ‘is’ a heterogeneous 
disease rather than ‘can be’ 
heterogeneous.  
Suggested text change: 
 
The company’s submission (CS) 
provides an appropriate overview of 
prostate cancer noting that prostate 
cancer is heterogeneous with regards 
to both treatment response and the 
types of disease progression 
observed. 
As stated on page 16, paragraph 1 
of the CS: 
 ‘…. prostate cancer tumours are in 
fact heterogeneous as they contain 
cells with a variety of malignant 
genetic changes. 
It is important to highlight that 
prostate cancer is a heterogeneous 
disease. 
The ERG has made 
the proposed change. 
 Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
Issue 3 Page 20 Figure 1 We apologise for the omission of this The original figure was supplied 
without a footnote in error and was 
No change required. 
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Footnote …’The CS does not provide a 
foot note for ‘*’ in the figure’ 
footnote in the CS. 
The footnote should read. 
‘* Radium-223 is licenced for patients 
with two or more bone metastases but 
no visceral metastases’ 
missed in final review. This footnote 
will be incorporated into the 
redacted version for the NICE 
website. 
It is important to include this as we 
do recognise that radium-223 is a 
therapeutic option for some 
patients but have not included it in 
the analysis for the reasons given 
in the CS. 
 Description of problem  Description of proposed amendment  Justification for 
amendment 
ERG response 
Issue 4 Page 57. Table 10, row 3. 
The number of patients completing 
10 cycles of treatment is not 
correct. 
 
 
Please change to: 
 Cabazitaxel 
(n=378) 
Mitoxantrone 
(n=377) 
Number of 
patients 
completing 
planned 10 
cycles of study 
treatment 
109(29.4%) 50 (13.5%) 
Data is incorrectly reported.  Whilst this is not a 
factual error, the ERG 
has changed the 
number of patients 
completing 10 cycles 
of treatment to be 
now based on the 
more mature data, as 
requested. 
 Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
Issue 5 Page 84 paragraph 2 
Diarrhoea is a key AE in ALSYMPCA and 
is missing from this list. 
Suggested text change: 
 
‘The most common AEs in 
Clarity on the key AEs in 
ALSYMPCA is important. Diarrhoea 
is a key AE and is missing from the 
Whilst this is not a 
factual error, the ERG 
has made the 
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Text … ‘The most common AEs in 
ALSYMPCA in the relevant patient 
subgroup (those who had previously 
received docetaxel) were bone pain 
(53%), nausea (40%) and fatigue (27%). 
ALSYMPCA in the relevant patient 
subgroup (those who had previously 
received docetaxel) were bone pain 
(53%), nausea (40%) fatigue (27%) 
and diarrhoea (25%)’ 
list. 
 
 
proposed change. 
 Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
Issue 6 Page 106 ‘Stable disease‘ paragraph. 
The body surface area of patients should 
include m2 as the units: 
Text… ‘Within the submission the 
company assumed that the mean BSA 
was 1.9 (with a standard error of 0.21 
used to estimate the average number of 
vials required per patient), with vial 
sharing for cabazitaxel but not for 
mitoxantrone. The value of 1.9 was based 
on the clinical opinion of UK experts; the 
mean BSA observed in the TROPIC (2.01) 
was used in a scenario analysis. The 
standard error of 0.21 was based on 
TROPIC data. The ERG queried why the 
TROPIC-derived BSA was used in the 
base-case for the original submission 
(TA255), but not for this submission. The 
company justified this change by stating 
that the value of 1.9 is more likely to 
reflect values observed in the UK’ 
Suggested changes incorporate the 
units: 
 
‘Within the submission the company 
assumed that the mean BSA was 1.9 
m2 (with a standard error of 0.21 used 
to estimate the average number of 
vials required per patient), with vial 
sharing for cabazitaxel but not for 
mitoxantrone. The value of 1.9 m2 was 
based on the clinical opinion of UK 
experts; the mean BSA observed in 
the TROPIC (2.01 m2) was used in a 
scenario analysis. The standard error 
of 0.21 was based on TROPIC data. 
The ERG queried why the TROPIC-
derived BSA was used in the base-
case for the original submission 
(TA255), but not for this submission. 
The company justified this change by 
stating that the value of 1.9 m2 is more 
likely to reflect values observed in the 
UK’ 
Typographic amendment  Whilst this is not a 
factual error, the ERG 
has made the 
proposed change. 
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 Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
Issue 7 Page 107 paragraph 1 
 
Text… ‘it was assumed that mitoxantrone 
would require an hour of pharmacy time 
and cabazitaxel would require 15 
minutes’. 
 
Further clarification around the disparity in 
pharmacist time should be provided. 
 
Suggest the text should include: 
The shorter pharmacist time required 
for cabazitaxel reflects the fact that 
cabazitaxel will be provided in prefilled 
bags with a tailored dose appropriate 
for specific patients. Hence no time is 
needed to make up the IV infusions. 
This additional time is required for 
mitoxantrone delivery. 
We provide an explanation for the 
difference in answer to question B3 
at the clarification stage. 
Whilst this is not a 
factual error, the ERG 
has made the 
proposed change. 
 Description of problem  Description 
of proposed 
amendment  
Justification for 
amendment 
ERG response 
Issue 8 Page 106 paragraph 3 
 
Text… ‘The ERG further noted that in the company’s base-case there appeared to 
be no wastage assumed for either cabazitaxel or mitoxantrone.’ 
 
However this was not what was stated in the CS on page 165, table 63 which was:  
 
Active intervention: 
cabazitaxel 
47.50 mg per 3 
weekly cycle plus 
daily 10 mg 
prednisolone 
Based on dose of 25 mg/m2, 
BSA of 1.9 m2 assuming no 
wastage. 
No 
amendment 
proposed.  
For information: 
Correcting the 
model to reflect the 
use of vials for 
mitoxantrone as we 
had intended in our 
base-case leads to 
a deterministic 
ICER of £48,256.  
The probabilistic 
ICER is estimated 
to be £49,856 and 
the probability of 
being cost effective 
at a threshold 
No change required. 
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Comparator: 
mitoxantrone 
1 or 2 vials of 20 
mg plus daily 10 
mg prednisolone 
Based on dose of 12 mg/m2, 
BSA of 1.9 m2 and 
assumption of no vial sharing 
 
We thank the ERG for bringing this to our attention. 
It is an important clarification as this may affect the committees view on the cost 
effectiveness of cabazitaxel in the comparison with BSC. 
It was not our intention to present the analysis including mg of mitoxantrone in the 
base-case 
willingness to pay 
of £50K is 51%. 
The disaggregated 
costs and method 
of calculation using 
the company model 
are shown in 
appendix A to this 
document (see 
below). 
 
 Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
Issue 9 Page 107 Table 31 
Value 4th column, row 3: £3696 
£3696 is not the cost per 3 week cycle of 
cabazitaxel used in the model and does not 
reflect either the PAS price or the per mg 
dose. (Note the correct information should 
be redacted). 
Notwithstanding our comment in issue 8 
above the footnote text does not reflect the 
actual vials used in the base-case for 
cabazitaxel. 
Footnote text… ‘*Mitoxantrone and 
cabazitaxel are estimated by the company 
to require 1.73 and 1.00 vials per cycle, 
respectively.’ 
 
 
The PAS cost of cabazitaxel per mg is 
provided in table 64 on page 167 of 
the CS and the number of mg used in 
the modelling is shown in on page 
165, table 63. The product of these 
figures is the cost per patient per cycle 
of cabazitaxel. This cost should be 
redacted. 
Suggested change to the footnote text: 
‘*Mitoxantrone is estimated by the 
company to require 1.73 vials per cycle 
and 0.79 vials of cabazitaxel. NOTE The 
PAS adjusted cost is used for cabazitaxel.’ 
 
The cost for cabazitaxel for each 3 
weekly cycle is overstated in the table 
as the PAS price per mg is used in the 
base-case.  
 
Whilst this is not a 
factual error, the ERG 
has changed the title 
of Table 31 to clarify 
that list prices are 
displayed. In addition, 
the following footnote 
has been added: 
“The PAS price is 
used for cabazitaxel 
in the main analyses. 
The PAS prices for 
abiraterone and 
enzalutamide are 
used in the 
confidential 
appendix.”. 
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 Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
Issue 
10 
Page 107 paragraph 3 
 
Text…’ For patients with stable disease, 
the direct treatment costs (as detailed in 
Error! Reference source not found.), 
along with administration costs and pre-
medication costs were incurred for either 
the first ten cycles of treatment (for 
cabazitaxel and mitoxantrone) or until 
disease progression or death (for 
abiraterone and enzalutamide).’ 
The costs for mitoxantrone or cabazitaxel 
were incurred for 10 cycles, progression 
or death whichever comes first. 
Suggest the text should include: 
For patients with stable disease, the 
direct treatment costs (as detailed in 
Error! Reference source not found.), 
along with administration costs and pre-
medication costs were incurred for 
either ten cycles of treatment or until 
disease progression or death for 
cabazitaxel and mitoxantrone. Patients 
persist on treatment until progression 
for abiraterone and enzalutamide. 
The text suggests that costs were 
incurred for all 10 cycles for the 
chemotherapy drugs. This is only 
the case for those patients who 
had not progressed during this 
time. 
The ERG has made 
the proposed change. 
The ERG has also 
changed the last 
sentence in the 
proposed amendment 
to read: “Patients 
persist on treatment 
until progression or 
death for abiraterone 
and enzalutamide.” 
 Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
Issue 
11 
Page 114 paragraph 3 
Text…’Use of the log-logistic curve for OS 
decreased the ICER from the base-case 
value of £49,327 to £41,875 (it is believed 
that there is a typographical error in the 
CS that reports this as £41,920).’ 
 
No proposed amendment. We agree that this was a 
typographical error in the CS 
 
No change required. 
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 Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
Issue 
12 
Page 118 paragraph 1 
Text… ‘The ERG believes that differences 
in post-second line treatment were 
unlikely to have contributed to differences 
in OS for the TROPIC trial. Hence the 
ERG believes that the same post-second 
line treatment costs should be used for 
cabazitaxel and each of the comparators. 
The ERG performed an analysis which 
used the values from the UK clinical audit 
for cabazitaxel and all of the comparators. 
This increased the ICER comparing 
cabazitaxel with mitoxantrone by 2.3% to 
£50,444.’ 
The inclusion of the audit data is selective 
in this analysis. 
We understand the rationale for the 
inclusion of the UK audit data in the 
ERG base-case. However the audit 
data comes in two parts. The post 
second line treatment mix was used in 
the ERG base-case but the proportions 
of patients to which post second line 
treatments are applied does not appear 
to have been used. 
If the both sets of information are used 
the ICER is decreased by 1% to 
provide a deterministic ICER of 
£48,908. The probabilistic ICER is 
estimated to be £48,819 and the 
probability of cabazitaxel being cost 
effective at a threshold willingness to 
pay of £50,000 is 50.3%. See Appendix 
B. 
 
A breakdown of how this affects the 
overall ERG base-case ICER is also 
provided below in Appendix C. 
 
We believe that if the UK audit is 
to be used in the base-case then it 
should be implemented fully with 
both treatment mix and also 
proportion of patients considered. 
The company base-case including 
the post second line treatment mix 
and patient proportions derived 
from TROPIC provided a more 
conservative estimate of the ICER. 
 
The ERG base-case 
ICER has been 
amended to also use 
the UK audit data for 
the proportion of 
patients to which post 
second line 
treatments are 
applied. This applies 
to all analyses 
involving the ERG 
base-case, in both 
the main report and 
the confidential 
appendix. In addition, 
analysis A4 in Table 
36, and the text 
describing this on 
page 119 have been 
amended. 
 Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
Issue 
13 
Page 117 paragraph 2 
Text… ‘For the company’s base-case 
analysis, OS and PFS were modelled 
 For information we provide a 
revised estimate for the ERG 
base-case. 
No change required. 
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using separate Weibull and log-normal 
curves (respectively) for both treatment 
arms. In response to clarification question 
B1, which queried why piecewise curves 
were not used, the company presented 
the results using a hybrid method for 
estimating OS following cabazitaxel 
treatment with the mitoxantrone OS curve 
unchanged. This method used Kaplan-
Meier curves for the first 2.1 months and a 
Weibull curve for the remaining lifetime for 
the cabazitaxel arm. Under this method 
the base-case ICER reduced by 1.6% to 
£48,543. The ERG believes that this 
hybrid method is likely to be more 
appropriate than the base-case method. 
However, it is noted that details regarding 
the Weibull curve used for the hybrid 
method were not provided, so the ERG 
was not able to replicate this analysis.’ 
The updated company model, which 
included the additional curve fits was not 
supplied to the ERG. This was our 
oversight.  
In summary this includes 
 eMIT costs 
 No discontinuation 
 UK audit data for 
proportion and mix in 
second line treatment 
 Utility maintained until 
death in the PD state 
 Hybrid curve fits 
 Vials instead of mg for 
mitoxantrone 
The revised estimate for the ERG 
base-case which includes the 
updated curve fits and vials of 
mitoxantrone is £50,195. The 
probabilistic ICER is estimated to 
be £50,819. These results are 
shown in full Appendix D below. 
 
 Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
Issue 
14 
Page 119 paragraph 8 
Missing word (‘utility’) in the text…’ The 
value used in the base-case was 0.6266, 
based on data from the UK EAP.’ 
 
Suggest the text should be amended to 
include the word ‘utility’: 
The utility value used in the base-case 
was 0.6266, based on data from the UK 
EAP.’ 
It is unclear what the value 
‘0.6266’ refers to. 
Whilst this is not a 
factual error, the 
ERG has made the 
proposed change. 
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 Description of problem  Description of proposed 
amendment  
Justification for amendment ERG response 
Issue 
15 
Page 128 paragraph 4 
Text…’ The company did not consider if 
cabazitaxel met this criteria when 
compared to other treatments.’ 
This does not precisely reflect the 
statement on page 21 of the CS.  
‘For patients previously treated with the 
advanced hormonal agents, or for those 
no-longer suitable for them, cabazitaxel 
represents a life-extending EoL therapy’  
The statement in the ERG report suggests 
that we did not indicate that criterion 2 
could be considered to be met. In the 
response to the scope, the decision 
problem meeting and in the CS we 
indicated that cabazitaxel meets this 
criterion where patients have 
BSC/mitoxantrone as their only option. 
Text…’ The company considered that  
for patients previously treated with the 
advanced hormonal agents, or for those 
no-longer suitable for them, cabazitaxel 
represents a life-extending EoL therapy 
but did not consider if cabazitaxel met 
this criteria when compared to other 
treatments.’ 
 
 
Given the uncertainty in the 
analysis versus abiraterone and 
enzalutamide we believe this 
comparison to be largely 
uninformative. The ERG concurred 
with this in the report on page 87…
‘The ERG consider that the results 
of the NMA can be used as an 
indication of the treatment effects 
between relevant comparators, but 
should be treated with caution due 
to the described uncertainty in the 
suitability of the effect measure, in 
addition the other stated concerns 
in terms of implementation of the 
NMA. ‘ 
We also believe that the 
restrictions placed on the use of 
the advanced hormonal agents 
along with the expected (and 
established) place in therapy for 
cabazitaxel mean that the 
cabazitaxel patient is not directly 
comparable to the patient who 
might be treated with abiraterone 
or enzalutamide. We believe these 
issues should also extend to any 
comparison with radium-223. 
The ERG believe that 
it can be argued 
whether or not this 
represents a factual 
error. The ERG have 
not made any 
changes, the 
company can make 
this issue clear if 
necessary during the 
Appraisal Committee 
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Appendix A. See Issue 8 Error in the Company model. 
Updated base-case including vials of mitoxantrone rather than mg. This analysis is made possible by changing the contents of cell 
T20 on the ‘Cost treatment’ worksheet in the company model from: 
=IF(CostCalcPerPatCabaChoice= "Price based on vial",VialMitox+MgPred,MgMitox+MgPred) 
To 
= VialMitox+MgPred 
Table 1 Updated deterministic results 
Cabazitaxel Mitoxantrone 
Total costs (£) xxxxx xxxxx 
Total LYG xxxxx xxxxx 
Total QALYs xxxxx xxxxx 
Incremental costs (£) £11,202 
Incremental LYG 0.338 
Incremental QALYs 0.232 
ICER (£) versus baseline (QALYS) £48,256 
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Figure 1 Probabilistic results from the updated analysis 
  
The probability of being cost-effective at a threshold willingness to pay of £50,000 is 51% 
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Appendix B See issue 12  Inclusion of the full UK audit data. 
Table 2 Updated deterministic results 
Cabazitaxel Mitoxantrone 
Total costs (£) xxxxx xxxxx 
Total LYG xxxxx xxxxx 
Total QALYs xxxxx xxxxx 
Incremental costs (£) £11,353 
Incremental LYG 0.338 
Incremental QALYs 0.232 
ICER (£) versus baseline (QALYS) £48,908 
Figure 2 Probabilistic sensitivity results for the updated ERG analysis A4 
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Appendix C. See issue 12  Inclusion of the full UK audit data. 
Individual changes made at each step 
Cabazitaxel Mitoxantrone Incremental values 
Compound 
ICER (£) 
Total costs 
(£) 
Total 
QALYs 
Total costs 
(£) 
Total 
QALYs Costs (£) QALYS 
A1) Use eMIT prices* xxxxx xxxxx xxxxx  xxxxx 11,994 0.232 51,667 
A2) Discontinuation for reasons other than 
disease progression not modelled 
xxxxx xxxxx xxxxx  xxxxx 
12,242 0.232 52,736 
A3) Reduced disutility in the last 3 months 
of progressive disease not modelled 
xxxxx xxxxx xxxxx  xxxxx 
12,242 0.230 53,126 
A4) Post-second line treatment resource 
use from UK audit for all treatments. 
xxxxx xxxxx xxxxx  xxxxx 
11,825 0.230 51,316 
A5) Network meta-analysis results using a 
weakly informative prior (does not affect 
the comparison with mitoxantrone). 
xxxxx xxxxx xxxxx  xxxxx 
11,825 0.230 51,316 
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Appendix D. See issue 13. Updated ERG base-case including hybrid curve fit. 
Table 3 Updated deterministic results including hybrid curve fit 
Cabazitaxel Mitoxantrone 
Total costs (£) xxxxx xxxxx 
Total LYG xxxxx xxxxx 
Total QALYs xxxxx xxxxx 
Incremental costs (£) £11,874 
Incremental LYG 0.347 
Incremental QALYs 0.237 
ICER (£) versus baseline (QALYS) £50,195 
Figure 3 Probabilistic sensitivity results for the updated ERG base-case including hybrid curve fit 
   
